<SEC-DOCUMENT>0000078003-21-000065.txt : 20210513
<SEC-HEADER>0000078003-21-000065.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513113226
ACCESSION NUMBER:		0000078003-21-000065
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20210404
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		21917977

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pfe-20210404.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af,d:0aef9eb56eca43689ac2ec1e1a127ae4--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20210404" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20210404</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV8zLTEtMS0xLTA_999fa771-f59b-438c-8991-469683c56f7a">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV80LTEtMS0xLTA_e801aec7-c6e3-4085-be06-c51848ddec22">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV81LTEtMS0xLTA_941f9883-afd7-4474-afcb-342afcca7de0">2021</ix:nonNumeric><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV82LTEtMS0xLTA_1049a104-6dc4-4182-9c8b-a10262e2109a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV83LTEtMS0xLTA_32e188ce-eda7-4197-9d1f-662ef449cdd1">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20210404.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e0981b1456245b78310dd84b94917d6_I20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i05f859e329d9409390fed7a56b8d7dbd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad96abb481364caa9a72671a1c67d82f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68a5c0cb0954eccb168987e68a66426_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8432d19709754d54aa8831d0e0b91a10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e941de2442495c8df2676e0be6391b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dea6398b1c4543b9115d73e959887b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e4e86836694234959a3a15070601ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670092d056fe431492c1724b7d5cfb67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cc8f792ccf4742a85390af1b808b26_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f98424f39a64dedb002aa58aa06d599_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc01d70f4491494899c4a1be59cde841_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ffb761b6f624168a62f72e12228bb5a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298e3f59dab144afadd3175e4b2e4702_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba782e27bc644768676d5050e11dd16_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7f96cabae24782889c935aac35f1e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a8120f033f4276941d48877f9a9489_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if706bef9ba9e4a8087b6638c1a298410_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5802b7b756774508be8ac80fe45d2d09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb048b2301e439f88254780ad40d688_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6876e4533642569b2b72a9c6fd043b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9748b402be914193b56e1300e8f8d640_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ae0369567d42bba15dd6a743487769_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a0a3b5e3a447628cfe527319aaf597_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f5513825544a8381d81fce8b6348be_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00864a6cffcd489689813f7229308d3e_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4702654caf394c4098db2cd85620b59d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id47b6b8fdd594ac3b929fd46636184eb_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cea540ef86451da18644ee8a6e2767_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5d25c9530040899006db8fed3c6271_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887f2cb651164ba79b51cf28563d8588_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5affdf158b6444899bba4d555d785d25_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793a6170d7114594b0f7282bca5807aa_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a420875e0f49f2a79116b4b03bde63_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9e1b38766a45f1b70fef289bf08b46_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171b297bb091460caae274aa6fd2034c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12997ed07c6d40178b3062b257ac83bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fcec41f64847ed86b1c89a56896531_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a2b9079bc742749949e93c782f4af9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940e3dc38ca547fdbc8e066fc92a3705_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09c41fb46464505bcc32a3c43731505_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fac9c964894676b74a3dfea4fc6f74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb4d5f76cd341e2a3579da45c669e20_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a840208e554416a672c485a012d030_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if62466171dbf47ec977eb962afa99747_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8f63c6623f49adbf67a41d2e87119b_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d3a404ba354ee580c13bbafde8881a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6f2159d3d7436abcb7d83886acbb6f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49562007fd9547a48d0eb81e74591431_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4407292bed544ddd98da354a852701ac_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7055066225454fbd6b963b51debc30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e22c74513c4463863976ef5f21b01a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f00f1a9cab940258f6eed860c0bc028_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6820f138a34d1a88125938e6c7587e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29f6c9175e74ba2832cbc36256b21b7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneAndBioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i798490452fbf42df810cc73fc79edd72_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15de68e82a04995aadbd09ef4f4de3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c9aa8e82394528ad00529819678ef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2113534f48f444f8fad64562140b4ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4533886f346447ddb2e4466be3decd58_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3532a573af84231901dcba3a9f69146_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4864e09f901546cc81c976b2cae73fb3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62019f9f689b4fc982e85dd8eb7b261b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67345ed70af0415f9ed8e94420f395ec_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aae410224d44016a7744837424466a6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c17032a023943b39d6fe6d61373d0ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046ca4e1125f4096b86c8813e2f8970e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f1d50b4ddd4407b234fba600ed5d57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e3912c87b642259d22066a4deeedf3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39df5fe991d423c8bb366a5753affb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e21972aa8834adbb2e62df36a9290a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a996c859684b9ebfddd6a039f0965a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1336b9d91143e39d2fea5006a742b3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc333032422c470d9c553a603fed07e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i217da8c7f6f349b8b0412339d3adcdab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b273a61589b42c5baea01aad3398d3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521c003f78f74a16bf69168b25516b44_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb11cd15cf3432681d969a29d7dca79_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c84a33617f945aa95602f65e14fe7fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693fbbcedb904e0ca5820547935b4eeb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2496243c18b44e05838d5575a5b19b92_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2827e9872a441058d1e02032d2d742a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dad755ef938483cb63df05993af440c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b785935ffe4cc39bc8792585014a3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6590c03231c94832ab710135c629b5d6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a8285101fd4a4787791fc4108af409_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib397545be8ed42a894b7225f81be7b8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c6a57df8544c48b668c58d680c53a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie209ada8ef774920a8094ff1ffa8c791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6402b69d96a94b11983f4c4aff358cd9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8629e44fcf74299947158c6cf1db447_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic918fd2704ed4d59aa54d300420bf854_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia422b966324146868d032d47dda6f321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8e1a1c11cb40788c6dd041f5862427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12158fe468140509e594e5c9bea2ff0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef140b7ed3b4d09bed3385bae6d504d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b810fe2ae184c5097d5595af97f1ee9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia267f32cf11e4a86a297aa0b2be67c44_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5dcb775c5545cea010daed613c3d15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3354f5abddd4996bf3ccd71244e3b56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91073b1fe1b54677a90882344df8e229_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3537ba539cf4490799a0a791b894bbf6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdb406e79c94c318635d1add0655a54_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07835653ec374195b2d79068ec153977_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea25168e02e94f08b514acffde4e38cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a83ae2aba2486f95fe642a4c774464_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f9c25dfb8094cb598d568e3dac3e194_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7738ac04034c2db9a1b09fd2554159_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic017f9df9d9941eeb7f48073600c8293_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235004b31ec442a1a5ebf8037790737f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3112b7bd4ca945039be216b55807356f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5959213e06f24defac36f7a0fb92bbb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b990b5de1ed4f4db641cc793879a698_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2af150083d47d0bcf678532db4a34a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6648e1e65204f4eb444cb895f52ec9c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fd3e97335545368349e1b54a37f7ca_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b72ae9514a4dfdb73d54037e4297c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f3e802e12546cf9fa1294b3ad1be57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1bff202dda47268a07043474884dcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0d3ef6ac6b472b84a7134822008fef_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77e241651c349ada1bf16e3b6ecf828_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dfae630a4fe4e298addafa278e16b50_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2697970c25514e279413521fb973bba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea7690129214a9195f0424e82617486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4105c4d1d064369a467bf34c99b66d9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b19f59cbd344d648155105fd82aed69_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8bc471a60a4b02bd124ad08e30d367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27878b3c524d4ab463f64f7d71c33e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc1645da50f4723ac5e11374a83165e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2636525965a44944a8b505ad44b6fb94_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467531120efd4d1eb7bbc63d03b66773_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863eb072936745e9a6b8f3a4ef7207a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0074575f0ac44757b22db2f3767d4ee4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff43b50014b4281a9126121e4136253_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033c256fd9284f3c8ccdc121aeead211_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c4a625f98844cb89cf576d5f951717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic844430bda8d4a429c4c1873dec0c67b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1774875f27f34e3c942fbcdb9216c45c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9e05206d5d44bcb2b4c816762b2196_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0901fcaa75c4458bc09ff2e135283ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6218d250ab4b7588c930240dbe77bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e356b3ffe4f46d786b299299e8c73c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddecd2f6220e465abe9653d482f98cd7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0122d1ba5cd6421b87248774e8dd8097_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4bf8afa38545638247e4f6360ddf24_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dfe51f567c4463b153c45da57afb62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43a5c73f58e4950ab051b0f60f22af2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25ff69c6c384a5e9bec30440b609aaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if552fb30ac3f4a9986d136fac40d1ba0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadfb31e704964e379fa031ac9764d117_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9db44961644d99bc4a1be0ceaf3427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105edd316071419483c29294542bf610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc91087bf2c84f9db4657e286128b4ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71eb1561917b4fc8b8dd253cd6535303_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19135b26e5944d48147d848103fa4ab_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72626af54aa43d29c3a57a81672472f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361062f6aa914630bda2a1decde3d5fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9154af5cf4f54064a345265618b24fb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3cb663f517041b2b748758fddfc3042_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b7c33ade3f427b87cdc02e591b5d89_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id184353eda00420aa146f68eca8520d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6329d29a2efa4bf6be2047d1f4b55270_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6665bcfdc84fd9847decd31aab5d74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94b4929257f4fa59c82eaf1fff65f72_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3dd217f408a4c11b63dad378ca98d22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id54070b71d25429da086e63afcf1c41c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf94ef1797d492b92164bec12798fd6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7507c4602c4b85b91614510bb349ea_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3118a605697e4b6299c3e3e70f504737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6816514d37f949999a1c366c3691d629_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e189428ea0418bafaae25d5406511e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6892b733bc4dcf856bf74153b9127f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd7df84abf8144f9838662606d730b41_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59506893ef984409b375dbf340e24a0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436945b9fb544d1485596c97366973bf_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0b2bb17c2c45038528dc9568158637_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74e1896b3c246a98ee4bce0ead976d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if854a67683b84997921e0c8d08721493_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d11d6f169eb4129873cfe8da015081e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5584c105e0a1417da14d21d850e54027_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d153096cf74722befa5ea904fa6b4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d739b69c924476ab9fc489134e052f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcaa753284e740be9e09512ba86381ee_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f3171903a684fc3919479487e325172_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea937bd52464448b93d716a8cf093ae8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0661f5622ccf41418edc8cfa0839da72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief79afe80dd041288f169705b94e7059_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40f67d115f744f597392dd0dafbaa4e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie113bce7166d40bdacd5506226e15172_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb29d5d4227b48adb270b164dfc6d257_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4317cb0568ef4d6aa675535e255cdab3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0635462155884026ba26888ed78b96f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36997883bf644fda424001760b39437_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5d302584f242a887a90c5ba675f0f7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9cb52c2c4d4db882a1c475c695052f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96110322c78c4e7d8e3fd05494f58fbb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4631e305af2483e8890f326b9fef89d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3aa408a10c644979d8878d88bca2e75_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>pfe:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>pfe:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i02973e07500446c182f01c27b105cb67_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i104649887c064a40a045fee23a147e9b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="classaction"><xbrli:measure>pfe:classAction</xbrli:measure></xbrli:unit><xbrli:context id="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ArraySecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ZantacRanitidineNDMALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lagoon"><xbrli:measure>pfe:lagoon</xbrli:measure></xbrli:unit><xbrli:context id="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3825cb911e8746189fdd8101073ce536_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c5094c3226447689dc0560d6f61760_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00018897a8a546288611fca2330ad40d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaee0a8c94344749aad179a107f5379d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d86911b85754856a091d39a9a619036_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15547904869341898a05e8608012fdf7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia665187179da484eb6e599146133e64c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6217a5b597e247debffac06a2be42229_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d647526b664456a53481f1fcd29c09_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia251f6f252be4fca87be237b62587e21_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9846250722404133a31c34c978297518_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9903f105558492aac6500bc30eaadca_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217f041566f14b16a835176fc12cebe4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4045f62b3268485d984a63420d9173d9_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadcb9082716e49ad8217f6c35c00c9da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Mg_08e96159-65d6-474a-aa62-622804f3ffa1">10-Q</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Nw_6a541688-d6bc-46d6-832c-853b2dd5b33b">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTE_3e929d21-0de1-4c3d-8e6e-c7bde83c4b30">April&#160;4, 2021</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMjA_cff4a14a-e09e-4c07-9801-332146421349">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the transition period from _______ to _______</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8zOTI_e07c1201-8838-4787-8d00-b83353d967fb">1-3619</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">----</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80MDI_301742a9-dc6f-4bcf-ba0a-c366d9029362">PFIZER INC</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTAtMS0xLTA_8f0fba66-4257-473d-a9b2-c8d16eaf8534">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTEtMS0xLTA_16305be9-2aeb-4f8a-bec4-dbb7f5f1cc24">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTk1_58ba744a-afb0-4944-858a-55616d672281" continuedAt="i4067a375fa5846c3b34a38b80b7bdc82"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">235 East 42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">nd</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i4067a375fa5846c3b34a38b80b7bdc82"> Street</ix:continuation>, <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80ODg_bf062ef8-3831-4075-a3f0-c010d8fd716b">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTI_8a3c1f47-8eea-4a1f-923c-ae81b0391d9e">New York</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTY_8c744406-ef50-47b1-8982-6ea852711237">10017</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)&#160;&#160;(zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTQ_f8e40062-659a-48ca-88b6-00ebd2305cf2">212</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">) <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTg_b0faf57e-775c-4b16-af16-740c42b70830">733-2323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTAtMS0xLTA_09b24bae-7753-4580-9921-a91b53c8ba04">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTItMS0xLTA_d910026e-da26-442d-b31d-19415639b9fd">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTQtMS0xLTA_9d62c8d4-7eb4-477d-990d-74af97847f58">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTAtMS0xLTA_0d0a45bf-1f6e-4d15-aabb-41c2c9426500">0.250% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTItMS0xLTA_5d480107-61cc-4958-a919-dcedf31a2016">PFE22</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTQtMS0xLTA_478ec0a6-bc26-479d-84dc-3668d706d1cd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTAtMS0xLTA_5d6cc54d-1757-40d1-9bac-f075b0148eb2">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTItMS0xLTA_563da661-e643-407a-98e0-ea44ffbfb40f">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTQtMS0xLTA_d19a3f37-ce2f-4467-9c96-8523ecc53743">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OGFkYmIwMmU3NTAwNGFiMWIzMjI1NzQ4MDczZmM3N2EvdGFibGVyYW5nZTo4YWRiYjAyZTc1MDA0YWIxYjMyMjU3NDgwNzNmYzc3YV8wLTAtMS0xLTA_1d5c067a-4f80-42aa-8390-0cdfd876ef67">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OTE0OGViMzgzOTQ3NDMyZTlkZjIyZjI2YmYxNWJlZjkvdGFibGVyYW5nZTo5MTQ4ZWIzODM5NDc0MzJlOWRmMjJmMjZiZjE1YmVmOV8wLTAtMS0xLTA_6a75608f-aedf-4019-ba8c-e5a412b47f78">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNjA1_0b13429a-2451-42f6-9411-ac922445b2bb">Large Accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzIy_a4005452-5931-426b-a5f1-67595cce2fa2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzUw_9c51cf51-0806-42ab-8036-835ada900f11">&#9744;</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NWMyNmYyM2I2M2QxNGMwZGFhYTY3OGU1N2M0NjgwNjUvdGFibGVyYW5nZTo1YzI2ZjIzYjYzZDE0YzBkYWFhNjc4ZTU3YzQ2ODA2NV8wLTEtMS0xLTA_fbd0685e-aab9-4aa3-875e-7027fbfc4e2c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At May&#160;10, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3e0981b1456245b78310dd84b94917d6_I20210510" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTMz_f3e64ca4-fd98-4371-a22f-cf02f4b0c278">5,597,693,867</ix:nonFraction> shares of the issuer&#8217;s voting common stock were outstanding.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_7"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:92.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_13">PART I.&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_19">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_19">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_22">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_25">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_31">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_31">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_34">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_37">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management&#8217;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_133">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_133">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">51</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">51</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_226">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">Item </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">6</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_253">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_253">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINED TERMS </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. References to &#8220;Notes&#8221; in this Form 10-Q are to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2020 Form 10-K</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the fiscal year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Allogene</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">AML</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acute Myeloid Leukemia</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Array</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Array BioPharma Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BNT162b2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conditional marketing authorization</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, Canada, Australia, South Korea and New Zealand</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Japan, Canada, Australia, South Korea and New Zealand</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Eastern Europe, Latin America, Central Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quarterly Report on Form 10-Q for the quarterly period ended April 4, 2021</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GIST</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">gastrointestinal stromal tumors</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GlaxoSmithKline plc</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Eli Lilly &amp; Company</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">managed care organization</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MTM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">mark-to-market</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan-Japan collaboration</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pharmacy benefit manager</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PGS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sandoz</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sandoz, Inc., a division of Novartis AG</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SI&amp;A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">selling, informational and administrative</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer&#8217;s global, primarily off-patent branded and generics business, which includes a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_13"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:47.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I.&#160; FINANCIAL INFORMATION</span></td></tr></table></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_16"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_19"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi02LTEtMS0w_0462800b-6f25-45c0-b1e3-8777053d63b0">14,582</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi04LTEtMS0w_08750704-3781-40b4-a61b-fed2de241e6f">10,083</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd">4,211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56">1,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae">2,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc">2,541</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2">2,014</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126">1,672</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy02LTEtMS0w_c15c26ed-5813-4012-a38a-129be83423ba">872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy04LTEtMS0w_9a3d6d0d-4347-4412-9558-f5b1496e3263">849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC02LTEtMS0w_f41f95b1-a6d2-4984-9e65-2cd903255bad">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC04LTEtMS0w_ebe5fbeb-b685-4132-bacb-3048968b70d2">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS02LTEtMS0w_4ca070a1-0f32-4bde-a041-9813ca34b413">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS04LTEtMS0w_554a687d-cbf7-4d27-913b-7a7871fa254b">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtNi0xLTEtMA_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf">5,683</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtOC0xLTEtMA_82638985-d87e-4d19-83f9-35ac23cb0316">2,842</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItNi0xLTEtMA_d6a31f7c-a51a-4074-9737-47e32947c8ef">805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItOC0xLTEtMA_b8472e14-0a68-41d2-9348-eb9d50c460a3">359</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtNi0xLTEtMA_9ac659e3-4349-42bc-990d-f4cde183a0e7">4,877</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtOC0xLTEtMA_cab68903-79e4-434f-8480-22af9c902f33">2,483</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtNi0xLTEtMA_33b79d80-57b2-425b-8cb8-a4c3b19b5192">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtOC0xLTEtMA_11166465-dd3c-4aba-b037-16fb7e609c74">881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtNi0xLTEtMA_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtOC0xLTEtMA_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktNi0xLTEtMA_8ed91be1-1847-4b68-96b9-b6fc37642b75">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktOC0xLTEtMA_1492d746-172c-42c1-8601-49d85ea42956">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtNi0xLTEtMA_f7319f6b-201b-4644-bf83-f647ec7dbf11">4,877</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtOC0xLTEtMA_3ad21e9d-4916-46a3-be5d-5e9916f84c40">3,355</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtNi0xLTEtMA_75b7133b-7b8d-4749-ae65-9eca8dc2ec41">0.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtOC0xLTEtMA_0ad41313-4c51-4bb7-b815-6df61bc17314">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtNi0xLTEtMA_f1d431d7-e33e-49e8-81e9-b399c079757d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtOC0xLTEtMA_b38d95a7-f497-451a-a668-541c33faf446">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtNi0xLTEtMA_5fae1b27-b998-4f4d-8b17-ea0c71804d2a">0.87</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtOC0xLTEtMA_a85c270d-3dd9-4d4f-b87a-b672be7959e3">0.60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtNi0xLTEtMA_83a08fc6-5a94-455d-bd21-674b27a0506a">0.86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtOC0xLTEtMA_20550d10-89e1-4fac-81dd-154718ea283b">0.44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktNi0xLTEtMA_eb0b828b-e1f2-42da-a9cd-00ad72d78436">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktOC0xLTEtMA_d533696a-7d6b-4c6b-9843-f64b3d7d9d23">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtNi0xLTEtMA_ccebed80-aeef-40fa-bade-64f59e94c84c">0.86</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtOC0xLTEtMA_f11106ea-d63e-4bab-9b51-2cebf2989dd4">0.60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItNi0xLTEtMA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9">5,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItOC0xLTEtMA_5bf044da-3a7b-4e82-ba6f-54ebfda40193">5,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;diluted</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtNi0xLTEtMA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da">5,662</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtOC0xLTEtMA_56fa12c0-55ed-4708-b561-3527a11165d8">5,613</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1L </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></ix:footnote></div><div style="margin-top:175pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER&#160;INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi02LTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi04LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC02LTEtMS0w_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa">465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC04LTEtMS0w_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0">1,256</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy02LTEtMS0w_0d4b6fde-99cd-422e-a285-4370395347d7">214</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy04LTEtMS0w_0648e13d-ed25-45f8-81b0-5f67f2baae56">501</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45">259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS02LTEtMS0w_3b77c99c-d45b-4101-8c70-984b04268053">473</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS04LTEtMS0w_512efd4b-b6bc-4a07-921f-0a7269e640e4">482</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtNi0xLTEtMA_5c332a77-26be-4995-899d-581a58d4b46c">79</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtOC0xLTEtMA_bb0555b5-1327-4b22-8c73-92008b069f62">51</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8">242</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtNi0xLTEtMA_4ff72b90-b8d1-4de3-8703-cf6e8b70634f">163</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtOC0xLTEtMA_67e821cf-11f8-494b-a5d9-21c5ef4b4c95">36</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtNi0xLTEtMA_0343269b-d169-459d-b91f-4842a7e556a4">40</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtOC0xLTEtMA_4fd6d728-d7c8-4066-85a6-91067b5009e6">45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItNi0xLTEtMA_f95c299b-8217-47f7-8a34-bf2933f46094">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItOC0xLTEtMA_adccab60-e35e-4b21-8d24-b56a66ea336d">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtNi0xLTEtMA_5eb4ed92-385a-460d-8769-d7d2a55ca764">43</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtOC0xLTEtMA_1b6152fc-ee61-450e-ac36-36894364e0b8">45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtNi0xLTEtMA_78f653e8-6899-4cb7-97f1-e9457b00cd10">732</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtOC0xLTEtMA_90da3b81-38b0-4eb0-99d8-97b6d2accb52">1,821</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtNi0xLTEtMA_491a1642-d58b-44cc-b6f4-9543a582ef04">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtOC0xLTEtMA_5951f2d0-71ca-4d8f-8b42-a45bbaf37291">380</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtNi0xLTEtMA_b819206f-1bae-4c0b-9b25-9081eac6f8cc">647</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtOC0xLTEtMA_8c70dd79-c2ed-44eb-b89d-bf5c95798677">1,441</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctNi0xLTEtMA_448b9828-e7c3-4d2d-b206-f033542d3312">5,533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctOC0xLTEtMA_030628f9-8ff8-4e5d-ae66-c4f05de34ba1">1,923</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtNi0xLTEtMA_b59edafa-61b7-4757-8c32-1673da1f46d6">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtOC0xLTEtMA_8e63f5d7-483b-4b42-9d65-7785d409cec8">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktNi0xLTEtMA_bbf62bfa-d4ba-486d-b9be-7c41613edef9">5,523</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktOC0xLTEtMA_18c29f2f-6988-4eb3-9582-8a5b44fdebaa">1,914</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></ix:footnote></div><div style="text-indent:9pt"><span><br/></span></div><div style="margin-top:315pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy0yLTEtMS0w_740fe0b8-5c10-4ce3-a223-ad0ef459b73c">1,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy00LTEtMS0w_f23ded50-6fa8-4a10-872b-c69af92c5195">1,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC0yLTEtMS0w_00ffa628-db0a-4047-b367-6cf694c33b0c">11,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC00LTEtMS0w_1e5daf97-ed2d-45fc-aaa2-1138ac95672e">10,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfNzQ_a8fc3ed7-198e-49fd-b073-6f5184221071">512</ix:nonFraction>; 2020&#8212;$<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfODM_7902fc25-fb04-4d99-96b4-ec8bc99f3cdc">508</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0yLTEtMS0w_b56f4006-fe18-4b22-ab79-1c4435a8de6e">9,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi00LTEtMS0w_3cb2c394-8919-423c-9e96-4807bff41a07">7,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy0yLTEtMS0w_bdc110a8-3c29-4f42-a711-0e18f650dd73">8,493</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy00LTEtMS0w_130ebac4-9795-4b77-9e08-984726214796">8,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:OtherTaxAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC0yLTEtMS0w_2cd071e6-f7a4-41d3-9666-53cbfe4d64a5">3,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:OtherTaxAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC00LTEtMS0w_b0527ab6-6493-43e1-9c0c-67c0484bb4b7">3,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS0yLTEtMS0w_1b3f7369-7fb9-4dac-8af9-94a4662590a1">4,091</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS00LTEtMS0w_6eb4d8ec-c016-4873-8848-4f9650aad311">3,605</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtMi0xLTEtMA_0ba231dd-c9ba-4e9a-be42-80c886cc3b78">39,533</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtNC0xLTEtMA_14e92f3f-4580-449f-853a-08a57be436fa">35,067</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItMi0xLTEtMA_5c92dc31-9fff-4341-9299-461153d89a0a">16,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItNC0xLTEtMA_e26b48c4-5f59-4651-904c-47868c1d92b5">16,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtMi0xLTEtMA_3ea33e1f-4f93-40f3-9a15-5982a2668c13">3,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtNC0xLTEtMA_8fddbcf9-4fb2-4ef9-a1ee-516f13599c49">3,406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation: 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzcx_f8a5cc0d-ccf1-4b80-95b4-1532c7f74e9c">15,105</ix:nonFraction>; 2020&#8212;$<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzgw_a0357d2b-6f1a-45f9-8e4e-7f32002a600b">14,812</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMi0xLTEtMA_b6a0166a-9bc3-4a85-9e30-1421af996464">14,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtNC0xLTEtMA_97cbdbbf-b05a-48d3-8318-5b250bd8db62">13,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtMi0xLTEtMA_22ec22b2-a4fa-40fd-b07d-473b01878660">27,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtNC0xLTEtMA_54427191-5d1f-4af4-b844-58b6b3565eb5">28,471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtMi0xLTEtMA_a69b69e1-e128-44b0-af88-51092e42206d">49,791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtNC0xLTEtMA_f9308906-407a-4261-81dc-96b01eb28224">49,577</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctMi0xLTEtMA_58e3aa1e-50c9-41c9-80b9-72002976df4d">2,537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctNC0xLTEtMA_9e45962a-7ea1-4519-9a95-a293f3ec83bc">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtMi0xLTEtMA_95d738e4-7e0a-4d31-9830-d4e80d439dcd">4,744</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtNC0xLTEtMA_34f1ecd6-4611-416e-8c7a-f43f856fa8c6">4,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktMi0xLTEtMA_66224ce2-ec14-46e0-8bac-0f77c996c04f">158,818</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktNC0xLTEtMA_0aa1ccba-a043-4727-9334-6f26c16d0195">154,229</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzc3_209a44f0-bff7-4d61-8fce-81334abd5757">3,676</ix:nonFraction>; 2020&#8212;$<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzg2_051458c7-1e4a-41f9-b88b-d469a1301929">2,002</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMi0xLTEtMA_1f272255-31e2-48fc-b08f-290921eb77e3">4,352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItNC0xLTEtMA_88681e3e-690f-437d-825c-c2d4d1e04de4">2,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtMi0xLTEtMA_0722fceb-c9bc-434f-8668-3f0787b0b561">4,064</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtNC0xLTEtMA_731b2735-2a61-4935-89e3-d103124892aa">4,309</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtMi0xLTEtMA_b8f8f76a-46da-4a66-833a-1b045c22c618">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtNC0xLTEtMA_3bea0501-6eb0-4aac-b385-01a868de15a9">2,162</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtMi0xLTEtMA_ba2b86c8-d641-4897-9e3c-2aaa4371567a">1,401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtNC0xLTEtMA_6bafe616-32c9-4a2d-95dd-a190a54060a4">1,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtMi0xLTEtMA_8b601138-908d-4dbf-a205-7239762d4e56">1,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtNC0xLTEtMA_b0592247-8aba-446c-8912-b02f034e61b5">3,058</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMTI2MzA_c91d6654-9dd8-4c99-9396-fb2f34f619b5">2,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMTI2MzQ_aec0376d-dcc4-4187-a724-eadfd26cfa6b">1,113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMA_5c40c5d8-9bc6-4735-95f0-7d3328bc15be">12,798</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMA_a6774203-968a-4f04-ab53-27e9fab2bae8">11,527</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktMi0xLTEtMA_b0298880-5183-4a00-b0a4-5b1b07893b08">26,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktNC0xLTEtMA_230e2d0e-5fd2-4196-84f4-87e6b43b1a93">25,920</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtMi0xLTEtMA_edc917e8-d303-4298-a1ff-0c05ef9ce044">35,347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtNC0xLTEtMA_e7f1b6bc-818e-4c0d-bc9b-fe02a10ab80c">37,133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItMi0xLTEtMA_9bda7105-004b-4ad9-b67c-7f36661c8dfc">4,526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItNC0xLTEtMA_11cefec6-2605-4e1f-b0ce-910df4f36339">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtMi0xLTEtMA_f13fc6a8-7051-4d58-8257-a340ba70a084">635</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtNC0xLTEtMA_ec6315ef-4f3a-43f3-9da5-5479db3e32af">645</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtMi0xLTEtMA_134ee9af-92a8-4ebd-a3c7-8a2a0590f363">4,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtNC0xLTEtMA_e9398da8-8afb-42f0-8db8-8662dff89240">4,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtMi0xLTEtMA_a51b83b9-1421-457f-99d8-df7db3d38cc3">11,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtNC0xLTEtMA_cebcbfc5-d6ba-4873-8dd2-4db96c7e6c75">11,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtMi0xLTEtMA_614b2251-30ad-4608-9fd5-fac9be199afc">6,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtNC0xLTEtMA_a00e8651-5626-4f21-8d6e-02167648a446">6,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctMi0xLTEtMA_a65bd4ba-1820-4b22-abc8-5d7f3f3d1e2a">89,953</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctNC0xLTEtMA_7ab205c7-c38b-48d1-a711-c7eb0d55ca7a">90,756</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktMi0xLTEtMA_db66f237-38ba-41f8-afba-81484e69caa0"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktNC0xLTEtMA_e16b226d-65da-4e2e-a89a-5550600d098f"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItMi0xLTEtMA_65002b14-afa2-4cd3-aa13-a4adc4c9010c">472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItNC0xLTEtMA_079a2b96-79f3-4ebd-b3d5-80ea09bfbd9c">470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtMi0xLTEtMA_7b19a4a2-fed5-4b91-9292-4493e7679b22">89,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtNC0xLTEtMA_78b4f964-01a2-46c1-a807-92a9a119244f">88,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtMi0xLTEtMA_88c35372-b1b7-4891-955c-27b937077475">111,349</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtNC0xLTEtMA_d6ac26b6-92e4-44e5-bdb3-cb7c3f43a309">110,988</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtMi0xLTEtMA_4230f24a-8374-427f-871b-86020d61874e">95,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtNC0xLTEtMA_6e45a608-125b-446f-9410-ffed17eef45e">90,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctMi0xLTEtMA_82d67c83-f36b-4492-af61-5ad383337bed">4,664</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctNC0xLTEtMA_2a43c97a-bec1-453d-8e24-b4c3002d34a5">5,310</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pfizer Inc. shareholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtMi0xLTEtMA_0e2008fb-9408-43fe-a6ee-d9a7b65a466f">68,620</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtNC0xLTEtMA_887d4715-307b-4df0-9abf-a8a4ffea4cc0">63,238</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktMi0xLTEtMA_fae1e498-49c0-4e4d-9881-5320e27def8a">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktNC0xLTEtMA_5b9a1299-e345-4667-9c4b-a51bc6d78143">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtMi0xLTEtMA_f83933a8-7029-4e83-af83-a7b500489083">68,865</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtNC0xLTEtMA_7b05c05d-5019-425a-beac-7115e3f28c02">63,473</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtMi0xLTEtMA_c29302e6-1b07-4403-9902-b837be498a6b">158,818</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtNC0xLTEtMA_0e7ded34-07fd-4b5e-ace4-42244a13ce42">154,229</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:65pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:23.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="75" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:23.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="57" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Stated Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, January&#160;1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad96abb481364caa9a72671a1c67d82f_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yLTEtMS0w_f15b5774-2bbe-4a35-b407-84d721ea8e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad96abb481364caa9a72671a1c67d82f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy00LTEtMS0w_5bdb67ae-50cf-43ea-b010-7d1a289ccdd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68a5c0cb0954eccb168987e68a66426_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy02LTEtMS0w_2c9b6c1e-66ca-4973-aae4-0b8f2a158e19">9,407</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68a5c0cb0954eccb168987e68a66426_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy04LTEtMS0w_cc8431de-fb76-457f-a4cb-d55ffc25a74e">470</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8432d19709754d54aa8831d0e0b91a10_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMC0xLTEtMA_e702f24d-6dcd-4075-a74c-2f27e22a157f">88,674</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMi0xLTEtMA_b1b3407d-0c3e-4277-bcb9-cdc0fa1e3703">3,840</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNC0xLTEtMA_a2ef4872-ef20-45e1-a359-0b47f3ec1d64">110,988</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e941de2442495c8df2676e0be6391b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNi0xLTEtMA_daad96ed-65cc-42c3-9fbf-84f58baf8e68">90,392</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dea6398b1c4543b9115d73e959887b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xOC0xLTEtMA_b8b06f10-4b5f-4c60-a268-4976ac867c38">5,310</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e4e86836694234959a3a15070601ef_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMC0xLTEtMA_c29b4cc5-b0ba-4dd5-9bb6-70c93f80cbae">63,238</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670092d056fe431492c1724b7d5cfb67_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMi0xLTEtMA_abcdce4a-ae84-4989-abbb-4b8a8b62b387">235</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yNC0xLTEtMA_3cd68fd2-561f-47b1-b3d9-bab9234fa77a">63,473</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0xNi0xLTEtMA_0961e0ea-cc17-46aa-aae0-9845bd2a2d60">4,877</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMC0xLTEtMA_69bf811c-445d-4be6-8b44-dd7f1672f72d">4,877</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMi0xLTEtMA_93827e26-b2a6-4807-8468-95af0ad762c9">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yNC0xLTEtMA_61233e8c-0c58-4e6e-87d1-44969d11da6a">4,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0xOC0xLTEtMA_f0afb907-4c72-4938-8b45-cb84cb709efc">646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMC0xLTEtMA_47055b71-5341-404d-814d-45444679060b">646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMi0xLTEtMA_db94dd9c-420a-48da-9858-5b7bd1800777">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yNC0xLTEtMA_16e952a4-7089-43a1-a496-9a4802a487c3">647</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0wLTEtMS02MTU5L3RleHRyZWdpb246M2UwODhkZjU1MWYyNDQyOTlhYzdhY2EzNDM0OTkxZGNfMjc0ODc3OTA2OTQ2OQ_3be1813e-7605-4f06-aa0d-cf642672cbcd">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0xNi0xLTEtMA_39e8a983-43a7-4559-9481-205398d4064f">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yMC0xLTEtMA_9a168129-f87f-4358-b323-bbb1de338a2f">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yNC0xLTEtMA_728c4207-5710-494f-8ce3-d22a59243b2c">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOC0yNC0xLTEtMA_4133dd05-252b-478e-9495-388f0b591ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOS0yNC0xLTEtMA_2c658a56-8aba-4885-803d-c84f6ec06c59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtNi0xLTEtMA_fc5b028a-04da-4a91-839b-f47ac7553c40">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtOC0xLTEtMA_3e972744-97a3-4993-8e3f-20b80e7dd284">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTAtMS0xLTA_a8317233-11a6-4b1f-9f07-a6be958c517b">329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTItMS0xLTA_fd37cea9-1831-4e27-acc4-54057dd69ccd">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTQtMS0xLTA_236f3c9c-9ce3-4f74-99ff-30211da83255">361</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjAtMS0xLTA_01ac7a3e-4540-4d20-895e-487262adeebd">30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjQtMS0xLTA_4486d61e-0dbb-42c1-86aa-e8b877e8b696">30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTEtMjQtMS0xLTA_319c9084-e7e9-4c50-92e3-56d4777e5211">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTItMjQtMS0xLTA_5fa61122-2cc1-40ba-9376-efd72a449702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMTYtMS0xLTA_ecfa475f-bb12-48e8-b2d7-9e56d3c97f0c">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjAtMS0xLTA_e715b706-a35d-4e4d-aa0c-bc8b28e6c777">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjQtMS0xLTA_e94ee728-56ce-4eae-8be7-bedc3b1831fa">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404" decimals="0" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMi0xLTEtMA_d60df586-5b6b-41ac-8636-93ea0a5aa7e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNC0xLTEtMA_45d53a65-712f-4e75-989e-7f41aa7ee8d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8cc8f792ccf4742a85390af1b808b26_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNi0xLTEtMA_e8f99745-96de-4f72-83c6-b88ba54f6355">9,445</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cc8f792ccf4742a85390af1b808b26_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtOC0xLTEtMA_6b7f1174-4c8a-4544-ac3a-10c3acb39c55">472</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98424f39a64dedb002aa58aa06d599_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTAtMS0xLTA_7b640c08-a265-4d93-9431-97f035b66c70">89,002</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icc01d70f4491494899c4a1be59cde841_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTItMS0xLTA_2af89896-69d5-48e1-b246-5214b7d256e7">3,851</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc01d70f4491494899c4a1be59cde841_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTQtMS0xLTA_9fc2fb48-94c7-484c-879f-f3304f046ca9">111,349</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTYtMS0xLTA_9ba829a1-53b0-4250-b71b-14e86d585468">95,158</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ffb761b6f624168a62f72e12228bb5a_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTgtMS0xLTA_ac1a2838-a7c4-494f-8ae4-4d8e5c0cded0">4,664</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298e3f59dab144afadd3175e4b2e4702_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjAtMS0xLTA_648f9162-821f-4b23-83a5-65df4a0f36e8">68,620</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba782e27bc644768676d5050e11dd16_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjItMS0xLTA_c5214294-ed17-4072-ad98-094cf47c1148">245</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjQtMS0xLTA_6454bd49-d058-4dca-afe1-e874de0f37b5">68,865</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="75" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="57" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Stated Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, January&#160;1, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice7f96cabae24782889c935aac35f1e1_I20191231" decimals="0" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMi0xLTEtMA_c6a8a055-e5b5-4bfc-b3a6-c112bdf6349d">431</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7f96cabae24782889c935aac35f1e1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNC0xLTEtMA_b7016aa1-a5e6-48eb-a7da-f60d7017b423">17</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a8120f033f4276941d48877f9a9489_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNi0xLTEtMA_3356b2d8-681e-4b57-9945-4afef80f577b">9,369</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a8120f033f4276941d48877f9a9489_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktOC0xLTEtMA_5662ebe6-16ad-4b9f-84fd-d80e5bb730a1">468</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if706bef9ba9e4a8087b6638c1a298410_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTAtMS0xLTA_8d726f32-d157-44e8-8f86-c55c3bcddcf4">87,428</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5802b7b756774508be8ac80fe45d2d09_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTItMS0xLTA_33345091-314a-4617-b893-abe085066083">3,835</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5802b7b756774508be8ac80fe45d2d09_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTQtMS0xLTA_d4856369-e06d-4b03-87b7-3a474268a1ca">110,801</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb048b2301e439f88254780ad40d688_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTYtMS0xLTA_4b608b45-0eab-4b68-b744-ae81c451247a">91,397</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice6876e4533642569b2b72a9c6fd043b_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTgtMS0xLTA_0db18202-8771-446a-9b29-04325ba46993">5,367</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9748b402be914193b56e1300e8f8d640_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjAtMS0xLTA_6d224647-ef74-4d1a-a417-34f8d07fdf85">63,143</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ae0369567d42bba15dd6a743487769_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjItMS0xLTA_b783645f-2129-4c16-8a85-15dcb3dddfda">303</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a0a3b5e3a447628cfe527319aaf597_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjQtMS0xLTA_89c9c5a5-c3b3-45cf-8598-8dcd13c5cdb8">63,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f5513825544a8381d81fce8b6348be_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMTYtMS0xLTA_025e2da8-c497-4549-bb23-f27c0b6625c4">3,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjAtMS0xLTA_f67fad01-af63-4898-8cd0-59b774b2e483">3,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00864a6cffcd489689813f7229308d3e_D20200101-20200329" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjItMS0xLTA_dc696168-7e0a-49f5-ac7b-f6968ec66f08">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjQtMS0xLTA_7e3df2d9-a9e8-4d6e-b434-6dd0dd6e5e81">3,364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMTgtMS0xLTA_079d6547-3044-4a5f-86d5-e78a7b828ead">1,441</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjAtMS0xLTA_1b1e8f80-4886-4c48-afe8-60cecc3497cc">1,441</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjQtMS0xLTA_3e71f848-2eaa-48a6-8c00-76ac3326e102">1,441</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjItMC0xLTEtNTE5OC90ZXh0cmVnaW9uOjVlNmIyYWZlY2M0ZTQwYTliYjVhZTQ5NWNkNDM4NDViXzI3NDg3NzkwNjk1MDQ_8b7d4a58-60d4-4dfd-8f3d-1154a4fc5641">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47f5513825544a8381d81fce8b6348be_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMTYtMS0xLTA_da29de7d-12e2-499c-b25f-2bc7ca52bc69">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjAtMS0xLTA_5cb53328-3657-48b0-8381-a6119f808969">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjQtMS0xLTA_f8398f0b-15c3-4a8d-aca1-25304957dd3c">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjQtMjQtMS0xLTA_69dd7e3c-80ce-4b67-a375-ed04e7bca374">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjUtMjQtMS0xLTA_dd04f700-c9e2-48ec-80f2-feed8e4ef29a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtNi0xLTEtMA_c739731f-32fa-4636-854f-7263a9d9fe4e">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtOC0xLTEtMA_7f4b8dbc-8c6a-4314-ba1e-58cc587c3915">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTAtMS0xLTA_513d27a9-6b5a-413a-bcb0-8c2c00b26c09">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4702654caf394c4098db2cd85620b59d_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTItMS0xLTA_357f32f2-70a1-4303-a30a-dadd9a25318c">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4702654caf394c4098db2cd85620b59d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTQtMS0xLTA_c3295571-92f9-4397-97d2-fc6a535da768">209</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjAtMS0xLTA_2fec075d-92b5-41ff-b74e-9f08aa419706">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjQtMS0xLTA_0ddf063a-6bb8-4c9e-9131-f66c2949e313">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjctMjQtMS0xLTA_3bb47f19-e2dd-48de-a953-3b00f26e186d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329" decimals="0" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMi0xLTEtMA_ebc17ad1-cad6-48c6-8e1c-33953cf8ceba">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtNC0xLTEtMA_97f79acc-1105-4d39-9b96-784249f301bf">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMTAtMS0xLTA_c9eb8e23-8c74-420e-bf59-cd9b22074f32">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjAtMS0xLTA_9d52c371-c5f0-4913-aaab-58c0341e1293">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjQtMS0xLTA_eb3a96d1-23ac-483b-8c11-d5d0c24fd469">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjktMjQtMS0xLTA_97352884-c446-420b-a8f1-ab99fdc240df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, March 29, 2020</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329" decimals="0" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMi0xLTEtMA_5767c048-2391-4586-9a33-9462b898f13a">417</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNC0xLTEtMA_07a86f4d-8da3-4d2f-98ea-7eae12b46e5b">17</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNi0xLTEtMA_8c436f94-1f1d-49cc-9b68-b5765b910501">9,393</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtOC0xLTEtMA_a208530c-3305-47fe-b104-d303b837b81a">470</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47b6b8fdd594ac3b929fd46636184eb_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTAtMS0xLTA_2ac8c3b9-7ae5-495b-a574-1c9f01b434cf">87,680</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i98cea540ef86451da18644ee8a6e2767_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTItMS0xLTA_83be8de5-0406-45b6-8c2d-a382ffa27844">3,841</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98cea540ef86451da18644ee8a6e2767_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTQtMS0xLTA_9ba2660a-3af9-4aec-8a48-b484cdfe0e70">111,010</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5d25c9530040899006db8fed3c6271_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTYtMS0xLTA_3dc36453-8c6a-449b-a6f5-c9ffc3ba2630">94,680</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i887f2cb651164ba79b51cf28563d8588_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTgtMS0xLTA_373ed0f1-e737-4928-b845-1cdba1102087">6,808</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjAtMS0xLTA_227e91fd-7b8d-447c-ae13-5ddfb0a9c3ac">65,028</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5affdf158b6444899bba4d555d785d25_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjItMS0xLTA_1ecc22cd-f50c-47a8-a836-6730a8a5dd45">312</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793a6170d7114594b0f7282bca5807aa_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjQtMS0xLTA_6e58f181-01e0-4b5d-9a2f-e410096c3fcb">65,341</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:220pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_34"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy0yLTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy00LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from discontinued operations&#8212;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC0yLTEtMS00NDcz_db0ebba8-3fd7-4565-aaf5-efe9613f3091">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC00LTEtMS00NDcz_eae0c9bd-0a1a-4f1b-bf43-0c8e939219d3">881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS00NDcz_9f5eb126-01e0-443f-9fff-ae69f589e878">4,877</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS00NDcz_a60fe1c1-dafe-455a-a520-26ef02e167ac">2,483</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS0w_34ad4ab7-792f-4752-adb5-034667c57e29">1,226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS0w_695b90c5-9d58-47d5-b3e4-bae522498a38">1,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi0yLTEtMS0w_d7dc09db-217e-4b6e-b603-cee16c9570df">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi00LTEtMS0w_23412bf2-68a9-4c64-84f6-43d604ff0e94">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC0yLTEtMS0w_e104219f-58b6-4444-ad17-1af7f79179f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC00LTEtMS0w_99778cad-166c-4c54-a6db-d05c20a7f8e3">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS0yLTEtMS0w_1ea33e6c-7708-4c00-b5c9-2651169adf48">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS00LTEtMS0w_015e7392-390f-48a2-9831-f50f2622e334">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtMi0xLTEtMA_0ce0c4e8-66fc-4968-b02d-2a3a6aaeb69a">172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtNC0xLTEtMA_1519ce42-fb9a-48fa-a911-af267d85844d">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItMi0xLTEtMA_edcd0655-8b98-45b0-8ca0-4b6e06b18860">373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItNC0xLTEtMA_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d">276</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtMi0xLTEtMA_c019a12f-677f-4dd9-a0e1-1075c720183d">291</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtNC0xLTEtMA_758f03c3-70a8-4ae2-87c6-06d28099658e">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtMi0xLTEtMA_254eaf9d-75cc-4d2a-94f0-9db515048fc1">1,327</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtNC0xLTEtMA_f5f3a07c-f5eb-411d-b598-f1955722f297">1,515</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctMi0xLTEtNDQ4NA_ef040139-1c85-4172-9204-607523073595">4,530</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctNC0xLTEtNDQ4NA_56e3c096-4efc-422f-974e-650c16500ee4">2,155</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtNDQ4NA_b8e3494b-7584-4888-bfc3-9c002c0c3d6d">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtNDQ4NA_b21a14af-601d-4969-9838-eeb52caf8fb2">978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtMi0xLTEtMA_286dd32f-26fa-448e-8474-34202419f304">4,538</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtNC0xLTEtMA_a93cf4af-9457-4e58-9cce-f3e856e8abc8">3,133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtMA_de34efc3-eeaf-4416-91be-8e23366b2159">554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtMA_31319a43-4f88-47ab-889f-8c23f765d55b">449</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktMi0xLTEtMA_d6be0354-08ef-4ff3-847a-7907999762e1">6,054</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktNC0xLTEtMA_f9e00c31-5988-4158-9235-c70146f75c4b">2,551</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtMi0xLTEtMA_37d1fac3-fa92-47d0-9417-1352578091f1">5,465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtNC0xLTEtMA_1074effd-4f49-4eea-b467-a70533f5326a">3,257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtMi0xLTEtMA_7dcaa28d-bf38-4289-95d2-58d1ea2bbdaf">996</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtNC0xLTEtMA_d21bc066-280e-4cd6-9507-e7302d7f51f1">416</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItMi0xLTEtMA_cbb2f89d-1b3a-41b5-9946-15af486ba36c">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItNC0xLTEtMA_d16636c3-1549-4500-bf15-e194652780bc">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtMi0xLTEtMA_81773875-5156-4561-b878-9b3eb4e95f20">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtNC0xLTEtMA_2acb95d2-60e3-4c87-8d5b-050e665645df">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctMi0xLTEtMA_711cdfd0-132d-42a6-bca3-50885ca83911">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctNC0xLTEtMA_2fc77c15-9e2e-47f6-995f-fb1ebe9a2797">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtNDQ5MA_aa468a25-1dfb-4b04-8e1a-48b80697b71e">1,747</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtNDQ5MA_cee2d8ba-0fdd-4af1-ab4a-330447e93035">53</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtNDQ5MA_668d7fa5-3dd6-4257-9cb5-e09563b47e82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtNDQ5MA_b75e3fdb-83e8-4807-ae37-4aa185fa9e33">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtMi0xLTEtMA_14cd609a-2135-45e4-b235-5b721bad35fd">1,747</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtNC0xLTEtMA_8e2b1d2b-38c8-47ad-9d9e-e73c42e35568">71</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtMA_00eaef87-7032-4eee-9cc8-e2ab901bddb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtMA_14130354-dbe7-4d76-aa8b-fd709264e90d">5,302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Principal payments on short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtMA_19b32bfb-855f-4cad-ae5c-314dca61eb5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtMA_f3d452a9-a292-471c-80e7-e574a6db0ac4">7,551</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtMi0xLTEtMA_85d37f78-e030-4f24-96b4-73c5312d98a8">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtNC0xLTEtMA_e4f4931d-7e64-44d3-8052-8c5e831be111">3,207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtMi0xLTEtMA_ab96f559-9a8b-4f9b-80da-679699f1702c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtNC0xLTEtMA_84ce470d-0aa9-454c-8550-4acdfac719e3">1,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtMi0xLTEtMA_4b2f0fc7-cb53-489c-9a38-97d0e2aef4b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtNC0xLTEtMA_21bf8e65-fb29-4351-9681-6b77ec19f66d">2,181</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctMi0xLTEtMA_e83cf0c2-292e-406b-9257-2c1125e6c4cd">2,172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctNC0xLTEtMA_17c5bd85-e12d-4c6f-a1c3-383fb2539528">2,105</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktMi0xLTEtMA_9c0ea444-d93f-48ad-8cf5-e25baff85eb0">610</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktNC0xLTEtMA_7fbc7f61-35c2-4aa8-85ac-fa0d4a6cde47">113</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtMi0xLTEtNDQ5NA_5d1f84e9-247f-4848-8abb-cc0768a30c1e">2,807</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtNC0xLTEtNDQ5NA_d1c3d278-edbe-4e39-af3e-3c8c5ff971a5">2,200</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtMi0xLTEtMA_186b0d02-4fa1-462d-a084-7b0809883da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtNC0xLTEtMA_367ae77c-36c2-494f-91f7-39e03656449b">15</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItMi0xLTEtMA_d6a6733a-22c7-4acd-93b8-3385c85a022b">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItNC0xLTEtMA_23381d8f-4fd7-4bbb-aea8-ec623bef4777">846</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtMi0xLTEtMA_1b02424a-10a0-41fd-8e99-9d4348c3047a">1,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a0a3b5e3a447628cfe527319aaf597_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtNC0xLTEtMA_fc2e07f8-9b12-4a61-85aa-579a99fee24b">1,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtMi0xLTEtMA_663c02cc-3e50-43e2-8c44-d3a29be0f409">1,809</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793a6170d7114594b0f7282bca5807aa_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtNC0xLTEtMA_702d2f60-010b-4e95-bbea-f4335925ea0b">2,196</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid (received) during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtMi0xLTEtMA_0f7d9b37-4660-466e-bf27-3bd56ef85f2b">394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtNC0xLTEtMA_91bf8f47-9ad1-4b3a-bde5-0fbdeaaf02fb">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtMi0xLTEtMA_b4a37513-5a1b-4633-9d3b-968102b80d74">445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtNC0xLTEtMA_28de0820-c712-4149-a66f-ded950d90766">472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtMi0xLTEtMA_1579cb8d-5f64-4f33-946f-198a6b8fbffe">10</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtNC0xLTEtMA_9089d041-6a7b-4819-8321-6ec658f7caac">11</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:55pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_40"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI4OA_7c0851ba-5089-4c21-a853-242939e447c1" continuedAt="ib3723758b8994aceb4d340618f1c68e0" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib3723758b8994aceb4d340618f1c68e0" continuedAt="i88d8fcc7580a4ae49041cf57a1a51c41"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODMyOQ_34978c98-23a9-425f-9f9c-53aa2eeca2ec" continuedAt="i0637b0f1d044423f8d74a8b68b0ed6cb" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0637b0f1d044423f8d74a8b68b0ed6cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;28, 2021 and February&#160;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&#160;4, 2021 and March&#160;29, 2020.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer&#8217;s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&#160;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5MA_51711fb1-8391-4988-80de-12acbb9be2f5" continuedAt="i9019764cae164c92b64ff81581425894" escape="true">New Accounting Standard Adopted in 2021</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9019764cae164c92b64ff81581425894">On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards adopted in 2020, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MTE_a89d8a41-6dbb-450d-aa96-e9dced05fd39" continuedAt="i0ab475c025b942e5938ec60dcf1886cc" escape="true">Change in Accounting Principle</ix:nonNumeric></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><ix:continuation id="i0ab475c025b942e5938ec60dcf1886cc" continuedAt="i160d33e6413a4e0e9fe553522d091fa5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (&#8220;MTM Accounting&#8221;).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a &#8220;corridor&#8221; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $<ix:nonFraction unitRef="usd" contextRef="i08a420875e0f49f2a79116b4b03bde63_I20200101" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_8d8646ae-fc98-4927-ba4f-f3ce611419fe"><ix:nonFraction unitRef="usd" contextRef="i08a420875e0f49f2a79116b4b03bde63_I20200101" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_b5653272-8d5e-475f-8b89-bcb9f92e8b72">6.3</ix:nonFraction></ix:nonFraction> billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i160d33e6413a4e0e9fe553522d091fa5">We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.</ix:continuation> </span></div></ix:continuation><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MDg_f4c2e5d0-778e-400f-b8f7-6294c682241c" continuedAt="i04f781aa708044f586fbcb2fe2243a21" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i88d8fcc7580a4ae49041cf57a1a51c41" continuedAt="i7564010e48f64a6192cc4e60d4d48666"><div style="margin-bottom:6pt"><ix:continuation id="i04f781aa708044f586fbcb2fe2243a21"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March&#160;29, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0yLTEtMS04Mzgw_5dab9db7-896e-45aa-9206-7c49d1af0780">857</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi00LTEtMS0xMzY0NQ_7d7bf6e3-9d1e-4ce8-a958-5bce4bf08fa1">146</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMy02LTEtMS04MDk5_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi04LTEtMS0xMzY1MA_df171ed0-a427-4ded-bebc-0eda237e083f">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMC0xLTEtMTM2NTA_290ce6ad-87b8-4fc4-8de6-a5a9e14dd406">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0xMi0xLTEtOTA5MQ_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0yLTEtMS04Mzgw_e48a94ef-3c74-43df-a6ec-74c11d480af3">5,536</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy00LTEtMS0xMzY0NQ_a8ef75f5-edf8-4550-9597-bc0d57d4e3a3">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MjQ1_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf">5,683</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy04LTEtMS0xMzY1MA_7bc427cd-1e98-4118-8ebc-ebda5b056bce">2,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMC0xLTEtMTM2NTA_6498ecf2-43bd-4a7c-b8d3-132873239af4">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0xMi0xLTEtOTA5MQ_82638985-d87e-4d19-83f9-35ac23cb0316">2,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0yLTEtMS04Mzgw_bf39697a-ced1-4cef-a87f-0ef7d577b507">773</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC00LTEtMS0xMzY0NQ_91f42c4a-b118-425e-a118-49661bbe9013">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTIz_d6a31f7c-a51a-4074-9737-47e32947c8ef">805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC04LTEtMS0xMzY1MA_b671c90a-7b41-4de4-952b-8b4e22f66f3b">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC0xMC0xLTEtMTM2NTA_619c9ad4-3594-4c13-bcd7-a50bfc755e25">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMi0xLTEtOTA5MQ_b8472e14-0a68-41d2-9348-eb9d50c460a3">359</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS0xMzY0Nw_40fb72b7-01fb-4639-9985-27120145fa82">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS00LTEtMS0xMzY0NQ_503d730e-7a31-4067-b994-fb2a89171a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS0xMDA3NQ_33b79d80-57b2-425b-8cb8-a4c3b19b5192">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS04LTEtMS0xMDA4MQ_b9590803-6217-4104-ba79-b2089aadc9c5">948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMC0xLTEtMTM2NTA_50ef09c5-cdcb-4ecf-b9b4-cb0986406850">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtMTAwNzc_11166465-dd3c-4aba-b037-16fb7e609c74">881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtMTQzNTE_bea51b29-8111-4693-b1aa-5b9bc281e279">4,772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTQzNTE_febdf589-16a3-4c4c-9c2f-17b673119d9a">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNi0xLTEtMTQzNTE_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTQzNTE_60a41266-7cca-41c6-833b-5490bce7025c">3,410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTE0MzUx_f956ef5d-dc46-48a7-bb24-d0ed6e9e0bfa">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTE0MzUx_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0yLTEtMS04Mzgw_0c1b6c6e-9152-4d26-8b67-d67e50e3405a">4,763</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTM2NDU_0b27c47c-1205-4de7-91f2-d04fcbe905b3">114</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTEx_f7319f6b-201b-4644-bf83-f647ec7dbf11">4,877</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTM2NTA_7db8681e-dd60-4c10-8768-1770b685b5d1">3,401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTEzNjUw_4d3fa8b0-43a6-4d4c-ba02-b3284b5a0e9e">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMi0xLTEtOTA5MQ_3ad21e9d-4916-46a3-be5d-5e9916f84c40">3,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMi0xLTEtMTM2NTY_dd252889-722e-41a7-b004-5bf407174997">0.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNC0xLTEtMTMwMzk_cf92f801-dc9a-40d4-ae7e-13049bbab2b5">0.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtMTMwMjc_75b7133b-7b8d-4749-ae65-9eca8dc2ec41">0.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtOC0xLTEtMTM2NjA_10696dfa-6602-4c40-86e5-0173ffcb7613">0.44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTAtMS0xLTEzNjYw_8acfb86a-4096-4c78-91a5-50d287916db8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTItMS0xLTEzMDM3_0ad41313-4c51-4bb7-b815-6df61bc17314">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtMTM2NTY_cf7e27dc-81b6-4b81-9fda-96598e7bd1c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNC0xLTEtMTM2NTg_9bec4602-b014-4973-8ae0-a7963bf61707">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtMTMwMjc_f1d431d7-e33e-49e8-81e9-b399c079757d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtOC0xLTEtMTM2NjA_faa2854b-bdd9-475d-bf3b-b4bdf09e371c">0.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTAtMS0xLTEzNjYw_56375208-0799-443c-aee5-1d674b1fc69b">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTEzMDM3_b38d95a7-f497-451a-a668-541c33faf446">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtMTM2NTY_b75242d4-1f87-447a-b122-4271dc2d6b71">0.85</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNC0xLTEtMTM2NTg_6ac6f350-2dee-4a59-9ee9-d1bae43c1c92">0.02</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtMTMwMjc_5fae1b27-b998-4f4d-8b17-ea0c71804d2a">0.87</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtOC0xLTEtMTM2NjA_b0739781-3f08-472a-979f-063c3af35045">0.61</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTAtMS0xLTEzNjYw_b57f8d60-aca4-49f7-bf38-ff4da8772b68">0.01</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTEzMDM3_a85c270d-3dd9-4d4f-b87a-b672be7959e3">0.60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtMTM2NTY_024eddc5-7310-4864-bc99-77d30ca454e9">0.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNC0xLTEtMTM2NTg_b684e132-229f-4f14-a5f4-97c04e607c1a">0.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNi0xLTEtMTMwMzA_83a08fc6-5a94-455d-bd21-674b27a0506a">0.86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctOC0xLTEtMTM2NjA_1cf40a4b-3b3e-4dfe-88e8-486a56555a24">0.44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTAtMS0xLTEzNjYw_75395125-4049-48de-8e1f-0fd8c70cd47c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTEzMDM0_20550d10-89e1-4fac-81dd-154718ea283b">0.44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS04Mzgw_eba685e9-b01a-4551-9a99-5b2383bb1cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtNC0xLTEtMTMwMzg_7026c5b1-319d-455a-84a6-39a41ec3ad9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC02LTEtMS04MTUz_eb0b828b-e1f2-42da-a9cd-00ad72d78436">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtOC0xLTEtMTM2NjA_e19a9d50-cc92-4ecf-b30b-1ed14e4c8437">0.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtMTAtMS0xLTEzNjYw_ebf0a702-3ed3-4237-ae41-eba838c5e96b">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtOTA5Mw_d533696a-7d6b-4c6b-9843-f64b3d7d9d23">0.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtODM4MA_873d32a7-5d8e-4595-a4e9-e8030fd1fe90">0.84</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktNC0xLTEtMTM2NTg_3011635b-90ef-4123-88f3-76cc6dcfb9ac">0.02</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS04MTU1_ccebed80-aeef-40fa-bade-64f59e94c84c">0.86</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktOC0xLTEtMTM2NjA_6ecf4906-1f34-45f2-ab90-f4ecf2e8fcaa">0.61</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktMTAtMS0xLTEzNjYw_dfb2cff6-b945-404d-824f-47a2312548dc">0.01</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTkwOTM_f11106ea-d63e-4bab-9b51-2cebf2989dd4">0.60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMi0xLTEtMTU4MDk_eefdbbbd-57fb-4a19-8c8a-c11af8925fce">546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTU4MDk_0c0e1e51-cd54-4302-8daf-987ba94ec250">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNi0xLTEtMTU4MTY_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa">465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTU4MTM_77c0e017-f41e-4d3f-9c54-d9bf4a5ce366">1,272</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTE1ODEz_603f9712-c0b0-4899-b620-e38c481e5062">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTItMS0xLTE1ODIw_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0">1,256</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtODM4MA_de328a85-7e0f-4afc-85cb-15d114ee2b67">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTM2OTE_a40fb0df-3563-45e9-bb7b-18dae25c2bd3">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtODIzMg_81d619e1-c56d-478c-b00b-bdc4762e66f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTM2OTY_745045e0-c575-4b24-a178-77c6c2ac9899">166</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTEzNjk2_427f4c5c-74fd-4816-a36f-0910e6646fd0">166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTkwOTU_389a2d98-d4bb-4be1-97a0-f30099054ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtODM4MA_9e04eeed-0457-4cbb-a75f-75cf0b254aca">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtNC0xLTEtMTM2OTE_afd5b122-b05c-40fb-8811-de18bd289523">75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtODIzMg_4a588c90-bf2b-4bef-b074-79334b894fe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTM2OTY_52d203a0-c548-4ff5-bca5-ef526a9c5c18">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtMTAtMS0xLTEzNjk2_f50e3500-d5c6-49f4-8343-30d40ecb4aa6">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTkwOTU_d9022c32-4db1-4663-9ed6-349f6053ba28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMi0xLTEtODM4MA_0615b6b9-0251-462d-b18d-ad111b73de5e">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtNC0xLTEtMTM2OTE_2f67ec5d-2bb2-4000-bce3-d4ef5a5f9965">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtODIzMg_5c0bc19b-ae84-42a7-8525-fc30229df49b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtOC0xLTEtMTM2OTY_cdea3887-3b40-4a4c-998a-7a76af9c9849">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtMTAtMS0xLTEzNjk2_c2856c32-007b-46f3-9699-8026854ba23c">53</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMTItMS0xLTkwOTU_949ddb31-8811-4e31-8486-1b69301fc736">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtODM4MA_7bd874d7-b0f4-4fa2-adcc-94e8be7978bd">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtNC0xLTEtMTM2OTE_80e0b940-3c87-4375-b482-98b0518375f1">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtNi0xLTEtODIzMg_f033076b-0c76-40f6-aedf-91081fdd6f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtOC0xLTEtMTM2OTY_02210909-814b-43d2-8924-3d62f632f8e4">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtMTAtMS0xLTEzNjk2_7d5c1ece-b94a-438e-85e7-3455a0f7ea89">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTkwOTU_7a22fba8-c4d4-4a44-8281-048374465961">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMi0xLTEtMTQzMDE_9695b009-4fc3-45da-9da3-bc7a84205173">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNC0xLTEtMTU3Njg_e1558817-8454-4bae-aa69-59e1530a38b3">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNi0xLTEtMTQyOTQ_491a1642-d58b-44cc-b6f4-9543a582ef04">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctOC0xLTEtMTQ4Nzg_03de7da4-0a2b-4cab-b71e-126614e429bf">377</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTAtMS0xLTE1Nzcz_cfbfa4ff-c663-4a8f-9afb-19b529c18a75">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTItMS0xLTE0Mjk2_5951f2d0-71ca-4d8f-8b42-a45bbaf37291">380</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMi0xLTEtMTU3Mzc_2c929d65-b71f-4fe9-99b6-afe42c66f26c">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTU3ODM_db8c6e57-8d93-4e2c-a589-4144ac80c1f5">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNi0xLTEtMTU3MjU_1ea33e6c-7708-4c00-b5c9-2651169adf48">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtOC0xLTEtMTU3MzM_dcb6064e-e710-4aef-a49b-e4f40320434b">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTE1Nzc4_b591beb4-892e-4a2b-bd5e-69490e66f533">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTE1NzI3_015e7392-390f-48a2-9831-f50f2622e334">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjItMi0xLTEtODM4MA_d6eddeb4-ee9f-472b-b46c-eeb23caa351d">226</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTM3MDA_1a61d7a0-6036-41d3-a40a-20bace06b0f0">146</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtNi0xLTEtODMyNg_edcd0655-8b98-45b0-8ca0-4b6e06b18860">373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTE3OTA_1195e993-5355-4c17-bdb8-924f7fd2ec3a">250</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTEzNzA0_0967c9ea-066b-471b-aa7b-63ca44b58b13">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjEtMTItMS0xLTkwOTc_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d">276</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMi0xLTEtMTUwODY_fecb5532-694a-404d-b182-bfb4904dd5ff">2,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" sign="-" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNC0xLTEtMTU3ODQ_8e8dc98a-b221-4645-9679-36b98609d7d5">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtMTUwNzY_58e3aa1e-50c9-41c9-80b9-72002976df4d">2,537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTUwODI_f1ca5888-a423-4d2c-92e4-38871f63c28f">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtMTAtMS0xLTE1Nzkz_26138068-b065-4e93-8fcb-be140261e21f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTItMS0xLTE1MDc5_9e45962a-7ea1-4519-9a95-a293f3ec83bc">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMi0xLTEtMjA2NTc_3e3274a3-c7d7-4cb0-ad0e-d5c9ae4e82b1">4,738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMjA2NjA_e3e8f388-f2f5-4549-936a-34e87d2ef190">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNi0xLTEtMjA2NDk_95d738e4-7e0a-4d31-9830-d4e80d439dcd">4,744</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMjA2Njk_1f2be8d9-b433-4c15-8449-0f9a0b9084ad">4,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTIwNjY5_64d51ccc-b643-4ace-a1b2-71925d5248d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTItMS0xLTIwNjUx_34f1ecd6-4611-416e-8c7a-f43f856fa8c6">4,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjktMi0xLTEtODM4NA_ee06e3a6-6bfa-4c3a-b9be-cc419eba2c2b">4,527</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNC0xLTEtMTM3MTM_048ac843-d653-4e16-8db9-34362ec2884e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzUtNi0xLTEtODI2Mg_9bda7105-004b-4ad9-b67c-7f36661c8dfc">4,526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTM3MTU_6b7e7465-0ceb-4a47-8405-4438d1bb4fa7">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTAtMS0xLTEzNzE1_8e59d7b3-ce77-44f3-950d-e8264ed2d972">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtMTItMS0xLTkwOTk_11cefec6-2605-4e1f-b0ce-910df4f36339">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMi0xLTEtODM4NA_d602c50f-ca60-4269-9ee4-f718b8b15d5c">95,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktNC0xLTEtMTM3MTM_d473b86e-5f9f-4c12-9df6-2d00930fe30b">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtODI3Ng_4230f24a-8374-427f-871b-86020d61874e">95,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktOC0xLTEtMTM3MTU_7580f644-c600-4231-bbd3-e67bb4574450">96,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktMTAtMS0xLTEzNzE1_dc6788e4-94b9-4e5f-86cb-bbded14c4a5c">6,378</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTkwOTk_6e45a608-125b-446f-9410-ffed17eef45e">90,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzItMi0xLTEtODM4NA_cfcd4507-2a87-4f30-81ff-c6b3f0f5e239">4,523</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMTM3MTM_9b5943fb-9452-427b-a756-7fadf972440c">141</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNi0xLTEtODI5OQ_82d67c83-f36b-4492-af61-5ad383337bed">4,664</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMTM3MTU_cb7dfdf0-f063-4d27-9bd8-81cd8a433119">11,688</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTEzNzE1_f27e39b6-6fd4-4442-a088-4f4e5d199fd9">6,378</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMTItMS0xLTkwOTk_2a43c97a-bec1-453d-8e24-b4c3002d34a5">5,310</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODM0OA_9a96f313-1767-408b-89f4-03bdd57e4dca" continuedAt="ida8a45f5e65d4d719fcfc03aed87d430" escape="true">Revenues and Trade Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="ida8a45f5e65d4d719fcfc03aed87d430" continuedAt="ie90f112fb2804faa8bbdef53a711a49e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7564010e48f64a6192cc4e60d4d48666"><ix:continuation id="ie90f112fb2804faa8bbdef53a711a49e"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5OA_91d136b2-f031-4290-a0c7-e9628c53eb7e" continuedAt="i8e52cc7958844a799b3faa5d251a37e7" escape="true">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><ix:continuation id="i8e52cc7958844a799b3faa5d251a37e7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fcec41f64847ed86b1c89a56896531_I20210404" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS0yLTEtMS0w_68aef472-330b-488e-b305-ffab9c991fd7">848</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a2b9079bc742749949e93c782f4af9_I20201231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS00LTEtMS0w_057c355f-e8b7-4712-aafe-bbf71bd1383e">861</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:AccruedRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy0yLTEtMS0w_97f6047f-ac20-4623-b409-c7cb97449d91">3,211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:AccruedRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy00LTEtMS0w_75640e3b-54fa-470c-8100-fc6da00652f2">3,017</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC0yLTEtMS0w_8cfb899d-1e89-4ce7-a0e3-21dec094bbc3">449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC00LTEtMS0w_9440259a-8bf7-49e8-92f5-2b0c96f6a9d7">436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09c41fb46464505bcc32a3c43731505_I20210404" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS0yLTEtMS0w_bb0f4e42-cf04-4a5e-bd64-64384657929e">340</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0fac9c964894676b74a3dfea4fc6f74_I20201231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS00LTEtMS0w_27606924-0656-4d84-b891-bebb28ef50c4">399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi0yLTEtMS0w_1792f97f-2172-45ce-9d39-7231a477dc79">4,848</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi00LTEtMS0w_ad863a6a-7370-4d15-975e-c45a13adf941">4,712</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;4, 2021 and March&#160;29, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_46"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3OQ_ba908374-5f20-47da-8017-88149f62cde1" continuedAt="i8da9a5ba79894b1ba17b377add1230b5" escape="true">Discontinued Operations and Equity-Method Investment</ix:nonNumeric></span></div><ix:continuation id="i8da9a5ba79894b1ba17b377add1230b5" continuedAt="i0d8c9f7189724770b014b78e8967006e"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Upjohn Separation and Combination with Mylan</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the first three months of 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $<ix:nonFraction unitRef="usd" contextRef="i1fb4d5f76cd341e2a3579da45c669e20_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY0MjUzMg_50774283-f6ba-43df-a9c0-40a28e34fa82">871</ix:nonFraction> million as of April&#160;4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTY0OTI2NzQ3NzY3OQ_6aca0054-cc97-4954-8ee1-a7145065e166">401</ix:nonFraction> million as of December 31, 2020. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $<ix:nonFraction unitRef="usd" contextRef="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTg5NTYwNDc0MTUwNw_1d818c86-cf20-4276-bdcf-4ce1b88acf35">277</ix:nonFraction> million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was recorded as a payable to Viatris in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax.</span></div></ix:continuation><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2NzAyMDc_f5625749-9e7d-4e39-a6d0-b74de25ea1a0" continuedAt="i922f3ec188d549489ad6ebec14e28143" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i0d8c9f7189724770b014b78e8967006e"><ix:continuation id="i922f3ec188d549489ad6ebec14e28143"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:71.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619">27</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b">1,946</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8">442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee">19</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f">1,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159">881</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#8217;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Formation of Consumer Healthcare JV</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a <ix:nonFraction unitRef="number" contextRef="if62466171dbf47ec977eb962afa99747_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjQ4Mg_646bf3f2-97e4-4b5b-b9e7-b0757aca1a05">32</ix:nonFraction>% equity stake in the new company and GSK owns the remaining <ix:nonFraction unitRef="number" contextRef="iec8f63c6623f49adbf67a41d2e87119b_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjU0NA_f7f52eeb-ad64-4267-98fd-e8842ad35705">68</ix:nonFraction>%.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in the Consumer Healthcare JV is $<ix:nonFraction unitRef="usd" contextRef="i84d3a404ba354ee580c13bbafde8881a_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgxMw_4d0505c9-cd85-45d5-a433-876e5cfa35ea">16.3</ix:nonFraction> billion as of April&#160;4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgyOQ_aa05ee60-8af5-484c-a368-3c2680acf6d9">16.7</ix:nonFraction> billion as of December 31, 2020 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&#160;4, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $<ix:nonFraction unitRef="usd" contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDM3Ng_2fdb8715-0567-4a85-ac5e-c4dbfb060788">126</ix:nonFraction> million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as well as dividends totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDQ4OQ_bbcc03b5-4446-47de-92fc-5ddd7ee33281">274</ix:nonFraction> million, partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in the first quarter of 2021, was $<ix:nonFraction unitRef="usd" contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTcwNTcxNg_28ac2727-3769-4b63-85fd-750476acff82">71</ix:nonFraction> million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2019, which we recorded in our operating results in the first quarter of 2020 was $<ix:nonFraction unitRef="usd" contextRef="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY1NzA3Mg_d753092b-100f-4fd8-ad2f-9799c9e48782">11</ix:nonFraction> million. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-top:5pt;padding-right:9pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3NA_44a44697-50d5-4dee-8e93-3ca8dcdd3af4" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:53.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.776%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi0yLTEtMS0w_4532fe78-d3d4-432f-b8d7-92112e58b778">3,096</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi00LTEtMS0xNTk5_982aacd9-051d-4422-97e2-d19bc4103353">3,188</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy0yLTEtMS0w_9539cada-5336-4daf-a8e0-1afda6f9d024">1,188</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy00LTEtMS0xNTk5_202ea05f-df1a-42a3-9633-8d77416531d8">1,811</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC0yLTEtMS0w_3df5fdae-2e06-4dba-a770-a45a8ec78ccb">1,908</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC00LTEtMS0xNTk5_2c6886cd-75cd-4422-a3b8-e609edf2ae4a">1,377</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS0yLTEtMS0w_aba530f0-e913-44e1-b132-9a647a0fed0b">233</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS00LTEtMS0xNTk5_79073324-7f00-45f7-b5dc-3bd73fe42d99">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi0yLTEtMS0w_416dc2a5-e841-4dfc-82c5-438425bee612">233</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi00LTEtMS0xNTk5_17e970e6-b55e-4f20-899e-d0e5351332bc">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy0yLTEtMS0w_cd87a5c4-e88e-41df-9ba3-d564c9f38e97">221</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy00LTEtMS0xNTk5_dd4ec1e2-8496-4f2d-b912-8eae9eb45dd2">37</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjExOA_27eb074a-149b-45fa-98f9-adc9fd28e25c" continuedAt="ib9e1fbccfd5b47b78a06b16ca1f95c22" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonNumeric></span></div><ix:continuation id="ib9e1fbccfd5b47b78a06b16ca1f95c22" continuedAt="iecd2e6400c0d471db9f9e89fa1d0e708"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base aligns appropriately with our revenue base. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. In addition, we are taking steps to restructure our corporate enabling functions to appropriately support and drive the purpose of our business and R&amp;D and PGS platform functions. The program costs discussed below are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect costs for this program, primarily related to corporate enabling functions, to total $<ix:nonFraction unitRef="usd" contextRef="ice6f2159d3d7436abcb7d83886acbb6f_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzMzQxMA_07e6fc4c-e559-42bc-90ab-26497f16abb9">1.6</ix:nonFraction> billion on a pre-tax basis, with substantially all costs to be cash expenditures. Actions will include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of this program, we expect to incur costs related to manufacturing network optimization, including certain legacy cost-reduction initiatives, of $<ix:nonFraction unitRef="usd" contextRef="i49562007fd9547a48d0eb81e74591431_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAxMw_14041156-967c-4d93-87b0-3f155bc2ac32">500</ix:nonFraction> million, with approximately <ix:nonFraction unitRef="number" contextRef="i4407292bed544ddd98da354a852701ac_D20210101-20210404" decimals="2" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAzNw_29eccbf6-131e-466e-a149-d380d1c91f84">20</ix:nonFraction>% of the costs to be non-cash. The costs for this effort will include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through April&#160;4, 2021, we incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjQz_baecc405-330d-422d-8204-69e27bab3e74">1.0</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0Nw_4bee2ea2-188a-4a08-8602-2e647072a22e" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC0yLTEtMS0w_301ae934-f19f-4d8f-bf13-608344d6369d">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC00LTEtMS0w_93bfa226-828b-494b-a432-d2d2e66d9031">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS0yLTEtMS0w_b586cc58-6854-42c6-9603-9998af0221df">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS00LTEtMS0w_c3a57e3c-3266-44a2-8dff-3a8f35f458ab">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500">18</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4">41</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtMi0xLTEtMA_6bd7a23a-9c47-462b-8783-c08797543a15">23</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtNC0xLTEtMA_1bff97d6-aa66-4f36-88ae-16aa7084c06f">54</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b">8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40">10</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a">75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f">22</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtMi0xLTEtMA_f8a24f99-7e34-4283-b997-d8fed6896efe">116</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtNC0xLTEtMA_afe902ec-0a48-4d46-ad48-43be71df2391">77</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents acquisition-related costs ($<ix:nonFraction unitRef="usd" contextRef="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk4_6f7d1cd7-fedc-45ac-9084-86d11b0a67d2">6</ix:nonFraction> million credit in 2021) and cost-reduction/productivity initiatives ($<ix:nonFraction unitRef="usd" contextRef="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTY3_01a1911d-d185-4baf-95af-00ea682001ba">25</ix:nonFraction> million charge in 2021 and a $<ix:nonFraction unitRef="usd" contextRef="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTg3_084cef96-bf16-432a-bcfe-42e6851b8e72">40</ix:nonFraction> million charge in 2020).</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NA_60a80000-3ea5-492d-9a39-7eecee55dbeb" continuedAt="i1d4fb77728484994b5ead409fa00c65a" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iecd2e6400c0d471db9f9e89fa1d0e708"><ix:continuation id="i1d4fb77728484994b5ead409fa00c65a"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:40.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7055066225454fbd6b963b51debc30_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b">782</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e22c74513c4463863976ef5f21b01a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f00f1a9cab940258f6eed860c0bc028_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3">15</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e">798</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy0yLTEtMS0w_865c6d73-5164-4256-a6d8-cf036e933a1d">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy00LTEtMS0w_c7253501-a393-4ef2-a534-85fbd644a092">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy02LTEtMS0w_da606571-9143-48cb-8a28-5d9b4f2f97b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy04LTEtMS0w_aa52b20e-aa2e-4ad4-ac30-0a24298e0cb3">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68">102</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404" decimals="-6" sign="-" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&#160;4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6820f138a34d1a88125938e6c7587e_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d">702</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29f6c9175e74ba2832cbc36256b21b7_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac">15</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113">717</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTkzMw_104c0158-0022-4de4-a313-c68b266f49f1">628</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="ic0fac9c964894676b74a3dfea4fc6f74_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTk3MQ_9c317e36-dc75-4c3b-a9fa-6cc29266d2f3">169</ix:nonFraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjA3MA_38e0c684-ece5-48da-b31a-176a4b43deb5">561</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="ib09c41fb46464505bcc32a3c43731505_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEwOA_6ac882f8-c550-4ac0-a185-02e8cfdecc8f">156</ix:nonFraction> million).</span></ix:footnote></div></ix:continuation></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_58"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA3Mg_d3d8f1ec-587e-436c-8a9a-441ebeacec6b" continuedAt="i981e382c415e4e04b96ef66801e78c84" escape="true">Other (Income)/Deductions&#8212;Net</ix:nonNumeric></span></div><ix:continuation id="i981e382c415e4e04b96ef66801e78c84"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2MQ_d6c96c7b-836b-44e6-bbec-0883a4f640a4" escape="true"><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy02LTEtMS0w_93dd2970-806f-4c10-bec3-5c467be54c26">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy04LTEtMS0w_6789808f-b98c-4eb2-9de8-10920a76c88f">34</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC02LTEtMS0w_c0df218b-66f2-4928-b011-5b00ba100a27">336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC04LTEtMS0w_1192c25e-e2f9-4cd2-9a4c-ee46ccd197b5">390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS02LTEtMS0w_7aa993ba-85c5-4ec9-8063-b1625a2ea0ad">336</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS04LTEtMS0w_3ff4f4a3-0b8d-459a-a15e-a8d97668cfc8">356</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi02LTEtMS0w_092bdb67-0a71-49af-aea0-cfa327c33724">176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi04LTEtMS0w_dcf39154-57d1-4fc3-9419-59727f37ed9f">119</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy02LTEtMS0w_d8d30f59-4029-4a00-b55f-b620fa5c81c2">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy04LTEtMS0w_54439b9e-8f96-405c-bd79-64698286b690">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e">401</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e">255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8">231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1">115</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb">266</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278">103</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItNi0xLTEtMA_ffbcf04b-f605-4c80-ae5f-ad22998d3069">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItOC0xLTEtMA_2b67ee07-94e2-48b2-b117-264f5fdaa0d4">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctNi0xLTEtMA_76cd50fb-1e50-47e6-8353-716a69717150">216</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctOC0xLTEtMA_c1380247-7818-4355-b379-ee288ed8bf80">126</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" footnoteRole="http://www.xbrl.org/2003/role/footnote">The gains in the first quarter of 2021 include, among other things, unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3MTYwOQ_f215fd58-5b81-41f5-b934-e70bcea046aa">409</ix:nonFraction>&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfOTc_e7e8be57-77a4-4566-8a7b-aa1e101fecab">134</ix:nonFraction> million related to our investment in Allogene. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" footnoteRole="http://www.xbrl.org/2003/role/footnote">The first quarter of 2021 includes, among other things, $<ix:nonFraction unitRef="usd" contextRef="i798490452fbf42df810cc73fc79edd72_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3ODY4Mg_37a0c2b5-21cd-406f-8e77-3af73fab5b07">188</ix:nonFraction>&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $<ix:nonFraction unitRef="usd" contextRef="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA4ODA4MQ_6f5f92f7-c39a-45a6-835d-190051bcd613">75</ix:nonFraction> million from our sale of our CK1 assets to Biogen, Inc.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_64"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzIwNg_966a7b07-774f-4aee-aeca-5719f3589cb6" continuedAt="i60f43a67b4fe44c689604670e4966259" escape="true">Tax Matters</ix:nonNumeric></span></div><ix:continuation id="i60f43a67b4fe44c689604670e4966259" continuedAt="ieeae66e703064ba594f07bfb1d127d56"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was <ix:nonFraction unitRef="number" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTE2_2ce20265-e7d2-40ea-96a8-df63fff720f2">14.2</ix:nonFraction>% for the first quarter of 2021, compared to <ix:nonFraction unitRef="number" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTU3_a2cc1bdc-a838-4c18-8441-030e8750b634">12.6</ix:nonFraction>% for the first quarter of 2020. The higher effective tax rate was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMjE5OTAyMzI2MDQ1OQ_85d3d084-6d2b-420b-9771-6ddb878399e2">15</ix:nonFraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of April&#160;4, 2021. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#8217;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ieeae66e703064ba594f07bfb1d127d56"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2010.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE3NA_b97df153-2aa9-4966-89c8-0dbf6efdfa4d" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622">21</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea">247</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC0yLTEtMS0w_fa7d641b-6695-42a1-85f2-e77e3910f9b6">59</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC00LTEtMS0w_7c4708de-27e0-45e9-9f61-0eabed9a0861">133</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS0yLTEtMS0w_f45df937-a876-4a1f-9a07-a9214eea0722">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS00LTEtMS0w_bdfc137a-0f29-41cb-83da-87e30c6f54a2">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi0yLTEtMS0w_bb3f16b6-f4fc-4e62-9152-fce24b4d23ec">93</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi00LTEtMS0w_7301bc21-74af-4001-8194-a3657d24a992">118</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy0yLTEtMS0w_6e6680fb-8deb-48ff-8c26-58d89ac486da">10</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy00LTEtMS0w_1b230f48-9cb6-4b5c-9d5f-ac3313a8606f">6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC0yLTEtMS0w_498ddd0d-ba18-49a3-b29d-a80b023fe87e">30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC00LTEtMS0w_3ebabdf5-e730-47eb-84d4-0e622db07442">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS0yLTEtMS0w_7a688379-bf48-4e2f-ab82-439303d6da9f">20</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS00LTEtMS0w_e7810623-4689-421b-81c9-64727ca768ab">5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtMi0xLTEtMA_f5f79b1f-8d87-4e56-bcac-7daabf972fd9">10</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtNC0xLTEtMA_727ca201-9284-412c-b244-f322850fd7cf">11</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtMi0xLTEtMA_b5825082-d0e0-4755-a950-9287668bc2d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtNC0xLTEtMA_ba7ba68b-4e8d-4cfa-9306-eb5a8e7dec65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktMi0xLTEtMA_3bb0ec19-82a9-4f7a-b307-ca76d16e5f27">10</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktNC0xLTEtMA_1661a2cb-f7e9-4f76-a1de-caafb1c74ec2">11</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtMi0xLTEtMA_abd44777-fa20-4f82-99e3-ac0891a50623">84</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtNC0xLTEtMA_3320ae5d-664b-4748-a2c5-c280dddd68de">380</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" footnoteRole="http://www.xbrl.org/2003/role/footnote">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_67"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfNzk5_8dec60aa-09ab-42f1-9a3d-81e765da40e2" continuedAt="i11a6fc7f0db64e02845c4bd5fc181d45" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="i11a6fc7f0db64e02845c4bd5fc181d45"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODEx_cec26bc2-4128-4406-bdbd-abccf3c95895" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.818%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4">5,450</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if15de68e82a04995aadbd09ef4f4de3e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953">428</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c9aa8e82394528ad00529819678ef4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9">116</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2113534f48f444f8fad64562140b4ea_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c">452</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dea6398b1c4543b9115d73e959887b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033">5,310</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4533886f346447ddb2e4466be3decd58_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c">442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802">380</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5">142</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f">646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3532a573af84231901dcba3a9f69146_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0yLTEtMS0w_a09c29ce-324a-4478-990d-395016c176e7">5,008</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi00LTEtMS0w_e6ee5e01-a667-4cbc-9046-765a019d7763">48</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4864e09f901546cc81c976b2cae73fb3_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi02LTEtMS0w_cd029b4c-f232-45fc-b99d-5d977a96ccab">26</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62019f9f689b4fc982e85dd8eb7b261b_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMC0xLTEtMA_033e1787-ecc0-426c-b652-4a63af44335a">419</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ffb761b6f624168a62f72e12228bb5a_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMi0xLTEtMA_e2e2e7bf-4409-43c8-9c6d-8a3d4bdbd3f1">4,664</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_70"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjQyMQ_a5739606-ec0d-4e33-bf89-86e61a06550e" continuedAt="i0c41ecae481e4d048992892633dd0b7e" escape="true">Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0c41ecae481e4d048992892633dd0b7e" continuedAt="ia9769bc32afc46fe8ddf31ea4e49e8cb"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUzNQ_ffefc116-646e-4f43-818c-0197e239c005" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67345ed70af0415f9ed8e94420f395ec_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0yLTEtMS0w_39c27294-e181-4cd2-a2e3-fd35df45bef8">1,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS00LTEtMS0w_1c85c489-9d18-43a3-a7c4-a0218bdc0a11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aae410224d44016a7744837424466a6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS02LTEtMS0w_82cf3568-1c97-4bf6-a440-2af7ab298f63">1,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c17032a023943b39d6fe6d61373d0ef_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMC0xLTEtMA_edfae60c-2a95-4c4b-81db-fd348be30d1e">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046ca4e1125f4096b86c8813e2f8970e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMi0xLTEtMA_d10c70b7-c8a5-4cfc-bf82-6e880f23f5ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f1d50b4ddd4407b234fba600ed5d57_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xNC0xLTEtMA_81f2fce3-988c-4855-bde9-64bbe639a769">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0yLTEtMS0w_7612d814-1429-4b44-beaf-8b9f83f3b70d">6,169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC00LTEtMS0w_15999192-fe21-42d2-9a36-fc3d4f120122">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e3912c87b642259d22066a4deeedf3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC02LTEtMS0w_192292da-2145-431e-8c1d-8a8a7555bc81">6,169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMC0xLTEtMA_e8c41fb5-9730-450f-87ac-83226e49af1c">7,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39df5fe991d423c8bb366a5753affb5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMi0xLTEtMA_6da90f81-d984-40d6-a3fa-267afda94fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e21972aa8834adbb2e62df36a9290a9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xNC0xLTEtMA_a505431a-048d-4cba-9d86-18714383a2fd">7,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a996c859684b9ebfddd6a039f0965a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0yLTEtMS0w_2ef48b90-dd37-4fe9-949b-37355044a781">1,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1336b9d91143e39d2fea5006a742b3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS00LTEtMS0w_4e8b94a5-25c4-43d2-a8c4-adda65038eb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS02LTEtMS0w_65bceaad-4ae9-4ee6-a1b3-10f3990ac087">1,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc333032422c470d9c553a603fed07e7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMC0xLTEtMA_e8d58585-ee47-44cd-8218-ca215c1c5c40">982</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i217da8c7f6f349b8b0412339d3adcdab_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMi0xLTEtMA_dad94c05-0449-4652-a1f1-94a88720dbba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b273a61589b42c5baea01aad3398d3d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xNC0xLTEtMA_1d8a1b6f-9f1b-492e-ab8f-42b076d8e15e">982</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMi0xLTEtMA_25a887c3-a89e-4f6d-b78f-4d14f6ae8d04">902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521c003f78f74a16bf69168b25516b44_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNC0xLTEtMA_2dbab1a8-c7a7-44d3-9f9a-a97faab0d175">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb11cd15cf3432681d969a29d7dca79_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNi0xLTEtMA_40f76bdb-6cf2-42a1-9f1b-776443334496">902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTAtMS0xLTA_e159b30e-9548-451e-9e1f-3f065dbd2520">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTItMS0xLTA_5ccd829b-1cc7-408f-a952-c32282048958">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c84a33617f945aa95602f65e14fe7fd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTQtMS0xLTA_65aa9f82-c5b0-46c8-a765-6d988a3f12f2">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693fbbcedb904e0ca5820547935b4eeb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMi0xLTEtMA_196bbf1c-a073-4b3c-97df-5748def8ddd4">8,292</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2496243c18b44e05838d5575a5b19b92_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNC0xLTEtMA_da75f563-8a34-4494-9ca1-c58236d77420">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2827e9872a441058d1e02032d2d742a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNi0xLTEtMA_e1c7d04f-ff26-49e0-9df0-50a8d72b39b2">8,292</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dad755ef938483cb63df05993af440c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTAtMS0xLTA_1e3e00aa-5465-408a-8e5c-e7039652db10">9,709</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTItMS0xLTA_03fd2647-ca29-43a1-bad5-978794638608">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b785935ffe4cc39bc8792585014a3b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTQtMS0xLTA_18ab15ba-8aa7-4248-a8e4-ee3e83a26f30">9,709</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693fbbcedb904e0ca5820547935b4eeb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMi0xLTEtMA_553b3ee5-dda5-4472-8cdf-4f7429059136">9,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2496243c18b44e05838d5575a5b19b92_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNC0xLTEtMA_06ad4c61-71f9-4b2d-a536-00f4c486d185">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2827e9872a441058d1e02032d2d742a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNi0xLTEtMA_62d45867-a6ed-48f3-8361-dd356dc5eb8d">9,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dad755ef938483cb63df05993af440c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTAtMS0xLTA_479b529a-fa10-48a6-b8f8-e2465c756ece">10,276</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTItMS0xLTA_a43c8e66-03f8-4b29-a9f9-14baa1151d80">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b785935ffe4cc39bc8792585014a3b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTQtMS0xLTA_45069de7-1bc5-4e47-add3-5797764129af">10,276</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMi0xLTEtMA_33aac98e-f994-44fa-9aa1-c02b6b3c457f">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6590c03231c94832ab710135c629b5d6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNC0xLTEtMA_335ed2c2-70d1-4bff-96a6-8d0ce8977505">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a8285101fd4a4787791fc4108af409_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNi0xLTEtMA_8950ba41-025c-47b4-a719-258056b8ddf9">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib397545be8ed42a894b7225f81be7b8c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTAtMS0xLTA_b1cb523f-ade7-4cd6-a0f2-7e613b67becb">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c6a57df8544c48b668c58d680c53a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTItMS0xLTA_5d7c4dab-0943-4a3a-b67b-2c0dd4bf162e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie209ada8ef774920a8094ff1ffa8c791_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTQtMS0xLTA_06fe8cbd-1030-4cf8-b221-a83b2be65f39">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6402b69d96a94b11983f4c4aff358cd9_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMi0xLTEtMA_606e56cd-8006-4328-ac58-c5fd32206201">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8629e44fcf74299947158c6cf1db447_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNC0xLTEtMA_de99f44c-2a06-4701-a478-e92a50742c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic918fd2704ed4d59aa54d300420bf854_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNi0xLTEtMA_c23d4c7f-b6e9-44f5-aa53-8aed75e2f366">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia422b966324146868d032d47dda6f321_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTAtMS0xLTA_feb5ba34-3f58-4e98-9431-bb780e037c54">234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8e1a1c11cb40788c6dd041f5862427_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTItMS0xLTA_75202bf0-4b49-4b0e-92a9-6307c74f7fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12158fe468140509e594e5c9bea2ff0_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTQtMS0xLTA_d8e5556d-4610-4e33-9ada-49e32948e934">234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef140b7ed3b4d09bed3385bae6d504d_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMi0xLTEtMA_2fb36fd3-05db-429f-a3e8-2ab0d8555b0d">394</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b810fe2ae184c5097d5595af97f1ee9_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNC0xLTEtMA_477b8fb4-325a-4a97-9a92-a88b7cdfacd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia267f32cf11e4a86a297aa0b2be67c44_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNi0xLTEtMA_9789c228-57dc-4cce-90ea-d5797baad736">394</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5dcb775c5545cea010daed613c3d15_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTAtMS0xLTA_b3cc0765-30ba-400b-babd-3acd2d21b76f">251</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3354f5abddd4996bf3ccd71244e3b56_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTItMS0xLTA_da47ef13-2dfd-43f5-99b9-76d106703c88">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91073b1fe1b54677a90882344df8e229_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTQtMS0xLTA_29cf1cc4-e21b-4c5e-bea8-ee3c40a9f02a">251</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625">3,123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b">3,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365">2,809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7738ac04034c2db9a1b09fd2554159_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMi0xLTEtMA_90869fbb-28d6-4b16-8210-6951936f5e36">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic017f9df9d9941eeb7f48073600c8293_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNC0xLTEtMA_5435e736-ec3c-4792-a06b-14afdf9cfc0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235004b31ec442a1a5ebf8037790737f_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNi0xLTEtMA_12c1a6b7-4a62-4629-8706-564e7da92a29">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3112b7bd4ca945039be216b55807356f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTAtMS0xLTA_d2cbe56f-0e14-4d54-9858-96298978b4a3">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5959213e06f24defac36f7a0fb92bbb4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTItMS0xLTA_d9d60376-3849-4c09-9fd6-445dcc46501e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b990b5de1ed4f4db641cc793879a698_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTQtMS0xLTA_ca05ab39-1ed3-4de3-8542-5c4e443e7da1">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2af150083d47d0bcf678532db4a34a_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMi0xLTEtMA_ee1bca5d-8a4d-4113-a9c4-06860af944f4">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6648e1e65204f4eb444cb895f52ec9c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNC0xLTEtMA_28b39024-dc70-41c0-847b-fac11bbc421c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fd3e97335545368349e1b54a37f7ca_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNi0xLTEtMA_73e13363-1cc2-4b47-ab39-7098c5308657">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b72ae9514a4dfdb73d54037e4297c5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTAtMS0xLTA_d8433eff-77e8-4d18-ae1a-579eaa72825b">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f3e802e12546cf9fa1294b3ad1be57_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTItMS0xLTA_594b689c-e34c-4025-830c-220846d02612">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1bff202dda47268a07043474884dcb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTQtMS0xLTA_c0c563f7-7207-4288-9bb4-de08fb430d50">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0d3ef6ac6b472b84a7134822008fef_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMi0xLTEtMA_90fe0c4d-d173-4693-b64e-b0c050a2b639">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77e241651c349ada1bf16e3b6ecf828_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNC0xLTEtMA_ea79e0a1-07b0-4c6f-b1f2-51cc4adb71f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfae630a4fe4e298addafa278e16b50_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNi0xLTEtMA_22a4b13c-eb74-4e2e-acf1-067b3aacbd04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTAtMS0xLTA_e9d5a851-c96f-4c03-9003-08e07f68577b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2697970c25514e279413521fb973bba7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTItMS0xLTA_ac0799fc-9731-4eb8-bbee-28c75aea77d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea7690129214a9195f0424e82617486_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTQtMS0xLTA_ca2cd08f-dbd7-47ad-8740-edb9bb8639f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMi0xLTEtMA_f2e6af77-ea84-40b8-b9ec-25cee0b93052">75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNC0xLTEtMA_81f3aed5-da25-40da-8dca-d5c618561922">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNi0xLTEtMA_b5d21d46-f03f-4adc-8bb9-45c0cde5a3f6">75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTAtMS0xLTA_214d34a3-19b6-40f2-a55d-ac46e108f603">128</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTItMS0xLTA_27c73584-1d65-40bc-9647-d815ea03b0f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTQtMS0xLTA_649a19b0-1674-41c1-87c2-6dd029baab88">128</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMi0xLTEtMA_7191b257-cfd1-495c-aab6-e132444eefd9">3,198</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNC0xLTEtMA_52b13242-b757-49d9-82fe-1370db13bf55">3,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNi0xLTEtMA_ec4657ae-3dc9-4d24-9693-37105de97fba">152</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTAtMS0xLTA_34c7a5de-27e2-4990-80d0-9c0b1625891b">2,936</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTItMS0xLTA_279a2d3a-2b4b-4a08-993f-9351dafe29bd">2,776</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTQtMS0xLTA_20aa55e1-e073-4d9c-a4ac-13d7c255188d">160</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4105c4d1d064369a467bf34c99b66d9_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMi0xLTEtMA_39cbb353-3cdf-4754-b6f1-6e951c24dd35">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b19f59cbd344d648155105fd82aed69_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNC0xLTEtMA_ba32453b-5c59-4d17-8630-21c2e24aa45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNi0xLTEtMA_5bbe4d70-40a8-4823-b6c8-808f048e2a8a">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8bc471a60a4b02bd124ad08e30d367_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTAtMS0xLTA_66029dd0-c662-4664-b737-018bc1066a4f">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27878b3c524d4ab463f64f7d71c33e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTItMS0xLTA_c5a8ff6f-16f3-44b3-aa3b-4c7baa13623e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTQtMS0xLTA_4cde7ade-e883-4a4c-9cc2-1480462d2a37">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc1645da50f4723ac5e11374a83165e_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMi0xLTEtMA_b534b43b-8d17-4f35-84bf-f611ea67ce0e">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2636525965a44944a8b505ad44b6fb94_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNC0xLTEtMA_367f2eaa-1ed7-48f6-8706-15d2694c0d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNi0xLTEtMA_e82a9b42-5069-4b41-8ee5-aaf48b4d4eed">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTAtMS0xLTA_7223fa27-0c05-450a-b7c1-6f727f958b5f">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467531120efd4d1eb7bbc63d03b66773_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTItMS0xLTA_704c447c-82e9-40d6-8586-3cea528fbea6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863eb072936745e9a6b8f3a4ef7207a6_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTQtMS0xLTA_3e60bd95-69a8-45fc-ad83-92ebb74d901e">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMi0xLTEtMA_212299f9-ee5c-4521-bc12-1316b6cfc442">127</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNC0xLTEtMA_2406de4f-c4ec-4cdc-93b7-a050b28da72c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNi0xLTEtMA_d01f18a7-4ba4-419e-a203-46817dfabce8">127</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTAtMS0xLTA_c7af8c39-7306-40a3-85ab-e80c18935379">122</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTItMS0xLTA_a0d204a1-6d06-40de-a2ee-df15949c1ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTQtMS0xLTA_a52f1996-2caa-4cec-9fa0-a13c45654587">122</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9">726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb">726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMi0xLTEtMA_32d08bcb-e4f8-4e02-9224-d2b53c44b419">853</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNC0xLTEtMA_9e9b9d1c-39c2-45b4-9be6-80618aabb702">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNi0xLTEtMA_391bfe5d-0a17-4c5e-b339-848ba931f7d9">853</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTAtMS0xLTA_cfdd753e-b8bc-449b-a1ed-b0f7833b54cf">814</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTItMS0xLTA_19b9b6a8-1f01-4132-a497-51d750472ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTQtMS0xLTA_3487a75a-0351-4649-b2b5-10008121546a">814</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMi0xLTEtMA_9332f2e0-06c8-48d6-a999-58a6a2b74ac6">14,165</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1774875f27f34e3c942fbcdb9216c45c_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNC0xLTEtMA_5b4d1345-9f7b-44e9-ae2c-454b2d12c355">3,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9e05206d5d44bcb2b4c816762b2196_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNi0xLTEtMA_720e3fe3-d498-49a5-9cb0-786fbdbaf086">11,119</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTAtMS0xLTA_96911fd7-4893-4065-9fc8-1747aec85293">14,278</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6218d250ab4b7588c930240dbe77bb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTItMS0xLTA_19685fd7-bd4c-416f-8ece-c7a510a3e599">2,776</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e356b3ffe4f46d786b299299e8c73c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTQtMS0xLTA_600cadd0-c5a7-483b-b77c-bc47bee517a3">11,501</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddecd2f6220e465abe9653d482f98cd7_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMi0xLTEtMA_89d821e0-edca-4290-9825-a9ee9259c57f">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0122d1ba5cd6421b87248774e8dd8097_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNC0xLTEtMA_015c2414-aa6d-4104-b3f8-bf1f59dedd98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4bf8afa38545638247e4f6360ddf24_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNi0xLTEtMA_9794113d-60d3-45e6-8440-beae5f1bbe3a">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38dfe51f567c4463b153c45da57afb62_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTAtMS0xLTA_f2879ab7-3334-433f-bc89-7734a62125c5">501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43a5c73f58e4950ab051b0f60f22af2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTItMS0xLTA_7022fd12-9cbe-4b48-a0b7-ee8bd49c9e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25ff69c6c384a5e9bec30440b609aaf_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTQtMS0xLTA_906ecbef-80e3-4a09-bc95-e8db2103f978">501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMi0xLTEtMA_97699ac4-1a52-4c81-a907-528b5a13473f">239</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if552fb30ac3f4a9986d136fac40d1ba0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNC0xLTEtMA_7b49cdd8-454e-4622-8846-b76e957e413b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfb31e704964e379fa031ac9764d117_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNi0xLTEtMA_f2038a8b-9a16-40f9-a2e7-8ce386ce240e">239</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9db44961644d99bc4a1be0ceaf3427_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTAtMS0xLTA_111a7671-fd11-42e1-afea-d29b99427ee2">501</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105edd316071419483c29294542bf610_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTItMS0xLTA_70a35d71-12f5-49dc-9ba7-1395d08cf943">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc91087bf2c84f9db4657e286128b4ce_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTQtMS0xLTA_ba565120-308b-4c26-be47-19e73cf38be9">501</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71eb1561917b4fc8b8dd253cd6535303_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMi0xLTEtMA_f1fcdebb-4eb4-4d41-8a48-64f766981d59">494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19135b26e5944d48147d848103fa4ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNC0xLTEtMA_31bafd5a-fd8f-414e-9bbb-7eb936aced89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNi0xLTEtMA_9aad64e5-b0f3-4354-b882-29f55410f5f9">494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72626af54aa43d29c3a57a81672472f_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTAtMS0xLTA_dd5c0e74-7816-486d-a134-1468d5d1a5d3">599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361062f6aa914630bda2a1decde3d5fd_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTItMS0xLTA_b44809d4-2e63-4d48-b098-3deb9ac770d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9154af5cf4f54064a345265618b24fb4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTQtMS0xLTA_b65c4d69-f5ba-423a-ac56-4f66eddcd0f9">599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cb663f517041b2b748758fddfc3042_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMi0xLTEtMA_5ccfe6af-a813-4c31-9622-075f6f1261ec">494</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7c33ade3f427b87cdc02e591b5d89_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNC0xLTEtMA_283d2fda-a288-4306-a12d-07b7a222527d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNi0xLTEtMA_10d0091d-1f1c-48cb-b4d2-b36fc5d7d2ea">494</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id184353eda00420aa146f68eca8520d9_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTAtMS0xLTA_98d25155-d83d-453b-8155-3ff66905df94">599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6329d29a2efa4bf6be2047d1f4b55270_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTItMS0xLTA_1e70e188-0d2e-4618-b05a-6453011fedec">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6665bcfdc84fd9847decd31aab5d74_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTQtMS0xLTA_dbe0e900-097f-4935-bba3-c0eea74207bd">599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMi0xLTEtMA_be677e6b-1557-4558-ae5f-80b2b7f0d6eb">732</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1774875f27f34e3c942fbcdb9216c45c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNC0xLTEtMA_cbb3c4ee-f272-4f62-91dc-b65c2dd4c29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9e05206d5d44bcb2b4c816762b2196_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNi0xLTEtMA_6b00fbc9-e589-4296-8238-ede807ea589f">732</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTAtMS0xLTA_e67dafe0-8ed2-4c38-8f1a-c24ab18571ad">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6218d250ab4b7588c930240dbe77bb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTItMS0xLTA_6f66ba72-16f7-4314-a19b-d38a7774632b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e356b3ffe4f46d786b299299e8c73c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTQtMS0xLTA_af8bb059-432e-4fd0-9a9d-992c2f266c09">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" footnoteRole="http://www.xbrl.org/2003/role/footnote">Long-term equity securities of $<ix:nonFraction unitRef="usd" contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjM1Mg_eab63920-0c1f-486b-b954-e10cc4438fa9">168</ix:nonFraction> million as of April&#160;4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjQwMg_2ab03d8c-ad25-4300-9626-b759a59bf2d1">190</ix:nonFraction> million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia9769bc32afc46fe8ddf31ea4e49e8cb" continuedAt="i32fe2ceb6ae54d47ae9dcca803b29f00"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUwNQ_a3f573d3-55b2-4829-9f68-0430eed83639" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying values and estimated fair values using a market approach:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding the current portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94b4929257f4fa59c82eaf1fff65f72_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0yLTEtMS0w_0fc8b902-1c63-485b-9fcc-9897ce477bd8">35,347</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS02LTEtMS0w_82c8bc47-e8db-4715-a6f0-12111a0bd6da">40,504</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dd217f408a4c11b63dad378ca98d22_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xMC0xLTEtMA_5abd8e26-f222-4149-a203-042f3c60ecd3">37,133</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54070b71d25429da086e63afcf1c41c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xNC0xLTEtMA_a1d2d60f-0400-4dbd-9290-5ab7ef54a14c">45,533</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April&#160;4, 2021 and December 31, 2020. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_73"></div><ix:continuation id="i32fe2ceb6ae54d47ae9dcca803b29f00" continuedAt="i8b5aa3f235884378a2d9df5387d169d6"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzE_15442d9d-9eeb-4150-93a3-c532d4d33be9" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937">1,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC0yLTEtMS00NTAx_00e8a2bc-954d-43e2-905b-754ad656db1e">8,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC00LTEtMS00NTAx_8cd28a90-b102-464c-8d4c-f7fd1c15a6ce">9,709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS0yLTEtMS00NTAx_b26ef72c-2631-43be-ae05-da9f8c3ccc4e">2,180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS00LTEtMS00NTAx_73f95e2a-36de-4b24-888f-303fefed9a5e">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi0yLTEtMS00NTAx_5d5f4a34-3d71-4066-8387-3aac9965227e">11,899</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi00LTEtMS00NTAx_8688b140-ba2c-4c5b-86a6-6cfd4cb5d1b1">10,437</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS0yLTEtMS00NTAx_9ec2c979-8c6e-489d-a9bd-b3a5250c54b6">3,123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS00LTEtMS00NTAx_361315d0-52c2-435c-a5b0-c287dc5a19c9">2,809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtMi0xLTEtNDUwMQ_67541eb0-c530-4cc3-8715-133343085dc8">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtNC0xLTEtNDUwMQ_459338be-6398-4ce8-8bbb-2062b6f596a5">128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItMi0xLTEtNDUwMQ_8f689449-587a-466f-b267-94c31b861f01">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItNC0xLTEtNDUwMQ_d7652dc1-28b3-4cd4-834a-40d7f9840880">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtMi0xLTEtNDUwMQ_3ea33e1f-4f93-40f3-9a15-5982a2668c13">3,696</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtNC0xLTEtNDUwMQ_146265da-bdd3-4973-8182-f4f47692966c">3,406</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtMi0xLTEtNDUwMQ_5c92dc31-9fff-4341-9299-461153d89a0a">16,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtNC0xLTEtNDUwMQ_c8ca2aa1-944d-425e-8079-a9cc750d2d8c">16,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtMi0xLTEtNDUwMQ_c6968b7f-dbba-4ed0-883a-6d94354a7d10">20,228</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtNC0xLTEtNDUwMQ_362fb2ec-2587-4867-8014-69a15ee1ef37">20,262</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctMi0xLTEtNDUwMQ_ed8fdc5c-96c2-41e6-be85-3490add9040c">60</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctNC0xLTEtNDUwMQ_66ab2d23-7257-4339-b086-6d6a0620f252">89</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represent investments in the life sciences sector</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:3pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY1_b8eed8d4-98a0-4ecf-a320-14a08823bf35" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY3_84bc4319-9f30-4871-8144-5a8a6b829ae5" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjky_39001d03-a4b4-4b71-abb1-688dd6e01550" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yLTEtMS0w_a3998398-a7c2-4eda-bba2-a4b111d6ac9c">6,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS00LTEtMS0w_6bbeda6a-d77c-41c5-bebe-ff7e0ceba734">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS02LTEtMS0w_6e83696e-2c05-4c01-ba03-c3471fd7f715">54</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS04LTEtMS0w_f9dc7afa-ad04-4684-a6ba-b5dafca39c59">6,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMC0xLTEtMA_26d03eb4-99f7-4ff0-bfac-26d6ba6b0d9d">6,169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMi0xLTEtMA_2a0ac447-afc8-421a-9f10-9b78eec7a615">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xNC0xLTEtMA_46bb6121-3571-40c3-983a-3ba985d7d6ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xOC0xLTEtMA_f7463dc5-e815-49a5-91d6-7d9195c18037">7,593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMC0xLTEtMA_6305f883-63bb-4b93-b18b-0913ee945900">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMi0xLTEtMA_1acf2f15-7d6e-49d3-ba21-25b7aca0be1f">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yNC0xLTEtMA_867bb904-2835-43d7-b840-0f4b0aedbff8">7,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yLTEtMS0w_cd68fe98-061d-4133-8506-dece5731acb6">1,288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi00LTEtMS0w_69eeee87-a0e4-444b-8876-9a3bcb992064">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi02LTEtMS0w_3cdaf98a-d2ca-4f97-b7cf-93eb6cc60cf0">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi04LTEtMS0w_dfab7f29-227a-4f7e-9ece-beafd1aae312">1,287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMC0xLTEtMA_eeb607c8-b603-47ce-a32f-6805b870d20f">1,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMi0xLTEtMA_38477d12-f8c0-48aa-b256-f9362c61be51">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xNC0xLTEtMA_acd60349-5779-43c3-b960-3056af64c58e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xOC0xLTEtMA_3315eef7-ab12-47b5-bd40-4dc31a5a0589">1,104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMC0xLTEtMA_99e8c318-6d60-4128-a739-b2f4c5122eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMi0xLTEtMA_2ef93a16-23f8-409b-87d5-35dbcb398123">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yNC0xLTEtMA_10bbb966-76ef-4f89-8fcc-b24c800947d7">1,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yLTEtMS0w_d781df9d-a0f4-492d-bea8-dd5576e1a397">900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy00LTEtMS0w_e32b5e1d-95fa-451a-be8b-04640c74eae0">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy02LTEtMS0w_9dc69f6e-5f96-40dc-b047-4a2d899dd543">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy04LTEtMS0w_57cefaf3-cfb1-4e8b-9cbb-3607567bf323">903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMC0xLTEtMA_842cd1af-b0d8-49da-bc75-f1567abca27a">902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMi0xLTEtMA_29814f0e-bc7e-4100-bad3-1714e261b4a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xNC0xLTEtMA_1b5679be-f28f-421b-8cd7-4c0d796062c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xOC0xLTEtMA_8319d658-af6e-4107-9a2b-97469a2e0e23">1,006</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMC0xLTEtMA_981a195b-99eb-4375-84ac-946bb1f7f744">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMi0xLTEtMA_81714873-dfd0-4416-8789-c809f10bb3b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yNC0xLTEtMA_b1f9e746-2cd7-4443-ae8b-4e5de58aaa2e">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yLTEtMS0w_07bbd241-db3f-4a76-b736-99f2072855e5">423</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS00LTEtMS0w_b7846d78-10ec-4f7c-90cf-c886a14027ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS02LTEtMS0w_a7992b20-5a4f-4174-97f5-628b30dc042b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS04LTEtMS0w_78835436-7ff8-495b-b41f-abf30d90a7a3">423</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMC0xLTEtMA_22980516-f8eb-457a-9de6-8cc2f78bdec8">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMi0xLTEtMA_6692adbd-eb15-4881-a102-93a4de78a7ac">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xNC0xLTEtMA_64da2a00-bd0e-49e7-a2ca-9bc072ca1e1f">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xOC0xLTEtMA_47315d7a-2b13-404f-9ffd-5f8a7518b943">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMC0xLTEtMA_694901df-c7ec-440a-a097-f71dfeaf6ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMi0xLTEtMA_25e4299c-38ee-4e88-aa6b-71916287f8a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yNC0xLTEtMA_12143adf-04af-40c4-a3c0-87f8235ed8bc">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMi0xLTEtMA_0523175b-ee1d-46d7-811d-5f135f4d589d">1,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNC0xLTEtMA_6af4f2b7-0a49-4fc0-9068-36b5478505d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNi0xLTEtMA_4693f36a-e15e-4431-89cd-8bf768a6e3f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtOC0xLTEtMA_62e4d649-4206-4b52-bd13-bfa6637effb0">1,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTAtMS0xLTA_40030f7e-df23-487c-a49e-28ad16b8b90b">1,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTItMS0xLTA_b9fa7a41-59b6-4511-96c3-1b5215401bbe">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTQtMS0xLTA_5d809b8a-31cb-432a-b8c6-3e0fc17388da">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTgtMS0xLTA_3ef76328-6b43-4a30-9082-f8c75e27488a">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjAtMS0xLTA_ebb48102-cfe5-4d68-a70d-852d743ed8af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjItMS0xLTA_69502d65-af09-4fcd-a2d3-014eada26b1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjQtMS0xLTA_af444c52-e807-41ae-a980-f256bb800d5f">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMi0xLTEtMA_2faf7650-002d-4131-8034-d67a61917359">10,667</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNC0xLTEtMA_fc634e99-2a61-41e2-9b77-9cf00174d592">25</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNi0xLTEtMA_ffc30947-e969-4c8b-a5e9-9d4ca68add49">55</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtOC0xLTEtMA_5d541135-bd56-4c0c-bbb4-4f86bc9fdf8c">10,637</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTAtMS0xLTA_93ccaafd-26c3-4d9e-a492-d2f0b7ae6d17">10,531</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTItMS0xLTA_3fda55ac-4a62-48f1-8a1a-81063c6fe543">94</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTQtMS0xLTA_8923ff43-4923-45cd-be72-6901c801e610">11</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTgtMS0xLTA_ffd865e9-c609-4b22-97c0-f77c11a56627">9,991</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjAtMS0xLTA_b3cc89a9-6569-4657-9d0e-13e558185759">138</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjItMS0xLTA_08cb45b6-7f51-48a2-b469-86e85d181e0b">5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjQtMS0xLTA_de5d4ba9-2770-4d85-843c-7ba91c4fee4f">10,124</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8b5aa3f235884378a2d9df5387d169d6" continuedAt="i99a8dbddbb254d9c992631c8a88fad0c"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Securities</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjc3_fbaabee9-676b-4c51-83ac-148affb14314" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729">401</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34">255</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC02LTEtMS0w_e85d31b4-7e34-4f7d-8ab3-f6eaaffff246">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC04LTEtMS0w_4e4c035e-a8b9-4f2a-9c76-72cba39d4df9">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334">372</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8">274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" footnoteRole="http://www.xbrl.org/2003/role/footnote">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTM0_0d4bbf9f-5b32-49d9-bb4d-4669d501516e">87</ix:nonFraction> million and upward adjustments of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTYz_89b19814-08e4-4b5d-8e72-15ab252b4446">61</ix:nonFraction> million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_76"></div><ix:continuation id="i99a8dbddbb254d9c992631c8a88fad0c" continuedAt="iee6c6446a01143c7937854f8171c0bed"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE0_2e959cd4-7572-43ce-a292-c4e0d5e72883" escape="true"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi0yLTEtMS0w_33657463-feab-4e9c-9752-b9c2821c3791">416</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi00LTEtMS0w_61ac9564-751f-4e2e-9782-64e1817f61f4">556</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy0yLTEtMS0w_2987c532-4e30-4a8e-89f5-615455f56a88">3,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy00LTEtMS0w_aecda62c-763e-4896-9ae4-7346eccd4a09">2,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d">260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermDebtGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS0yLTEtMS0w_cee0442c-b1d5-4c26-9de7-ab31e1b9a44b">4,355</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermDebtGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS00LTEtMS0w_10467dc7-0814-4205-8366-d8380d31b429">2,705</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi0yLTEtMS0w_5c714e3e-bbe1-4700-8c94-380bb5f111d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi00LTEtMS0w_4d88a5d4-2002-47db-b7a7-c945cfb04edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy0yLTEtMS0w_5f37b799-925c-46b6-9cbd-0ddd5a2c992c">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy00LTEtMS0w_bce079da-fccd-48f2-8ecd-7bbce2d61982">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC0yLTEtMS0w_72d93fda-5e7d-4a9e-ab3d-27e50241651a">4,352</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC00LTEtMS0w_34c6a606-76ad-4f8f-a649-1c75df868591">2,703</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_79"></div><ix:continuation id="iee6c6446a01143c7937854f8171c0bed" continuedAt="i7a6cde35a74a4f2289b13fd6c2546276"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-top:3pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RleHRyZWdpb246YTJiNTIxYWM4ZDIwNDRjNWI0MTcyYjBkY2M4MDg3MjNfMjY5OQ_ef125897-ae55-4ce5-9b1c-1fe095cb4fbf" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi0yLTEtMS0w_7ae6da20-02a6-4aa6-be34-6a266ff518fa">34,032</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi00LTEtMS0w_123082d4-f070-4e47-8476-67495d947c49">35,774</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy0yLTEtMS0w_b1a01d0f-4bec-4784-a867-3211eb25f89d">1,512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy00LTEtMS0w_1d5f8428-95f5-41ac-8282-0e23ea473d69">1,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC0yLTEtMS0w_d7a3d27a-4774-4d96-b381-b557c28a2376">200</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC00LTEtMS0w_d58506eb-d78b-41ae-9dd0-4eb75115a2b0">207</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS0yLTEtMS0w_943aa348-2aff-4bb7-87bf-bc8b6333802a">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS00LTEtMS0w_64512150-c4f6-4a12-88f6-2b55681cf12d">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi0yLTEtMS0w_79f9ca2e-83e2-4623-86c3-1e5bdf895193">35,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi00LTEtMS0w_aa736eec-6a59-454e-b1f8-be5ca74d6d11">37,133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy0yLTEtMS0w_2f0637f7-0995-4145-82fe-d4562b1c7875">3,676</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy00LTEtMS0w_84c71c8f-ee4b-4f08-b614-53956d38e8b2">2,002</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_85"></div><ix:continuation id="i7a6cde35a74a4f2289b13fd6c2546276" continuedAt="iea3da355ddad499bb0743c90458d2c64"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona, Canadian dollar and Chinese renminbi. Additionally, we hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar for up to <ix:nonNumeric contextRef="i436945b9fb544d1485596c97366973bf_D20210101-20210404" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA3NDg1Ng_2be46d00-b5e6-419b-b38c-59d7da129be2">two years</ix:nonNumeric>.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iea3da355ddad499bb0743c90458d2c64" continuedAt="icc14df8fac83414fa39b13be4a48e62f"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0MQ_1c965ef1-4037-4b1c-a709-2106ed1a2aa2" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0Nw_0e008520-46e6-4e1a-b7a7-1f83810219d0" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE5MA_78a3ddf3-a5c0-4bb8-bfdb-d38b7dc4edc9" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c">22,799</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c">408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822">654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8">24,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e">1,005</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0yLTEtMS0w_3a958cba-4715-48e1-8bb7-118dd66db395">450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi00LTEtMS0w_1761eb60-97cf-4e7f-8d8d-481e46a55a77">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi02LTEtMS0w_9f3fc9a6-1fa2-46c5-9642-7c3d1dc517e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi04LTEtMS0w_614ca566-8364-4220-96d7-5960680b1d3f">1,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMC0xLTEtMA_db9464c2-fb50-483b-8021-e3b88a258c0a">135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMi0xLTEtMA_b5e88ff0-b256-4656-8387-d6ee84a20841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5584c105e0a1417da14d21d850e54027_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy00LTEtMS0w_c588893a-0845-4e72-9819-a2e904364b09">435</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5584c105e0a1417da14d21d850e54027_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy02LTEtMS0w_f199ce52-5ac3-44a8-974c-f9a0bb93c456">654</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d153096cf74722befa5ea904fa6b4f_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMC0xLTEtMA_f9c16a73-bec2-4cd4-9f61-295c27518fc7">280</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d153096cf74722befa5ea904fa6b4f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMi0xLTEtMA_d948488b-07c5-4ceb-971a-556c1ebcb51b">1,005</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMi0xLTEtMA_8e74d3fb-6a23-4430-aa81-982b1650df63">14,726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNC0xLTEtMA_45a603dd-2b5d-49dd-8f8d-280f75196dbd">86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNi0xLTEtMA_35d7698a-ca6b-4088-af1b-b9ef133a3cd1">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtOC0xLTEtMA_bb0052e3-9ef7-47c7-9893-83a429516f00">15,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTAtMS0xLTA_0efdf456-38a8-4ff8-ae56-e0fc881d0434">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTItMS0xLTA_c67f3af8-1e1b-4b8a-91ee-179cc84bfdd1">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNC0xLTEtMA_588bf4de-9f3b-4fd6-bac3-b554a2f9a1cb">521</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNi0xLTEtMA_afdae661-fa74-47b4-918e-6720f8f866c9">732</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTAtMS0xLTA_56603fdf-c2cb-4086-b264-66f70613f317">373</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTItMS0xLTA_3aa28942-fc2f-4020-8f84-4d3807740f23">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" footnoteRole="http://www.xbrl.org/2003/role/footnote">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonFraction unitRef="usd" contextRef="ie3d739b69c924476ab9fc489134e052f_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595">5.1</ix:nonFraction> billion as of April&#160;4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1">5.0</ix:nonFraction> billion as of December 31, 2020.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0NA_259b0f86-551d-4f94-aca0-5a7d19cf623f" continuedAt="i79a3908baa7e4b95b52c7f492342ff58" escape="true"><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785">202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5">529</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d">268</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc">386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056">386</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a">384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a">147</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52">45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcaa753284e740be9e09512ba86381ee_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5">42</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee">59</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab">460</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31">83</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc">230</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcaa753284e740be9e09512ba86381ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153">23</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="icc14df8fac83414fa39b13be4a48e62f" continuedAt="i5dd47355cfd2448d9310d0e1df2634b9"><ix:continuation id="i79a3908baa7e4b95b52c7f492342ff58"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" continuedAt="i175226f007db4092b6cb44061ed091af" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI into COS were:</ix:footnote></span></div><ix:continuation id="i175226f007db4092b6cb44061ed091af"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $<ix:nonFraction unitRef="usd" contextRef="i5f3171903a684fc3919479487e325172_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYwMw_b0a8ecb0-2cfa-4532-b323-63e4b6ecec6b">45</ix:nonFraction> million in the first quarter of 2021; and</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $<ix:nonFraction unitRef="usd" contextRef="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYzOQ_52488f92-a4e6-4772-aa85-547239d4eaf6">70</ix:nonFraction> million in the first quarter of 2020. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjgzMQ_6400a353-5a9e-45a7-9a99-8ef9cfb5aded">20</ix:nonFraction> million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonNumeric contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" format="ixt-sec:duryear" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MzA0OQ_7920a480-e60e-4a8f-9bd0-ccaaa2fc75c9">22</ix:nonNumeric> years and relates to foreign currency debt. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" footnoteRole="http://www.xbrl.org/2003/role/footnote">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $<ix:nonFraction unitRef="usd" contextRef="iea937bd52464448b93d716a8cf093ae8_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MTY3NQ_a4a55cd9-af84-436c-9b3a-a90fc1d23ba5">1.2</ix:nonFraction> billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="iea937bd52464448b93d716a8cf093ae8_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMzE1MA_35ea1271-218c-40e1-a508-2807fc83ed0b">872</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0661f5622ccf41418edc8cfa0839da72_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MjIwMg_2591fdf1-2144-4862-9168-41b1bbc579a5">2.1</ix:nonFraction> billion, respectively.</ix:footnote></span></div></ix:continuation><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3MQ_d0dd2570-be24-49ff-b8e0-ff2a06aeabb9" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289">494</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy00LTEtMS0w_770f16d8-49ea-49e3-bf14-98b4833707ad">21</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy02LTEtMS0w_e0fe65e8-9aca-48cd-90dc-9c488dfe8ebe">1,202</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b">2,016</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMC0xLTEtMA_4178d95c-8f13-4b8f-847e-07bcf294c65c">117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMi0xLTEtMA_bf551ad1-557c-43d9-92d6-7c9b8dda588a">1,149</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" footnoteRole="http://www.xbrl.org/2003/role/footnote">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_91"></div><ix:continuation id="i5dd47355cfd2448d9310d0e1df2634b9" continuedAt="i4a648fb11ce847fa821c421efb98310b"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from drug wholesalers. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., U.K., Germany, France, Japan and Canada.</span></div></ix:continuation><div><span><br/></span></div><div><ix:continuation id="i4a648fb11ce847fa821c421efb98310b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&#160;4, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjQ4OA_b1ec973b-7377-41c3-b716-5a93e7aa0bbd">613</ix:nonFraction> million, for which we have posted collateral of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjUzMg_06037b28-5528-4ce2-b957-14eb2f05c586">675</ix:nonFraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of April&#160;4, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjczMg_d1ae70fc-a071-4554-b119-0f7d9f415b12">53</ix:nonFraction>&#160;million, for which we have received collateral of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3Mjc3OA_87068f9e-1540-4a59-b911-ae15fb63db72">124</ix:nonFraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_94"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzUw_3e7953e3-b4ea-4ff9-a04a-7a47f34d5ab3" continuedAt="ib96f70fe9f5f46cfbe1cedbab4185083" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="ib96f70fe9f5f46cfbe1cedbab4185083" continuedAt="i2b10f177a6d84b0bb3e3efc576b3c138"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM1_a36b9ba9-a689-4188-a72d-47a010f6647e" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzU5_3332a7de-1085-4771-8a8c-d29eacb33bed" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi0yLTEtMS0w_661eb3d8-831f-467d-b168-e26c414f81fc">3,289</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi00LTEtMS0w_d1a6fc00-5937-4ead-8286-a5475ddfd251">2,878</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy0yLTEtMS0w_402e2127-d6fb-40d6-9756-054e3866e171">4,364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy00LTEtMS0w_0d8c0f2b-2520-4da7-981b-115bc6924801">4,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC0yLTEtMS0w_959c1455-3c94-463b-a3a1-5d097abaf83a">840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC00LTEtMS0w_4bac4008-392a-45ab-8d95-fb42212dabd9">738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959">8,493</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f">8,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc">981</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3">890</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" footnoteRole="http://www.xbrl.org/2003/role/footnote">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></ix:footnote></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i2b10f177a6d84b0bb3e3efc576b3c138" continuedAt="i0def74b84d6841d783ff6bcdbe7253fb">Other current liabilities</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0def74b84d6841d783ff6bcdbe7253fb"> related to the gross margin split with BioNTech for BNT162b2 totaled $<ix:nonFraction unitRef="usd" contextRef="if40f67d115f744f597392dd0dafbaa4e_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTcyNQ_1e3e8133-5bad-4af6-973d-c230e6ac3938">1.4</ix:nonFraction>&#160;billion as of April 4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie113bce7166d40bdacd5506226e15172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTc0NA_7f23cac2-a3d1-48de-a85f-bf20d048b160">25</ix:nonFraction>&#160;million as of December 31, 2020.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_97"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwMw_cfab5511-c498-4695-81c3-e9902fa1a5ca" continuedAt="i7c111a9cc1b14abeadaacc83652577cc" escape="true">Identifiable Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i7c111a9cc1b14abeadaacc83652577cc"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1OQ_240060ae-aa21-4342-a5ca-6d2fd61a610b" escape="true"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc3Ng_411ebbe7-a724-4981-b743-ae3dd88c4500" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f">74,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e">51,840</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7">22,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e">73,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4">50,902</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5">22,643</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0yLTEtMS0w_57ffaeb8-ef50-4f03-96bf-85e8e1debe68">922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS00LTEtMS0w_1c436919-9f5b-46fa-ae00-2db25b374627">782</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS02LTEtMS0w_e66d8482-0a5a-4d6e-93bd-52628b3bf06a">140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS04LTEtMS0w_5c3156eb-a804-46ec-aaea-76b7c63c4b3b">922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMC0xLTEtMA_eea1ccc3-f558-4bcd-98e4-5a203e57c583">774</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMi0xLTEtMA_2eb936e2-e300-4733-829e-b7d774fbb0e3">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0yLTEtMS0w_d2a4d4eb-792d-469d-8cd2-8d03787db944">2,305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi00LTEtMS0w_903337d3-be4c-4ebc-ba30-c7eb59f70b95">1,223</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi02LTEtMS0w_afd53bde-ae40-485b-a3cc-315b5f5756c7">1,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi04LTEtMS0w_b2c909d4-864f-4ae2-9aa5-e945ece94dd0">2,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMC0xLTEtMA_948d361f-08f3-4ff2-957d-70dee7dd975c">1,186</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMi0xLTEtMA_ea5d323f-80e2-4126-8cf9-b30b00a2067d">1,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0yLTEtMS0w_17f0d32f-fc4a-4638-b53d-cab80a618b42">77,284</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC00LTEtMS0w_aa39b511-1159-4618-a7d3-8efb650bc89e">53,845</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC02LTEtMS0w_49a0e508-ab6f-4056-8305-2aa8c460fe00">23,439</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC04LTEtMS0w_d4dbb544-4a8b-479f-a6a0-661df11bfb7d">76,759</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMC0xLTEtMA_808eabda-ba6c-42ef-844d-acc2cf61c368">52,862</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMi0xLTEtMA_7cce6d33-2af3-4fef-8ed3-8bf619184a9f">23,896</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5d302584f242a887a90c5ba675f0f7_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMi0xLTEtMA_21e0af34-2a12-46e2-b8d9-e49cab2d4696">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5d302584f242a887a90c5ba675f0f7_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtNi0xLTEtMA_92421b8b-a67c-4818-8eff-e48b38da0df6">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9cb52c2c4d4db882a1c475c695052f_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtOC0xLTEtMA_efacb928-2066-41fd-a3f7-6a6d22774775">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9cb52c2c4d4db882a1c475c695052f_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMTItMS0xLTA_03e9776c-6053-47ef-b7b5-1424442aae28">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMi0xLTEtMA_a275d43a-7336-432f-a95c-7cee9c1861ab">3,135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtNi0xLTEtMA_77d8c623-6b87-4997-b311-01049540d5c9">3,135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4631e305af2483e8890f326b9fef89d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtOC0xLTEtMA_e4becf38-ee61-4cbb-8e99-2daf35227ff7">3,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4631e305af2483e8890f326b9fef89d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMTItMS0xLTA_28d8c399-5add-4f29-81ec-7d543142f052">3,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3aa408a10c644979d8878d88bca2e75_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMi0xLTEtMA_4c8ca8de-e276-48c0-b518-986b8566fb19">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3aa408a10c644979d8878d88bca2e75_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItNi0xLTEtMA_7f2667b7-d939-4d7e-ba0c-f07c315852ac">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItOC0xLTEtMA_84186afa-80e2-40dc-ab67-16603619fc4a">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMTItMS0xLTA_785b6755-5573-4c6d-ad4a-59fcdfd38ca2">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMi0xLTEtMA_1a1aa527-03b0-4f20-92e2-afb58c8f7eb1">4,535</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtNi0xLTEtMA_9b8f0a38-2570-4e77-8aa5-b0bfcc8cd912">4,535</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtOC0xLTEtMA_cba7b496-64b2-4e5b-bbe5-6df7c075fa48">4,575</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMTItMS0xLTA_7d6cbbd7-70a8-4b97-b1c1-d8c421231cdb">4,575</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858">81,819</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a">53,845</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934">27,974</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610">81,334</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7">52,862</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6">28,471</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase in the gross carrying amount primarily reflects $<ix:nonFraction unitRef="usd" contextRef="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYzMg_ec8a44d4-8876-45ea-9f2e-7366615c50b2">300</ix:nonFraction> million of capitalized BNT162b2 sales milestones due to BioNTech.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" footnoteRole="http://www.xbrl.org/2003/role/footnote">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly all of our identifiable intangible assets are managed by our commercial organization, with only <ix:nonFraction unitRef="number" contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="2" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYyNw_52442337-e16e-4ee9-be53-e91ca7a24e8e">9</ix:nonFraction>% of total IPR&amp;D assets managed by our R&amp;D organization.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ0Ng_2c508c5e-b98b-47bb-b20a-61ecd80c5f89">883</ix:nonFraction> million for the first quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ3OA_b9eb3dbb-e3b0-48c1-9e6b-51069273e904">861</ix:nonFraction> million for the first quarter of 2020.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_103"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzM5OQ_264568b5-6a8d-4797-ab10-591a5e009433" continuedAt="ib0daa565a6b04b44bcb55aad52d73389" escape="true">Pension and Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="ib0daa565a6b04b44bcb55aad52d73389"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzQxNQ_6a2add9a-9548-4003-b208-30111899700b" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMi0xLTEtMA_8687b3ce-db3e-4cb2-bfbf-ec42a396982b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtNC0xLTEtMA_8a939fa7-2d34-493f-ae2f-9102f6506285">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTAtMS0xLTA_a8dfa0cd-d993-4d8a-afd4-456f681bc72c">33</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTItMS0xLTA_ce2d5b3a-1a61-4b0c-99be-39e93b20b725">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTQtMS0xLTA_b6b825d7-439f-4d37-b2c5-995c131591ad">9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTYtMS0xLTA_1c911f5c-11cb-4034-86e2-a7b4a69d2795">10</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMi0xLTEtMA_ba9272fe-72a6-486c-813d-cbdcacfb796c">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtNC0xLTEtMA_c75929a4-d3d3-4db7-b2a1-e8f2b84223cb">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTAtMS0xLTA_20ca625b-08c8-4088-bbc9-a2b47ef13616">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTItMS0xLTA_70f018c0-3d15-4208-bc06-f0cae88d2201">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTQtMS0xLTA_0eee66b5-36eb-4ea2-8d19-e94784e66fe6">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTYtMS0xLTA_0ee67451-f51d-46d4-9af9-3dd979d4604f">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMi0xLTEtMA_f23540e6-9c8b-44fe-ae0c-98cc746c5f18">261</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctNC0xLTEtMA_81e605c1-cec9-4885-988e-523c910d6f05">252</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTAtMS0xLTA_779c6d88-5c3e-4ebf-8d68-05ddc941f75b">82</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTItMS0xLTA_a5768e51-76da-4789-ab9c-ee900aa74cbd">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTQtMS0xLTA_120b8bfe-2971-4685-b205-11934317ad9f">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTYtMS0xLTA_b747664b-d8fa-4585-9ce9-122d619f0076">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTItMS0xLTA_bd80891a-acc2-4214-bc84-1a6ab5c39836">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTQtMS0xLTA_e2322c30-936d-4e52-9fb2-036af65cd0bc">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEwLTEtMS0w_5ce3488e-10a0-4810-a358-0feadd783023">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEyLTEtMS0w_964fb994-e5fd-42d7-91b6-b4d0cd226fac">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE0LTEtMS0w_1ce86a28-0f04-4fd2-a084-f040ae3ce5e6">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE2LTEtMS0w_656bd82b-911b-48ba-a196-b19f37c69159">43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTItMS0xLTA_ff97d46c-fced-476a-b2a5-54106c04e446">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTQtMS0xLTA_5f84e636-9bbf-4595-8639-ea37be2b0c54">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEwLTEtMS0w_044b0c2c-994d-416e-83b6-e67d5f636a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEyLTEtMS0w_d51533d3-6263-4abf-91a0-3da58876c737">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE0LTEtMS0w_0bf5e105-1467-4fb9-8409-5f0d8cd83943">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE2LTEtMS0w_b1fbfc66-3292-4a4f-b592-602046d88abb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTItMS0xLTA_5ae04baf-f60c-4f40-acb6-c2306ef6700f">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTQtMS0xLTA_d015451d-2db4-467d-ac30-e4346ce7e5e8">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEwLTEtMS0w_603a616e-3578-438d-b9ad-ad0ec331fff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEyLTEtMS0w_8842c90b-452f-4485-bdab-713c259e6abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE0LTEtMS0w_dd0e93ac-3718-441e-8a41-4b8d0bc1f4d5">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE2LTEtMS0w_60213122-1ebf-497d-ba70-0f5a512abd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTItMS0xLTA_9fefa320-0775-408d-a824-2607b2160ab4">187</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTQtMS0xLTA_68520c5b-b502-4386-a00f-427048342f84">53</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEwLTEtMS0w_244d5c8d-eaff-472f-a1bb-92d486288ae1">12</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEyLTEtMS0w_2a57a0ab-238e-479f-bcbd-4f94673d4750">1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE0LTEtMS0w_6f6beb1f-cefc-4e0c-89b8-90a419443c5e">32</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE2LTEtMS0w_cedf8bff-dc8d-4f66-8a38-261a00606227">30</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April 4, 2021, we contributed $<ix:nonFraction unitRef="usd" contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTE_61d9fc06-f971-4e1a-bd1b-60702afc5d59">83</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTY_bceb8feb-be42-41c5-95f8-393229dd26c0">40</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NjU_d1d72d09-6397-47cf-a422-479864a03710">19</ix:nonFraction> million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_112"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI1NA_f96deb72-44b6-40d9-9803-8891bc8b5b7b" continuedAt="if4a9e3dae89e440ea4608ef2df9be514" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonNumeric></span></div><ix:continuation id="if4a9e3dae89e440ea4608ef2df9be514"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI0MQ_366e801e-c252-4bec-9279-8d6ce96bfe50" escape="true"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtNi0xLTEtMA_1125ce2f-542b-4f09-aa91-14cc328e1643">4,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtOC0xLTEtMA_4c7ca253-9bac-4b7f-939d-2a2c06753108">2,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctNi0xLTEtMA_6f8d4680-ddfb-4616-81de-e822e9e17389">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctOC0xLTEtMA_14a58154-6cc7-4314-a23c-e958f0e54318">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtNi0xLTEtMA_a73aafb6-82db-4f69-96c9-860c812b3103">4,868</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtOC0xLTEtMA_511b2ca2-dbed-45a0-ba60-7fe83af468ab">2,474</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktNi0xLTEtMA_5944ba14-19d5-4c71-a51c-16b551a6353e">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktOC0xLTEtMA_4132dcb7-62f2-4428-a3ac-59e2f71702c0">881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTYtMS0xLTA_67bad856-d181-47b8-a462-bb33c85c5142">4,877</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTgtMS0xLTA_a6e25586-5a1b-4152-bc03-0750e704b661">3,354</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTYtMS0xLTA_3930246c-ef83-4ef5-9f57-118b0fc5b2f9">4,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTgtMS0xLTA_f7a6ccef-0247-4155-84d1-600db8211e57">2,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTYtMS0xLTA_ece5396d-10ea-4d1d-96f8-96e7cda58994">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTgtMS0xLTA_786e5dfd-6dca-415e-98a5-8c1527a41f8f">881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTYtMS0xLTA_3bf9d328-0a72-40a8-b86c-8a084ea4d727">4,877</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTgtMS0xLTA_20ae953a-8de0-4b65-9256-3f5d7a042ecc">3,355</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTYtMS0xLTA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9">5,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTgtMS0xLTA_1ce1f538-b793-443a-8e14-be3400178559">5,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTYtMS0xLTA_fade8507-b85c-420b-837d-7b877518ba4b">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTgtMS0xLTA_3ba6178b-fcaf-4f1e-8a63-086f591f54a7">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTYtMS0xLTA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da">5,662</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTgtMS0xLTA_56fa12c0-55ed-4708-b561-3527a11165d8">5,613</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67">2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663">3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" footnoteRole="http://www.xbrl.org/2003/role/footnote">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_115"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzM4MjU0_045665f4-6571-4532-95a6-ced1712f9abe" continuedAt="if6f98a86ddd34966a91ba5fc0bedbd88" escape="true">Contingencies and Certain Commitments</ix:nonNumeric></span></div><ix:continuation id="if6f98a86ddd34966a91ba5fc0bedbd88" continuedAt="ic51a937890a44a1a91830ac8d0ee8711"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic51a937890a44a1a91830ac8d0ee8711" continuedAt="i375e5dd649b945ce872cdcbbce212b30"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. In August 2020, the SEC amended its disclosure rules regarding the threshold for disclosure of proceedings under environmental laws to which a governmental authority is a party. In accordance with the amended rule, we have adopted a disclosure threshold for such proceedings of $<ix:nonFraction unitRef="usd" contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5Mjk4MDg_b242f245-28fd-48cc-b7e2-19d4308d5b7f">1</ix:nonFraction> million in potential or actual governmental monetary sanctions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings, which remain pending, with respect to <ix:nonFraction unitRef="patent" contextRef="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NTYxNDI_b2627468-3145-4b6a-a6ab-2ce69ebcc070">two</ix:nonFraction> of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those <ix:nonFraction unitRef="patent" contextRef="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5NDc_77c6a750-e364-489f-93c0-284ee70769b7">two</ix:nonFraction> patents, and <ix:nonFraction unitRef="patent" contextRef="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5Nzg_5a441330-748b-431a-94d2-f5706f4cd8c7">one</ix:nonFraction> other patent, are now being challenged in federal court in Delaware. Challenges to other pneumococcal vaccine patents remain pending outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor&#8217;s vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i375e5dd649b945ce872cdcbbce212b30" continuedAt="ibf6b4773fa134d4e8d6da4aad1bb2ba1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) asserting the infringement and validity of <ix:nonFraction unitRef="patent" contextRef="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NzEyMjI_288e97f8-41cd-4d69-9b4a-02865f9bcade">three</ix:nonFraction> patents: the patent covering the active ingredient expiring in December 2025 (the 2025 Patent), the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023 (the 2023 Patent), which Zydus challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2020, we settled the case against Zydus on terms not material to us. In February 2021, we brought a separate patent-infringement action against Zydus asserting the infringement and validity of our composition of matter and crystalline form patents challenged by Zydus in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2021, we settled our remaining action against Zydus on terms not material to us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the 2025 Patent and the 2023 Patent, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance. The companies assert the invalidity and non-infringement of <ix:nonFraction unitRef="patent" contextRef="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5ODI3Mzg_d1cdeca3-fb26-463a-890c-5b8db8696bad">two</ix:nonFraction> composition of matter patents, one of which expires in 2023 and one of which expires in 2027, as a result of a U.S. Patent Term Extension certificate issued in January 2021, and a method of use patent covering palbociclib, which expires in 2023. In 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonFraction unitRef="defendant" contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyNumberofDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDE5NjI_0814ad79-3138-4bea-bfec-5e4ec5e97291">twenty-five</ix:nonFraction> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the <ix:nonFraction unitRef="patent" contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIxODE_b9c86de9-60b5-4db7-8dd9-5e122e5032ae">three</ix:nonFraction> patents listed in the Orange Book for Eliquis. <ix:nonFraction unitRef="patent" contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIyMzI_099b6f05-21ef-4f1e-b175-8053924514ed">One</ix:nonFraction> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibf6b4773fa134d4e8d6da4aad1bb2ba1" continuedAt="i07abeb37cd424590acaf199ebe49f91b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all <ix:nonFraction unitRef="patent" contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDI5MTY_d113a473-d837-4ddd-b8d6-76bdc1f97633">three</ix:nonFraction> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i07abeb37cd424590acaf199ebe49f91b" continuedAt="ia1519dc3968a449ab3110fb1b918a25f"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least <ix:nonFraction unitRef="lawsuit" contextRef="i02973e07500446c182f01c27b105cb67_I20210404" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyNumberOfLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDMxMzM_4c051b5e-7e11-41d1-99e8-3a143c43e2ea">one</ix:nonFraction> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, a new lawsuit was filed in the U.S. District Court for the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonFraction unitRef="manufacturer" contextRef="i104649887c064a40a045fee23a147e9b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY1NTQ_edc14692-2ca4-4fa7-8989-81c9a2231a3f">eight</ix:nonFraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia1519dc3968a449ab3110fb1b918a25f" continuedAt="id74b5cfbae8c4d87a67d19b9499b231a"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Array Securities Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonFraction unitRef="classaction" contextRef="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyClassActionsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY4Njc_56f66725-4c77-40f0-a3f3-4bf5f497a549">two</ix:nonFraction> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In 2018, the actions were consolidated into a single proceeding. In March 2021, the parties reached an agreement in principle to resolve the litigation on terms not material to us, which is subject to Court approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. From June to December 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of <ix:nonFraction unitRef="classaction" contextRef="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyClassActionsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDg2MTY_dc06a69e-9cf7-46bc-8552-b1b8bb708859">two</ix:nonFraction> Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico; and (iv) Pfizer received service of a suit filed by the Mayor and City Council of Baltimore naming Pfizer and other defendants alleging various claims under Maryland law.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id74b5cfbae8c4d87a67d19b9499b231a" continuedAt="i3102daf9593f46239357722c0d85a66a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative Order on Consent with the EPA. In 2019, the EPA acknowledged that construction of the site remedy has been completed. In March 2021, the State of Connecticut, Department of Energy &amp; Environmental Protection issued a Stewardship Permit to Pharmacia &amp; Upjohn Company LLC, our wholly-owned subsidiary, that will govern the ongoing operation, maintenance, and management of the North Haven site, and which will not have a material impact on Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy to address the discharge of impacted groundwater from the facility to the Raritan River. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for <ix:nonFraction unitRef="lagoon" contextRef="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:FeasibilityStudyNumberOfLagoons" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzAyNDQ_0ba37e9b-bfa7-4454-bedd-6bb05d58a2f5">two</ix:nonFraction> adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the <ix:nonFraction unitRef="lagoon" contextRef="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:FeasibilityStudyNumberOfLagoons" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzA3MjY_9a70d49c-7f8b-49b7-b2ea-175879c0f1e6">two</ix:nonFraction> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and, in 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. The plaintiffs are appealing the District Court&#8217;s decision. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In 2018, the District Court dismissed the lawsuit. In 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian. That suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breach of Contract&#8211;&#8211;Xalkori/Lorbrena</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i3102daf9593f46239357722c0d85a66a" continuedAt="iaf3a18971ea4436386818f7e8fd6d938"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General Generics Antitrust Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State of New Mexico Civil Action</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A2. Contingencies and Certain Commitments: Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iaf3a18971ea4436386818f7e8fd6d938"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April&#160;4, 2021, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages. In addition, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_121"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NzE_ad2b7d5c-3a7d-499e-b0e6-3ca6da407328" continuedAt="i25425e7e7ce548099c029dd20dba2a85" escape="true">Product, Geographic and Other Revenue Information</ix:nonNumeric></span></div><ix:continuation id="i25425e7e7ce548099c029dd20dba2a85" continuedAt="i98985c723dcb4553aae15fc7bdfbf59c"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Geographic Information</span></div><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzOTA_bf3f5d34-59cf-4e71-aeeb-171700febc4b" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3825cb911e8746189fdd8101073ce536_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtMi0xLTEtMA_de616e87-1519-47cd-9d73-0bcf081dad42">7,597</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNC0xLTEtMA_b5af4009-5eda-4358-a596-188d87a9f7df">5,289</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3825cb911e8746189fdd8101073ce536_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNi0xLTEtMA_e5ff1e2c-68e3-4b01-ae44-60d27e63a162">44</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtMi0xLTEtMA_01253d63-32a6-4ac7-99b6-3af454234e37">3,038</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNC0xLTEtMA_1eb771c2-4ae9-446f-bb60-dd7ac1730661">1,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNi0xLTEtMA_a356971f-6228-4e86-b047-2c6d428572a0">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtMi0xLTEtMA_caa8c2c5-70f2-4f42-a281-455ba55a28bb">1,123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNC0xLTEtMA_77192e04-c3ab-4179-8c09-24e7cb03264f">919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNi0xLTEtMA_d82da09a-6f12-483a-83ce-4051f6ccdc81">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtMi0xLTEtMA_f4d97e43-ba99-43e5-bfbb-054297d02cf4">2,824</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNC0xLTEtMA_4cc4c45d-28e1-4d20-b64d-41e921c59925">2,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNi0xLTEtMA_5e8e94de-c1f4-4740-9605-a313777e45c9">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctMi0xLTEtMA_b07bfd7f-a947-4f55-8fbf-7c1b292bb668">14,582</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNC0xLTEtMA_37369dd6-3ee5-4f7a-a187-378163a1cc80">10,083</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNi0xLTEtMA_e2672cd5-c588-4984-a57b-33a273632093">45</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 under such agreements. We currently sell the BNT162b2 vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February 2021 with the European Commission (EC) on behalf of the different EU member states and certain other countries. Each EU member state submits its own BNT162b2 vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Revenue Information</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K. Additionally, revenues from sales of BNT162b2 to the U.S. Government represented <ix:nonFraction unitRef="number" contextRef="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4NzM_201eed17-5824-4b80-b7e8-ba039c52ba9e">14</ix:nonFraction>% of total revenues for the three months ended April&#160;4, 2021. Accounts receivable from sales of BNT162b2 to the U.S. Government represented <ix:nonFraction unitRef="number" contextRef="i66c5094c3226447689dc0560d6f61760_D20210101-20210404" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4Nzk_f2fd3772-681a-4779-a755-28b9caf83164">12</ix:nonFraction>% of total trade accounts receivable as of April&#160;4, 2021.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i98985c723dcb4553aae15fc7bdfbf59c" continuedAt="i123d02fa33c34cd0ab980020160d5226"><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonNumeric contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzODY_c0e2d0ec-3d0b-4518-aee1-3f82aff1a47f" continuedAt="i8ffe1a600d0042c7b31b644dc5739386" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.856%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747">14,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711">10,083</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Vaccines</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtNDEx_b6cd2341-d5eb-423a-b6f7-bd4311b1fcd3">4,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtNDEx_1239f2e4-df26-4abe-912d-6aa92d6c05da">1,611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BNT162b2 alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtNDEx_047f2551-2d31-4a04-945d-b1aee1a1574a">3,462</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtNDEx_75508515-00df-4d48-b53e-e1f8f79259ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtNDEx_8afd91f6-c82c-4872-aa5c-593b5b1a1dc2">1,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtNDEx_76e08ad5-aa23-4561-9c06-72739acbfba5">1,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME/IMMUN-TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMTU0Njk_cdd602b5-de4f-421a-8c2c-916e3ada821f">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMTU0Njk_b9f4d774-f901-4bb3-96f6-a35e5d73852f">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtNDEx_8726d48d-8349-4710-bd7c-e0f10a7c0b99">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtNDEx_acc2ac48-92c9-470a-9769-004bccb56a5b">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Vaccines</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNC0xLTEtNDEx_6ce406ec-37a0-4b1e-9221-b03994d0e0c8">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNi0xLTEtNDEx_5f483b36-9728-4c58-b9fd-29878c1e5ace">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00018897a8a546288611fca2330ad40d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtNDIx_928ced8e-9364-4991-91fd-c1d23fb2a965">2,862</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtNDIx_e7f64f4b-8131-40ee-8a62-3d37973a10d3">2,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTQtMS0xLTQyMQ_8a6df27e-b519-48c7-adc2-6729f72aeaf0">1,254</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTYtMS0xLTQyMQ_bb8a2b8e-6188-45bd-82b6-17110ded7572">1,248</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTQtMS0xLTQyMQ_7b83ff17-208f-493a-9933-90d9502a39eb">267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTYtMS0xLTQyMQ_2f4a5b71-9ec8-4cee-94a3-88c3b568e0c2">209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTE1NDc5_bceabdd8-7534-4cea-a052-c38e0d3e6633">229</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTE1NDc5_db811494-315b-4d83-a24e-549adae28480">169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTQyMQ_0db56c24-c460-464d-a8e2-a7b6e742ff1b">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTQyMQ_c48e51fd-c9dc-4449-b947-dd36146c9671">205</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTQtMS0xLTQyMQ_ca32fa01-cc30-405f-ac07-b427eda4bdbd">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTYtMS0xLTQyMQ_31f833f6-7c86-4a66-b12b-6542c47c563a">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTQtMS0xLTQyMQ_417f3cc0-13fe-4f1b-9985-eec2b6361b66">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTYtMS0xLTQyMQ_d346a5cf-775f-4676-8c95-1f09b9273b9a">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f">86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTQyMQ_3ade3a2d-1545-405b-b634-f67e081a3366">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTQyMQ_403841b9-443a-439b-8c4c-ff0163ecaa7e">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTE1OTE5_739edb05-224b-4255-bbc3-e9bf50ab2d7d">52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaee0a8c94344749aad179a107f5379d_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTE1OTIx_5cf5a222-3fff-4ab3-bc51-355906a66881">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTQtMS0xLTE1OTE5_bb3a233d-7d4d-458e-9f0f-88f0c696b71c">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTYtMS0xLTE1OTIx_988e52bd-6b03-4dfc-9ab2-d9853c4496f5">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTQtMS0xLTQyNw_045f8b7a-7116-4421-a75d-65e7355959ac">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTYtMS0xLTQyNw_13d5fa33-ad3d-4226-b1d5-f7bc20b713a9">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTQyNw_e37145f4-b52f-4d1b-8f0c-2445176083da">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTQyNw_a68467e4-52d7-4bb7-b8fe-7ef2b559ef1c">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTQtMS0xLTQzMw_f450758b-8d5a-410b-9288-185b6a433d67">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTYtMS0xLTQzMw_07090c70-f7cd-4d57-884a-d76c1575f1e1">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Internal Medicine</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d86911b85754856a091d39a9a619036_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtMA_339104d8-f2a4-4d92-84f7-27a037baaa1d">2,594</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtMA_5014e54f-62a2-4e20-98eb-ddb9f083ea7d">2,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtMA_edb58811-4e34-4158-b753-89b65192d859">1,643</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtMA_733a49ad-6056-4006-a78f-f628caf2663d">1,300</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15547904869341898a05e8608012fdf7_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtMA_98ecd8b0-ce73-4f0e-ad3b-b4e6d421f10c">217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia665187179da484eb6e599146133e64c_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtMA_e86b12cc-2864-4a84-8391-1f89eddd02a2">270</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMA_5c35c781-e928-457a-a06d-00e984fa2688">143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMA_94c3315b-2bc4-4522-a5f5-9ea8155295f5">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTQtMS0xLTE1OTI1_f3c4b946-e74d-4718-834d-f3aaefd26598">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6217a5b597e247debffac06a2be42229_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTYtMS0xLTE1OTI3_0e370ed6-70bb-4668-84b9-3c50308f771d">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTQtMS0xLTE1NTA2_39aa5fb6-f7ab-4c36-9267-8ce00c67fe65">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d647526b664456a53481f1fcd29c09_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTYtMS0xLTE1NTA2_705ed196-8bdd-4fd9-8ede-323e57b5669b">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtMA_33dc4f68-76c4-4c27-8126-a984b828a987">474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtMA_a1dfa7ac-d7e6-429d-bf04-d09ab44960ce">509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9">2,343</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5">2,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTQtMS0xLTA_49b33136-137f-4266-b009-9abe46fa6a7b">192</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTYtMS0xLTA_de5f1774-8826-4e53-9fd3-e3c6d33f793d">187</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTQtMS0xLTA_2b5ce3e7-021e-4d46-b192-8d36813d04d2">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTYtMS0xLTA_851f1a5b-b3a2-4039-bc1e-d270c02c061b">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTE1NTEy_c42c1f8f-dc46-4a67-a03a-c301c52f9ac1">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTE1NTEy_65d30d6c-b9fb-441e-8d25-f0ab9195d9a8">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTQtMS0xLTA_6374d573-a87c-4a36-bd53-98926d72ed72">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTYtMS0xLTA_f696e168-af9b-41fc-8d90-2dc8ad63a4e2">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTQtMS0xLTA_7040c689-76f9-435e-9e12-73c7b0f245dd">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTYtMS0xLTA_71555e69-a4a7-44e1-880f-f09dcfe9899d">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTQtMS0xLTA_58e27134-cc8c-411c-8d27-cfb478f8478e">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTYtMS0xLTA_c121e5fe-55af-468a-87a8-47ed849c8cc7">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">EpiPen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Epinephrine injection used in treatment of life-threatening allergic reactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTQtMS0xLTE1NTE4_abd76629-91b8-4df2-9764-2f1b7d507e15">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia251f6f252be4fca87be237b62587e21_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTYtMS0xLTE1NTE4_38330553-8b6c-4ea4-90b7-4aa3f8986b35">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zyvox</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTA_93246ed8-93c0-4762-8596-8ccda3564dec">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTA_c84d0308-24dd-46a9-8f30-1d958b299b8a">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Precedex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTQtMS0xLTA_a888aabe-459b-4a99-ba25-7fc696a5a372">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTYtMS0xLTA_2467aa26-882b-48e1-9dd4-df09ca9d7188">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">IVIg Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9846250722404133a31c34c978297518_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f">391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9903f105558492aac6500bc30eaadca_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTQtMS0xLTA_ca95dd51-916a-4255-bd9d-a716c45cc979">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTYtMS0xLTA_a4546b05-e2e6-4e18-a4e6-db2aa4824564">395</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Hospital</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTQtMS0xLTA_61c4df76-99cb-4cb9-b405-9868e8bf29b6">648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTYtMS0xLTA_196978d1-8811-4173-805a-cb4e89c79f3e">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTQtMS0xLTA_7ecad3a3-8c46-4190-8dd2-fa2e19fb293e">1,065</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTYtMS0xLTA_95e4717a-1518-49fc-970b-c5b38526cae5">978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTQtMS0xLTA_ddadfa0c-9ceb-4970-9c72-4859224c3b9d">538</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTYtMS0xLTA_935639d7-1a10-4379-8129-801d55562c24">451</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTQtMS0xLTA_9a855437-f4ba-439f-88b9-eebfb24bceae">319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTYtMS0xLTA_a513e818-5ce6-49b2-8931-4fdcd584d3cb">347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i123d02fa33c34cd0ab980020160d5226"><ix:continuation id="i8ffe1a600d0042c7b31b644dc5739386"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.856%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49">158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other I&amp;I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTQtMS0xLTA_8293a04a-3b4a-46a1-b694-c678651ea32d">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTYtMS0xLTA_4a57a4d2-851b-4e9e-9c13-45638fb3d25e">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Rare Disease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTQtMS0xLTA_d56874f4-3998-4385-af11-fc158e9be52a">824</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTYtMS0xLTA_5b8ba429-9a55-4fa7-93e6-42409ade7405">639</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTQtMS0xLTA_aad9c342-75af-47a6-9620-bc10c9e7c4e0">453</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTYtMS0xLTA_2d16c412-a3f1-41de-b782-cebb95709037">231</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTQtMS0xLTA_e2c0992f-ed1e-4545-9c37-d622e529bb27">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i217f041566f14b16a835176fc12cebe4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTYtMS0xLTA_2bcb6ee4-01d5-497a-9d1c-7669f2b87f28">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTE1NTM4_b7c97c54-0a5a-4451-9752-829a7a659ddf">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTE1NTM4_1d8d54d4-8fc6-4aff-93c7-7cdd6a7f7c02">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTA_bde9b100-345e-488a-b63d-754151871331">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTA_e213e133-cc55-4c55-a28e-3a455669d91a">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTQtMS0xLTA_ed4ac610-7ee3-4bf9-bbac-228146dd059a">65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4045f62b3268485d984a63420d9173d9_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTYtMS0xLTA_ed64a288-fd5e-4f2b-9812-25b5cddf0101">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTQtMS0xLTA_875bf804-d477-4808-b4b3-10d13202e587">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTYtMS0xLTA_e8fb6c9c-3db1-40f8-9b5c-8e868eae59d5">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTQtMS0xLTA_1f83642f-54d9-4c7e-bdf4-a904b5ac0eb4">1,770</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTYtMS0xLTA_c58ca481-4b90-46ab-a793-9fc2f7b5a2c8">1,382</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5">530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353">288</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c">1,482</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d">1,401</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" footnoteRole="http://www.xbrl.org/2003/role/footnote">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev</ix:footnote>.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" footnoteRole="http://www.xbrl.org/2003/role/footnote">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" footnoteRole="http://www.xbrl.org/2003/role/footnote">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" footnoteRole="http://www.xbrl.org/2003/role/footnote">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</ix:footnote></span></div></ix:continuation><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of BNT162b2. The deferred revenues associated with the advance payments related to BNT162b2 total $<ix:nonFraction unitRef="usd" contextRef="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzI5ODA_82b6ca28-7195-461b-94d1-537364e140ea">1.9</ix:nonFraction> billion as of April&#160;4, 2021 and $<ix:nonFraction unitRef="usd" contextRef="iadcb9082716e49ad8217f6c35c00c9da_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDY2NjU_51ec06dc-3a69-4560-a820-b394619b1382">957</ix:nonFraction> million as of December 31, 2020 and are recorded in current liabilities. The increase in the BNT162b2 deferred revenues during the first quarter of 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries. During the first quarter of 2021, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDc3ODU_1d94c7b1-9909-4901-92b7-865fbbbda8d2">192</ix:nonFraction> million that was included in the balance of BNT162b2 deferred revenues as of December 31, 2020. The BNT162b2 deferred revenues as of April&#160;4, 2021 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, which we expect to occur within the next 12 months. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the end of our fiscal first quarter of 2021 and through April 30, 2021, we received or were due additional advance payments associated with agreements to supply BNT162b2 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NDAyOTY_a59c8cee-4655-44be-bb86-1c3bc049ce01">3.8</ix:nonFraction> billion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENTS&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF<br/> OPERATIONS</span></div><div><span><br/></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_136"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business and Strategy</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenues come from the manufacture and sale of biopharmaceutical products. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off and combination of our Upjohn Business with Mylan in November 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. The financial results of the Upjohn Business and the Mylan-Japan collaboration are reflected as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 70% has been incurred since inception and through the first quarter of 2021. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business, strategy and operating environment, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities by advancing our own product pipeline and maximizing the value of our existing products, as well as through various business development activities.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant recent business development activities include:</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Amplyx Pharmaceuticals, Inc.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(Amplyx)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In April 2021, we announced that we acquired Amplyx, a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx&#8217;s lead compound, Fosmanogepix (APX001), is a novel investigational asset in Phase 2 development for the treatment of invasive fungal infections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, including discussion of recent significant business development activities, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the more significant recent transactions through February&#160;25, 2021, the filing date of our 2020 Form 10-K, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our First Quarter 2021 Performance</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $4.5 billion, or 45%, in the first quarter of 2021, compared to the same period in 2020, reflecting an operational increase of $4.2 billion, or 42%, as well as a favorable impact of foreign exchange of $284 million, or 3%. Excluding revenues from BNT162b2 of $3.5 billion, revenues increased 8% operationally, including a negative 5% impact from pricing. The 8% operational growth reflects strong growth in Eliquis, Vyndaqel/Vyndamax, Xeljanz, Xtandi, Inlyta, Biosimilars and the Hospital therapeutic area, partially offset by Prevnar 13/Prevenar 13, Ibrance and Chantix in the U.S. and Enbrel internationally. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were favorably impacted by approximately $400 million as a result of the first quarter of 2021 having three additional selling days in the U.S. and four additional selling days in international markets as compared to the first quarter of 2020. This increase in selling days will be offset in the fourth quarter of 2021 resulting in essentially the same number of selling days in the full year of 2021 as full year 2020. The favorable impact in the first quarter of 2021 from selling days was partially offset by the non-recurrence of favorable impacts related to COVID-19 on the first quarter of 2020, including increased demand for certain products of approximately $150 million and additional wholesaler inventories of approximately $100 million. The net favorable impact on the first of quarter 2021 revenues of all of the above factors was approximately $150 million, accounting for approximately 1.5 percentage points of operational growth.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geography</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections for more information, including a discussion of key drivers of our revenue performance. For information regarding the primary indications or class of certain products, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from continuing operations before provision for taxes on income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.8&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the first quarter of 2021, compared to the same period in 2020, was primarily attributable to higher revenues, net gains in the first quarter of 2021 versus net losses in the first quarter of 2020 on equity securities, higher net periodic benefit credits related to pension and postretirement plans and higher income from collaborations, partially offset by higher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Cost of sales, Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within this MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operating Environment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below and in our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years. For example, the basic product patent for Chantix in the U.S. expired in November 2020. While multi-source generic competition for Chantix has not yet begun, it could commence at any time. Also, the basic product patent for Sutent in the U.S. will expire in August 2021. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2021 through 2025. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant in relation to our business as a whole, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A1.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing of medicines and vaccines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, vaccines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Federal and state governments and private third-party payers in the U.S. continue to take action to manage the utilization of drugs and cost of drugs, including increasingly employing formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. We consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often provide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set by healthcare providers and insurers. Governments globally may use a variety of measures, including proposing pricing reform or legislation, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. In the U.S., we expect to see continued focus on regulating pricing resulting in additional legislation and regulation under the newly elected Congress and the Biden Administration. We anticipate that these and similar initiatives will continue to increase pricing pressures globally. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Global Economic Environment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to the economic cycle. For additional information, please see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuation of the COVID-19 pandemic has impacted our business, operations and financial condition and results. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Response to COVID-19</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to confronting the public health challenge posed by the pandemic by collaborating with industry partners, global regulators and academic institutions to develop potential approaches to prevent and treat COVID-19. We have made some important advances, including, among others:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">As discussed in our 2020 Form 10-K, in December 2020, the FDA authorized the distribution and use of BNT162b2 in the U.S. to help prevent COVID-19 for individuals 16 years of age and older under an EUA. In May 2021, the FDA expanded the EUA to authorize the use in individuals 12 to 15 years of age. BNT162b2 has not been approved or licensed by the FDA. The EUA authorizes distribution and use of this product subject to the conditions set forth in the EUA, and only for the duration of the declaration by the Department of Health &amp; Human Services that circumstances exist justifying authorization of emergency use of drugs and biological products (such as BNT162b2) during the COVID-19 pandemic under Section 564 of the U.S. Federal Food, Drug and Cosmetic Act (the Declaration), or until revocation of the EUA by the FDA. The FDA has issued EUAs to certain other companies for products intended for the prevention or treatment of COVID-19 and may continue to do so during the duration of the Declaration. The FDA expects EUA holders to work towards submission of a BLA as soon as possible. BNT162b2 has now been granted a CMA, EUA or temporary authorization in many other countries around the world. In addition, the companies have requested similar amendments to expand the authorizations for use in individuals 12 to 15 years of age by other regulatory authorities worldwide. We also announced in May 2021 the initiation of a rolling submission of a BLA with the FDA seeking full approval for BNT162b2 for individuals 16 years of age and older. We are continuing to study vaccines to help prevent COVID-19, including evaluating BNT162b2 in additional populations, booster doses and emerging variants. Subject to continuous process improvements, expansion at current facilities and adding new suppliers and contract manufacturers, the companies believe that they can potentially manufacture at least 2.5 billion doses in total by the end of 2021 and at least 3 billion doses in 2022. The companies have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 to governments under such agreements. We also signed agreements with Israel and Canada to supply BNT162b2 doses in 2022 and beyond and are currently negotiating similar potential agreements with multiple other countries. As of May 4, 2021, based on the 1.6 billion doses that are to be delivered in 2021 under agreements that have been signed through mid-April 2021, we forecasted approximately $26 billion in revenues in 2021 from BNT162b2, with gross margin to be split evenly with BioNTech. This forecast may be adjusted in the future as additional agreements are signed and as circumstances warrant.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In March 2021, we initiated a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for COVID-19, PF-07321332, which is a SARS-CoV2-3CL protease inhibitor. This Phase 1 trial is being conducted in the U.S. We also have an ongoing Phase 1b clinical trial for an intravenously administered investigational protease inhibitor for COVID-19, PF-07304814.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our significant investments and efforts, any of our ongoing development programs related to COVID-19 may not be successful as the risk of failure is significant, and there can be no certainty these efforts will yield a successful product or that costs will ultimately be recouped.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impact of COVID-19 on Our Business and Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our on-going monitoring and assessment, we have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, as well as COVID-19 vaccine supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and enabling functions globally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our 2020 Form 10-K, our business and operations were impacted in 2020 by the pandemic in various ways, which is ongoing in 2021. For detail on the impact of the COVID-19 pandemic on our products, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8212;Revenues&#8212;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within this MD&amp;A. In 2021, we have continued not to see a significant disruption to our supply chain to date, and all of our manufacturing sites globally have continued to operate at or near normal levels. However, we are seeing an increase in overall demand in the industry for certain components and raw materials potentially constraining available supply, which could have a future impact on our business. We are continuing to monitor and implement mitigation strategies in an effort to reduce any potential impact. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the pandemic. Future developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, or if demand for our products is significantly reduced as a result of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic, we could experience a material adverse impact on our business, operations and financial condition and results. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors&#8212;COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_142"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Fair Value (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Asset Impairments (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Tax Assets and Liabilities and Income Tax Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2020 Form 10-K. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K for a discussion about the risks associated with estimates and assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard, a change in accounting principle related to our pension and postretirement plans, and significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1B, 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 1D.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_145"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_148"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change in Revenues</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">First Quarter of 2021 vs. First Quarter of 2020</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the worldwide change in revenues by geographic areas in the first quarter of 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended April 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Growth from BNT162b2, Eliquis, Vyndaqel/Vyndamax, Xeljanz, Xtandi, Inlyta, Biosimilars and the Hospital therapeutic area, partially offset by declines from Prevnar 13/Prevenar 13 and Ibrance. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Analysis of the Condensed Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lower revenues for Chantix/Champix and Enbrel. The decrease in Chantix/Champix was driven by the U.S. and primarily reflects a negative impact of the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. in November 2020. The decrease for Enbrel internationally primarily reflects continued biosimilar competition in most developed Europe markets and Japan, which is expected to continue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,499&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues increased $658 million, or 30%, in the first quarter of 2021 to $2.8 billion from $2.2 billion in the first quarter of 2020, reflecting an operational increase of $672 million, or 31%, and an unfavorable impact from foreign exchange of approximately 1%. The operational increase in emerging markets was primarily driven by revenues from BNT162b2 and growth from Eliquis.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Deductions</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of related obligations and, as such, knowledge </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues&#8211;&#8211;Selected Product Discussion</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BNT162b2</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$3,462</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Driven by global uptake, following a CMA, EUA or temporary authorization. </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,643</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 25%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by continued increased adoption in non-valvular atrial fibrillation as well as oral anti-coagulant market share gains, as well as a favorable adjustment related to the Medicare &#8220;coverage gap&#8221; provision resulting from lower than previously expected discounts in prior periods.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Prevnar 13/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevenar 13</span></div></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,284</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 12% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by decline in the U.S., resulting from:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">disruptions to wellness visits due to COVID-19-related mobility restrictions or limitations, including adults delaying other vaccinations while receiving COVID-19 inoculations due to CDC guidance;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">impact of the revised ACIP recommendation for the adult indication to shared clinical decision making, which means the decision to vaccinate should be made at the individual level between healthcare providers and their patients, as well as the continued impact of a lower remaining eligible adult population; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">decline for the pediatric indication, primarily reflecting the unfavorable impact of COVID-19 and lower year-over-year birth rates. </span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:26pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,254</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Down 1%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by decline in the U.S., which reflects relatively stable U.S. prescription volume demand and Ibrance&#8217;s continued strong leadership position within the CDK 4/6 class, but also an increase in the proportion of patients accessing Ibrance through our Patient Assistance Program due to economic hardships brought on by the COVID-19 pandemic which is expected to normalize over time as the economic impact of the pandemic subsides. Also reflects continued strong volume growth internationally, partially offset by pricing pressures.</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$538</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 18% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by the U.S., reflecting higher volumes within the RA, PsA and UC indications, enabled by improvements in formulary access. Also reflects operational growth internationally mainly driven by continued uptake in the RA indication and, to a lesser extent, the UC indication in certain developed markets.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel/ <br/>Vyndamax</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$453</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 88%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by the approval in February 2020 of the ATTR-CM indication in the EU, as well as continued strong uptake of the ATTR-CM indication in the U.S. and Japan.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$267</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 28% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by continued strong demand for Xtandi in the mCRPC and nmCRPC indications, as well as the mCSPC indication, which was approved in the U.S. in December 2019. </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$229</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 34% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily due to increased demand in the U.S. and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$530</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 79% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by recent oncology monoclonal antibody biosimilar launches globally and continued growth from Retacrit in the U.S.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$2,343</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 10% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by Pfizer CentreOne, our contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris under manufacturing and supply agreements and remdesivir to Gilead Sciences Inc., as well as growth from recent anti-infective product launches in international markets, partially offset by lower year-over-year volume for certain products globally due to a COVID-19-related surge in demand in the prior-year quarter. </span></div></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Calculation is not meaningful or results are equal to or greater than 100%.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the primary indications or class of the selected products discussed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Developments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer&#8217;s development pipeline was published as of May&#160;4, 2021 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan. The table below includes only approvals for products that have occurred in the last twelve months and does not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.652%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DISEASE AREA</span></td><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">PF-07302048 (COVID-19 Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (16 years of age and older)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bavencio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(avelumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line maintenance urothelial cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Nyvepria<br/>(pegfilgrastim-apgf)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Neutropenia in patients undergoing cancer chemotherapy (biosimilar)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Braftovi (encorafenib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Second or third-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC (combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab))</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Second or third-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC (combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab))</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xtandi</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"> </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">mCSPC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">abrocitinib (PF-04965842)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Infliximab Pfizer (infliximab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ankylosing spondylitis (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bevacizumab Pfizer (bevacizumab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">NSCLC (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sept.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Rituximab Pfizer (rituximab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Chronic idiopathic thrombocytopenic purpura (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">tanezumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Chronic pain due to moderate-to-severe osteoarthritis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bosulif <br/>(bosutinib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line chronic myelogenous leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Daurismo <br/>(glasdegib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with low-dose cytarabine for AML</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xeljanz <br/>(tofacitinib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ankylosing spondylitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Uterine fibroids (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Lorbrena </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(lorlatinib)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First- line ALK-positive NSCLC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mar. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">somatrogon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">PF-06482077</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Vaccine)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent invasive and non-invasive pneumococcal infections (adults)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">TicoVac<br/>(Vaccine)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent tick-borne encephalitis</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.5pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">PF-07302048 or BNT162b2 (Pfizer/BioNTech COVID-19 vaccine) received EUA from the FDA in December 2020 and CMA from the EMA in December 2020 for use in individuals 16 years of age and older. In May 2021, the FDA expanded the EUA to include the use of BNT162b2 in individuals 12 to 15 years of age. Pfizer and BioNTech have  requested similar amendments to expand the authorizations for use in individuals 12 to 15 years of age by other regulatory authorities worldwide. In May 2021, Pfizer and BioNTech initiated a rolling submission of a BLA with the FDA for approval of the COVID-19 vaccine in individuals 16 years of age and older. The Prescription Drug User Fee Act goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the FDA.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Merck KGaA, Germany.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Astellas. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Lilly. In March 2021, the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab resulted in a 19:1 against vote on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure benefits outweigh risks. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.47pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with OPKO. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:12.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS<br/>FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Bavencio (avelumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line NSCLC</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06482077 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Invasive and non-invasive pneumococcal infections (pediatric)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Adult growth hormone deficiency</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">tanezumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Cancer pain</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for endometriosis</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for contraceptive efficacy </span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (pembrolizumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="11" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">aztreonam-avibactam<br/>(PF-06947387)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Treatment of infections caused by Gram-negative bacteria </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">fidanacogene elaparvovec (PF-06838435)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia B</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(PF-07055480)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia A</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06425090 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Primary clostridioides difficile infection</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06886992 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Serogroups meningococcal (adolescent and young adults)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06928316 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Respiratory syncytial virus infection (maternal)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-07265803</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dilated cardiomyopathy due to Lamin A/C gene mutation</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Alopecia areata</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Duchenne muscular dystrophy</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Merck KGaA, Germany.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with the Alliance Foundation Trial.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Lilly. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.47pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_178"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSTS AND EXPENSES</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>&#160;Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8212;net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $2.3 billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of BNT162b2, which includes a charge for the 50% gross margin split with BioNTech and royalty expenses;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased sales volumes of other products, driven by Pfizer CentreOne; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the unfavorable impact of foreign exchange and hedging activity on intercompany inventory.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percentage of revenues in the first quarter of 2021, compared to the same period in 2020, was primarily due to all of the factors discussed above, partially offset by an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Informational and Administrative Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI&amp;A expenses increased $242 million, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase to expense resulting from the increase in our liability to be paid to participants of our supplemental savings plan; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs related to BNT162b2, primarily driven by a higher provision for healthcare reform fees based on sales; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase in external, incremental costs directly related to implementing our cost-reduction/productivity initiatives,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending on Chantix following the loss of patent protection in the U.S. in November 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $342 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">external spending on Pfizer&#8217;s efforts to develop BNT162b2 and therapeutics to help treat COVID-19; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase in the value of the portfolio performance share grants reflecting changes in the price of Pfizer&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was relatively flat.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transforming to a More Focused Company Program</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with the costs primarily related to the corporate enabling functions initiatives, we expect gross cost savings of $1.0 billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, to be achieved primarily from 2021 through 2022. In connection with manufacturing network optimization, including legacy cost reduction initiatives, we expect net cost savings of $300 million to be achieved primarily from 2020 through 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain qualifying costs for this program were recorded in the first quarters of 2021 and 2020 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of this MD&amp;A.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Deductions&#8212;Net</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income&#8212;net increased $1.2 billion, mainly due to:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">net gains on equity securities in the first quarter of 2021 versus net losses recorded in the first quarter of 2020;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">higher net periodic benefit credits other than service costs related to pension and postretirement plans; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">higher income from collaborations, out-licensing arrangements and sales of compound/product rights.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROVISION FOR TAXES ON INCOME</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCONTINUED OPERATIONS </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_187"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance in conjunction with other performance measures. As such, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide&#8211;&#8211;prior to considering certain income statement elements as follows:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Illustrative Use</span></td></tr><tr style="height:57pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Monthly managerial analysis of our operating results and our annual budgets are prepared using these non-GAAP measures</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Senior management&#8217;s compensation is determined, in part, using these non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:86pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, each before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:48pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">EPS attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part by three metrics, one of which is Adjusted diluted EPS, which is derived from Adjusted income and accounts for 40% of the bonus pool funding. Additionally, the payout for Performance Share Awards is determined in part by Adjusted net income, which is derived from Adjusted income. Effective for the 2020 performance year and consistent with shareholder feedback received in 2019, the Compensation Committee of the BOD approved adding an R&amp;D pipeline achievement factor to the existing short-term incentive financial metrics.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income, and its components and Adjusted diluted EPS, are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented solely to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8212;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the first quarters of 2021 and 2020 below. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Purchase Accounting Adjustments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our therapeutic areas and product lines for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. For a non-inclusive list of certain significant items see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, we exclude pension and postretirement actuarial remeasurement gains and losses from our measure of Adjusted income because of their inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A of our 2020 Form 10-K for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Three Months Ended April 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase Accounting Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,582&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(763)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">954&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.09&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.93&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Three Months Ended March 29, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase Accounting Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,083&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(262)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">678&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.16)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.08&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.63&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">For details of adjustments, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The effective tax rate on Non-GAAP Adjusted income was 15.3% in the first quarter of 2021, compared to 16.0% in the first quarter of 2020. The decrease was primarily due to a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase accounting adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization, depreciation and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments&#8211;&#8211;pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total acquisition-related items&#8211;&#8211;pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total acquisition-related items&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Certain significant items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cost reduction initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Implementation costs and additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business and legal entity alignment costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(k)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total certain significant items&#8211;&#8211;pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total certain significant items&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments, acquisition-related items, discontinued operations and certain significant items&#8211;&#8211;net of tax, attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included primarily in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying the applicable tax rate. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Relates to our cost-reduction and productivity initiatives not related to acquisitions (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For the three months ended April&#160;4, 2021, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($21 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($64 million). For the three months ended March&#160;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($14 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($15 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">For the three months ended April&#160;4, 2021, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($17 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($53 million) and for the three months ended March&#160;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($11 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($61 million)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and mainly represents costs for consulting, legal, tax and advisory services associated with the internal reorganization of legal entities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.1pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three months ended April&#160;4, 2021, includes a $47 million interim actuarial remeasurement pre-tax gain and for the three months ended March&#160;29, 2020, includes an $81 million interim actuarial remeasurement pre-tax loss. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.1pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">For the three months ended April&#160;4, 2021, primarily included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($77 million). For the three months ended March&#160;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($17 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($164 million). Among other things, the three months ended April&#160;4, 2021 includes charges of $49 million and the three months ended March&#160;29, 2020 includes charges of $160 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">representing our pro rata share of restructuring and business combination accounting charges recorded by the Consumer Healthcare JV. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Continuing Operations</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:49.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven primarily by higher net income and advance payments in 2021 for BNT162b2 recorded in deferred revenue. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change also reflects the impact of timing of receipts and payments in the ordinary course of business.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is driven primarily by an increase in net unrealized gains on equity securities and an increase in equity income, partially offset by an increase in equity method dividends received and an increase in net losses on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,747)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven mainly by a $3.5&#160;billion increase in purchases of short-term investments with original maturities of greater than three months and a $580&#160;million increase in net purchases of short-term investments with original maturities of three months or less, partially offset by a $2.2&#160;billion increase in redemptions of short-term investments with original maturities of greater than three months.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities from continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,807)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven mostly by a $3.2&#160;billion decrease in proceeds from short-term borrowings with maturities of three months or less, a $1.2&#160;billion decrease in proceeds from issuances of long-term debt, and a $277 million payment to Viatris in connection with the spin-off of the Upjohn business, partially offset by a $2.2&#160;billion net reduction in repayments of short-term borrowings with maturities of greater than three months and a $2.2&#160;billion reduction in principal repayments on long-term debt.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from discontinued operations relate to our former Upjohn Business and the Mylan-Japan collaboration (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_205"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely largely on operating cash flows, short-term investments or commercial paper borrowings and long-term debt to provide for our liquidity requirements. We strive to improve cash inflows through working capital efficiencies. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We have taken and will continue to take a conservative approach to our financial investments and monitoring of our liquidity position in response to market changes. Our debt investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Capacity&#8211;&#8211;Lines of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of April&#160;4, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we had access to a $7 billion U.S. revolving credit facility expiring in 2025. In addition, our lenders have provided us an additional $317 million in lines of credit, of which $283 million expire within one year. Essentially all lines of credit were unused as of April&#160;4, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selected Measures of Liquidity and Capital Resources</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:71.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following presents certain relevant measures of our liquidity and capital resources:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT RATIOS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selected financial assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term investments, excluding private equity securities at cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,895&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,195&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,699&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,835&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selected net financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22,803)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24,641)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Working capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ratio of current assets to current liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.48:1</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.35:1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for a description of certain assets held and for a description of credit risk related to our financial instruments held.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in working capital was primarily driven by an increase in short-term investments due to operating cash flow generation, and the timing of accruals, cash receipts and payments in the ordinary course of business, partially offset by capital expenditures.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about the sources and uses of our funds, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about credit ratings, interest rate risk and LIBOR, global economic conditions, and market risk, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk&#8212;Selected Measures of Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within MD&amp;A in our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Purchase Plans and Accelerated Share Repurchase Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;4, 2021, our remaining share-purchase authorization was approximately $5.3 billion, with no repurchases in the first three months of 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K for more information on our publicly announced share-purchase plans.</span></div><div><span><br/></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, our BOD declared a dividend of $0.39 per share, payable on June 4, 2021, to shareholders of record at the close of business on May 7, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BOD decided to maintain Pfizer&#8217;s quarterly dividend at its current level for the second quarter of 2021 despite the recent declaration of a dividend payment by Viatris that is payable to those Pfizer shareholders that continue to hold, as of the Viatris dividend record date, Viatris shares received from the combination of Upjohn and Mylan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer&#8217;s BOD and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standard</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Standard, Not Adopted as of April&#160;4, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect on the Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference rate reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The new guidance provides the following optional expedients: </span></div><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elections can be adopted prospectively at any time through December 31, 2022.</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</span></td></tr></table></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_214"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek&#8221; and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our anticipated operating and financial performance, reorganizations, business plans and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-Q includes statements relating to specific future actions and effects, including, among others, our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitors, the forecasted revenue contribution of BNT162b2 and the potential number of doses that we and BioNTech believe can be manufactured; our expectations regarding the impact of COVID-19 on our business; the expected impact of patent expiries and competition from generic manufacturers; the benefits expected from our business development transactions; our anticipated liquidity position; our expectations regarding Ibrance; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; our planned capital spending; and the expectations for our quarterly dividend payments.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form  10-Q. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K and within this MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below or in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators on a timely basis or at all; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; the impact of recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or any potential actions by regulatory authorities based on analysis of ORAL Surveillance or other data;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our or our third party suppliers&#8217; facilities; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, marketing, research and development and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to develop a vaccine to help prevent COVID-19 and potential treatments for COVID-19, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, civil unrest or military action;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings:</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations, including, among others, any potential changes to the existing tax law by the current U.S. Presidential administration and Congress increasing the corporate tax rate and/or the tax rate on foreign earnings;</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Security:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to protect our patents and other intellectual property, including against claims of invalidity that could result in LOE, unasserted intellectual property claims and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products, including our vaccine to help prevent COVID-19 and potential treatments for COVID-19.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_220"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk&#8212;Selected Measures of Liquidity and Capital Resources&#8212;Market Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_223"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_226"></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II.&#160; OTHER INFORMATION</span></td></tr></table></div><div><span><br/></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_229"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_232"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the &#8220;Our Operating Environment&#8221;, &#8220;The Global Economic Environment&#8221;, &#8220;COVID-19 Pandemic&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of the MD&amp;A of this Form 10-Q and to Part I, Item 1A, &#8220;Risk Factors&#8221; of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_238"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the first quarter of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:700;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Paid per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Approximate Value of Shares That May Yet Be Purchased Under the Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1 through January 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,147&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">26.60&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">February 1 through February 28, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,967,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 1 through April&#160;4, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,654,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10,638,957&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.90&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents (i) 10,633,238 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 5,719 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_250"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh18x0404202110q.htm">Exhibit 18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferability Letter of KPMG dated May 13, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh22x0404202110q.htm">Exhibit 22</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiary Issuers of Guaranteed Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh311x0404202110q.htm">Exhibit 31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh312x0404202110q.htm">Exhibit 31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh321x0404202110q.htm">Exhibit 32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section<br/>1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh322x0404202110q.htm">Exhibit 32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section<br/>1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH<br/>EX-101.CAL<br/>EX-101.LAB<br/>EX-101.PRE<br/>EX-101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema<br/>Inline XBRL Taxonomy Extension Calculation Linkbase<br/>Inline XBRL Taxonomy Extension Label Linkbase<br/>Inline XBRL Taxonomy Extension Presentation Linkbase<br/>Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_253"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer B. Damico, Senior Vice President and<br/>Controller<br/>(Principal Accounting Officer and<br/>Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-18
<SEQUENCE>2
<FILENAME>pfe-exh18x0404202110q.htm
<DESCRIPTION>EX-18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iaa51c6d408944c22bc71ffee789c47f8_1"></div><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EXHIBIT 18</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">May 13, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Pfizer Inc.</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">New York, New York </font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Ladies and Gentlemen&#58; </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We have been furnished with a copy of the quarterly report on Form 10-Q of Pfizer Inc. and Subsidiary Companies (the Company) for the three months ended April 4, 2021, and have read the Company's statements contained in Note 1C to the condensed consolidated financial statements included therein. As stated in Note 1C, the Company changed its method of accounting for pension and postretirement plans to immediately recognize actuarial gains and losses in the consolidated statements of income and states that the newly adopted accounting principle is preferable in the circumstances because it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements. In accordance with your request, we have reviewed and discussed with Company officials the circumstances and business judgment and planning upon which the decision to make this change in the method of accounting was based.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We have not audited any financial statements of the Company as of any date or for any period subsequent to December 31, 2020, nor have we audited the information set forth in the aforementioned Note 1C to the condensed consolidated financial statements&#59; accordingly, we do not express an opinion concerning the factual information contained therein.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">With regard to the aforementioned accounting change, authoritative criteria have not been established for evaluating the preferability of one acceptable method of accounting over another acceptable method. However, for purposes of the Company's compliance with the requirements of the Securities and Exchange Commission, we are furnishing this letter.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Based on our review and discussion, with reliance on management's business judgment and planning, we concur that the newly adopted method of accounting is preferable in the Company's circumstances. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Very truly yours,</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; KPMG LLP</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">New York, New York</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>3
<FILENAME>pfe-exh22x0404202110q.htm
<DESCRIPTION>EX-22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic3bdc2aaf5b74306bac805051a88888a_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT  22</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subsidiary Issuer of Guaranteed Securities</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of April 4, 2021, Pfizer Inc. (Parent Guarantor) was the unconditional and irrevocable guarantor of the following unsecured registered notes issued by wholly-owned subsidiaries of Parent Guarantor&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:29.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name of Subsidiary Issuer</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">State of Formation of Issuer</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Description of Registered Notes</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wyeth LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.25% Notes due 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wyeth LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.45% Notes due 2024</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacia LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.75% Debentures due 2027</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacia LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.60% Debentures due 2028</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wyeth LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.50% Notes due 2034</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wyeth LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.00% Notes due 2036</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wyeth LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delaware</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.95% Notes due 2037</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:324pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pfe-exh311x0404202110q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i46216441d71a479eb8b616414dc6a334_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Albert Bourla, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;May&#160;13, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pfe-exh312x0404202110q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i405813049f5745058bf060557ed7cedf_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Frank A. D'Amelio, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;May&#160;13, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK A. D'AMELIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Frank A. D'Amelio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Executive Vice President,<br>Global Supply</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pfe-exh321x0404202110q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icc2cb9c865cb463e89f929153f7a3837_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended April&#160;4, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>pfe-exh322x0404202110q.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i572a4e34074a43fcb40d4087521b53d3_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the fiscal quarter ended April&#160;4, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK A. D'AMELIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Frank A. D'Amelio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Executive Vice President, <br>Global Supply</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pfe-20210404.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20210404" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20210404">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20210404_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20210404_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20210404_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20210404_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails">
        <link:definition>2406403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestment" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment">
        <link:definition>2107102 - Disclosure - Discontinued Operations and Equity-Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestmentTables" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables">
        <link:definition>2308302 - Disclosure - Discontinued Operations and Equity-Method Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails">
        <link:definition>2409404 - Disclosure - Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails">
        <link:definition>2410405 - Disclosure - Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails">
        <link:definition>2411406 - Disclosure - Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails">
        <link:definition>2412407 - Disclosure - Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives">
        <link:definition>2113103 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables">
        <link:definition>2314303 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails">
        <link:definition>2415408 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail">
        <link:definition>2416409 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail">
        <link:definition>2417410 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>2118104 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>2319304 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail">
        <link:definition>2420411 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail">
        <link:definition>2421412 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>2122105 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>2323305 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetail" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail">
        <link:definition>2424413 - Disclosure - Tax Matters - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail">
        <link:definition>2425414 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>2126106 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>2327306 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
        <link:definition>2428415 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>2129107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>2330307 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail">
        <link:definition>2431416 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2432417 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsbyClassificationTypeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails">
        <link:definition>2433418 - Disclosure - Financial Instruments - Investments by Classification Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails">
        <link:definition>2434419 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1">
        <link:definition>2434419 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails">
        <link:definition>2435420 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails">
        <link:definition>2436421 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShorttermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails">
        <link:definition>2437422 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>2438423 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails">
        <link:definition>2439424 - Disclosure - Financial Instruments - Derivative Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
        <link:definition>2440425 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
        <link:definition>2441426 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
        <link:definition>2442427 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
        <link:definition>2443428 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCreditRiskDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails">
        <link:definition>2444429 - Disclosure - Financial Instruments - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.pfizer.com/role/OtherFinancialInformation">
        <link:definition>2145108 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables">
        <link:definition>2346308 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationInventoriesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails">
        <link:definition>2447430 - Disclosure - Other Financial Information - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherCurrentLiabilitiesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails">
        <link:definition>2448431 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssets" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets">
        <link:definition>2149109 - Disclosure - Identifiable Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables">
        <link:definition>2350309 - Disclosure - Identifiable Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail">
        <link:definition>2451432 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1">
        <link:definition>2451432 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsNarrativeDetail" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail">
        <link:definition>2452433 - Disclosure - Identifiable Intangible Assets - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlans" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans">
        <link:definition>2153110 - Disclosure - Pension and Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansTables" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables">
        <link:definition>2354310 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
        <link:definition>2455434 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansNarrativeDetail" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail">
        <link:definition>2456435 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders">
        <link:definition>2157111 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables">
        <link:definition>2358311 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails">
        <link:definition>2459436 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitments" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments">
        <link:definition>2160112 - Disclosure - Contingencies and Certain Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsPatentLitigationDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails">
        <link:definition>2461437 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails">
        <link:definition>2462438 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductGeographicandOtherRevenueInformation" roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation">
        <link:definition>2163113 - Disclosure - Product, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductGeographicandOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables">
        <link:definition>2364312 - Disclosure - Product, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>2465439 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductGeographicandOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail">
        <link:definition>2466440 - Disclosure - Product, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>2467441 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" abstract="false" name="ShorttermInvestmentsExcludingHeldToMaturitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InterestPaidReceivedInterestRateHedges" abstract="false" name="InterestPaidReceivedInterestRateHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HedgedItemAxis" abstract="true" name="HedgedItemAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" abstract="false" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" abstract="false" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherOncologyProductsMember" abstract="true" name="OtherOncologyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RareDiseaseMember" abstract="true" name="RareDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_IbranceMember" abstract="true" name="IbranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherIncomeDeductionsAndCostOfSalesMember" abstract="true" name="OtherIncomeDeductionsAndCostOfSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ForeignCurrencyDebtMember" abstract="true" name="ForeignCurrencyDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" abstract="false" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FSMEIMMUNTicoVacMember" abstract="true" name="FSMEIMMUNTicoVacMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesTable" abstract="true" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherVaccinesProductsMember" abstract="true" name="OtherVaccinesProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" abstract="false" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" abstract="false" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_XtandiAllianceRevenuesMember" abstract="true" name="XtandiAllianceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ZaviceftaMember" abstract="true" name="ZaviceftaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherAccruals" abstract="false" name="OtherAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" abstract="false" name="GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" abstract="false" name="LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_FeasibilityStudyNumberOfLagoons" abstract="false" name="FeasibilityStudyNumberOfLagoons" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" abstract="false" name="PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InflectraRemsimaMember" abstract="true" name="InflectraRemsimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" abstract="false" name="GainContingencyPatentsWithoutCourtProceedingsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_SulperazonMember" abstract="true" name="SulperazonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_EliquisMember" abstract="true" name="EliquisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" abstract="false" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" abstract="false" name="IntangibleAssetsNetPercentageofIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BioNTechMember" abstract="true" name="BioNTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_TotalBiosimilarsMember" abstract="true" name="TotalBiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherHospitalProductsMember" abstract="true" name="OtherHospitalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BosulifMember" abstract="true" name="BosulifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" abstract="false" name="IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_XalkoriMember" abstract="true" name="XalkoriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ImplementationCosts" abstract="false" name="ImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PrevnarPrevenarFamilyMember" abstract="true" name="PrevnarPrevenarFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PercentageChangeInRevenue" abstract="false" name="PercentageChangeInRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pfe_SutentMember" abstract="true" name="SutentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" abstract="false" name="StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_AllOtherInflammationandImmunologyProductsMember" abstract="true" name="AllOtherInflammationandImmunologyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" abstract="false" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ReFactoAfXynthaMember" abstract="true" name="ReFactoAfXynthaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ToviazMember" abstract="true" name="ToviazMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ShorttermDebtGross" abstract="false" name="ShorttermDebtGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FragminMember" abstract="true" name="FragminMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_HedgedItemDomain" abstract="true" name="HedgedItemDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_RetacritMember" abstract="true" name="RetacritMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PristiqMember" abstract="true" name="PristiqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AllogeneAndBioNTechMember" abstract="true" name="AllogeneAndBioNTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_LossContingencyClassActionsFiledNumber" abstract="false" name="LossContingencyClassActionsFiledNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_ScenarioPreviousAccountingPrincipleMember" abstract="true" name="ScenarioPreviousAccountingPrincipleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherNonoperatingIncomeExpenseNet" abstract="false" name="OtherNonoperatingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RebatesAndDiscountsAccrual" abstract="false" name="RebatesAndDiscountsAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsumerHealthcareJVMember" abstract="true" name="ConsumerHealthcareJVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_EpiPenMember" abstract="true" name="EpiPenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PfizerCentreOneMember" abstract="true" name="PfizerCentreOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" abstract="false" name="StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GainContingencyNumberofDefendants" abstract="false" name="GainContingencyNumberofDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_LossContingencyNumberOfLawsuits" abstract="false" name="LossContingencyNumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_PatentInfringementMember" abstract="true" name="PatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_MektoviMember" abstract="true" name="MektoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ZithromaxZmaxMember" abstract="true" name="ZithromaxZmaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PfizerVersusZydusMember" abstract="true" name="PfizerVersusZydusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ForeignCurrencyShortTermBorrowingsMember" abstract="true" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherPatentInfringementMember" abstract="true" name="OtherPatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_MedrolMember" abstract="true" name="MedrolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AllogeneMember" abstract="true" name="AllogeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_GenotropinMember" abstract="true" name="GenotropinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PremarinFamilyMember" abstract="true" name="PremarinFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" abstract="false" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_NotesDue20220.250Member" abstract="true" name="NotesDue20220.250Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" abstract="false" name="EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EnbrelMember" abstract="true" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" abstract="false" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HospitalMember" abstract="true" name="HospitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesLineItems" abstract="true" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_TotalAllianceBiopharmaceuticalsMember" abstract="true" name="TotalAllianceBiopharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_XeljanzMember" abstract="true" name="XeljanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfIncomeAbstract" abstract="true" name="ConsolidatedStatementsOfIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_LongtermInvestmentsMember" abstract="true" name="LongtermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_LorbrenaMember" abstract="true" name="LorbrenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AssetImpairmentsMember" abstract="true" name="AssetImpairmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_IVIgProductsMember" abstract="true" name="IVIgProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_InlytaMember" abstract="true" name="InlytaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AllOtherInternalMedicineMember" abstract="true" name="AllOtherInternalMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherTaxAssetsCurrent" abstract="false" name="OtherTaxAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ArraySecuritiesLitigationMember" abstract="true" name="ArraySecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DevelopedRestOfWorldMember" abstract="true" name="DevelopedRestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" abstract="false" name="ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pfe_BNT162b2Member" abstract="true" name="BNT162b2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherAntiinfectivesMember" abstract="true" name="OtherAntiinfectivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" abstract="true" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" abstract="true" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_FocusedCompanyPlanMember" abstract="true" name="FocusedCompanyPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" abstract="false" name="LossContingencyNumberOfDefendantsOtherThanMainDefendant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_GovernmentAndGovernmentSponsoredMember" abstract="true" name="GovernmentAndGovernmentSponsoredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ZirabevMember" abstract="true" name="ZirabevMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_NimenrixMember" abstract="true" name="NimenrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_EquitySecuritiesFVNINoncurrent" abstract="false" name="EquitySecuritiesFVNINoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" abstract="false" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pfe_TotalSterileInjectablePharmaceuticalsMember" abstract="true" name="TotalSterileInjectablePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" abstract="false" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LicensingAgreementsAndOtherMember" abstract="true" name="LicensingAgreementsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" abstract="false" name="DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" abstract="false" name="LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RuxienceMember" abstract="true" name="RuxienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" abstract="true" name="ScenarioChangeInAccountingPrincipleAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_EquitySecuritiesFVNIRestrictedNoncurrent" abstract="false" name="EquitySecuritiesFVNIRestrictedNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VaccinesMember" abstract="true" name="VaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ManufacturingOptimizationMember" abstract="true" name="ManufacturingOptimizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ZyvoxMember" abstract="true" name="ZyvoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CostReductionInitiativesMember" abstract="true" name="CostReductionInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EnvironmentalRemediationLitigationMember" abstract="true" name="EnvironmentalRemediationLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" abstract="true" name="BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_ViatrisMember" abstract="true" name="ViatrisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BeneFIXMember" abstract="true" name="BeneFIXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AllOtherRareDiseaseProductsMember" abstract="true" name="AllOtherRareDiseaseProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAmortizedCostBasis" abstract="false" name="DebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GSKMember" abstract="true" name="GSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PneumococcalVaccinePatentInfringementMember" abstract="true" name="PneumococcalVaccinePatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_AromasinMember" abstract="true" name="AromasinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PfizerVersusGenericCompaniesMember" abstract="true" name="PfizerVersusGenericCompaniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_BesponsaMember" abstract="true" name="BesponsaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" abstract="false" name="DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DevelopedEuropeMember" abstract="true" name="DevelopedEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DocetaxelMember" abstract="true" name="DocetaxelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" abstract="true" name="PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" abstract="false" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VyndaqelMember" abstract="true" name="VyndaqelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_InternalMedicineMember" abstract="true" name="InternalMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_RestructuringAssetImpairmentCharges" abstract="false" name="RestructuringAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SomavertMember" abstract="true" name="SomavertMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_InflammationandImmunologyMember" abstract="true" name="InflammationandImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VfendMember" abstract="true" name="VfendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DerivativeNetReceivablePositionAggregateFairValue" abstract="false" name="DerivativeNetReceivablePositionAggregateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PrecedexMember" abstract="true" name="PrecedexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ZantacRanitidineNDMALitigationMember" abstract="true" name="ZantacRanitidineNDMALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" abstract="false" name="SiteContingencyRegulatoryProceedingsDisclosureThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" abstract="true" name="ConsolidatedStatementsOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_CK1AssetsSoldToBiogenIncMember" abstract="true" name="CK1AssetsSoldToBiogenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" abstract="false" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HeldToMaturityCashEquivalents" abstract="false" name="HeldToMaturityCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DeconsolidationGainLossAmountNetOfCashConveyed" abstract="false" name="DeconsolidationGainLossAmountNetOfCashConveyed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PrivateEquityInvestments" abstract="false" name="PrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" abstract="false" name="PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ChantixChampixMember" abstract="true" name="ChantixChampixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pfe_BraftoviMember" abstract="true" name="BraftoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>pfe-20210404_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20210404.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5edb87f1-104f-4539-a4b6-6c407e747d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3586dadc-f868-47bc-a970-2a2b7820a2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5edb87f1-104f-4539-a4b6-6c407e747d57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3586dadc-f868-47bc-a970-2a2b7820a2e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1c11f2ec-2274-4c43-ad91-1c2182fc6c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5edb87f1-104f-4539-a4b6-6c407e747d57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1c11f2ec-2274-4c43-ad91-1c2182fc6c97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5afa7bd8-b7e0-4e7e-9347-48a17bfb8f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b71ea29c-2203-4286-b836-1fed06160c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5afa7bd8-b7e0-4e7e-9347-48a17bfb8f7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b71ea29c-2203-4286-b836-1fed06160c61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0857a530-55c6-43fd-a035-6238dd43307e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5afa7bd8-b7e0-4e7e-9347-48a17bfb8f7f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0857a530-55c6-43fd-a035-6238dd43307e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5660a78-7d36-45a7-9f75-0f456db49ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5660a78-7d36-45a7-9f75-0f456db49ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7ac5875a-0295-4081-9814-c22e1038ce69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7ac5875a-0295-4081-9814-c22e1038ce69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a82bda76-6b21-4032-9fd3-41842915f839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a82bda76-6b21-4032-9fd3-41842915f839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e05ff3d-17be-4cb7-b2fd-e0f59d483f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e05ff3d-17be-4cb7-b2fd-e0f59d483f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_3e587b76-b407-4f84-bc3e-37c0683c49de" xlink:href="pfe-20210404.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_3e587b76-b407-4f84-bc3e-37c0683c49de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_296f1a48-8f8b-4be4-8157-c6978d437443" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_296f1a48-8f8b-4be4-8157-c6978d437443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_396feb02-31d6-4401-bad7-5500cccb0e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_396feb02-31d6-4401-bad7-5500cccb0e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31ca6444-379b-4a02-a3cb-3db6f0c15099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7a070b0f-b603-43cd-82de-a909a53d2ec9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31ca6444-379b-4a02-a3cb-3db6f0c15099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3348da4f-d38c-4002-a072-441aa1a4b02c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f8ba5737-646e-4ced-b87e-5665f825c27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3348da4f-d38c-4002-a072-441aa1a4b02c" xlink:to="loc_us-gaap_ProfitLoss_f8ba5737-646e-4ced-b87e-5665f825c27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_553b1114-97f2-4a1b-885a-fcdd58e6f650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3348da4f-d38c-4002-a072-441aa1a4b02c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_553b1114-97f2-4a1b-885a-fcdd58e6f650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dea42391-296c-42da-994b-a861f2ce8441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96f3001f-acac-4a0b-95a7-528677b3368f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dea42391-296c-42da-994b-a861f2ce8441" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96f3001f-acac-4a0b-95a7-528677b3368f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c35b55c0-ed4c-42df-a8f2-b47b15bfaee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dea42391-296c-42da-994b-a861f2ce8441" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c35b55c0-ed4c-42df-a8f2-b47b15bfaee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02bc11b7-5407-4ba2-a175-88d5a9e840e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9ae40cc4-1b99-45e6-8f9d-43c4faaffa14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_02bc11b7-5407-4ba2-a175-88d5a9e840e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9ae40cc4-1b99-45e6-8f9d-43c4faaffa14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_02d48e66-84b8-42ec-8bf8-ce99d2d731a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_02bc11b7-5407-4ba2-a175-88d5a9e840e0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_02d48e66-84b8-42ec-8bf8-ce99d2d731a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e5fd7fe-4cfc-4f29-83f0-6ca84344cc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_53965f8c-b154-428d-ae04-2044444c4787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e5fd7fe-4cfc-4f29-83f0-6ca84344cc52" xlink:to="loc_us-gaap_ProfitLoss_53965f8c-b154-428d-ae04-2044444c4787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d2fda2e-2890-4dcd-9e9f-24d0d2ca32e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e5fd7fe-4cfc-4f29-83f0-6ca84344cc52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d2fda2e-2890-4dcd-9e9f-24d0d2ca32e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04b34636-0991-4f69-8ff4-52f5df179ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d6e6a985-bca9-483b-a513-ffbf86c56fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04b34636-0991-4f69-8ff4-52f5df179ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d6e6a985-bca9-483b-a513-ffbf86c56fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_bd24a991-c4cf-4563-9a71-62809d4356e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04b34636-0991-4f69-8ff4-52f5df179ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_bd24a991-c4cf-4563-9a71-62809d4356e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d650be4-2384-438b-aa60-bea5f387ec54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d533cbe-82dc-4e61-8985-70be5ab47044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d650be4-2384-438b-aa60-bea5f387ec54" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d533cbe-82dc-4e61-8985-70be5ab47044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_00910f63-6903-4120-92de-a53bd1c86a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d650be4-2384-438b-aa60-bea5f387ec54" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_00910f63-6903-4120-92de-a53bd1c86a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4683cc68-6382-42e1-9658-533b5093d362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_38106f36-ed85-4a6a-b67a-92ec9e9282ac" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4683cc68-6382-42e1-9658-533b5093d362" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_38106f36-ed85-4a6a-b67a-92ec9e9282ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_d7e03776-3bf5-41f1-aa03-e55d55272ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4683cc68-6382-42e1-9658-533b5093d362" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_d7e03776-3bf5-41f1-aa03-e55d55272ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_1052f13a-c396-4ee6-a73d-4a5d0dc270a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_7aa777cb-d282-40cb-97eb-02a153f0411d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_1052f13a-c396-4ee6-a73d-4a5d0dc270a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_7aa777cb-d282-40cb-97eb-02a153f0411d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3e20128b-9011-49d0-addf-f2a26b9bdb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_1052f13a-c396-4ee6-a73d-4a5d0dc270a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_3e20128b-9011-49d0-addf-f2a26b9bdb51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_05915770-cd3d-4610-a62e-8b41a335d4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7357dd67-9377-4b55-8f35-5a21178ebadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_05915770-cd3d-4610-a62e-8b41a335d4a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7357dd67-9377-4b55-8f35-5a21178ebadf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a44495c2-ca46-4ec9-87e5-f330aa2eb356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_05915770-cd3d-4610-a62e-8b41a335d4a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a44495c2-ca46-4ec9-87e5-f330aa2eb356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5beb6941-1afc-4852-a623-8bbef30f47f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_1c03cb88-d019-4ea7-b9ad-77d9960f18e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5beb6941-1afc-4852-a623-8bbef30f47f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_1c03cb88-d019-4ea7-b9ad-77d9960f18e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_21412fa9-c7a2-49ae-84b7-e0e37940cc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5beb6941-1afc-4852-a623-8bbef30f47f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_21412fa9-c7a2-49ae-84b7-e0e37940cc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_8bceb37e-2de1-4cee-9940-e492173f986a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5beb6941-1afc-4852-a623-8bbef30f47f0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_8bceb37e-2de1-4cee-9940-e492173f986a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_33507e84-6d87-4c5f-bd98-a81d29568983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5beb6941-1afc-4852-a623-8bbef30f47f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_33507e84-6d87-4c5f-bd98-a81d29568983" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d30cee66-faf5-49f5-ba5f-b2b880037b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d30cee66-faf5-49f5-ba5f-b2b880037b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1a41e986-8c15-4afd-aa15-19d9e6c4f016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1a41e986-8c15-4afd-aa15-19d9e6c4f016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cca2def2-2ee2-42b5-80e4-b5768f75f6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_us-gaap_InventoryNet_cca2def2-2ee2-42b5-80e4-b5768f75f6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_022505c3-b84a-4322-8df8-694db1421b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_us-gaap_OtherAssetsCurrent_022505c3-b84a-4322-8df8-694db1421b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_763c7cd5-37e3-4b5c-9e83-14ba744f7203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_us-gaap_OtherShortTermInvestments_763c7cd5-37e3-4b5c-9e83-14ba744f7203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_bd1ef61c-b067-4a49-8607-22b4352ce031" xlink:href="pfe-20210404.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39bf6ea4-8f93-47e4-91d4-2849bb41862d" xlink:to="loc_pfe_OtherTaxAssetsCurrent_bd1ef61c-b067-4a49-8607-22b4352ce031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e8d778f0-3d57-4dd3-b598-a543b3afadde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_DebtCurrent_e8d778f0-3d57-4dd3-b598-a543b3afadde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_51e4c882-6d18-4b42-85e3-225ba501880f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_AccountsPayableCurrent_51e4c882-6d18-4b42-85e3-225ba501880f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_39097180-4767-43fd-95a4-59444d826136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_DividendsPayableCurrent_39097180-4767-43fd-95a4-59444d826136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_0a7f61ba-cae1-4a34-a91a-756a4269ffed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_TaxesPayableCurrent_0a7f61ba-cae1-4a34-a91a-756a4269ffed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38512626-3b1b-4e93-8ce7-0af60c75a59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38512626-3b1b-4e93-8ce7-0af60c75a59a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a4dbb2ff-437e-4898-a184-36fde1a78c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a4dbb2ff-437e-4898-a184-36fde1a78c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_980d62e4-7e5b-491b-9304-b29cbc03d7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f5f3399-e5f5-4bea-9425-0a3dcbd27d22" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_980d62e4-7e5b-491b-9304-b29cbc03d7f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3994bf-4892-480c-ad46-bbeba8369c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de8b490a-95b7-4427-a75d-59fc45f1ecaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3994bf-4892-480c-ad46-bbeba8369c96" xlink:to="loc_us-gaap_Liabilities_de8b490a-95b7-4427-a75d-59fc45f1ecaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6fef8e6d-dc05-4426-bb36-a7d2a1c72a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3994bf-4892-480c-ad46-bbeba8369c96" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6fef8e6d-dc05-4426-bb36-a7d2a1c72a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29207d1a-5349-45ef-9749-f02a14cea197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e3994bf-4892-480c-ad46-bbeba8369c96" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29207d1a-5349-45ef-9749-f02a14cea197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f7ce35de-34d9-483f-8185-10304d8120d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_LiabilitiesCurrent_f7ce35de-34d9-483f-8185-10304d8120d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_646ec13d-0a8f-41bc-9fcf-632740d54dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_646ec13d-0a8f-41bc-9fcf-632740d54dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_d2310f89-e053-4602-9f35-12a5ffe021a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_d2310f89-e053-4602-9f35-12a5ffe021a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_ea1649cc-1134-445e-a4c9-e4864c885cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_ea1649cc-1134-445e-a4c9-e4864c885cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7059cabe-1b96-4ed5-b5d4-d4ac579ed42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7059cabe-1b96-4ed5-b5d4-d4ac579ed42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47a8d574-f8a4-471c-8c18-e44bd1d98338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47a8d574-f8a4-471c-8c18-e44bd1d98338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_6176baff-1fcb-462a-bae7-c5461fe948a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_38a9302e-2270-40f8-9e5b-b31e599f285f" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_6176baff-1fcb-462a-bae7-c5461fe948a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_91f815ce-e2b4-4562-b71c-c09f03fef548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_AssetsCurrent_91f815ce-e2b4-4562-b71c-c09f03fef548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_cd96a8bf-6b87-4863-95f5-81bfaa709a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_OtherLongTermInvestments_cd96a8bf-6b87-4863-95f5-81bfaa709a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_66f071bc-4666-49d9-bfc4-13df1ff9d4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_66f071bc-4666-49d9-bfc4-13df1ff9d4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d7caad03-dad4-4be7-8170-0b7a9cd0d330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d7caad03-dad4-4be7-8170-0b7a9cd0d330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_505fd47a-0c93-4412-b18e-4914d79c4b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_Goodwill_505fd47a-0c93-4412-b18e-4914d79c4b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_e0b265f8-3f36-48dc-af92-f8039017776c" xlink:href="pfe-20210404.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_e0b265f8-3f36-48dc-af92-f8039017776c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d796702c-9af3-4b47-94cf-78f1a99b4df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d796702c-9af3-4b47-94cf-78f1a99b4df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2eacea40-15dc-48aa-8cea-5dedf7d9a9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5df514b5-685e-44b4-94fa-fb73cab54f42" xlink:to="loc_us-gaap_EquityMethodInvestments_2eacea40-15dc-48aa-8cea-5dedf7d9a9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_70c5748b-24f4-4763-979d-b31230eeb5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:to="loc_us-gaap_CommonStockValue_70c5748b-24f4-4763-979d-b31230eeb5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_18094f46-f4fc-4f41-a2d8-cabbfd9a028d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:to="loc_us-gaap_AdditionalPaidInCapital_18094f46-f4fc-4f41-a2d8-cabbfd9a028d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8e4b48f4-5498-4bb7-9182-4552eecfe906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:to="loc_us-gaap_TreasuryStockValue_8e4b48f4-5498-4bb7-9182-4552eecfe906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_277d83fc-be28-4244-ad60-474aa126578e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_277d83fc-be28-4244-ad60-474aa126578e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87bcec98-e9fc-4871-9f56-e442d1e4e512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_103969a1-734b-4025-9e82-d4bf50da7343" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87bcec98-e9fc-4871-9f56-e442d1e4e512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e4495f3-bab4-4393-939d-330585654a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9fe7950-b299-4b7d-8add-531275008a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e4495f3-bab4-4393-939d-330585654a38" xlink:to="loc_us-gaap_StockholdersEquity_a9fe7950-b299-4b7d-8add-531275008a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9d47ee78-f910-44f5-8b31-baeecafae6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e4495f3-bab4-4393-939d-330585654a38" xlink:to="loc_us-gaap_MinorityInterest_9d47ee78-f910-44f5-8b31-baeecafae6fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95fdb611-a2ad-4300-b0a6-fd2fbfe79a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_020700fe-5df6-4fc8-bb9f-03b07600018f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95fdb611-a2ad-4300-b0a6-fd2fbfe79a36" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_020700fe-5df6-4fc8-bb9f-03b07600018f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b344569f-148e-4130-80f0-1af052afcc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95fdb611-a2ad-4300-b0a6-fd2fbfe79a36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b344569f-148e-4130-80f0-1af052afcc40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_8eedb2bb-f882-46e1-9cbd-239ca521936e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_8eedb2bb-f882-46e1-9cbd-239ca521936e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_ad8207c5-5adb-46a6-8681-7f5d15feeda4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_ad8207c5-5adb-46a6-8681-7f5d15feeda4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_2dbe4585-fa2e-4457-a71e-a91e312cb0f1" xlink:href="pfe-20210404.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_2dbe4585-fa2e-4457-a71e-a91e312cb0f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0f0b6150-98f3-44fd-9791-98b2f0b559f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0f0b6150-98f3-44fd-9791-98b2f0b559f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_797aa149-b012-493d-bcc6-aedba3c64c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_797aa149-b012-493d-bcc6-aedba3c64c00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fac95a8c-332c-454b-9ad8-797d5448cf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fac95a8c-332c-454b-9ad8-797d5448cf93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d681507e-ff69-4ba8-994f-18ef0c03640f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7b830134-2868-4976-a8d4-78093912c49e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d681507e-ff69-4ba8-994f-18ef0c03640f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db670b48-c88e-48ad-8c70-a90813eaabd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_349b1898-42fe-4455-a7a5-5a7bc529579e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db670b48-c88e-48ad-8c70-a90813eaabd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_349b1898-42fe-4455-a7a5-5a7bc529579e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9e51de8-47b4-480a-8457-dd5e8ee907d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db670b48-c88e-48ad-8c70-a90813eaabd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9e51de8-47b4-480a-8457-dd5e8ee907d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca1990fb-90cc-4e60-9ff4-e6b6eb5137d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db670b48-c88e-48ad-8c70-a90813eaabd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca1990fb-90cc-4e60-9ff4-e6b6eb5137d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6c2d45f-8624-45c6-a5d6-6fd872934ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db670b48-c88e-48ad-8c70-a90813eaabd3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6c2d45f-8624-45c6-a5d6-6fd872934ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_238bc125-7cc7-4a3a-a9d6-e2a21948eb35" xlink:href="pfe-20210404.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_238bc125-7cc7-4a3a-a9d6-e2a21948eb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_4440421c-4528-484c-954c-7651a7976096" xlink:href="pfe-20210404.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_4440421c-4528-484c-954c-7651a7976096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_83af0fd1-8944-4117-9d29-6cf43ed7d8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_us-gaap_ShareBasedCompensation_83af0fd1-8944-4117-9d29-6cf43ed7d8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3612d375-1d5b-481c-b0ea-d4c5f8ffae98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3612d375-1d5b-481c-b0ea-d4c5f8ffae98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7fdcc830-0bf1-460b-ab8b-007b44c0fbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_7fdcc830-0bf1-460b-ab8b-007b44c0fbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_110ed97c-a5cb-409a-a9cd-74aded8459db" xlink:href="pfe-20210404.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_110ed97c-a5cb-409a-a9cd-74aded8459db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4c99ed8a-3c3e-4929-ba7f-4a5d32a585c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4c99ed8a-3c3e-4929-ba7f-4a5d32a585c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b37106f6-8300-4e14-81f3-230646596b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b37106f6-8300-4e14-81f3-230646596b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_d7dad6de-19fa-4b5d-ba94-168fdb1ce2eb" xlink:href="pfe-20210404.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_179b46d0-be58-40e6-8833-4675c197cb15" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_d7dad6de-19fa-4b5d-ba94-168fdb1ce2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be78ab0-fd7e-47de-9ea7-0f3985f12822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_359f5cb6-4902-47e8-9c9e-908b924ce88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be78ab0-fd7e-47de-9ea7-0f3985f12822" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_359f5cb6-4902-47e8-9c9e-908b924ce88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_da422044-9f06-4380-8665-ab022159877c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be78ab0-fd7e-47de-9ea7-0f3985f12822" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_da422044-9f06-4380-8665-ab022159877c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_a326acc6-9bc9-4470-9bbb-eb5674981886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_a326acc6-9bc9-4470-9bbb-eb5674981886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ac2e92c9-64ab-4474-8dfd-49bbf1e0fede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ac2e92c9-64ab-4474-8dfd-49bbf1e0fede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_101d6f91-7f92-4119-9f47-abfa28c39cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_101d6f91-7f92-4119-9f47-abfa28c39cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_96e40362-3ca0-40aa-9be4-df8eaddedee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_96e40362-3ca0-40aa-9be4-df8eaddedee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c935803-ebb0-4d2b-a5ea-9ad905c5f440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c935803-ebb0-4d2b-a5ea-9ad905c5f440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_cad2c02c-cfa9-415f-b0f6-21e006673a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_cad2c02c-cfa9-415f-b0f6-21e006673a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_0624f928-f872-4517-9729-8e5c07284fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b3fed6c-e2a8-4012-842b-3e4097ac13d5" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_0624f928-f872-4517-9729-8e5c07284fc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestment"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_96d718e7-6044-4240-abf2-c75849bd9459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_96d718e7-6044-4240-abf2-c75849bd9459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_ef45ba40-978b-4b01-9371-bdebfdb9c8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_ef45ba40-978b-4b01-9371-bdebfdb9c8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_9839783a-923a-4cd3-8131-29a1800fba68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_9839783a-923a-4cd3-8131-29a1800fba68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_d28dd48f-d8c1-4198-8075-8cb56544c0db" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_d28dd48f-d8c1-4198-8075-8cb56544c0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_607a4006-9af7-4a50-a744-f7dbc0848622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_607a4006-9af7-4a50-a744-f7dbc0848622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0fdc9956-786e-4224-bc9d-b1c2b46a4c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0fdc9956-786e-4224-bc9d-b1c2b46a4c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c82f49e3-1ca7-4f30-a738-b9b098caafee" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ce5acbe8-6ccb-414d-8250-848572350db8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c82f49e3-1ca7-4f30-a738-b9b098caafee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0cca1c4f-dfed-40e8-aa73-daf95aec75d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_96b29ac7-1098-4db2-b02e-10b4a3360e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0cca1c4f-dfed-40e8-aa73-daf95aec75d3" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_96b29ac7-1098-4db2-b02e-10b4a3360e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c0c8e4cf-db62-4c5f-a331-554f05fad99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0cca1c4f-dfed-40e8-aa73-daf95aec75d3" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c0c8e4cf-db62-4c5f-a331-554f05fad99b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e198fed8-4343-480f-aeb8-f8a189e85f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ac61a6a3-fb6f-4682-a87b-6a14dcbc4ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_e198fed8-4343-480f-aeb8-f8a189e85f8a" xlink:to="loc_us-gaap_CostOfRevenue_ac61a6a3-fb6f-4682-a87b-6a14dcbc4ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_94f66821-4f72-4c2e-96af-69bbed8a014b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_e198fed8-4343-480f-aeb8-f8a189e85f8a" xlink:to="loc_us-gaap_Revenues_94f66821-4f72-4c2e-96af-69bbed8a014b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3b7ffce0-ad08-42cb-8b8a-c3233771f1e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c48aa51d-967d-447f-8123-8d4c098d4af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_3b7ffce0-ad08-42cb-8b8a-c3233771f1e9" xlink:to="loc_us-gaap_SeveranceCosts1_c48aa51d-967d-447f-8123-8d4c098d4af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_16d6acdb-b344-4804-a271-f34ae392f76a" xlink:href="pfe-20210404.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_3b7ffce0-ad08-42cb-8b8a-c3233771f1e9" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_16d6acdb-b344-4804-a271-f34ae392f76a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84d9e376-1f3b-47fc-93ac-dc2de7664131" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_063bba89-de4c-4522-b821-b328ceb63327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84d9e376-1f3b-47fc-93ac-dc2de7664131" xlink:to="loc_us-gaap_RestructuringCharges_063bba89-de4c-4522-b821-b328ceb63327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_3cc42a66-cf45-4fd7-aad7-470b98602d4a" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84d9e376-1f3b-47fc-93ac-dc2de7664131" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_3cc42a66-cf45-4fd7-aad7-470b98602d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_cca75718-fa7c-4f95-b896-0c8ec73c1430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84d9e376-1f3b-47fc-93ac-dc2de7664131" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_cca75718-fa7c-4f95-b896-0c8ec73c1430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_98dccbc7-0dcf-40dd-af90-0bf3299bdb57" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_9137dbeb-9c1a-4624-9875-7829304a09ea" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_98dccbc7-0dcf-40dd-af90-0bf3299bdb57" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_9137dbeb-9c1a-4624-9875-7829304a09ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_14397015-1117-41d7-ad92-00ea216387de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_98dccbc7-0dcf-40dd-af90-0bf3299bdb57" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_14397015-1117-41d7-ad92-00ea216387de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_3db7700e-18ee-4d22-9657-25697556d78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_98dccbc7-0dcf-40dd-af90-0bf3299bdb57" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_3db7700e-18ee-4d22-9657-25697556d78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_554d7570-e7df-4841-96f1-0aed0e46c844" xlink:href="pfe-20210404.xsd#pfe_ImplementationCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_98dccbc7-0dcf-40dd-af90-0bf3299bdb57" xlink:to="loc_pfe_ImplementationCosts_554d7570-e7df-4841-96f1-0aed0e46c844" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNet"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_e43a8174-9452-43c2-b397-7cd4572ff475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8afa41bb-00d8-4d9a-8091-8c0e70293d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_e43a8174-9452-43c2-b397-7cd4572ff475" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8afa41bb-00d8-4d9a-8091-8c0e70293d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_69e14152-2ab0-441f-a4f8-7a26db1da10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_e43a8174-9452-43c2-b397-7cd4572ff475" xlink:to="loc_us-gaap_InterestExpense_69e14152-2ab0-441f-a4f8-7a26db1da10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_314697b0-3028-46a3-ab61-b8a1bd12801a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_314697b0-3028-46a3-ab61-b8a1bd12801a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_96e164e0-88e1-4312-bda3-b2b93d94383c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_96e164e0-88e1-4312-bda3-b2b93d94383c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4b962329-c2a1-4101-83d2-6d912501374a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4b962329-c2a1-4101-83d2-6d912501374a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4e766993-c774-434f-b507-9fcc9d6aef31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4e766993-c774-434f-b507-9fcc9d6aef31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_29cf2184-073f-4b84-82f9-881b3411816f" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_29cf2184-073f-4b84-82f9-881b3411816f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_69bbae75-ae26-49f1-ad4e-8dfa2dc31662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_69bbae75-ae26-49f1-ad4e-8dfa2dc31662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7cda7e4a-d5da-42aa-b878-68bcfc44565b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7cda7e4a-d5da-42aa-b878-68bcfc44565b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_d6007d61-b097-4048-82b5-05005f205e9c" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_d6007d61-b097-4048-82b5-05005f205e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_f773dbae-62f6-4e7f-b445-c11539ac9b92" xlink:href="pfe-20210404.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_180652e7-fa4d-42e2-8b5f-74708d4b00f6" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_f773dbae-62f6-4e7f-b445-c11539ac9b92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetFootnotesDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMatters"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1a9e2db2-c345-46e9-a3bf-948c331cef02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_82becb9d-56de-46d1-a1a8-1f2bee37f611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1a9e2db2-c345-46e9-a3bf-948c331cef02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_82becb9d-56de-46d1-a1a8-1f2bee37f611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_079b6fad-f9ca-403d-a877-f88a7c96832a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1a9e2db2-c345-46e9-a3bf-948c331cef02" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_079b6fad-f9ca-403d-a877-f88a7c96832a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c3b95f6a-458a-4908-8896-449c846e91f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_73d8561f-64dc-447d-aa63-4b690e14a134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c3b95f6a-458a-4908-8896-449c846e91f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_73d8561f-64dc-447d-aa63-4b690e14a134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_936e54ef-5342-410a-b5af-00483a189011" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_c3b95f6a-458a-4908-8896-449c846e91f6" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_936e54ef-5342-410a-b5af-00483a189011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_9cb90b15-e02f-47a1-89c4-d0f7c259ae40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b0130cf3-d8e6-4e11-bd6d-95570e0be077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_9cb90b15-e02f-47a1-89c4-d0f7c259ae40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b0130cf3-d8e6-4e11-bd6d-95570e0be077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_f26dabf4-74ab-43f0-a5b6-69ac1e4c1a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_9cb90b15-e02f-47a1-89c4-d0f7c259ae40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_f26dabf4-74ab-43f0-a5b6-69ac1e4c1a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_78cc2ab9-7595-4048-bacd-9745c3212e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_252b1375-d5cc-4a3b-90f8-f9ed2074e46f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_78cc2ab9-7595-4048-bacd-9745c3212e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_252b1375-d5cc-4a3b-90f8-f9ed2074e46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_138c847a-7918-49be-9c53-e4170a9e167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_78cc2ab9-7595-4048-bacd-9745c3212e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_138c847a-7918-49be-9c53-e4170a9e167f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_6464417a-a0a8-47bc-88b0-bb72f4f1eaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_78cc2ab9-7595-4048-bacd-9745c3212e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_6464417a-a0a8-47bc-88b0-bb72f4f1eaba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_0edb9482-52ce-4131-9a95-005eaf6f5766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_78cc2ab9-7595-4048-bacd-9745c3212e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_0edb9482-52ce-4131-9a95-005eaf6f5766" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_02022925-4647-48bc-b075-068f340b5f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_b093643e-319d-40a7-b38f-c1d5e149b250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_02022925-4647-48bc-b075-068f340b5f8c" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_b093643e-319d-40a7-b38f-c1d5e149b250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f067aab0-0637-4d5d-9798-58678ab99c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_02022925-4647-48bc-b075-068f340b5f8c" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f067aab0-0637-4d5d-9798-58678ab99c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_5606f172-9ca0-485a-8f63-2a2edde369e2" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_099dba36-43e2-4a31-b93a-138069a3291e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_5606f172-9ca0-485a-8f63-2a2edde369e2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_099dba36-43e2-4a31-b93a-138069a3291e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bf627f8-3bdf-4d27-88f0-b1ad1c014692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_5606f172-9ca0-485a-8f63-2a2edde369e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bf627f8-3bdf-4d27-88f0-b1ad1c014692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_07eeb6c4-bd26-4ae8-ba49-155e9bc1585d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_5606f172-9ca0-485a-8f63-2a2edde369e2" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_07eeb6c4-bd26-4ae8-ba49-155e9bc1585d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd5da1bf-5603-4248-a293-81a385db994e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_80d859b5-752d-48db-bed9-85f39ae01d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_bd5da1bf-5603-4248-a293-81a385db994e" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_80d859b5-752d-48db-bed9-85f39ae01d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_07cf9db0-3dfa-406c-8c24-f601bcde0bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_bd5da1bf-5603-4248-a293-81a385db994e" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_07cf9db0-3dfa-406c-8c24-f601bcde0bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7ebc8e3e-95f6-4d97-92e3-32b4103aea84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_66034cf4-cc77-4bf6-bd60-1546ec58c27f" xlink:href="pfe-20210404.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ebc8e3e-95f6-4d97-92e3-32b4103aea84" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_66034cf4-cc77-4bf6-bd60-1546ec58c27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_f5236f26-9004-4548-94a9-97628b310da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ebc8e3e-95f6-4d97-92e3-32b4103aea84" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_f5236f26-9004-4548-94a9-97628b310da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_9f8e3bdb-c8b6-4dd1-8d19-a3eedbe0f4e7" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ebc8e3e-95f6-4d97-92e3-32b4103aea84" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_9f8e3bdb-c8b6-4dd1-8d19-a3eedbe0f4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a56111a3-af9c-474f-a5c4-b2ee2b6a1ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7ebc8e3e-95f6-4d97-92e3-32b4103aea84" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a56111a3-af9c-474f-a5c4-b2ee2b6a1ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1f33f8ed-56ea-442a-9f39-4a8a33e7bd0c" xlink:href="pfe-20210404.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cabfdfaa-8a7b-4229-80d7-a83f21549d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1f33f8ed-56ea-442a-9f39-4a8a33e7bd0c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cabfdfaa-8a7b-4229-80d7-a83f21549d28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1156531e-9367-4256-a32b-408b1aafb777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_1f33f8ed-56ea-442a-9f39-4a8a33e7bd0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1156531e-9367-4256-a32b-408b1aafb777" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d5faaebc-635f-4f27-8ba8-ec4266d7ff7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7cbc96c1-650e-45c9-a01a-195b3e195b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_d5faaebc-635f-4f27-8ba8-ec4266d7ff7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7cbc96c1-650e-45c9-a01a-195b3e195b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b7deb3b5-dec9-4ce0-81dc-70be4e6baa66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_d5faaebc-635f-4f27-8ba8-ec4266d7ff7e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b7deb3b5-dec9-4ce0-81dc-70be4e6baa66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_125305ae-50fd-4e43-85ca-0981a5494b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_d5faaebc-635f-4f27-8ba8-ec4266d7ff7e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_125305ae-50fd-4e43-85ca-0981a5494b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_3a21921d-ff69-430d-8896-a22acc3da42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_1ec97cb3-03ab-43d9-94cc-513c27fc07b1" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_3a21921d-ff69-430d-8896-a22acc3da42b" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_1ec97cb3-03ab-43d9-94cc-513c27fc07b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7ed584f5-9c84-4686-9fea-176d2324ca2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_3a21921d-ff69-430d-8896-a22acc3da42b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7ed584f5-9c84-4686-9fea-176d2324ca2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_caefa74f-8635-4019-9e29-39902d982e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_3a21921d-ff69-430d-8896-a22acc3da42b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_caefa74f-8635-4019-9e29-39902d982e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_3a0a4107-3438-470e-9087-db4a72d61d46" xlink:href="pfe-20210404.xsd#pfe_PrivateEquityInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_3a21921d-ff69-430d-8896-a22acc3da42b" xlink:to="loc_pfe_PrivateEquityInvestments_3a0a4107-3438-470e-9087-db4a72d61d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_99088bb7-32a4-43d7-9897-7a474152e9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_542a4858-febc-430e-bc0c-c1fb6bdc1ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_99088bb7-32a4-43d7-9897-7a474152e9f7" xlink:to="loc_us-gaap_OtherLongTermInvestments_542a4858-febc-430e-bc0c-c1fb6bdc1ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d21bc5de-6b44-4996-8b6f-62270c631d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_99088bb7-32a4-43d7-9897-7a474152e9f7" xlink:to="loc_us-gaap_EquityMethodInvestments_d21bc5de-6b44-4996-8b6f-62270c631d56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_571d5851-3cf0-4129-b92d-11bde92e2e0e" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_56f7a9d5-8f0c-4ad4-9a6e-ae3adf6327a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_571d5851-3cf0-4129-b92d-11bde92e2e0e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_56f7a9d5-8f0c-4ad4-9a6e-ae3adf6327a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c5ef5437-a0d5-4cd0-afcb-5cfaeae95559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_571d5851-3cf0-4129-b92d-11bde92e2e0e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c5ef5437-a0d5-4cd0-afcb-5cfaeae95559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4553e26-27ad-4356-ae74-0fcc74bfb548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d4ab5571-7b04-49a1-8e37-fd749894a2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4553e26-27ad-4356-ae74-0fcc74bfb548" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d4ab5571-7b04-49a1-8e37-fd749894a2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d396125-b07d-4318-a314-9ef47cb14af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4553e26-27ad-4356-ae74-0fcc74bfb548" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d396125-b07d-4318-a314-9ef47cb14af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1532485-5fbb-41a2-b4a4-05bc02b8ca15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4553e26-27ad-4356-ae74-0fcc74bfb548" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1532485-5fbb-41a2-b4a4-05bc02b8ca15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_c37248aa-fd61-400e-b7eb-cd4527380bd3" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_d88f2cf1-b588-486f-ae09-c2f27417b576" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_c37248aa-fd61-400e-b7eb-cd4527380bd3" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_d88f2cf1-b588-486f-ae09-c2f27417b576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_d427f2e3-18e6-43ba-8d5f-4136c6a613b2" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_c37248aa-fd61-400e-b7eb-cd4527380bd3" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_d427f2e3-18e6-43ba-8d5f-4136c6a613b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_358fce90-987d-44d6-98ed-07ecb56561c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_c37248aa-fd61-400e-b7eb-cd4527380bd3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_358fce90-987d-44d6-98ed-07ecb56561c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_85eda5cb-db0d-49ec-ac1a-66eb429e3d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6aa557bf-06e2-4cfd-a89e-7cfb21c90d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_85eda5cb-db0d-49ec-ac1a-66eb429e3d77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6aa557bf-06e2-4cfd-a89e-7cfb21c90d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f588049c-2d50-47b0-acde-24114d1132de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_85eda5cb-db0d-49ec-ac1a-66eb429e3d77" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f588049c-2d50-47b0-acde-24114d1132de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_cfef972a-221a-44f1-89fa-142c314b7a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_ba1d7beb-5e5b-442e-9f5b-b94d41eb9f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cfef972a-221a-44f1-89fa-142c314b7a84" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_ba1d7beb-5e5b-442e-9f5b-b94d41eb9f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_e3825f08-0245-45ae-ac8b-e32714fb3214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cfef972a-221a-44f1-89fa-142c314b7a84" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_e3825f08-0245-45ae-ac8b-e32714fb3214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b3f5ea26-0df4-43a4-813a-0f1eea2d8cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_cfef972a-221a-44f1-89fa-142c314b7a84" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b3f5ea26-0df4-43a4-813a-0f1eea2d8cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_1d29ba9a-962c-4b9c-ac0c-3151d6cf1358" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8626505f-3d88-4e51-8b87-fefd00373350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_1d29ba9a-962c-4b9c-ac0c-3151d6cf1358" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8626505f-3d88-4e51-8b87-fefd00373350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8188d6a-fff7-4217-816d-cf16107eb73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_1d29ba9a-962c-4b9c-ac0c-3151d6cf1358" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8188d6a-fff7-4217-816d-cf16107eb73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c5ed442c-45f9-4f1a-a2d9-af3030b35ac2" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_b0bb1941-9199-4756-b66a-9266a2eafb76" xlink:href="pfe-20210404.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c5ed442c-45f9-4f1a-a2d9-af3030b35ac2" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_b0bb1941-9199-4756-b66a-9266a2eafb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_19a27fc2-9159-41dd-ae34-bb9d59b43140" xlink:href="pfe-20210404.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c5ed442c-45f9-4f1a-a2d9-af3030b35ac2" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_19a27fc2-9159-41dd-ae34-bb9d59b43140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6dd02e8-4723-4923-a648-719d8f4ac981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d5456af1-912a-4efb-abe4-c519b0ab5766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6dd02e8-4723-4923-a648-719d8f4ac981" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d5456af1-912a-4efb-abe4-c519b0ab5766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_43a1bdf9-3a0e-4663-b7e2-0a19866b7df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6dd02e8-4723-4923-a648-719d8f4ac981" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_43a1bdf9-3a0e-4663-b7e2-0a19866b7df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_2c2f3a0a-cfdc-4b20-b17f-05edbf97fdde" xlink:href="pfe-20210404.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6dd02e8-4723-4923-a648-719d8f4ac981" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_2c2f3a0a-cfdc-4b20-b17f-05edbf97fdde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_10a1207c-95ed-41d6-92a8-107280ccdc4a" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_83f79260-afe3-429f-b7b0-12d0fa92a1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_10a1207c-95ed-41d6-92a8-107280ccdc4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_83f79260-afe3-429f-b7b0-12d0fa92a1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_f1c482c2-bdb4-486b-9bd9-b10e53293704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_10a1207c-95ed-41d6-92a8-107280ccdc4a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_f1c482c2-bdb4-486b-9bd9-b10e53293704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_33f357ab-f7ea-47d3-9ba0-2bb252070a62" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7df1ed9d-0f26-4300-aebd-8d245cd579d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_33f357ab-f7ea-47d3-9ba0-2bb252070a62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7df1ed9d-0f26-4300-aebd-8d245cd579d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_005f1c5d-b831-46b5-8e3d-398701349d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_33f357ab-f7ea-47d3-9ba0-2bb252070a62" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_005f1c5d-b831-46b5-8e3d-398701349d20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_67b0da5c-4290-4639-a6d8-f55241748c73" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e186b493-36bc-4694-b396-7f5b42cbb5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_67b0da5c-4290-4639-a6d8-f55241748c73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e186b493-36bc-4694-b396-7f5b42cbb5e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_dbb90ad4-9a0a-4531-a674-ca6e912f8531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_67b0da5c-4290-4639-a6d8-f55241748c73" xlink:to="loc_us-gaap_HeldToMaturitySecurities_dbb90ad4-9a0a-4531-a674-ca6e912f8531" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_56f109a2-fe04-4964-a363-6cbc667ab058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_aa8a6f46-b7f3-4324-869e-f1ed9f0e4e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_56f109a2-fe04-4964-a363-6cbc667ab058" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_aa8a6f46-b7f3-4324-869e-f1ed9f0e4e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee19c5cb-b5af-4667-92da-f9cf5a619df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_56f109a2-fe04-4964-a363-6cbc667ab058" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee19c5cb-b5af-4667-92da-f9cf5a619df0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_1ae13caa-72a5-40be-9184-566482458618" xlink:href="pfe-20210404.xsd#pfe_ShorttermDebtGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_1a129f3b-18ec-4166-a532-c15dfa7736b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_1ae13caa-72a5-40be-9184-566482458618" xlink:to="loc_us-gaap_CommercialPaper_1a129f3b-18ec-4166-a532-c15dfa7736b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_20cecd2b-b6e8-4e46-ba94-b38cef23de0a" xlink:href="pfe-20210404.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_1ae13caa-72a5-40be-9184-566482458618" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_20cecd2b-b6e8-4e46-ba94-b38cef23de0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_137ec969-a96b-4fde-8d5b-c385dd680602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_1ae13caa-72a5-40be-9184-566482458618" xlink:to="loc_us-gaap_OtherShortTermBorrowings_137ec969-a96b-4fde-8d5b-c385dd680602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_dc56604f-c6c4-44b1-adb4-6a457f386165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_561f1952-2d91-4081-ac8c-b706c0190b45" xlink:href="pfe-20210404.xsd#pfe_ShorttermDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_dc56604f-c6c4-44b1-adb4-6a457f386165" xlink:to="loc_pfe_ShorttermDebtGross_561f1952-2d91-4081-ac8c-b706c0190b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_b4a42c9a-5b51-4da6-a22a-ecc9b7efc9a5" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_dc56604f-c6c4-44b1-adb4-6a457f386165" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_b4a42c9a-5b51-4da6-a22a-ecc9b7efc9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0f61f293-e64e-4fbc-bb74-1b224d7f526b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_dc56604f-c6c4-44b1-adb4-6a457f386165" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0f61f293-e64e-4fbc-bb74-1b224d7f526b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_98c56df9-2fc5-4edb-aa32-89034bee9a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_03561e09-3991-404c-b3e7-333eb3616a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_98c56df9-2fc5-4edb-aa32-89034bee9a51" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_03561e09-3991-404c-b3e7-333eb3616a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_92b2bddd-f337-4d0b-8eee-948d26e94021" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_98c56df9-2fc5-4edb-aa32-89034bee9a51" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_92b2bddd-f337-4d0b-8eee-948d26e94021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eebbb4b-9f36-414c-88de-4fb6f952e246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_98c56df9-2fc5-4edb-aa32-89034bee9a51" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eebbb4b-9f36-414c-88de-4fb6f952e246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_a47866e6-1bd2-4b64-aa2b-cecd2e6fcac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_98c56df9-2fc5-4edb-aa32-89034bee9a51" xlink:to="loc_us-gaap_OtherLongTermDebt_a47866e6-1bd2-4b64-aa2b-cecd2e6fcac0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCreditRiskDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e72e78eb-95b4-416e-b0de-a19ca357a200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bd9f789a-8044-48c3-aec9-9bdfccf6624c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e72e78eb-95b4-416e-b0de-a19ca357a200" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bd9f789a-8044-48c3-aec9-9bdfccf6624c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_bc610409-6c7f-4ce6-8fba-86356d6dcbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e72e78eb-95b4-416e-b0de-a19ca357a200" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_bc610409-6c7f-4ce6-8fba-86356d6dcbad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c6f825d6-560c-43fd-9c91-38f537a3725b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e72e78eb-95b4-416e-b0de-a19ca357a200" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c6f825d6-560c-43fd-9c91-38f537a3725b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_79d492f2-43c2-4a5f-bc58-7d4196098467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dbe6a5b8-1f9d-455e-a6ac-ef1c57293fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_79d492f2-43c2-4a5f-bc58-7d4196098467" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dbe6a5b8-1f9d-455e-a6ac-ef1c57293fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_52444687-3fff-4b54-8e74-1c26ff761eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_79d492f2-43c2-4a5f-bc58-7d4196098467" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_52444687-3fff-4b54-8e74-1c26ff761eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e1968-732d-4fb9-b195-bf3f95e0d5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9906d00f-1465-4366-8665-789815015324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e1968-732d-4fb9-b195-bf3f95e0d5f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9906d00f-1465-4366-8665-789815015324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f3bd5276-7953-43a6-916b-e5f2518b6777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_008e1968-732d-4fb9-b195-bf3f95e0d5f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f3bd5276-7953-43a6-916b-e5f2518b6777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45dfba27-874c-4731-9c2a-3da765c910f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_00a84c6d-a816-4523-b112-c5f57c2c5c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45dfba27-874c-4731-9c2a-3da765c910f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_00a84c6d-a816-4523-b112-c5f57c2c5c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d21bfe4e-769d-464a-b578-0755ecd65bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_45dfba27-874c-4731-9c2a-3da765c910f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d21bfe4e-769d-464a-b578-0755ecd65bf7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e74c47cf-08b2-4e12-9ecd-9f79eb598c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_770899fe-3d7b-400d-9a80-8854f240f218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e74c47cf-08b2-4e12-9ecd-9f79eb598c81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_770899fe-3d7b-400d-9a80-8854f240f218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a1982808-c833-4f35-8919-c57f51e6cd29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e74c47cf-08b2-4e12-9ecd-9f79eb598c81" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a1982808-c833-4f35-8919-c57f51e6cd29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_a0824c84-c1f4-42c3-8649-cfd95d397b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_a0824c84-c1f4-42c3-8649-cfd95d397b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_3bb1f859-14dc-4a65-980e-ff8c9219ace3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_3bb1f859-14dc-4a65-980e-ff8c9219ace3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bec63b18-b1b8-400b-a531-a2d91faf42bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bec63b18-b1b8-400b-a531-a2d91faf42bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41ad7955-20fe-4549-ac1e-01f9435fc2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41ad7955-20fe-4549-ac1e-01f9435fc2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_923cfe6f-4f5a-4327-8a9f-0648a9fd03b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_923cfe6f-4f5a-4327-8a9f-0648a9fd03b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_1b642a9b-2973-4c15-8656-e6843ad88469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_ed836aee-46a3-474d-9c02-350fd42b45f6" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_1b642a9b-2973-4c15-8656-e6843ad88469" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_56bab520-3912-492f-9ab1-f65b590b0d25" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4d1b8019-4122-4ee0-8a77-3320d960f6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_56bab520-3912-492f-9ab1-f65b590b0d25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4d1b8019-4122-4ee0-8a77-3320d960f6b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_5973b44a-da0e-4779-a546-24d6c3c33df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_56bab520-3912-492f-9ab1-f65b590b0d25" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_5973b44a-da0e-4779-a546-24d6c3c33df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e5f6e18-10c3-4da6-ba25-58fa2ffc97fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0af1c60-0fd3-46e6-b2ee-2dda8a32ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e5f6e18-10c3-4da6-ba25-58fa2ffc97fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0af1c60-0fd3-46e6-b2ee-2dda8a32ed48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d03e7f32-827b-4a39-8812-22cbb42da002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e5f6e18-10c3-4da6-ba25-58fa2ffc97fa" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d03e7f32-827b-4a39-8812-22cbb42da002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4105891c-5ead-4f35-b33e-f55e75ffaad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_4a7f5617-afee-4af9-b6bc-e8fe54490994" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4105891c-5ead-4f35-b33e-f55e75ffaad5" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_4a7f5617-afee-4af9-b6bc-e8fe54490994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d41cd301-9d57-429d-b06c-65e4f5875954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4105891c-5ead-4f35-b33e-f55e75ffaad5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d41cd301-9d57-429d-b06c-65e4f5875954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_feb88834-679e-47ce-b07c-f5b1cd0fd183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_f24dfb3a-2b7d-4b2c-911c-6902bf6be9d8" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_feb88834-679e-47ce-b07c-f5b1cd0fd183" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_f24dfb3a-2b7d-4b2c-911c-6902bf6be9d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_823b5b58-7bbf-42a6-89f4-a84733f43630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_feb88834-679e-47ce-b07c-f5b1cd0fd183" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_823b5b58-7bbf-42a6-89f4-a84733f43630" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitments"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformation"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationTables"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>pfe-20210404_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20210404.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" id="iffdf81b5ba82428da36098117c4b244c_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5ae5c59d-0a41-48af-b6f0-2c975b9ca07b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentType_5ae5c59d-0a41-48af-b6f0-2c975b9ca07b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c88d0254-922f-4034-9be9-c8b2f6d10213" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentQuarterlyReport_c88d0254-922f-4034-9be9-c8b2f6d10213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e1240b45-5071-4737-b309-d9adf4c50f26" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentPeriodEndDate_e1240b45-5071-4737-b309-d9adf4c50f26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b7960ca7-6c44-4d64-953d-4062601953f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentTransitionReport_b7960ca7-6c44-4d64-953d-4062601953f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_75a06fd9-508a-4ebb-8f70-2a53f0296421" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityFileNumber_75a06fd9-508a-4ebb-8f70-2a53f0296421" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_21db3a3c-d417-46a2-be2a-a6aa30990be9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityRegistrantName_21db3a3c-d417-46a2-be2a-a6aa30990be9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f28b1e36-4428-4b99-901f-222c17f78907" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f28b1e36-4428-4b99-901f-222c17f78907" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cf056c78-daa3-40cb-b83e-32c4faeebe5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityTaxIdentificationNumber_cf056c78-daa3-40cb-b83e-32c4faeebe5e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_70f29d0e-e68d-400e-9f5f-b65e4a30c2a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressAddressLine1_70f29d0e-e68d-400e-9f5f-b65e4a30c2a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d4679871-a9d1-4242-9a8e-6f16475eae03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressCityOrTown_d4679871-a9d1-4242-9a8e-6f16475eae03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c1f97478-af96-4277-b976-3c331a333ca6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressStateOrProvince_c1f97478-af96-4277-b976-3c331a333ca6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a225005c-88d1-4a93-ae6c-4ec2c07213db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressPostalZipCode_a225005c-88d1-4a93-ae6c-4ec2c07213db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fc06c3a2-94ed-44b4-bfbb-476ec2758e28" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_CityAreaCode_fc06c3a2-94ed-44b4-bfbb-476ec2758e28" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2457eec2-7cc1-434d-adf1-38d87a065957" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_LocalPhoneNumber_2457eec2-7cc1-434d-adf1-38d87a065957" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4b8e64ae-854c-45b3-a9d7-ac85af5eb71f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_Security12bTitle_4b8e64ae-854c-45b3-a9d7-ac85af5eb71f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_990d67be-86e0-4edb-8022-57cb2e7fdddd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_TradingSymbol_990d67be-86e0-4edb-8022-57cb2e7fdddd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6cf9d7a2-3633-462c-a87d-187b4478e941" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_SecurityExchangeName_6cf9d7a2-3633-462c-a87d-187b4478e941" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_36f34453-d919-43ba-b03f-adda4e1453f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCurrentReportingStatus_36f34453-d919-43ba-b03f-adda4e1453f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_436a96fa-8f7f-4144-b35e-2f5915726e06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityInteractiveDataCurrent_436a96fa-8f7f-4144-b35e-2f5915726e06" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_32dd1ab1-5683-4559-8592-07090f9f2209" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityFilerCategory_32dd1ab1-5683-4559-8592-07090f9f2209" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5e9df3a0-e9a4-4847-b577-7654d3c110ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntitySmallBusiness_5e9df3a0-e9a4-4847-b577-7654d3c110ab" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6ca23569-3ccd-4361-b194-2584c41dd34a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityEmergingGrowthCompany_6ca23569-3ccd-4361-b194-2584c41dd34a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4256e998-d611-43ea-a45e-8206f416486a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityShellCompany_4256e998-d611-43ea-a45e-8206f416486a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_988ed6b7-2cc2-4401-b27e-2052d134fc86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_988ed6b7-2cc2-4401-b27e-2052d134fc86" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7cb2e8cb-a0dc-4c86-aa56-f1d78fd5fc3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCentralIndexKey_7cb2e8cb-a0dc-4c86-aa56-f1d78fd5fc3d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3a132c7c-2f4c-4f76-b944-c476a147d8b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_CurrentFiscalYearEndDate_3a132c7c-2f4c-4f76-b944-c476a147d8b5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fc105843-e542-4c80-acb4-c913e29fe78b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentFiscalYearFocus_fc105843-e542-4c80-acb4-c913e29fe78b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8292b943-a499-4d9f-a397-fbbad8ca9be7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8292b943-a499-4d9f-a397-fbbad8ca9be7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9364c9b2-f287-421b-a34d-fa73318e76a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_AmendmentFlag_9364c9b2-f287-421b-a34d-fa73318e76a9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0452983c-500c-4902-99b9-d1c566c5d166_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:to="loc_us-gaap_ClassOfStockDomain_0452983c-500c-4902-99b9-d1c566c5d166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:to="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48fab872-9c61-483c-a71a-71c43d3bf2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_us-gaap_CommonStockMember_48fab872-9c61-483c-a71a-71c43d3bf2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member_9376ef58-f094-4008-9dd4-5ebf407f3bfd" xlink:href="pfe-20210404.xsd#pfe_NotesDue20220.250Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_pfe_NotesDue20220.250Member_9376ef58-f094-4008-9dd4-5ebf407f3bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_2d203c86-49c3-4c21-8382-f2cd399ab222" xlink:href="pfe-20210404.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_pfe_NotesDue20271.000Member_2d203c86-49c3-4c21-8382-f2cd399ab222" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended" id="i907018f63c814eb397afe2a7867d1398_CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended" id="i47a7398cd49d4fe8809791c0110ebb30_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i43a31a7b637646ac93ecf69d93886f6b_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended" id="i5cc7cfeeffc24da1ba86ecfd101b9ee3_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="extended" id="ia99d9e1dad644ddfa1fc4499f94adb4f_CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c068f3e4-c1ef-49f9-8995-520b2af0a0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_SharesIssued_c068f3e4-c1ef-49f9-8995-520b2af0a0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3524296-1573-4ae4-98c5-a564502494c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3524296-1573-4ae4-98c5-a564502494c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e57af26-fdd8-4449-84e1-f0f885f6e835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_ProfitLoss_8e57af26-fdd8-4449-84e1-f0f885f6e835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0415ad3-6d74-419d-ae7f-97ac2ead173f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0415ad3-6d74-419d-ae7f-97ac2ead173f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a4293bd0-f6a8-4d19-993b-dc5dae0e4c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_DividendsCommonStockCash_a4293bd0-f6a8-4d19-993b-dc5dae0e4c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_d3f6f60b-742b-4314-9841-7cc3118c1657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_DividendsPreferredStockCash_d3f6f60b-742b-4314-9841-7cc3118c1657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_527f0136-2605-4fbc-9434-2a5bbf2a31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_527f0136-2605-4fbc-9434-2a5bbf2a31f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_afd34257-9656-4817-a1b3-6743976ac448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_afd34257-9656-4817-a1b3-6743976ac448" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5cb290c-be58-4e3c-a8fc-398e73131f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5cb290c-be58-4e3c-a8fc-398e73131f46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_144aa29f-a640-410d-8e91-88ea22dbc6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_144aa29f-a640-410d-8e91-88ea22dbc6ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_02555920-5e0b-4e30-bd1b-a6e377654b53" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_02555920-5e0b-4e30-bd1b-a6e377654b53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_65665432-5e67-4c5f-afff-42574a1e8dc9" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_65665432-5e67-4c5f-afff-42574a1e8dc9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_becacc79-b5dd-4e39-9f3a-1cd697c37cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockholdersEquityOther_becacc79-b5dd-4e39-9f3a-1cd697c37cf6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8bd5edfb-57e5-4d2f-ab0f-c61880fdbf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0be88c98-445e-43be-b288-8a8cd35337d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:to="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58d2959c-80ef-4ecd-8ece-574a6a8d79c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:to="loc_us-gaap_EquityComponentDomain_58d2959c-80ef-4ecd-8ece-574a6a8d79c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:to="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c47b61c3-9da6-496c-aa77-4d38941a2b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_PreferredStockMember_c47b61c3-9da6-496c-aa77-4d38941a2b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8d014ab-71f2-4907-b353-5eda9fce7205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_CommonStockMember_e8d014ab-71f2-4907-b353-5eda9fce7205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6a407cdc-da63-410e-9c8e-b37551ae57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6a407cdc-da63-410e-9c8e-b37551ae57e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_02593467-42bf-4cc0-8f45-abe17c394a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_TreasuryStockMember_02593467-42bf-4cc0-8f45-abe17c394a22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f2c12bdf-d2de-44ab-8ad3-1bf7c253183d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_RetainedEarningsMember_f2c12bdf-d2de-44ab-8ad3-1bf7c253183d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_377694f5-9637-46c2-9735-f2d40e4978d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_377694f5-9637-46c2-9735-f2d40e4978d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_3e426b47-7dde-4b48-9b90-cf30d5fc01d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_ParentMember_3e426b47-7dde-4b48-9b90-cf30d5fc01d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9efe05c2-ca94-4b9c-aaa2-b7b6969ace0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9efe05c2-ca94-4b9c-aaa2-b7b6969ace0b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="extended" id="ie7758989e410416ab67ecb7c071e7379_CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended" id="i3821affd319649e68fc2c03ed6d83b77_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended" id="i10b46d9a0d6f4806a5eeaf46f39ca9e9_BasisofPresentationandSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i1b22c155d2df4b4f8c67401d605fdef1_BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended" id="i4c701f4409544b7a8944affb7c13010c_BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i56174454dd3441eb8919eca5e784a98a_BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3b13b7f-36be-4c44-8c99-bf59d311cdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3b13b7f-36be-4c44-8c99-bf59d311cdf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebb00944-9e66-458e-baba-b9f76f5bafba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebb00944-9e66-458e-baba-b9f76f5bafba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:to="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_265782ec-2673-4ce4-9ac0-920f8e184e76_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:to="loc_srt_RestatementDomain_265782ec-2673-4ce4-9ac0-920f8e184e76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:to="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_0702a847-880d-40a0-865a-5b8eaf0fcd05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:to="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_0702a847-880d-40a0-865a-5b8eaf0fcd05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="extended" id="i46f260a7bd114d9ea4fe4c6419d37090_BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_38b864db-2948-4050-8a56-60c826846125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_38b864db-2948-4050-8a56-60c826846125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b37f451-3382-4b0f-9dad-77fa31f5e4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b37f451-3382-4b0f-9dad-77fa31f5e4d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6e6cf31-131a-484e-a5bf-52eda49fbf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e6e6cf31-131a-484e-a5bf-52eda49fbf8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fb71d120-73ab-4a94-a5cb-df19725d9c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fb71d120-73ab-4a94-a5cb-df19725d9c24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b5a0649c-330d-4c2a-8494-42763d74744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_ProfitLoss_b5a0649c-330d-4c2a-8494-42763d74744f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b2b4541-2dc7-4120-8e42-a8bb9276e246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_NetIncomeLoss_9b2b4541-2dc7-4120-8e42-a8bb9276e246" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1a3dea1b-ace3-4e8d-ab3d-ce0f7bce4f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1a3dea1b-ace3-4e8d-ab3d-ce0f7bce4f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46f7ba43-3bb8-4114-9445-543dc443adf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46f7ba43-3bb8-4114-9445-543dc443adf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_56fb8c75-7401-4877-a441-273598b3aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_EarningsPerShareBasic_56fb8c75-7401-4877-a441-273598b3aabd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97eddfb6-49f3-4072-940b-65a0524e3059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97eddfb6-49f3-4072-940b-65a0524e3059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6fc0cb7f-4b08-4f69-9f17-b552569e456a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6fc0cb7f-4b08-4f69-9f17-b552569e456a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e220e753-4936-4f0c-858a-4eddacff0594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e220e753-4936-4f0c-858a-4eddacff0594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_dc15cba2-6951-43c3-a2b0-9468321dedee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_dc15cba2-6951-43c3-a2b0-9468321dedee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_886ff1d1-d258-43e0-80db-71d5ad3fb810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_886ff1d1-d258-43e0-80db-71d5ad3fb810" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_002dd87f-4c91-4ab1-b6b1-13b7a4fa32de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_002dd87f-4c91-4ab1-b6b1-13b7a4fa32de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_774c7ed6-1645-4e8e-9326-d8a254d1593c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_774c7ed6-1645-4e8e-9326-d8a254d1593c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_52d50d59-c9a8-49c9-8f19-3efadad70797" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_52d50d59-c9a8-49c9-8f19-3efadad70797" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_6a009370-3fe7-42f9-8fe1-30f4616eb8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_6a009370-3fe7-42f9-8fe1-30f4616eb8c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4c06665-2958-4a26-bb39-75b47e51c7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4c06665-2958-4a26-bb39-75b47e51c7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b8402fe-a304-4d71-a138-3bb6f89365f8" xlink:href="pfe-20210404.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b8402fe-a304-4d71-a138-3bb6f89365f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_be41850b-da97-44db-972e-d5cff2de4e30" xlink:href="pfe-20210404.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_be41850b-da97-44db-972e-d5cff2de4e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8e0e4644-d94b-4980-b7b2-41ffc4641808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8e0e4644-d94b-4980-b7b2-41ffc4641808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_05bebcdd-8e50-4811-a812-29ae38ab4b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_05bebcdd-8e50-4811-a812-29ae38ab4b92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa60bb06-e3b1-4d76-ba3a-314a943a952e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa60bb06-e3b1-4d76-ba3a-314a943a952e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36548b2d-5cd8-468d-ba4e-98e650d0d1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36548b2d-5cd8-468d-ba4e-98e650d0d1b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:to="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c6da19d2-9360-45d2-a240-2f53d7906bd5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:to="loc_srt_RestatementDomain_c6da19d2-9360-45d2-a240-2f53d7906bd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:to="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember_2e0f1266-c9f0-4921-9ca7-3df487b0365c" xlink:href="pfe-20210404.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:to="loc_pfe_ScenarioPreviousAccountingPrincipleMember_2e0f1266-c9f0-4921-9ca7-3df487b0365c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_da6d3725-c62d-43cc-9544-f9a054a86feb" xlink:href="pfe-20210404.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:to="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_da6d3725-c62d-43cc-9544-f9a054a86feb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="extended" id="i7766c247af424677893f580c3c726faf_BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_aa2563b9-0472-47bd-87ab-437911252a1b" xlink:href="pfe-20210404.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_aa2563b9-0472-47bd-87ab-437911252a1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_2919b07a-be0b-4182-90e9-cfd78fe05d4a" xlink:href="pfe-20210404.xsd#pfe_AccruedRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_AccruedRebates_2919b07a-be0b-4182-90e9-cfd78fe05d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_51dbfe3a-acf3-4407-b232-86f79fa90be5" xlink:href="pfe-20210404.xsd#pfe_OtherAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_OtherAccruals_51dbfe3a-acf3-4407-b232-86f79fa90be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_eec566ac-49b2-4005-a6b6-1958c184b01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_AccountsReceivableMember_eec566ac-49b2-4005-a6b6-1958c184b01c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f7b8226c-299b-4ac5-b54f-5ffad3bbba8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f7b8226c-299b-4ac5-b54f-5ffad3bbba8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fd71e705-92ff-495a-8d2d-1676099a3e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fd71e705-92ff-495a-8d2d-1676099a3e3b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestment"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="extended" id="i7acbdbaa9fed47e2a00690f7d82ab775_DiscontinuedOperationsandEquityMethodInvestment"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="extended" id="i4b42951b71b74b4db08b53e893749df4_DiscontinuedOperationsandEquityMethodInvestmentTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="extended" id="i000f99acb32d4f47a601c40a4e839f7d_DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_c8ae2826-2366-42f1-aabd-4027390164b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_c8ae2826-2366-42f1-aabd-4027390164b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_9da01c1a-9df8-406c-8bc9-3d683c46fe5e" xlink:href="pfe-20210404.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_9da01c1a-9df8-406c-8bc9-3d683c46fe5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:to="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7657233-c9e4-44f7-8892-42e24111bcbc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7657233-c9e4-44f7-8892-42e24111bcbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_d4b41f41-9434-4a7c-81fa-2ee1611d2ba0" xlink:href="pfe-20210404.xsd#pfe_ViatrisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:to="loc_pfe_ViatrisMember_d4b41f41-9434-4a7c-81fa-2ee1611d2ba0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended" id="ie62661b925224525b3674ab0ccf08cc9_DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_81a29ce0-1f30-4d4b-8ee0-b3af09986914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_81a29ce0-1f30-4d4b-8ee0-b3af09986914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8468d4f1-2cd7-460e-aea5-84e19aef279f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8468d4f1-2cd7-460e-aea5-84e19aef279f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_b58773b2-7acd-43c1-96df-f46a933deaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_b58773b2-7acd-43c1-96df-f46a933deaa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_b7b6fcfc-555c-4d30-9827-f2dc3c97ffda" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_b7b6fcfc-555c-4d30-9827-f2dc3c97ffda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_31b71bd5-bea3-4516-9ae2-9f464ff7ae29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_31b71bd5-bea3-4516-9ae2-9f464ff7ae29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_21a3dc7c-a109-4d18-9197-258b674637ba" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_21a3dc7c-a109-4d18-9197-258b674637ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_61eef381-cdbf-4f41-b09b-4229e6112b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_61eef381-cdbf-4f41-b09b-4229e6112b75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7001cd02-4692-44cf-af83-6f445035117b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7001cd02-4692-44cf-af83-6f445035117b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_521138ea-192f-480b-aad8-e21adc1a5dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_521138ea-192f-480b-aad8-e21adc1a5dbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b21a6590-ae41-4be0-88ea-984fa68c62bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b21a6590-ae41-4be0-88ea-984fa68c62bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_79a43184-54a9-49d3-9a9a-c19834a2f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_79a43184-54a9-49d3-9a9a-c19834a2f17c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="extended" id="i654adb6cabb64583abe3ccfabf312c0d_DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ab979c2-750b-4a6e-bd8b-ff45623659c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ab979c2-750b-4a6e-bd8b-ff45623659c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5c0770a0-5fab-408b-b0ee-d9ec70a430df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestments_5c0770a0-5fab-408b-b0ee-d9ec70a430df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_d335971f-4346-4567-b6ae-80ef9b558a53" xlink:href="pfe-20210404.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_d335971f-4346-4567-b6ae-80ef9b558a53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_2a9e6f87-a3ea-479d-a5b7-926b1555eafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_2a9e6f87-a3ea-479d-a5b7-926b1555eafa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2cf4288-fbdc-489f-a9b4-92705f3c23e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2cf4288-fbdc-489f-a9b4-92705f3c23e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:to="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4fae0fa3-51d6-41fb-8203-03506750ac07_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:to="loc_dei_EntityDomain_4fae0fa3-51d6-41fb-8203-03506750ac07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:to="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_0eacd8c1-13d7-4f45-bba8-24ef91193db5" xlink:href="pfe-20210404.xsd#pfe_GSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:to="loc_pfe_GSKMember_0eacd8c1-13d7-4f45-bba8-24ef91193db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9390332e-3417-485d-8ae1-32424e38327d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9390332e-3417-485d-8ae1-32424e38327d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVMember_342cb66d-8dc7-4873-aa26-588e082d7298" xlink:href="pfe-20210404.xsd#pfe_ConsumerHealthcareJVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:to="loc_pfe_ConsumerHealthcareJVMember_342cb66d-8dc7-4873-aa26-588e082d7298" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="extended" id="iea01e54767364c21a8eea6748d7622cd_DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_48b62ee7-f9a7-468b-9ad5-7a8313fb386a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_Revenues_48b62ee7-f9a7-468b-9ad5-7a8313fb386a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_d55954bb-cf27-49b9-bec5-2711c7eebfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_CostOfRevenue_d55954bb-cf27-49b9-bec5-2711c7eebfc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_068c4fe8-5e57-43e8-9859-127462a51eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_GrossProfit_068c4fe8-5e57-43e8-9859-127462a51eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cec13a67-34a8-4208-8ba8-6ad355245368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cec13a67-34a8-4208-8ba8-6ad355245368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1aa4b86e-9931-4817-8190-e80ae55c7cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_ProfitLoss_1aa4b86e-9931-4817-8190-e80ae55c7cc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11c888e6-adaa-465c-a259-b7c9bc3d7d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_NetIncomeLoss_11c888e6-adaa-465c-a259-b7c9bc3d7d34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7fbec8da-9807-4b54-96cf-71e79b0f9330_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7fbec8da-9807-4b54-96cf-71e79b0f9330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVMember_498ce61b-103e-46db-8504-df7b16709b86" xlink:href="pfe-20210404.xsd#pfe_ConsumerHealthcareJVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:to="loc_pfe_ConsumerHealthcareJVMember_498ce61b-103e-46db-8504-df7b16709b86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="extended" id="if8718bd442284b6397b5e8b5aaef4c52_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="extended" id="i3e5691367ce746dabc00958d78046ccd_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended" id="ie9e6638ad4d14485829cdcf81398bba5_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef9951c2-14b5-4516-9973-3fa676bb03c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef9951c2-14b5-4516-9973-3fa676bb03c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_ea0f48c1-62d6-4700-b5f4-be67a71b3486" xlink:href="pfe-20210404.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_ea0f48c1-62d6-4700-b5f4-be67a71b3486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8d1ba054-de1d-42aa-b47c-145e7ed2ff34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8d1ba054-de1d-42aa-b47c-145e7ed2ff34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_82d392f3-b2ec-46c0-bf5c-1d7f231505c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_82d392f3-b2ec-46c0-bf5c-1d7f231505c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_72949234-2d9b-4417-8ea9-46476d0af373" xlink:href="pfe-20210404.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:to="loc_pfe_ManufacturingOptimizationMember_72949234-2d9b-4417-8ea9-46476d0af373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:to="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6e43e21c-0864-40a6-83d3-6da91f48f5ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:to="loc_us-gaap_RestructuringPlanDomain_6e43e21c-0864-40a6-83d3-6da91f48f5ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:to="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_694f75ca-a0ca-4634-b3cc-815c88c141e8" xlink:href="pfe-20210404.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:to="loc_pfe_FocusedCompanyPlanMember_694f75ca-a0ca-4634-b3cc-815c88c141e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended" id="i8774c1f19b394eecadee15b9e5d8adb0_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_119bf09c-42e0-44da-8966-64b61f0b20ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_us-gaap_SeveranceCosts1_119bf09c-42e0-44da-8966-64b61f0b20ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_2b91adc1-98bb-4113-a9fe-2637af3888d0" xlink:href="pfe-20210404.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_2b91adc1-98bb-4113-a9fe-2637af3888d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f1368971-6624-4fd4-9db1-ff5a0b6156cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_us-gaap_RestructuringCharges_f1368971-6624-4fd4-9db1-ff5a0b6156cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_b3eab2aa-c128-4eb7-aa09-f70d66647bf4" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_b3eab2aa-c128-4eb7-aa09-f70d66647bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_523cd93c-50a5-48a8-8ba1-922a51b3a423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_523cd93c-50a5-48a8-8ba1-922a51b3a423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_ee7bad1c-2447-47c9-88dc-335a2c0e190e" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_ee7bad1c-2447-47c9-88dc-335a2c0e190e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_47c9da8b-7f57-4311-8af9-e8af3061ef58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_47c9da8b-7f57-4311-8af9-e8af3061ef58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_abb7c24f-8c09-4c82-bf5d-febf84dcb0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_abb7c24f-8c09-4c82-bf5d-febf84dcb0cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_37a86100-8846-4d8a-b409-bcb412dedc28" xlink:href="pfe-20210404.xsd#pfe_ImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_ImplementationCosts_37a86100-8846-4d8a-b409-bcb412dedc28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_95189fc2-2170-4f50-9e40-9fe3acd0a24e" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_95189fc2-2170-4f50-9e40-9fe3acd0a24e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_276c060e-5147-4341-9d49-3ff7207f4051_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_276c060e-5147-4341-9d49-3ff7207f4051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_faeaf8f2-60d8-432d-90dc-a7267322e997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_faeaf8f2-60d8-432d-90dc-a7267322e997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_daefdcde-d20f-4119-9583-4ee16e3598fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_CostOfSalesMember_daefdcde-d20f-4119-9583-4ee16e3598fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8bbf7a38-a794-4723-9f67-a6d9a8ca109f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8bbf7a38-a794-4723-9f67-a6d9a8ca109f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a404036f-cd93-4602-9a04-8589fb16de02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a404036f-cd93-4602-9a04-8589fb16de02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8500a874-6d42-4508-a29b-f0b5128405d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8500a874-6d42-4508-a29b-f0b5128405d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_bab0c711-e99a-42a1-8b17-320ee6a51e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_bab0c711-e99a-42a1-8b17-320ee6a51e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember_9023bb95-060f-4294-8bcf-39a654c3ab18" xlink:href="pfe-20210404.xsd#pfe_CostReductionInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:to="loc_pfe_CostReductionInitiativesMember_9023bb95-060f-4294-8bcf-39a654c3ab18" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="extended" id="ib059084fd31f4f2f9986f08ac0d3d923_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a39ae44c-91d8-400e-9d8c-f0977ae7c09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_us-gaap_RestructuringReserve_a39ae44c-91d8-400e-9d8c-f0977ae7c09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_be7f553a-2136-458a-a4b8-4c3161e6c5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_us-gaap_RestructuringCharges_be7f553a-2136-458a-a4b8-4c3161e6c5ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_6f118ce9-41ad-4f0b-b73d-8aa5ca332b05" xlink:href="pfe-20210404.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_6f118ce9-41ad-4f0b-b73d-8aa5ca332b05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_47206aff-00f7-43a6-9ae2-370195b23777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9fcd8ca9-533a-4362-9924-10941c0cfe27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9fcd8ca9-533a-4362-9924-10941c0cfe27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_c3b29249-a46a-4b2d-8a67-a7fdc4659550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_us-gaap_EmployeeSeveranceMember_c3b29249-a46a-4b2d-8a67-a7fdc4659550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_51c0e77b-d591-4ca1-8a47-08fc115c4083" xlink:href="pfe-20210404.xsd#pfe_AssetImpairmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_pfe_AssetImpairmentsMember_51c0e77b-d591-4ca1-8a47-08fc115c4083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_e46b4f9c-6f80-4955-a4a9-da337d018527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_us-gaap_OtherRestructuringMember_e46b4f9c-6f80-4955-a4a9-da337d018527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f0505b67-f234-4752-a9ed-3fe1a742873e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f0505b67-f234-4752-a9ed-3fe1a742873e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8ace1040-7d8d-458d-b0e1-8d9757de6473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8ace1040-7d8d-458d-b0e1-8d9757de6473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_74f17dcc-0bc0-4b1a-a368-df1654bde421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_74f17dcc-0bc0-4b1a-a368-df1654bde421" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNet"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" id="i6fe0aff4f6f345f197f5798e85941715_OtherIncomeDeductionsNet"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" id="i9e0b3648196f4d3da12e90fcba796b8e_OtherIncomeDeductionsNetTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="extended" id="i0354508265b547d68963f437eedaf561_OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetFootnotesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended" id="ia47af71d228b4579aba3c60f8673104e_OtherIncomeDeductionsNetFootnotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4c38f3d2-cd68-47e4-97f4-f836e1afae4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4c38f3d2-cd68-47e4-97f4-f836e1afae4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_3e8e497f-77fa-465b-b350-0a27d659c2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_ProceedsFromCollaborators_3e8e497f-77fa-465b-b350-0a27d659c2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_0a647908-7df3-499b-801a-5b4f9e2e4b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_0a647908-7df3-499b-801a-5b4f9e2e4b9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_406eb972-24e2-467d-a0d4-cab33e61dca5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_406eb972-24e2-467d-a0d4-cab33e61dca5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4ba253e-60f5-4a46-a25f-daaef5fda440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4ba253e-60f5-4a46-a25f-daaef5fda440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ad516c72-9a4c-4d80-a699-6243bd1deaf7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ad516c72-9a4c-4d80-a699-6243bd1deaf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_8deff68f-f804-44d4-8f08-9cad8b837ec3" xlink:href="pfe-20210404.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_8deff68f-f804-44d4-8f08-9cad8b837ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3dc7b4c-d8b8-4150-a359-74b707b99600_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3dc7b4c-d8b8-4150-a359-74b707b99600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_afbd4537-9195-4256-a8c9-26ad9040a86d" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:to="loc_pfe_BioNTechMember_afbd4537-9195-4256-a8c9-26ad9040a86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b160379a-5f2a-41ee-b5e1-8bb3c69830f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b160379a-5f2a-41ee-b5e1-8bb3c69830f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_95174ee5-169c-4e4d-98ea-826a0dee2962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:to="loc_us-gaap_CollaborativeArrangementMember_95174ee5-169c-4e4d-98ea-826a0dee2962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b8c0f113-ade5-4c4e-8bc4-9572b319cf19_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b8c0f113-ade5-4c4e-8bc4-9572b319cf19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneAndBioNTechMember_53bf8970-37d0-433d-b6b7-6c9a07d2473a" xlink:href="pfe-20210404.xsd#pfe_AllogeneAndBioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:to="loc_pfe_AllogeneAndBioNTechMember_53bf8970-37d0-433d-b6b7-6c9a07d2473a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneMember_1bf70b11-adbd-4bcf-9df7-bedf02292fda" xlink:href="pfe-20210404.xsd#pfe_AllogeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:to="loc_pfe_AllogeneMember_1bf70b11-adbd-4bcf-9df7-bedf02292fda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMatters"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" id="i846f9e2dfe49470d9825072ed86e6b40_TaxMatters"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" id="icbe8136970d54b2c9c15290ef2b55e0f_TaxMattersTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended" id="ic79209021e014b638b6826aad1853745_TaxMattersNarrativeDetail"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="extended" id="i2bd1fc8b05c649e88c048bd72d2d1902_TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" id="i80fa61a5fbb842c691d8b1fec6909df0_AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" id="iabc58415a3a2487198d2d5bf2e2fb60c_AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended" id="i6fe7d0f0d89b46d187fb98ed6eca98bb_AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74113af9-98ca-436c-8970-8a89cede88e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74113af9-98ca-436c-8970-8a89cede88e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1ea5a99-a86b-48f8-b530-98aee594ba41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1ea5a99-a86b-48f8-b530-98aee594ba41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b1b1c6b-fef7-456b-b05f-cf465b980ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fef1d464-55d6-4dd2-ac43-8ba450fdd837_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:to="loc_us-gaap_EquityComponentDomain_fef1d464-55d6-4dd2-ac43-8ba450fdd837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:to="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aef21fa3-615f-4788-a5a0-9012cac46230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aef21fa3-615f-4788-a5a0-9012cac46230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bcb41318-74da-40e5-9004-da1de0735a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bcb41318-74da-40e5-9004-da1de0735a81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_62f0e80f-a2c7-4e4e-9431-0d0286fc7455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_62f0e80f-a2c7-4e4e-9431-0d0286fc7455" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_d1a344a2-25b3-411c-b788-10d39a48b4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_d1a344a2-25b3-411c-b788-10d39a48b4d5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" id="i31ec4414f8d54b7ebc277640707add2d_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i87d0025577604073820ce6c66377ef25_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended" id="i3e9ac5020eec427caf04ae577355d0df_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f3a491a5-e0af-4fcc-9f2e-3becae5bff8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f3a491a5-e0af-4fcc-9f2e-3becae5bff8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1611de01-46c5-4958-9fef-83d6e30c7243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1611de01-46c5-4958-9fef-83d6e30c7243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_9944588b-e622-458c-a5a0-f7a1b5dc43eb" xlink:href="pfe-20210404.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_9944588b-e622-458c-a5a0-f7a1b5dc43eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_f97b299b-2f5f-4eca-ad42-c20a2a94136d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_f97b299b-2f5f-4eca-ad42-c20a2a94136d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c9bdf986-6518-4446-8c51-0a741873f927" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c9bdf986-6518-4446-8c51-0a741873f927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8137a608-43bf-4c2d-a06d-07d595a45b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8137a608-43bf-4c2d-a06d-07d595a45b1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_06e6b3b8-3fbc-45be-8039-89a15cfa33fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_06e6b3b8-3fbc-45be-8039-89a15cfa33fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3e872a18-5e09-473a-af6f-5fa67294f0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3e872a18-5e09-473a-af6f-5fa67294f0fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d2e2d254-0b7e-411c-8e29-5157d479c6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_Assets_d2e2d254-0b7e-411c-8e29-5157d479c6c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_45f68c59-368a-4c1c-b38a-8d69f6553a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_45f68c59-368a-4c1c-b38a-8d69f6553a5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_486e69f2-f54c-4ec5-bb58-e62facef83fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_486e69f2-f54c-4ec5-bb58-e62facef83fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_65194172-1f23-4a26-a206-fa62258eefe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilities_65194172-1f23-4a26-a206-fa62258eefe9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_9f4d394c-7891-4cc4-95ff-1dd4f88d1632" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_9f4d394c-7891-4cc4-95ff-1dd4f88d1632" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0008b4b-8294-48e1-9d48-c81337066afe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0008b4b-8294-48e1-9d48-c81337066afe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_397199c2-42d4-421f-a79b-6d4a04d1d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_MoneyMarketFundsMember_397199c2-42d4-421f-a79b-6d4a04d1d1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_733e0d3b-6a61-4728-af0a-c048f00704d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_733e0d3b-6a61-4728-af0a-c048f00704d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d4c99373-4a1b-4839-ab58-8b050de6bdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d4c99373-4a1b-4839-ab58-8b050de6bdec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_29bca77a-557a-48db-a4a0-ae5da63836e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_29bca77a-557a-48db-a4a0-ae5da63836e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e823083a-766c-4d66-8956-854156bd3fcd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e823083a-766c-4d66-8956-854156bd3fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c137e7d-3464-43cc-b02c-17686b940e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c137e7d-3464-43cc-b02c-17686b940e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0c4200c3-a5cd-45aa-a48d-4c8165032243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0c4200c3-a5cd-45aa-a48d-4c8165032243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96cd182a-4e17-4a07-9bf6-7b93caec74bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96cd182a-4e17-4a07-9bf6-7b93caec74bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_69343a39-4c8b-4b7b-8d97-b83959bfd130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_69343a39-4c8b-4b7b-8d97-b83959bfd130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9d7ff9a5-3639-4d7d-97c1-a95bd1720e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9d7ff9a5-3639-4d7d-97c1-a95bd1720e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_d5bf141e-b8ef-4054-92a4-7db56548007d" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_pfe_LongtermInvestmentsMember_d5bf141e-b8ef-4054-92a4-7db56548007d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_496ee368-0326-41ff-9208-ba92200022cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_496ee368-0326-41ff-9208-ba92200022cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_569fb0d0-8d3c-49f1-9743-c09af6262ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_569fb0d0-8d3c-49f1-9743-c09af6262ee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a18a7fe-a1ee-4c03-8b4b-5db9099752d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a18a7fe-a1ee-4c03-8b4b-5db9099752d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c573ce25-bb48-4065-8fb1-ace626dfd235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c573ce25-bb48-4065-8fb1-ace626dfd235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0eb9f7e1-1657-4df9-91b3-18016fd75372_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0eb9f7e1-1657-4df9-91b3-18016fd75372_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c2c179d8-26a3-4b74-ace2-f081813acbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:to="loc_us-gaap_InterestRateContractMember_c2c179d8-26a3-4b74-ace2-f081813acbf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ee697317-9fae-4463-a110-b4a94a978e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ee697317-9fae-4463-a110-b4a94a978e8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="id0db44cdaeab4e548a4ed9b2e030cbd6_FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e6e40bcb-e12d-4a8d-8a65-ee082d0657cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:to="loc_us-gaap_LongTermDebtFairValue_e6e40bcb-e12d-4a8d-8a65-ee082d0657cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c9b9c04c-6f76-49b3-af71-9913be8e7015_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c9b9c04c-6f76-49b3-af71-9913be8e7015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a6983c52-cbf0-443f-b2b4-3b4dc14f1ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a6983c52-cbf0-443f-b2b4-3b4dc14f1ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_859274c3-54cd-443a-9026-0477c05732dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_859274c3-54cd-443a-9026-0477c05732dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c2ea04b4-3b14-4b1f-891c-0d485a6cd9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c2ea04b4-3b14-4b1f-891c-0d485a6cd9f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="extended" id="i992a539bf5e141cfba40949a8426a2d9_FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended" id="ic33bf4d9c5a44e928265b0cd0017a7cc_FinancialInstrumentsScheduleofInvestmentSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc9673cd-524b-4dc3-a6c3-72bd43141f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc9673cd-524b-4dc3-a6c3-72bd43141f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f5634af-687b-4be2-b717-0beadb74a44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f5634af-687b-4be2-b717-0beadb74a44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71a1bd08-c0f2-481e-936d-1f6caddb9e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71a1bd08-c0f2-481e-936d-1f6caddb9e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2c55f66-0c5b-43af-921d-e19d22bed504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2c55f66-0c5b-43af-921d-e19d22bed504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_936993b3-91c2-4c3b-a3e3-31ed6825151a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_936993b3-91c2-4c3b-a3e3-31ed6825151a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3fd7520-948b-4b25-98c1-879f25cf1349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3fd7520-948b-4b25-98c1-879f25cf1349" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_dca4c682-d5fd-4fe3-8f82-8b05ec5001b5" xlink:href="pfe-20210404.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_dca4c682-d5fd-4fe3-8f82-8b05ec5001b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_882ba5e0-9192-4f14-8e0e-fef6840724ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_97827489-1257-45b2-80a0-32e3cb9c1b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecurities_97827489-1257-45b2-80a0-32e3cb9c1b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_5b55a6f6-8953-494e-bd81-66d0f49bcc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_5b55a6f6-8953-494e-bd81-66d0f49bcc29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_20f68f45-2438-423a-be75-c4763152c0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_20f68f45-2438-423a-be75-c4763152c0ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e0aa3c34-4742-4742-8574-f9129026e028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e0aa3c34-4742-4742-8574-f9129026e028" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_daa3c8b1-9ff1-4181-af56-8bd71835acca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_daa3c8b1-9ff1-4181-af56-8bd71835acca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_88e616a3-b91b-40ca-a5fa-aecb06a84cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_88e616a3-b91b-40ca-a5fa-aecb06a84cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_c35c5fa0-3a73-4076-a25d-1c33e93f4a36" xlink:href="pfe-20210404.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_c35c5fa0-3a73-4076-a25d-1c33e93f4a36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_5c286de3-2d62-4c5f-8aac-e463bcb7c4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_c9749db5-8935-4821-9c05-07d3cd791bf3" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_c9749db5-8935-4821-9c05-07d3cd791bf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_5fca70ea-63db-4642-b41b-49a818a2340a" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_5fca70ea-63db-4642-b41b-49a818a2340a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_85f8f0bb-8dbb-4d58-8fb5-ac0c1c77b069" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_85f8f0bb-8dbb-4d58-8fb5-ac0c1c77b069" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_d4ef6722-c3f9-49fb-97c4-23a5cd5bdc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_d4ef6722-c3f9-49fb-97c4-23a5cd5bdc63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_48e5f1fd-76d2-4694-9afa-042235d24a3c" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_48e5f1fd-76d2-4694-9afa-042235d24a3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_cc4ea40b-ae84-4cc1-add2-32e85a4e9f93" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_cc4ea40b-ae84-4cc1-add2-32e85a4e9f93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c8884ce0-5184-4a4f-b2e5-76847f899c19" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c8884ce0-5184-4a4f-b2e5-76847f899c19" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e2aab8c7-0c18-4848-a368-308a023d8350_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e2aab8c7-0c18-4848-a368-308a023d8350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_17a6ea6e-2d6b-415b-a666-be6fe0782c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_BankTimeDepositsMember_17a6ea6e-2d6b-415b-a666-be6fe0782c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d9820951-b4e3-41c4-93b1-925ee0a2f019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d9820951-b4e3-41c4-93b1-925ee0a2f019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26b45698-f544-4224-a269-27aec5989374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26b45698-f544-4224-a269-27aec5989374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c19cb04f-223a-411b-95d5-b3a0b5d35da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c19cb04f-223a-411b-95d5-b3a0b5d35da2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended" id="i0ae9e10f7be64dec8db7c0d76f1c663f_FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="extended" id="i092be1b09be54fecb11ce2b596331d81_FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="extended" id="i7f7aa1e0ee984e98b1d0336124b2c1d8_FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended" id="ib7738f8f1d6b4d348f400c8ec7260779_FinancialInstrumentsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8cdbbd27-975e-4509-a76c-7ef304ba46fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8cdbbd27-975e-4509-a76c-7ef304ba46fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_9617f3d4-c856-4eb6-9e93-ac82fa5f9fde" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_9617f3d4-c856-4eb6-9e93-ac82fa5f9fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f4f4867-2678-4cb9-b32b-0b63e2446784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f4f4867-2678-4cb9-b32b-0b63e2446784" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_1d5b5d12-f15f-43f1-b402-e1a65c6170e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_OtherLongTermDebt_1d5b5d12-f15f-43f1-b402-e1a65c6170e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_902d900a-a0e3-4830-b533-75e9bca632db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_902d900a-a0e3-4830-b533-75e9bca632db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f64580c5-c7d5-4843-af69-69e902786fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_LongTermDebtCurrent_f64580c5-c7d5-4843-af69-69e902786fb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_db1b02dc-6042-4e1f-81fb-a61099765b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:to="loc_us-gaap_UnsecuredDebtMember_db1b02dc-6042-4e1f-81fb-a61099765b71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended" id="i3e680c506bf44648a4daa7b1e632a1b0_FinancialInstrumentsDerivativeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_64c9b0dc-14b7-4e95-8dcc-763ab8bbf402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:to="loc_us-gaap_DerivativeTermOfContract_64c9b0dc-14b7-4e95-8dcc-763ab8bbf402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:to="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95c88543-cb8e-4e6c-92a1-04e3b2cee270_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95c88543-cb8e-4e6c-92a1-04e3b2cee270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a32ed64e-4de2-4d5c-afd4-8c3c41ed539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a32ed64e-4de2-4d5c-afd4-8c3c41ed539d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended" id="i3458b52bc26747e6a5fce29b42d63d8b_FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8505af2c-cf49-4da2-ba76-e3e82b032560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8505af2c-cf49-4da2-ba76-e3e82b032560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f22095a4-217b-4f53-91e6-8178c779cc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeAssets_f22095a4-217b-4f53-91e6-8178c779cc1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c5872820-cdd9-4c30-a009-055b359f9e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeLiabilities_c5872820-cdd9-4c30-a009-055b359f9e69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:href="pfe-20210404.xsd#pfe_HedgedItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_6741ddd5-df86-46cf-b64e-9767c8a6ce0d_default" xlink:href="pfe-20210404.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:to="loc_pfe_HedgedItemDomain_6741ddd5-df86-46cf-b64e-9767c8a6ce0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:href="pfe-20210404.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:to="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_3020d8c8-a656-4713-a90b-e364cff47852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:to="loc_us-gaap_SalesMember_3020d8c8-a656-4713-a90b-e364cff47852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bfe74092-cca4-423d-8fb9-3506b0137073_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:to="loc_us-gaap_HedgingDesignationDomain_bfe74092-cca4-423d-8fb9-3506b0137073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:to="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88abe2cc-2ec1-4073-9a4b-adb2dfeb426d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88abe2cc-2ec1-4073-9a4b-adb2dfeb426d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a0b728a9-553c-43c8-bf79-ea1c5747449f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:to="loc_us-gaap_NondesignatedMember_a0b728a9-553c-43c8-bf79-ea1c5747449f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7f05a986-23cb-412f-8cf8-675a4602e1c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7f05a986-23cb-412f-8cf8-675a4602e1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a452d475-dde2-45cb-9214-ced87b4b1417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a452d475-dde2-45cb-9214-ced87b4b1417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a034ab61-269e-445f-8abf-b37462fa0234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:to="loc_us-gaap_InterestRateContractMember_a034ab61-269e-445f-8abf-b37462fa0234" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended" id="ia78d69306fb64c4490f117fc46e36721_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6b5e79c0-aa1c-46e7-aac1-96130a5a7e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6b5e79c0-aa1c-46e7-aac1-96130a5a7e58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ec747373-77d7-411d-999a-2ce9cd43e93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ec747373-77d7-411d-999a-2ce9cd43e93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c2797630-a5ce-443c-bc6d-ad9c49282630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c2797630-a5ce-443c-bc6d-ad9c49282630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e65ce894-50a1-43aa-904d-4aa980d68b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e65ce894-50a1-43aa-904d-4aa980d68b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c5825d6f-b8f8-4566-a0f6-c183c9a422d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c5825d6f-b8f8-4566-a0f6-c183c9a422d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_a125dadb-e45d-4060-9b4c-6f17bfd9f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_a125dadb-e45d-4060-9b4c-6f17bfd9f816" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_bef59cef-cc8a-4335-9cfe-e3e3d5858082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_bef59cef-cc8a-4335-9cfe-e3e3d5858082" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_b1ca0bc9-90ba-494f-b5fb-fedf2f126cab" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_b1ca0bc9-90ba-494f-b5fb-fedf2f126cab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_e4f80eb5-ddb6-4767-8245-50ca32380168" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_e4f80eb5-ddb6-4767-8245-50ca32380168" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_ce267598-1f44-4bc4-b837-e88fd37c5f7c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_ce267598-1f44-4bc4-b837-e88fd37c5f7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_83aad5c6-0ed4-4d69-886c-ca7c47c51784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_83aad5c6-0ed4-4d69-886c-ca7c47c51784" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_aa002962-bd18-4df1-bc46-f9b1d211383d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_aa002962-bd18-4df1-bc46-f9b1d211383d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_bad87e6d-0a90-4add-bd9c-a7af031a4641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_bad87e6d-0a90-4add-bd9c-a7af031a4641" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_57f9e9d7-40d1-461e-9a07-2a97f16a6eec" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_57f9e9d7-40d1-461e-9a07-2a97f16a6eec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_20c70c8f-08ff-4651-8d12-71042b51475c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_20c70c8f-08ff-4651-8d12-71042b51475c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_c884d13a-e594-40d5-9669-14114401c310" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_c884d13a-e594-40d5-9669-14114401c310" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_72a6526a-c24e-43a1-92dd-cba291e56c58_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:to="loc_us-gaap_HedgingRelationshipDomain_72a6526a-c24e-43a1-92dd-cba291e56c58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_8b6630bd-e151-45a1-a865-2a3649ed422c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:to="loc_us-gaap_CashFlowHedgingMember_8b6630bd-e151-45a1-a865-2a3649ed422c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1fa873b1-4def-49d4-85ce-d1cb649ce010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1fa873b1-4def-49d4-85ce-d1cb649ce010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0d22123e-5932-483e-8386-7b239e8bde83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:to="loc_us-gaap_HedgingDesignationDomain_0d22123e-5932-483e-8386-7b239e8bde83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:to="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0cad5e31-5c74-4bd8-b0a9-8968827fce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0cad5e31-5c74-4bd8-b0a9-8968827fce5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5976068d-4374-44d0-b651-42d1e43cdca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:to="loc_us-gaap_NondesignatedMember_5976068d-4374-44d0-b651-42d1e43cdca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_948be04f-b8e2-4153-84a4-e7a7dbdf14eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_948be04f-b8e2-4153-84a4-e7a7dbdf14eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_baa47a3c-838a-4c1f-8fb5-df49780715e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_baa47a3c-838a-4c1f-8fb5-df49780715e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_5bc3ca5a-14d3-4946-b653-dda1527eb5f7" xlink:href="pfe-20210404.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_5bc3ca5a-14d3-4946-b653-dda1527eb5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b5faaf7-7988-4565-8b96-e5a745554312_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b5faaf7-7988-4565-8b96-e5a745554312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93382cf9-a857-4109-937f-3eba287f7cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93382cf9-a857-4109-937f-3eba287f7cc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_27949ca3-54c2-4f4c-aec5-ec4248438b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_us-gaap_InterestRateContractMember_27949ca3-54c2-4f4c-aec5-ec4248438b69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_c5bcb5d8-1fd7-41ed-a97d-1b61be97b7b6" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_c5bcb5d8-1fd7-41ed-a97d-1b61be97b7b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_38e9a65d-04ed-4e1b-9158-af02c0c60afb" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_pfe_ForeignCurrencyDebtMember_38e9a65d-04ed-4e1b-9158-af02c0c60afb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended" id="i3c4cc507a14940b88a75e798ca7e567f_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ffb736c-8271-4ac4-81fb-5b7d8ae36595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ffb736c-8271-4ac4-81fb-5b7d8ae36595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_97b3155f-7296-4ce3-9591-8a7720bd2f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_97b3155f-7296-4ce3-9591-8a7720bd2f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_cfa2ff37-41f6-4d59-b244-f5a1ba5ac945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_cfa2ff37-41f6-4d59-b244-f5a1ba5ac945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_0c364ab7-8045-4515-b780-4e7325ac0f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_DebtCurrent_0c364ab7-8045-4515-b780-4e7325ac0f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_851d3292-e1c6-4429-9a87-80b0447a9291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_LongTermDebt_851d3292-e1c6-4429-9a87-80b0447a9291" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_64fe717f-e3df-4641-93a7-7a8a64cfa7a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:to="loc_us-gaap_HedgingDesignationDomain_64fe717f-e3df-4641-93a7-7a8a64cfa7a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6e7ed468-2a15-48d6-a9b3-bb4f0a59e3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6e7ed468-2a15-48d6-a9b3-bb4f0a59e3e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_90607e8e-83fc-45b8-ba64-2793e1776d33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_90607e8e-83fc-45b8-ba64-2793e1776d33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16554262-c44d-42b1-80ee-2ccb140124de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:to="loc_us-gaap_CostOfSalesMember_16554262-c44d-42b1-80ee-2ccb140124de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f8361026-7522-4753-848f-b8c6667935b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f8361026-7522-4753-848f-b8c6667935b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73778387-3c7b-44b2-9c71-e2fd08d2fd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73778387-3c7b-44b2-9c71-e2fd08d2fd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_d36ec837-b8ee-491d-9fa7-b5ee37874d6e" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:to="loc_pfe_ForeignCurrencyDebtMember_d36ec837-b8ee-491d-9fa7-b5ee37874d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_523719f1-c3fe-4f0c-9562-7a10f5aa20c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_523719f1-c3fe-4f0c-9562-7a10f5aa20c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a62a6f10-a992-4b25-8cd6-96e6e7c0984b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:to="loc_us-gaap_UnsecuredDebtMember_a62a6f10-a992-4b25-8cd6-96e6e7c0984b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended" id="i806f5f3a8b314ad99e97d67fc29905bb_FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_84dee205-47f4-44b5-9192-85f708e14fab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_84dee205-47f4-44b5-9192-85f708e14fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f581f3b2-89f7-47e3-97ca-03514d99021f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f581f3b2-89f7-47e3-97ca-03514d99021f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_d64c0921-3318-4e50-b709-dab2778b067e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_d64c0921-3318-4e50-b709-dab2778b067e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bbd369fc-b023-46d6-8a1b-06fcc0a82d65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bbd369fc-b023-46d6-8a1b-06fcc0a82d65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_19f80720-ae87-4de2-a642-359a1b99569e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:to="loc_us-gaap_LongTermDebtMember_19f80720-ae87-4de2-a642-359a1b99569e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended" id="i49661d22056644ec9eb503098979c9b8_FinancialInstrumentsCreditRiskDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="extended" id="i4cc496c12edc4fae8a7ed5089bef1bde_OtherFinancialInformation"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="extended" id="idcf696e9391744d084fee26880e124c1_OtherFinancialInformationTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended" id="i6a675361a3fd42a4b86d6637ed09bdc4_OtherFinancialInformationInventoriesDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended" id="ifacad3f1cb6e400187d89d81b10bd812_OtherFinancialInformationOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_084e864e-cfd7-4ae9-b126-e6dc6088d0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_084e864e-cfd7-4ae9-b126-e6dc6088d0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3335f11e-d132-4b80-8e86-c36b4ed39103_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3335f11e-d132-4b80-8e86-c36b4ed39103_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_531f8795-e4e5-48e6-9f90-1250a2866647" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:to="loc_pfe_BioNTechMember_531f8795-e4e5-48e6-9f90-1250a2866647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_738888eb-2e87-4479-b166-aa4f32993e4e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:to="loc_srt_ProductsAndServicesDomain_738888eb-2e87-4479-b166-aa4f32993e4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:to="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_7a2dc011-efde-477d-a05f-b943ba0fff0b" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:to="loc_pfe_BNT162b2Member_7a2dc011-efde-477d-a05f-b943ba0fff0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efe06207-f7df-4dd0-a470-d17d13018bf7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efe06207-f7df-4dd0-a470-d17d13018bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9e5d2469-f834-4733-9fc1-0f894e8e649e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9e5d2469-f834-4733-9fc1-0f894e8e649e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="extended" id="iacd53f4a36854651be26334ccb8ba76b_IdentifiableIntangibleAssets"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="extended" id="iaf48f25985764a269802aedeb6c645df_IdentifiableIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended" id="i183466382f234aababfd08b94fc67039_IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad597843-3592-4fec-a787-5d3332a2f2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad597843-3592-4fec-a787-5d3332a2f2aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_358f1cff-4ea6-419f-896c-838213556c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_358f1cff-4ea6-419f-896c-838213556c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9afff204-4b50-46d4-ae6a-3256fc461427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9afff204-4b50-46d4-ae6a-3256fc461427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_94ecf7a2-0965-4572-8eae-c1eb637325f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_94ecf7a2-0965-4572-8eae-c1eb637325f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70c8a9ff-8558-4aa1-ae70-4da33915cd0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70c8a9ff-8558-4aa1-ae70-4da33915cd0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4551453a-bae6-4151-9ca3-130171f31daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4551453a-bae6-4151-9ca3-130171f31daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ec74dda4-721f-41c5-9f59-c1e061b2f670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_us-gaap_TradeNamesMember_ec74dda4-721f-41c5-9f59-c1e061b2f670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_54bdf6f3-f33e-409e-86b3-58b43cef7c36" xlink:href="pfe-20210404.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_54bdf6f3-f33e-409e-86b3-58b43cef7c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_5198c7f5-088c-4efa-8cd0-1c2bbff141c1" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:to="loc_pfe_BioNTechMember_5198c7f5-088c-4efa-8cd0-1c2bbff141c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fda4053-147f-42b3-aba4-8bad2b6278c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:to="loc_srt_ProductsAndServicesDomain_0fda4053-147f-42b3-aba4-8bad2b6278c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:to="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_93fdc5be-df2f-472a-ba7f-f2e06b8e1c9e" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:to="loc_pfe_BNT162b2Member_93fdc5be-df2f-472a-ba7f-f2e06b8e1c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_afc78a9d-6704-4189-a7a9-8a7de56cb279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_afc78a9d-6704-4189-a7a9-8a7de56cb279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e92b9d37-3599-4290-9fba-9eb9219736cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e92b9d37-3599-4290-9fba-9eb9219736cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7354a19e-c5bc-442e-b97b-9954104e9520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_us-gaap_TradeNamesMember_7354a19e-c5bc-442e-b97b-9954104e9520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d2236cbe-f37b-4092-8c7c-ca8f6ef497de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d2236cbe-f37b-4092-8c7c-ca8f6ef497de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_507c5899-a78c-4e14-8d74-404ae6984238" xlink:href="pfe-20210404.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_507c5899-a78c-4e14-8d74-404ae6984238" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="extended" id="id6777e9b3b824a0eac11e89108ba14f9_IdentifiableIntangibleAssetsNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_2e861237-2a08-42b7-b95d-028f6ec0d8c1" xlink:href="pfe-20210404.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_2e861237-2a08-42b7-b95d-028f6ec0d8c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_354026ff-cf52-4b29-9d5e-1f4b97b4a251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_354026ff-cf52-4b29-9d5e-1f4b97b4a251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22a836ff-9361-437c-a499-70bc6972215d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_22a836ff-9361-437c-a499-70bc6972215d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_2acbdf27-7d73-455b-aef6-c9f01698a378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_2acbdf27-7d73-455b-aef6-c9f01698a378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_04b2e187-4575-48e4-8c8b-d828c2645e7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_04b2e187-4575-48e4-8c8b-d828c2645e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_90d6287b-0064-4736-b969-e18c5f07022c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_90d6287b-0064-4736-b969-e18c5f07022c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="extended" id="i97a199128ecf46aba2d7777cab55ea6f_PensionandPostretirementBenefitPlans"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="extended" id="ifa2e4152c4b64f9091d2b78192a1c9d4_PensionandPostretirementBenefitPlansTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended" id="i418a7d4b21fc471dbdf30b64f7f6161a_PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8d52539a-c5f8-446b-879d-2b6fe7de3c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8d52539a-c5f8-446b-879d-2b6fe7de3c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_367fb7a4-ebc6-4d1d-b12e-005ddbd24780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_367fb7a4-ebc6-4d1d-b12e-005ddbd24780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47e6b21d-4fb3-4f7f-8875-be5e4beb9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47e6b21d-4fb3-4f7f-8875-be5e4beb9aab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b915e40e-b347-4193-a4f9-f4d0bf893d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b915e40e-b347-4193-a4f9-f4d0bf893d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_cc2e85a8-ac8a-42d9-b294-1d017b4b57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_cc2e85a8-ac8a-42d9-b294-1d017b4b57e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_76042972-4bd6-4c85-ba83-479e5ba13b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_76042972-4bd6-4c85-ba83-479e5ba13b71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a4fe4b5d-00bc-4b2e-a637-8cd92bb7c783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a4fe4b5d-00bc-4b2e-a637-8cd92bb7c783" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_436b4ed2-75d4-46fb-9328-cb3d92c2640d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_436b4ed2-75d4-46fb-9328-cb3d92c2640d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_eb5ab985-3acb-4599-b8d9-8e137167a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_eb5ab985-3acb-4599-b8d9-8e137167a26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8b540c0a-b06f-4535-b31e-bb93141ae394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8b540c0a-b06f-4535-b31e-bb93141ae394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f6f2544c-5356-4b74-a082-64a468311545_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f6f2544c-5356-4b74-a082-64a468311545_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:to="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ee2d2741-2b9c-492c-971e-415e0a24c0af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:to="loc_country_US_ee2d2741-2b9c-492c-971e-415e0a24c0af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d6634284-3772-4107-a1fc-d8c4921b3f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:to="loc_us-gaap_ForeignPlanMember_d6634284-3772-4107-a1fc-d8c4921b3f98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="extended" id="i5e7a1e6b81654343b329086f4349b2a3_PensionandPostretirementBenefitPlansNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bb9f5f71-7ff5-4d05-858e-9289bf1a147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bb9f5f71-7ff5-4d05-858e-9289bf1a147c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_71860b69-a57f-4e27-9bb1-5e29a7f47ee5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_71860b69-a57f-4e27-9bb1-5e29a7f47ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f8f8712f-5e08-4961-96af-d8ddb5e7c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f8f8712f-5e08-4961-96af-d8ddb5e7c106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_acea8531-8624-4b11-bd31-d17968d60914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_acea8531-8624-4b11-bd31-d17968d60914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_483318fc-5691-475b-adbf-d536cc362fef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_483318fc-5691-475b-adbf-d536cc362fef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:to="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1d0171f8-3769-4296-be2a-d9f25552b950" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:to="loc_country_US_1d0171f8-3769-4296-be2a-d9f25552b950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_055ff4b1-5b81-4a47-9906-c4f28377eb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:to="loc_us-gaap_ForeignPlanMember_055ff4b1-5b81-4a47-9906-c4f28377eb5d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="extended" id="ifd84e5dd549541b18caeac8f60b6e723_EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="extended" id="i7c6b6d1fba1d4ccd93605c31937f9d53_EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended" id="i2ead7c5035cd4c0690353bbdf6456c0c_EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitments"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="extended" id="i9ac114bf50834e04b7f8285746cb9315_ContingenciesandCertainCommitments"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended" id="i917ccf0b83b844d8a010717af311faf1_ContingenciesandCertainCommitmentsPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_32dd89a8-16a4-4a77-84ef-c3901b600552" xlink:href="pfe-20210404.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_32dd89a8-16a4-4a77-84ef-c3901b600552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_57139534-5c58-4013-a780-eadb39fd8165" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_57139534-5c58-4013-a780-eadb39fd8165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_8d1617a3-d4e6-44dc-a94c-e1536a6db252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_8d1617a3-d4e6-44dc-a94c-e1536a6db252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_4610d24c-abe4-43c5-89c9-b37bab1ccffb" xlink:href="pfe-20210404.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyNumberofDefendants_4610d24c-abe4-43c5-89c9-b37bab1ccffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_11ed7640-bf09-4f68-b106-fd2276f84fbb" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_11ed7640-bf09-4f68-b106-fd2276f84fbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4aa6945f-111a-4989-8ee7-29160ee4e716_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:to="loc_srt_ProductsAndServicesDomain_4aa6945f-111a-4989-8ee7-29160ee4e716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:to="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_c1395df6-f9d4-4d07-a4c9-6b840942795e" xlink:href="pfe-20210404.xsd#pfe_XeljanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:to="loc_pfe_XeljanzMember_c1395df6-f9d4-4d07-a4c9-6b840942795e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_baa48a9f-aec7-46c2-834f-f3357d9e6a33" xlink:href="pfe-20210404.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:to="loc_pfe_EliquisMember_baa48a9f-aec7-46c2-834f-f3357d9e6a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6ae8c7ec-70f7-45d9-a4df-a65de44adde2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:to="loc_srt_LitigationCaseTypeDomain_6ae8c7ec-70f7-45d9-a4df-a65de44adde2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:to="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusZydusMember_2f89b2b4-ebbc-4b8b-898b-c7e0ed78633d" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusZydusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerVersusZydusMember_2f89b2b4-ebbc-4b8b-898b-c7e0ed78633d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_3b2ee32e-bc16-49cb-b795-4701a9301fa9" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusGenericCompaniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_3b2ee32e-bc16-49cb-b795-4701a9301fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_29d892a2-db5c-4255-a875-f0f0535f3bf7" xlink:href="pfe-20210404.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_29d892a2-db5c-4255-a875-f0f0535f3bf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_3f0b1835-1567-4ba6-94e9-7982c957abb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_3f0b1835-1567-4ba6-94e9-7982c957abb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember_2297fac4-2e87-4daa-858a-255acd719955" xlink:href="pfe-20210404.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_PneumococcalVaccinePatentInfringementMember_2297fac4-2e87-4daa-858a-255acd719955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember_a4a6251b-1ca2-40b2-a4c7-dfab71e7aaa7" xlink:href="pfe-20210404.xsd#pfe_OtherPatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_OtherPatentInfringementMember_a4a6251b-1ca2-40b2-a4c7-dfab71e7aaa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_dfcaa137-f9d7-43a5-ab50-96d1b01ca293" xlink:href="pfe-20210404.xsd#pfe_PatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_PatentInfringementMember_dfcaa137-f9d7-43a5-ab50-96d1b01ca293" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_384bea6e-f652-4325-a0b3-83e35cb14a1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:to="loc_us-gaap_LitigationStatusDomain_384bea6e-f652-4325-a0b3-83e35cb14a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:to="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_56bcc628-b9d0-4d6e-a968-8527677c4ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:to="loc_us-gaap_SettledLitigationMember_56bcc628-b9d0-4d6e-a968-8527677c4ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_b45e146d-5832-4126-9855-2054e488904b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:to="loc_us-gaap_PendingLitigationMember_b45e146d-5832-4126-9855-2054e488904b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="extended" id="iacd424c366734de2b53b88d0131a9057_ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_3de21df5-7130-42ce-9603-dac25ed4de0e" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_3de21df5-7130-42ce-9603-dac25ed4de0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_44cce058-417c-4b4d-9633-d0c3dc137310" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_44cce058-417c-4b4d-9633-d0c3dc137310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_808b4568-6ab1-4f93-8a3b-e7d82574b244" xlink:href="pfe-20210404.xsd#pfe_LossContingencyClassActionsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_808b4568-6ab1-4f93-8a3b-e7d82574b244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_4c9688e8-d274-480a-bcf5-09c0e5beb08d" xlink:href="pfe-20210404.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_4c9688e8-d274-480a-bcf5-09c0e5beb08d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44858f14-7eeb-4301-bf84-00412111221a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:to="loc_srt_RangeMember_44858f14-7eeb-4301-bf84-00412111221a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:to="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a1536d4-d056-448d-ac6a-77186eadcd71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:to="loc_srt_MinimumMember_7a1536d4-d056-448d-ac6a-77186eadcd71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_746fcdd9-c6cb-4a60-9fde-a7f7dd281482_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:to="loc_us-gaap_LossContingencyNatureDomain_746fcdd9-c6cb-4a60-9fde-a7f7dd281482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:to="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_fb24de3e-cd48-4645-9109-64dd01dcd0b3" xlink:href="pfe-20210404.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_fb24de3e-cd48-4645-9109-64dd01dcd0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_22c470eb-6284-4436-a329-94145885e765_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:to="loc_srt_LitigationCaseTypeDomain_22c470eb-6284-4436-a329-94145885e765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:to="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_8d601851-7918-4b88-b425-63d876fcefcc" xlink:href="pfe-20210404.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_8d601851-7918-4b88-b425-63d876fcefcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArraySecuritiesLitigationMember_5fb31bdf-04c8-4806-a7e4-e1c72e24e629" xlink:href="pfe-20210404.xsd#pfe_ArraySecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_ArraySecuritiesLitigationMember_5fb31bdf-04c8-4806-a7e4-e1c72e24e629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZantacRanitidineNDMALitigationMember_8ca41f7f-a8cd-4e8b-83bb-3c32e271c553" xlink:href="pfe-20210404.xsd#pfe_ZantacRanitidineNDMALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_ZantacRanitidineNDMALitigationMember_8ca41f7f-a8cd-4e8b-83bb-3c32e271c553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dce11f03-ab94-4f93-8c6e-245edef891d4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:to="loc_srt_ProductsAndServicesDomain_dce11f03-ab94-4f93-8c6e-245edef891d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:to="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_b9c2e8ef-17a7-4826-848f-2b89728d3fb7" xlink:href="pfe-20210404.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:to="loc_pfe_EpiPenMember_b9c2e8ef-17a7-4826-848f-2b89728d3fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_174e31c9-1fd9-448c-8abb-dea8fe55268a" xlink:href="pfe-20210404.xsd#pfe_DocetaxelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:to="loc_pfe_DocetaxelMember_174e31c9-1fd9-448c-8abb-dea8fe55268a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4e296714-fdd1-49ac-b781-4e839c7a2a15_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:to="loc_us-gaap_LitigationStatusDomain_4e296714-fdd1-49ac-b781-4e839c7a2a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:to="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_11101f7c-f0ca-42da-a124-d1bfcbef40b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:to="loc_us-gaap_PendingLitigationMember_11101f7c-f0ca-42da-a124-d1bfcbef40b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformation"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="extended" id="i70a09a6daa9a43b39f2619cd922ee85d_ProductGeographicandOtherRevenueInformation"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationTables"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="extended" id="if5f54e785a4f4b3fa9fd2c70cf12aa01_ProductGeographicandOtherRevenueInformationTables"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" id="i64be47b7a7584068875f96d1e8854708_ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b67a875-8c49-433f-8c55-38cd9ccd9c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b67a875-8c49-433f-8c55-38cd9ccd9c99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue_5a67307a-a2eb-404e-99b4-44a507400fb4" xlink:href="pfe-20210404.xsd#pfe_PercentageChangeInRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:to="loc_pfe_PercentageChangeInRevenue_5a67307a-a2eb-404e-99b4-44a507400fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:to="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a433886-15de-44aa-b538-a55c5757aee1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:to="loc_srt_SegmentGeographicalDomain_6a433886-15de-44aa-b538-a55c5757aee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:to="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b4d46b63-c733-4338-8df4-f1abbc58b975" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_country_US_b4d46b63-c733-4338-8df4-f1abbc58b975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_e68e440c-1aa3-492b-a875-fa42ed31f483" xlink:href="pfe-20210404.xsd#pfe_DevelopedEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_DevelopedEuropeMember_e68e440c-1aa3-492b-a875-fa42ed31f483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_1e3cb8cd-c0b7-4862-9ed6-48fc85a203a1" xlink:href="pfe-20210404.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_DevelopedRestOfWorldMember_1e3cb8cd-c0b7-4862-9ed6-48fc85a203a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_e4d7c776-f766-49b5-b7c5-bead7adfdab5" xlink:href="pfe-20210404.xsd#pfe_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_EmergingMarketsMember_e4d7c776-f766-49b5-b7c5-bead7adfdab5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended" id="if83280807e984bae92c08f1d897c128d_ProductGeographicandOtherRevenueInformationNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_769af8cd-a0c9-4773-b088-8fd8fc4f5652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_769af8cd-a0c9-4773-b088-8fd8fc4f5652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6752db29-6e01-4d65-845e-a3b030c5f7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6752db29-6e01-4d65-845e-a3b030c5f7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ff976aa5-d603-4f90-9b96-4e746bc11a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ff976aa5-d603-4f90-9b96-4e746bc11a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e84bb74f-5379-4012-85ea-0a0f3f608533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e84bb74f-5379-4012-85ea-0a0f3f608533" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:to="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_d95afbd2-5070-4602-919c-e916ae6fb557" xlink:href="pfe-20210404.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_d95afbd2-5070-4602-919c-e916ae6fb557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bef020f6-6cfd-4176-a696-fb9fd444102c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:to="loc_srt_ProductsAndServicesDomain_bef020f6-6cfd-4176-a696-fb9fd444102c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:to="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_ed44dfa0-5a31-404b-9121-3a69bd98f15a" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:to="loc_pfe_BNT162b2Member_ed44dfa0-5a31-404b-9121-3a69bd98f15a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8fbfb30a-21e7-456c-9af8-be207471a93d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8fbfb30a-21e7-456c-9af8-be207471a93d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5858afb4-9219-4599-ba61-fd0c1670f1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:to="loc_us-gaap_SubsequentEventMember_5858afb4-9219-4599-ba61-fd0c1670f1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6fadcd9-8062-40fb-b4a0-392b4d88d096_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6fadcd9-8062-40fb-b4a0-392b4d88d096_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4da910a0-0279-41cd-810d-45fe5d3382ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:to="loc_us-gaap_SalesRevenueNetMember_4da910a0-0279-41cd-810d-45fe5d3382ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_f28e467e-14de-434d-a002-d4cad3d40abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:to="loc_us-gaap_AccountsReceivableMember_f28e467e-14de-434d-a002-d4cad3d40abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8a0f63a3-0b60-484a-bd5f-5702ecbaf714_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8a0f63a3-0b60-484a-bd5f-5702ecbaf714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_ed88b6be-1884-4639-8beb-02f6c3bcf566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_ed88b6be-1884-4639-8beb-02f6c3bcf566" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" id="ic83a0827f1874704b666d5ec97381d41_ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_845c9570-0c6c-4d78-a122-cbcf17f1a355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_845c9570-0c6c-4d78-a122-cbcf17f1a355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:to="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_ba4902c8-7d9a-4283-b73f-14fde289d8ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:to="loc_us-gaap_ReportingUnitDomain_ba4902c8-7d9a-4283-b73f-14fde289d8ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:to="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember_aee7cf73-d3d6-4fde-86e4-fc91f28cf035" xlink:href="pfe-20210404.xsd#pfe_VaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_VaccinesMember_aee7cf73-d3d6-4fde-86e4-fc91f28cf035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_b5b136fc-3a5c-4603-ae69-8f851f6b310d" xlink:href="pfe-20210404.xsd#pfe_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_OncologyMember_b5b136fc-3a5c-4603-ae69-8f851f6b310d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember_8344a214-01d8-4c1d-b472-0ef089f482dd" xlink:href="pfe-20210404.xsd#pfe_InternalMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_InternalMedicineMember_8344a214-01d8-4c1d-b472-0ef089f482dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember_7635606e-097a-4c1a-9fc1-c27cd6f378fc" xlink:href="pfe-20210404.xsd#pfe_HospitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_HospitalMember_7635606e-097a-4c1a-9fc1-c27cd6f378fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember_b1d8b5da-aa24-4ac5-83a7-bf5f9e2a62f5" xlink:href="pfe-20210404.xsd#pfe_InflammationandImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_InflammationandImmunologyMember_b1d8b5da-aa24-4ac5-83a7-bf5f9e2a62f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember_057e1a89-585e-4fb7-af9e-932b46240ac3" xlink:href="pfe-20210404.xsd#pfe_RareDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_RareDiseaseMember_057e1a89-585e-4fb7-af9e-932b46240ac3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:to="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:to="loc_srt_ProductsAndServicesDomain_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:to="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_39198bd9-2966-424d-a8b6-6dc5add78d2a" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BNT162b2Member_39198bd9-2966-424d-a8b6-6dc5add78d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_ce708951-c986-4c10-896a-f6dc2bdde954" xlink:href="pfe-20210404.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_ce708951-c986-4c10-896a-f6dc2bdde954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_e4847d45-47de-4cbc-bd17-97d62738a100" xlink:href="pfe-20210404.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_e4847d45-47de-4cbc-bd17-97d62738a100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_9aab7ef8-31d4-4c25-92c8-f2e698d254ae" xlink:href="pfe-20210404.xsd#pfe_NimenrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_NimenrixMember_9aab7ef8-31d4-4c25-92c8-f2e698d254ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember_aa6b6aa6-2184-4f77-9446-ef6b5128c5ca" xlink:href="pfe-20210404.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherVaccinesProductsMember_aa6b6aa6-2184-4f77-9446-ef6b5128c5ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_37117d2d-f7b8-49a2-ae6b-55a28c070eda" xlink:href="pfe-20210404.xsd#pfe_IbranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_IbranceMember_37117d2d-f7b8-49a2-ae6b-55a28c070eda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_62159969-3ddc-4a60-853d-bfbf9cb6108e" xlink:href="pfe-20210404.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_62159969-3ddc-4a60-853d-bfbf9cb6108e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_07f549b8-16af-42f9-a1a8-e79eff63bcde" xlink:href="pfe-20210404.xsd#pfe_InlytaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_InlytaMember_07f549b8-16af-42f9-a1a8-e79eff63bcde" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_a4e0421d-11c0-4a07-a4d0-2f798e702b73" xlink:href="pfe-20210404.xsd#pfe_SutentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SutentMember_a4e0421d-11c0-4a07-a4d0-2f798e702b73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_3c5ba0d7-c9d0-48f9-9cf5-6c4ad31f765c" xlink:href="pfe-20210404.xsd#pfe_XalkoriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XalkoriMember_3c5ba0d7-c9d0-48f9-9cf5-6c4ad31f765c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_8ff94922-d21d-40da-a710-aaafd4db04f8" xlink:href="pfe-20210404.xsd#pfe_BosulifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BosulifMember_8ff94922-d21d-40da-a710-aaafd4db04f8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_a38a0281-ffaf-4284-a36e-f6bc780c25e8" xlink:href="pfe-20210404.xsd#pfe_RetacritMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_RetacritMember_a38a0281-ffaf-4284-a36e-f6bc780c25e8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_9f729818-bd57-4da1-9169-c6eb4f73211d" xlink:href="pfe-20210404.xsd#pfe_RuxienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_RuxienceMember_9f729818-bd57-4da1-9169-c6eb4f73211d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_7de5a0ae-b0be-4c71-b844-b225a4d22c65" xlink:href="pfe-20210404.xsd#pfe_ZirabevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZirabevMember_7de5a0ae-b0be-4c71-b844-b225a4d22c65" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_5ea4941b-021e-4e66-860d-e14e2a200f88" xlink:href="pfe-20210404.xsd#pfe_LorbrenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_LorbrenaMember_5ea4941b-021e-4e66-860d-e14e2a200f88" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_eb626a94-86cc-48da-82a0-77f6e8bc9765" xlink:href="pfe-20210404.xsd#pfe_AromasinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AromasinMember_eb626a94-86cc-48da-82a0-77f6e8bc9765" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_785b95b8-9c19-40dc-b5f9-68548795d304" xlink:href="pfe-20210404.xsd#pfe_BesponsaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BesponsaMember_785b95b8-9c19-40dc-b5f9-68548795d304" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_94a5391e-2e4a-4998-ae97-2e6826d75cf2" xlink:href="pfe-20210404.xsd#pfe_BraftoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BraftoviMember_94a5391e-2e4a-4998-ae97-2e6826d75cf2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_2bf55a81-a2fd-480b-a024-e023d41ff89a" xlink:href="pfe-20210404.xsd#pfe_MektoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_MektoviMember_2bf55a81-a2fd-480b-a024-e023d41ff89a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_889e68e8-122a-482c-913d-d63600f42653" xlink:href="pfe-20210404.xsd#pfe_OtherOncologyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherOncologyProductsMember_889e68e8-122a-482c-913d-d63600f42653" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_37cb2e0f-f403-4e6c-9035-59d99c5da05b" xlink:href="pfe-20210404.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EliquisMember_37cb2e0f-f403-4e6c-9035-59d99c5da05b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_7f93b1a2-9a8e-4165-a688-2182719cac43" xlink:href="pfe-20210404.xsd#pfe_ChantixChampixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ChantixChampixMember_7f93b1a2-9a8e-4165-a688-2182719cac43" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_ba44ef8e-e006-49b4-9ad4-20b362cdbc34" xlink:href="pfe-20210404.xsd#pfe_PremarinFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PremarinFamilyMember_ba44ef8e-e006-49b4-9ad4-20b362cdbc34" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember_d6594a1e-7ddb-4f3f-a2c3-859d4f98df9f" xlink:href="pfe-20210404.xsd#pfe_PristiqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PristiqMember_d6594a1e-7ddb-4f3f-a2c3-859d4f98df9f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_4bca1898-394c-4ef5-b72b-776554da95f4" xlink:href="pfe-20210404.xsd#pfe_ToviazMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ToviazMember_4bca1898-394c-4ef5-b72b-776554da95f4" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember_a5a28d28-f3f4-4233-9fc9-c7b1bedc6e5a" xlink:href="pfe-20210404.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherInternalMedicineMember_a5a28d28-f3f4-4233-9fc9-c7b1bedc6e5a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_93d17156-4b46-41a1-a3fc-8035e64e757c" xlink:href="pfe-20210404.xsd#pfe_SulperazonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SulperazonMember_93d17156-4b46-41a1-a3fc-8035e64e757c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_9f0a8ba6-e281-4e4c-b5ae-294cb35736e1" xlink:href="pfe-20210404.xsd#pfe_MedrolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_MedrolMember_9f0a8ba6-e281-4e4c-b5ae-294cb35736e1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_3adf2623-dfc4-45ee-a968-4bcfb205c6a9" xlink:href="pfe-20210404.xsd#pfe_ZaviceftaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZaviceftaMember_3adf2623-dfc4-45ee-a968-4bcfb205c6a9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_04a4c0d2-5622-4921-9305-6ee774f8ac2e" xlink:href="pfe-20210404.xsd#pfe_ZithromaxZmaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZithromaxZmaxMember_04a4c0d2-5622-4921-9305-6ee774f8ac2e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_76333e0d-098d-4e97-89aa-b713bc2c6e25" xlink:href="pfe-20210404.xsd#pfe_VfendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_VfendMember_76333e0d-098d-4e97-89aa-b713bc2c6e25" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_28c07b16-6e68-4f59-90f5-756609a6fe2e" xlink:href="pfe-20210404.xsd#pfe_FragminMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_FragminMember_28c07b16-6e68-4f59-90f5-756609a6fe2e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_858c339c-6abd-4fcf-9ec1-707609309c07" xlink:href="pfe-20210404.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EpiPenMember_858c339c-6abd-4fcf-9ec1-707609309c07" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember_fdea3533-f030-4369-898c-8abb2edf5bda" xlink:href="pfe-20210404.xsd#pfe_ZyvoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZyvoxMember_fdea3533-f030-4369-898c-8abb2edf5bda" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember_26047d2e-8357-42cb-bd4a-77b729725830" xlink:href="pfe-20210404.xsd#pfe_PrecedexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PrecedexMember_26047d2e-8357-42cb-bd4a-77b729725830" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember_c344230d-626f-400d-84cb-0aa4c06113f5" xlink:href="pfe-20210404.xsd#pfe_IVIgProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_IVIgProductsMember_c344230d-626f-400d-84cb-0aa4c06113f5" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember_0298dcc6-52df-4330-a4a5-6e97dc29ff48" xlink:href="pfe-20210404.xsd#pfe_PfizerCentreOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PfizerCentreOneMember_0298dcc6-52df-4330-a4a5-6e97dc29ff48" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_f17ac5b4-d64d-43f8-8b9f-7d2e4b71c8d2" xlink:href="pfe-20210404.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherAntiinfectivesMember_f17ac5b4-d64d-43f8-8b9f-7d2e4b71c8d2" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember_b4b33130-0269-40a9-91b9-466e128bed64" xlink:href="pfe-20210404.xsd#pfe_OtherHospitalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherHospitalProductsMember_b4b33130-0269-40a9-91b9-466e128bed64" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_3e025f7f-d20f-4bdc-9fc9-5ef1720adef2" xlink:href="pfe-20210404.xsd#pfe_XeljanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XeljanzMember_3e025f7f-d20f-4bdc-9fc9-5ef1720adef2" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_ef35c225-4d6e-496d-9c62-8edb7e8ac899" xlink:href="pfe-20210404.xsd#pfe_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EnbrelMember_ef35c225-4d6e-496d-9c62-8edb7e8ac899" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember_9aa2015f-47d5-469c-b65c-ac80aa7e9583" xlink:href="pfe-20210404.xsd#pfe_InflectraRemsimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_InflectraRemsimaMember_9aa2015f-47d5-469c-b65c-ac80aa7e9583" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6a6b81ca-67f6-4763-8bea-a1b887409544" xlink:href="pfe-20210404.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6a6b81ca-67f6-4763-8bea-a1b887409544" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_1f36d3d0-048d-4151-b8ba-798ba6840916" xlink:href="pfe-20210404.xsd#pfe_VyndaqelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_VyndaqelMember_1f36d3d0-048d-4151-b8ba-798ba6840916" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_09da271d-680a-4c0a-891e-f29ee4df7283" xlink:href="pfe-20210404.xsd#pfe_BeneFIXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BeneFIXMember_09da271d-680a-4c0a-891e-f29ee4df7283" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_ae762767-3c21-4830-83a2-d5c393ad7dc9" xlink:href="pfe-20210404.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ReFactoAfXynthaMember_ae762767-3c21-4830-83a2-d5c393ad7dc9" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_4422a176-72be-41e9-b5cf-d039d3a33e80" xlink:href="pfe-20210404.xsd#pfe_GenotropinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_GenotropinMember_4422a176-72be-41e9-b5cf-d039d3a33e80" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_2478efed-dfa1-4f45-af69-2d80a2e3996e" xlink:href="pfe-20210404.xsd#pfe_SomavertMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SomavertMember_2478efed-dfa1-4f45-af69-2d80a2e3996e" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_a04bb006-14a1-4c28-8b3a-24835af93436" xlink:href="pfe-20210404.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_a04bb006-14a1-4c28-8b3a-24835af93436" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_eae8c353-fd0d-4364-8538-0bcc9367de02" xlink:href="pfe-20210404.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_eae8c353-fd0d-4364-8538-0bcc9367de02" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember_1269b214-d025-4532-adb5-c33f7c637a9f" xlink:href="pfe-20210404.xsd#pfe_TotalBiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalBiosimilarsMember_1269b214-d025-4532-adb5-c33f7c637a9f" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_a5b9ec91-2f9c-45b6-89e6-e2b902c12f18" xlink:href="pfe-20210404.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_a5b9ec91-2f9c-45b6-89e6-e2b902c12f18" xlink:type="arc" order="51"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>pfe-20210404_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_ae78eef1-2182-4fe5-8244-cbc9b5562df1_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_ab5be240-a561-4ca2-8958-17cbf24479af_terseLabel_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_label_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_documentation_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:href="pfe-20210404.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:to="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_91d4c676-f956-4a1f-b4e8-f2106e6a51e2_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_97dd7a7d-4d1c-430c-98b9-66ff4df75f13_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SomavertMember_a2b4af4e-3bf5-4d9e-bc7d-6137ff41a686_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_label_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_documentation_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember" xlink:href="pfe-20210404.xsd#pfe_SomavertMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember" xlink:to="lab_pfe_SomavertMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b33329a2-63b2-45fd-aca8-dedcaf3a2fd8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ff0bfc66-0dc4-48a2-8c4a-96623a8cd20d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0f7f31eb-52ac-43e8-9385-7317b17cff72_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a8666473-2982-4db6-bd24-3bd0cc8a9086_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Certain Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_e379617a-8ae5-4d84-9fe9-69e24f15b090_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_67a2a5a8-7577-44ca-914f-ff9512e2f671_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class actions filed</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_label_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_documentation_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber" xlink:href="pfe-20210404.xsd#pfe_LossContingencyClassActionsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyClassActionsFiledNumber" xlink:to="lab_pfe_LossContingencyClassActionsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_ee95815f-6e7d-44e3-a764-85f7a17c4193_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_167846d2-fd2a-4ea2-973a-137c34dbffad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_e1a12f57-6212-4268-a351-0fb105018a1e_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5d215bbd-a94a-49c5-9aed-9f8d36e7a427_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ArraySecuritiesLitigationMember_01a1f728-f929-4ec2-904d-a24dd7c25689_terseLabel_en-US" xlink:label="lab_pfe_ArraySecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array Securities Litigation [Member]</link:label>
    <link:label id="lab_pfe_ArraySecuritiesLitigationMember_label_en-US" xlink:label="lab_pfe_ArraySecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array Securities Litigation [Member]</link:label>
    <link:label id="lab_pfe_ArraySecuritiesLitigationMember_documentation_en-US" xlink:label="lab_pfe_ArraySecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArraySecuritiesLitigationMember" xlink:href="pfe-20210404.xsd#pfe_ArraySecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArraySecuritiesLitigationMember" xlink:to="lab_pfe_ArraySecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_1818faf2-48f1-4456-82cb-e76c5717341d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8a5a62af-e901-415a-a1d9-672b4fcc3782_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a69ef0e6-17d3-4624-ab9b-bb51bb5c14ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_b3dfbb95-1223-4bc8-a487-54e1a9fb8f34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_bbcc63c2-ba9f-40ac-ac48-fa49bb50ccd0_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:href="pfe-20210404.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c027a01b-b4d8-49cd-a5d1-b05889b0ee20_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_47e0dac0-b9cd-4a32-98f3-44d3326b6d1d_terseLabel_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_label_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_documentation_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember" xlink:href="pfe-20210404.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAntiinfectivesMember" xlink:to="lab_pfe_OtherAntiinfectivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6927946e-d13f-418b-bd2f-68bf2dd2c730_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_d3b63b9c-10ec-4b16-af6a-ea5312d0cd77_terseLabel_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility study, number of lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_label_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_documentation_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons" xlink:href="pfe-20210404.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeasibilityStudyNumberOfLagoons" xlink:to="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e2c1eb9d-a234-4bc8-a14a-7415a8c9f344_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ec24dcc7-2a87-4730-9a18-14cee7c8ed35_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_a0aff261-6dc2-4244-b787-e02d5ff63607_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_841700fb-23cd-4a45-976c-3ad04bb39823_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Principle</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5710edc1-1dd6-4038-9581-cb512098aaaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ToviazMember_4bf43869-1b55-4b95-b649-8d72374da8a9_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_label_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_documentation_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember" xlink:href="pfe-20210404.xsd#pfe_ToviazMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember" xlink:to="lab_pfe_ToviazMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_daef3f3c-dcf0-48df-b9fe-e51aa1886b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_09ae5e29-58b1-457c-afd3-f69d0e6c5429_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_c7d1350b-5540-44e3-af2c-72af978efe15_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_51f101f2-8b14-4121-8a50-d3a3b715e451_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_157431b0-560c-4115-b98d-27ef0ac6c9e0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6a23bc49-372c-499c-9cb2-f54c45fc74eb_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IVIgProductsMember_d2847449-e616-4604-bd44-e1b2791559f4_terseLabel_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products [Member]</link:label>
    <link:label id="lab_pfe_IVIgProductsMember_label_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products [Member]</link:label>
    <link:label id="lab_pfe_IVIgProductsMember_documentation_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember" xlink:href="pfe-20210404.xsd#pfe_IVIgProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IVIgProductsMember" xlink:to="lab_pfe_IVIgProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_6ee6093d-0e77-4be5-ad40-ec3c9f5375ec_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_df8ea076-f80b-4f5a-976b-ac9ebcefa545_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term borrowings, principal amount</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_45801618-116a-40ca-868c-5e0e58082988_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f99edec6-2649-4c6a-923e-d9a40e71445b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EnbrelMember_39c51b63-e9cb-4404-a8df-02ce5c976152_verboseLabel_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel (Outside the U.S. and Canada) [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_label_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_documentation_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember" xlink:href="pfe-20210404.xsd#pfe_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember" xlink:to="lab_pfe_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_83e35382-4b18-49a2-b2ba-5f0892401387_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gains and Losses on Investment Securities</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_label_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:to="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_9bd6b412-d429-4e52-9f61-14884547b955_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:href="pfe-20210404.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_56e2b0d9-ff21-4939-9d07-42dcbe545b74_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AromasinMember_03eb8738-58a0-4fd1-a6ac-6b083492f66f_terseLabel_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_label_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_documentation_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember" xlink:href="pfe-20210404.xsd#pfe_AromasinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AromasinMember" xlink:to="lab_pfe_AromasinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MedrolMember_2b3ddf1b-dc58-4840-a568-eb60bf3e6904_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_label_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_documentation_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember" xlink:href="pfe-20210404.xsd#pfe_MedrolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember" xlink:to="lab_pfe_MedrolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a91d2f41-8d80-481c-b663-9cd01fa098c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7ccb640a-5295-4bed-900c-1619b9c4304a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_053108cb-3197-4877-9e2b-6387761e3b41_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_83dcf00d-c819-41ed-a4ae-8e9cc096a1a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4c7e247-1726-4315-968b-ab7cb392b1a0_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_c3c45875-e15e-4593-992b-212a76a3ff45_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c0cc4e49-4304-4e87-81d5-f589fec67d86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_bd7832ca-934c-4a37-8ca3-178e49149cfe_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_cfba2b7a-fbbb-4fdd-9824-6a1e9bb84e56_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants" xlink:href="pfe-20210404.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants" xlink:to="lab_pfe_GainContingencyNumberofDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fb510926-2c9e-4643-92bd-f75551dc938a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dc2ae0f3-a64d-40a0-a115-2495e0e4114e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_d10923b2-6ce6-4819-801c-5a29ae64f829_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss), before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_4d18d26d-3074-4ea3-8af0-5d72d748c85c_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_7c54ec02-ba2a-415c-ba31-9de7ee4c2631_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_33651fdf-f058-4b15-9f12-55e45c3cb608_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_df570f76-d405-4785-8ad7-a26a05260a38_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f578eba-9bc7-4813-b124-9c39004df39e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_c55c2ae5-0505-496d-8496-4351f27592c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_d6f17163-0b46-4e70-9771-48abecfc4aea_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product concentration risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_fbe03fae-ec4b-4bd9-8eee-9eeca5c5ced0_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short-term borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9980ed9b-5e81-48bf-aefd-83eda3131331_terseLabel_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_label_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_documentation_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:href="pfe-20210404.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:to="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b03166b2-4f01-49cf-9287-9e760849f9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermDebtGross_1f8ecbb6-13c6-47ea-b9a5-28dad6bbb9a3_totalLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term borrowings, principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross" xlink:href="pfe-20210404.xsd#pfe_ShorttermDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross" xlink:to="lab_pfe_ShorttermDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_441cf7eb-8584-419e-a8e7-70fafe16f809_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional depreciation&#8211;&#8211;asset restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b023b7e6-f9e3-4c71-98ef-bb7e74924fc3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_03855125-610a-4b5a-aec9-026f468d6eb2_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_4a7e22a4-adaf-41a7-938b-141ce2b6e3be_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_5baa77d9-3717-4046-bf97-96296ad5ceb5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_bb03f22d-29fd-49cc-a881-6f2a6035b23c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_42728334-92de-4231-9986-4ac520ce8748_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_14e656f8-088c-4903-bc54-df5658d562ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2724bcdc-6a18-428b-8709-1837c0db81d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_aa74a7b7-6a5d-4e00-998f-d32025105a5e_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_29c65b3e-fc94-4a8a-b148-94581f4a8f55_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_a8ac2271-b993-4724-a3cf-1709d6cd22b2_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents without court proceedings</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:to="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_b4e46569-c8bf-4732-974a-bae7efc04ce3_terseLabel_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 assets sold to Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_label_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_documentation_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember" xlink:href="pfe-20210404.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CK1AssetsSoldToBiogenIncMember" xlink:to="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_9d7e608e-ea14-4816-b6b1-958afeca2e68_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_268fdad9-caae-4eb4-8a78-a438ef4a9d9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7eebd66f-b458-4381-b0ce-131d85fa2dd7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0cdf1dab-6ef6-4281-bc2d-7959d7c78a7c_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan contributions in excess of expense/income</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:href="pfe-20210404.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_cd0d1027-8bb7-469a-841e-478e2502d021_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_4cfdf6c3-2b7c-4649-b4a9-1bf83d267929_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_bd0b8bce-a5a1-43dd-9e66-dc45096784a3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_cffe7884-5474-4d8b-8e42-58abba11699e_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40b3d4d6-cfbc-433d-8b1b-f6e9ee2d4b00_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_963afdc4-801a-4d89-b8a5-bf4b7c0d991d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2df29e1f-301e-4618-8b74-6da44bdc7a8c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2dde456e-31b9-4785-9fdf-a83d4304b0fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bb0e8f88-e68a-44d4-bcbe-e0a0e8887179_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_c6572394-efa1-468b-a0cd-978db140ac65_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RareDiseaseMember_5af5c377-d548-4fdd-b0a2-d5ddcd527ae1_terseLabel_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_label_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_documentation_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember" xlink:href="pfe-20210404.xsd#pfe_RareDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RareDiseaseMember" xlink:to="lab_pfe_RareDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3a9939ad-6ce3-46ce-884c-d13d6bea0868_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_65b63af0-1a65-4c32-91b5-93f5a7345873_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_91d2e76d-8418-4d7e-b547-9d9c26295b77_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0d07984e-75ba-434c-9004-be23eb6b4178_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5143a1a7-44ba-4d4a-b196-99ef3f617d50_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_1ca7028d-7195-44b6-9aee-c06ae61ce641_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_af1324f3-a63f-4022-9f79-c4e38b771c14_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_8aba79f5-8723-468e-932b-1ffe083af7d1_terseLabel_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_label_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_documentation_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:href="pfe-20210404.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:to="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_c1335ace-3922-4012-97de-937fab57e238_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements and Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember" xlink:href="pfe-20210404.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_04433902-ea49-4d1c-8282-cd29b22ee97e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_41c4b77d-7290-4a9f-9bdf-3d9385594ac9_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c955071f-c90c-423c-8a9b-86e62857ccf3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_36e880a6-8e2a-4804-9151-1e476ff363e8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_eaec028a-6fa4-4b8a-86ac-4b3727dab025_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_676f766c-f07d-4d12-9afa-f5f1e682ab9d_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock conversions and redemptions</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4eede6ff-48b1-4d37-8990-cc601a8ab024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c4e08e1d-70b3-45e0-a6a1-db46f4ddb76b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4ed82017-7c64-48a0-aad3-b0ba5b45e40e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_c47c6b1f-a866-48e8-b74c-4d769264e925_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_0562ed7b-83cb-455c-8d2e-2a981623ec2b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_c3900e84-8678-4d9e-949e-c8367ce9c3c8_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent" xlink:href="pfe-20210404.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent" xlink:to="lab_pfe_OtherTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FragminMember_09a44ebe-d1ee-46b5-9c04-3261eb063767_terseLabel_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_label_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_documentation_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember" xlink:href="pfe-20210404.xsd#pfe_FragminMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember" xlink:to="lab_pfe_FragminMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrivateEquityInvestments_38ed6cbf-28cc-45f8-930a-af20a7f53f4f_terseLabel_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private equity securities at cost</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments" xlink:href="pfe-20210404.xsd#pfe_PrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrivateEquityInvestments" xlink:to="lab_pfe_PrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetImpairmentsMember_3e896df9-ad81-4ec0-93f3-43acf5bc8ee8_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember" xlink:href="pfe-20210404.xsd#pfe_AssetImpairmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember" xlink:to="lab_pfe_AssetImpairmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2b5ebde2-c4fe-43de-b4f1-0b54a9c109c7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_95e83df4-464f-4000-ba91-92b9f0a48c7a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_53e58c6f-d3d8-46f1-9efe-f89385aa2802_terseLabel_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade receivables</link:label>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_48f7e5a3-a82f-43e3-a264-28d230c81473_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Actively Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_9a4dfd28-d855-4436-b5b0-8e0a2c0e6775_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c45e2232-05c7-4e27-aee9-9541b5a03458_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d1001ffd-7f36-4128-876b-7a23e4163726_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_6b8bb47b-851f-4460-9c22-3b5e386a2cf2_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs and Expenses [Abstract]</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_68b73eec-8c17-4243-9135-d3478cf705c2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_125098da-b273-48b5-a733-66f99f20de67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_b9ed2476-2ec8-41b9-b620-77de5297b2e1_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain" xlink:to="lab_us-gaap_GainContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_aa92878f-8875-4f5e-9c3e-68d24a84f457_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total identifiable intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_label_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:href="pfe-20210404.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:to="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dab8504e-97d9-4362-b411-e24db505d01a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_79b0dde8-4038-415d-bd47-12c5c2f647a4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5474364f-e5a0-4c99-b7ee-b942a6b93451_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_c994863b-06a5-482e-a392-929148de13dc_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_794efbaf-8b40-4a86-9117-be3562599fe5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_57accd99-7a64-4c5e-a92a-693649203869_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b02ae5c6-5fbc-4062-a0d6-7bceea7a7ab5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_175abbd0-2891-4378-8131-d50adfb3fbb1_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0d08edaa-0fa8-46de-8ea0-d12f3c4c4a98_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3020765-4d71-47eb-aa41-dd336fdf795a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_5cc80466-56b1-438c-9e4c-e4ea9bf54139_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1d9f52d9-712a-4382-9feb-e75cddc68336_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_26cffdc4-5459-4600-aae7-6cd30f04de06_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_ef8e54b9-8735-4afe-b17e-fcea452a2b79_terseLabel_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_label_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_documentation_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember" xlink:href="pfe-20210404.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FSMEIMMUNTicoVacMember" xlink:to="lab_pfe_FSMEIMMUNTicoVacMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_be55e50c-0da4-45e0-a14e-16598156b98a_terseLabel_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previous Accounting Principle [Member]</link:label>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_label_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Previous Accounting Principle [Member]</link:label>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_documentation_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Previous Accounting Principle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:href="pfe-20210404.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:to="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_4ad32cce-dd9e-436c-9b47-1f586d37f820_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_d84ef9a2-265e-455f-8698-866b1c8f9e6e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_9f9eda1e-9478-4fc5-b7eb-00ba9c70be09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-related income</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_56e4f906-ae0c-4b32-b251-aec878ccfe1c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4497a587-a586-4469-91fc-208b17b58fae_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_74131a2c-036a-4c05-8e7d-e1848e5ea693_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c2af8196-4401-423c-b3e5-0ea58c380855_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_28041dc2-7ab8-4b1a-8a61-1850d9bbccbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2decc657-41ac-4d2a-9ab6-79c7713a3cf3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f2aabe4f-242f-446e-adb3-843bb0467574_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_458567e8-86f2-4a27-8f44-99d7755728d2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3541ae9d-c646-49d8-ae7a-6d70e393c564_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5fdd1ac2-d0fd-45b1-95a9-a8ecf45be4a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a416a429-e9d6-49bf-b568-32cc150c66cf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a3cceabd-ace6-4b42-8785-67b05d7a95bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_acaf4880-7c72-4f1f-8a23-06997efbbbb4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8da67f42-fe4a-46cc-bb06-c101da29d3ec_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_cbc7e824-95cc-4cc4-8a61-d62424edd480_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d2515225-9c89-4801-9171-54cd6fc55797_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_49975973-f992-478a-8a74-9d9119c1d691_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_138b308e-7787-46e2-905a-45988d82db38_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PremarinFamilyMember_814274ec-9f81-4959-bcc9-9d12fcf3df04_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember" xlink:href="pfe-20210404.xsd#pfe_PremarinFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember" xlink:to="lab_pfe_PremarinFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZaviceftaMember_7b142f0d-eef8-4588-8c67-ef91471168a4_terseLabel_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_label_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_documentation_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember" xlink:href="pfe-20210404.xsd#pfe_ZaviceftaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZaviceftaMember" xlink:to="lab_pfe_ZaviceftaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ce58faa4-c6a2-4cfe-bb17-7ba1defc8403_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_f8452832-d078-4d2c-a927-421d13e54631_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefit obligations</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_df638fc2-f144-4b32-912d-a6e112a2a4f1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs/(credits) other than service costs</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_38f0bf8a-20d1-4ac4-83bb-9e8eb0f0d02a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemDomain_217d3e9b-7f64-4622-b21e-33abd324c3ac_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_label_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_documentation_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain" xlink:href="pfe-20210404.xsd#pfe_HedgedItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemDomain" xlink:to="lab_pfe_HedgedItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_175ef3b6-472a-4bb9-a138-75759e07ee8f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_29b79864-beae-4b14-81d9-168cf99ef524_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9c3b2e3e-36b7-421f-97bf-95d0640ab235_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3e55e7ae-d224-43fb-b6a1-d1756a679a8e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_89ddd37f-a830-4226-a424-62189fd97600_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_949b8506-52c0-47ad-ad1b-156491ab5369_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cbad9d14-b083-4828-ab77-37fd83c42dc4_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZithromaxZmaxMember_439b272d-d7e2-4bc8-a6b7-b5303ab02754_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember" xlink:href="pfe-20210404.xsd#pfe_ZithromaxZmaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember" xlink:to="lab_pfe_ZithromaxZmaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EpiPenMember_be6457ee-cd67-437e-96b1-1f22197045ac_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_label_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_documentation_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember" xlink:href="pfe-20210404.xsd#pfe_EpiPenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember" xlink:to="lab_pfe_EpiPenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f9d2238c-27f0-4bb4-9e83-eee74d874fd2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2e97d566-74e2-40e9-92fe-672e9c65aab5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_6525c68a-485a-4b88-a413-51f47b986902_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b6421729-f1c1-47b5-8416-dc162cbcf987_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fbfb3f34-5e16-4e53-8129-5a2adb787ad5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ba3337e4-8c65-49d5-8e15-f4b769eabd34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f7ceae12-3a70-468e-a77a-b26cfe7bc177_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZyvoxMember_671dc9d7-509c-41fb-bab8-b0a37c0f9ffe_terseLabel_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_label_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_documentation_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember" xlink:href="pfe-20210404.xsd#pfe_ZyvoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZyvoxMember" xlink:to="lab_pfe_ZyvoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VfendMember_8667c302-5a94-4199-8552-7cbc6b27efea_terseLabel_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_label_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_documentation_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember" xlink:href="pfe-20210404.xsd#pfe_VfendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember" xlink:to="lab_pfe_VfendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_04ef5e62-fbd3-49ac-a858-33516f4daf38_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2e5768a7-6358-4b66-bc88-96c6eccf4a4c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_e4ff3147-1a21-495a-bdc7-abc989baa76e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalBiosimilarsMember_05c3ea9e-0df0-48c0-87be-1d7f9ddd3eff_terseLabel_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_label_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_documentation_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember" xlink:href="pfe-20210404.xsd#pfe_TotalBiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalBiosimilarsMember" xlink:to="lab_pfe_TotalBiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_26ba1697-f691-414d-8320-6efb7a77ddba_verboseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_659cd62d-b1c0-4b7e-a1c8-2df8b05d03d3_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_dfcd1dc2-d9e3-4126-a963-2a05af90f96b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3fc13901-8747-4fd6-91e4-c2c8c26224df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_615e3658-675e-4bb2-b591-d01dc5029b4a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_e576d0dc-5343-49be-b7de-85984b9c1367_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a58c46d9-0fb0-4615-a13d-f85c4e07c81b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_cf61e249-ba04-4125-9628-1f2665f78c2c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1671b10a-1219-49be-bf2d-39dbc4930616_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency - non U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3bb0d18b-28e0-4c13-99dc-53253f00424e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_eb2aeab2-b768-4f9b-b58f-e801a86534b8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_3c53df3e-5eff-4470-9461-165245c1b5c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_3e180cc9-db15-4a9d-8f59-652bb4a076d6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_a4c506cc-186a-431e-aeb1-117fad3ef4b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_67915995-e0a0-46d4-9a07-efe817193b8c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_9f1cadbf-e61a-47f9-a00c-fbd063b27add_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_3d69a0de-bfbc-41d0-b565-1eb1e523c161_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3be9065c-fb4a-4742-82a1-120fee00041a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_186d4aa7-2865-4821-a6f6-04bbf44a84fb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d9b35d49-8d27-43a1-a70f-96c0240d662c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_70198219-cb09-4523-b98c-036cb33f5821_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IbranceMember_03113094-6664-4254-8b0a-1f39865c3938_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_label_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_documentation_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember" xlink:href="pfe-20210404.xsd#pfe_IbranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember" xlink:to="lab_pfe_IbranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_068e426c-1cad-47fd-a2e3-611cdf9b2c64_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllogeneMember_494c691d-0e1a-4e5e-8759-02d3bcdbc626_terseLabel_en-US" xlink:label="lab_pfe_AllogeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_label_en-US" xlink:label="lab_pfe_AllogeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_documentation_en-US" xlink:label="lab_pfe_AllogeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneMember" xlink:href="pfe-20210404.xsd#pfe_AllogeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllogeneMember" xlink:to="lab_pfe_AllogeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_8703ac1e-d7ce-4a5c-985e-c29b4416aa4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_0112f2e0-f4fa-4d6c-ac6d-92c4f455fe54_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_6e1f6066-f0f9-4bde-aafa-f26c35e70bae_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8f2f29f1-f5df-4648-962c-4707992bd880_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fefaebd9-c8c3-4c58-812d-0ac81a8a71ad_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b3d755b9-7a55-4d77-9573-acc635203f6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Accounting Principle</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GSKMember_62e59caf-faf7-49c8-92b2-237ef438cd33_terseLabel_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_label_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_documentation_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember" xlink:href="pfe-20210404.xsd#pfe_GSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKMember" xlink:to="lab_pfe_GSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_35b5b25b-7efc-4836-96b7-ab431d03f6ea_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_1bf784e5-bf52-4b52-bb60-aa783d57c564_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:href="pfe-20210404.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb1d9e2a-0590-49ee-a64c-cd4b962152a4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZantacRanitidineNDMALitigationMember_52b367ac-c96b-4882-8710-82d9145a99e8_terseLabel_en-US" xlink:label="lab_pfe_ZantacRanitidineNDMALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac/Ranitidine NDMA Litigation [Member]</link:label>
    <link:label id="lab_pfe_ZantacRanitidineNDMALitigationMember_label_en-US" xlink:label="lab_pfe_ZantacRanitidineNDMALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac/Ranitidine NDMA Litigation [Member]</link:label>
    <link:label id="lab_pfe_ZantacRanitidineNDMALitigationMember_documentation_en-US" xlink:label="lab_pfe_ZantacRanitidineNDMALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac/Ranitidine NDMA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZantacRanitidineNDMALitigationMember" xlink:href="pfe-20210404.xsd#pfe_ZantacRanitidineNDMALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZantacRanitidineNDMALitigationMember" xlink:to="lab_pfe_ZantacRanitidineNDMALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e75194aa-89a7-45a9-b9ba-80eb831c8acd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_fbae84b7-7ff4-4e86-a3aa-bf5c901f1c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_e9c55056-8bb1-4fcf-a11b-a3c3296ea822_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_e7813f33-1184-4e7d-b8f6-f91cb5e18785_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_07b9e2eb-a3f6-4195-9485-59399cc9f979_terseLabel_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Change [Member]</link:label>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_label_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_documentation_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Change in Accounting Principle, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:href="pfe-20210404.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:to="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_eeec32ee-2fec-4e57-8ae8-02879a3c4d1e_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory sales [Member]</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_5adc21f1-46b1-43b8-80ad-21734e439c58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_c6d07976-5fc9-41c7-b2e7-6f36a33dd957_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_01410a33-378a-41bf-97ae-892d903aeb21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_3ab2929c-6920-4b1f-b072-b005c975e516_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_d7e8535e-93a8-4a9d-9b64-2ba233dca901_terseLabel_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment pursuant to terms of the separation agreement</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_label_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_documentation_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:href="pfe-20210404.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:to="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_69470983-1e74-4347-8088-b0591fd9db29_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da1272b-1b32-467c-bf84-99bb327a9b4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_49f88fb2-4467-4176-83b2-ec536cb98a5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_de8fb441-a179-43e4-828b-f54075730512_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_00a9bd48-510a-48a2-9f46-cbb7df3b686a_terseLabel_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract" xlink:href="pfe-20210404.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract" xlink:to="lab_pfe_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_729d90da-78a9-4bee-82ef-ed14bf21a85e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e8548ecf-3ef4-4fdf-b508-1386a43602d9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_537eaac1-55ec-4fbf-9d98-d564bb7f7a89_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs [Member]</link:label>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:to="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_7f1fac93-f84c-455d-ab43-926a36b460ff_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_68a26f28-96d3-420f-978a-5360ba6b24a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_f54d3462-f4a0-4098-a242-576408a9a344_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statements of Comprehensive Income:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SulperazonMember_a973a38d-d3aa-48e3-8930-0abff99304ff_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_label_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_documentation_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember" xlink:href="pfe-20210404.xsd#pfe_SulperazonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember" xlink:to="lab_pfe_SulperazonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAccruals_551a6604-0162-4a83-8db5-050616d04b50_terseLabel_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_label_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_documentation_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals" xlink:href="pfe-20210404.xsd#pfe_OtherAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAccruals" xlink:to="lab_pfe_OtherAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BraftoviMember_5d8aca8a-d454-45bd-96f7-9726412fd71b_terseLabel_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_label_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_documentation_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember" xlink:href="pfe-20210404.xsd#pfe_BraftoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BraftoviMember" xlink:to="lab_pfe_BraftoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7adac0ff-9a92-4d0e-9b59-75d717590333_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add'l Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9df6a4f9-53c3-4c32-85af-c07a107130c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_8dd28f08-1dc4-4cb4-8781-62c832cc215f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8e646160-f1e1-48fd-bd54-f3e8fc9e2be8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e023964c-aebc-481a-b216-0eb8ef955d32_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_13678000-a3d9-43e3-bdb6-99b9d5cc21d2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0a0553a-3a75-4e05-9e97-969fe8323cbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c42cc836-bc1c-46bf-a400-1f189782189d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_fe3d496e-dfd7-4230-8f39-b05d7e1b5ef8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b06bc617-c15e-41b6-974c-79ce318cc1a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_121602a7-8e3f-45c3-b485-dd159732eee2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedEuropeMember_c5bb5029-d117-4006-bd24-330a82eed737_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember" xlink:href="pfe-20210404.xsd#pfe_DevelopedEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember" xlink:to="lab_pfe_DevelopedEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_55106adb-ada3-4ed5-a370-3d6f11459d59_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_cf237605-091c-47ef-ad11-687379aa8983_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_5a1b8c55-b98e-4304-a1d5-3e38667e8d9d_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c88ef96a-7ee9-4ce9-8b9d-df3425cb4e98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_862aa8f8-1228-4166-9dfa-50eb5b9c03b4_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statements of Income:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Income [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_96150033-4b0b-4f8a-a138-84a4aaaec647_negatedTotalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_6813cded-912d-4420-89fd-638e04ae4907_negatedTerseLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:href="pfe-20210404.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerVersusZydusMember_23b38976-5431-427b-90e6-d101767ddd59_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_label_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_documentation_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusZydusMember" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusZydusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusZydusMember" xlink:to="lab_pfe_PfizerVersusZydusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb85dd98-6a68-48e4-8131-495d74abc858_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84137536-3cb6-40bd-91aa-1691c98e3906_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_379303c4-485f-446e-918d-5e6f9ef8af8f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_d0ff1cac-1530-4986-ac5f-9b121baad902_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of expected costs to be non-cash</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:href="pfe-20210404.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_9678a2bf-1758-487b-b126-1115c4fa2eac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Disclosures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_8591cf14-5192-4f68-9138-655db5d1576e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_de9d532b-341f-430f-a4d4-2a7c8e204972_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration costs and other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0a4736cf-f07d-488c-9ee6-b4862bddea96_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_63af0f51-1496-455c-8e3c-e7c5b0f56fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a10a30c0-ea50-4bc4-8bd7-13aae77e3dab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_b8d1d22f-55af-4421-bc33-047dbb5b5f18_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PatentInfringementMember_d5ee5b92-7d75-415c-b7ff-ed2dc0cc3773_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_label_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember" xlink:href="pfe-20210404.xsd#pfe_PatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember" xlink:to="lab_pfe_PatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a7fce629-8d71-4f48-8e22-519ea06d7045_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_94320126-dae7-4381-8eb3-c730ea38e89f_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_label_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_documentation_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:href="pfe-20210404.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:to="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_14b74ab6-f029-435d-afae-abc4403b31d9_terseLabel_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_label_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Settlement Contracts, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:to="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a87156b7-2d19-4365-90bf-0d9c40d8d310_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1d2f8ade-6852-47d3-bcfe-b762f50059fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b5e2625d-c049-43a3-8e42-cbe47879cf66_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accum. Other Comp. Loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cf507aa3-09a3-4972-a843-6c486214eee9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_704895a6-29a4-481d-a6cb-f407e5996728_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_694a8849-c9e4-4e32-86ef-ca7c8fccf0c7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_28083c00-32bc-4cc4-8f83-0e7db8980b9e_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses on asset disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_815fe93f-f8b6-47c2-a093-197183320e69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_b217a920-d1cc-461d-a420-fcbdfebf8ef0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_62635042-8ed0-4836-843f-6298d5abddd4_terseLabel_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for disclosure of proceedings under environmental laws</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_label_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_documentation_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:href="pfe-20210404.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:to="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_e16c3cfe-e5d8-421f-bc5c-d2c63b9962d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2e1b03cc-0c5f-4b21-af9d-3edbfcf9adc3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25506814-d23f-4354-8668-00768a6da4d6_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_78ea8756-1c44-44b6-a87b-afb2de5acb3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemAxis_ca623e26-ec29-40c8-9ece-0fbf494a4337_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_label_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_documentation_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis" xlink:href="pfe-20210404.xsd#pfe_HedgedItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemAxis" xlink:to="lab_pfe_HedgedItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_26bdef26-1f40-4725-9ac9-4e0243113e84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_a2d9bf67-00fb-42b4-ad1f-df03869cf74d_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_label_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_documentation_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember" xlink:href="pfe-20210404.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInternalMedicineMember" xlink:to="lab_pfe_AllOtherInternalMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_a80e94e8-de20-4ab9-ba92-3b8e087c1c4f_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:to="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_58fadfed-d708-4867-b7b6-78f7ea106b86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, period increase</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_8cc2eda0-1759-4695-a4f1-adaf02cd515b_terseLabel_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20210404.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_35b0a1de-6df8-41d9-a814-491712f1977c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_d15c3f23-c7af-4dd0-945f-71836e81d3de_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BesponsaMember_f1eb0537-e95e-439a-8aec-1734de646d92_terseLabel_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_label_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_documentation_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember" xlink:href="pfe-20210404.xsd#pfe_BesponsaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BesponsaMember" xlink:to="lab_pfe_BesponsaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_8c5400da-762a-4468-9b08-c078ebd2a0cb_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8adf010f-aee9-4d0a-ac32-952134c90d33_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_52a14157-306b-40b1-ae8c-faeca3a689a7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8074e882-fc3a-4ddf-875d-8892fc7b4cf2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_b83a9c4f-f636-4651-83d6-d0f87bdfe4da_terseLabel_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_label_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_documentation_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember" xlink:href="pfe-20210404.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FocusedCompanyPlanMember" xlink:to="lab_pfe_FocusedCompanyPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3bf21087-e4d5-4e45-987c-764d97431a3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_ddbdb8be-74cc-42c3-af3c-d75d47f8c41b_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfLawsuits" xlink:to="lab_pfe_LossContingencyNumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1abb9862-adc2-4042-bb3d-19fccec6ed2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1efd49f8-13c1-463f-b266-fd2cf4c0f95b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1cb7863e-3cd6-4a23-9f93-9680cf00ec85_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e7cf3367-201e-4691-8abd-59c3ab487aa1_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_296d62f9-7c40-4539-92be-196283b9506d_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_42543383-f921-4208-8d85-269de771493e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_43cfeb3c-1924-4b9e-a2c2-7b049663aa49_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Equity-Method Investment</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_72c893ab-2ee7-44c6-948c-13c740a047e3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_f519f75d-e91c-4bdc-a6ae-7d76ac328eb8_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Balance Sheets:</link:label>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_39c2bca0-deb7-4e6a-a615-e89a5a920321_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ada6a3f2-fb82-4b42-88c4-4f59297d8759_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c47f5bc8-aec8-448e-9051-47769251e8dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b2ccb247-f493-4e3f-96cc-12f987427dd3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_80e1db62-68fe-4830-9a3a-ebb58bec1598_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon, expired December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_197eb778-fbbd-4bfa-9fab-778f54c15c1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_35538c84-2ade-4afb-9cf2-73134d816b5d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_234a8c15-a4d0-4bb3-a284-28d660bcf74f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_88ee7603-efc4-4bba-9881-90468458661d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c783614c-aacc-4137-9ab3-d83f5b8654b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c2b3b897-e6f0-4c08-a879-26bcdf2293ab_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CostReductionInitiativesMember_070523b4-7993-4ef7-b571-d18633ed8d89_terseLabel_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost reduction/productivity initiatives [Member]</link:label>
    <link:label id="lab_pfe_CostReductionInitiativesMember_label_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Initiatives [Member]</link:label>
    <link:label id="lab_pfe_CostReductionInitiativesMember_documentation_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember" xlink:href="pfe-20210404.xsd#pfe_CostReductionInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CostReductionInitiativesMember" xlink:to="lab_pfe_CostReductionInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_64021112-57e6-4135-a3a8-20ce2b6c19ff_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8619918b-81e4-485a-ada0-e6deb5849b09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_47d0a170-6134-4bdf-b43a-0b8bde184a1b_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_6e1f945d-d5fd-4c10-82bd-8e4cfb8bc68d_terseLabel_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, principal amount</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_label_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:href="pfe-20210404.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:to="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_e1235d75-535d-42ed-ac14-60c17ab3ed60_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend received</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LorbrenaMember_61a5bb44-ae5a-4312-92a7-27b9433243fd_terseLabel_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_label_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_documentation_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember" xlink:href="pfe-20210404.xsd#pfe_LorbrenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LorbrenaMember" xlink:to="lab_pfe_LorbrenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_5b51a642-5929-4d8b-b066-bbd3be61cfb4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_32c31cab-8fb3-45c5-a064-2b63776864bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d463f905-56f0-44d0-be83-f5cd4b64d59e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c5844889-a7f8-4eb2-9750-0d5a378a9d0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_1098fce7-77da-44cd-8e42-cfd711e5e4ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_39d51104-4dc5-4738-b22c-227855c28da1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_8d91235a-00c8-4f3b-ab0d-f2f8adf04cf1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_833edffa-9d20-476c-bcd4-c90d967b9abb_netLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges" xlink:href="pfe-20210404.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20220.250Member_66a9989a-2c65-4ab1-9133-156cfe25a84b_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes due 2022 [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_label_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member" xlink:href="pfe-20210404.xsd#pfe_NotesDue20220.250Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20220.250Member" xlink:to="lab_pfe_NotesDue20220.250Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e3b4baca-76ff-4575-b3bf-57e9c9f2b7d5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2db88d9f-8d24-4e9c-8574-ac60cd78b13f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_17037102-75ae-49f1-b8aa-bd2101c735e9_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0a04dc84-1c4c-4772-9919-057f1c13a23e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_73bda468-4648-41d8-98fc-a505ccba9efe_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairment losses and downward price adjustments on equity securities</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_324e5961-4bbc-449c-91c9-94d807b2af7e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bef22998-8f8e-43ca-b9be-68691dfb9947_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_e96b5a2a-02c2-404a-9187-cae2c273ca21_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other I &amp; I [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_label_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_documentation_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:href="pfe-20210404.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:to="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a871f770-5069-42ae-a7f3-21cf12799e72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6b4358d1-34c2-4763-ad10-3a4c1c3434d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_f37b4f92-4f8d-4674-978a-86a86fdae788_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from effectiveness testing and amortized into earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c23f3e45-277c-4566-8044-30330416209d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VyndaqelMember_56c2bbde-dd5e-4444-be9b-9290fa4a8eac_terseLabel_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel/Vyndamax [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_label_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_documentation_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember" xlink:href="pfe-20210404.xsd#pfe_VyndaqelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VyndaqelMember" xlink:to="lab_pfe_VyndaqelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_eb1f6584-7410-43a2-906e-0788feaf89b0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_9edecc19-96a2-4bea-a9ad-abf463e00e47_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from collaborations, out-licensing arrangements and sales of compound/product rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_label_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:to="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55717077-23a9-4827-9741-58c127c109f8_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NimenrixMember_2f60590f-7f16-475f-949a-5d738ae8b618_terseLabel_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_label_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_documentation_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember" xlink:href="pfe-20210404.xsd#pfe_NimenrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NimenrixMember" xlink:to="lab_pfe_NimenrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EmergingMarketsMember_da9e3126-6e76-494d-aa4e-ac70384a080d_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember" xlink:href="pfe-20210404.xsd#pfe_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember" xlink:to="lab_pfe_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9d1a7ffb-84e6-4d6d-9e7c-2b1d85fd7bb7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f0d19d26-7f3a-4483-a213-17a1c76e3961_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e5042829-fafa-4743-aaa7-3f8ce6a625dc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_73f85d31-768a-4499-a463-c8a95786dd72_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_da59c459-0f67-462c-8da2-ad8db805edda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87ae810b-fd1e-4042-91d6-596e995023b1_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost/(credit) reported in income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_881a83f6-5dae-4119-b4ad-ffcf491cadfd_terseLabel_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity cash equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_label_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_documentation_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents" xlink:href="pfe-20210404.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldToMaturityCashEquivalents" xlink:to="lab_pfe_HeldToMaturityCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f259c969-25a0-466e-b005-e841cf13d298_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d1438830-8d06-4b1a-a413-67f0b87a40f1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dd8ea207-df5e-4eb9-81a3-19adf5f7a9dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_9efbed21-e9b9-4fc5-b3bf-0965b8bacd3e_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_13d0997e-2015-46aa-9e6c-6d917da4b8ce_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dde4797d-3a54-4a7c-a490-d6213dd63f46_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InflammationandImmunologyMember_8ac1c333-7e9e-457e-addb-431888d347af_terseLabel_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology (I&amp;I) [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_label_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_documentation_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember" xlink:href="pfe-20210404.xsd#pfe_InflammationandImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflammationandImmunologyMember" xlink:to="lab_pfe_InflammationandImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_34c82b02-9dd5-4a1d-9512-c7de80d7ac26_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_31491b88-e973-4973-b92a-0d22233d59b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_3420377f-511a-4198-85df-dbd1aba2d501_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9227a32b-f6a7-4e92-ac90-12b27afd06aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_c6fefefa-0da2-4fac-bcf9-881ad8031839_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_6c0c8e59-cce7-4449-9c97-e23e8e747734_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_14373bc5-be73-43bd-b1b6-e2f7ae073a62_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_987d1880-0893-4306-aee5-c8ced670590b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_88850f30-7f12-4957-9983-5aa0c7700daa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_4268da39-e3ea-47cf-8a8c-fec1fdc1687c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_7a597286-ab0f-47c2-ae56-79f29c048dfa_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV equity method (income)/loss</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_label_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:to="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_2d527583-b7bd-4e54-9b53-cb7c37c385f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_3bf125f4-814f-4f0c-88fb-db9945b6e1fd_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:href="pfe-20210404.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_d79970a5-5f22-4949-b092-f3bc505b63a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_f9fbd8ae-0cc9-4fbe-8f3b-36697fcc8584_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember" xlink:href="pfe-20210404.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember" xlink:to="lab_pfe_DevelopedRestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_391572f1-e4c0-4782-8c77-a3cc593003e4_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_31cce517-5ab5-4215-8887-5a88b90050bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustments on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_aed55cb4-0b76-47e2-8116-0d70ae90f54a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_451ee641-0afc-408e-b4dd-dd770fbcb18e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans: actuarial gains/(losses), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7ec45ddf-b7b2-4f4c-99c0-c79bfbc2bf27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_593a244a-9fb9-4e02-883b-c17d40089d0a_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_d889921b-97fb-4194-9cc5-d96eed51c77a_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_681d7f21-3c6a-4275-b748-f3e1c77e4084_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Not Designated as Hedges [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4d0db2b2-926a-4998-afea-3d8727834589_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OncologyMember_2641e1a0-eff8-4b4d-be6c-5234b8c3eee3_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_label_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_documentation_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember" xlink:href="pfe-20210404.xsd#pfe_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember" xlink:to="lab_pfe_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_73c4f136-412c-46ec-b704-49f4be8c115d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$512; 2020&#8212;$508</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1c53c149-a41b-411e-b704-c0f17e357d43_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Preferred stock dividends&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_8efac056-bd54-4b47-a111-6d15102cb081_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_6f9845e9-6ab5-48ed-89d7-0d7db59c1eae_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2bde9e7f-2e30-4550-90d5-693e04d27728_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_15900579-011f-4cb0-9915-3743023b792c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareJVMember_0b6ebd15-67df-4e23-8b62-440ff7259854_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareJVMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareJVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVMember" xlink:href="pfe-20210404.xsd#pfe_ConsumerHealthcareJVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareJVMember" xlink:to="lab_pfe_ConsumerHealthcareJVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_786357c4-562f-42f8-b474-c041269b71d6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2cfeeb2-5c12-48c9-bb48-c2f2cc27747e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b6a7e8c2-46a4-46bd-bf68-46d7e0696831_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_daa318b6-384a-4aad-a997-68f8b4af8e70_terseLabel_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Vaccines [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_label_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember" xlink:href="pfe-20210404.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherVaccinesProductsMember" xlink:to="lab_pfe_OtherVaccinesProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_a2860dc9-3d7d-4a4f-bf16-7ee315ad6fec_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_5123454d-338f-4883-a74a-11c057de09d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_8ca6d050-5ff7-41a6-a2cf-ad4468228e12_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_3bb49dc0-9be5-41d0-86cf-affdcb9a75d7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_43b1ede6-a174-49a0-9966-b51e9dff64cc_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_cf37f87d-5320-46b9-8a36-f2302eb7fb7d_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReFacto AF/Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember" xlink:href="pfe-20210404.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember" xlink:to="lab_pfe_ReFactoAfXynthaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_70747816-ac4e-4f13-a9cd-7ef27a9a8da6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f4ed5a7e-fee3-4ee7-9381-d74efa1d0ec0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RuxienceMember_a35a3ad3-7134-4a08-bf49-d04233baa7eb_terseLabel_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_label_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_documentation_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember" xlink:href="pfe-20210404.xsd#pfe_RuxienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RuxienceMember" xlink:to="lab_pfe_RuxienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d38e73be-dc46-4463-9702-2e3c35246309_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_22ae245e-9831-40ec-a69f-12190f8dd42a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_c0c4d5bc-6d65-4395-b4d6-ca2d6969631b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6b459844-c284-48a4-b7bc-2b6277d9b373_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ff300363-64c3-4a62-aa9c-b1260e37047f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_06bc5645-a758-464d-a1dd-6389c8d62552_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_90d11ff6-9ec8-433a-b3a7-c9c1d53b7ad2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_50091208-f790-4d81-a9d8-269d5ba60522_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e1af897c-070f-4343-a48f-85a2824d015b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_427e54e3-3325-4884-8229-3b1cd76caae3_terseLabel_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net receivable position</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_label_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_documentation_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:href="pfe-20210404.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:to="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_8a88e7b1-0125-4bfa-b604-9d702d92d521_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_label_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_documentation_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusGenericCompaniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusGenericCompaniesMember" xlink:to="lab_pfe_PfizerVersusGenericCompaniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_413c2069-7afe-451f-84f6-33c5d54fd777_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9df9afcb-f345-4f28-bd6e-e18916389f00_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_6bfdd066-5cc9-4ffa-bfad-cf0d0cbb2d48_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_16e13319-6270-4b1d-8210-fdf783a05c1c_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_f8f21a9b-c22e-4335-8d15-37d003cafb78_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7c1264ed-cb73-45db-8e6b-6a3a8d4d8ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e10c5e9-00ff-49f4-9248-a8a8348e48c6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66ba0a32-1caf-437b-8c6e-85a9569353f8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract" xlink:href="pfe-20210404.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherFinancialInformationAbstract" xlink:to="lab_pfe_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_483a737e-bbb0-482a-82fd-ccbe5f0bae08_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e0fd1eda-1267-4262-b506-2bcd0051a226_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InflectraRemsimaMember_bafaa29d-88a7-4d48-8709-9810e6b1be03_terseLabel_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_label_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_documentation_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember" xlink:href="pfe-20210404.xsd#pfe_InflectraRemsimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraRemsimaMember" xlink:to="lab_pfe_InflectraRemsimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_d200108b-a6dc-479f-b6fa-ac1fb1ed1911_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_c684923d-c03b-45ea-a743-24668f3c1dfc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c3bc558a-a2bd-484e-86fe-bc5e8ddde2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_ca9c9f74-8edc-49df-82e5-7052f6d6df1f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_58e345f1-3dfe-4028-b488-99dc4e27a4da_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_95f3fbfa-ed8d-4d5a-ab5e-e5d0ab31ffc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_80cd6801-6f70-4397-a700-faa5e83cc1ef_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d4108be6-56e4-40d1-b91c-22208e38b1b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_cb4539cf-bc28-4d8d-8388-a73ac80da1a9_negatedTerseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease due to foreign currency translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:href="pfe-20210404.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:to="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_48184a99-871a-43a2-88cb-eb782b50db45_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_c17fc9ed-fc3a-435c-9212-27733f0a53a2_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a87785a7-e1e2-4a75-b348-7b064b2ef245_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_352e3604-5297-4a04-bd2d-32bcee3c5ce5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_82d80e55-b655-4c66-9a00-6b3d98d8bab7_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_e8039d4a-0720-4ec9-81e8-85229e36996e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Financial Information of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2a0f256-9bd6-4d9e-a10f-baa33e5827f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8a2a06a3-a935-4e6c-9742-ea514bef099a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a11fcd75-b0d7-4753-9997-b12d5d2711a2_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherPatentInfringementMember_20308e09-16af-438f-a211-b04a27f7f9dc_terseLabel_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_OtherPatentInfringementMember_label_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_OtherPatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember" xlink:href="pfe-20210404.xsd#pfe_OtherPatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherPatentInfringementMember" xlink:to="lab_pfe_OtherPatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_28bece49-b686-439c-85ee-9b96af86c1d6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bf5e56c4-6c39-44e1-bdd6-72160c8b75b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a3680990-9a2b-40a8-abe7-bbb710f56627_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_67ff4b91-4b5b-4acd-86cf-4f16c7036c8a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments and equity-method investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_27237025-61a2-4562-b3ac-1eba0fab1295_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2445dc2a-54d7-452a-9fa2-afc80343fbcb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_2855bcc8-6b0f-4e06-ab68-1d5f29f71469_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_404b8e53-212a-4a42-b004-860fdfc38202_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_aeb6e11d-e4eb-40ec-bd05-293d8c7a9b62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_07aa137e-9afd-4efb-ae82-7a4d3e4b4727_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0f317563-9025-45a0-af92-ffdb2d95a649_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_922d0bb5-5e0e-410b-befc-b04b76627810_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_b7ecf7cd-35f6-43da-81e2-c28a86003ca7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_625da922-3df4-4523-a6e8-804411c7cf84_totalLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_1fd0b4ac-9868-44b8-9c70-f01739c923d8_terseLabel_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20210404.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_1e2bd4ff-8983-4865-81b8-4e40122a5f42_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_9552e3b9-d429-407e-a14b-410615bec22f_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants other than main defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:to="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_374c7ef9-a222-45bf-9e8d-b0fd232d36aa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1512d908-05ae-4e18-a2f0-d542049bfe9b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d8efc7f5-3193-4527-9640-b7f25c023a5f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_d770fb62-ec79-4537-b3f1-97e910be718f_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_label_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_documentation_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember" xlink:href="pfe-20210404.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingOptimizationMember" xlink:to="lab_pfe_ManufacturingOptimizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_d1aff3bb-e9e5-4f36-b41b-c1edb7ddc425_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$3,676; 2020&#8212;$2,002</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_9e0692ac-1af9-4cf9-b50b-2bca0580302a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_684aed2a-6b05-4659-8340-0eb550322970_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_a137d27b-261d-4c44-9438-4896d461ff71_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_90f5f230-bd6d-480b-8bbb-579f93033cd6_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_47d47c9c-fdb0-4d97-a6de-1c909ed8f78c_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:to="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_7a561d14-0b6b-4bb0-bdd9-8570c11dcc51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax loss expected to be reclassified within the next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_f5fdcedc-9a69-43c5-b7f3-1f436a662d8e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_b677dc43-3bea-40e2-91b3-953ff663c448_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2027 [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20210404.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_65c77f05-f94a-4762-bfe6-dacd436aa9f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1c56ef8e-a61e-4b3c-adbf-fa0499847b50_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_55dd7b48-accc-485e-9bda-662b2b9b409e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_cb4cc67b-3470-4937-ae33-1760ef05c1d1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_9d14aca0-455a-4a6f-bad1-e7038c75bad8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5f4f8327-c14e-4c6d-ab30-8155c38c0324_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_814855c7-6b4c-47a6-80b7-88cbf1375d60_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e385bbaa-532f-4aad-b313-a42ff5773063_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherHospitalProductsMember_bff4aa4b-7db4-4ebb-8d9f-6db5ac71f48e_terseLabel_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Hospital [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_label_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember" xlink:href="pfe-20210404.xsd#pfe_OtherHospitalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherHospitalProductsMember" xlink:to="lab_pfe_OtherHospitalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BosulifMember_c8fe7ddd-b1f8-43b6-8074-ca9acf726aa7_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_label_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_documentation_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember" xlink:href="pfe-20210404.xsd#pfe_BosulifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember" xlink:to="lab_pfe_BosulifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_b211ac20-9dd1-4c29-9bfa-19b318e05ad1_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_c4a27053-6ad7-44de-a929-cd0636d29e8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) on completion of Consumer Healthcare JV transaction</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MektoviMember_9c12a2a7-91c2-481b-a74a-ef65eaa3cc18_terseLabel_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_label_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_documentation_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember" xlink:href="pfe-20210404.xsd#pfe_MektoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MektoviMember" xlink:to="lab_pfe_MektoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13b2400b-fc58-46c2-8b66-ba543e9d4fee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c79c7e73-bb4f-4dcd-8fca-df9aaf9e223f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PristiqMember_b22c65aa-5624-4515-92b9-5c7628fd47ff_terseLabel_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_label_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_documentation_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember" xlink:href="pfe-20210404.xsd#pfe_PristiqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PristiqMember" xlink:to="lab_pfe_PristiqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_f63330fe-0a5e-4215-ae4f-1a79167ce37d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_5ba1e2a0-151d-4419-8800-8f22d6cff673_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_825a8b6c-e41f-4927-97c7-44422105e2ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c3ceb229-3080-4c4c-b544-6b097ad98d8a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f346379b-ce75-462d-9116-d487ad7c8d57_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_91ad79a8-9548-471d-95ad-b079c06c6bfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains)/losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9897c247-85f2-4be0-ba69-1fc9ce867b1c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bd925a9c-0f5c-454f-9620-fb8be6b0590c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_21bd3f0c-dac0-4be3-b23f-79ffe158940e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2e905268-9800-451f-9782-b46fef381069_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_37b145d0-cfd2-46eb-8bb3-bc335738ece5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_41761359-fa08-438c-88f3-e1ec1745e43f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_562e66a2-2c24-4395-b9ab-b943c27fd161_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_d1270494-efe7-406e-942d-f5cf4fd510c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51e519a7-e869-4837-9a3d-9aa3a954be3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00e294ad-0570-4e0a-b195-20e51106e5c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_fa477eb0-7891-443e-a1a6-4e03f86e55dd_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a990db21-ce09-45ee-8d8a-ea6c5a3fd2c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fdf9902d-6d25-49ad-bbb9-65d222ebea5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_45409130-3258-4bb5-8798-3653ef60c744_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_051e17ff-b5a4-4de2-8387-ab627773230d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b8363f-7b00-4ffd-948a-71a557838bb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_043b27ee-b020-4a3d-b988-4a914bb9eb61_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_93c8e3d5-c70d-4471-813c-b5c3260b21d9_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_c9598478-eea6-4005-8ea6-24a73ca10dcd_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity [Member]</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f76ea1c-7cc8-444f-96ee-ea35b88cdfde_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7ed058c0-c7c2-48af-afdc-70d058cb908f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BeneFIXMember_1a4044c9-a1e8-4dab-a3ea-6e52d5bf462d_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_label_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember" xlink:href="pfe-20210404.xsd#pfe_BeneFIXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember" xlink:to="lab_pfe_BeneFIXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c79512d2-4399-4639-9662-0dfa5d5db2a2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive common stock equivalents (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_88c4e78d-7b1d-405b-8e3b-b9af5977afa9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_b6a1c205-abfe-4d61-a030-5e1a364c0dd7_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_label_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember" xlink:href="pfe-20210404.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceRevenuesMember" xlink:to="lab_pfe_XtandiAllianceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_65dfddae-654b-4f24-b7e7-80272c06945b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Classification Type</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_53cb9953-5d58-4751-9560-63f5f31d01fa_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_79a90fbc-03f8-475f-9610-873eb2294644_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a520af5d-a8e4-4888-a1dc-dad0065eb3cd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1ed75f31-6701-4d46-8e3e-f9ce819c4a1e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_be25f094-6747-4432-85a3-cc98d45db990_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XeljanzMember_ed437bdf-fc9e-47e4-82ef-8ee5bba4517b_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_label_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_documentation_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember" xlink:href="pfe-20210404.xsd#pfe_XeljanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember" xlink:to="lab_pfe_XeljanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b8ad00a9-ddf6-4eab-822e-e66dc45d1cac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InlytaMember_30d5446c-fdd3-4f33-8063-99c0a3950378_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_label_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_documentation_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember" xlink:href="pfe-20210404.xsd#pfe_InlytaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember" xlink:to="lab_pfe_InlytaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_4fb11cd1-9d8d-4382-9ade-4394c07be0b3_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:to="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_79774f8c-a307-4a90-8d0f-7c87badc92ba_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BNT162b2Member_b27c51c4-d243-4d62-8e2d-72c534682eaf_terseLabel_en-US" xlink:label="lab_pfe_BNT162b2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BNT162b2 alliance revenues and direct sales [Member]</link:label>
    <link:label id="lab_pfe_BNT162b2Member_label_en-US" xlink:label="lab_pfe_BNT162b2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BNT162b2 [Member]</link:label>
    <link:label id="lab_pfe_BNT162b2Member_documentation_en-US" xlink:label="lab_pfe_BNT162b2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BNT162b2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BNT162b2Member" xlink:to="lab_pfe_BNT162b2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_13d8f397-8e97-4367-b3ff-9cf405db3373_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, less accumulated depreciation: 2021&#8212;$15,105; 2020&#8212;$14,812</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bf22fac7-6c61-458f-befc-79c3b6f1cfc5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_51144496-b0ba-4d3d-8b6e-eec72c42a9e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_b812c756-00ab-46cf-b6be-52f302364c31_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7903c20e-ffd1-4d61-94b5-2509a70305b9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e4a3877-609c-4bda-ad31-1558d0702015_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ba5e33bf-b6b4-4751-9fcb-1d4bbd8db892_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_dea7741d-3cc9-460a-8dce-4f6dd4132bd7_terseLabel_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_label_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_documentation_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember" xlink:href="pfe-20210404.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherRareDiseaseProductsMember" xlink:to="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3d3b9cfb-7159-4204-aefe-f4696a89f9a5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d0f9796e-77ba-4d91-b51e-2fa2e30f7d2e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_6f5bd20f-5ba3-4442-9379-49e6e92a32b9_verboseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:href="pfe-20210404.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_f083674c-0519-4787-998d-bee1371121dc_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_f10785ad-c6f6-48c5-96f0-111732a92fc1_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43a4fa15-611c-48ed-9a0e-894b68cb369e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_90298660-1a52-40d1-aca5-a09565337f59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_940adb81-d08e-479b-afcb-40100d7bf45d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_49e90c10-4912-4290-9554-d2d81b072bd0_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_9124f495-ab83-4a13-8745-8703fa6d4d40_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar 13/Prevenar 13 [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember" xlink:href="pfe-20210404.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_0580a1f1-3118-400b-ad31-b180c8b7e795_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VaccinesMember_ac453218-8385-4ca2-b179-aac9e5f3fedf_terseLabel_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_label_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_documentation_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember" xlink:href="pfe-20210404.xsd#pfe_VaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VaccinesMember" xlink:to="lab_pfe_VaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_41431906-1259-4351-b870-c7ff8168681d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f523a9cd-b67f-4796-baa8-1e9665e107f2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b020781a-4497-42ef-afeb-d55f7c7bffa6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_c3343e77-dbb5-4c87-98c0-dfa4b72bf486_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_7a9f46e0-bff8-4926-a1d1-6a6b93c86952_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_label_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_documentation_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:href="pfe-20210404.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:to="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9a8b88f0-2cd0-42c1-b232-2ff13adfbe6a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income/(loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4028f06a-c619-4fbf-81f5-55fe51de8d5c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_edda425e-a055-4aaa-8b5e-008c5c3e44ac_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_4bd23524-0bb6-4ea2-9298-49ec50b186fc_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_ece3825e-cb30-45d6-a4e9-e2395a2c0e79_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RetacritMember_f72b6940-fba0-474e-98e7-3a40d4ada18f_terseLabel_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_label_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_documentation_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember" xlink:href="pfe-20210404.xsd#pfe_RetacritMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RetacritMember" xlink:to="lab_pfe_RetacritMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_52a5af7d-9ee7-4bc7-aa1d-c92db76da4ce_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ChantixChampixMember_87e94737-0422-4729-980b-189626a6bebd_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_label_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember" xlink:href="pfe-20210404.xsd#pfe_ChantixChampixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember" xlink:to="lab_pfe_ChantixChampixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_affa26e6-8136-4707-9d7b-a04c0e680307_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_a78a01ff-f43d-4b52-9751-a76bbf2261cd_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d878d8c5-4a60-4eb0-85a2-b42c64b00bd1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_b43159d1-609b-4d70-95b6-a2c53ee51307_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining period of hedging exposure</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_3e3ce748-53d8-4373-ba94-78135d361ccb_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_376cb003-3696-4240-9f46-5d625236f6b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_de14602a-2031-4550-8d4b-26eec56d6f54_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bab92b27-b0df-4c35-ba0e-f4f06eea3f89_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PercentageChangeInRevenue_5620ecbc-1bff-4a1f-b97b-1deb9f4618fc_terseLabel_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_label_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Revenue</link:label>
    <link:label id="lab_pfe_PercentageChangeInRevenue_documentation_en-US" xlink:label="lab_pfe_PercentageChangeInRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage change in revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue" xlink:href="pfe-20210404.xsd#pfe_PercentageChangeInRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PercentageChangeInRevenue" xlink:to="lab_pfe_PercentageChangeInRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_37f84a6e-b302-4556-a6c8-82cf755a1731_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_e170791e-f2f4-4171-bd2d-30816a89ca7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ffc879a6-250c-4a33-b08b-bde245fabc1d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_71c13755-3357-43b4-81ab-61cc937c4318_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5f023e01-7100-48cc-8ce6-e73f97c04529_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_bfbb8169-398f-40ef-bced-c6e0d0b595b9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid (received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DocetaxelMember_d50d77f4-368c-4a55-b388-c941cd341b11_terseLabel_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_label_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_documentation_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember" xlink:href="pfe-20210404.xsd#pfe_DocetaxelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocetaxelMember" xlink:to="lab_pfe_DocetaxelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_eaa70482-6928-4fc9-8d82-d3fea38241b6_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, within 1 year, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cecf61a5-e8ad-40cf-aba2-069c268ad4cc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7f6c4797-f7fb-4939-9d5f-d1d3d5d1de83_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $.05 par value [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_2b43bf05-2954-40bf-aef8-05198d093257_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_869c3c77-9d4c-4283-9835-9f251f4be6e2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_0932586f-f7a0-4110-a5a1-e7501954e1c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViatrisMember_b26e197d-907e-4ee9-ae7d-c5bdef948fbe_terseLabel_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_label_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_documentation_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember" xlink:href="pfe-20210404.xsd#pfe_ViatrisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViatrisMember" xlink:to="lab_pfe_ViatrisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a50fb7f4-41a0-4809-8438-7629804b093a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_86509d61-2ac9-4bf4-87bb-8159f85d5f9a_totalLabel_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term investments</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_label_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_documentation_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:href="pfe-20210404.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:to="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_db4ecd1b-5e0b-4802-ad77-2f7c2cecc984_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:href="pfe-20210404.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_17b2c966-e438-4741-8c99-ae2e6ed9653a_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_b7da9a18-9d4e-40eb-825c-33e0242c4dd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_aeac7714-df3a-423b-9e01-deb869559b4a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_f163c3d6-ce92-46ff-94c6-64b529e8e66a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits):</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_51aaf05b-74a3-462f-8c0e-746b295a457a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6c5e26f1-a027-4827-a9a9-79f44aa3e6c2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_e6acb868-d8fe-4659-9344-ad4853c3d327_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_d37bfd19-999e-4ad6-95d0-ae19b1c28dd8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OID [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ba047fe1-44ef-405f-a5e6-7ded0b7dafc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_4d66d4a6-b289-453b-8004-b7e61560d8c7_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_3f025586-7945-4365-9bad-456c4ea1442b_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f57cbef7-19ce-46df-988b-92d7fdb79afd_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_ae3a3070-8c50-4460-8c6a-be5648b7ac49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AccruedRebates_20d159e1-9dac-4988-bdf5-6cd3ab8eb11a_terseLabel_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_label_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_documentation_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates" xlink:href="pfe-20210404.xsd#pfe_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccruedRebates" xlink:to="lab_pfe_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2616fe95-d1f6-44ac-ad45-4b1069a1af7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_63f0011a-6af6-4ef6-8e21-a45939ef378d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_39fed215-1452-4d2e-9306-15348de5f270_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HospitalMember_032c2d57-0b63-47c3-a324-42dfdea8907a_terseLabel_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_label_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_documentation_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember" xlink:href="pfe-20210404.xsd#pfe_HospitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospitalMember" xlink:to="lab_pfe_HospitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bcd25b1-d5dc-4f50-9ead-059f86953655_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_3344cdac-ad8e-4c75-863a-b62f8d75bd2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_3b0ec5d9-f174-4ddc-9cec-3ba5d7c0ebd0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_53ae65a2-dcd7-460a-a9ef-227c967fe8e3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_685697b8-c4ae-4a75-8a0b-ae5a5dce88f8_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyDebtMember" xlink:to="lab_pfe_ForeignCurrencyDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_f79df857-9a3e-4ffd-8a7c-b7ecce5ca287_negatedLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:href="pfe-20210404.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechMember_5cbfd932-39d9-4e34-bba1-064db512d575_terseLabel_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_label_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_documentation_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BionTech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechMember" xlink:to="lab_pfe_BioNTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c781c657-df33-4f8e-85c9-676e4e78d932_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_add35d94-99ea-42df-a346-a6bb5ba1e29c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged item</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_56482453-dd0d-4111-8d80-73863a1aec1b_terseLabel_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued rebates and other sales-related accruals</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_label_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Discounts Accrual</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_documentation_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual" xlink:href="pfe-20210404.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndDiscountsAccrual" xlink:to="lab_pfe_RebatesAndDiscountsAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_18b73537-8c55-49cf-a055-05319088a3eb_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db6e5884-42ca-45f3-9676-007de3b35e05_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f6b7971-0178-47b5-9799-a1f315bbdc2e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c712d103-7ab8-486c-9c00-781059d33ecd_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_6838e3b0-6e8a-402a-9402-8b02af66f395_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SutentMember_db72328f-c716-4a87-8a61-8a02a5afd96c_terseLabel_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_label_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_documentation_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember" xlink:href="pfe-20210404.xsd#pfe_SutentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember" xlink:to="lab_pfe_SutentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_bd085990-4467-48d3-84be-0f9325487130_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_7f5ddf53-32d1-4d3c-9725-91b648d09574_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d80654c0-4970-47c1-ac6d-635556727a7a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9672f24f-5822-44e0-a9a0-6a73a492da95_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fb92b657-3f45-475f-955e-13101ed3e042_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_932ecde8-4e16-4837-a492-4594adc6778a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2373ab33-eebb-4f20-b300-d4798d907e44_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_e23273a1-7131-4c03-8604-c31d32308ea8_terseLabel_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_label_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember" xlink:href="pfe-20210404.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PneumococcalVaccinePatentInfringementMember" xlink:to="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EliquisMember_dace6125-0da9-4377-8168-bbea461fddeb_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_label_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_documentation_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember" xlink:href="pfe-20210404.xsd#pfe_EliquisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember" xlink:to="lab_pfe_EliquisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherOncologyProductsMember_cb7f3e8f-83bc-4e9e-bb0e-68e1908ec616_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other Oncology [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember" xlink:href="pfe-20210404.xsd#pfe_OtherOncologyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember" xlink:to="lab_pfe_OtherOncologyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca6f49ff-195e-4fde-8b56-cf6286c1c558_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_631553c8-5a21-4586-acb0-ad82ac336ef7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c53d69b-0cbf-47bc-b83e-c37bfeaaf88d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b827a62b-e7a2-4a02-8455-0b4f12775f8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2e42d050-3847-4613-98bc-44e3648d6e46_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_d43354a7-743d-43c3-acc8-a1573b0c29f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, excluding the current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c351b592-7f3f-42bc-afb3-2cdcefd5af25_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_03929a77-fe18-45dd-8b54-d7cf4b0bebf3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_976effd1-e4b3-490d-bcb5-09598b4b7e20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_75d39a6e-2995-450c-a14f-e2b200bf669f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2b527aa2-c4f8-401a-89c5-6d7bf7bd462a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_82477ff4-a7b0-48e5-8a59-945b28109c55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_e012aadf-a23d-4197-8390-f181a25ca4cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b721d227-030a-40cf-8d82-fdeaafa98625_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7cde72d-5d4f-4c1d-804a-be2080484509_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_27f49246-d3d9-44df-b0f5-cbf219ea9c51_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Classification of Accruals</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:to="lab_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a46aac61-e50d-47a3-bacf-693079048e0f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_f098a7ce-e618-4a79-9c17-4bc5e12ce084_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_67525841-7699-4b9b-a9dd-c5a9ccc9f7dd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_051fd06e-6ee6-46d7-9e7d-8e5f00b22f03_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_71c2546f-8e80-4749-8cc5-69aad5b92020_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllogeneAndBioNTechMember_d573781b-2351-4ead-8fea-66aa8bcbeadb_terseLabel_en-US" xlink:label="lab_pfe_AllogeneAndBioNTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene and BioNTech [Member]</link:label>
    <link:label id="lab_pfe_AllogeneAndBioNTechMember_label_en-US" xlink:label="lab_pfe_AllogeneAndBioNTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene and BioNTech [Member]</link:label>
    <link:label id="lab_pfe_AllogeneAndBioNTechMember_documentation_en-US" xlink:label="lab_pfe_AllogeneAndBioNTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene and BioNTech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneAndBioNTechMember" xlink:href="pfe-20210404.xsd#pfe_AllogeneAndBioNTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllogeneAndBioNTechMember" xlink:to="lab_pfe_AllogeneAndBioNTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e0d3186a-1621-4cdc-9bbf-b70bd8106c67_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_9e335bf4-be4e-442d-9851-c4bd970fde2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c6aa1b19-c286-49f8-b163-6a5b3b203f86_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerCentreOneMember_81ed08c8-0456-4327-ae88-67e5c3fe134d_terseLabel_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_label_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_documentation_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember" xlink:href="pfe-20210404.xsd#pfe_PfizerCentreOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerCentreOneMember" xlink:to="lab_pfe_PfizerCentreOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_bf6fbdff-2c79-46ef-9ce3-fe2eb47abd09_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e953864d-b1a9-4fd2-b7e4-8a633c86e8df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_ec2bac35-099e-4528-995b-ecfb34b63641_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ImplementationCosts_a8a95e61-b172-4818-89be-1305af1aa132_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_label_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts" xlink:href="pfe-20210404.xsd#pfe_ImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts" xlink:to="lab_pfe_ImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a5d6a707-a4c2-4594-9207-8ae48ce97a79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5f1d304c-29d0-461c-a749-6946e4b631f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_33d55154-9059-410f-ae5e-ab972fda349d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c0c626e7-bd8a-4098-959e-58cb53493aca_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f67c4a9e-11fd-43ae-a8c4-55b31a055fe8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1dd5bd07-94ac-45cc-8753-d57dac6dff91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_28a1994e-6915-481a-ba9f-f40f7e93c4e5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_4c6b4b3e-49aa-4214-95b9-0e49c0adc322_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InternalMedicineMember_6879030c-b299-4d65-b826-8c7a7cbd18c1_terseLabel_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_label_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_documentation_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember" xlink:href="pfe-20210404.xsd#pfe_InternalMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternalMedicineMember" xlink:to="lab_pfe_InternalMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_32ca1ec7-fc6e-42f7-a735-192c40a5da00_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8cb69ab9-7eed-4d09-a007-5ec50ade6385_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XalkoriMember_a0924fa0-12c6-44cc-b40b-32be04b64fee_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_label_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_documentation_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember" xlink:href="pfe-20210404.xsd#pfe_XalkoriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember" xlink:to="lab_pfe_XalkoriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCashAbstract_05bd8a1d-6684-45fc-ba93-239277c73bd9_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared, per share</link:label>
    <link:label id="lab_us-gaap_DividendsCashAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCashAbstract" xlink:to="lab_us-gaap_DividendsCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b721ecf2-1201-4572-a5cd-5d48bf018caf_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37e74895-2ece-4c01-9358-a9d3d67f54e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_896b9891-a516-48ad-878a-97edbdcdd3b2_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_label_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_documentation_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:href="pfe-20210404.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:to="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_997b7784-2261-4ffd-acaa-939b3cb22dba_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GenotropinMember_9200077c-d5cf-4c7e-8007-0eb72f6268bf_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_label_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_documentation_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember" xlink:href="pfe-20210404.xsd#pfe_GenotropinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember" xlink:to="lab_pfe_GenotropinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_6a98d7ea-d99c-4224-b3f0-6037e634deec_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:href="pfe-20210404.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_590b4ad5-bc9c-4601-ab6e-e91782a98cfc_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_af07ed71-433f-4471-ae8d-c0e6f78f3cbe_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_a4d48c16-eba6-4833-8f6d-69bfd966724f_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_b7ab9d8d-1d27-470e-aa45-b425504519c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_fcd67067-623d-4755-b8c5-e6701b380194_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZirabevMember_2b8ebd30-c23e-4516-8931-47f5a4e528c9_terseLabel_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_label_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_documentation_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember" xlink:href="pfe-20210404.xsd#pfe_ZirabevMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZirabevMember" xlink:to="lab_pfe_ZirabevMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1a4e915d-9438-4c6f-8cbe-11a4e8bdc701_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e913f480-4ef6-4cdc-bc56-e42b188e0749_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_8b27e328-8df1-4499-8c29-233eef214802_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_f785bb16-8af1-4c27-918f-cb76e1d6bc64_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other, net - Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0a8a3892-44a4-4cc5-8e56-3d6cb5508174_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f0af2ba-1dc4-4832-b8b9-286a796dff2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d65a5270-ca09-4859-aaf0-a56645b65c3f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_40240022-7eba-4a30-a18a-ca237393e44b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_49184427-452c-4ab5-9f62-89b0e050840d_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_133e9663-b65d-4d90-86ec-9bff6af680a5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f82a355a-b0a9-47a7-8a9d-23012f5f60c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Plans [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_de4e2b9d-cbd5-4f70-a6d5-99b9c443cf4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_db9ea0e1-12e4-42d5-b6db-699bf8658ada_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components and Changes in Restructuring Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_58883f90-da43-48ba-a161-7fbbd768dfa9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsMember_b16281d8-08e2-4bb4-b827-919ca2c4c2ad_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember" xlink:to="lab_pfe_LongtermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_023b7073-3ee7-4fe4-b49e-aac6ba5c8d38_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_b64a4f7b-92ac-4c8e-9b05-8c13752fc73f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7a438025-06f6-4a4e-81c6-7f791082e6ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_e231beba-4fe0-42a8-89df-c16e51e01cb4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrecedexMember_63e27dd1-bf83-4009-bd26-a32bbc849ca6_terseLabel_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_label_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_documentation_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember" xlink:href="pfe-20210404.xsd#pfe_PrecedexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexMember" xlink:to="lab_pfe_PrecedexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_5021e456-29e5-410c-b3ed-9e61191e05ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_490976e0-6d3e-4af0-9420-2d554c101a6a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_aaf29eff-74eb-4f80-a83d-804adce0902b_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock conversions and redemptions (in shares)</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_50b813a0-8105-4cb7-8bf3-665bbce7102b_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3211710d-399a-408a-bc9b-7bc10cddb27b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_54433be6-6978-4b60-845f-b59c0ea4d8ef_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f2524b78-44ce-437d-a121-ed08b3400476_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_3e145784-c186-494e-a4c5-8c3f3f1eebfb_terseLabel_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_label_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_documentation_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember" xlink:href="pfe-20210404.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnvironmentalRemediationLitigationMember" xlink:to="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_136bdb5d-2a43-47d8-805c-83f7853af921_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4a2b3a27-caa3-433f-bcfe-b8107768a021_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_81f8e670-e7b5-4db2-b384-81adc29cedee_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_846cdaa9-4aa7-46df-bb79-61436afd786e_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNINoncurrent" xlink:to="lab_pfe_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9818ea7a-3e83-42df-9cad-aecd8766947b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_2192e2a5-f28f-477a-9c63-1d23cf0013d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0455a7a4-208b-4e2b-b55d-6564db96abab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standard Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2fc5f0e9-b77f-4d93-91c7-52c3e8cb6cd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_67699774-5c77-4f82-8436-0a7eeb5990bd_terseLabel_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_label_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid (Received), Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestPaidReceivedInterestRateHedges_documentation_en-US" xlink:label="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid (Received), Interest Rate Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestPaidReceivedInterestRateHedges" xlink:href="pfe-20210404.xsd#pfe_InterestPaidReceivedInterestRateHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestPaidReceivedInterestRateHedges" xlink:to="lab_pfe_InterestPaidReceivedInterestRateHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4579389d-a0a3-43b1-b211-3a721dbefb96_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_e8d8846f-62e7-4e7d-83e3-f80e270a0e1f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_08bf31f8-41fa-47e6-be7b-9553964a09e9_totalLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>pfe-20210404_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20210404.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4d48a839-b922-4140-a341-17ee33f3f9bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d48a839-b922-4140-a341-17ee33f3f9bd" xlink:to="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0452983c-500c-4902-99b9-d1c566c5d166" xlink:to="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48fab872-9c61-483c-a71a-71c43d3bf2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_us-gaap_CommonStockMember_48fab872-9c61-483c-a71a-71c43d3bf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member_9376ef58-f094-4008-9dd4-5ebf407f3bfd" xlink:href="pfe-20210404.xsd#pfe_NotesDue20220.250Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_pfe_NotesDue20220.250Member_9376ef58-f094-4008-9dd4-5ebf407f3bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_2d203c86-49c3-4c21-8382-f2cd399ab222" xlink:href="pfe-20210404.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d4af210e-41ed-4bfc-b0ad-a748daa723df" xlink:to="loc_pfe_NotesDue20271.000Member_2d203c86-49c3-4c21-8382-f2cd399ab222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1392f33a-5644-44f5-a8b9-72e07b2f26cf" xlink:to="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5ae5c59d-0a41-48af-b6f0-2c975b9ca07b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentType_5ae5c59d-0a41-48af-b6f0-2c975b9ca07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c88d0254-922f-4034-9be9-c8b2f6d10213" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentQuarterlyReport_c88d0254-922f-4034-9be9-c8b2f6d10213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e1240b45-5071-4737-b309-d9adf4c50f26" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentPeriodEndDate_e1240b45-5071-4737-b309-d9adf4c50f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b7960ca7-6c44-4d64-953d-4062601953f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentTransitionReport_b7960ca7-6c44-4d64-953d-4062601953f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_75a06fd9-508a-4ebb-8f70-2a53f0296421" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityFileNumber_75a06fd9-508a-4ebb-8f70-2a53f0296421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_21db3a3c-d417-46a2-be2a-a6aa30990be9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityRegistrantName_21db3a3c-d417-46a2-be2a-a6aa30990be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f28b1e36-4428-4b99-901f-222c17f78907" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f28b1e36-4428-4b99-901f-222c17f78907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cf056c78-daa3-40cb-b83e-32c4faeebe5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityTaxIdentificationNumber_cf056c78-daa3-40cb-b83e-32c4faeebe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_70f29d0e-e68d-400e-9f5f-b65e4a30c2a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressAddressLine1_70f29d0e-e68d-400e-9f5f-b65e4a30c2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d4679871-a9d1-4242-9a8e-6f16475eae03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressCityOrTown_d4679871-a9d1-4242-9a8e-6f16475eae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c1f97478-af96-4277-b976-3c331a333ca6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressStateOrProvince_c1f97478-af96-4277-b976-3c331a333ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a225005c-88d1-4a93-ae6c-4ec2c07213db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityAddressPostalZipCode_a225005c-88d1-4a93-ae6c-4ec2c07213db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fc06c3a2-94ed-44b4-bfbb-476ec2758e28" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_CityAreaCode_fc06c3a2-94ed-44b4-bfbb-476ec2758e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2457eec2-7cc1-434d-adf1-38d87a065957" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_LocalPhoneNumber_2457eec2-7cc1-434d-adf1-38d87a065957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4b8e64ae-854c-45b3-a9d7-ac85af5eb71f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_Security12bTitle_4b8e64ae-854c-45b3-a9d7-ac85af5eb71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_990d67be-86e0-4edb-8022-57cb2e7fdddd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_TradingSymbol_990d67be-86e0-4edb-8022-57cb2e7fdddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6cf9d7a2-3633-462c-a87d-187b4478e941" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_SecurityExchangeName_6cf9d7a2-3633-462c-a87d-187b4478e941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_36f34453-d919-43ba-b03f-adda4e1453f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCurrentReportingStatus_36f34453-d919-43ba-b03f-adda4e1453f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_436a96fa-8f7f-4144-b35e-2f5915726e06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityInteractiveDataCurrent_436a96fa-8f7f-4144-b35e-2f5915726e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_32dd1ab1-5683-4559-8592-07090f9f2209" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityFilerCategory_32dd1ab1-5683-4559-8592-07090f9f2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5e9df3a0-e9a4-4847-b577-7654d3c110ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntitySmallBusiness_5e9df3a0-e9a4-4847-b577-7654d3c110ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6ca23569-3ccd-4361-b194-2584c41dd34a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityEmergingGrowthCompany_6ca23569-3ccd-4361-b194-2584c41dd34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4256e998-d611-43ea-a45e-8206f416486a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityShellCompany_4256e998-d611-43ea-a45e-8206f416486a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_988ed6b7-2cc2-4401-b27e-2052d134fc86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_988ed6b7-2cc2-4401-b27e-2052d134fc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7cb2e8cb-a0dc-4c86-aa56-f1d78fd5fc3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_EntityCentralIndexKey_7cb2e8cb-a0dc-4c86-aa56-f1d78fd5fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3a132c7c-2f4c-4f76-b944-c476a147d8b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_CurrentFiscalYearEndDate_3a132c7c-2f4c-4f76-b944-c476a147d8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fc105843-e542-4c80-acb4-c913e29fe78b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentFiscalYearFocus_fc105843-e542-4c80-acb4-c913e29fe78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8292b943-a499-4d9f-a397-fbbad8ca9be7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8292b943-a499-4d9f-a397-fbbad8ca9be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9364c9b2-f287-421b-a34d-fa73318e76a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_188cedb1-7446-4107-8a58-b3708cb5ddcf" xlink:to="loc_dei_AmendmentFlag_9364c9b2-f287-421b-a34d-fa73318e76a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14b895ea-7c5c-4031-85ec-3285f52fe106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14b895ea-7c5c-4031-85ec-3285f52fe106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_31b04d18-a4a9-4a0c-be57-d71aaa5ef199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_31b04d18-a4a9-4a0c-be57-d71aaa5ef199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a2332a43-94d0-4dce-94ce-49dcfded9698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a2332a43-94d0-4dce-94ce-49dcfded9698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5b6e06a2-e8b6-4792-b9a9-14d5de81b757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5b6e06a2-e8b6-4792-b9a9-14d5de81b757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_d55394d4-8a67-4106-97dc-c7dde7deb751" xlink:href="pfe-20210404.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_d55394d4-8a67-4106-97dc-c7dde7deb751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_5dbbe917-c5e3-475f-9d1f-08480be70425" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_5dbbe917-c5e3-475f-9d1f-08480be70425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_5ef4781f-f614-4421-bedf-56e037765f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_5ef4781f-f614-4421-bedf-56e037765f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1b6aa6cb-5ac4-4f40-a15a-3feaa8bbed5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3189a011-6e6a-434f-bbf4-199bb7e5e90e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1b6aa6cb-5ac4-4f40-a15a-3feaa8bbed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_464b18ec-c882-4137-b4a3-b187cdd9fc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_464b18ec-c882-4137-b4a3-b187cdd9fc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c43022c3-a590-4de6-83df-33c2473ca5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c43022c3-a590-4de6-83df-33c2473ca5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3d6c74f4-a81f-4713-9e20-f4cebe0492e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3d6c74f4-a81f-4713-9e20-f4cebe0492e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_232ca44a-7a5a-4445-82f3-a83666518b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_232ca44a-7a5a-4445-82f3-a83666518b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_48ed7181-2454-4957-9242-f44050152b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_ProfitLoss_48ed7181-2454-4957-9242-f44050152b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c5f1455-e948-440f-b769-04590b3db3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c5f1455-e948-440f-b769-04590b3db3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd8e0918-3b4a-42fa-8af5-761f47c41b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_NetIncomeLoss_fd8e0918-3b4a-42fa-8af5-761f47c41b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_b2cf5148-2228-4eff-85dd-64749e919a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_b2cf5148-2228-4eff-85dd-64749e919a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_98ff094f-b5a7-4606-a9a1-348ad6aef3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b2cf5148-2228-4eff-85dd-64749e919a61" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_98ff094f-b5a7-4606-a9a1-348ad6aef3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_ec7aed13-37b3-4cc0-9b50-b74980efbef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b2cf5148-2228-4eff-85dd-64749e919a61" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_ec7aed13-37b3-4cc0-9b50-b74980efbef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8cc51e78-11b6-465f-8639-30dcb404ecc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_b2cf5148-2228-4eff-85dd-64749e919a61" xlink:to="loc_us-gaap_EarningsPerShareBasic_8cc51e78-11b6-465f-8639-30dcb404ecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_b54b65f6-e88e-4a64-bbeb-2f3ab1ff4dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_b54b65f6-e88e-4a64-bbeb-2f3ab1ff4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aaebaefb-2ea0-4e56-9890-16452243b2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_b54b65f6-e88e-4a64-bbeb-2f3ab1ff4dac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_aaebaefb-2ea0-4e56-9890-16452243b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_b4c239ab-3332-4e32-961d-8ba284dd6b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_b54b65f6-e88e-4a64-bbeb-2f3ab1ff4dac" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_b4c239ab-3332-4e32-961d-8ba284dd6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b1e5c4d-ee0d-4a65-856e-7142aae5ecaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_b54b65f6-e88e-4a64-bbeb-2f3ab1ff4dac" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b1e5c4d-ee0d-4a65-856e-7142aae5ecaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1dd1d33-be41-4797-b59b-2f69b0fc9d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1dd1d33-be41-4797-b59b-2f69b0fc9d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f87fecd8-4c85-43e8-8d55-7e567215510d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fbe0e16b-036a-4a11-9f56-94996dffb3f0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f87fecd8-4c85-43e8-8d55-7e567215510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d76eacb5-6ca5-4eff-926b-fc003cd392c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_ProfitLoss_d76eacb5-6ca5-4eff-926b-fc003cd392c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_75c6049c-8c50-496c-8679-05146c2830b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_75c6049c-8c50-496c-8679-05146c2830b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_27521ec5-5069-41df-ba9f-e525c6b848db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_27521ec5-5069-41df-ba9f-e525c6b848db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_86b33a44-2d91-4a26-9ab5-015afadda977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_86b33a44-2d91-4a26-9ab5-015afadda977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d2bfbe92-f6e7-4f0f-b72e-cd25600f0e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_d2bfbe92-f6e7-4f0f-b72e-cd25600f0e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ebb866ab-db49-45e5-8f7b-054fd125f236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ebb866ab-db49-45e5-8f7b-054fd125f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_ea6ce74a-efdb-4e48-a117-3420ba4e6248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_ea6ce74a-efdb-4e48-a117-3420ba4e6248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_665c151c-9cb6-46a0-9668-464af5e63c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_665c151c-9cb6-46a0-9668-464af5e63c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_ab869a69-a1a7-4d80-add2-aa52d495f035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_ab869a69-a1a7-4d80-add2-aa52d495f035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_3f594c57-8d00-490e-aefd-22f3a14cdae5" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_3f594c57-8d00-490e-aefd-22f3a14cdae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4a3d8fdf-fdef-48eb-96b1-a220ebac6730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4a3d8fdf-fdef-48eb-96b1-a220ebac6730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_f6b2cf60-aad5-4089-ba2c-31f55109a00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_f6b2cf60-aad5-4089-ba2c-31f55109a00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_0f1f6330-2c0e-4ec2-89e9-8fa10baa5f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_0f1f6330-2c0e-4ec2-89e9-8fa10baa5f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_542de1d4-820a-4063-83bb-2d04050e290d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_542de1d4-820a-4063-83bb-2d04050e290d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6c17ddc8-b4b3-4b9c-b0fe-c90ecbc14928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6c17ddc8-b4b3-4b9c-b0fe-c90ecbc14928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eb762e26-3642-45b4-9938-29a2e72f9545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eb762e26-3642-45b4-9938-29a2e72f9545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_49fc7f94-3d05-46e2-8f3d-b1268650da91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a562db02-cf3b-4c19-b084-096650510aa5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_49fc7f94-3d05-46e2-8f3d-b1268650da91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4b6f9a60-2cc6-4c26-8bfe-98613742a1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b6f9a60-2cc6-4c26-8bfe-98613742a1bd" xlink:to="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd47337b-03a3-4981-8760-15bee12fb13c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd47337b-03a3-4981-8760-15bee12fb13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_7a707263-7ed9-4cd8-a587-02a93aa09980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_OtherShortTermInvestments_7a707263-7ed9-4cd8-a587-02a93aa09980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3cb66e6b-71e0-4018-9203-199b6ae9cce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3cb66e6b-71e0-4018-9203-199b6ae9cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33d0d185-936c-4e40-80e2-83b8652abda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_InventoryNet_33d0d185-936c-4e40-80e2-83b8652abda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_b4a284a3-e818-483d-acf6-c89da7cdf263" xlink:href="pfe-20210404.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_pfe_OtherTaxAssetsCurrent_b4a284a3-e818-483d-acf6-c89da7cdf263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b80659eb-036b-4e96-ba31-0b0cd72183fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_OtherAssetsCurrent_b80659eb-036b-4e96-ba31-0b0cd72183fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9760f040-5696-4d4c-937f-602265b18860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_AssetsCurrent_9760f040-5696-4d4c-937f-602265b18860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b6a9f9b8-e3fb-4ad0-a28c-8bfa8eae7a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_EquityMethodInvestments_b6a9f9b8-e3fb-4ad0-a28c-8bfa8eae7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_5c8bb527-d6cf-4252-81b3-162154c19e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_OtherLongTermInvestments_5c8bb527-d6cf-4252-81b3-162154c19e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a8fb7f4-fd52-4ab6-aa27-44561b1a978d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9a8fb7f4-fd52-4ab6-aa27-44561b1a978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7352263-b8e3-4bbd-ab81-a36757b6c69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7352263-b8e3-4bbd-ab81-a36757b6c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_794b853f-b0ed-4be1-b56a-01ba694b6de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_Goodwill_794b853f-b0ed-4be1-b56a-01ba694b6de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_657c18f5-5e8c-45c4-9c45-4bafb318867f" xlink:href="pfe-20210404.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_657c18f5-5e8c-45c4-9c45-4bafb318867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1270423a-5d38-438e-96f7-5e12b0654607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1270423a-5d38-438e-96f7-5e12b0654607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c1f0d510-a602-42dd-9641-1ac86232cfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_566d6b6c-b38b-4b5f-96ef-95d58bb3f35d" xlink:to="loc_us-gaap_Assets_c1f0d510-a602-42dd-9641-1ac86232cfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b6f9a60-2cc6-4c26-8bfe-98613742a1bd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b049415c-59a9-43da-893b-f9ff98f63b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_DebtCurrent_b049415c-59a9-43da-893b-f9ff98f63b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_10f575af-6dfa-4244-a00a-fd9f7647093e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_AccountsPayableCurrent_10f575af-6dfa-4244-a00a-fd9f7647093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_53a05f74-e5a1-4b57-9c61-bfca1b3e2040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_DividendsPayableCurrent_53a05f74-e5a1-4b57-9c61-bfca1b3e2040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_fcb67b93-6957-40a2-a47d-6fce84263e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_TaxesPayableCurrent_fcb67b93-6957-40a2-a47d-6fce84263e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a27c0bb2-b34b-4c72-9cf2-afa8daef4d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a27c0bb2-b34b-4c72-9cf2-afa8daef4d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c17ba422-9e1b-43d2-a2bb-b8874cce2016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c17ba422-9e1b-43d2-a2bb-b8874cce2016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_21b2cdd7-5b34-4181-aa9f-017f9ca92427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_21b2cdd7-5b34-4181-aa9f-017f9ca92427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34c46272-34b5-47d7-8fc4-0490a7731a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_LiabilitiesCurrent_34c46272-34b5-47d7-8fc4-0490a7731a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f5c2c4aa-3b23-4316-b73b-cee99219e850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f5c2c4aa-3b23-4316-b73b-cee99219e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_9914bb6b-ae2d-447f-840b-3813167c4c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_9914bb6b-ae2d-447f-840b-3813167c4c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_6c99bfab-a757-456e-a453-e554398841be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_6c99bfab-a757-456e-a453-e554398841be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_00e3e5a1-c854-42e7-9574-d8305f90f9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_00e3e5a1-c854-42e7-9574-d8305f90f9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_c5505a35-0c03-4744-9940-1a7ab971cc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_c5505a35-0c03-4744-9940-1a7ab971cc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_855798f4-1a77-42ef-a111-81e06c9553ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_855798f4-1a77-42ef-a111-81e06c9553ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab9f1b10-7a07-4f18-bdd7-e2966356646b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_Liabilities_ab9f1b10-7a07-4f18-bdd7-e2966356646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_835fc056-91b9-4379-99f7-a343ddf08a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_835fc056-91b9-4379-99f7-a343ddf08a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a5e2e786-7121-4c80-98a7-463221c0d237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_CommonStockValue_a5e2e786-7121-4c80-98a7-463221c0d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c8361423-411b-456f-8c1e-6fc7232ade5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c8361423-411b-456f-8c1e-6fc7232ade5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_fb3f558e-5b18-4bb2-8f45-82522c32e3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_TreasuryStockValue_fb3f558e-5b18-4bb2-8f45-82522c32e3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6742365-f6ee-49a1-92d8-92281b4b960b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6742365-f6ee-49a1-92d8-92281b4b960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_40af0725-7e8c-4f10-a264-c1c03fce1d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_40af0725-7e8c-4f10-a264-c1c03fce1d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4cda85a7-70d3-46a8-a521-916a9b121ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_StockholdersEquity_4cda85a7-70d3-46a8-a521-916a9b121ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0eab8a93-74c1-46b4-a806-a3cee54c45e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_MinorityInterest_0eab8a93-74c1-46b4-a806-a3cee54c45e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a46a0d4-8725-48cd-af15-72cd48bebf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a46a0d4-8725-48cd-af15-72cd48bebf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bf9b492-7525-476d-a992-9f8b1fdf6ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6619491-b177-47e3-8e64-f581639119f4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4bf9b492-7525-476d-a992-9f8b1fdf6ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d851494e-3a95-4436-9003-75d8b372fdd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b956c8cd-f1d0-45a1-a14f-db62fd702774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d851494e-3a95-4436-9003-75d8b372fdd8" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b956c8cd-f1d0-45a1-a14f-db62fd702774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db519d5-95a8-46bb-a66e-ca77d80d152e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d851494e-3a95-4436-9003-75d8b372fdd8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db519d5-95a8-46bb-a66e-ca77d80d152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f610edba-7081-4118-b6da-566c138b8097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d851494e-3a95-4436-9003-75d8b372fdd8" xlink:to="loc_us-gaap_LongTermDebtCurrent_f610edba-7081-4118-b6da-566c138b8097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d7808a3e-2f02-4df7-9820-bf715e1966b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d7808a3e-2f02-4df7-9820-bf715e1966b1" xlink:to="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58d2959c-80ef-4ecd-8ece-574a6a8d79c1" xlink:to="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c47b61c3-9da6-496c-aa77-4d38941a2b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_PreferredStockMember_c47b61c3-9da6-496c-aa77-4d38941a2b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8d014ab-71f2-4907-b353-5eda9fce7205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_CommonStockMember_e8d014ab-71f2-4907-b353-5eda9fce7205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6a407cdc-da63-410e-9c8e-b37551ae57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6a407cdc-da63-410e-9c8e-b37551ae57e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_02593467-42bf-4cc0-8f45-abe17c394a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_TreasuryStockMember_02593467-42bf-4cc0-8f45-abe17c394a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f2c12bdf-d2de-44ab-8ad3-1bf7c253183d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_RetainedEarningsMember_f2c12bdf-d2de-44ab-8ad3-1bf7c253183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_377694f5-9637-46c2-9735-f2d40e4978d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_377694f5-9637-46c2-9735-f2d40e4978d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_3e426b47-7dde-4b48-9b90-cf30d5fc01d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_ParentMember_3e426b47-7dde-4b48-9b90-cf30d5fc01d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9efe05c2-ca94-4b9c-aaa2-b7b6969ace0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e4b7ba3e-cd7f-467f-ac2c-75c36fc4486b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9efe05c2-ca94-4b9c-aaa2-b7b6969ace0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6647419c-da40-461f-b7b8-6070daeaf01d" xlink:to="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cb5a68ac-6aae-47b1-9cdc-54f125637c60" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c068f3e4-c1ef-49f9-8995-520b2af0a0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_SharesIssued_c068f3e4-c1ef-49f9-8995-520b2af0a0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3524296-1573-4ae4-98c5-a564502494c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3524296-1573-4ae4-98c5-a564502494c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e57af26-fdd8-4449-84e1-f0f885f6e835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_ProfitLoss_8e57af26-fdd8-4449-84e1-f0f885f6e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0415ad3-6d74-419d-ae7f-97ac2ead173f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0415ad3-6d74-419d-ae7f-97ac2ead173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCashAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a4293bd0-f6a8-4d19-993b-dc5dae0e4c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_DividendsCommonStockCash_a4293bd0-f6a8-4d19-993b-dc5dae0e4c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_d3f6f60b-742b-4314-9841-7cc3118c1657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_DividendsPreferredStockCash_d3f6f60b-742b-4314-9841-7cc3118c1657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_527f0136-2605-4fbc-9434-2a5bbf2a31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCashAbstract_f2930877-ea9c-420a-b1a6-e10aa474c328" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_527f0136-2605-4fbc-9434-2a5bbf2a31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_afd34257-9656-4817-a1b3-6743976ac448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_afd34257-9656-4817-a1b3-6743976ac448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5cb290c-be58-4e3c-a8fc-398e73131f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5cb290c-be58-4e3c-a8fc-398e73131f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_144aa29f-a640-410d-8e91-88ea22dbc6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_144aa29f-a640-410d-8e91-88ea22dbc6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_02555920-5e0b-4e30-bd1b-a6e377654b53" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_02555920-5e0b-4e30-bd1b-a6e377654b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_65665432-5e67-4c5f-afff-42574a1e8dc9" xlink:href="pfe-20210404.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_65665432-5e67-4c5f-afff-42574a1e8dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_becacc79-b5dd-4e39-9f3a-1cd697c37cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockholdersEquityOther_becacc79-b5dd-4e39-9f3a-1cd697c37cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8bd5edfb-57e5-4d2f-ab0f-c61880fdbf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_SharesIssued_8bd5edfb-57e5-4d2f-ab0f-c61880fdbf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0be88c98-445e-43be-b288-8a8cd35337d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c074325c-1c79-4d95-9c41-c67cb7a6eb49" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0be88c98-445e-43be-b288-8a8cd35337d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_106a9868-bf37-4d14-9786-94cef5fb061d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8fa04025-e95c-41fd-baaf-147bf380ab29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_106a9868-bf37-4d14-9786-94cef5fb061d" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8fa04025-e95c-41fd-baaf-147bf380ab29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="pfe-20210404.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fa134409-8415-41da-9a28-903e1fc35e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_ProfitLoss_fa134409-8415-41da-9a28-903e1fc35e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5529125b-05f8-459b-a73b-06696a294633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5529125b-05f8-459b-a73b-06696a294633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_473384c8-af80-4399-ab45-ce48556fcd92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_473384c8-af80-4399-ab45-ce48556fcd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_b0d6cfbb-c41f-4098-bc48-794e3e575c25" xlink:href="pfe-20210404.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_b0d6cfbb-c41f-4098-bc48-794e3e575c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0efe0c5b-6a11-4ba5-967f-7e034455bede" xlink:href="pfe-20210404.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0efe0c5b-6a11-4ba5-967f-7e034455bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_f1fa893e-530c-49fe-bd15-011f86497eb4" xlink:href="pfe-20210404.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_f1fa893e-530c-49fe-bd15-011f86497eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_445a0c87-34ce-40a4-bfe1-598db6fc0e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_445a0c87-34ce-40a4-bfe1-598db6fc0e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1e0e8bec-6daf-4443-9a73-c406145ca377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_us-gaap_ShareBasedCompensation_1e0e8bec-6daf-4443-9a73-c406145ca377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_fcb3e266-8637-4521-b732-386bb74331c0" xlink:href="pfe-20210404.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_fcb3e266-8637-4521-b732-386bb74331c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e2a7746a-5d92-49bf-ba15-708a9f81ce27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e2a7746a-5d92-49bf-ba15-708a9f81ce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_a964499b-7cc5-42bd-bbbf-2e76afff978c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc425178-4cf0-40c4-b22d-86f6b45f06b2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_a964499b-7cc5-42bd-bbbf-2e76afff978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e2bdd3c8-a453-4398-b38c-c9b85d38f1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e2bdd3c8-a453-4398-b38c-c9b85d38f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6c3ca040-f845-4907-8b06-2fd465f1d427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6c3ca040-f845-4907-8b06-2fd465f1d427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7980067-7f3a-4357-a01e-acbb1a4ad3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36cbb7bf-99e7-427f-8d9c-639e0447c5f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7980067-7f3a-4357-a01e-acbb1a4ad3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4e904949-1e7f-4e36-a586-143c45be25b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4e904949-1e7f-4e36-a586-143c45be25b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2e1fa1b5-4c3d-4ee2-8ad3-eff3060cd995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2e1fa1b5-4c3d-4ee2-8ad3-eff3060cd995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_6061e3bc-d02c-4b9f-bc35-66fc8c95f18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_6061e3bc-d02c-4b9f-bc35-66fc8c95f18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_a98e427b-8cb0-46c1-9ac9-e2dd85f82d2a" xlink:href="pfe-20210404.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_a98e427b-8cb0-46c1-9ac9-e2dd85f82d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45188218-5d64-4ee3-b1b2-b7863c0033f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45188218-5d64-4ee3-b1b2-b7863c0033f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_4cd83f21-6ccd-4125-91ce-ab3cc3640254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_4cd83f21-6ccd-4125-91ce-ab3cc3640254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6663b60f-bc03-4da2-be12-090b74b562e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6663b60f-bc03-4da2-be12-090b74b562e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_e6895750-50b3-4be7-8bb4-bd7ca071cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_e6895750-50b3-4be7-8bb4-bd7ca071cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4dafbcb5-3bcf-416c-be11-18a2b960692b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4dafbcb5-3bcf-416c-be11-18a2b960692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65f8ccad-f855-402c-9c89-3dd0551260a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56517b1b-565b-4476-9340-8dfcef39e1fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65f8ccad-f855-402c-9c89-3dd0551260a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_6f31d6f5-a296-484b-98bc-bc52fffcd090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_6f31d6f5-a296-484b-98bc-bc52fffcd090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_bf4c991a-e25b-42dc-9932-9c8f09ab995a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_bf4c991a-e25b-42dc-9932-9c8f09ab995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_f1a2357d-08f0-4cbf-82f6-b5f901588505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_f1a2357d-08f0-4cbf-82f6-b5f901588505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7108d657-e350-4925-8cd1-967043d9ace1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7108d657-e350-4925-8cd1-967043d9ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3cb75e61-8878-453b-8204-8285d02b2ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3cb75e61-8878-453b-8204-8285d02b2ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_6c2cb465-684f-43dd-8c2a-6ec9ebe9d9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_6c2cb465-684f-43dd-8c2a-6ec9ebe9d9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_731ecb8e-9ff0-4946-84f3-d22fdc4d9833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_731ecb8e-9ff0-4946-84f3-d22fdc4d9833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9b742b9c-1362-43ce-b40a-07e44f12e7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1bf67620-1416-4567-bd9d-9222fac38d56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9b742b9c-1362-43ce-b40a-07e44f12e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d930f054-71d9-4f48-97d3-7e7afb8cf852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d930f054-71d9-4f48-97d3-7e7afb8cf852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_023fec9b-1790-4af4-b578-0e6f639227d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_023fec9b-1790-4af4-b578-0e6f639227d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea39febd-c170-4faa-862d-286e2d7b1289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea39febd-c170-4faa-862d-286e2d7b1289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_113aef92-045d-45e3-962b-16a70f1a5d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_113aef92-045d-45e3-962b-16a70f1a5d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_9f9d1b84-9dac-4008-840d-eb59bddac053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60fac712-21a2-4058-8ef9-5997b5c05617" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_9f9d1b84-9dac-4008-840d-eb59bddac053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_afa86bdd-cbe1-4be7-8c1d-47e83c85d317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_9f9d1b84-9dac-4008-840d-eb59bddac053" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_afa86bdd-cbe1-4be7-8c1d-47e83c85d317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_85d7fb7c-57d2-4f74-acef-438b6356a7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afa86bdd-cbe1-4be7-8c1d-47e83c85d317" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_85d7fb7c-57d2-4f74-acef-438b6356a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a82b7ef8-0224-4970-b749-405c358b4eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afa86bdd-cbe1-4be7-8c1d-47e83c85d317" xlink:to="loc_us-gaap_InterestPaidNet_a82b7ef8-0224-4970-b749-405c358b4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestPaidReceivedInterestRateHedges_73eaaf2c-9cc2-49e7-83a9-bf458072b5b1" xlink:href="pfe-20210404.xsd#pfe_InterestPaidReceivedInterestRateHedges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afa86bdd-cbe1-4be7-8c1d-47e83c85d317" xlink:to="loc_pfe_InterestPaidReceivedInterestRateHedges_73eaaf2c-9cc2-49e7-83a9-bf458072b5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e7c2593-8f81-416f-baf2-5863c3ae6796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7baa7d45-e376-4699-9d11-e55463145fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e7c2593-8f81-416f-baf2-5863c3ae6796" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7baa7d45-e376-4699-9d11-e55463145fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3461293-e17c-4613-aa4a-6e27070a967d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_617e3574-1861-458f-84e4-18592c76348b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3461293-e17c-4613-aa4a-6e27070a967d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_617e3574-1861-458f-84e4-18592c76348b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0982f470-59b1-4a0c-a0f0-66847bba4ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3461293-e17c-4613-aa4a-6e27070a967d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0982f470-59b1-4a0c-a0f0-66847bba4ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_2223dcf1-9a45-4181-a608-7cba934409fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3461293-e17c-4613-aa4a-6e27070a967d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_2223dcf1-9a45-4181-a608-7cba934409fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8df664ef-172f-4e1b-b2e8-ebd5e144902d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3461293-e17c-4613-aa4a-6e27070a967d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8df664ef-172f-4e1b-b2e8-ebd5e144902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6064f916-1c60-4545-a447-d67a997db2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_179364b5-4ae0-4bc2-9cae-a251aa45bf97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6064f916-1c60-4545-a447-d67a997db2f0" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_179364b5-4ae0-4bc2-9cae-a251aa45bf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_5482136d-9238-4e17-b767-5bc812b891dc" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6064f916-1c60-4545-a447-d67a997db2f0" xlink:to="loc_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock_5482136d-9238-4e17-b767-5bc812b891dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b73fb69-95bb-47f3-9c04-334aa88d98a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b73fb69-95bb-47f3-9c04-334aa88d98a1" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:to="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_265782ec-2673-4ce4-9ac0-920f8e184e76" xlink:to="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_0702a847-880d-40a0-865a-5b8eaf0fcd05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_964af74a-a33a-4b77-a741-9f0f2831d3fd" xlink:to="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_0702a847-880d-40a0-865a-5b8eaf0fcd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d5444b93-e3dc-4319-82e3-06c89dc2ec5b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3b13b7f-36be-4c44-8c99-bf59d311cdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3b13b7f-36be-4c44-8c99-bf59d311cdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebb00944-9e66-458e-baba-b9f76f5bafba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_672f090d-9441-4585-9adc-1831d749181d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ebb00944-9e66-458e-baba-b9f76f5bafba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d6ff709-65b7-4eb2-b31b-1ebe54b177fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d6ff709-65b7-4eb2-b31b-1ebe54b177fb" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:to="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_c6da19d2-9360-45d2-a240-2f53d7906bd5" xlink:to="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember_2e0f1266-c9f0-4921-9ca7-3df487b0365c" xlink:href="pfe-20210404.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:to="loc_pfe_ScenarioPreviousAccountingPrincipleMember_2e0f1266-c9f0-4921-9ca7-3df487b0365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_da6d3725-c62d-43cc-9544-f9a054a86feb" xlink:href="pfe-20210404.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_51b7d35e-4a6f-4408-a759-5e477840b07c" xlink:to="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_da6d3725-c62d-43cc-9544-f9a054a86feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_34e6ae10-54a0-420b-ab67-614d57b4ba39" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_38b864db-2948-4050-8a56-60c826846125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_38b864db-2948-4050-8a56-60c826846125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b37f451-3382-4b0f-9dad-77fa31f5e4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b37f451-3382-4b0f-9dad-77fa31f5e4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6e6cf31-131a-484e-a5bf-52eda49fbf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e6e6cf31-131a-484e-a5bf-52eda49fbf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fb71d120-73ab-4a94-a5cb-df19725d9c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fb71d120-73ab-4a94-a5cb-df19725d9c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b5a0649c-330d-4c2a-8494-42763d74744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_ProfitLoss_b5a0649c-330d-4c2a-8494-42763d74744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b2b4541-2dc7-4120-8e42-a8bb9276e246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_NetIncomeLoss_9b2b4541-2dc7-4120-8e42-a8bb9276e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1a3dea1b-ace3-4e8d-ab3d-ce0f7bce4f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1a3dea1b-ace3-4e8d-ab3d-ce0f7bce4f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46f7ba43-3bb8-4114-9445-543dc443adf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46f7ba43-3bb8-4114-9445-543dc443adf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_56fb8c75-7401-4877-a441-273598b3aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c162c20e-80fd-4a53-b25d-ce33a43cae7c" xlink:to="loc_us-gaap_EarningsPerShareBasic_56fb8c75-7401-4877-a441-273598b3aabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_bbc69ac7-ffbd-4b72-a14e-4e4ec14fd93f" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97eddfb6-49f3-4072-940b-65a0524e3059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_97eddfb6-49f3-4072-940b-65a0524e3059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6fc0cb7f-4b08-4f69-9f17-b552569e456a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6fc0cb7f-4b08-4f69-9f17-b552569e456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e220e753-4936-4f0c-858a-4eddacff0594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a27afaa6-15df-4014-9397-53e85dc6fcda" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e220e753-4936-4f0c-858a-4eddacff0594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_dc15cba2-6951-43c3-a2b0-9468321dedee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_dc15cba2-6951-43c3-a2b0-9468321dedee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_886ff1d1-d258-43e0-80db-71d5ad3fb810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_886ff1d1-d258-43e0-80db-71d5ad3fb810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_002dd87f-4c91-4ab1-b6b1-13b7a4fa32de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_002dd87f-4c91-4ab1-b6b1-13b7a4fa32de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_774c7ed6-1645-4e8e-9326-d8a254d1593c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_774c7ed6-1645-4e8e-9326-d8a254d1593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_52d50d59-c9a8-49c9-8f19-3efadad70797" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_52d50d59-c9a8-49c9-8f19-3efadad70797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_6a009370-3fe7-42f9-8fe1-30f4616eb8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_935c87fa-2656-472d-8b41-3de55296323a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_6a009370-3fe7-42f9-8fe1-30f4616eb8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4c06665-2958-4a26-bb39-75b47e51c7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4c06665-2958-4a26-bb39-75b47e51c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b8402fe-a304-4d71-a138-3bb6f89365f8" xlink:href="pfe-20210404.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_7e3be5dc-26ba-48a3-805d-d25aac32d84f" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b8402fe-a304-4d71-a138-3bb6f89365f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:href="pfe-20210404.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_84a7fbdc-7816-48c1-9146-4043e7ec45ad" xlink:to="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_be41850b-da97-44db-972e-d5cff2de4e30" xlink:href="pfe-20210404.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_be41850b-da97-44db-972e-d5cff2de4e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8e0e4644-d94b-4980-b7b2-41ffc4641808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8e0e4644-d94b-4980-b7b2-41ffc4641808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_05bebcdd-8e50-4811-a812-29ae38ab4b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_05bebcdd-8e50-4811-a812-29ae38ab4b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa60bb06-e3b1-4d76-ba3a-314a943a952e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa60bb06-e3b1-4d76-ba3a-314a943a952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36548b2d-5cd8-468d-ba4e-98e650d0d1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_026e7fef-e7c2-4843-a438-6d332faaf7ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36548b2d-5cd8-468d-ba4e-98e650d0d1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10d2eb85-752f-405e-88e5-3c253b5cfc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10d2eb85-752f-405e-88e5-3c253b5cfc7d" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0d6f5852-b4a3-4b78-a5fa-f9724d65bc42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_eec566ac-49b2-4005-a6b6-1958c184b01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_AccountsReceivableMember_eec566ac-49b2-4005-a6b6-1958c184b01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f7b8226c-299b-4ac5-b54f-5ffad3bbba8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f7b8226c-299b-4ac5-b54f-5ffad3bbba8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fd71e705-92ff-495a-8d2d-1676099a3e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1eaeda0f-4c58-42ae-a9b6-5210996a6a51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fd71e705-92ff-495a-8d2d-1676099a3e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_30ed4a8c-e111-4374-bb1a-57393c83c742" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_aa2563b9-0472-47bd-87ab-437911252a1b" xlink:href="pfe-20210404.xsd#pfe_RebatesAndDiscountsAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_aa2563b9-0472-47bd-87ab-437911252a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_2919b07a-be0b-4182-90e9-cfd78fe05d4a" xlink:href="pfe-20210404.xsd#pfe_AccruedRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_AccruedRebates_2919b07a-be0b-4182-90e9-cfd78fe05d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_51dbfe3a-acf3-4407-b232-86f79fa90be5" xlink:href="pfe-20210404.xsd#pfe_OtherAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_e7c2abc7-e9e3-4a1e-8430-99c16840d63b" xlink:to="loc_pfe_OtherAccruals_51dbfe3a-acf3-4407-b232-86f79fa90be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestment"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_703dbef7-3396-41e4-acf6-554ffbb7d933" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_705a892a-fdd6-4161-ae3e-66fed6a0e61f" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_703dbef7-3396-41e4-acf6-554ffbb7d933" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock_705a892a-fdd6-4161-ae3e-66fed6a0e61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6badd441-b89c-4180-a730-769276c9910d" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6e015be2-e28a-4ebf-8464-59b486f0a1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6badd441-b89c-4180-a730-769276c9910d" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6e015be2-e28a-4ebf-8464-59b486f0a1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_000d5f3b-98a4-4912-9cdf-93be802f9fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_6badd441-b89c-4180-a730-769276c9910d" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_000d5f3b-98a4-4912-9cdf-93be802f9fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_a481b12e-ac7b-4bdc-af42-bc44e6a5854e" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_a481b12e-ac7b-4bdc-af42-bc44e6a5854e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:to="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a7657233-c9e4-44f7-8892-42e24111bcbc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_d4b41f41-9434-4a7c-81fa-2ee1611d2ba0" xlink:href="pfe-20210404.xsd#pfe_ViatrisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88113932-5d96-4ad7-9ae5-659286627464" xlink:to="loc_pfe_ViatrisMember_d4b41f41-9434-4a7c-81fa-2ee1611d2ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_83c9cd3e-e422-4a96-baca-68ae61405703" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_c8ae2826-2366-42f1-aabd-4027390164b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_c8ae2826-2366-42f1-aabd-4027390164b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_9da01c1a-9df8-406c-8bc9-3d683c46fe5e" xlink:href="pfe-20210404.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4f7b48d5-d5e8-4417-8a48-4bc736cf370c" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_9da01c1a-9df8-406c-8bc9-3d683c46fe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_0fa71ddc-715f-4734-b68c-9de2eb37477c" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_0fa71ddc-715f-4734-b68c-9de2eb37477c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f3f14ac0-2b9b-45e4-a8ae-e0ce210fb1a8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_79a43184-54a9-49d3-9a9a-c19834a2f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9f327d4a-5a5f-40d2-b2d7-ba494b335239" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_79a43184-54a9-49d3-9a9a-c19834a2f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6fed9ea7-ddb1-4110-becd-7d25aded6407" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2c25cdea-aa3b-4226-a9c0-88f2a7c490cf" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_81a29ce0-1f30-4d4b-8ee0-b3af09986914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_81a29ce0-1f30-4d4b-8ee0-b3af09986914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8468d4f1-2cd7-460e-aea5-84e19aef279f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8468d4f1-2cd7-460e-aea5-84e19aef279f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_b58773b2-7acd-43c1-96df-f46a933deaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_b58773b2-7acd-43c1-96df-f46a933deaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_b7b6fcfc-555c-4d30-9827-f2dc3c97ffda" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_b7b6fcfc-555c-4d30-9827-f2dc3c97ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_31b71bd5-bea3-4516-9ae2-9f464ff7ae29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_31b71bd5-bea3-4516-9ae2-9f464ff7ae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_21a3dc7c-a109-4d18-9197-258b674637ba" xlink:href="pfe-20210404.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_21a3dc7c-a109-4d18-9197-258b674637ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_61eef381-cdbf-4f41-b09b-4229e6112b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ed5f7ddf-9016-48f6-8a1f-1273a870baaf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_61eef381-cdbf-4f41-b09b-4229e6112b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7001cd02-4692-44cf-af83-6f445035117b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7001cd02-4692-44cf-af83-6f445035117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_521138ea-192f-480b-aad8-e21adc1a5dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_521138ea-192f-480b-aad8-e21adc1a5dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b21a6590-ae41-4be0-88ea-984fa68c62bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_a5e20e12-b088-4a1d-ad2c-b51e07edf7d8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b21a6590-ae41-4be0-88ea-984fa68c62bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_ca92208a-5b67-4a6e-b2b6-5201cfc13be2" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_ca92208a-5b67-4a6e-b2b6-5201cfc13be2" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:to="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4fae0fa3-51d6-41fb-8203-03506750ac07" xlink:to="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_0eacd8c1-13d7-4f45-bba8-24ef91193db5" xlink:href="pfe-20210404.xsd#pfe_GSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_35af0ad9-0ffd-4ef0-a932-7f8fc29e37b2" xlink:to="loc_pfe_GSKMember_0eacd8c1-13d7-4f45-bba8-24ef91193db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9390332e-3417-485d-8ae1-32424e38327d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVMember_342cb66d-8dc7-4873-aa26-588e082d7298" xlink:href="pfe-20210404.xsd#pfe_ConsumerHealthcareJVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_30bbec99-b988-4122-ac47-466df95ba3a3" xlink:to="loc_pfe_ConsumerHealthcareJVMember_342cb66d-8dc7-4873-aa26-588e082d7298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86cecc5a-e617-4398-ae59-d2cb4fa5c44b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ab979c2-750b-4a6e-bd8b-ff45623659c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2ab979c2-750b-4a6e-bd8b-ff45623659c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5c0770a0-5fab-408b-b0ee-d9ec70a430df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestments_5c0770a0-5fab-408b-b0ee-d9ec70a430df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_d335971f-4346-4567-b6ae-80ef9b558a53" xlink:href="pfe-20210404.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_d335971f-4346-4567-b6ae-80ef9b558a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_2a9e6f87-a3ea-479d-a5b7-926b1555eafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_2a9e6f87-a3ea-479d-a5b7-926b1555eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2cf4288-fbdc-489f-a9b4-92705f3c23e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfb2f8c8-0b4b-4cbf-b0af-4e79f6405a1f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2cf4288-fbdc-489f-a9b4-92705f3c23e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_60eb7aa7-c0d5-4109-954d-ddc906f181eb" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_60eb7aa7-c0d5-4109-954d-ddc906f181eb" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_7fbec8da-9807-4b54-96cf-71e79b0f9330" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareJVMember_498ce61b-103e-46db-8504-df7b16709b86" xlink:href="pfe-20210404.xsd#pfe_ConsumerHealthcareJVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_58107b4b-ef9e-4213-8c4b-e3fa8d573242" xlink:to="loc_pfe_ConsumerHealthcareJVMember_498ce61b-103e-46db-8504-df7b16709b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a4bec472-2a43-4b93-bf91-dac0210b589e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_48b62ee7-f9a7-468b-9ad5-7a8313fb386a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_Revenues_48b62ee7-f9a7-468b-9ad5-7a8313fb386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_d55954bb-cf27-49b9-bec5-2711c7eebfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_CostOfRevenue_d55954bb-cf27-49b9-bec5-2711c7eebfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_068c4fe8-5e57-43e8-9859-127462a51eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_GrossProfit_068c4fe8-5e57-43e8-9859-127462a51eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cec13a67-34a8-4208-8ba8-6ad355245368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cec13a67-34a8-4208-8ba8-6ad355245368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1aa4b86e-9931-4817-8190-e80ae55c7cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_ProfitLoss_1aa4b86e-9931-4817-8190-e80ae55c7cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11c888e6-adaa-465c-a259-b7c9bc3d7d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_daf7add9-3ad3-4d8c-a956-bd53b7e2f73a" xlink:to="loc_us-gaap_NetIncomeLoss_11c888e6-adaa-465c-a259-b7c9bc3d7d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d7385e7-3f4a-4c1c-84a1-f2f30857a9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_fbe330c8-b1cb-4b09-a202-e4990e5aa8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d7385e7-3f4a-4c1c-84a1-f2f30857a9b3" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_fbe330c8-b1cb-4b09-a202-e4990e5aa8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9234bbbc-ec02-46e1-ada7-22111bcf2211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f0318f3a-7634-4ac9-9d5e-d6362c96a653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9234bbbc-ec02-46e1-ada7-22111bcf2211" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f0318f3a-7634-4ac9-9d5e-d6362c96a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_221b9781-4b34-4e9f-8b7f-917170f4dc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9234bbbc-ec02-46e1-ada7-22111bcf2211" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_221b9781-4b34-4e9f-8b7f-917170f4dc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_81ceed4a-b117-40bf-a906-d21b8b31ff47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_81ceed4a-b117-40bf-a906-d21b8b31ff47" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_82d392f3-b2ec-46c0-bf5c-1d7f231505c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_72949234-2d9b-4417-8ea9-46476d0af373" xlink:href="pfe-20210404.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_c7df3d17-dcfa-4a20-b974-6c72b84958b0" xlink:to="loc_pfe_ManufacturingOptimizationMember_72949234-2d9b-4417-8ea9-46476d0af373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:to="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6e43e21c-0864-40a6-83d3-6da91f48f5ac" xlink:to="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_694f75ca-a0ca-4634-b3cc-815c88c141e8" xlink:href="pfe-20210404.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d225ca87-dd29-4fb1-a331-2bf3013a2a15" xlink:to="loc_pfe_FocusedCompanyPlanMember_694f75ca-a0ca-4634-b3cc-815c88c141e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c85febb-c893-40fd-a378-41984b0bfcc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef9951c2-14b5-4516-9973-3fa676bb03c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef9951c2-14b5-4516-9973-3fa676bb03c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_ea0f48c1-62d6-4700-b5f4-be67a71b3486" xlink:href="pfe-20210404.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_ea0f48c1-62d6-4700-b5f4-be67a71b3486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8d1ba054-de1d-42aa-b47c-145e7ed2ff34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_443adf69-6ccc-448d-97b7-fada22495246" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8d1ba054-de1d-42aa-b47c-145e7ed2ff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1855f268-a7f0-481c-b433-abd09da0a43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1855f268-a7f0-481c-b433-abd09da0a43f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_276c060e-5147-4341-9d49-3ff7207f4051" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_faeaf8f2-60d8-432d-90dc-a7267322e997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_faeaf8f2-60d8-432d-90dc-a7267322e997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_daefdcde-d20f-4119-9583-4ee16e3598fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_CostOfSalesMember_daefdcde-d20f-4119-9583-4ee16e3598fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8bbf7a38-a794-4723-9f67-a6d9a8ca109f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8bbf7a38-a794-4723-9f67-a6d9a8ca109f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a404036f-cd93-4602-9a04-8589fb16de02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f15a4ef-92c9-4485-931d-b0189009827d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a404036f-cd93-4602-9a04-8589fb16de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8500a874-6d42-4508-a29b-f0b5128405d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_bab0c711-e99a-42a1-8b17-320ee6a51e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_bab0c711-e99a-42a1-8b17-320ee6a51e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember_9023bb95-060f-4294-8bcf-39a654c3ab18" xlink:href="pfe-20210404.xsd#pfe_CostReductionInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_aebd1c36-b487-45a1-8a3e-742814e063e2" xlink:to="loc_pfe_CostReductionInitiativesMember_9023bb95-060f-4294-8bcf-39a654c3ab18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ad6514c-204a-49b8-8846-ee3fbe553c3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_119bf09c-42e0-44da-8966-64b61f0b20ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_us-gaap_SeveranceCosts1_119bf09c-42e0-44da-8966-64b61f0b20ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_2b91adc1-98bb-4113-a9fe-2637af3888d0" xlink:href="pfe-20210404.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_2b91adc1-98bb-4113-a9fe-2637af3888d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f1368971-6624-4fd4-9db1-ff5a0b6156cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1f9df08a-1489-4552-8298-66f5fde0cf8a" xlink:to="loc_us-gaap_RestructuringCharges_f1368971-6624-4fd4-9db1-ff5a0b6156cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_b3eab2aa-c128-4eb7-aa09-f70d66647bf4" xlink:href="pfe-20210404.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_b3eab2aa-c128-4eb7-aa09-f70d66647bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_523cd93c-50a5-48a8-8ba1-922a51b3a423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_523cd93c-50a5-48a8-8ba1-922a51b3a423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_ee7bad1c-2447-47c9-88dc-335a2c0e190e" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_ee7bad1c-2447-47c9-88dc-335a2c0e190e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_47c9da8b-7f57-4311-8af9-e8af3061ef58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_47c9da8b-7f57-4311-8af9-e8af3061ef58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_abb7c24f-8c09-4c82-bf5d-febf84dcb0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_abb7c24f-8c09-4c82-bf5d-febf84dcb0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_37a86100-8846-4d8a-b409-bcb412dedc28" xlink:href="pfe-20210404.xsd#pfe_ImplementationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_ImplementationCosts_37a86100-8846-4d8a-b409-bcb412dedc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_95189fc2-2170-4f50-9e40-9fe3acd0a24e" xlink:href="pfe-20210404.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c80a4aed-4270-4f87-8282-5c07a67f72b3" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_95189fc2-2170-4f50-9e40-9fe3acd0a24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c714ad8-7fe1-4563-b5be-724e6f5a1ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c714ad8-7fe1-4563-b5be-724e6f5a1ffa" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9fcd8ca9-533a-4362-9924-10941c0cfe27" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_c3b29249-a46a-4b2d-8a67-a7fdc4659550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_us-gaap_EmployeeSeveranceMember_c3b29249-a46a-4b2d-8a67-a7fdc4659550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_51c0e77b-d591-4ca1-8a47-08fc115c4083" xlink:href="pfe-20210404.xsd#pfe_AssetImpairmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_pfe_AssetImpairmentsMember_51c0e77b-d591-4ca1-8a47-08fc115c4083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_e46b4f9c-6f80-4955-a4a9-da337d018527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a39827a5-7c3d-4c21-8c6e-7482ab3af194" xlink:to="loc_us-gaap_OtherRestructuringMember_e46b4f9c-6f80-4955-a4a9-da337d018527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f0505b67-f234-4752-a9ed-3fe1a742873e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8ace1040-7d8d-458d-b0e1-8d9757de6473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8ace1040-7d8d-458d-b0e1-8d9757de6473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_74f17dcc-0bc0-4b1a-a368-df1654bde421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f20bdbaf-120a-4530-9966-bcea7bdd4588" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_74f17dcc-0bc0-4b1a-a368-df1654bde421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ab04df0-4724-47b1-ae56-4451a41aecc9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_98c9c1ce-7fd7-4df7-9600-b3ab43671e71" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a39ae44c-91d8-400e-9d8c-f0977ae7c09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_us-gaap_RestructuringReserve_a39ae44c-91d8-400e-9d8c-f0977ae7c09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_be7f553a-2136-458a-a4b8-4c3161e6c5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_us-gaap_RestructuringCharges_be7f553a-2136-458a-a4b8-4c3161e6c5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_6f118ce9-41ad-4f0b-b73d-8aa5ca332b05" xlink:href="pfe-20210404.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_6f118ce9-41ad-4f0b-b73d-8aa5ca332b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_47206aff-00f7-43a6-9ae2-370195b23777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e0ce47fb-d9f0-4921-90cf-47179e519092" xlink:to="loc_us-gaap_RestructuringReserve_47206aff-00f7-43a6-9ae2-370195b23777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNet"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_a76338c3-bcb5-4992-b1ad-2170fc11122b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_68be2bc1-4222-4aa8-a8b1-2c5a0390f993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_a76338c3-bcb5-4992-b1ad-2170fc11122b" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_68be2bc1-4222-4aa8-a8b1-2c5a0390f993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_36e875e6-9c50-404f-a4a6-9aea915a4771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a11823f5-a28f-457b-9a49-e54e955b384f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_36e875e6-9c50-404f-a4a6-9aea915a4771" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a11823f5-a28f-457b-9a49-e54e955b384f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_45d2fa0f-6a1b-4b00-bfb6-80085729cc91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_45d2fa0f-6a1b-4b00-bfb6-80085729cc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f93c2ad2-0d63-45ef-8257-4c56ebd2ac36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_InterestExpense_f93c2ad2-0d63-45ef-8257-4c56ebd2ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_220774d0-2d89-431f-aa6f-37ae99f66365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_220774d0-2d89-431f-aa6f-37ae99f66365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_0c17107c-5e2d-4204-b3ff-c9a958aa6979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_0c17107c-5e2d-4204-b3ff-c9a958aa6979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_33c6386f-00b4-4164-a79d-dc62b13153ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_33c6386f-00b4-4164-a79d-dc62b13153ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0aedfaac-5076-4111-9dc8-d48572f8c253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0aedfaac-5076-4111-9dc8-d48572f8c253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_4a1b5282-bd57-40e5-ba02-c0491db786f0" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_4a1b5282-bd57-40e5-ba02-c0491db786f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b5697229-9edb-43cd-9806-3710bb45b264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b5697229-9edb-43cd-9806-3710bb45b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_be07edf2-7134-4268-ba97-3158752ba117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_be07edf2-7134-4268-ba97-3158752ba117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_c3d8d6d1-801c-44ad-acfb-477c457d582f" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_c3d8d6d1-801c-44ad-acfb-477c457d582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_5517f552-b868-4f31-a7e1-9e6ca1b30bb6" xlink:href="pfe-20210404.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_5517f552-b868-4f31-a7e1-9e6ca1b30bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_577ad9f2-a3d4-4e4d-a7eb-ac2b05020745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b2eec61d-cb2e-4789-8136-7d39f24a54c1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_577ad9f2-a3d4-4e4d-a7eb-ac2b05020745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherIncomeDeductionsNetFootnotesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_581f3729-30fb-4c5b-af1f-4291f01a17ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_581f3729-30fb-4c5b-af1f-4291f01a17ae" xlink:to="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_406eb972-24e2-467d-a0d4-cab33e61dca5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4ba253e-60f5-4a46-a25f-daaef5fda440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a3eb5289-e9c7-42de-bed9-73a8cda92dcd" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f4ba253e-60f5-4a46-a25f-daaef5fda440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad516c72-9a4c-4d80-a699-6243bd1deaf7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_8deff68f-f804-44d4-8f08-9cad8b837ec3" xlink:href="pfe-20210404.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1e4017b-750f-4bb3-af56-c7da0c4e45f4" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_8deff68f-f804-44d4-8f08-9cad8b837ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3dc7b4c-d8b8-4150-a359-74b707b99600" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_afbd4537-9195-4256-a8c9-26ad9040a86d" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_398a26cc-f5db-4f7f-9d51-51a6bc338400" xlink:to="loc_pfe_BioNTechMember_afbd4537-9195-4256-a8c9-26ad9040a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b160379a-5f2a-41ee-b5e1-8bb3c69830f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_95174ee5-169c-4e4d-98ea-826a0dee2962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c908609-63e8-4067-9cd8-9535c33bf062" xlink:to="loc_us-gaap_CollaborativeArrangementMember_95174ee5-169c-4e4d-98ea-826a0dee2962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b8c0f113-ade5-4c4e-8bc4-9572b319cf19" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneAndBioNTechMember_53bf8970-37d0-433d-b6b7-6c9a07d2473a" xlink:href="pfe-20210404.xsd#pfe_AllogeneAndBioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:to="loc_pfe_AllogeneAndBioNTechMember_53bf8970-37d0-433d-b6b7-6c9a07d2473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllogeneMember_1bf70b11-adbd-4bcf-9df7-bedf02292fda" xlink:href="pfe-20210404.xsd#pfe_AllogeneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d552b2-fb3a-40be-8ee9-89b5663578bb" xlink:to="loc_pfe_AllogeneMember_1bf70b11-adbd-4bcf-9df7-bedf02292fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bfef5fde-12e9-42b4-8bcb-4ff9ca03f2bd" xlink:to="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4c38f3d2-cd68-47e4-97f4-f836e1afae4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4c38f3d2-cd68-47e4-97f4-f836e1afae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_3e8e497f-77fa-465b-b350-0a27d659c2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_ProceedsFromCollaborators_3e8e497f-77fa-465b-b350-0a27d659c2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_0a647908-7df3-499b-801a-5b4f9e2e4b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_89571076-188c-4499-905c-270398e71317" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_0a647908-7df3-499b-801a-5b4f9e2e4b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMatters"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_95ba5da4-a40d-42b8-93eb-05bc6951ec25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9212703b-5d1d-47b9-9070-7715f2de631f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95ba5da4-a40d-42b8-93eb-05bc6951ec25" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9212703b-5d1d-47b9-9070-7715f2de631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e472cf71-33b8-4bec-bd15-7919cdfbdf45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_445b0fe3-b8a3-4511-8e06-109c75bcd456" xlink:href="pfe-20210404.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e472cf71-33b8-4bec-bd15-7919cdfbdf45" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_445b0fe3-b8a3-4511-8e06-109c75bcd456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_998251dd-7bab-44be-a6a9-977a57501c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a2f066ef-eaca-44dc-8a4d-6015844293de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_998251dd-7bab-44be-a6a9-977a57501c59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a2f066ef-eaca-44dc-8a4d-6015844293de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4a0b87d8-10ec-44e0-806d-a7b810b1ab25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_998251dd-7bab-44be-a6a9-977a57501c59" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4a0b87d8-10ec-44e0-806d-a7b810b1ab25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_ae58ac1e-3a43-44a1-ba01-2682091fb96d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_ae58ac1e-3a43-44a1-ba01-2682091fb96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_ec0db910-27e1-4167-993a-e50f65ecd208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_ec0db910-27e1-4167-993a-e50f65ecd208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_6bfefd26-45bd-43ca-a318-438e6435946d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_6bfefd26-45bd-43ca-a318-438e6435946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_d42e0ee6-7ea0-4d46-b750-e7f3e70b16eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_d42e0ee6-7ea0-4d46-b750-e7f3e70b16eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_908c5f81-0a4d-477f-9f17-a320dcbfc8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_908c5f81-0a4d-477f-9f17-a320dcbfc8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_818461f4-9843-4b78-997e-6116ba2868ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_818461f4-9843-4b78-997e-6116ba2868ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_430e7ebc-c1e4-4914-9ebe-c179fd72193c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_430e7ebc-c1e4-4914-9ebe-c179fd72193c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_25611d57-5bdf-49e3-9463-2dad77f72d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_25611d57-5bdf-49e3-9463-2dad77f72d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_5dc2e5dd-e5c3-46f5-91ca-937c890caffb" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_5dc2e5dd-e5c3-46f5-91ca-937c890caffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_633dfea6-451a-48b0-b22d-458ec1ea34f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_633dfea6-451a-48b0-b22d-458ec1ea34f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3fc8fce4-71a0-4402-90ce-3bb7c931b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93521e82-f954-42ea-9244-9173e5631e9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3fc8fce4-71a0-4402-90ce-3bb7c931b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cd33ec0b-11b7-47bd-858a-24ed6e7767bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_b2a8b3a7-bf8e-4f6a-9651-d9e59fce8f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cd33ec0b-11b7-47bd-858a-24ed6e7767bb" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_b2a8b3a7-bf8e-4f6a-9651-d9e59fce8f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f3a3196d-b374-45bf-bc93-5147504ec89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_aeea5434-d758-456a-94ef-0eee2145cb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f3a3196d-b374-45bf-bc93-5147504ec89b" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_aeea5434-d758-456a-94ef-0eee2145cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fa33f0ba-b3ca-411c-9834-caa523ce68a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fa33f0ba-b3ca-411c-9834-caa523ce68a0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fef1d464-55d6-4dd2-ac43-8ba450fdd837" xlink:to="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_707feb14-dd3b-40c4-991f-6ced5d44fe23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aef21fa3-615f-4788-a5a0-9012cac46230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aef21fa3-615f-4788-a5a0-9012cac46230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bcb41318-74da-40e5-9004-da1de0735a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bcb41318-74da-40e5-9004-da1de0735a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_62f0e80f-a2c7-4e4e-9431-0d0286fc7455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_62f0e80f-a2c7-4e4e-9431-0d0286fc7455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_d1a344a2-25b3-411c-b788-10d39a48b4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81faae91-1126-47e9-8dfe-720c6a71b566" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_d1a344a2-25b3-411c-b788-10d39a48b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f45cdd3c-dddc-4f7b-8dee-2432d11ae602" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adbdf9fd-e18f-4afa-b07f-09af78991814" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74113af9-98ca-436c-8970-8a89cede88e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74113af9-98ca-436c-8970-8a89cede88e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1ea5a99-a86b-48f8-b530-98aee594ba41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1ea5a99-a86b-48f8-b530-98aee594ba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b1b1c6b-fef7-456b-b05f-cf465b980ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f2bdcfd-b227-440c-9805-dc2ea13f4f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b1b1c6b-fef7-456b-b05f-cf465b980ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0b5e7e86-bbd1-492d-a6a7-13a695661967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f4f60459-0ab5-4014-ae26-4c40f906d95d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0b5e7e86-bbd1-492d-a6a7-13a695661967" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f4f60459-0ab5-4014-ae26-4c40f906d95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9472ec70-795b-4ab8-aefa-2dc29bfd5801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9472ec70-795b-4ab8-aefa-2dc29bfd5801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f9f61493-7e68-45f8-a907-fa222005e762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f9f61493-7e68-45f8-a907-fa222005e762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_1d906b3c-cd88-494e-8ff6-582601ec68a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_1d906b3c-cd88-494e-8ff6-582601ec68a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_65b390d6-679d-4d6f-a8b2-8e67fd4e2b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_65b390d6-679d-4d6f-a8b2-8e67fd4e2b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7d48a190-9d7f-4844-9a58-80cee00af1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7d48a190-9d7f-4844-9a58-80cee00af1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_afcfaee0-1b86-4ec5-938f-7b1794dcf09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_afcfaee0-1b86-4ec5-938f-7b1794dcf09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_5037697d-23a1-48c2-a790-48fcaf19f2e7" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_5037697d-23a1-48c2-a790-48fcaf19f2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_d5cdebcf-9f01-423c-8c39-80ed5d0540f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_d5cdebcf-9f01-423c-8c39-80ed5d0540f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1a045d59-9173-432d-b852-c0655e868eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1a045d59-9173-432d-b852-c0655e868eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_20e277b4-62a2-460b-9714-7b2761c47199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_20e277b4-62a2-460b-9714-7b2761c47199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_5d088e03-90b1-423a-9c6a-698b991ce324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_5d088e03-90b1-423a-9c6a-698b991ce324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ff3ca724-5550-4273-98b2-bedbb9ece4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ff3ca724-5550-4273-98b2-bedbb9ece4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0aee9ded-c476-4496-a84d-e060ab10cfcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0aee9ded-c476-4496-a84d-e060ab10cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3655d33b-a4ad-4317-85d8-8ccfc6c2524a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060a3c92-e8e4-499f-8f85-c1f6466793b9" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3655d33b-a4ad-4317-85d8-8ccfc6c2524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22a29bb7-776c-48d2-b070-59c737461b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22a29bb7-776c-48d2-b070-59c737461b9e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c0008b4b-8294-48e1-9d48-c81337066afe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_397199c2-42d4-421f-a79b-6d4a04d1d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_MoneyMarketFundsMember_397199c2-42d4-421f-a79b-6d4a04d1d1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_733e0d3b-6a61-4728-af0a-c048f00704d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_733e0d3b-6a61-4728-af0a-c048f00704d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d4c99373-4a1b-4839-ab58-8b050de6bdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d4c99373-4a1b-4839-ab58-8b050de6bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_29bca77a-557a-48db-a4a0-ae5da63836e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6eb14b5-4a9a-4dfb-9445-200396984d97" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_29bca77a-557a-48db-a4a0-ae5da63836e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e823083a-766c-4d66-8956-854156bd3fcd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c137e7d-3464-43cc-b02c-17686b940e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c137e7d-3464-43cc-b02c-17686b940e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0c4200c3-a5cd-45aa-a48d-4c8165032243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6ec2db6-d888-4051-9b73-816b6ef0dfe3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0c4200c3-a5cd-45aa-a48d-4c8165032243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_96cd182a-4e17-4a07-9bf6-7b93caec74bb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_69343a39-4c8b-4b7b-8d97-b83959bfd130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_69343a39-4c8b-4b7b-8d97-b83959bfd130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_9d7ff9a5-3639-4d7d-97c1-a95bd1720e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_9d7ff9a5-3639-4d7d-97c1-a95bd1720e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_d5bf141e-b8ef-4054-92a4-7db56548007d" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_pfe_LongtermInvestmentsMember_d5bf141e-b8ef-4054-92a4-7db56548007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_496ee368-0326-41ff-9208-ba92200022cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_496ee368-0326-41ff-9208-ba92200022cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_569fb0d0-8d3c-49f1-9743-c09af6262ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_569fb0d0-8d3c-49f1-9743-c09af6262ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a18a7fe-a1ee-4c03-8b4b-5db9099752d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a47591-acc2-4e35-8545-524e71e4b380" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8a18a7fe-a1ee-4c03-8b4b-5db9099752d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f2ffd0-17ab-4caa-8d25-fcb69909c9fd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c573ce25-bb48-4065-8fb1-ace626dfd235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_92d9d5bb-3b65-480f-90ba-9e1d71363eb6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c573ce25-bb48-4065-8fb1-ace626dfd235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0eb9f7e1-1657-4df9-91b3-18016fd75372" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c2c179d8-26a3-4b74-ace2-f081813acbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:to="loc_us-gaap_InterestRateContractMember_c2c179d8-26a3-4b74-ace2-f081813acbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ee697317-9fae-4463-a110-b4a94a978e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6483ad91-302a-4da3-83d0-e08b661bf128" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ee697317-9fae-4463-a110-b4a94a978e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ef8f82-203f-4026-b90a-121c7c3243d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f3a491a5-e0af-4fcc-9f2e-3becae5bff8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f3a491a5-e0af-4fcc-9f2e-3becae5bff8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1611de01-46c5-4958-9fef-83d6e30c7243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1611de01-46c5-4958-9fef-83d6e30c7243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_9944588b-e622-458c-a5a0-f7a1b5dc43eb" xlink:href="pfe-20210404.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_9944588b-e622-458c-a5a0-f7a1b5dc43eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_f97b299b-2f5f-4eca-ad42-c20a2a94136d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_f97b299b-2f5f-4eca-ad42-c20a2a94136d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c9bdf986-6518-4446-8c51-0a741873f927" xlink:href="pfe-20210404.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c9bdf986-6518-4446-8c51-0a741873f927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8137a608-43bf-4c2d-a06d-07d595a45b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8137a608-43bf-4c2d-a06d-07d595a45b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_06e6b3b8-3fbc-45be-8039-89a15cfa33fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_06e6b3b8-3fbc-45be-8039-89a15cfa33fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3e872a18-5e09-473a-af6f-5fa67294f0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3e872a18-5e09-473a-af6f-5fa67294f0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d2e2d254-0b7e-411c-8e29-5157d479c6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_Assets_d2e2d254-0b7e-411c-8e29-5157d479c6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_45f68c59-368a-4c1c-b38a-8d69f6553a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_45f68c59-368a-4c1c-b38a-8d69f6553a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_486e69f2-f54c-4ec5-bb58-e62facef83fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_486e69f2-f54c-4ec5-bb58-e62facef83fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_65194172-1f23-4a26-a206-fa62258eefe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_us-gaap_DerivativeLiabilities_65194172-1f23-4a26-a206-fa62258eefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_9f4d394c-7891-4cc4-95ff-1dd4f88d1632" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_99a82321-ac5a-4fa0-bc6f-b2798a807ef6" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_9f4d394c-7891-4cc4-95ff-1dd4f88d1632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_894bca52-c578-4d25-87e4-5b44e3267e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_894bca52-c578-4d25-87e4-5b44e3267e28" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c9b9c04c-6f76-49b3-af71-9913be8e7015" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0b5f7718-3d81-488e-86ee-d5eff456de05" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a6983c52-cbf0-443f-b2b4-3b4dc14f1ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a6983c52-cbf0-443f-b2b4-3b4dc14f1ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_859274c3-54cd-443a-9026-0477c05732dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c9f5dce-f73c-405f-a3e3-fc097d0300bb" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_859274c3-54cd-443a-9026-0477c05732dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6750d25f-cd2a-4d1c-b86a-32abb9cd1a8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c2ea04b4-3b14-4b1f-891c-0d485a6cd9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a488289-05b9-425e-8c72-28d656736b37" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c2ea04b4-3b14-4b1f-891c-0d485a6cd9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d38afe8-7b11-40fc-88f9-1c543feea8f7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e6e40bcb-e12d-4a8d-8a65-ee082d0657cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2db1bc1f-fa85-4e7c-80a9-a4d446aefe3c" xlink:to="loc_us-gaap_LongTermDebtFairValue_e6e40bcb-e12d-4a8d-8a65-ee082d0657cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsbyClassificationTypeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d42e96bc-888e-4d14-bba7-293458faa347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d42e96bc-888e-4d14-bba7-293458faa347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cfd9d030-6af5-4357-8462-b46364580476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cfd9d030-6af5-4357-8462-b46364580476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_e489c81b-62c6-4e5c-a33f-04aaf53aacbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_e489c81b-62c6-4e5c-a33f-04aaf53aacbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a0495abb-a3b5-4fc3-8509-c91a4a45955e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_545ceddd-f4b1-4baa-9efc-6ec4bcb04782" xlink:to="loc_us-gaap_ShortTermInvestments_a0495abb-a3b5-4fc3-8509-c91a4a45955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_205db5a4-fedf-4473-aed5-0b6fda9f8d08" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_205db5a4-fedf-4473-aed5-0b6fda9f8d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_796b127c-fbeb-41b7-b5ba-b527b1838cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_796b127c-fbeb-41b7-b5ba-b527b1838cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_b752b6c3-58c8-4ba9-88d2-941c18b0b93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_b752b6c3-58c8-4ba9-88d2-941c18b0b93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_106f2494-4342-4b2c-8e5d-1725716fdda2" xlink:href="pfe-20210404.xsd#pfe_PrivateEquityInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:to="loc_pfe_PrivateEquityInvestments_106f2494-4342-4b2c-8e5d-1725716fdda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_b19b07eb-d88e-4f63-86c3-65516fe6af3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_16247a8a-fece-49a6-bfc1-a725b4064cf4" xlink:to="loc_us-gaap_OtherLongTermInvestments_b19b07eb-d88e-4f63-86c3-65516fe6af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4f74533c-adf0-4131-b1a3-8cae217385aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:to="loc_us-gaap_EquityMethodInvestments_4f74533c-adf0-4131-b1a3-8cae217385aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_8efd9f52-2dfe-4949-8393-245dce3afa1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:to="loc_us-gaap_LongTermInvestments_8efd9f52-2dfe-4949-8393-245dce3afa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_aa090c52-7cc7-46e5-9c26-ac443c5fd07d" xlink:href="pfe-20210404.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61e1ef1f-af21-41d3-a914-17d0ed42c1d2" xlink:to="loc_pfe_HeldToMaturityCashEquivalents_aa090c52-7cc7-46e5-9c26-ac443c5fd07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b57f846-07df-46f7-ada9-9dfa7fb2ce0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b57f846-07df-46f7-ada9-9dfa7fb2ce0d" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2aab8c7-0c18-4848-a368-308a023d8350" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_17a6ea6e-2d6b-415b-a666-be6fe0782c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_BankTimeDepositsMember_17a6ea6e-2d6b-415b-a666-be6fe0782c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d9820951-b4e3-41c4-93b1-925ee0a2f019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d9820951-b4e3-41c4-93b1-925ee0a2f019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26b45698-f544-4224-a269-27aec5989374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26b45698-f544-4224-a269-27aec5989374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c19cb04f-223a-411b-95d5-b3a0b5d35da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cd556c8-9cce-439a-8162-32f00e57ed85" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c19cb04f-223a-411b-95d5-b3a0b5d35da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:href="pfe-20210404.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_59a7c34a-e419-4c03-bc54-aadc874b848c" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc9673cd-524b-4dc3-a6c3-72bd43141f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc9673cd-524b-4dc3-a6c3-72bd43141f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f5634af-687b-4be2-b717-0beadb74a44e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f5634af-687b-4be2-b717-0beadb74a44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71a1bd08-c0f2-481e-936d-1f6caddb9e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71a1bd08-c0f2-481e-936d-1f6caddb9e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2c55f66-0c5b-43af-921d-e19d22bed504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_80087092-5711-498a-a93e-ae0ac7844547" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2c55f66-0c5b-43af-921d-e19d22bed504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_936993b3-91c2-4c3b-a3e3-31ed6825151a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_936993b3-91c2-4c3b-a3e3-31ed6825151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3fd7520-948b-4b25-98c1-879f25cf1349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e3fd7520-948b-4b25-98c1-879f25cf1349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_dca4c682-d5fd-4fe3-8f82-8b05ec5001b5" xlink:href="pfe-20210404.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_dca4c682-d5fd-4fe3-8f82-8b05ec5001b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_882ba5e0-9192-4f14-8e0e-fef6840724ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aec498ed-933b-4497-b321-85415641ada5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_882ba5e0-9192-4f14-8e0e-fef6840724ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_97827489-1257-45b2-80a0-32e3cb9c1b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecurities_97827489-1257-45b2-80a0-32e3cb9c1b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_5b55a6f6-8953-494e-bd81-66d0f49bcc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_5b55a6f6-8953-494e-bd81-66d0f49bcc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_20f68f45-2438-423a-be75-c4763152c0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_20f68f45-2438-423a-be75-c4763152c0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e0aa3c34-4742-4742-8574-f9129026e028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_7066ae4b-655b-48be-bf80-13a602e37eba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e0aa3c34-4742-4742-8574-f9129026e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_daa3c8b1-9ff1-4181-af56-8bd71835acca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_daa3c8b1-9ff1-4181-af56-8bd71835acca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_88e616a3-b91b-40ca-a5fa-aecb06a84cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_88e616a3-b91b-40ca-a5fa-aecb06a84cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_c35c5fa0-3a73-4076-a25d-1c33e93f4a36" xlink:href="pfe-20210404.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_c35c5fa0-3a73-4076-a25d-1c33e93f4a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_5c286de3-2d62-4c5f-8aac-e463bcb7c4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_1d53538c-b1cb-4148-b369-460d9e44ba2c" xlink:to="loc_us-gaap_HeldToMaturitySecurities_5c286de3-2d62-4c5f-8aac-e463bcb7c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_c9749db5-8935-4821-9c05-07d3cd791bf3" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_c9749db5-8935-4821-9c05-07d3cd791bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_5fca70ea-63db-4642-b41b-49a818a2340a" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_5fca70ea-63db-4642-b41b-49a818a2340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_85f8f0bb-8dbb-4d58-8fb5-ac0c1c77b069" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_85f8f0bb-8dbb-4d58-8fb5-ac0c1c77b069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_d4ef6722-c3f9-49fb-97c4-23a5cd5bdc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_d4ef6722-c3f9-49fb-97c4-23a5cd5bdc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_48e5f1fd-76d2-4694-9afa-042235d24a3c" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_48e5f1fd-76d2-4694-9afa-042235d24a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_cc4ea40b-ae84-4cc1-add2-32e85a4e9f93" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_cc4ea40b-ae84-4cc1-add2-32e85a4e9f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c8884ce0-5184-4a4f-b2e5-76847f899c19" xlink:href="pfe-20210404.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_0a90d3a1-4a9c-4cfd-9383-cc3cdfc98b23" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_c8884ce0-5184-4a4f-b2e5-76847f899c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_60a9a423-5c8a-473a-8593-b91f68ea61e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0f253d14-e369-47cf-923f-7a3dc816cc36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60a9a423-5c8a-473a-8593-b91f68ea61e3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0f253d14-e369-47cf-923f-7a3dc816cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f1094b39-0b67-43bf-b2cb-2829604c0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60a9a423-5c8a-473a-8593-b91f68ea61e3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f1094b39-0b67-43bf-b2cb-2829604c0e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e2fddf7a-c10b-47d5-85a6-18149f6e9a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60a9a423-5c8a-473a-8593-b91f68ea61e3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e2fddf7a-c10b-47d5-85a6-18149f6e9a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26c731d9-2626-4b12-ba39-b9887b450c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_b77261bb-3bd3-4339-90de-4dfbb74a6f85" xlink:href="pfe-20210404.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26c731d9-2626-4b12-ba39-b9887b450c7f" xlink:to="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_b77261bb-3bd3-4339-90de-4dfbb74a6f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_5a39837b-3f3c-4489-bbed-c7a0084a6518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26c731d9-2626-4b12-ba39-b9887b450c7f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_5a39837b-3f3c-4489-bbed-c7a0084a6518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_d44274d9-bb36-465b-bdc9-215a683c3b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_us-gaap_CommercialPaper_d44274d9-bb36-465b-bdc9-215a683c3b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_267fcbd6-fb55-4a00-92a1-ce96ff902a73" xlink:href="pfe-20210404.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_267fcbd6-fb55-4a00-92a1-ce96ff902a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_47526e59-7a43-4ae2-be02-4d6c21a35de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_us-gaap_OtherShortTermBorrowings_47526e59-7a43-4ae2-be02-4d6c21a35de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_8b71d118-2070-464e-8f9c-3eacc95d9440" xlink:href="pfe-20210404.xsd#pfe_ShorttermDebtGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_pfe_ShorttermDebtGross_8b71d118-2070-464e-8f9c-3eacc95d9440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_8e301d62-f96c-4427-9a16-68b26505e2c0" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_8e301d62-f96c-4427-9a16-68b26505e2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_93238905-3f24-4fed-b394-3c3b3f581cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_93238905-3f24-4fed-b394-3c3b3f581cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_66e442fb-5b20-4400-8061-29687bf29f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8af1dc7-dc11-46b6-a498-5a6a873971e0" xlink:to="loc_us-gaap_DebtCurrent_66e442fb-5b20-4400-8061-29687bf29f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1cfb1a7c-1d63-4054-a081-4d3e6bff14c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1cfb1a7c-1d63-4054-a081-4d3e6bff14c3" xlink:to="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6a30c0b-6daa-45ea-a8fc-73afccd7ae1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_db1b02dc-6042-4e1f-81fb-a61099765b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f6c415f9-71e3-4a59-a7cf-262da587d690" xlink:to="loc_us-gaap_UnsecuredDebtMember_db1b02dc-6042-4e1f-81fb-a61099765b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_437fc178-a792-4de5-b436-b462e610ef6f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8cdbbd27-975e-4509-a76c-7ef304ba46fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8cdbbd27-975e-4509-a76c-7ef304ba46fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_9617f3d4-c856-4eb6-9e93-ac82fa5f9fde" xlink:href="pfe-20210404.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_9617f3d4-c856-4eb6-9e93-ac82fa5f9fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f4f4867-2678-4cb9-b32b-0b63e2446784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f4f4867-2678-4cb9-b32b-0b63e2446784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_1d5b5d12-f15f-43f1-b402-e1a65c6170e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_OtherLongTermDebt_1d5b5d12-f15f-43f1-b402-e1a65c6170e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_902d900a-a0e3-4830-b533-75e9bca632db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_902d900a-a0e3-4830-b533-75e9bca632db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f64580c5-c7d5-4843-af69-69e902786fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33de6f6e-a98f-4f18-ad8a-9e58b80dc69d" xlink:to="loc_us-gaap_LongTermDebtCurrent_f64580c5-c7d5-4843-af69-69e902786fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_638eafd0-4bd5-452e-b92c-9b8305383324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_638eafd0-4bd5-452e-b92c-9b8305383324" xlink:to="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95c88543-cb8e-4e6c-92a1-04e3b2cee270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a32ed64e-4de2-4d5c-afd4-8c3c41ed539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9db2b4cf-2fe8-405a-b920-2f75054f2f80" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a32ed64e-4de2-4d5c-afd4-8c3c41ed539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2cd91811-8d80-47ee-a6ea-36ad2f30bfa6" xlink:to="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_64c9b0dc-14b7-4e95-8dcc-763ab8bbf402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d374bae6-fe12-46a3-bd09-8533a55031b5" xlink:to="loc_us-gaap_DerivativeTermOfContract_64c9b0dc-14b7-4e95-8dcc-763ab8bbf402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8a0deb5e-a1a1-485b-a74e-f098003bdab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8a0deb5e-a1a1-485b-a74e-f098003bdab6" xlink:to="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:href="pfe-20210404.xsd#pfe_HedgedItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:href="pfe-20210404.xsd#pfe_HedgedItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemAxis_6741ddd5-df86-46cf-b64e-9767c8a6ce0d" xlink:to="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_3020d8c8-a656-4713-a90b-e364cff47852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemDomain_1ac41f67-d497-4e1a-bb8e-893612af2a09" xlink:to="loc_us-gaap_SalesMember_3020d8c8-a656-4713-a90b-e364cff47852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfe74092-cca4-423d-8fb9-3506b0137073" xlink:to="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88abe2cc-2ec1-4073-9a4b-adb2dfeb426d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_88abe2cc-2ec1-4073-9a4b-adb2dfeb426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a0b728a9-553c-43c8-bf79-ea1c5747449f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_11a4f60a-9b11-4321-b3f1-e04c4fe0eb86" xlink:to="loc_us-gaap_NondesignatedMember_a0b728a9-553c-43c8-bf79-ea1c5747449f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7f05a986-23cb-412f-8cf8-675a4602e1c8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a452d475-dde2-45cb-9214-ced87b4b1417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a452d475-dde2-45cb-9214-ced87b4b1417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a034ab61-269e-445f-8abf-b37462fa0234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a96f25b0-a94a-4ad9-89ba-613e2c14e354" xlink:to="loc_us-gaap_InterestRateContractMember_a034ab61-269e-445f-8abf-b37462fa0234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_12544474-382a-4764-b8f4-0ce3959c8c32" xlink:to="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8505af2c-cf49-4da2-ba76-e3e82b032560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8505af2c-cf49-4da2-ba76-e3e82b032560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f22095a4-217b-4f53-91e6-8178c779cc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeAssets_f22095a4-217b-4f53-91e6-8178c779cc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c5872820-cdd9-4c30-a009-055b359f9e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a6c54218-c28c-412f-ba2c-61812a781ff1" xlink:to="loc_us-gaap_DerivativeLiabilities_c5872820-cdd9-4c30-a009-055b359f9e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ce2042b-e9b6-4102-8438-e3fa50b714a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ce2042b-e9b6-4102-8438-e3fa50b714a8" xlink:to="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_72a6526a-c24e-43a1-92dd-cba291e56c58" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_8b6630bd-e151-45a1-a865-2a3649ed422c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:to="loc_us-gaap_CashFlowHedgingMember_8b6630bd-e151-45a1-a865-2a3649ed422c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1fa873b1-4def-49d4-85ce-d1cb649ce010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e766e011-e993-492d-863f-f3a3e0e2b019" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1fa873b1-4def-49d4-85ce-d1cb649ce010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0d22123e-5932-483e-8386-7b239e8bde83" xlink:to="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0cad5e31-5c74-4bd8-b0a9-8968827fce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0cad5e31-5c74-4bd8-b0a9-8968827fce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5976068d-4374-44d0-b651-42d1e43cdca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_faa944b2-c64e-49c1-b62f-eb83660424b5" xlink:to="loc_us-gaap_NondesignatedMember_5976068d-4374-44d0-b651-42d1e43cdca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_948be04f-b8e2-4153-84a4-e7a7dbdf14eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_baa47a3c-838a-4c1f-8fb5-df49780715e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_baa47a3c-838a-4c1f-8fb5-df49780715e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_5bc3ca5a-14d3-4946-b653-dda1527eb5f7" xlink:href="pfe-20210404.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e41b96c6-e8d6-4a62-b197-371f3dafc539" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_5bc3ca5a-14d3-4946-b653-dda1527eb5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b5faaf7-7988-4565-8b96-e5a745554312" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93382cf9-a857-4109-937f-3eba287f7cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93382cf9-a857-4109-937f-3eba287f7cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_27949ca3-54c2-4f4c-aec5-ec4248438b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_us-gaap_InterestRateContractMember_27949ca3-54c2-4f4c-aec5-ec4248438b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_c5bcb5d8-1fd7-41ed-a97d-1b61be97b7b6" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_c5bcb5d8-1fd7-41ed-a97d-1b61be97b7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_38e9a65d-04ed-4e1b-9158-af02c0c60afb" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_92b68044-9e6c-426f-ab9b-6e5ee6368411" xlink:to="loc_pfe_ForeignCurrencyDebtMember_38e9a65d-04ed-4e1b-9158-af02c0c60afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_17fd2d6c-4f4c-4c2c-8725-8eb422765459" xlink:to="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6b5e79c0-aa1c-46e7-aac1-96130a5a7e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6b5e79c0-aa1c-46e7-aac1-96130a5a7e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ec747373-77d7-411d-999a-2ce9cd43e93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ec747373-77d7-411d-999a-2ce9cd43e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c2797630-a5ce-443c-bc6d-ad9c49282630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c2797630-a5ce-443c-bc6d-ad9c49282630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e65ce894-50a1-43aa-904d-4aa980d68b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_e65ce894-50a1-43aa-904d-4aa980d68b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c5825d6f-b8f8-4566-a0f6-c183c9a422d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c5825d6f-b8f8-4566-a0f6-c183c9a422d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_a125dadb-e45d-4060-9b4c-6f17bfd9f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_a125dadb-e45d-4060-9b4c-6f17bfd9f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_bef59cef-cc8a-4335-9cfe-e3e3d5858082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_bef59cef-cc8a-4335-9cfe-e3e3d5858082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_b1ca0bc9-90ba-494f-b5fb-fedf2f126cab" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_b1ca0bc9-90ba-494f-b5fb-fedf2f126cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_e4f80eb5-ddb6-4767-8245-50ca32380168" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_e4f80eb5-ddb6-4767-8245-50ca32380168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_ce267598-1f44-4bc4-b837-e88fd37c5f7c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_ce267598-1f44-4bc4-b837-e88fd37c5f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_83aad5c6-0ed4-4d69-886c-ca7c47c51784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_83aad5c6-0ed4-4d69-886c-ca7c47c51784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_aa002962-bd18-4df1-bc46-f9b1d211383d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_aa002962-bd18-4df1-bc46-f9b1d211383d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_bad87e6d-0a90-4add-bd9c-a7af031a4641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_bad87e6d-0a90-4add-bd9c-a7af031a4641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_57f9e9d7-40d1-461e-9a07-2a97f16a6eec" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_57f9e9d7-40d1-461e-9a07-2a97f16a6eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_20c70c8f-08ff-4651-8d12-71042b51475c" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_20c70c8f-08ff-4651-8d12-71042b51475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_c884d13a-e594-40d5-9669-14114401c310" xlink:href="pfe-20210404.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c2e33ec0-9a7a-45c0-838f-d3a61dbb94de" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_c884d13a-e594-40d5-9669-14114401c310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_44ae8088-8a71-4901-8faa-2fad4df0a96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_44ae8088-8a71-4901-8faa-2fad4df0a96c" xlink:to="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_64fe717f-e3df-4641-93a7-7a8a64cfa7a3" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6e7ed468-2a15-48d6-a9b3-bb4f0a59e3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee85619-7879-43f3-9e01-432ab91813a0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6e7ed468-2a15-48d6-a9b3-bb4f0a59e3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90607e8e-83fc-45b8-ba64-2793e1776d33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16554262-c44d-42b1-80ee-2ccb140124de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8375b1b-bfa0-44ee-81a6-8d2d1c8f5261" xlink:to="loc_us-gaap_CostOfSalesMember_16554262-c44d-42b1-80ee-2ccb140124de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f8361026-7522-4753-848f-b8c6667935b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73778387-3c7b-44b2-9c71-e2fd08d2fd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73778387-3c7b-44b2-9c71-e2fd08d2fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_d36ec837-b8ee-491d-9fa7-b5ee37874d6e" xlink:href="pfe-20210404.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0a74bd72-384f-4ae5-9b40-b2462acafdf5" xlink:to="loc_pfe_ForeignCurrencyDebtMember_d36ec837-b8ee-491d-9fa7-b5ee37874d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_523719f1-c3fe-4f0c-9562-7a10f5aa20c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a62a6f10-a992-4b25-8cd6-96e6e7c0984b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e57763-94fd-4adf-944a-e09596178bfc" xlink:to="loc_us-gaap_UnsecuredDebtMember_a62a6f10-a992-4b25-8cd6-96e6e7c0984b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_40a75036-d4a7-438e-a069-2f64977fff49" xlink:to="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ffb736c-8271-4ac4-81fb-5b7d8ae36595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4ffb736c-8271-4ac4-81fb-5b7d8ae36595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_97b3155f-7296-4ce3-9591-8a7720bd2f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_97b3155f-7296-4ce3-9591-8a7720bd2f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_cfa2ff37-41f6-4d59-b244-f5a1ba5ac945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_cfa2ff37-41f6-4d59-b244-f5a1ba5ac945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_0c364ab7-8045-4515-b780-4e7325ac0f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_DebtCurrent_0c364ab7-8045-4515-b780-4e7325ac0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_851d3292-e1c6-4429-9a87-80b0447a9291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a584db7f-cba7-4ea5-a750-49e82dd64b18" xlink:to="loc_us-gaap_LongTermDebt_851d3292-e1c6-4429-9a87-80b0447a9291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6ee5845e-de05-49f1-84b2-036599074f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ee5845e-de05-49f1-84b2-036599074f85" xlink:to="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bbd369fc-b023-46d6-8a1b-06fcc0a82d65" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_19f80720-ae87-4de2-a642-359a1b99569e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0383038f-a9ce-44a6-b20d-b933468022fc" xlink:to="loc_us-gaap_LongTermDebtMember_19f80720-ae87-4de2-a642-359a1b99569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_294aac6d-c1a5-485e-9148-829d5d0ab310" xlink:to="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_84dee205-47f4-44b5-9192-85f708e14fab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_84dee205-47f4-44b5-9192-85f708e14fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f581f3b2-89f7-47e3-97ca-03514d99021f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f581f3b2-89f7-47e3-97ca-03514d99021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_d64c0921-3318-4e50-b709-dab2778b067e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4e9b87dc-7d76-4bfe-a97a-64d0555e2d09" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_d64c0921-3318-4e50-b709-dab2778b067e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#FinancialInstrumentsCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_8f140a82-c639-4aef-af2d-f43de3a261b0" xlink:href="pfe-20210404.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_74137e16-5d86-4772-b10c-71c736016a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8f140a82-c639-4aef-af2d-f43de3a261b0" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_74137e16-5d86-4772-b10c-71c736016a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b22048b0-5b55-4fc9-8f85-ee8a6ea6f406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8f140a82-c639-4aef-af2d-f43de3a261b0" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_b22048b0-5b55-4fc9-8f85-ee8a6ea6f406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_b575582c-70b3-4e12-bc60-292f23242571" xlink:href="pfe-20210404.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8f140a82-c639-4aef-af2d-f43de3a261b0" xlink:to="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_b575582c-70b3-4e12-bc60-292f23242571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_e45e1ba2-3bc3-45c5-b9fa-2581230712dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_8f140a82-c639-4aef-af2d-f43de3a261b0" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_e45e1ba2-3bc3-45c5-b9fa-2581230712dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_97792cee-19cf-45d1-b86c-13c243431b45" xlink:href="pfe-20210404.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f46628ca-d9eb-43ec-8bd7-7162e29a1163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_97792cee-19cf-45d1-b86c-13c243431b45" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f46628ca-d9eb-43ec-8bd7-7162e29a1163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_6cd81141-fbae-4790-9345-014eecb2b57d" xlink:href="pfe-20210404.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e870ec67-819d-4df0-8979-b73b56594254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_6cd81141-fbae-4790-9345-014eecb2b57d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e870ec67-819d-4df0-8979-b73b56594254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_5f4ae687-f032-45a0-98e9-ceb2b23cdf76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_6cd81141-fbae-4790-9345-014eecb2b57d" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_5f4ae687-f032-45a0-98e9-ceb2b23cdf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:href="pfe-20210404.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_038e28ee-ee4d-4aa8-9892-6b22b318e531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_038e28ee-ee4d-4aa8-9892-6b22b318e531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1103becc-e2b1-496c-ad63-7759a074eb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1103becc-e2b1-496c-ad63-7759a074eb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4a474612-51c7-4aaa-a5b5-92d47aa6b891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4a474612-51c7-4aaa-a5b5-92d47aa6b891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b4a86f18-a416-4caa-9f96-b998c62828ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:to="loc_us-gaap_InventoryNet_b4a86f18-a416-4caa-9f96-b998c62828ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d9641b01-ecf5-4c25-bb44-d81bb6e255ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9a86a36b-e90d-4048-aee4-14d853c4eed5" xlink:to="loc_us-gaap_InventoryNoncurrent_d9641b01-ecf5-4c25-bb44-d81bb6e255ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_9339d6ea-eff5-499a-af9f-a5e6309f188c" xlink:href="pfe-20210404.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_9339d6ea-eff5-499a-af9f-a5e6309f188c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3335f11e-d132-4b80-8e86-c36b4ed39103" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_531f8795-e4e5-48e6-9f90-1250a2866647" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2336273d-6777-4f98-997d-44e033620298" xlink:to="loc_pfe_BioNTechMember_531f8795-e4e5-48e6-9f90-1250a2866647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_738888eb-2e87-4479-b166-aa4f32993e4e" xlink:to="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_7a2dc011-efde-477d-a05f-b943ba0fff0b" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f5316f5-3eee-44ce-8292-94d6e6bcdee0" xlink:to="loc_pfe_BNT162b2Member_7a2dc011-efde-477d-a05f-b943ba0fff0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efe06207-f7df-4dd0-a470-d17d13018bf7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9e5d2469-f834-4733-9fc1-0f894e8e649e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c0fe1d0-0e5f-4aaa-b5f7-729b51a7c058" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9e5d2469-f834-4733-9fc1-0f894e8e649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_16e52721-eaa3-4c20-bcc0-648b2cf55fc6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_084e864e-cfd7-4ae9-b126-e6dc6088d0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d8da4a64-2471-475f-9f13-e893e0e6d86f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_084e864e-cfd7-4ae9-b126-e6dc6088d0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d602a55-3a60-42e5-bd2b-99cdcbdeace0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_07cbfecb-8412-4f3e-97eb-fc3c8cb63b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d602a55-3a60-42e5-bd2b-99cdcbdeace0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_07cbfecb-8412-4f3e-97eb-fc3c8cb63b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bab0a1cd-6c6a-4ecc-83c0-d6c4dd61da75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_372a0579-5b94-43de-9fdb-08863bf50c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bab0a1cd-6c6a-4ecc-83c0-d6c4dd61da75" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_372a0579-5b94-43de-9fdb-08863bf50c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1657be5c-2e9b-488e-86b5-21633b2c3218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bab0a1cd-6c6a-4ecc-83c0-d6c4dd61da75" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1657be5c-2e9b-488e-86b5-21633b2c3218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8a9ff-8558-4aa1-ae70-4da33915cd0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4551453a-bae6-4151-9ca3-130171f31daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4551453a-bae6-4151-9ca3-130171f31daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ec74dda4-721f-41c5-9f59-c1e061b2f670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_us-gaap_TradeNamesMember_ec74dda4-721f-41c5-9f59-c1e061b2f670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_54bdf6f3-f33e-409e-86b3-58b43cef7c36" xlink:href="pfe-20210404.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f627fd9c-e3ac-4de5-9e7f-86148e5a2f1e" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_54bdf6f3-f33e-409e-86b3-58b43cef7c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cf9d1fe8-72df-4236-8e30-0bfeb0985e2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_5198c7f5-088c-4efa-8cd0-1c2bbff141c1" xlink:href="pfe-20210404.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8b630e9-383b-43ba-86ea-92d692277bba" xlink:to="loc_pfe_BioNTechMember_5198c7f5-088c-4efa-8cd0-1c2bbff141c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0fda4053-147f-42b3-aba4-8bad2b6278c0" xlink:to="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_93fdc5be-df2f-472a-ba7f-f2e06b8e1c9e" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55105f47-13cf-4b61-89fc-00963d181685" xlink:to="loc_pfe_BNT162b2Member_93fdc5be-df2f-472a-ba7f-f2e06b8e1c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb5a4193-abe7-4f24-be67-639754905d85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad597843-3592-4fec-a787-5d3332a2f2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ad597843-3592-4fec-a787-5d3332a2f2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_358f1cff-4ea6-419f-896c-838213556c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_358f1cff-4ea6-419f-896c-838213556c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9afff204-4b50-46d4-ae6a-3256fc461427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9afff204-4b50-46d4-ae6a-3256fc461427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_94ecf7a2-0965-4572-8eae-c1eb637325f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e45f7407-643a-473b-9478-f597f2c5cf5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_94ecf7a2-0965-4572-8eae-c1eb637325f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e92b9d37-3599-4290-9fba-9eb9219736cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7354a19e-c5bc-442e-b97b-9954104e9520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_us-gaap_TradeNamesMember_7354a19e-c5bc-442e-b97b-9954104e9520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d2236cbe-f37b-4092-8c7c-ca8f6ef497de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d2236cbe-f37b-4092-8c7c-ca8f6ef497de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_507c5899-a78c-4e14-8d74-404ae6984238" xlink:href="pfe-20210404.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88433a06-8a9e-4951-a8de-687292aab532" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_507c5899-a78c-4e14-8d74-404ae6984238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e9923d69-2fe8-4042-95dc-f36f64c771d7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_afc78a9d-6704-4189-a7a9-8a7de56cb279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_83c367be-4539-4fc3-96dc-6bd60f25bebc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_afc78a9d-6704-4189-a7a9-8a7de56cb279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a0f9858e-4f40-40bb-a780-dd5ef82dccef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a0f9858e-4f40-40bb-a780-dd5ef82dccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6dd78b1e-e8c1-4aa7-9a47-1762096d52b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6dd78b1e-e8c1-4aa7-9a47-1762096d52b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d86cbddb-b894-401a-898f-fe7501865eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_444c1104-547d-48aa-8375-74063d70dd72" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d86cbddb-b894-401a-898f-fe7501865eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#IdentifiableIntangibleAssetsNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bad271f5-7b79-40ee-892a-ff5eee7f6eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bad271f5-7b79-40ee-892a-ff5eee7f6eaa" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_22a836ff-9361-437c-a499-70bc6972215d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_2acbdf27-7d73-455b-aef6-c9f01698a378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e87cb99-5476-42a9-a10a-30249b1e5815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_2acbdf27-7d73-455b-aef6-c9f01698a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04b2e187-4575-48e4-8c8b-d828c2645e7b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_90d6287b-0064-4736-b969-e18c5f07022c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3abe91c-821e-4f1c-81fa-1fb82177dd8b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_90d6287b-0064-4736-b969-e18c5f07022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da5a0d14-1b7a-4801-8281-6cbbfc5e9af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_2e861237-2a08-42b7-b95d-028f6ec0d8c1" xlink:href="pfe-20210404.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_2e861237-2a08-42b7-b95d-028f6ec0d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_354026ff-cf52-4b29-9d5e-1f4b97b4a251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c73f7c9f-b915-4cdd-a900-e2281095ee07" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_354026ff-cf52-4b29-9d5e-1f4b97b4a251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76722246-fff7-41fb-b9a6-b361f946930c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_72ad5955-a7be-49c2-bf2a-1ebb1b0bbd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76722246-fff7-41fb-b9a6-b361f946930c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_72ad5955-a7be-49c2-bf2a-1ebb1b0bbd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2bcfb0d4-f65c-44a5-9358-58b2b5cff1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_528aa1f1-045c-4d17-8654-0a3e1417fa84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2bcfb0d4-f65c-44a5-9358-58b2b5cff1ff" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_528aa1f1-045c-4d17-8654-0a3e1417fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2cb54200-f749-40d9-b2d7-705b3753c273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2cb54200-f749-40d9-b2d7-705b3753c273" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_436b4ed2-75d4-46fb-9328-cb3d92c2640d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_eb5ab985-3acb-4599-b8d9-8e137167a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_eb5ab985-3acb-4599-b8d9-8e137167a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8b540c0a-b06f-4535-b31e-bb93141ae394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_726d9d1a-cbb9-4708-a20c-a21998a983f1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8b540c0a-b06f-4535-b31e-bb93141ae394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f6f2544c-5356-4b74-a082-64a468311545" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:to="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ee2d2741-2b9c-492c-971e-415e0a24c0af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_46ed5361-f595-4f66-96d0-0c16488840ef" xlink:to="loc_country_US_ee2d2741-2b9c-492c-971e-415e0a24c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d6634284-3772-4107-a1fc-d8c4921b3f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03b055d7-0221-48c3-b741-958be6d255e7" xlink:to="loc_us-gaap_ForeignPlanMember_d6634284-3772-4107-a1fc-d8c4921b3f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5bb0987a-7c72-40cd-bf98-e04bff334154" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8d52539a-c5f8-446b-879d-2b6fe7de3c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8d52539a-c5f8-446b-879d-2b6fe7de3c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_367fb7a4-ebc6-4d1d-b12e-005ddbd24780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_367fb7a4-ebc6-4d1d-b12e-005ddbd24780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47e6b21d-4fb3-4f7f-8875-be5e4beb9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_47e6b21d-4fb3-4f7f-8875-be5e4beb9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b915e40e-b347-4193-a4f9-f4d0bf893d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b915e40e-b347-4193-a4f9-f4d0bf893d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_cc2e85a8-ac8a-42d9-b294-1d017b4b57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_cc2e85a8-ac8a-42d9-b294-1d017b4b57e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_76042972-4bd6-4c85-ba83-479e5ba13b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_76042972-4bd6-4c85-ba83-479e5ba13b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a4fe4b5d-00bc-4b2e-a637-8cd92bb7c783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70602a9d-ed46-418a-99c2-074565ec8b40" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a4fe4b5d-00bc-4b2e-a637-8cd92bb7c783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#PensionandPostretirementBenefitPlansNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_395ebee1-0a80-4be5-b57a-d32643629abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_395ebee1-0a80-4be5-b57a-d32643629abd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71860b69-a57f-4e27-9bb1-5e29a7f47ee5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f8f8712f-5e08-4961-96af-d8ddb5e7c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f8f8712f-5e08-4961-96af-d8ddb5e7c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_acea8531-8624-4b11-bd31-d17968d60914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1ab5cff3-f3b3-4b0e-8184-f193b40d6a39" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_acea8531-8624-4b11-bd31-d17968d60914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_483318fc-5691-475b-adbf-d536cc362fef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:to="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1d0171f8-3769-4296-be2a-d9f25552b950" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_940d7553-a46c-48a2-966a-4ab9f5dcbd5d" xlink:to="loc_country_US_1d0171f8-3769-4296-be2a-d9f25552b950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_055ff4b1-5b81-4a47-9906-c4f28377eb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f0da156a-8a35-4803-b3a7-c1eb1f6a083f" xlink:to="loc_us-gaap_ForeignPlanMember_055ff4b1-5b81-4a47-9906-c4f28377eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e046af-0b35-4454-8af9-4802e100fec1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bb9f5f71-7ff5-4d05-858e-9289bf1a147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2a6135d5-4ba6-4b48-b02a-6170faf84667" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_bb9f5f71-7ff5-4d05-858e-9289bf1a147c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e6c1169-59ca-470f-8236-0dfd7ae28f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6dda7346-4ff6-4b83-89ab-0f98e06a3957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e6c1169-59ca-470f-8236-0dfd7ae28f2e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6dda7346-4ff6-4b83-89ab-0f98e06a3957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_43a81696-4764-479c-b161-b77dee881bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a19f49da-a0df-48d0-a9e5-87dac514012e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43a81696-4764-479c-b161-b77dee881bdd" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a19f49da-a0df-48d0-a9e5-87dac514012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db2d0dea-3f68-4cf3-964b-afbf081c131e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db2d0dea-3f68-4cf3-964b-afbf081c131e" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_3c334c53-c1b5-4146-a214-7ba487db0b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_3c334c53-c1b5-4146-a214-7ba487db0b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_2204a96a-499c-48e6-8210-d61ff5ea86ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_2204a96a-499c-48e6-8210-d61ff5ea86ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_896a8435-e12f-4ac2-9c40-7d79b172078d" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_896a8435-e12f-4ac2-9c40-7d79b172078d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_55033ca8-8fbd-4bfe-aa91-81dd1d61bb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_55033ca8-8fbd-4bfe-aa91-81dd1d61bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_082ff781-1838-4cfd-add8-d9f22a229ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_12acef26-48b4-406f-a721-4891149d9f81" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_082ff781-1838-4cfd-add8-d9f22a229ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_8c552cbe-a172-4aa4-98d2-716971954560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db2d0dea-3f68-4cf3-964b-afbf081c131e" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_8c552cbe-a172-4aa4-98d2-716971954560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_38b95b7e-9988-4f79-9fd6-66771e562684" xlink:href="pfe-20210404.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8c552cbe-a172-4aa4-98d2-716971954560" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_38b95b7e-9988-4f79-9fd6-66771e562684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_32f4432f-6ddb-41cc-b5aa-8fa752a7eb0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8c552cbe-a172-4aa4-98d2-716971954560" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_32f4432f-6ddb-41cc-b5aa-8fa752a7eb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_917faa8d-e82f-409a-b3ed-c047e85aa916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8c552cbe-a172-4aa4-98d2-716971954560" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_917faa8d-e82f-409a-b3ed-c047e85aa916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db2d0dea-3f68-4cf3-964b-afbf081c131e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ec519bf-b44c-4a31-af67-70532147efd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ec519bf-b44c-4a31-af67-70532147efd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2b949303-6996-44b4-8c84-eaa292d6604e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2b949303-6996-44b4-8c84-eaa292d6604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7b9b5a0-b1ed-479b-8495-98e13941c8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7b9b5a0-b1ed-479b-8495-98e13941c8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2876296f-0afb-49e4-995e-4978e717a16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_471d940a-02c2-4211-a57f-d644002f4d90" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2876296f-0afb-49e4-995e-4978e717a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_42d86130-adb0-436a-8ed0-307210193ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_726b15f1-ba4c-49a0-9749-860968e7c623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_42d86130-adb0-436a-8ed0-307210193ab1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_726b15f1-ba4c-49a0-9749-860968e7c623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f929e9d6-ce15-4781-b3dc-97f6bd73105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f929e9d6-ce15-4781-b3dc-97f6bd73105f" xlink:to="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4aa6945f-111a-4989-8ee7-29160ee4e716" xlink:to="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_c1395df6-f9d4-4d07-a4c9-6b840942795e" xlink:href="pfe-20210404.xsd#pfe_XeljanzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:to="loc_pfe_XeljanzMember_c1395df6-f9d4-4d07-a4c9-6b840942795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_baa48a9f-aec7-46c2-834f-f3357d9e6a33" xlink:href="pfe-20210404.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c459dbe4-dab8-4bec-9b70-3e0230d98ea9" xlink:to="loc_pfe_EliquisMember_baa48a9f-aec7-46c2-834f-f3357d9e6a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6ae8c7ec-70f7-45d9-a4df-a65de44adde2" xlink:to="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusZydusMember_2f89b2b4-ebbc-4b8b-898b-c7e0ed78633d" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusZydusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerVersusZydusMember_2f89b2b4-ebbc-4b8b-898b-c7e0ed78633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_3b2ee32e-bc16-49cb-b795-4701a9301fa9" xlink:href="pfe-20210404.xsd#pfe_PfizerVersusGenericCompaniesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_3b2ee32e-bc16-49cb-b795-4701a9301fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_29d892a2-db5c-4255-a875-f0f0535f3bf7" xlink:href="pfe-20210404.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8a8dd4e3-a8fc-429a-b049-50d6df00232f" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_29d892a2-db5c-4255-a875-f0f0535f3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_3f0b1835-1567-4ba6-94e9-7982c957abb7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember_2297fac4-2e87-4daa-858a-255acd719955" xlink:href="pfe-20210404.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_PneumococcalVaccinePatentInfringementMember_2297fac4-2e87-4daa-858a-255acd719955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember_a4a6251b-1ca2-40b2-a4c7-dfab71e7aaa7" xlink:href="pfe-20210404.xsd#pfe_OtherPatentInfringementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_OtherPatentInfringementMember_a4a6251b-1ca2-40b2-a4c7-dfab71e7aaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_dfcaa137-f9d7-43a5-ab50-96d1b01ca293" xlink:href="pfe-20210404.xsd#pfe_PatentInfringementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_029cefc8-7bc1-4399-ad3e-8bb0971666b7" xlink:to="loc_pfe_PatentInfringementMember_dfcaa137-f9d7-43a5-ab50-96d1b01ca293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_384bea6e-f652-4325-a0b3-83e35cb14a1a" xlink:to="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_56bcc628-b9d0-4d6e-a968-8527677c4ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:to="loc_us-gaap_SettledLitigationMember_56bcc628-b9d0-4d6e-a968-8527677c4ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_b45e146d-5832-4126-9855-2054e488904b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a9b9f1a2-b5e6-4c60-9fd2-6d5c48f0f0c6" xlink:to="loc_us-gaap_PendingLitigationMember_b45e146d-5832-4126-9855-2054e488904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_b6dc0507-603e-4e5b-81f8-18d91ed26e16" xlink:to="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_32dd89a8-16a4-4a77-84ef-c3901b600552" xlink:href="pfe-20210404.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_32dd89a8-16a4-4a77-84ef-c3901b600552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_57139534-5c58-4013-a780-eadb39fd8165" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_57139534-5c58-4013-a780-eadb39fd8165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_8d1617a3-d4e6-44dc-a94c-e1536a6db252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_8d1617a3-d4e6-44dc-a94c-e1536a6db252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_4610d24c-abe4-43c5-89c9-b37bab1ccffb" xlink:href="pfe-20210404.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyNumberofDefendants_4610d24c-abe4-43c5-89c9-b37bab1ccffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_11ed7640-bf09-4f68-b106-fd2276f84fbb" xlink:href="pfe-20210404.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_f68c94cb-1716-4714-b2ac-a83d2d4fe121" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_11ed7640-bf09-4f68-b106-fd2276f84fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="simple" xlink:href="pfe-20210404.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d26bfd6-8374-4c8c-97f7-eda3d633ae9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d26bfd6-8374-4c8c-97f7-eda3d633ae9a" xlink:to="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_44858f14-7eeb-4301-bf84-00412111221a" xlink:to="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a1536d4-d056-448d-ac6a-77186eadcd71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf4359b1-30fa-494d-b8a6-2523df3a7a88" xlink:to="loc_srt_MinimumMember_7a1536d4-d056-448d-ac6a-77186eadcd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_746fcdd9-c6cb-4a60-9fde-a7f7dd281482" xlink:to="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_fb24de3e-cd48-4645-9109-64dd01dcd0b3" xlink:href="pfe-20210404.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0988e2a5-3ee4-4b42-8cec-19d8008b0e9c" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_fb24de3e-cd48-4645-9109-64dd01dcd0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_22c470eb-6284-4436-a329-94145885e765" xlink:to="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_8d601851-7918-4b88-b425-63d876fcefcc" xlink:href="pfe-20210404.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_8d601851-7918-4b88-b425-63d876fcefcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArraySecuritiesLitigationMember_5fb31bdf-04c8-4806-a7e4-e1c72e24e629" xlink:href="pfe-20210404.xsd#pfe_ArraySecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_ArraySecuritiesLitigationMember_5fb31bdf-04c8-4806-a7e4-e1c72e24e629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZantacRanitidineNDMALitigationMember_8ca41f7f-a8cd-4e8b-83bb-3c32e271c553" xlink:href="pfe-20210404.xsd#pfe_ZantacRanitidineNDMALitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5ad5ff56-455c-4cad-adb3-f6ab3a2b9ac0" xlink:to="loc_pfe_ZantacRanitidineNDMALitigationMember_8ca41f7f-a8cd-4e8b-83bb-3c32e271c553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dce11f03-ab94-4f93-8c6e-245edef891d4" xlink:to="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_b9c2e8ef-17a7-4826-848f-2b89728d3fb7" xlink:href="pfe-20210404.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:to="loc_pfe_EpiPenMember_b9c2e8ef-17a7-4826-848f-2b89728d3fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_174e31c9-1fd9-448c-8abb-dea8fe55268a" xlink:href="pfe-20210404.xsd#pfe_DocetaxelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8da5d5cc-8b02-4e4a-b765-59eac329d9d0" xlink:to="loc_pfe_DocetaxelMember_174e31c9-1fd9-448c-8abb-dea8fe55268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4e296714-fdd1-49ac-b781-4e839c7a2a15" xlink:to="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_11101f7c-f0ca-42da-a124-d1bfcbef40b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_72735aad-0f9e-45a8-9dd9-10af7e93fdef" xlink:to="loc_us-gaap_PendingLitigationMember_11101f7c-f0ca-42da-a124-d1bfcbef40b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65590192-09e7-4f9b-ab86-9b80fd7416d9" xlink:to="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_3de21df5-7130-42ce-9603-dac25ed4de0e" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_3de21df5-7130-42ce-9603-dac25ed4de0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_44cce058-417c-4b4d-9633-d0c3dc137310" xlink:href="pfe-20210404.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_44cce058-417c-4b4d-9633-d0c3dc137310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_808b4568-6ab1-4f93-8a3b-e7d82574b244" xlink:href="pfe-20210404.xsd#pfe_LossContingencyClassActionsFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_808b4568-6ab1-4f93-8a3b-e7d82574b244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_4c9688e8-d274-480a-bcf5-09c0e5beb08d" xlink:href="pfe-20210404.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b5bea11b-6ad4-4c64-9984-820cd1788c66" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_4c9688e8-d274-480a-bcf5-09c0e5beb08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3d95171a-1483-43f7-9a86-8701c6945724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_58c71561-740d-47f2-9f6a-d3ec474a3ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3d95171a-1483-43f7-9a86-8701c6945724" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_58c71561-740d-47f2-9f6a-d3ec474a3ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5e76b0b4-ae7b-482b-9c47-969d7d4f8ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a7ef0b7c-cd12-4cd5-bd15-94fbd0c632f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5e76b0b4-ae7b-482b-9c47-969d7d4f8ca1" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a7ef0b7c-cd12-4cd5-bd15-94fbd0c632f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_972f548f-554f-4319-9e19-b53d1283e1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5e76b0b4-ae7b-482b-9c47-969d7d4f8ca1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_972f548f-554f-4319-9e19-b53d1283e1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0b0af957-52b6-44c3-8f8c-88c23ffba096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b0af957-52b6-44c3-8f8c-88c23ffba096" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:to="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6a433886-15de-44aa-b538-a55c5757aee1" xlink:to="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b4d46b63-c733-4338-8df4-f1abbc58b975" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_country_US_b4d46b63-c733-4338-8df4-f1abbc58b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_e68e440c-1aa3-492b-a875-fa42ed31f483" xlink:href="pfe-20210404.xsd#pfe_DevelopedEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_DevelopedEuropeMember_e68e440c-1aa3-492b-a875-fa42ed31f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_1e3cb8cd-c0b7-4862-9ed6-48fc85a203a1" xlink:href="pfe-20210404.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_DevelopedRestOfWorldMember_1e3cb8cd-c0b7-4862-9ed6-48fc85a203a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_e4d7c776-f766-49b5-b7c5-bead7adfdab5" xlink:href="pfe-20210404.xsd#pfe_EmergingMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b92a426d-f438-4d99-ba70-68270d9254b0" xlink:to="loc_pfe_EmergingMarketsMember_e4d7c776-f766-49b5-b7c5-bead7adfdab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4f2af488-83f5-4174-9ce3-7414d61077e0" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b67a875-8c49-433f-8c55-38cd9ccd9c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b67a875-8c49-433f-8c55-38cd9ccd9c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PercentageChangeInRevenue_5a67307a-a2eb-404e-99b4-44a507400fb4" xlink:href="pfe-20210404.xsd#pfe_PercentageChangeInRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a099eccf-80cb-4b38-9293-e1e3953d7bae" xlink:to="loc_pfe_PercentageChangeInRevenue_5a67307a-a2eb-404e-99b4-44a507400fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_30a0a50e-bf87-4613-9048-19b53d202d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_30a0a50e-bf87-4613-9048-19b53d202d8a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_eb15d9b0-58f6-4b25-a91a-24fd250b3ac5" xlink:to="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_d95afbd2-5070-4602-919c-e916ae6fb557" xlink:href="pfe-20210404.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f35d80d3-eec7-4e2e-b625-9ce0d3ad565e" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_d95afbd2-5070-4602-919c-e916ae6fb557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bef020f6-6cfd-4176-a696-fb9fd444102c" xlink:to="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_ed44dfa0-5a31-404b-9121-3a69bd98f15a" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f01c83ec-a87e-4678-8a6a-28e4431712c6" xlink:to="loc_pfe_BNT162b2Member_ed44dfa0-5a31-404b-9121-3a69bd98f15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8fbfb30a-21e7-456c-9af8-be207471a93d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5858afb4-9219-4599-ba61-fd0c1670f1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b34f7d5-723d-4c1c-83ed-fc25c6af97b2" xlink:to="loc_us-gaap_SubsequentEventMember_5858afb4-9219-4599-ba61-fd0c1670f1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b6fadcd9-8062-40fb-b4a0-392b4d88d096" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4da910a0-0279-41cd-810d-45fe5d3382ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:to="loc_us-gaap_SalesRevenueNetMember_4da910a0-0279-41cd-810d-45fe5d3382ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_f28e467e-14de-434d-a002-d4cad3d40abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29dbe7f0-2d39-4340-9c6a-f54e450c3c30" xlink:to="loc_us-gaap_AccountsReceivableMember_f28e467e-14de-434d-a002-d4cad3d40abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8a0f63a3-0b60-484a-bd5f-5702ecbaf714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_ed88b6be-1884-4639-8beb-02f6c3bcf566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_44a758a0-ef60-4644-a40d-49130b890bc6" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_ed88b6be-1884-4639-8beb-02f6c3bcf566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_34aa5948-9b21-4828-9d8f-02279b89ee01" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_769af8cd-a0c9-4773-b088-8fd8fc4f5652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_769af8cd-a0c9-4773-b088-8fd8fc4f5652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6752db29-6e01-4d65-845e-a3b030c5f7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6752db29-6e01-4d65-845e-a3b030c5f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ff976aa5-d603-4f90-9b96-4e746bc11a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ff976aa5-d603-4f90-9b96-4e746bc11a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e84bb74f-5379-4012-85ea-0a0f3f608533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_655cfcb2-0614-4922-bdc1-d911c45402fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e84bb74f-5379-4012-85ea-0a0f3f608533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20210404.xsd#ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4588a06b-1724-4ad1-ba9e-8b7e4778f984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4588a06b-1724-4ad1-ba9e-8b7e4778f984" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:to="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_ba4902c8-7d9a-4283-b73f-14fde289d8ff" xlink:to="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember_aee7cf73-d3d6-4fde-86e4-fc91f28cf035" xlink:href="pfe-20210404.xsd#pfe_VaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_VaccinesMember_aee7cf73-d3d6-4fde-86e4-fc91f28cf035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_b5b136fc-3a5c-4603-ae69-8f851f6b310d" xlink:href="pfe-20210404.xsd#pfe_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_OncologyMember_b5b136fc-3a5c-4603-ae69-8f851f6b310d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember_8344a214-01d8-4c1d-b472-0ef089f482dd" xlink:href="pfe-20210404.xsd#pfe_InternalMedicineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_InternalMedicineMember_8344a214-01d8-4c1d-b472-0ef089f482dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember_7635606e-097a-4c1a-9fc1-c27cd6f378fc" xlink:href="pfe-20210404.xsd#pfe_HospitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_HospitalMember_7635606e-097a-4c1a-9fc1-c27cd6f378fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember_b1d8b5da-aa24-4ac5-83a7-bf5f9e2a62f5" xlink:href="pfe-20210404.xsd#pfe_InflammationandImmunologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_InflammationandImmunologyMember_b1d8b5da-aa24-4ac5-83a7-bf5f9e2a62f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember_057e1a89-585e-4fb7-af9e-932b46240ac3" xlink:href="pfe-20210404.xsd#pfe_RareDiseaseMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_67038b1a-09b9-47c2-9036-713ac4ca2c46" xlink:to="loc_pfe_RareDiseaseMember_057e1a89-585e-4fb7-af9e-932b46240ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:to="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c5ec6a2-8c9d-4214-8ac6-46563b656bbf" xlink:to="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BNT162b2Member_39198bd9-2966-424d-a8b6-6dc5add78d2a" xlink:href="pfe-20210404.xsd#pfe_BNT162b2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BNT162b2Member_39198bd9-2966-424d-a8b6-6dc5add78d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_ce708951-c986-4c10-896a-f6dc2bdde954" xlink:href="pfe-20210404.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_ce708951-c986-4c10-896a-f6dc2bdde954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_e4847d45-47de-4cbc-bd17-97d62738a100" xlink:href="pfe-20210404.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_e4847d45-47de-4cbc-bd17-97d62738a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_9aab7ef8-31d4-4c25-92c8-f2e698d254ae" xlink:href="pfe-20210404.xsd#pfe_NimenrixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_NimenrixMember_9aab7ef8-31d4-4c25-92c8-f2e698d254ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember_aa6b6aa6-2184-4f77-9446-ef6b5128c5ca" xlink:href="pfe-20210404.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherVaccinesProductsMember_aa6b6aa6-2184-4f77-9446-ef6b5128c5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_37117d2d-f7b8-49a2-ae6b-55a28c070eda" xlink:href="pfe-20210404.xsd#pfe_IbranceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_IbranceMember_37117d2d-f7b8-49a2-ae6b-55a28c070eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_62159969-3ddc-4a60-853d-bfbf9cb6108e" xlink:href="pfe-20210404.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_62159969-3ddc-4a60-853d-bfbf9cb6108e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_07f549b8-16af-42f9-a1a8-e79eff63bcde" xlink:href="pfe-20210404.xsd#pfe_InlytaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_InlytaMember_07f549b8-16af-42f9-a1a8-e79eff63bcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_a4e0421d-11c0-4a07-a4d0-2f798e702b73" xlink:href="pfe-20210404.xsd#pfe_SutentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SutentMember_a4e0421d-11c0-4a07-a4d0-2f798e702b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_3c5ba0d7-c9d0-48f9-9cf5-6c4ad31f765c" xlink:href="pfe-20210404.xsd#pfe_XalkoriMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XalkoriMember_3c5ba0d7-c9d0-48f9-9cf5-6c4ad31f765c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_8ff94922-d21d-40da-a710-aaafd4db04f8" xlink:href="pfe-20210404.xsd#pfe_BosulifMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BosulifMember_8ff94922-d21d-40da-a710-aaafd4db04f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_a38a0281-ffaf-4284-a36e-f6bc780c25e8" xlink:href="pfe-20210404.xsd#pfe_RetacritMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_RetacritMember_a38a0281-ffaf-4284-a36e-f6bc780c25e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_9f729818-bd57-4da1-9169-c6eb4f73211d" xlink:href="pfe-20210404.xsd#pfe_RuxienceMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_RuxienceMember_9f729818-bd57-4da1-9169-c6eb4f73211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_7de5a0ae-b0be-4c71-b844-b225a4d22c65" xlink:href="pfe-20210404.xsd#pfe_ZirabevMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZirabevMember_7de5a0ae-b0be-4c71-b844-b225a4d22c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_5ea4941b-021e-4e66-860d-e14e2a200f88" xlink:href="pfe-20210404.xsd#pfe_LorbrenaMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_LorbrenaMember_5ea4941b-021e-4e66-860d-e14e2a200f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_eb626a94-86cc-48da-82a0-77f6e8bc9765" xlink:href="pfe-20210404.xsd#pfe_AromasinMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AromasinMember_eb626a94-86cc-48da-82a0-77f6e8bc9765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_785b95b8-9c19-40dc-b5f9-68548795d304" xlink:href="pfe-20210404.xsd#pfe_BesponsaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BesponsaMember_785b95b8-9c19-40dc-b5f9-68548795d304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_94a5391e-2e4a-4998-ae97-2e6826d75cf2" xlink:href="pfe-20210404.xsd#pfe_BraftoviMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BraftoviMember_94a5391e-2e4a-4998-ae97-2e6826d75cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_2bf55a81-a2fd-480b-a024-e023d41ff89a" xlink:href="pfe-20210404.xsd#pfe_MektoviMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_MektoviMember_2bf55a81-a2fd-480b-a024-e023d41ff89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_889e68e8-122a-482c-913d-d63600f42653" xlink:href="pfe-20210404.xsd#pfe_OtherOncologyProductsMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherOncologyProductsMember_889e68e8-122a-482c-913d-d63600f42653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_37cb2e0f-f403-4e6c-9035-59d99c5da05b" xlink:href="pfe-20210404.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EliquisMember_37cb2e0f-f403-4e6c-9035-59d99c5da05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_7f93b1a2-9a8e-4165-a688-2182719cac43" xlink:href="pfe-20210404.xsd#pfe_ChantixChampixMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ChantixChampixMember_7f93b1a2-9a8e-4165-a688-2182719cac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_ba44ef8e-e006-49b4-9ad4-20b362cdbc34" xlink:href="pfe-20210404.xsd#pfe_PremarinFamilyMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PremarinFamilyMember_ba44ef8e-e006-49b4-9ad4-20b362cdbc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember_d6594a1e-7ddb-4f3f-a2c3-859d4f98df9f" xlink:href="pfe-20210404.xsd#pfe_PristiqMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PristiqMember_d6594a1e-7ddb-4f3f-a2c3-859d4f98df9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_4bca1898-394c-4ef5-b72b-776554da95f4" xlink:href="pfe-20210404.xsd#pfe_ToviazMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ToviazMember_4bca1898-394c-4ef5-b72b-776554da95f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember_a5a28d28-f3f4-4233-9fc9-c7b1bedc6e5a" xlink:href="pfe-20210404.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherInternalMedicineMember_a5a28d28-f3f4-4233-9fc9-c7b1bedc6e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_93d17156-4b46-41a1-a3fc-8035e64e757c" xlink:href="pfe-20210404.xsd#pfe_SulperazonMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SulperazonMember_93d17156-4b46-41a1-a3fc-8035e64e757c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_9f0a8ba6-e281-4e4c-b5ae-294cb35736e1" xlink:href="pfe-20210404.xsd#pfe_MedrolMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_MedrolMember_9f0a8ba6-e281-4e4c-b5ae-294cb35736e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_3adf2623-dfc4-45ee-a968-4bcfb205c6a9" xlink:href="pfe-20210404.xsd#pfe_ZaviceftaMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZaviceftaMember_3adf2623-dfc4-45ee-a968-4bcfb205c6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_04a4c0d2-5622-4921-9305-6ee774f8ac2e" xlink:href="pfe-20210404.xsd#pfe_ZithromaxZmaxMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZithromaxZmaxMember_04a4c0d2-5622-4921-9305-6ee774f8ac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_76333e0d-098d-4e97-89aa-b713bc2c6e25" xlink:href="pfe-20210404.xsd#pfe_VfendMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_VfendMember_76333e0d-098d-4e97-89aa-b713bc2c6e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_28c07b16-6e68-4f59-90f5-756609a6fe2e" xlink:href="pfe-20210404.xsd#pfe_FragminMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_FragminMember_28c07b16-6e68-4f59-90f5-756609a6fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_858c339c-6abd-4fcf-9ec1-707609309c07" xlink:href="pfe-20210404.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EpiPenMember_858c339c-6abd-4fcf-9ec1-707609309c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember_fdea3533-f030-4369-898c-8abb2edf5bda" xlink:href="pfe-20210404.xsd#pfe_ZyvoxMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ZyvoxMember_fdea3533-f030-4369-898c-8abb2edf5bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember_26047d2e-8357-42cb-bd4a-77b729725830" xlink:href="pfe-20210404.xsd#pfe_PrecedexMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PrecedexMember_26047d2e-8357-42cb-bd4a-77b729725830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember_c344230d-626f-400d-84cb-0aa4c06113f5" xlink:href="pfe-20210404.xsd#pfe_IVIgProductsMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_IVIgProductsMember_c344230d-626f-400d-84cb-0aa4c06113f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember_0298dcc6-52df-4330-a4a5-6e97dc29ff48" xlink:href="pfe-20210404.xsd#pfe_PfizerCentreOneMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_PfizerCentreOneMember_0298dcc6-52df-4330-a4a5-6e97dc29ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_f17ac5b4-d64d-43f8-8b9f-7d2e4b71c8d2" xlink:href="pfe-20210404.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherAntiinfectivesMember_f17ac5b4-d64d-43f8-8b9f-7d2e4b71c8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember_b4b33130-0269-40a9-91b9-466e128bed64" xlink:href="pfe-20210404.xsd#pfe_OtherHospitalProductsMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_OtherHospitalProductsMember_b4b33130-0269-40a9-91b9-466e128bed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_3e025f7f-d20f-4bdc-9fc9-5ef1720adef2" xlink:href="pfe-20210404.xsd#pfe_XeljanzMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_XeljanzMember_3e025f7f-d20f-4bdc-9fc9-5ef1720adef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_ef35c225-4d6e-496d-9c62-8edb7e8ac899" xlink:href="pfe-20210404.xsd#pfe_EnbrelMember"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_EnbrelMember_ef35c225-4d6e-496d-9c62-8edb7e8ac899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember_9aa2015f-47d5-469c-b65c-ac80aa7e9583" xlink:href="pfe-20210404.xsd#pfe_InflectraRemsimaMember"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_InflectraRemsimaMember_9aa2015f-47d5-469c-b65c-ac80aa7e9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6a6b81ca-67f6-4763-8bea-a1b887409544" xlink:href="pfe-20210404.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_6a6b81ca-67f6-4763-8bea-a1b887409544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_1f36d3d0-048d-4151-b8ba-798ba6840916" xlink:href="pfe-20210404.xsd#pfe_VyndaqelMember"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_VyndaqelMember_1f36d3d0-048d-4151-b8ba-798ba6840916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_09da271d-680a-4c0a-891e-f29ee4df7283" xlink:href="pfe-20210404.xsd#pfe_BeneFIXMember"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_BeneFIXMember_09da271d-680a-4c0a-891e-f29ee4df7283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_ae762767-3c21-4830-83a2-d5c393ad7dc9" xlink:href="pfe-20210404.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_ReFactoAfXynthaMember_ae762767-3c21-4830-83a2-d5c393ad7dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_4422a176-72be-41e9-b5cf-d039d3a33e80" xlink:href="pfe-20210404.xsd#pfe_GenotropinMember"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_GenotropinMember_4422a176-72be-41e9-b5cf-d039d3a33e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_2478efed-dfa1-4f45-af69-2d80a2e3996e" xlink:href="pfe-20210404.xsd#pfe_SomavertMember"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_SomavertMember_2478efed-dfa1-4f45-af69-2d80a2e3996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_a04bb006-14a1-4c28-8b3a-24835af93436" xlink:href="pfe-20210404.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_a04bb006-14a1-4c28-8b3a-24835af93436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_eae8c353-fd0d-4364-8538-0bcc9367de02" xlink:href="pfe-20210404.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_eae8c353-fd0d-4364-8538-0bcc9367de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember_1269b214-d025-4532-adb5-c33f7c637a9f" xlink:href="pfe-20210404.xsd#pfe_TotalBiosimilarsMember"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalBiosimilarsMember_1269b214-d025-4532-adb5-c33f7c637a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_a5b9ec91-2f9c-45b6-89e6-e2b902c12f18" xlink:href="pfe-20210404.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f44cdd57-04bd-4288-8b8a-10d6e68fa213" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_a5b9ec91-2f9c-45b6-89e6-e2b902c12f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_43fb420b-d409-4cf1-bce0-6479ab324b06" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_845c9570-0c6c-4d78-a122-cbcf17f1a355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_530ae64b-44bd-49e6-af94-79c2e7ee836c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_845c9570-0c6c-4d78-a122-cbcf17f1a355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>pfe-20210404_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20210404"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20210404.xsd" xlink:type="simple"/>
    <context id="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3e0981b1456245b78310dd84b94917d6_I20210510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i05f859e329d9409390fed7a56b8d7dbd_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icab05669a9bf4c4b91e115cdf8dcca85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad96abb481364caa9a72671a1c67d82f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib68a5c0cb0954eccb168987e68a66426_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8432d19709754d54aa8831d0e0b91a10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2e941de2442495c8df2676e0be6391b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44dea6398b1c4543b9115d73e959887b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76e4e86836694234959a3a15070601ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i670092d056fe431492c1724b7d5cfb67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if8cc8f792ccf4742a85390af1b808b26_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6f98424f39a64dedb002aa58aa06d599_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icc01d70f4491494899c4a1be59cde841_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4ffb761b6f624168a62f72e12228bb5a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i298e3f59dab144afadd3175e4b2e4702_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0ba782e27bc644768676d5050e11dd16_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ice7f96cabae24782889c935aac35f1e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96a8120f033f4276941d48877f9a9489_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if706bef9ba9e4a8087b6638c1a298410_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5802b7b756774508be8ac80fe45d2d09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieeb048b2301e439f88254780ad40d688_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice6876e4533642569b2b72a9c6fd043b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9748b402be914193b56e1300e8f8d640_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7ae0369567d42bba15dd6a743487769_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67a0a3b5e3a447628cfe527319aaf597_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47f5513825544a8381d81fce8b6348be_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i00864a6cffcd489689813f7229308d3e_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4702654caf394c4098db2cd85620b59d_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="id47b6b8fdd594ac3b929fd46636184eb_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i98cea540ef86451da18644ee8a6e2767_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i8c5d25c9530040899006db8fed3c6271_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i887f2cb651164ba79b51cf28563d8588_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i5affdf158b6444899bba4d555d785d25_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i793a6170d7114594b0f7282bca5807aa_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i08a420875e0f49f2a79116b4b03bde63_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5ab1163b18294401849660276bdbc17a_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ide9e1b38766a45f1b70fef289bf08b46_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i171b297bb091460caae274aa6fd2034c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12997ed07c6d40178b3062b257ac83bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99fcec41f64847ed86b1c89a56896531_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie4a2b9079bc742749949e93c782f4af9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i940e3dc38ca547fdbc8e066fc92a3705_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib09c41fb46464505bcc32a3c43731505_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic0fac9c964894676b74a3dfea4fc6f74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fb4d5f76cd341e2a3579da45c669e20_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i82a840208e554416a672c485a012d030_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if62466171dbf47ec977eb962afa99747_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="iec8f63c6623f49adbf67a41d2e87119b_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i84d3a404ba354ee580c13bbafde8881a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice6f2159d3d7436abcb7d83886acbb6f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i49562007fd9547a48d0eb81e74591431_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4407292bed544ddd98da354a852701ac_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2f7055066225454fbd6b963b51debc30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6e22c74513c4463863976ef5f21b01a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f00f1a9cab940258f6eed860c0bc028_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8b6820f138a34d1a88125938e6c7587e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia29f6c9175e74ba2832cbc36256b21b7_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneAndBioNTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i798490452fbf42df810cc73fc79edd72_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if15de68e82a04995aadbd09ef4f4de3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2c9aa8e82394528ad00529819678ef4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2113534f48f444f8fad64562140b4ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4533886f346447ddb2e4466be3decd58_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie3532a573af84231901dcba3a9f69146_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4864e09f901546cc81c976b2cae73fb3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i62019f9f689b4fc982e85dd8eb7b261b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i67345ed70af0415f9ed8e94420f395ec_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8aae410224d44016a7744837424466a6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2c17032a023943b39d6fe6d61373d0ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i046ca4e1125f4096b86c8813e2f8970e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88f1d50b4ddd4407b234fba600ed5d57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i49e3912c87b642259d22066a4deeedf3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie39df5fe991d423c8bb366a5753affb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e21972aa8834adbb2e62df36a9290a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4a996c859684b9ebfddd6a039f0965a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ief1336b9d91143e39d2fea5006a742b3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ibc333032422c470d9c553a603fed07e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i217da8c7f6f349b8b0412339d3adcdab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b273a61589b42c5baea01aad3398d3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i521c003f78f74a16bf69168b25516b44_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4bb11cd15cf3432681d969a29d7dca79_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c84a33617f945aa95602f65e14fe7fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i693fbbcedb904e0ca5820547935b4eeb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2496243c18b44e05838d5575a5b19b92_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia2827e9872a441058d1e02032d2d742a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7dad755ef938483cb63df05993af440c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49b785935ffe4cc39bc8792585014a3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6590c03231c94832ab710135c629b5d6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id2a8285101fd4a4787791fc4108af409_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib397545be8ed42a894b7225f81be7b8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8c6a57df8544c48b668c58d680c53a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie209ada8ef774920a8094ff1ffa8c791_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6402b69d96a94b11983f4c4aff358cd9_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie8629e44fcf74299947158c6cf1db447_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic918fd2704ed4d59aa54d300420bf854_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia422b966324146868d032d47dda6f321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd8e1a1c11cb40788c6dd041f5862427_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic12158fe468140509e594e5c9bea2ff0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idef140b7ed3b4d09bed3385bae6d504d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1b810fe2ae184c5097d5595af97f1ee9_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia267f32cf11e4a86a297aa0b2be67c44_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ida5dcb775c5545cea010daed613c3d15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3354f5abddd4996bf3ccd71244e3b56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91073b1fe1b54677a90882344df8e229_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3537ba539cf4490799a0a791b894bbf6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icbdb406e79c94c318635d1add0655a54_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i07835653ec374195b2d79068ec153977_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iea25168e02e94f08b514acffde4e38cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5a83ae2aba2486f95fe642a4c774464_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f9c25dfb8094cb598d568e3dac3e194_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d7738ac04034c2db9a1b09fd2554159_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic017f9df9d9941eeb7f48073600c8293_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i235004b31ec442a1a5ebf8037790737f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3112b7bd4ca945039be216b55807356f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5959213e06f24defac36f7a0fb92bbb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b990b5de1ed4f4db641cc793879a698_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc2af150083d47d0bcf678532db4a34a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia6648e1e65204f4eb444cb895f52ec9c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie5fd3e97335545368349e1b54a37f7ca_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i93b72ae9514a4dfdb73d54037e4297c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60f3e802e12546cf9fa1294b3ad1be57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d1bff202dda47268a07043474884dcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a0d3ef6ac6b472b84a7134822008fef_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia77e241651c349ada1bf16e3b6ecf828_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3dfae630a4fe4e298addafa278e16b50_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2697970c25514e279413521fb973bba7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ea7690129214a9195f0424e82617486_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4105c4d1d064369a467bf34c99b66d9_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3b19f59cbd344d648155105fd82aed69_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iba8bc471a60a4b02bd124ad08e30d367_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d27878b3c524d4ab463f64f7d71c33e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bc1645da50f4723ac5e11374a83165e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2636525965a44944a8b505ad44b6fb94_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i467531120efd4d1eb7bbc63d03b66773_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i863eb072936745e9a6b8f3a4ef7207a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0074575f0ac44757b22db2f3767d4ee4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7ff43b50014b4281a9126121e4136253_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i033c256fd9284f3c8ccdc121aeead211_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3c4a625f98844cb89cf576d5f951717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic844430bda8d4a429c4c1873dec0c67b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1774875f27f34e3c942fbcdb9216c45c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3f9e05206d5d44bcb2b4c816762b2196_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if0901fcaa75c4458bc09ff2e135283ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad6218d250ab4b7588c930240dbe77bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e356b3ffe4f46d786b299299e8c73c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddecd2f6220e465abe9653d482f98cd7_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0122d1ba5cd6421b87248774e8dd8097_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6b4bf8afa38545638247e4f6360ddf24_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i38dfe51f567c4463b153c45da57afb62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie43a5c73f58e4950ab051b0f60f22af2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if25ff69c6c384a5e9bec30440b609aaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if552fb30ac3f4a9986d136fac40d1ba0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iadfb31e704964e379fa031ac9764d117_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ide9db44961644d99bc4a1be0ceaf3427_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i105edd316071419483c29294542bf610_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc91087bf2c84f9db4657e286128b4ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71eb1561917b4fc8b8dd253cd6535303_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia19135b26e5944d48147d848103fa4ab_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if72626af54aa43d29c3a57a81672472f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i361062f6aa914630bda2a1decde3d5fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9154af5cf4f54064a345265618b24fb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3cb663f517041b2b748758fddfc3042_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id2b7c33ade3f427b87cdc02e591b5d89_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id184353eda00420aa146f68eca8520d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6329d29a2efa4bf6be2047d1f4b55270_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife6665bcfdc84fd9847decd31aab5d74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib94b4929257f4fa59c82eaf1fff65f72_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic3dd217f408a4c11b63dad378ca98d22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id54070b71d25429da086e63afcf1c41c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcf94ef1797d492b92164bec12798fd6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i311aff5e47cb4f0aaa689dd672a89de7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea7507c4602c4b85b91614510bb349ea_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3118a605697e4b6299c3e3e70f504737_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6816514d37f949999a1c366c3691d629_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i22e189428ea0418bafaae25d5406511e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iea6892b733bc4dcf856bf74153b9127f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd7df84abf8144f9838662606d730b41_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i59506893ef984409b375dbf340e24a0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i436945b9fb544d1485596c97366973bf_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9a0b2bb17c2c45038528dc9568158637_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic74e1896b3c246a98ee4bce0ead976d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if854a67683b84997921e0c8d08721493_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8d11d6f169eb4129873cfe8da015081e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5584c105e0a1417da14d21d850e54027_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i53d153096cf74722befa5ea904fa6b4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3d739b69c924476ab9fc489134e052f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idcaa753284e740be9e09512ba86381ee_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5f3171903a684fc3919479487e325172_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iea937bd52464448b93d716a8cf093ae8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0661f5622ccf41418edc8cfa0839da72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief79afe80dd041288f169705b94e7059_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if40f67d115f744f597392dd0dafbaa4e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie113bce7166d40bdacd5506226e15172_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb29d5d4227b48adb270b164dfc6d257_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4317cb0568ef4d6aa675535e255cdab3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0635462155884026ba26888ed78b96f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if36997883bf644fda424001760b39437_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f5d302584f242a887a90c5ba675f0f7_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3d9cb52c2c4d4db882a1c475c695052f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96110322c78c4e7d8e3fd05494f58fbb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia4631e305af2483e8890f326b9fef89d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3aa408a10c644979d8878d88bca2e75_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i088397c030f64354a28cbf48f10fa861_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i02973e07500446c182f01c27b105cb67_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i104649887c064a40a045fee23a147e9b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ArraySecuritiesLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:ZantacRanitidineNDMALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3825cb911e8746189fdd8101073ce536_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i66c5094c3226447689dc0560d6f61760_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i00018897a8a546288611fca2330ad40d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idaee0a8c94344749aad179a107f5379d_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6d86911b85754856a091d39a9a619036_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i15547904869341898a05e8608012fdf7_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia665187179da484eb6e599146133e64c_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6217a5b597e247debffac06a2be42229_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i39d647526b664456a53481f1fcd29c09_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia251f6f252be4fca87be237b62587e21_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9846250722404133a31c34c978297518_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib9903f105558492aac6500bc30eaadca_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i217f041566f14b16a835176fc12cebe4_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4045f62b3268485d984a63420d9173d9_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iadcb9082716e49ad8217f6c35c00c9da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="patent">
        <measure>pfe:patent</measure>
    </unit>
    <unit id="defendant">
        <measure>pfe:defendant</measure>
    </unit>
    <unit id="lawsuit">
        <measure>pfe:lawsuit</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pfe:manufacturer</measure>
    </unit>
    <unit id="classaction">
        <measure>pfe:classAction</measure>
    </unit>
    <unit id="lagoon">
        <measure>pfe:lagoon</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV8zLTEtMS0xLTA_999fa771-f59b-438c-8991-469683c56f7a">0000078003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV80LTEtMS0xLTA_e801aec7-c6e3-4085-be06-c51848ddec22">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV81LTEtMS0xLTA_941f9883-afd7-4474-afcb-342afcca7de0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV82LTEtMS0xLTA_1049a104-6dc4-4182-9c8b-a10262e2109a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV83LTEtMS0xLTA_32e188ce-eda7-4197-9d1f-662ef449cdd1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Mg_08e96159-65d6-474a-aa62-622804f3ffa1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Nw_6a541688-d6bc-46d6-832c-853b2dd5b33b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTE_3e929d21-0de1-4c3d-8e6e-c7bde83c4b30">2021-04-04</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMjA_cff4a14a-e09e-4c07-9801-332146421349">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8zOTI_e07c1201-8838-4787-8d00-b83353d967fb">1-3619</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80MDI_301742a9-dc6f-4bcf-ba0a-c366d9029362">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTAtMS0xLTA_8f0fba66-4257-473d-a9b2-c8d16eaf8534">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTEtMS0xLTA_16305be9-2aeb-4f8a-bec4-dbb7f5f1cc24">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTk1_58ba744a-afb0-4944-858a-55616d672281">235 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80ODg_bf062ef8-3831-4075-a3f0-c010d8fd716b">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTI_8a3c1f47-8eea-4a1f-923c-ae81b0391d9e">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTY_8c744406-ef50-47b1-8982-6ea852711237">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTQ_f8e40062-659a-48ca-88b6-00ebd2305cf2">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTg_b0faf57e-775c-4b16-af16-740c42b70830">733-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTAtMS0xLTA_09b24bae-7753-4580-9921-a91b53c8ba04">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTItMS0xLTA_d910026e-da26-442d-b31d-19415639b9fd">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTQtMS0xLTA_9d62c8d4-7eb4-477d-990d-74af97847f58">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTAtMS0xLTA_0d0a45bf-1f6e-4d15-aabb-41c2c9426500">0.250% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTItMS0xLTA_5d480107-61cc-4958-a919-dcedf31a2016">PFE22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTQtMS0xLTA_478ec0a6-bc26-479d-84dc-3668d706d1cd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTAtMS0xLTA_5d6cc54d-1757-40d1-9bac-f075b0148eb2">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTItMS0xLTA_563da661-e643-407a-98e0-ea44ffbfb40f">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTQtMS0xLTA_d19a3f37-ce2f-4467-9c96-8523ecc53743">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OGFkYmIwMmU3NTAwNGFiMWIzMjI1NzQ4MDczZmM3N2EvdGFibGVyYW5nZTo4YWRiYjAyZTc1MDA0YWIxYjMyMjU3NDgwNzNmYzc3YV8wLTAtMS0xLTA_1d5c067a-4f80-42aa-8390-0cdfd876ef67">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OTE0OGViMzgzOTQ3NDMyZTlkZjIyZjI2YmYxNWJlZjkvdGFibGVyYW5nZTo5MTQ4ZWIzODM5NDc0MzJlOWRmMjJmMjZiZjE1YmVmOV8wLTAtMS0xLTA_6a75608f-aedf-4019-ba8c-e5a412b47f78">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNjA1_0b13429a-2451-42f6-9411-ac922445b2bb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzIy_a4005452-5931-426b-a5f1-67595cce2fa2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzUw_9c51cf51-0806-42ab-8036-835ada900f11">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NWMyNmYyM2I2M2QxNGMwZGFhYTY3OGU1N2M0NjgwNjUvdGFibGVyYW5nZTo1YzI2ZjIzYjYzZDE0YzBkYWFhNjc4ZTU3YzQ2ODA2NV8wLTEtMS0xLTA_fbd0685e-aab9-4aa3-875e-7027fbfc4e2c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3e0981b1456245b78310dd84b94917d6_I20210510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTMz_f3e64ca4-fd98-4371-a22f-cf02f4b0c278"
      unitRef="shares">5597693867</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi02LTEtMS0w_0462800b-6f25-45c0-b1e3-8777053d63b0"
      unitRef="usd">14582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi04LTEtMS0w_08750704-3781-40b4-a61b-fed2de241e6f"
      unitRef="usd">10083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd"
      unitRef="usd">4211000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56"
      unitRef="usd">1940000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae"
      unitRef="usd">2783000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc"
      unitRef="usd">2541000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2"
      unitRef="usd">2014000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126"
      unitRef="usd">1672000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy02LTEtMS0w_c15c26ed-5813-4012-a38a-129be83423ba"
      unitRef="usd">872000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy04LTEtMS0w_9a3d6d0d-4347-4412-9558-f5b1496e3263"
      unitRef="usd">849000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC02LTEtMS0w_f41f95b1-a6d2-4984-9e65-2cd903255bad"
      unitRef="usd">23000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC04LTEtMS0w_ebe5fbeb-b685-4132-bacb-3048968b70d2"
      unitRef="usd">54000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS02LTEtMS0w_4ca070a1-0f32-4bde-a041-9813ca34b413"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS04LTEtMS0w_554a687d-cbf7-4d27-913b-7a7871fa254b"
      unitRef="usd">6000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681"
      unitRef="usd">1004000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13"
      unitRef="usd">-190000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtNi0xLTEtMA_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf"
      unitRef="usd">5683000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtOC0xLTEtMA_82638985-d87e-4d19-83f9-35ac23cb0316"
      unitRef="usd">2842000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItNi0xLTEtMA_d6a31f7c-a51a-4074-9737-47e32947c8ef"
      unitRef="usd">805000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItOC0xLTEtMA_b8472e14-0a68-41d2-9348-eb9d50c460a3"
      unitRef="usd">359000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtNi0xLTEtMA_9ac659e3-4349-42bc-990d-f4cde183a0e7"
      unitRef="usd">4877000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtOC0xLTEtMA_cab68903-79e4-434f-8480-22af9c902f33"
      unitRef="usd">2483000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtNi0xLTEtMA_33b79d80-57b2-425b-8cb8-a4c3b19b5192"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtOC0xLTEtMA_11166465-dd3c-4aba-b037-16fb7e609c74"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtNi0xLTEtMA_b93a5f55-b8ee-41e9-ae00-863374a23097"
      unitRef="usd">4886000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtOC0xLTEtMA_cad182ae-42d2-4615-922c-b2e1dcaeb3ac"
      unitRef="usd">3364000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktNi0xLTEtMA_8ed91be1-1847-4b68-96b9-b6fc37642b75"
      unitRef="usd">9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktOC0xLTEtMA_1492d746-172c-42c1-8601-49d85ea42956"
      unitRef="usd">9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtNi0xLTEtMA_f7319f6b-201b-4644-bf83-f647ec7dbf11"
      unitRef="usd">4877000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtOC0xLTEtMA_3ad21e9d-4916-46a3-be5d-5e9916f84c40"
      unitRef="usd">3355000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtNi0xLTEtMA_75b7133b-7b8d-4749-ae65-9eca8dc2ec41"
      unitRef="usdPerShare">0.87</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtOC0xLTEtMA_0ad41313-4c51-4bb7-b815-6df61bc17314"
      unitRef="usdPerShare">0.45</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtNi0xLTEtMA_f1d431d7-e33e-49e8-81e9-b399c079757d"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtOC0xLTEtMA_b38d95a7-f497-451a-a668-541c33faf446"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtNi0xLTEtMA_5fae1b27-b998-4f4d-8b17-ea0c71804d2a"
      unitRef="usdPerShare">0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtOC0xLTEtMA_a85c270d-3dd9-4d4f-b87a-b672be7959e3"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtNi0xLTEtMA_83a08fc6-5a94-455d-bd21-674b27a0506a"
      unitRef="usdPerShare">0.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtOC0xLTEtMA_20550d10-89e1-4fac-81dd-154718ea283b"
      unitRef="usdPerShare">0.44</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktNi0xLTEtMA_eb0b828b-e1f2-42da-a9cd-00ad72d78436"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktOC0xLTEtMA_d533696a-7d6b-4c6b-9843-f64b3d7d9d23"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtNi0xLTEtMA_ccebed80-aeef-40fa-bade-64f59e94c84c"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtOC0xLTEtMA_f11106ea-d63e-4bab-9b51-2cebf2989dd4"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItNi0xLTEtMA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9"
      unitRef="shares">5584000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItOC0xLTEtMA_5bf044da-3a7b-4e82-ba6f-54ebfda40193"
      unitRef="shares">5545000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtNi0xLTEtMA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da"
      unitRef="shares">5662000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtOC0xLTEtMA_56fa12c0-55ed-4708-b561-3527a11165d8"
      unitRef="shares">5613000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi02LTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097"
      unitRef="usd">4886000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi04LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac"
      unitRef="usd">3364000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC02LTEtMS0w_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa"
      unitRef="usd">465000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC04LTEtMS0w_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0"
      unitRef="usd">-1256000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy02LTEtMS0w_0d4b6fde-99cd-422e-a285-4370395347d7"
      unitRef="usd">214000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy04LTEtMS0w_0648e13d-ed25-45f8-81b0-5f67f2baae56"
      unitRef="usd">-501000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45"
      unitRef="usd">-259000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS02LTEtMS0w_3b77c99c-d45b-4101-8c70-984b04268053"
      unitRef="usd">473000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS04LTEtMS0w_512efd4b-b6bc-4a07-921f-0a7269e640e4"
      unitRef="usd">-482000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtNi0xLTEtMA_5c332a77-26be-4995-899d-581a58d4b46c"
      unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtOC0xLTEtMA_bb0555b5-1327-4b22-8c73-92008b069f62"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8"
      unitRef="usd">242000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtNi0xLTEtMA_4ff72b90-b8d1-4de3-8703-cf6e8b70634f"
      unitRef="usd">-163000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtOC0xLTEtMA_67e821cf-11f8-494b-a5d9-21c5ef4b4c95"
      unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtNi0xLTEtMA_0343269b-d169-459d-b91f-4842a7e556a4"
      unitRef="usd">-40000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtOC0xLTEtMA_4fd6d728-d7c8-4066-85a6-91067b5009e6"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItNi0xLTEtMA_f95c299b-8217-47f7-8a34-bf2933f46094"
      unitRef="usd">3000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItOC0xLTEtMA_adccab60-e35e-4b21-8d24-b56a66ea336d"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtNi0xLTEtMA_5eb4ed92-385a-460d-8769-d7d2a55ca764"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtOC0xLTEtMA_1b6152fc-ee61-450e-ac36-36894364e0b8"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtNi0xLTEtMA_78f653e8-6899-4cb7-97f1-e9457b00cd10"
      unitRef="usd">732000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtOC0xLTEtMA_90da3b81-38b0-4eb0-99d8-97b6d2accb52"
      unitRef="usd">-1821000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtNi0xLTEtMA_491a1642-d58b-44cc-b6f4-9543a582ef04"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtOC0xLTEtMA_5951f2d0-71ca-4d8f-8b42-a45bbaf37291"
      unitRef="usd">-380000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtNi0xLTEtMA_b819206f-1bae-4c0b-9b25-9081eac6f8cc"
      unitRef="usd">647000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtOC0xLTEtMA_8c70dd79-c2ed-44eb-b89d-bf5c95798677"
      unitRef="usd">-1441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctNi0xLTEtMA_448b9828-e7c3-4d2d-b206-f033542d3312"
      unitRef="usd">5533000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctOC0xLTEtMA_030628f9-8ff8-4e5d-ae66-c4f05de34ba1"
      unitRef="usd">1923000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtNi0xLTEtMA_b59edafa-61b7-4757-8c32-1673da1f46d6"
      unitRef="usd">10000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtOC0xLTEtMA_8e63f5d7-483b-4b42-9d65-7785d409cec8"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktNi0xLTEtMA_bbf62bfa-d4ba-486d-b9be-7c41613edef9"
      unitRef="usd">5523000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktOC0xLTEtMA_18c29f2f-6988-4eb3-9582-8a5b44fdebaa"
      unitRef="usd">1914000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy0yLTEtMS0w_740fe0b8-5c10-4ce3-a223-ad0ef459b73c"
      unitRef="usd">1768000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy00LTEtMS0w_f23ded50-6fa8-4a10-872b-c69af92c5195"
      unitRef="usd">1784000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC0yLTEtMS0w_00ffa628-db0a-4047-b367-6cf694c33b0c"
      unitRef="usd">11899000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC00LTEtMS0w_1e5daf97-ed2d-45fc-aaa2-1138ac95672e"
      unitRef="usd">10437000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfNzQ_a8fc3ed7-198e-49fd-b073-6f5184221071"
      unitRef="usd">512000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfODM_7902fc25-fb04-4d99-96b4-ec8bc99f3cdc"
      unitRef="usd">508000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0yLTEtMS0w_b56f4006-fe18-4b22-ab79-1c4435a8de6e"
      unitRef="usd">9864000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi00LTEtMS0w_3cb2c394-8919-423c-9e96-4807bff41a07"
      unitRef="usd">7930000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy0yLTEtMS0w_bdc110a8-3c29-4f42-a711-0e18f650dd73"
      unitRef="usd">8493000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy00LTEtMS0w_130ebac4-9795-4b77-9e08-984726214796"
      unitRef="usd">8046000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC0yLTEtMS0w_2cd071e6-f7a4-41d3-9666-53cbfe4d64a5"
      unitRef="usd">3419000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC00LTEtMS0w_b0527ab6-6493-43e1-9c0c-67c0484bb4b7"
      unitRef="usd">3264000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS0yLTEtMS0w_1b3f7369-7fb9-4dac-8af9-94a4662590a1"
      unitRef="usd">4091000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS00LTEtMS0w_6eb4d8ec-c016-4873-8848-4f9650aad311"
      unitRef="usd">3605000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtMi0xLTEtMA_0ba231dd-c9ba-4e9a-be42-80c886cc3b78"
      unitRef="usd">39533000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtNC0xLTEtMA_14e92f3f-4580-449f-853a-08a57be436fa"
      unitRef="usd">35067000000</us-gaap:AssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItMi0xLTEtMA_5c92dc31-9fff-4341-9299-461153d89a0a"
      unitRef="usd">16532000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItNC0xLTEtMA_e26b48c4-5f59-4651-904c-47868c1d92b5"
      unitRef="usd">16856000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtMi0xLTEtMA_3ea33e1f-4f93-40f3-9a15-5982a2668c13"
      unitRef="usd">3696000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtNC0xLTEtMA_8fddbcf9-4fb2-4ef9-a1ee-516f13599c49"
      unitRef="usd">3406000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzcx_f8a5cc0d-ccf1-4b80-95b4-1532c7f74e9c"
      unitRef="usd">15105000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzgw_a0357d2b-6f1a-45f9-8e4e-7f32002a600b"
      unitRef="usd">14812000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMi0xLTEtMA_b6a0166a-9bc3-4a85-9e30-1421af996464"
      unitRef="usd">14011000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtNC0xLTEtMA_97cbdbbf-b05a-48d3-8318-5b250bd8db62"
      unitRef="usd">13900000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtMi0xLTEtMA_22ec22b2-a4fa-40fd-b07d-473b01878660"
      unitRef="usd">27974000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtNC0xLTEtMA_54427191-5d1f-4af4-b844-58b6b3565eb5"
      unitRef="usd">28471000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtMi0xLTEtMA_a69b69e1-e128-44b0-af88-51092e42206d"
      unitRef="usd">49791000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtNC0xLTEtMA_f9308906-407a-4261-81dc-96b01eb28224"
      unitRef="usd">49577000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctMi0xLTEtMA_58e3aa1e-50c9-41c9-80b9-72002976df4d"
      unitRef="usd">2537000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctNC0xLTEtMA_9e45962a-7ea1-4519-9a95-a293f3ec83bc"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtMi0xLTEtMA_95d738e4-7e0a-4d31-9830-d4e80d439dcd"
      unitRef="usd">4744000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtNC0xLTEtMA_34f1ecd6-4611-416e-8c7a-f43f856fa8c6"
      unitRef="usd">4569000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktMi0xLTEtMA_66224ce2-ec14-46e0-8bac-0f77c996c04f"
      unitRef="usd">158818000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktNC0xLTEtMA_0aa1ccba-a043-4727-9334-6f26c16d0195"
      unitRef="usd">154229000000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzc3_209a44f0-bff7-4d61-8fce-81334abd5757"
      unitRef="usd">3676000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzg2_051458c7-1e4a-41f9-b88b-d469a1301929"
      unitRef="usd">2002000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMi0xLTEtMA_1f272255-31e2-48fc-b08f-290921eb77e3"
      unitRef="usd">4352000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItNC0xLTEtMA_88681e3e-690f-437d-825c-c2d4d1e04de4"
      unitRef="usd">2703000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtMi0xLTEtMA_0722fceb-c9bc-434f-8668-3f0787b0b561"
      unitRef="usd">4064000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtNC0xLTEtMA_731b2735-2a61-4935-89e3-d103124892aa"
      unitRef="usd">4309000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtMi0xLTEtMA_b8f8f76a-46da-4a66-833a-1b045c22c618"
      unitRef="usd">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtNC0xLTEtMA_3bea0501-6eb0-4aac-b385-01a868de15a9"
      unitRef="usd">2162000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtMi0xLTEtMA_ba2b86c8-d641-4897-9e3c-2aaa4371567a"
      unitRef="usd">1401000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtNC0xLTEtMA_6bafe616-32c9-4a2d-95dd-a190a54060a4"
      unitRef="usd">1049000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtMi0xLTEtMA_8b601138-908d-4dbf-a205-7239762d4e56"
      unitRef="usd">1985000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtNC0xLTEtMA_b0592247-8aba-446c-8912-b02f034e61b5"
      unitRef="usd">3058000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMTI2MzA_c91d6654-9dd8-4c99-9396-fb2f34f619b5"
      unitRef="usd">2052000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMTI2MzQ_aec0376d-dcc4-4187-a724-eadfd26cfa6b"
      unitRef="usd">1113000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMA_5c40c5d8-9bc6-4735-95f0-7d3328bc15be"
      unitRef="usd">12798000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMA_a6774203-968a-4f04-ab53-27e9fab2bae8"
      unitRef="usd">11527000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktMi0xLTEtMA_b0298880-5183-4a00-b0a4-5b1b07893b08"
      unitRef="usd">26652000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktNC0xLTEtMA_230e2d0e-5fd2-4196-84f4-87e6b43b1a93"
      unitRef="usd">25920000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtMi0xLTEtMA_edc917e8-d303-4298-a1ff-0c05ef9ce044"
      unitRef="usd">35347000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtNC0xLTEtMA_e7f1b6bc-818e-4c0d-bc9b-fe02a10ab80c"
      unitRef="usd">37133000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItMi0xLTEtMA_9bda7105-004b-4ad9-b67c-7f36661c8dfc"
      unitRef="usd">4526000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItNC0xLTEtMA_11cefec6-2605-4e1f-b0ce-910df4f36339"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtMi0xLTEtMA_f13fc6a8-7051-4d58-8257-a340ba70a084"
      unitRef="usd">635000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtNC0xLTEtMA_ec6315ef-4f3a-43f3-9da5-5479db3e32af"
      unitRef="usd">645000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtMi0xLTEtMA_134ee9af-92a8-4ebd-a3c7-8a2a0590f363"
      unitRef="usd">4355000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtNC0xLTEtMA_e9398da8-8afb-42f0-8db8-8662dff89240"
      unitRef="usd">4063000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtMi0xLTEtMA_a51b83b9-1421-457f-99d8-df7db3d38cc3"
      unitRef="usd">11759000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtNC0xLTEtMA_cebcbfc5-d6ba-4873-8dd2-4db96c7e6c75"
      unitRef="usd">11560000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtMi0xLTEtMA_614b2251-30ad-4608-9fd5-fac9be199afc"
      unitRef="usd">6677000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtNC0xLTEtMA_a00e8651-5626-4f21-8d6e-02167648a446"
      unitRef="usd">6669000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctMi0xLTEtMA_a65bd4ba-1820-4b22-abc8-5d7f3f3d1e2a"
      unitRef="usd">89953000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctNC0xLTEtMA_7ab205c7-c38b-48d1-a711-c7eb0d55ca7a"
      unitRef="usd">90756000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktMi0xLTEtMA_db66f237-38ba-41f8-afba-81484e69caa0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktNC0xLTEtMA_e16b226d-65da-4e2e-a89a-5550600d098f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItMi0xLTEtMA_65002b14-afa2-4cd3-aa13-a4adc4c9010c"
      unitRef="usd">472000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItNC0xLTEtMA_079a2b96-79f3-4ebd-b3d5-80ea09bfbd9c"
      unitRef="usd">470000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtMi0xLTEtMA_7b19a4a2-fed5-4b91-9292-4493e7679b22"
      unitRef="usd">89002000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtNC0xLTEtMA_78b4f964-01a2-46c1-a807-92a9a119244f"
      unitRef="usd">88674000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtMi0xLTEtMA_88c35372-b1b7-4891-955c-27b937077475"
      unitRef="usd">111349000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtNC0xLTEtMA_d6ac26b6-92e4-44e5-bdb3-cb7c3f43a309"
      unitRef="usd">110988000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtMi0xLTEtMA_4230f24a-8374-427f-871b-86020d61874e"
      unitRef="usd">95158000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtNC0xLTEtMA_6e45a608-125b-446f-9410-ffed17eef45e"
      unitRef="usd">90392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctMi0xLTEtMA_82d67c83-f36b-4492-af61-5ad383337bed"
      unitRef="usd">-4664000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctNC0xLTEtMA_2a43c97a-bec1-453d-8e24-b4c3002d34a5"
      unitRef="usd">-5310000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtMi0xLTEtMA_0e2008fb-9408-43fe-a6ee-d9a7b65a466f"
      unitRef="usd">68620000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtNC0xLTEtMA_887d4715-307b-4df0-9abf-a8a4ffea4cc0"
      unitRef="usd">63238000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktMi0xLTEtMA_fae1e498-49c0-4e4d-9881-5320e27def8a"
      unitRef="usd">245000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktNC0xLTEtMA_5b9a1299-e345-4667-9c4b-a51bc6d78143"
      unitRef="usd">235000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtMi0xLTEtMA_f83933a8-7029-4e83-af83-a7b500489083"
      unitRef="usd">68865000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtNC0xLTEtMA_7b05c05d-5019-425a-beac-7115e3f28c02"
      unitRef="usd">63473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtMi0xLTEtMA_c29302e6-1b07-4403-9902-b837be498a6b"
      unitRef="usd">158818000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtNC0xLTEtMA_0e7ded34-07fd-4b5e-ace4-42244a13ce42"
      unitRef="usd">154229000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="iad96abb481364caa9a72671a1c67d82f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yLTEtMS0w_f15b5774-2bbe-4a35-b407-84d721ea8e80"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad96abb481364caa9a72671a1c67d82f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy00LTEtMS0w_5bdb67ae-50cf-43ea-b010-7d1a289ccdd1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ib68a5c0cb0954eccb168987e68a66426_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy02LTEtMS0w_2c9b6c1e-66ca-4973-aae4-0b8f2a158e19"
      unitRef="shares">9407000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib68a5c0cb0954eccb168987e68a66426_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy04LTEtMS0w_cc8431de-fb76-457f-a4cb-d55ffc25a74e"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8432d19709754d54aa8831d0e0b91a10_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMC0xLTEtMA_e702f24d-6dcd-4075-a74c-2f27e22a157f"
      unitRef="usd">88674000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMi0xLTEtMA_b1b3407d-0c3e-4277-bcb9-cdc0fa1e3703"
      unitRef="shares">3840000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNC0xLTEtMA_a2ef4872-ef20-45e1-a359-0b47f3ec1d64"
      unitRef="usd">-110988000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e941de2442495c8df2676e0be6391b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNi0xLTEtMA_daad96ed-65cc-42c3-9fbf-84f58baf8e68"
      unitRef="usd">90392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44dea6398b1c4543b9115d73e959887b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xOC0xLTEtMA_b8b06f10-4b5f-4c60-a268-4976ac867c38"
      unitRef="usd">-5310000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76e4e86836694234959a3a15070601ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMC0xLTEtMA_c29b4cc5-b0ba-4dd5-9bb6-70c93f80cbae"
      unitRef="usd">63238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i670092d056fe431492c1724b7d5cfb67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMi0xLTEtMA_abcdce4a-ae84-4989-abbb-4b8a8b62b387"
      unitRef="usd">235000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yNC0xLTEtMA_3cd68fd2-561f-47b1-b3d9-bab9234fa77a"
      unitRef="usd">63473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0xNi0xLTEtMA_0961e0ea-cc17-46aa-aae0-9845bd2a2d60"
      unitRef="usd">4877000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMC0xLTEtMA_69bf811c-445d-4be6-8b44-dd7f1672f72d"
      unitRef="usd">4877000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMi0xLTEtMA_93827e26-b2a6-4807-8468-95af0ad762c9"
      unitRef="usd">9000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yNC0xLTEtMA_61233e8c-0c58-4e6e-87d1-44969d11da6a"
      unitRef="usd">4886000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0xOC0xLTEtMA_f0afb907-4c72-4938-8b45-cb84cb709efc"
      unitRef="usd">646000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMC0xLTEtMA_47055b71-5341-404d-814d-45444679060b"
      unitRef="usd">646000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMi0xLTEtMA_db94dd9c-420a-48da-9858-5b7bd1800777"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yNC0xLTEtMA_16e952a4-7089-43a1-a496-9a4802a487c3"
      unitRef="usd">647000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0wLTEtMS02MTU5L3RleHRyZWdpb246M2UwODhkZjU1MWYyNDQyOTlhYzdhY2EzNDM0OTkxZGNfMjc0ODc3OTA2OTQ2OQ_3be1813e-7605-4f06-aa0d-cf642672cbcd"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0xNi0xLTEtMA_39e8a983-43a7-4559-9481-205398d4064f"
      unitRef="usd">84000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yMC0xLTEtMA_9a168129-f87f-4358-b323-bbb1de338a2f"
      unitRef="usd">84000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yNC0xLTEtMA_728c4207-5710-494f-8ce3-d22a59243b2c"
      unitRef="usd">84000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOC0yNC0xLTEtMA_4133dd05-252b-478e-9495-388f0b591ddf"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOS0yNC0xLTEtMA_2c658a56-8aba-4885-803d-c84f6ec06c59"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtNi0xLTEtMA_fc5b028a-04da-4a91-839b-f47ac7553c40"
      unitRef="shares">38000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtOC0xLTEtMA_3e972744-97a3-4993-8e3f-20b80e7dd284"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTAtMS0xLTA_a8317233-11a6-4b1f-9f07-a6be958c517b"
      unitRef="usd">329000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTItMS0xLTA_fd37cea9-1831-4e27-acc4-54057dd69ccd"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTQtMS0xLTA_236f3c9c-9ce3-4f74-99ff-30211da83255"
      unitRef="usd">-361000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjAtMS0xLTA_01ac7a3e-4540-4d20-895e-487262adeebd"
      unitRef="usd">-30000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjQtMS0xLTA_4486d61e-0dbb-42c1-86aa-e8b877e8b696"
      unitRef="usd">-30000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTEtMjQtMS0xLTA_319c9084-e7e9-4c50-92e3-56d4777e5211"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTItMjQtMS0xLTA_5fa61122-2cc1-40ba-9376-efd72a449702"
      unitRef="usd">0</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMTYtMS0xLTA_ecfa475f-bb12-48e8-b2d7-9e56d3c97f0c"
      unitRef="usd">27000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjAtMS0xLTA_e715b706-a35d-4e4d-aa0c-bc8b28e6c777"
      unitRef="usd">27000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjQtMS0xLTA_e94ee728-56ce-4eae-8be7-bedc3b1831fa"
      unitRef="usd">27000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMi0xLTEtMA_d60df586-5b6b-41ac-8636-93ea0a5aa7e0"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNC0xLTEtMA_45d53a65-712f-4e75-989e-7f41aa7ee8d2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="if8cc8f792ccf4742a85390af1b808b26_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNi0xLTEtMA_e8f99745-96de-4f72-83c6-b88ba54f6355"
      unitRef="shares">9445000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8cc8f792ccf4742a85390af1b808b26_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtOC0xLTEtMA_6b7f1174-4c8a-4544-ac3a-10c3acb39c55"
      unitRef="usd">472000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f98424f39a64dedb002aa58aa06d599_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTAtMS0xLTA_7b640c08-a265-4d93-9431-97f035b66c70"
      unitRef="usd">89002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="icc01d70f4491494899c4a1be59cde841_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTItMS0xLTA_2af89896-69d5-48e1-b246-5214b7d256e7"
      unitRef="shares">3851000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc01d70f4491494899c4a1be59cde841_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTQtMS0xLTA_9fc2fb48-94c7-484c-879f-f3304f046ca9"
      unitRef="usd">-111349000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTYtMS0xLTA_9ba829a1-53b0-4250-b71b-14e86d585468"
      unitRef="usd">95158000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ffb761b6f624168a62f72e12228bb5a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTgtMS0xLTA_ac1a2838-a7c4-494f-8ae4-4d8e5c0cded0"
      unitRef="usd">-4664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i298e3f59dab144afadd3175e4b2e4702_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjAtMS0xLTA_648f9162-821f-4b23-83a5-65df4a0f36e8"
      unitRef="usd">68620000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ba782e27bc644768676d5050e11dd16_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjItMS0xLTA_c5214294-ed17-4072-ad98-094cf47c1148"
      unitRef="usd">245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjQtMS0xLTA_6454bd49-d058-4dca-afe1-e874de0f37b5"
      unitRef="usd">68865000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ice7f96cabae24782889c935aac35f1e1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMi0xLTEtMA_c6a8a055-e5b5-4bfc-b3a6-c112bdf6349d"
      unitRef="shares">431</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice7f96cabae24782889c935aac35f1e1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNC0xLTEtMA_b7016aa1-a5e6-48eb-a7da-f60d7017b423"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i96a8120f033f4276941d48877f9a9489_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNi0xLTEtMA_3356b2d8-681e-4b57-9945-4afef80f577b"
      unitRef="shares">9369000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96a8120f033f4276941d48877f9a9489_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktOC0xLTEtMA_5662ebe6-16ad-4b9f-84fd-d80e5bb730a1"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if706bef9ba9e4a8087b6638c1a298410_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTAtMS0xLTA_8d726f32-d157-44e8-8f86-c55c3bcddcf4"
      unitRef="usd">87428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5802b7b756774508be8ac80fe45d2d09_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTItMS0xLTA_33345091-314a-4617-b893-abe085066083"
      unitRef="shares">3835000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5802b7b756774508be8ac80fe45d2d09_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTQtMS0xLTA_d4856369-e06d-4b03-87b7-3a474268a1ca"
      unitRef="usd">-110801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieeb048b2301e439f88254780ad40d688_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTYtMS0xLTA_4b608b45-0eab-4b68-b744-ae81c451247a"
      unitRef="usd">91397000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice6876e4533642569b2b72a9c6fd043b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTgtMS0xLTA_0db18202-8771-446a-9b29-04325ba46993"
      unitRef="usd">-5367000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9748b402be914193b56e1300e8f8d640_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjAtMS0xLTA_6d224647-ef74-4d1a-a417-34f8d07fdf85"
      unitRef="usd">63143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7ae0369567d42bba15dd6a743487769_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjItMS0xLTA_b783645f-2129-4c16-8a85-15dcb3dddfda"
      unitRef="usd">303000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67a0a3b5e3a447628cfe527319aaf597_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjQtMS0xLTA_89c9c5a5-c3b3-45cf-8598-8dcd13c5cdb8"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i47f5513825544a8381d81fce8b6348be_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMTYtMS0xLTA_025e2da8-c497-4549-bb23-f27c0b6625c4"
      unitRef="usd">3355000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjAtMS0xLTA_f67fad01-af63-4898-8cd0-59b774b2e483"
      unitRef="usd">3355000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00864a6cffcd489689813f7229308d3e_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjItMS0xLTA_dc696168-7e0a-49f5-ac7b-f6968ec66f08"
      unitRef="usd">9000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjQtMS0xLTA_7e3df2d9-a9e8-4d6e-b434-6dd0dd6e5e81"
      unitRef="usd">3364000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMTgtMS0xLTA_079d6547-3044-4a5f-86d5-e78a7b828ead"
      unitRef="usd">-1441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjAtMS0xLTA_1b1e8f80-4886-4c48-afe8-60cecc3497cc"
      unitRef="usd">-1441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjQtMS0xLTA_3e71f848-2eaa-48a6-8c00-76ac3326e102"
      unitRef="usd">-1441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjItMC0xLTEtNTE5OC90ZXh0cmVnaW9uOjVlNmIyYWZlY2M0ZTQwYTliYjVhZTQ5NWNkNDM4NDViXzI3NDg3NzkwNjk1MDQ_8b7d4a58-60d4-4dfd-8f3d-1154a4fc5641"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i47f5513825544a8381d81fce8b6348be_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMTYtMS0xLTA_da29de7d-12e2-499c-b25f-2bc7ca52bc69"
      unitRef="usd">71000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjAtMS0xLTA_5cb53328-3657-48b0-8381-a6119f808969"
      unitRef="usd">71000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjQtMS0xLTA_f8398f0b-15c3-4a8d-aca1-25304957dd3c"
      unitRef="usd">71000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjQtMjQtMS0xLTA_69dd7e3c-80ce-4b67-a375-ed04e7bca374"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjUtMjQtMS0xLTA_dd04f700-c9e2-48ec-80f2-feed8e4ef29a"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtNi0xLTEtMA_c739731f-32fa-4636-854f-7263a9d9fe4e"
      unitRef="shares">23000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtOC0xLTEtMA_7f4b8dbc-8c6a-4314-ba1e-58cc587c3915"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTAtMS0xLTA_513d27a9-6b5a-413a-bcb0-8c2c00b26c09"
      unitRef="usd">252000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4702654caf394c4098db2cd85620b59d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTItMS0xLTA_357f32f2-70a1-4303-a30a-dadd9a25318c"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4702654caf394c4098db2cd85620b59d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTQtMS0xLTA_c3295571-92f9-4397-97d2-fc6a535da768"
      unitRef="usd">-209000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjAtMS0xLTA_2fec075d-92b5-41ff-b74e-9f08aa419706"
      unitRef="usd">44000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjQtMS0xLTA_0ddf063a-6bb8-4c9e-9131-f66c2949e313"
      unitRef="usd">44000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjctMjQtMS0xLTA_3bb47f19-e2dd-48de-a953-3b00f26e186d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMi0xLTEtMA_ebc17ad1-cad6-48c6-8e1c-33953cf8ceba"
      unitRef="shares">14</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtNC0xLTEtMA_97f79acc-1105-4d39-9b96-784249f301bf"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMTAtMS0xLTA_c9eb8e23-8c74-420e-bf59-cd9b22074f32"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjAtMS0xLTA_9d52c371-c5f0-4913-aaab-58c0341e1293"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjQtMS0xLTA_eb3a96d1-23ac-483b-8c11-d5d0c24fd469"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjktMjQtMS0xLTA_97352884-c446-420b-a8f1-ab99fdc240df"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMi0xLTEtMA_5767c048-2391-4586-9a33-9462b898f13a"
      unitRef="shares">417</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNC0xLTEtMA_07a86f4d-8da3-4d2f-98ea-7eae12b46e5b"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNi0xLTEtMA_8c436f94-1f1d-49cc-9b68-b5765b910501"
      unitRef="shares">9393000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtOC0xLTEtMA_a208530c-3305-47fe-b104-d303b837b81a"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id47b6b8fdd594ac3b929fd46636184eb_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTAtMS0xLTA_2ac8c3b9-7ae5-495b-a574-1c9f01b434cf"
      unitRef="usd">87680000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i98cea540ef86451da18644ee8a6e2767_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTItMS0xLTA_83be8de5-0406-45b6-8c2d-a382ffa27844"
      unitRef="shares">3841000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98cea540ef86451da18644ee8a6e2767_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTQtMS0xLTA_9ba2660a-3af9-4aec-8a48-b484cdfe0e70"
      unitRef="usd">-111010000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c5d25c9530040899006db8fed3c6271_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTYtMS0xLTA_3dc36453-8c6a-449b-a6f5-c9ffc3ba2630"
      unitRef="usd">94680000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i887f2cb651164ba79b51cf28563d8588_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTgtMS0xLTA_373ed0f1-e737-4928-b845-1cdba1102087"
      unitRef="usd">-6808000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjAtMS0xLTA_227e91fd-7b8d-447c-ae13-5ddfb0a9c3ac"
      unitRef="usd">65028000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5affdf158b6444899bba4d555d785d25_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjItMS0xLTA_1ecc22cd-f50c-47a8-a836-6730a8a5dd45"
      unitRef="usd">312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i793a6170d7114594b0f7282bca5807aa_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjQtMS0xLTA_6e58f181-01e0-4b5d-9a2f-e410096c3fcb"
      unitRef="usd">65341000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy0yLTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097"
      unitRef="usd">4886000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy00LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac"
      unitRef="usd">3364000000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC0yLTEtMS00NDcz_db0ebba8-3fd7-4565-aaf5-efe9613f3091"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC00LTEtMS00NDcz_eae0c9bd-0a1a-4f1b-bf43-0c8e939219d3"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS00NDcz_9f5eb126-01e0-443f-9fff-ae69f589e878"
      unitRef="usd">4877000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS00NDcz_a60fe1c1-dafe-455a-a520-26ef02e167ac"
      unitRef="usd">2483000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS0w_34ad4ab7-792f-4752-adb5-034667c57e29"
      unitRef="usd">1226000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS0w_695b90c5-9d58-47d5-b3e4-bae522498a38"
      unitRef="usd">1166000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi0yLTEtMS0w_d7dc09db-217e-4b6e-b603-cee16c9570df"
      unitRef="usd">46000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi00LTEtMS0w_23412bf2-68a9-4c64-84f6-43d604ff0e94"
      unitRef="usd">44000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC0yLTEtMS0w_e104219f-58b6-4444-ad17-1af7f79179f4"
      unitRef="usd">0</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC00LTEtMS0w_99778cad-166c-4c54-a6db-d05c20a7f8e3"
      unitRef="usd">6000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS0yLTEtMS0w_1ea33e6c-7708-4c00-b5c9-2651169adf48"
      unitRef="usd">199000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS00LTEtMS0w_015e7392-390f-48a2-9831-f50f2622e334"
      unitRef="usd">82000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtMi0xLTEtMA_0ce0c4e8-66fc-4968-b02d-2a3a6aaeb69a"
      unitRef="usd">172000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtNC0xLTEtMA_1519ce42-fb9a-48fa-a911-af267d85844d"
      unitRef="usd">57000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItMi0xLTEtMA_edcd0655-8b98-45b0-8ca0-4b6e06b18860"
      unitRef="usd">373000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItNC0xLTEtMA_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d"
      unitRef="usd">276000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtMi0xLTEtMA_c019a12f-677f-4dd9-a0e1-1075c720183d"
      unitRef="usd">291000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtNC0xLTEtMA_758f03c3-70a8-4ae2-87c6-06d28099658e"
      unitRef="usd">-120000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtMi0xLTEtMA_254eaf9d-75cc-4d2a-94f0-9db515048fc1"
      unitRef="usd">1327000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtNC0xLTEtMA_f5f3a07c-f5eb-411d-b598-f1955722f297"
      unitRef="usd">1515000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctMi0xLTEtNDQ4NA_ef040139-1c85-4172-9204-607523073595"
      unitRef="usd">4530000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctNC0xLTEtNDQ4NA_56e3c096-4efc-422f-974e-650c16500ee4"
      unitRef="usd">2155000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtNDQ4NA_b8e3494b-7584-4888-bfc3-9c002c0c3d6d"
      unitRef="usd">9000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtNDQ4NA_b21a14af-601d-4969-9838-eeb52caf8fb2"
      unitRef="usd">978000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtMi0xLTEtMA_286dd32f-26fa-448e-8474-34202419f304"
      unitRef="usd">4538000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtNC0xLTEtMA_a93cf4af-9457-4e58-9cce-f3e856e8abc8"
      unitRef="usd">3133000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtMA_de34efc3-eeaf-4416-91be-8e23366b2159"
      unitRef="usd">554000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtMA_31319a43-4f88-47ab-889f-8c23f765d55b"
      unitRef="usd">449000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktMi0xLTEtMA_d6be0354-08ef-4ff3-847a-7907999762e1"
      unitRef="usd">6054000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktNC0xLTEtMA_f9e00c31-5988-4158-9235-c70146f75c4b"
      unitRef="usd">2551000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtMi0xLTEtMA_37d1fac3-fa92-47d0-9417-1352578091f1"
      unitRef="usd">5465000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtNC0xLTEtMA_1074effd-4f49-4eea-b467-a70533f5326a"
      unitRef="usd">3257000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtMi0xLTEtMA_7dcaa28d-bf38-4289-95d2-58d1ea2bbdaf"
      unitRef="usd">996000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtNC0xLTEtMA_d21bc066-280e-4cd6-9507-e7302d7f51f1"
      unitRef="usd">416000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItMi0xLTEtMA_cbb2f89d-1b3a-41b5-9946-15af486ba36c"
      unitRef="usd">27000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItNC0xLTEtMA_d16636c3-1549-4500-bf15-e194652780bc"
      unitRef="usd">22000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtMi0xLTEtMA_81773875-5156-4561-b878-9b3eb4e95f20"
      unitRef="usd">256000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtNC0xLTEtMA_2acb95d2-60e3-4c87-8d5b-050e665645df"
      unitRef="usd">152000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctMi0xLTEtMA_711cdfd0-132d-42a6-bca3-50885ca83911"
      unitRef="usd">-163000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctNC0xLTEtMA_2fc77c15-9e2e-47f6-995f-fb1ebe9a2797"
      unitRef="usd">24000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtNDQ5MA_aa468a25-1dfb-4b04-8e1a-48b80697b71e"
      unitRef="usd">-1747000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtNDQ5MA_cee2d8ba-0fdd-4af1-ab4a-330447e93035"
      unitRef="usd">-53000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtNDQ5MA_668d7fa5-3dd6-4257-9cb5-e09563b47e82"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtNDQ5MA_b75e3fdb-83e8-4807-ae37-4aa185fa9e33"
      unitRef="usd">-19000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtMi0xLTEtMA_14cd609a-2135-45e4-b235-5b721bad35fd"
      unitRef="usd">-1747000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtNC0xLTEtMA_8e2b1d2b-38c8-47ad-9d9e-e73c42e35568"
      unitRef="usd">-71000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtMA_00eaef87-7032-4eee-9cc8-e2ab901bddb4"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtMA_14130354-dbe7-4d76-aa8b-fd709264e90d"
      unitRef="usd">5302000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtMA_19b32bfb-855f-4cad-ae5c-314dca61eb5a"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtMA_f3d452a9-a292-471c-80e7-e574a6db0ac4"
      unitRef="usd">7551000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtMi0xLTEtMA_85d37f78-e030-4f24-96b4-73c5312d98a8"
      unitRef="usd">-25000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtNC0xLTEtMA_e4f4931d-7e64-44d3-8052-8c5e831be111"
      unitRef="usd">3207000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtMi0xLTEtMA_ab96f559-9a8b-4f9b-80da-679699f1702c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtNC0xLTEtMA_84ce470d-0aa9-454c-8550-4acdfac719e3"
      unitRef="usd">1241000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtMi0xLTEtMA_4b2f0fc7-cb53-489c-9a38-97d0e2aef4b6"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtNC0xLTEtMA_21bf8e65-fb29-4351-9681-6b77ec19f66d"
      unitRef="usd">2181000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctMi0xLTEtMA_e83cf0c2-292e-406b-9257-2c1125e6c4cd"
      unitRef="usd">2172000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctNC0xLTEtMA_17c5bd85-e12d-4c6f-a1c3-383fb2539528"
      unitRef="usd">2105000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktMi0xLTEtMA_9c0ea444-d93f-48ad-8cf5-e25baff85eb0"
      unitRef="usd">-610000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktNC0xLTEtMA_7fbc7f61-35c2-4aa8-85ac-fa0d4a6cde47"
      unitRef="usd">-113000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtMi0xLTEtNDQ5NA_5d1f84e9-247f-4848-8abb-cc0768a30c1e"
      unitRef="usd">-2807000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtNC0xLTEtNDQ5NA_d1c3d278-edbe-4e39-af3e-3c8c5ff971a5"
      unitRef="usd">-2200000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtMi0xLTEtMA_186b0d02-4fa1-462d-a084-7b0809883da4"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtNC0xLTEtMA_367ae77c-36c2-494f-91f7-39e03656449b"
      unitRef="usd">-15000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItMi0xLTEtMA_d6a6733a-22c7-4acd-93b8-3385c85a022b"
      unitRef="usd">-15000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItNC0xLTEtMA_23381d8f-4fd7-4bbb-aea8-ec623bef4777"
      unitRef="usd">846000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtMi0xLTEtMA_1b02424a-10a0-41fd-8e99-9d4348c3047a"
      unitRef="usd">1825000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i67a0a3b5e3a447628cfe527319aaf597_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtNC0xLTEtMA_fc2e07f8-9b12-4a61-85aa-579a99fee24b"
      unitRef="usd">1350000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtMi0xLTEtMA_663c02cc-3e50-43e2-8c44-d3a29be0f409"
      unitRef="usd">1809000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i793a6170d7114594b0f7282bca5807aa_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtNC0xLTEtMA_702d2f60-010b-4e95-bbea-f4335925ea0b"
      unitRef="usd">2196000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtMi0xLTEtMA_0f7d9b37-4660-466e-bf27-3bd56ef85f2b"
      unitRef="usd">394000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtNC0xLTEtMA_91bf8f47-9ad1-4b3a-bde5-0fbdeaaf02fb"
      unitRef="usd">239000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtMi0xLTEtMA_b4a37513-5a1b-4633-9d3b-968102b80d74"
      unitRef="usd">445000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtNC0xLTEtMA_28de0820-c712-4149-a66f-ded950d90766"
      unitRef="usd">472000000</us-gaap:InterestPaidNet>
    <pfe:InterestPaidReceivedInterestRateHedges
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtMi0xLTEtMA_1579cb8d-5f64-4f33-946f-198a6b8fbffe"
      unitRef="usd">10000000</pfe:InterestPaidReceivedInterestRateHedges>
    <pfe:InterestPaidReceivedInterestRateHedges
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtNC0xLTEtMA_9089d041-6a7b-4819-8321-6ec658f7caac"
      unitRef="usd">-11000000</pfe:InterestPaidReceivedInterestRateHedges>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI4OA_7c0851ba-5089-4c21-a853-242939e447c1">Basis of Presentation and Significant Accounting Policies&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;28, 2021 and February&#160;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&#160;4, 2021 and March&#160;29, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business development activities impacted financial results in the periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form 10-K, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer&#x2019;s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&#160;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. New Accounting Standard Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For information on new accounting standards adopted in 2020, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Change in Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (&#x201c;MTM Accounting&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the prior policy, we deferred recognition of these gains and losses in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The accumulated actuarial gains/losses outside of a &#x201c;corridor&#x201d; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of $6.3 billion, with a corresponding offset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;4, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March&#160;29, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT PER COMMON SHARE DATA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income before allocation to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="21" style="padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Comprehensive Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Cash Flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred taxes from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plan contributions in excess of expense/income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;4, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pension benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customers&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended April&#160;4, 2021 and March&#160;29, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1G&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODMyOQ_34978c98-23a9-425f-9f9c-53aa2eeca2ec">Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;28, 2021 and February&#160;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&#160;4, 2021 and March&#160;29, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business development activities impacted financial results in the periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form 10-K, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer&#x2019;s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&#160;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5MA_51711fb1-8391-4988-80de-12acbb9be2f5">New Accounting Standard Adopted in 2021On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MTE_a89d8a41-6dbb-450d-aa96-e9dced05fd39">Change in Accounting Principle&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (&#x201c;MTM Accounting&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the prior policy, we deferred recognition of these gains and losses in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The accumulated actuarial gains/losses outside of a &#x201c;corridor&#x201d; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of $6.3 billion, with a corresponding offset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i08a420875e0f49f2a79116b4b03bde63_I20200101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_8d8646ae-fc98-4927-ba4f-f3ce611419fe"
      unitRef="usd">-6300000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i08a420875e0f49f2a79116b4b03bde63_I20200101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_b5653272-8d5e-475f-8b89-bcb9f92e8b72"
      unitRef="usd">6300000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MDg_f4c2e5d0-778e-400f-b8f7-6294c682241c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;4, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March&#160;29, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT PER COMMON SHARE DATA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income before allocation to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="21" style="padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Comprehensive Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="21" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Statements of Cash Flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred taxes from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plan contributions in excess of expense/income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;4, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pension benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0yLTEtMS04Mzgw_5dab9db7-896e-45aa-9206-7c49d1af0780"
      unitRef="usd">857000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi00LTEtMS0xMzY0NQ_7d7bf6e3-9d1e-4ce8-a958-5bce4bf08fa1"
      unitRef="usd">146000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMy02LTEtMS04MDk5_203cb90a-a50d-4aa1-92bc-8db2f6057681"
      unitRef="usd">1004000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi04LTEtMS0xMzY1MA_df171ed0-a427-4ded-bebc-0eda237e083f"
      unitRef="usd">-216000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMC0xLTEtMTM2NTA_290ce6ad-87b8-4fc4-8de6-a5a9e14dd406"
      unitRef="usd">25000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0xMi0xLTEtOTA5MQ_7428b9b0-6ab1-423e-b4da-93afa243cd13"
      unitRef="usd">-190000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0yLTEtMS04Mzgw_e48a94ef-3c74-43df-a6ec-74c11d480af3"
      unitRef="usd">5536000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy00LTEtMS0xMzY0NQ_a8ef75f5-edf8-4550-9597-bc0d57d4e3a3"
      unitRef="usd">146000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MjQ1_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf"
      unitRef="usd">5683000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy04LTEtMS0xMzY1MA_7bc427cd-1e98-4118-8ebc-ebda5b056bce"
      unitRef="usd">2817000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMC0xLTEtMTM2NTA_6498ecf2-43bd-4a7c-b8d3-132873239af4"
      unitRef="usd">25000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0xMi0xLTEtOTA5MQ_82638985-d87e-4d19-83f9-35ac23cb0316"
      unitRef="usd">2842000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0yLTEtMS04Mzgw_bf39697a-ced1-4cef-a87f-0ef7d577b507"
      unitRef="usd">773000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC00LTEtMS0xMzY0NQ_91f42c4a-b118-425e-a118-49661bbe9013"
      unitRef="usd">32000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTIz_d6a31f7c-a51a-4074-9737-47e32947c8ef"
      unitRef="usd">805000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC04LTEtMS0xMzY1MA_b671c90a-7b41-4de4-952b-8b4e22f66f3b"
      unitRef="usd">355000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC0xMC0xLTEtMTM2NTA_619c9ad4-3594-4c13-bcd7-a50bfc755e25"
      unitRef="usd">4000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMi0xLTEtOTA5MQ_b8472e14-0a68-41d2-9348-eb9d50c460a3"
      unitRef="usd">359000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS0xMzY0Nw_40fb72b7-01fb-4639-9985-27120145fa82"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS00LTEtMS0xMzY0NQ_503d730e-7a31-4067-b994-fb2a89171a95"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS0xMDA3NQ_33b79d80-57b2-425b-8cb8-a4c3b19b5192"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS04LTEtMS0xMDA4MQ_b9590803-6217-4104-ba79-b2089aadc9c5"
      unitRef="usd">948000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMC0xLTEtMTM2NTA_50ef09c5-cdcb-4ecf-b9b4-cb0986406850"
      unitRef="usd">-68000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtMTAwNzc_11166465-dd3c-4aba-b037-16fb7e609c74"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtMTQzNTE_bea51b29-8111-4693-b1aa-5b9bc281e279"
      unitRef="usd">4772000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTQzNTE_febdf589-16a3-4c4c-9c2f-17b673119d9a"
      unitRef="usd">114000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNi0xLTEtMTQzNTE_b93a5f55-b8ee-41e9-ae00-863374a23097"
      unitRef="usd">4886000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTQzNTE_60a41266-7cca-41c6-833b-5490bce7025c"
      unitRef="usd">3410000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTE0MzUx_f956ef5d-dc46-48a7-bb24-d0ed6e9e0bfa"
      unitRef="usd">-47000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTE0MzUx_cad182ae-42d2-4615-922c-b2e1dcaeb3ac"
      unitRef="usd">3364000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0yLTEtMS04Mzgw_0c1b6c6e-9152-4d26-8b67-d67e50e3405a"
      unitRef="usd">4763000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTM2NDU_0b27c47c-1205-4de7-91f2-d04fcbe905b3"
      unitRef="usd">114000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTEx_f7319f6b-201b-4644-bf83-f647ec7dbf11"
      unitRef="usd">4877000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTM2NTA_7db8681e-dd60-4c10-8768-1770b685b5d1"
      unitRef="usd">3401000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTEzNjUw_4d3fa8b0-43a6-4d4c-ba02-b3284b5a0e9e"
      unitRef="usd">-47000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMi0xLTEtOTA5MQ_3ad21e9d-4916-46a3-be5d-5e9916f84c40"
      unitRef="usd">3355000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMi0xLTEtMTM2NTY_dd252889-722e-41a7-b004-5bf407174997"
      unitRef="usdPerShare">0.85</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNC0xLTEtMTMwMzk_cf92f801-dc9a-40d4-ae7e-13049bbab2b5"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtMTMwMjc_75b7133b-7b8d-4749-ae65-9eca8dc2ec41"
      unitRef="usdPerShare">0.87</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtOC0xLTEtMTM2NjA_10696dfa-6602-4c40-86e5-0173ffcb7613"
      unitRef="usdPerShare">0.44</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTAtMS0xLTEzNjYw_8acfb86a-4096-4c78-91a5-50d287916db8"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTItMS0xLTEzMDM3_0ad41313-4c51-4bb7-b815-6df61bc17314"
      unitRef="usdPerShare">0.45</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtMTM2NTY_cf7e27dc-81b6-4b81-9fda-96598e7bd1c3"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNC0xLTEtMTM2NTg_9bec4602-b014-4973-8ae0-a7963bf61707"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtMTMwMjc_f1d431d7-e33e-49e8-81e9-b399c079757d"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtOC0xLTEtMTM2NjA_faa2854b-bdd9-475d-bf3b-b4bdf09e371c"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTAtMS0xLTEzNjYw_56375208-0799-443c-aee5-1d674b1fc69b"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTEzMDM3_b38d95a7-f497-451a-a668-541c33faf446"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtMTM2NTY_b75242d4-1f87-447a-b122-4271dc2d6b71"
      unitRef="usdPerShare">0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNC0xLTEtMTM2NTg_6ac6f350-2dee-4a59-9ee9-d1bae43c1c92"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtMTMwMjc_5fae1b27-b998-4f4d-8b17-ea0c71804d2a"
      unitRef="usdPerShare">0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtOC0xLTEtMTM2NjA_b0739781-3f08-472a-979f-063c3af35045"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTAtMS0xLTEzNjYw_b57f8d60-aca4-49f7-bf38-ff4da8772b68"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTEzMDM3_a85c270d-3dd9-4d4f-b87a-b672be7959e3"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtMTM2NTY_024eddc5-7310-4864-bc99-77d30ca454e9"
      unitRef="usdPerShare">0.84</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNC0xLTEtMTM2NTg_b684e132-229f-4f14-a5f4-97c04e607c1a"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNi0xLTEtMTMwMzA_83a08fc6-5a94-455d-bd21-674b27a0506a"
      unitRef="usdPerShare">0.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctOC0xLTEtMTM2NjA_1cf40a4b-3b3e-4dfe-88e8-486a56555a24"
      unitRef="usdPerShare">0.44</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTAtMS0xLTEzNjYw_75395125-4049-48de-8e1f-0fd8c70cd47c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTEzMDM0_20550d10-89e1-4fac-81dd-154718ea283b"
      unitRef="usdPerShare">0.44</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS04Mzgw_eba685e9-b01a-4551-9a99-5b2383bb1cef"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtNC0xLTEtMTMwMzg_7026c5b1-319d-455a-84a6-39a41ec3ad9e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC02LTEtMS04MTUz_eb0b828b-e1f2-42da-a9cd-00ad72d78436"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtOC0xLTEtMTM2NjA_e19a9d50-cc92-4ecf-b30b-1ed14e4c8437"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtMTAtMS0xLTEzNjYw_ebf0a702-3ed3-4237-ae41-eba838c5e96b"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtOTA5Mw_d533696a-7d6b-4c6b-9843-f64b3d7d9d23"
      unitRef="usdPerShare">0.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtODM4MA_873d32a7-5d8e-4595-a4e9-e8030fd1fe90"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktNC0xLTEtMTM2NTg_3011635b-90ef-4123-88f3-76cc6dcfb9ac"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS04MTU1_ccebed80-aeef-40fa-bade-64f59e94c84c"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktOC0xLTEtMTM2NjA_6ecf4906-1f34-45f2-ab90-f4ecf2e8fcaa"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktMTAtMS0xLTEzNjYw_dfb2cff6-b945-404d-824f-47a2312548dc"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTkwOTM_f11106ea-d63e-4bab-9b51-2cebf2989dd4"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMi0xLTEtMTU4MDk_eefdbbbd-57fb-4a19-8c8a-c11af8925fce"
      unitRef="usd">546000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTU4MDk_0c0e1e51-cd54-4302-8daf-987ba94ec250"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNi0xLTEtMTU4MTY_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa"
      unitRef="usd">465000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTU4MTM_77c0e017-f41e-4d3f-9c54-d9bf4a5ce366"
      unitRef="usd">-1272000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTE1ODEz_603f9712-c0b0-4899-b620-e38c481e5062"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTItMS0xLTE1ODIw_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0"
      unitRef="usd">-1256000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtODM4MA_de328a85-7e0f-4afc-85cb-15d114ee2b67"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTM2OTE_a40fb0df-3563-45e9-bb7b-18dae25c2bd3"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtODIzMg_81d619e1-c56d-478c-b00b-bdc4762e66f5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTM2OTY_745045e0-c575-4b24-a178-77c6c2ac9899"
      unitRef="usd">-166000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTEzNjk2_427f4c5c-74fd-4816-a36f-0910e6646fd0"
      unitRef="usd">166000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTkwOTU_389a2d98-d4bb-4be1-97a0-f30099054ecf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtODM4MA_9e04eeed-0457-4cbb-a75f-75cf0b254aca"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtNC0xLTEtMTM2OTE_afd5b122-b05c-40fb-8811-de18bd289523"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtODIzMg_4a588c90-bf2b-4bef-b074-79334b894fe5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTM2OTY_52d203a0-c548-4ff5-bca5-ef526a9c5c18"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtMTAtMS0xLTEzNjk2_f50e3500-d5c6-49f4-8343-30d40ecb4aa6"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTkwOTU_d9022c32-4db1-4663-9ed6-349f6053ba28"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMi0xLTEtODM4MA_0615b6b9-0251-462d-b18d-ad111b73de5e"
      unitRef="usd">-19000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtNC0xLTEtMTM2OTE_2f67ec5d-2bb2-4000-bce3-d4ef5a5f9965"
      unitRef="usd">19000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtODIzMg_5c0bc19b-ae84-42a7-8525-fc30229df49b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtOC0xLTEtMTM2OTY_cdea3887-3b40-4a4c-998a-7a76af9c9849"
      unitRef="usd">-53000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtMTAtMS0xLTEzNjk2_c2856c32-007b-46f3-9699-8026854ba23c"
      unitRef="usd">53000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMTItMS0xLTkwOTU_949ddb31-8811-4e31-8486-1b69301fc736"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtODM4MA_7bd874d7-b0f4-4fa2-adcc-94e8be7978bd"
      unitRef="usd">81000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtNC0xLTEtMTM2OTE_80e0b940-3c87-4375-b482-98b0518375f1"
      unitRef="usd">-81000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtNi0xLTEtODIzMg_f033076b-0c76-40f6-aedf-91081fdd6f0b"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtOC0xLTEtMTM2OTY_02210909-814b-43d2-8924-3d62f632f8e4"
      unitRef="usd">-16000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtMTAtMS0xLTEzNjk2_7d5c1ece-b94a-438e-85e7-3455a0f7ea89"
      unitRef="usd">16000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTkwOTU_7a22fba8-c4d4-4a44-8281-048374465961"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMi0xLTEtMTQzMDE_9695b009-4fc3-45da-9da3-bc7a84205173"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNC0xLTEtMTU3Njg_e1558817-8454-4bae-aa69-59e1530a38b3"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNi0xLTEtMTQyOTQ_491a1642-d58b-44cc-b6f4-9543a582ef04"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctOC0xLTEtMTQ4Nzg_03de7da4-0a2b-4cab-b71e-126614e429bf"
      unitRef="usd">-377000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTAtMS0xLTE1Nzcz_cfbfa4ff-c663-4a8f-9afb-19b529c18a75"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTItMS0xLTE0Mjk2_5951f2d0-71ca-4d8f-8b42-a45bbaf37291"
      unitRef="usd">-380000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMi0xLTEtMTU3Mzc_2c929d65-b71f-4fe9-99b6-afe42c66f26c"
      unitRef="usd">167000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTU3ODM_db8c6e57-8d93-4e2c-a589-4144ac80c1f5"
      unitRef="usd">32000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNi0xLTEtMTU3MjU_1ea33e6c-7708-4c00-b5c9-2651169adf48"
      unitRef="usd">199000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtOC0xLTEtMTU3MzM_dcb6064e-e710-4aef-a49b-e4f40320434b"
      unitRef="usd">77000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTE1Nzc4_b591beb4-892e-4a2b-bd5e-69490e66f533"
      unitRef="usd">4000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTE1NzI3_015e7392-390f-48a2-9831-f50f2622e334"
      unitRef="usd">82000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjItMi0xLTEtODM4MA_d6eddeb4-ee9f-472b-b46c-eeb23caa351d"
      unitRef="usd">226000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTM3MDA_1a61d7a0-6036-41d3-a40a-20bace06b0f0"
      unitRef="usd">146000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtNi0xLTEtODMyNg_edcd0655-8b98-45b0-8ca0-4b6e06b18860"
      unitRef="usd">373000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTE3OTA_1195e993-5355-4c17-bdb8-924f7fd2ec3a"
      unitRef="usd">250000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTEzNzA0_0967c9ea-066b-471b-aa7b-63ca44b58b13"
      unitRef="usd">25000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjEtMTItMS0xLTkwOTc_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d"
      unitRef="usd">276000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMi0xLTEtMTUwODY_fecb5532-694a-404d-b182-bfb4904dd5ff"
      unitRef="usd">2569000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i171b297bb091460caae274aa6fd2034c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNC0xLTEtMTU3ODQ_8e8dc98a-b221-4645-9679-36b98609d7d5"
      unitRef="usd">-32000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtMTUwNzY_58e3aa1e-50c9-41c9-80b9-72002976df4d"
      unitRef="usd">2537000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTUwODI_f1ca5888-a423-4d2c-92e4-38871f63c28f"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtMTAtMS0xLTE1Nzkz_26138068-b065-4e93-8fcb-be140261e21f"
      unitRef="usd">0</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTItMS0xLTE1MDc5_9e45962a-7ea1-4519-9a95-a293f3ec83bc"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMi0xLTEtMjA2NTc_3e3274a3-c7d7-4cb0-ad0e-d5c9ae4e82b1"
      unitRef="usd">4738000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i171b297bb091460caae274aa6fd2034c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMjA2NjA_e3e8f388-f2f5-4549-936a-34e87d2ef190"
      unitRef="usd">6000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNi0xLTEtMjA2NDk_95d738e4-7e0a-4d31-9830-d4e80d439dcd"
      unitRef="usd">4744000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMjA2Njk_1f2be8d9-b433-4c15-8449-0f9a0b9084ad"
      unitRef="usd">4569000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTIwNjY5_64d51ccc-b643-4ace-a1b2-71925d5248d7"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTItMS0xLTIwNjUx_34f1ecd6-4611-416e-8c7a-f43f856fa8c6"
      unitRef="usd">4569000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjktMi0xLTEtODM4NA_ee06e3a6-6bfa-4c3a-b9be-cc419eba2c2b"
      unitRef="usd">4527000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i171b297bb091460caae274aa6fd2034c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNC0xLTEtMTM3MTM_048ac843-d653-4e16-8db9-34362ec2884e"
      unitRef="usd">0</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzUtNi0xLTEtODI2Mg_9bda7105-004b-4ad9-b67c-7f36661c8dfc"
      unitRef="usd">4526000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTM3MTU_6b7e7465-0ceb-4a47-8405-4438d1bb4fa7"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTAtMS0xLTEzNzE1_8e59d7b3-ce77-44f3-950d-e8264ed2d972"
      unitRef="usd">0</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtMTItMS0xLTkwOTk_11cefec6-2605-4e1f-b0ce-910df4f36339"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMi0xLTEtODM4NA_d602c50f-ca60-4269-9ee4-f718b8b15d5c"
      unitRef="usd">95044000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i171b297bb091460caae274aa6fd2034c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktNC0xLTEtMTM3MTM_d473b86e-5f9f-4c12-9df6-2d00930fe30b"
      unitRef="usd">114000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtODI3Ng_4230f24a-8374-427f-871b-86020d61874e"
      unitRef="usd">95158000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktOC0xLTEtMTM3MTU_7580f644-c600-4231-bbd3-e67bb4574450"
      unitRef="usd">96770000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktMTAtMS0xLTEzNzE1_dc6788e4-94b9-4e5f-86cb-bbded14c4a5c"
      unitRef="usd">-6378000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTkwOTk_6e45a608-125b-446f-9410-ffed17eef45e"
      unitRef="usd">90392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ide9e1b38766a45f1b70fef289bf08b46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzItMi0xLTEtODM4NA_cfcd4507-2a87-4f30-81ff-c6b3f0f5e239"
      unitRef="usd">-4523000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i171b297bb091460caae274aa6fd2034c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMTM3MTM_9b5943fb-9452-427b-a756-7fadf972440c"
      unitRef="usd">-141000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNi0xLTEtODI5OQ_82d67c83-f36b-4492-af61-5ad383337bed"
      unitRef="usd">-4664000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMTM3MTU_cb7dfdf0-f063-4d27-9bd8-81cd8a433119"
      unitRef="usd">-11688000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i12997ed07c6d40178b3062b257ac83bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTEzNzE1_f27e39b6-6fd4-4442-a088-4f4e5d199fd9"
      unitRef="usd">6378000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMTItMS0xLTkwOTk_2a43c97a-bec1-453d-8e24-b4c3002d34a5"
      unitRef="usd">-5310000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODM0OA_9a96f313-1767-408b-89f4-03bdd57e4dca">Revenues and Trade Accounts Receivable&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customers&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.&lt;/span&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5OA_91d136b2-f031-4290-a0c7-e9628c53eb7e">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="i99fcec41f64847ed86b1c89a56896531_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS0yLTEtMS0w_68aef472-330b-488e-b305-ffab9c991fd7"
      unitRef="usd">848000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="ie4a2b9079bc742749949e93c782f4af9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS00LTEtMS0w_057c355f-e8b7-4712-aafe-bbf71bd1383e"
      unitRef="usd">861000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:AccruedRebates
      contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy0yLTEtMS0w_97f6047f-ac20-4623-b409-c7cb97449d91"
      unitRef="usd">3211000000</pfe:AccruedRebates>
    <pfe:AccruedRebates
      contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy00LTEtMS0w_75640e3b-54fa-470c-8100-fc6da00652f2"
      unitRef="usd">3017000000</pfe:AccruedRebates>
    <pfe:OtherAccruals
      contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC0yLTEtMS0w_8cfb899d-1e89-4ce7-a0e3-21dec094bbc3"
      unitRef="usd">449000000</pfe:OtherAccruals>
    <pfe:OtherAccruals
      contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC00LTEtMS0w_9440259a-8bf7-49e8-92f5-2b0c96f6a9d7"
      unitRef="usd">436000000</pfe:OtherAccruals>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="ib09c41fb46464505bcc32a3c43731505_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS0yLTEtMS0w_bb0f4e42-cf04-4a5e-bd64-64384657929e"
      unitRef="usd">340000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="ic0fac9c964894676b74a3dfea4fc6f74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS00LTEtMS0w_27606924-0656-4d84-b891-bebb28ef50c4"
      unitRef="usd">399000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi0yLTEtMS0w_1792f97f-2172-45ce-9d39-7231a477dc79"
      unitRef="usd">4848000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi00LTEtMS0w_ad863a6a-7370-4d15-975e-c45a13adf941"
      unitRef="usd">4712000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3OQ_ba908374-5f20-47da-8017-88149f62cde1">Discontinued Operations and Equity-Method Investment&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Upjohn Separation and Combination with Mylan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the first three months of 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $871 million as of April&#160;4, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net cash provided by operating activities from continuing operations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other financing activities, net, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and was recorded as a payable to Viatris in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;In the three months ended April 4, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#x2019;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Equity-Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Formation of Consumer Healthcare JV&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in the Consumer Healthcare JV is $16.3 billion as of April&#160;4, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of April&#160;4, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $126 million in pre-tax foreign currency translation adjustments (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), as well as dividends totaling approximately $274 million, partially offset by our share of the JV&#x2019;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in the first quarter of 2021, was $71 million. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2019, which we recorded in our operating results in the first quarter of 2020 was $11 million. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and was not material to our results of operations in the periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="i1fb4d5f76cd341e2a3579da45c669e20_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY0MjUzMg_50774283-f6ba-43df-a9c0-40a28e34fa82"
      unitRef="usd">871000000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTY0OTI2NzQ3NzY3OQ_6aca0054-cc97-4954-8ee1-a7145065e166"
      unitRef="usd">401000000</us-gaap:NontradeReceivablesCurrent>
    <pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities
      contextRef="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTg5NTYwNDc0MTUwNw_1d818c86-cf20-4276-bdcf-4ce1b88acf35"
      unitRef="usd">277000000</pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2NzAyMDc_f5625749-9e7d-4e39-a6d0-b74de25ea1a0">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;In the three months ended April 4, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#x2019;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619"
      unitRef="usd">27000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b"
      unitRef="usd">1946000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6"
      unitRef="usd">14000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8"
      unitRef="usd">442000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918"
      unitRef="usd">-8000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8"
      unitRef="usd">332000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe"
      unitRef="usd">1000000</pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef"
      unitRef="usd">51000000</pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2"
      unitRef="usd">36000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df"
      unitRef="usd">0</pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c"
      unitRef="usd">15000000</pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69"
      unitRef="usd">1000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716"
      unitRef="usd">70000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee"
      unitRef="usd">19000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f"
      unitRef="usd">1000000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df"
      unitRef="usd">10000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385"
      unitRef="usd">119000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i82a840208e554416a672c485a012d030_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if62466171dbf47ec977eb962afa99747_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjQ4Mg_646bf3f2-97e4-4b5b-b9e7-b0757aca1a05"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iec8f63c6623f49adbf67a41d2e87119b_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjU0NA_f7f52eeb-ad64-4267-98fd-e8842ad35705"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i84d3a404ba354ee580c13bbafde8881a_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgxMw_4d0505c9-cd85-45d5-a433-876e5cfa35ea"
      unitRef="usd">16300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgyOQ_aa05ee60-8af5-484c-a368-3c2680acf6d9"
      unitRef="usd">16700000000</us-gaap:EquityMethodInvestments>
    <pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation
      contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDM3Ng_2fdb8715-0567-4a85-ac5e-c4dbfb060788"
      unitRef="usd">-126000000</pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDQ4OQ_bbcc03b5-4446-47de-92fc-5ddd7ee33281"
      unitRef="usd">274000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTcwNTcxNg_28ac2727-3769-4b63-85fd-750476acff82"
      unitRef="usd">71000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY1NzA3Mg_d753092b-100f-4fd8-ad2f-9799c9e48782"
      unitRef="usd">11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3NA_44a44697-50d5-4dee-8e93-3ca8dcdd3af4">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:Revenues
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi0yLTEtMS0w_4532fe78-d3d4-432f-b8d7-92112e58b778"
      unitRef="usd">3096000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi00LTEtMS0xNTk5_982aacd9-051d-4422-97e2-d19bc4103353"
      unitRef="usd">3188000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy0yLTEtMS0w_9539cada-5336-4daf-a8e0-1afda6f9d024"
      unitRef="usd">1188000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy00LTEtMS0xNTk5_202ea05f-df1a-42a3-9633-8d77416531d8"
      unitRef="usd">1811000000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC0yLTEtMS0w_3df5fdae-2e06-4dba-a770-a45a8ec78ccb"
      unitRef="usd">1908000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC00LTEtMS0xNTk5_2c6886cd-75cd-4422-a3b8-e609edf2ae4a"
      unitRef="usd">1377000000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS0yLTEtMS0w_aba530f0-e913-44e1-b132-9a647a0fed0b"
      unitRef="usd">233000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS00LTEtMS0xNTk5_79073324-7f00-45f7-b5dc-3bd73fe42d99"
      unitRef="usd">46000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi0yLTEtMS0w_416dc2a5-e841-4dfc-82c5-438425bee612"
      unitRef="usd">233000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi00LTEtMS0xNTk5_17e970e6-b55e-4f20-899e-d0e5351332bc"
      unitRef="usd">46000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy0yLTEtMS0w_cd87a5c4-e88e-41df-9ba3-d564c9f38e97"
      unitRef="usd">221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy00LTEtMS0xNTk5_dd4ec1e2-8496-4f2d-b912-8eae9eb45dd2"
      unitRef="usd">37000000</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjExOA_27eb074a-149b-45fa-98f9-adc9fd28e25c">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Transforming to a More Focused Company Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base aligns appropriately with our revenue base. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. In addition, we are taking steps to restructure our corporate enabling functions to appropriately support and drive the purpose of our business and R&amp;amp;D and PGS platform functions. The program costs discussed below are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect costs for this program, primarily related to corporate enabling functions, to total $1.6 billion on a pre-tax basis, with substantially all costs to be cash expenditures. Actions will include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, as part of this program, we expect to incur costs related to manufacturing network optimization, including certain legacy cost-reduction initiatives, of $500 million, with approximately 20% of the costs to be non-cash. The costs for this effort will include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the start of this program in the fourth quarter of 2019 through April&#160;4, 2021, we incurred costs of $1.0&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, April&#160;4, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($628 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($169 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($561 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($156 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ice6f2159d3d7436abcb7d83886acbb6f_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzMzQxMA_07e6fc4c-e559-42bc-90ab-26497f16abb9"
      unitRef="usd">1600000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i49562007fd9547a48d0eb81e74591431_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAxMw_14041156-967c-4d93-87b0-3f155bc2ac32"
      unitRef="usd">500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="i4407292bed544ddd98da354a852701ac_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAzNw_29eccbf6-131e-466e-a149-d380d1c91f84"
      unitRef="number">0.20</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjQz_baecc405-330d-422d-8204-69e27bab3e74"
      unitRef="usd">1000000000.0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0Nw_4bee2ea2-188a-4a08-8602-2e647072a22e">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our condensed consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC0yLTEtMS0w_301ae934-f19f-4d8f-bf13-608344d6369d"
      unitRef="usd">22000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC00LTEtMS0w_93bfa226-828b-494b-a432-d2d2e66d9031"
      unitRef="usd">10000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS0yLTEtMS0w_b586cc58-6854-42c6-9603-9998af0221df"
      unitRef="usd">-4000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS00LTEtMS0w_c3a57e3c-3266-44a2-8dff-3a8f35f458ab"
      unitRef="usd">31000000</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:RestructuringCharges
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4"
      unitRef="usd">41000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69"
      unitRef="usd">0</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc"
      unitRef="usd">3000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3"
      unitRef="usd">5000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191"
      unitRef="usd">10000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtMi0xLTEtMA_6bd7a23a-9c47-462b-8783-c08797543a15"
      unitRef="usd">23000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtNC0xLTEtMA_1bff97d6-aa66-4f36-88ae-16aa7084c06f"
      unitRef="usd">54000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46"
      unitRef="usd">10000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4"
      unitRef="usd">5000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b"
      unitRef="usd">-5000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40"
      unitRef="usd">10000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9"
      unitRef="usd">11000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301"
      unitRef="usd">8000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8"
      unitRef="usd">64000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4"
      unitRef="usd">15000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a"
      unitRef="usd">75000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f"
      unitRef="usd">22000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtMi0xLTEtMA_f8a24f99-7e34-4283-b997-d8fed6896efe"
      unitRef="usd">116000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtNC0xLTEtMA_afe902ec-0a48-4d46-ad48-43be71df2391"
      unitRef="usd">77000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk4_6f7d1cd7-fedc-45ac-9084-86d11b0a67d2"
      unitRef="usd">-6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTY3_01a1911d-d185-4baf-95af-00ea682001ba"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTg3_084cef96-bf16-432a-bcfe-42e6851b8e72"
      unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NA_60a80000-3ea5-492d-9a39-7eecee55dbeb">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance, April&#160;4, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($628 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($169 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($561 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($156 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i2f7055066225454fbd6b963b51debc30_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b"
      unitRef="usd">782000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie6e22c74513c4463863976ef5f21b01a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2f00f1a9cab940258f6eed860c0bc028_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3"
      unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e"
      unitRef="usd">798000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy0yLTEtMS0w_865c6d73-5164-4256-a6d8-cf036e933a1d"
      unitRef="usd">22000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy00LTEtMS0w_c7253501-a393-4ef2-a534-85fbd644a092"
      unitRef="usd">-4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy02LTEtMS0w_da606571-9143-48cb-8a28-5d9b4f2f97b7"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy04LTEtMS0w_aa52b20e-aa2e-4ad4-ac30-0a24298e0cb3"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68"
      unitRef="usd">102000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f"
      unitRef="usd">-4000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69"
      unitRef="usd">0</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682"
      unitRef="usd">99000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="i8b6820f138a34d1a88125938e6c7587e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d"
      unitRef="usd">702000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia29f6c9175e74ba2832cbc36256b21b7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac"
      unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113"
      unitRef="usd">717000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i940e3dc38ca547fdbc8e066fc92a3705_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTkzMw_104c0158-0022-4de4-a313-c68b266f49f1"
      unitRef="usd">628000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic0fac9c964894676b74a3dfea4fc6f74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTk3MQ_9c317e36-dc75-4c3b-a9fa-6cc29266d2f3"
      unitRef="usd">169000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjA3MA_38e0c684-ece5-48da-b31a-176a4b43deb5"
      unitRef="usd">561000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib09c41fb46464505bcc32a3c43731505_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEwOA_6ac882f8-c550-4ac0-a185-02e8cfdecc8f"
      unitRef="usd">156000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA3Mg_d3d8f1ec-587e-436c-8a9a-441ebeacec6b">Other (Income)/Deductions&#x2014;Net&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2MQ_d6c96c7b-836b-44e6-bbec-0883a4f640a4">&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy02LTEtMS0w_93dd2970-806f-4c10-bec3-5c467be54c26"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy04LTEtMS0w_6789808f-b98c-4eb2-9de8-10920a76c88f"
      unitRef="usd">34000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC02LTEtMS0w_c0df218b-66f2-4928-b011-5b00ba100a27"
      unitRef="usd">336000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC04LTEtMS0w_1192c25e-e2f9-4cd2-9a4c-ee46ccd197b5"
      unitRef="usd">390000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS02LTEtMS0w_7aa993ba-85c5-4ec9-8063-b1625a2ea0ad"
      unitRef="usd">-336000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS04LTEtMS0w_3ff4f4a3-0b8d-459a-a15e-a8d97668cfc8"
      unitRef="usd">-356000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi02LTEtMS0w_092bdb67-0a71-49af-aea0-cfa327c33724"
      unitRef="usd">176000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi04LTEtMS0w_dcf39154-57d1-4fc3-9419-59727f37ed9f"
      unitRef="usd">119000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy02LTEtMS0w_d8d30f59-4029-4a00-b55f-b620fa5c81c2"
      unitRef="usd">39000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy04LTEtMS0w_54439b9e-8f96-405c-bd79-64698286b690"
      unitRef="usd">-1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e"
      unitRef="usd">401000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e"
      unitRef="usd">-255000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8"
      unitRef="usd">231000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1"
      unitRef="usd">115000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb"
      unitRef="usd">-266000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278"
      unitRef="usd">-103000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItNi0xLTEtMA_ffbcf04b-f605-4c80-ae5f-ad22998d3069"
      unitRef="usd">-51000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItOC0xLTEtMA_2b67ee07-94e2-48b2-b117-264f5fdaa0d4"
      unitRef="usd">-9000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6"
      unitRef="usd">62000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a"
      unitRef="usd">-33000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctNi0xLTEtMA_76cd50fb-1e50-47e6-8353-716a69717150"
      unitRef="usd">216000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctOC0xLTEtMA_c1380247-7818-4355-b379-ee288ed8bf80"
      unitRef="usd">126000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681"
      unitRef="usd">1004000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13"
      unitRef="usd">-190000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3MTYwOQ_f215fd58-5b81-41f5-b934-e70bcea046aa"
      unitRef="usd">409000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfOTc_e7e8be57-77a4-4566-8a7b-aa1e101fecab"
      unitRef="usd">-134000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i798490452fbf42df810cc73fc79edd72_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3ODY4Mg_37a0c2b5-21cd-406f-8e77-3af73fab5b07"
      unitRef="usd">188000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA4ODA4MQ_6f5f92f7-c39a-45a6-835d-190051bcd613"
      unitRef="usd">75000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzIwNg_966a7b07-774f-4aee-aeca-5719f3589cb6">Tax Matters&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective tax rate for continuing operations was 14.2% for the first quarter of 2021, compared to 12.6% for the first quarter of 2020. The higher effective tax rate was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date and is reported in current &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of April&#160;4, 2021. The remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#x2019;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2010.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTE2_2ce20265-e7d2-40ea-96a8-df63fff720f2"
      unitRef="number">0.142</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTU3_a2cc1bdc-a838-4c18-8441-030e8750b634"
      unitRef="number">0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMjE5OTAyMzI2MDQ1OQ_85d3d084-6d2b-420b-9771-6ddb878399e2"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE3NA_b97df153-2aa9-4966-89c8-0dbf6efdfa4d">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea"
      unitRef="usd">-247000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC0yLTEtMS0w_fa7d641b-6695-42a1-85f2-e77e3910f9b6"
      unitRef="usd">59000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC00LTEtMS0w_7c4708de-27e0-45e9-9f61-0eabed9a0861"
      unitRef="usd">-133000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS0yLTEtMS0w_f45df937-a876-4a1f-9a07-a9214eea0722"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS00LTEtMS0w_bdfc137a-0f29-41cb-83da-87e30c6f54a2"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi0yLTEtMS0w_bb3f16b6-f4fc-4e62-9152-fce24b4d23ec"
      unitRef="usd">93000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi00LTEtMS0w_7301bc21-74af-4001-8194-a3657d24a992"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy0yLTEtMS0w_6e6680fb-8deb-48ff-8c26-58d89ac486da"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy00LTEtMS0w_1b230f48-9cb6-4b5c-9d5f-ac3313a8606f"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC0yLTEtMS0w_498ddd0d-ba18-49a3-b29d-a80b023fe87e"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC00LTEtMS0w_3ebabdf5-e730-47eb-84d4-0e622db07442"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS0yLTEtMS0w_7a688379-bf48-4e2f-ab82-439303d6da9f"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS00LTEtMS0w_e7810623-4689-421b-81c9-64727ca768ab"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtMi0xLTEtMA_f5f79b1f-8d87-4e56-bcac-7daabf972fd9"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtNC0xLTEtMA_727ca201-9284-412c-b244-f322850fd7cf"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtMi0xLTEtMA_b5825082-d0e0-4755-a950-9287668bc2d5"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtNC0xLTEtMA_ba7ba68b-4e8d-4cfa-9306-eb5a8e7dec65"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktMi0xLTEtMA_3bb0ec19-82a9-4f7a-b307-ca76d16e5f27"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktNC0xLTEtMA_1661a2cb-f7e9-4f76-a1de-caafb1c74ec2"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtMi0xLTEtMA_abd44777-fa20-4f82-99e3-ac0891a50623"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtNC0xLTEtMA_3320ae5d-664b-4748-a2c5-c280dddd68de"
      unitRef="usd">-380000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfNzk5_8dec60aa-09ab-42f1-9a3d-81e765da40e2">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODEx_cec26bc2-4128-4406-bdbd-abccf3c95895">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4"
      unitRef="usd">-5450000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if15de68e82a04995aadbd09ef4f4de3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953"
      unitRef="usd">-428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2c9aa8e82394528ad00529819678ef4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9"
      unitRef="usd">116000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2113534f48f444f8fad64562140b4ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c"
      unitRef="usd">452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44dea6398b1c4543b9115d73e959887b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033"
      unitRef="usd">-5310000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4533886f346447ddb2e4466be3decd58_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c"
      unitRef="usd">442000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802"
      unitRef="usd">380000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5"
      unitRef="usd">-142000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f"
      unitRef="usd">646000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3532a573af84231901dcba3a9f69146_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0yLTEtMS0w_a09c29ce-324a-4478-990d-395016c176e7"
      unitRef="usd">-5008000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi00LTEtMS0w_e6ee5e01-a667-4cbc-9046-765a019d7763"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4864e09f901546cc81c976b2cae73fb3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi02LTEtMS0w_cd029b4c-f232-45fc-b99d-5d977a96ccab"
      unitRef="usd">-26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62019f9f689b4fc982e85dd8eb7b261b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMC0xLTEtMA_033e1787-ecc0-426c-b652-4a63af44335a"
      unitRef="usd">419000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ffb761b6f624168a62f72e12228bb5a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMi0xLTEtMA_e2e2e7bf-4409-43c8-9c6d-8a3d4bdbd3f1"
      unitRef="usd">-4664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjQyMQ_a5739606-ec0d-4e33-bf89-86e61a06550e">Financial Instruments&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value at Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value at Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April&#160;4, 2021 and December 31, 2020. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Total Short-Term, Long-Term and Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any expected credit losses to these portfolios would be immaterial to our financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Includes cash collateral. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona, Canadian dollar and Chinese renminbi. Additionally, we hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar for up to two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $45 million in the first quarter of 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $70 million in the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1.35pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;F. Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our trade accounts receivable balances are due from drug wholesalers. For additional information on our trade accounts receivables with significant customers, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2020 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;4, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., U.K., Germany, France, Japan and Canada.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&#160;4, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $613 million, for which we have posted collateral of $675 million with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of April&#160;4, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $53&#160;million, for which we have received collateral of $124 million with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term borrowings, including current portion of long-term debt.&lt;/span&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUzNQ_ffefc116-646e-4f43-818c-0197e239c005">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i67345ed70af0415f9ed8e94420f395ec_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0yLTEtMS0w_39c27294-e181-4cd2-a2e3-fd35df45bef8"
      unitRef="usd">1427000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS00LTEtMS0w_1c85c489-9d18-43a3-a7c4-a0218bdc0a11"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8aae410224d44016a7744837424466a6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS02LTEtMS0w_82cf3568-1c97-4bf6-a440-2af7ab298f63"
      unitRef="usd">1427000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2c17032a023943b39d6fe6d61373d0ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMC0xLTEtMA_edfae60c-2a95-4c4b-81db-fd348be30d1e"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i046ca4e1125f4096b86c8813e2f8970e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMi0xLTEtMA_d10c70b7-c8a5-4cfc-bf82-6e880f23f5ee"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i88f1d50b4ddd4407b234fba600ed5d57_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xNC0xLTEtMA_81f2fce3-988c-4855-bde9-64bbe639a769"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0yLTEtMS0w_7612d814-1429-4b44-beaf-8b9f83f3b70d"
      unitRef="usd">6169000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC00LTEtMS0w_15999192-fe21-42d2-9a36-fc3d4f120122"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49e3912c87b642259d22066a4deeedf3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC02LTEtMS0w_192292da-2145-431e-8c1d-8a8a7555bc81"
      unitRef="usd">6169000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMC0xLTEtMA_e8c41fb5-9730-450f-87ac-83226e49af1c"
      unitRef="usd">7719000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie39df5fe991d423c8bb366a5753affb5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMi0xLTEtMA_6da90f81-d984-40d6-a3fa-267afda94fbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e21972aa8834adbb2e62df36a9290a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xNC0xLTEtMA_a505431a-048d-4cba-9d86-18714383a2fd"
      unitRef="usd">7719000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4a996c859684b9ebfddd6a039f0965a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0yLTEtMS0w_2ef48b90-dd37-4fe9-949b-37355044a781"
      unitRef="usd">1221000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief1336b9d91143e39d2fea5006a742b3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS00LTEtMS0w_4e8b94a5-25c4-43d2-a8c4-adda65038eb4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS02LTEtMS0w_65bceaad-4ae9-4ee6-a1b3-10f3990ac087"
      unitRef="usd">1221000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc333032422c470d9c553a603fed07e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMC0xLTEtMA_e8d58585-ee47-44cd-8218-ca215c1c5c40"
      unitRef="usd">982000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i217da8c7f6f349b8b0412339d3adcdab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMi0xLTEtMA_dad94c05-0449-4652-a1f1-94a88720dbba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b273a61589b42c5baea01aad3398d3d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xNC0xLTEtMA_1d8a1b6f-9f1b-492e-ab8f-42b076d8e15e"
      unitRef="usd">982000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMi0xLTEtMA_25a887c3-a89e-4f6d-b78f-4d14f6ae8d04"
      unitRef="usd">902000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i521c003f78f74a16bf69168b25516b44_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNC0xLTEtMA_2dbab1a8-c7a7-44d3-9f9a-a97faab0d175"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bb11cd15cf3432681d969a29d7dca79_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNi0xLTEtMA_40f76bdb-6cf2-42a1-9f1b-776443334496"
      unitRef="usd">902000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTAtMS0xLTA_e159b30e-9548-451e-9e1f-3f065dbd2520"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTItMS0xLTA_5ccd829b-1cc7-408f-a952-c32282048958"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c84a33617f945aa95602f65e14fe7fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTQtMS0xLTA_65aa9f82-c5b0-46c8-a765-6d988a3f12f2"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i693fbbcedb904e0ca5820547935b4eeb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMi0xLTEtMA_196bbf1c-a073-4b3c-97df-5748def8ddd4"
      unitRef="usd">8292000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2496243c18b44e05838d5575a5b19b92_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNC0xLTEtMA_da75f563-8a34-4494-9ca1-c58236d77420"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2827e9872a441058d1e02032d2d742a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNi0xLTEtMA_e1c7d04f-ff26-49e0-9df0-50a8d72b39b2"
      unitRef="usd">8292000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7dad755ef938483cb63df05993af440c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTAtMS0xLTA_1e3e00aa-5465-408a-8e5c-e7039652db10"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTItMS0xLTA_03fd2647-ca29-43a1-bad5-978794638608"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49b785935ffe4cc39bc8792585014a3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTQtMS0xLTA_18ab15ba-8aa7-4248-a8e4-ee3e83a26f30"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i693fbbcedb904e0ca5820547935b4eeb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMi0xLTEtMA_553b3ee5-dda5-4472-8cdf-4f7429059136"
      unitRef="usd">9719000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i2496243c18b44e05838d5575a5b19b92_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNC0xLTEtMA_06ad4c61-71f9-4b2d-a536-00f4c486d185"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="ia2827e9872a441058d1e02032d2d742a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNi0xLTEtMA_62d45867-a6ed-48f3-8361-dd356dc5eb8d"
      unitRef="usd">9719000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i7dad755ef938483cb63df05993af440c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTAtMS0xLTA_479b529a-fa10-48a6-b8f8-e2465c756ece"
      unitRef="usd">10276000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTItMS0xLTA_a43c8e66-03f8-4b29-a9f9-14baa1151d80"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i49b785935ffe4cc39bc8792585014a3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTQtMS0xLTA_45069de7-1bc5-4e47-add3-5797764129af"
      unitRef="usd">10276000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMi0xLTEtMA_33aac98e-f994-44fa-9aa1-c02b6b3c457f"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6590c03231c94832ab710135c629b5d6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNC0xLTEtMA_335ed2c2-70d1-4bff-96a6-8d0ce8977505"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id2a8285101fd4a4787791fc4108af409_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNi0xLTEtMA_8950ba41-025c-47b4-a719-258056b8ddf9"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib397545be8ed42a894b7225f81be7b8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTAtMS0xLTA_b1cb523f-ade7-4cd6-a0f2-7e613b67becb"
      unitRef="usd">18000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic8c6a57df8544c48b668c58d680c53a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTItMS0xLTA_5d7c4dab-0943-4a3a-b67b-2c0dd4bf162e"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie209ada8ef774920a8094ff1ffa8c791_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTQtMS0xLTA_06fe8cbd-1030-4cf8-b221-a83b2be65f39"
      unitRef="usd">18000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6402b69d96a94b11983f4c4aff358cd9_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMi0xLTEtMA_606e56cd-8006-4328-ac58-c5fd32206201"
      unitRef="usd">389000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie8629e44fcf74299947158c6cf1db447_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNC0xLTEtMA_de99f44c-2a06-4701-a478-e92a50742c3f"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic918fd2704ed4d59aa54d300420bf854_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNi0xLTEtMA_c23d4c7f-b6e9-44f5-aa53-8aed75e2f366"
      unitRef="usd">389000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia422b966324146868d032d47dda6f321_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTAtMS0xLTA_feb5ba34-3f58-4e98-9431-bb780e037c54"
      unitRef="usd">234000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifd8e1a1c11cb40788c6dd041f5862427_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTItMS0xLTA_75202bf0-4b49-4b0e-92a9-6307c74f7fbd"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic12158fe468140509e594e5c9bea2ff0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTQtMS0xLTA_d8e5556d-4610-4e33-9ada-49e32948e934"
      unitRef="usd">234000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="idef140b7ed3b4d09bed3385bae6d504d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMi0xLTEtMA_2fb36fd3-05db-429f-a3e8-2ab0d8555b0d"
      unitRef="usd">394000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1b810fe2ae184c5097d5595af97f1ee9_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNC0xLTEtMA_477b8fb4-325a-4a97-9a92-a88b7cdfacd6"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia267f32cf11e4a86a297aa0b2be67c44_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNi0xLTEtMA_9789c228-57dc-4cce-90ea-d5797baad736"
      unitRef="usd">394000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ida5dcb775c5545cea010daed613c3d15_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTAtMS0xLTA_b3cc0765-30ba-400b-babd-3acd2d21b76f"
      unitRef="usd">251000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie3354f5abddd4996bf3ccd71244e3b56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTItMS0xLTA_da47ef13-2dfd-43f5-99b9-76d106703c88"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i91073b1fe1b54677a90882344df8e229_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTQtMS0xLTA_29cf1cc4-e21b-4c5e-bea8-ee3c40a9f02a"
      unitRef="usd">251000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625"
      unitRef="usd">3123000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icbdb406e79c94c318635d1add0655a54_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b"
      unitRef="usd">3046000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i07835653ec374195b2d79068ec153977_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d"
      unitRef="usd">77000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365"
      unitRef="usd">2809000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2"
      unitRef="usd">2776000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579"
      unitRef="usd">32000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d7738ac04034c2db9a1b09fd2554159_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMi0xLTEtMA_90869fbb-28d6-4b16-8210-6951936f5e36"
      unitRef="usd">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic017f9df9d9941eeb7f48073600c8293_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNC0xLTEtMA_5435e736-ec3c-4792-a06b-14afdf9cfc0b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i235004b31ec442a1a5ebf8037790737f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNi0xLTEtMA_12c1a6b7-4a62-4629-8706-564e7da92a29"
      unitRef="usd">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3112b7bd4ca945039be216b55807356f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTAtMS0xLTA_d2cbe56f-0e14-4d54-9858-96298978b4a3"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5959213e06f24defac36f7a0fb92bbb4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTItMS0xLTA_d9d60376-3849-4c09-9fd6-445dcc46501e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b990b5de1ed4f4db641cc793879a698_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTQtMS0xLTA_ca05ab39-1ed3-4de3-8542-5c4e443e7da1"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc2af150083d47d0bcf678532db4a34a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMi0xLTEtMA_ee1bca5d-8a4d-4113-a9c4-06860af944f4"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6648e1e65204f4eb444cb895f52ec9c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNC0xLTEtMA_28b39024-dc70-41c0-847b-fac11bbc421c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5fd3e97335545368349e1b54a37f7ca_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNi0xLTEtMA_73e13363-1cc2-4b47-ab39-7098c5308657"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93b72ae9514a4dfdb73d54037e4297c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTAtMS0xLTA_d8433eff-77e8-4d18-ae1a-579eaa72825b"
      unitRef="usd">121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60f3e802e12546cf9fa1294b3ad1be57_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTItMS0xLTA_594b689c-e34c-4025-830c-220846d02612"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d1bff202dda47268a07043474884dcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTQtMS0xLTA_c0c563f7-7207-4288-9bb4-de08fb430d50"
      unitRef="usd">121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a0d3ef6ac6b472b84a7134822008fef_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMi0xLTEtMA_90fe0c4d-d173-4693-b64e-b0c050a2b639"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia77e241651c349ada1bf16e3b6ecf828_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNC0xLTEtMA_ea79e0a1-07b0-4c6f-b1f2-51cc4adb71f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3dfae630a4fe4e298addafa278e16b50_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNi0xLTEtMA_22a4b13c-eb74-4e2e-acf1-067b3aacbd04"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTAtMS0xLTA_e9d5a851-c96f-4c03-9003-08e07f68577b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2697970c25514e279413521fb973bba7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTItMS0xLTA_ac0799fc-9731-4eb8-bbee-28c75aea77d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ea7690129214a9195f0424e82617486_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTQtMS0xLTA_ca2cd08f-dbd7-47ad-8740-edb9bb8639f5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMi0xLTEtMA_f2e6af77-ea84-40b8-b9ec-25cee0b93052"
      unitRef="usd">75000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbdb406e79c94c318635d1add0655a54_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNC0xLTEtMA_81f3aed5-da25-40da-8dca-d5c618561922"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07835653ec374195b2d79068ec153977_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNi0xLTEtMA_b5d21d46-f03f-4adc-8bb9-45c0cde5a3f6"
      unitRef="usd">75000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTAtMS0xLTA_214d34a3-19b6-40f2-a55d-ac46e108f603"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTItMS0xLTA_27c73584-1d65-40bc-9647-d815ea03b0f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTQtMS0xLTA_649a19b0-1674-41c1-87c2-6dd029baab88"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i3537ba539cf4490799a0a791b894bbf6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMi0xLTEtMA_7191b257-cfd1-495c-aab6-e132444eefd9"
      unitRef="usd">3198000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="icbdb406e79c94c318635d1add0655a54_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNC0xLTEtMA_52b13242-b757-49d9-82fe-1370db13bf55"
      unitRef="usd">3046000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i07835653ec374195b2d79068ec153977_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNi0xLTEtMA_ec4657ae-3dc9-4d24-9693-37105de97fba"
      unitRef="usd">152000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="iea25168e02e94f08b514acffde4e38cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTAtMS0xLTA_34c7a5de-27e2-4990-80d0-9c0b1625891b"
      unitRef="usd">2936000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="id5a83ae2aba2486f95fe642a4c774464_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTItMS0xLTA_279a2d3a-2b4b-4a08-993f-9351dafe29bd"
      unitRef="usd">2776000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i1f9c25dfb8094cb598d568e3dac3e194_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTQtMS0xLTA_20aa55e1-e073-4d9c-a4ac-13d7c255188d"
      unitRef="usd">160000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if4105c4d1d064369a467bf34c99b66d9_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMi0xLTEtMA_39cbb353-3cdf-4754-b6f1-6e951c24dd35"
      unitRef="usd">21000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3b19f59cbd344d648155105fd82aed69_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNC0xLTEtMA_ba32453b-5c59-4d17-8630-21c2e24aa45d"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNi0xLTEtMA_5bbe4d70-40a8-4823-b6c8-808f048e2a8a"
      unitRef="usd">21000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iba8bc471a60a4b02bd124ad08e30d367_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTAtMS0xLTA_66029dd0-c662-4664-b737-018bc1066a4f"
      unitRef="usd">117000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9d27878b3c524d4ab463f64f7d71c33e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTItMS0xLTA_c5a8ff6f-16f3-44b3-aa3b-4c7baa13623e"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTQtMS0xLTA_4cde7ade-e883-4a4c-9cc2-1480462d2a37"
      unitRef="usd">117000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1bc1645da50f4723ac5e11374a83165e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMi0xLTEtMA_b534b43b-8d17-4f35-84bf-f611ea67ce0e"
      unitRef="usd">106000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2636525965a44944a8b505ad44b6fb94_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNC0xLTEtMA_367f2eaa-1ed7-48f6-8706-15d2694c0d54"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNi0xLTEtMA_e82a9b42-5069-4b41-8ee5-aaf48b4d4eed"
      unitRef="usd">106000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTAtMS0xLTA_7223fa27-0c05-450a-b7c1-6f727f958b5f"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i467531120efd4d1eb7bbc63d03b66773_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTItMS0xLTA_704c447c-82e9-40d6-8586-3cea528fbea6"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i863eb072936745e9a6b8f3a4ef7207a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTQtMS0xLTA_3e60bd95-69a8-45fc-ad83-92ebb74d901e"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMi0xLTEtMA_212299f9-ee5c-4521-bc12-1316b6cfc442"
      unitRef="usd">127000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNC0xLTEtMA_2406de4f-c4ec-4cdc-93b7-a050b28da72c"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7ff43b50014b4281a9126121e4136253_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNi0xLTEtMA_d01f18a7-4ba4-419e-a203-46817dfabce8"
      unitRef="usd">127000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTAtMS0xLTA_c7af8c39-7306-40a3-85ab-e80c18935379"
      unitRef="usd">122000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTItMS0xLTA_a0d204a1-6d06-40de-a2ee-df15949c1ce1"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTQtMS0xLTA_a52f1996-2caa-4cec-9fa0-a13c45654587"
      unitRef="usd">122000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9"
      unitRef="usd">726000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i7ff43b50014b4281a9126121e4136253_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb"
      unitRef="usd">726000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698"
      unitRef="usd">693000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519"
      unitRef="usd">693000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0074575f0ac44757b22db2f3767d4ee4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMi0xLTEtMA_32d08bcb-e4f8-4e02-9224-d2b53c44b419"
      unitRef="usd">853000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNC0xLTEtMA_9e9b9d1c-39c2-45b4-9be6-80618aabb702"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7ff43b50014b4281a9126121e4136253_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNi0xLTEtMA_391bfe5d-0a17-4c5e-b339-848ba931f7d9"
      unitRef="usd">853000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTAtMS0xLTA_cfdd753e-b8bc-449b-a1ed-b0f7833b54cf"
      unitRef="usd">814000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i033c256fd9284f3c8ccdc121aeead211_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTItMS0xLTA_19b9b6a8-1f01-4132-a497-51d750472ad6"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic3c4a625f98844cb89cf576d5f951717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTQtMS0xLTA_3487a75a-0351-4649-b2b5-10008121546a"
      unitRef="usd">814000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMi0xLTEtMA_9332f2e0-06c8-48d6-a999-58a6a2b74ac6"
      unitRef="usd">14165000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1774875f27f34e3c942fbcdb9216c45c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNC0xLTEtMA_5b4d1345-9f7b-44e9-ae2c-454b2d12c355"
      unitRef="usd">3046000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3f9e05206d5d44bcb2b4c816762b2196_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNi0xLTEtMA_720e3fe3-d498-49a5-9cb0-786fbdbaf086"
      unitRef="usd">11119000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTAtMS0xLTA_96911fd7-4893-4065-9fc8-1747aec85293"
      unitRef="usd">14278000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iad6218d250ab4b7588c930240dbe77bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTItMS0xLTA_19685fd7-bd4c-416f-8ece-c7a510a3e599"
      unitRef="usd">2776000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7e356b3ffe4f46d786b299299e8c73c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTQtMS0xLTA_600cadd0-c5a7-483b-b77c-bc47bee517a3"
      unitRef="usd">11501000000</us-gaap:Assets>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iddecd2f6220e465abe9653d482f98cd7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMi0xLTEtMA_89d821e0-edca-4290-9825-a9ee9259c57f"
      unitRef="usd">239000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0122d1ba5cd6421b87248774e8dd8097_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNC0xLTEtMA_015c2414-aa6d-4104-b3f8-bf1f59dedd98"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i6b4bf8afa38545638247e4f6360ddf24_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNi0xLTEtMA_9794113d-60d3-45e6-8440-beae5f1bbe3a"
      unitRef="usd">239000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i38dfe51f567c4463b153c45da57afb62_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTAtMS0xLTA_f2879ab7-3334-433f-bc89-7734a62125c5"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie43a5c73f58e4950ab051b0f60f22af2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTItMS0xLTA_7022fd12-9cbe-4b48-a0b7-ee8bd49c9e29"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if25ff69c6c384a5e9bec30440b609aaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTQtMS0xLTA_906ecbef-80e3-4a09-bc95-e8db2103f978"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMi0xLTEtMA_97699ac4-1a52-4c81-a907-528b5a13473f"
      unitRef="usd">239000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if552fb30ac3f4a9986d136fac40d1ba0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNC0xLTEtMA_7b49cdd8-454e-4622-8846-b76e957e413b"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iadfb31e704964e379fa031ac9764d117_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNi0xLTEtMA_f2038a8b-9a16-40f9-a2e7-8ce386ce240e"
      unitRef="usd">239000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ide9db44961644d99bc4a1be0ceaf3427_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTAtMS0xLTA_111a7671-fd11-42e1-afea-d29b99427ee2"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i105edd316071419483c29294542bf610_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTItMS0xLTA_70a35d71-12f5-49dc-9ba7-1395d08cf943"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="icc91087bf2c84f9db4657e286128b4ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTQtMS0xLTA_ba565120-308b-4c26-be47-19e73cf38be9"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i71eb1561917b4fc8b8dd253cd6535303_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMi0xLTEtMA_f1fcdebb-4eb4-4d41-8a48-64f766981d59"
      unitRef="usd">494000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia19135b26e5944d48147d848103fa4ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNC0xLTEtMA_31bafd5a-fd8f-414e-9bbb-7eb936aced89"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNi0xLTEtMA_9aad64e5-b0f3-4354-b882-29f55410f5f9"
      unitRef="usd">494000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if72626af54aa43d29c3a57a81672472f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTAtMS0xLTA_dd5c0e74-7816-486d-a134-1468d5d1a5d3"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i361062f6aa914630bda2a1decde3d5fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTItMS0xLTA_b44809d4-2e63-4d48-b098-3deb9ac770d6"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9154af5cf4f54064a345265618b24fb4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTQtMS0xLTA_b65c4d69-f5ba-423a-ac56-4f66eddcd0f9"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie3cb663f517041b2b748758fddfc3042_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMi0xLTEtMA_5ccfe6af-a813-4c31-9622-075f6f1261ec"
      unitRef="usd">494000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id2b7c33ade3f427b87cdc02e591b5d89_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNC0xLTEtMA_283d2fda-a288-4306-a12d-07b7a222527d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNi0xLTEtMA_10d0091d-1f1c-48cb-b4d2-b36fc5d7d2ea"
      unitRef="usd">494000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id184353eda00420aa146f68eca8520d9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTAtMS0xLTA_98d25155-d83d-453b-8155-3ff66905df94"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6329d29a2efa4bf6be2047d1f4b55270_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTItMS0xLTA_1e70e188-0d2e-4618-b05a-6453011fedec"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ife6665bcfdc84fd9847decd31aab5d74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTQtMS0xLTA_dbe0e900-097f-4935-bba3-c0eea74207bd"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMi0xLTEtMA_be677e6b-1557-4558-ae5f-80b2b7f0d6eb"
      unitRef="usd">732000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1774875f27f34e3c942fbcdb9216c45c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNC0xLTEtMA_cbb3c4ee-f272-4f62-91dc-b65c2dd4c29b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3f9e05206d5d44bcb2b4c816762b2196_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNi0xLTEtMA_6b00fbc9-e589-4296-8238-ede807ea589f"
      unitRef="usd">732000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTAtMS0xLTA_e67dafe0-8ed2-4c38-8f1a-c24ab18571ad"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iad6218d250ab4b7588c930240dbe77bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTItMS0xLTA_6f66ba72-16f7-4314-a19b-d38a7774632b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7e356b3ffe4f46d786b299299e8c73c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTQtMS0xLTA_af8bb059-432e-4fd0-9a9d-992c2f266c09"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="ic844430bda8d4a429c4c1873dec0c67b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjM1Mg_eab63920-0c1f-486b-b954-e10cc4438fa9"
      unitRef="usd">168000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="if0901fcaa75c4458bc09ff2e135283ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjQwMg_2ab03d8c-ad25-4300-9626-b759a59bf2d1"
      unitRef="usd">190000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUwNQ_a3f573d3-55b2-4829-9f68-0430eed83639">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value at Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value at Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib94b4929257f4fa59c82eaf1fff65f72_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0yLTEtMS0w_0fc8b902-1c63-485b-9fcc-9897ce477bd8"
      unitRef="usd">35347000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS02LTEtMS0w_82c8bc47-e8db-4715-a6f0-12111a0bd6da"
      unitRef="usd">40504000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic3dd217f408a4c11b63dad378ca98d22_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xMC0xLTEtMA_5abd8e26-f222-4149-a203-042f3c60ecd3"
      unitRef="usd">37133000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id54070b71d25429da086e63afcf1c41c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xNC0xLTEtMA_a1d2d60f-0400-4dbd-9290-5ab7ef54a14c"
      unitRef="usd">45533000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzE_15442d9d-9eeb-4150-93a3-c532d4d33be9">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937"
      unitRef="usd">1427000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC0yLTEtMS00NTAx_00e8a2bc-954d-43e2-905b-754ad656db1e"
      unitRef="usd">8292000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC00LTEtMS00NTAx_8cd28a90-b102-464c-8d4c-f7fd1c15a6ce"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS0yLTEtMS00NTAx_b26ef72c-2631-43be-ae05-da9f8c3ccc4e"
      unitRef="usd">2180000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS00LTEtMS00NTAx_73f95e2a-36de-4b24-888f-303fefed9a5e"
      unitRef="usd">161000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi0yLTEtMS00NTAx_5d5f4a34-3d71-4066-8387-3aac9965227e"
      unitRef="usd">11899000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi00LTEtMS00NTAx_8688b140-ba2c-4c5b-86a6-6cfd4cb5d1b1"
      unitRef="usd">10437000000</us-gaap:ShortTermInvestments>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS0yLTEtMS00NTAx_9ec2c979-8c6e-489d-a9bd-b3a5250c54b6"
      unitRef="usd">3123000000</pfe:EquitySecuritiesFVNINoncurrent>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS00LTEtMS00NTAx_361315d0-52c2-435c-a5b0-c287dc5a19c9"
      unitRef="usd">2809000000</pfe:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtMi0xLTEtNDUwMQ_67541eb0-c530-4cc3-8715-133343085dc8"
      unitRef="usd">75000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtNC0xLTEtNDUwMQ_459338be-6398-4ce8-8bbb-2062b6f596a5"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItMi0xLTEtNDUwMQ_8f689449-587a-466f-b267-94c31b861f01"
      unitRef="usd">31000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItNC0xLTEtNDUwMQ_d7652dc1-28b3-4cd4-834a-40d7f9840880"
      unitRef="usd">37000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <pfe:PrivateEquityInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7"
      unitRef="usd">467000000</pfe:PrivateEquityInvestments>
    <pfe:PrivateEquityInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143"
      unitRef="usd">432000000</pfe:PrivateEquityInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtMi0xLTEtNDUwMQ_3ea33e1f-4f93-40f3-9a15-5982a2668c13"
      unitRef="usd">3696000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtNC0xLTEtNDUwMQ_146265da-bdd3-4973-8182-f4f47692966c"
      unitRef="usd">3406000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtMi0xLTEtNDUwMQ_5c92dc31-9fff-4341-9299-461153d89a0a"
      unitRef="usd">16532000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtNC0xLTEtNDUwMQ_c8ca2aa1-944d-425e-8079-a9cc750d2d8c"
      unitRef="usd">16856000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtMi0xLTEtNDUwMQ_c6968b7f-dbba-4ed0-883a-6d94354a7d10"
      unitRef="usd">20228000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtNC0xLTEtNDUwMQ_362fb2ec-2587-4867-8014-69a15ee1ef37"
      unitRef="usd">20262000000</us-gaap:LongTermInvestments>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctMi0xLTEtNDUwMQ_ed8fdc5c-96c2-41e6-be85-3490add9040c"
      unitRef="usd">60000000</pfe:HeldToMaturityCashEquivalents>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctNC0xLTEtNDUwMQ_66ab2d23-7257-4339-b086-6d6a0620f252"
      unitRef="usd">89000000</pfe:HeldToMaturityCashEquivalents>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY1_b8eed8d4-98a0-4ecf-a320-14a08823bf35">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY3_84bc4319-9f30-4871-8144-5a8a6b829ae5">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjky_39001d03-a4b4-4b71-abb1-688dd6e01550">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2013;&#x2013;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yLTEtMS0w_a3998398-a7c2-4eda-bba2-a4b111d6ac9c"
      unitRef="usd">6209000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS00LTEtMS0w_6bbeda6a-d77c-41c5-bebe-ff7e0ceba734"
      unitRef="usd">23000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS02LTEtMS0w_6e83696e-2c05-4c01-ba03-c3471fd7f715"
      unitRef="usd">54000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS04LTEtMS0w_f9dc7afa-ad04-4684-a6ba-b5dafca39c59"
      unitRef="usd">6178000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMC0xLTEtMA_26d03eb4-99f7-4ff0-bfac-26d6ba6b0d9d"
      unitRef="usd">6169000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMi0xLTEtMA_2a0ac447-afc8-421a-9f10-9b78eec7a615"
      unitRef="usd">9000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xNC0xLTEtMA_46bb6121-3571-40c3-983a-3ba985d7d6ee"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xOC0xLTEtMA_f7463dc5-e815-49a5-91d6-7d9195c18037"
      unitRef="usd">7593000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMC0xLTEtMA_6305f883-63bb-4b93-b18b-0913ee945900"
      unitRef="usd">136000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMi0xLTEtMA_1acf2f15-7d6e-49d3-ba21-25b7aca0be1f"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yNC0xLTEtMA_867bb904-2835-43d7-b840-0f4b0aedbff8"
      unitRef="usd">7725000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yLTEtMS0w_cd68fe98-061d-4133-8506-dece5731acb6"
      unitRef="usd">1288000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi00LTEtMS0w_69eeee87-a0e4-444b-8876-9a3bcb992064"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi02LTEtMS0w_3cdaf98a-d2ca-4f97-b7cf-93eb6cc60cf0"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi04LTEtMS0w_dfab7f29-227a-4f7e-9ece-beafd1aae312"
      unitRef="usd">1287000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMC0xLTEtMA_eeb607c8-b603-47ce-a32f-6805b870d20f"
      unitRef="usd">1221000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMi0xLTEtMA_38477d12-f8c0-48aa-b256-f9362c61be51"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="iea7507c4602c4b85b91614510bb349ea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xNC0xLTEtMA_acd60349-5779-43c3-b960-3056af64c58e"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xOC0xLTEtMA_3315eef7-ab12-47b5-bd40-4dc31a5a0589"
      unitRef="usd">1104000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMC0xLTEtMA_99e8c318-6d60-4128-a739-b2f4c5122eb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMi0xLTEtMA_2ef93a16-23f8-409b-87d5-35dbcb398123"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3118a605697e4b6299c3e3e70f504737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yNC0xLTEtMA_10bbb966-76ef-4f89-8fcc-b24c800947d7"
      unitRef="usd">1103000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yLTEtMS0w_d781df9d-a0f4-492d-bea8-dd5576e1a397"
      unitRef="usd">900000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy00LTEtMS0w_e32b5e1d-95fa-451a-be8b-04640c74eae0"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy02LTEtMS0w_9dc69f6e-5f96-40dc-b047-4a2d899dd543"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy04LTEtMS0w_57cefaf3-cfb1-4e8b-9cbb-3607567bf323"
      unitRef="usd">903000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMC0xLTEtMA_842cd1af-b0d8-49da-bc75-f1567abca27a"
      unitRef="usd">902000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMi0xLTEtMA_29814f0e-bc7e-4100-bad3-1714e261b4a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i6816514d37f949999a1c366c3691d629_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xNC0xLTEtMA_1b5679be-f28f-421b-8cd7-4c0d796062c8"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i22e189428ea0418bafaae25d5406511e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xOC0xLTEtMA_8319d658-af6e-4107-9a2b-97469a2e0e23"
      unitRef="usd">1006000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i22e189428ea0418bafaae25d5406511e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMC0xLTEtMA_981a195b-99eb-4375-84ac-946bb1f7f744"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i22e189428ea0418bafaae25d5406511e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMi0xLTEtMA_81714873-dfd0-4416-8789-c809f10bb3b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22e189428ea0418bafaae25d5406511e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yNC0xLTEtMA_b1f9e746-2cd7-4443-ae8b-4e5de58aaa2e"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yLTEtMS0w_07bbd241-db3f-4a76-b736-99f2072855e5"
      unitRef="usd">423000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS00LTEtMS0w_b7846d78-10ec-4f7c-90cf-c886a14027ca"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS02LTEtMS0w_a7992b20-5a4f-4174-97f5-628b30dc042b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS04LTEtMS0w_78835436-7ff8-495b-b41f-abf30d90a7a3"
      unitRef="usd">423000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMC0xLTEtMA_22980516-f8eb-457a-9de6-8cc2f78bdec8"
      unitRef="usd">397000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMi0xLTEtMA_6692adbd-eb15-4881-a102-93a4de78a7ac"
      unitRef="usd">16000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xNC0xLTEtMA_64da2a00-bd0e-49e7-a2ca-9bc072ca1e1f"
      unitRef="usd">10000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xOC0xLTEtMA_47315d7a-2b13-404f-9ffd-5f8a7518b943"
      unitRef="usd">283000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMC0xLTEtMA_694901df-c7ec-440a-a097-f71dfeaf6ebf"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMi0xLTEtMA_25e4299c-38ee-4e88-aa6b-71916287f8a2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iea6892b733bc4dcf856bf74153b9127f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yNC0xLTEtMA_12143adf-04af-40c4-a3c0-87f8235ed8bc"
      unitRef="usd">283000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMi0xLTEtMA_0523175b-ee1d-46d7-811d-5f135f4d589d"
      unitRef="usd">1847000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNC0xLTEtMA_6af4f2b7-0a49-4fc0-9068-36b5478505d1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNi0xLTEtMA_4693f36a-e15e-4431-89cd-8bf768a6e3f2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtOC0xLTEtMA_62e4d649-4206-4b52-bd13-bfa6637effb0"
      unitRef="usd">1847000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTAtMS0xLTA_40030f7e-df23-487c-a49e-28ad16b8b90b"
      unitRef="usd">1842000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTItMS0xLTA_b9fa7a41-59b6-4511-96c3-1b5215401bbe"
      unitRef="usd">4000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ibcf94ef1797d492b92164bec12798fd6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTQtMS0xLTA_5d809b8a-31cb-432a-b8c6-3e0fc17388da"
      unitRef="usd">1000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTgtMS0xLTA_3ef76328-6b43-4a30-9082-f8c75e27488a"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjAtMS0xLTA_ebb48102-cfe5-4d68-a70d-852d743ed8af"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjItMS0xLTA_69502d65-af09-4fcd-a2d3-014eada26b1d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjQtMS0xLTA_af444c52-e807-41ae-a980-f256bb800d5f"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMi0xLTEtMA_2faf7650-002d-4131-8034-d67a61917359"
      unitRef="usd">10667000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNC0xLTEtMA_fc634e99-2a61-41e2-9b77-9cf00174d592"
      unitRef="usd">25000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNi0xLTEtMA_ffc30947-e969-4c8b-a5e9-9d4ca68add49"
      unitRef="usd">55000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtOC0xLTEtMA_5d541135-bd56-4c0c-bbb4-4f86bc9fdf8c"
      unitRef="usd">10637000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTAtMS0xLTA_93ccaafd-26c3-4d9e-a492-d2f0b7ae6d17"
      unitRef="usd">10531000000</pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue>
    <pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTItMS0xLTA_3fda55ac-4a62-48f1-8a1a-81063c6fe543"
      unitRef="usd">94000000</pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue>
    <pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTQtMS0xLTA_8923ff43-4923-45cd-be72-6901c801e610"
      unitRef="usd">11000000</pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTgtMS0xLTA_ffd865e9-c609-4b22-97c0-f77c11a56627"
      unitRef="usd">9991000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjAtMS0xLTA_b3cc89a9-6569-4657-9d0e-13e558185759"
      unitRef="usd">138000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjItMS0xLTA_08cb45b6-7f51-48a2-b469-86e85d181e0b"
      unitRef="usd">5000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjQtMS0xLTA_de5d4ba9-2770-4d85-843c-7ba91c4fee4f"
      unitRef="usd">10124000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjc3_fbaabee9-676b-4c51-83ac-148affb14314">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729"
      unitRef="usd">401000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34"
      unitRef="usd">-255000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC02LTEtMS0w_e85d31b4-7e34-4f7d-8ab3-f6eaaffff246"
      unitRef="usd">28000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC04LTEtMS0w_4e4c035e-a8b9-4f2a-9c76-72cba39d4df9"
      unitRef="usd">19000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334"
      unitRef="usd">372000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8"
      unitRef="usd">-274000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTM0_0d4bbf9f-5b32-49d9-bb4d-4669d501516e"
      unitRef="usd">87000000</pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTYz_89b19814-08e4-4b5d-8e72-15ab252b4446"
      unitRef="usd">61000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE0_2e959cd4-7572-43ce-a292-c4e0d5e72883">&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Includes cash collateral. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:CommercialPaper
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi0yLTEtMS0w_33657463-feab-4e9c-9752-b9c2821c3791"
      unitRef="usd">416000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi00LTEtMS0w_61ac9564-751f-4e2e-9782-64e1817f61f4"
      unitRef="usd">556000000</us-gaap:CommercialPaper>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy0yLTEtMS0w_2987c532-4e30-4a8e-89f5-615455f56a88"
      unitRef="usd">3679000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy00LTEtMS0w_aecda62c-763e-4896-9ae4-7346eccd4a09"
      unitRef="usd">2004000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d"
      unitRef="usd">260000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a"
      unitRef="usd">145000000</us-gaap:OtherShortTermBorrowings>
    <pfe:ShorttermDebtGross
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS0yLTEtMS0w_cee0442c-b1d5-4c26-9de7-ab31e1b9a44b"
      unitRef="usd">4355000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS00LTEtMS0w_10467dc7-0814-4205-8366-d8380d31b429"
      unitRef="usd">2705000000</pfe:ShorttermDebtGross>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi0yLTEtMS0w_5c714e3e-bbe1-4700-8c94-380bb5f111d5"
      unitRef="usd">0</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi00LTEtMS0w_4d88a5d4-2002-47db-b7a7-c945cfb04edf"
      unitRef="usd">0</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy0yLTEtMS0w_5f37b799-925c-46b6-9cbd-0ddd5a2c992c"
      unitRef="usd">3000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy00LTEtMS0w_bce079da-fccd-48f2-8ecd-7bbce2d61982"
      unitRef="usd">2000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC0yLTEtMS0w_72d93fda-5e7d-4a9e-ab3d-27e50241651a"
      unitRef="usd">4352000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC00LTEtMS0w_34c6a606-76ad-4f8f-a649-1c75df868591"
      unitRef="usd">2703000000</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RleHRyZWdpb246YTJiNTIxYWM4ZDIwNDRjNWI0MTcyYjBkY2M4MDg3MjNfMjY5OQ_ef125897-ae55-4ce5-9b1c-1fe095cb4fbf">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi0yLTEtMS0w_7ae6da20-02a6-4aa6-be34-6a266ff518fa"
      unitRef="usd">34032000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi00LTEtMS0w_123082d4-f070-4e47-8476-67495d947c49"
      unitRef="usd">35774000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy0yLTEtMS0w_b1a01d0f-4bec-4784-a867-3211eb25f89d"
      unitRef="usd">1512000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy00LTEtMS0w_1d5f8428-95f5-41ac-8282-0e23ea473d69"
      unitRef="usd">1562000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC0yLTEtMS0w_d7a3d27a-4774-4d96-b381-b557c28a2376"
      unitRef="usd">200000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC00LTEtMS0w_d58506eb-d78b-41ae-9dd0-4eb75115a2b0"
      unitRef="usd">207000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherLongTermDebt
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS0yLTEtMS0w_943aa348-2aff-4bb7-87bf-bc8b6333802a"
      unitRef="usd">4000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS00LTEtMS0w_64512150-c4f6-4a12-88f6-2b55681cf12d"
      unitRef="usd">4000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi0yLTEtMS0w_79f9ca2e-83e2-4623-86c3-1e5bdf895193"
      unitRef="usd">35347000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi00LTEtMS0w_aa736eec-6a59-454e-b1f8-be5ca74d6d11"
      unitRef="usd">37133000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibd7df84abf8144f9838662606d730b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy0yLTEtMS0w_2f0637f7-0995-4145-82fe-d4562b1c7875"
      unitRef="usd">3676000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i59506893ef984409b375dbf340e24a0f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy00LTEtMS0w_84c71c8f-ee4b-4f08-b614-53956d38e8b2"
      unitRef="usd">2002000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DerivativeTermOfContract
      contextRef="i436945b9fb544d1485596c97366973bf_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA3NDg1Ng_2be46d00-b5e6-419b-b38c-59d7da129be2">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0MQ_1c965ef1-4037-4b1c-a709-2106ed1a2aa2">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0Nw_0e008520-46e6-4e1a-b7a7-1f83810219d0">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE5MA_78a3ddf3-a5c0-4bb8-bfdb-d38b7dc4edc9">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c"
      unitRef="usd">22799000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c"
      unitRef="usd">408000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i9a0b2bb17c2c45038528dc9568158637_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822"
      unitRef="usd">654000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8"
      unitRef="usd">24369000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4"
      unitRef="usd">145000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ic74e1896b3c246a98ee4bce0ead976d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if854a67683b84997921e0c8d08721493_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0yLTEtMS0w_3a958cba-4715-48e1-8bb7-118dd66db395"
      unitRef="usd">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="if854a67683b84997921e0c8d08721493_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi00LTEtMS0w_1761eb60-97cf-4e7f-8d8d-481e46a55a77"
      unitRef="usd">26000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if854a67683b84997921e0c8d08721493_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi02LTEtMS0w_9f3fc9a6-1fa2-46c5-9642-7c3d1dc517e3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi04LTEtMS0w_614ca566-8364-4220-96d7-5960680b1d3f"
      unitRef="usd">1950000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMC0xLTEtMA_db9464c2-fb50-483b-8021-e3b88a258c0a"
      unitRef="usd">135000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8d11d6f169eb4129873cfe8da015081e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMi0xLTEtMA_b5e88ff0-b256-4656-8387-d6ee84a20841"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i5584c105e0a1417da14d21d850e54027_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy00LTEtMS0w_c588893a-0845-4e72-9819-a2e904364b09"
      unitRef="usd">435000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5584c105e0a1417da14d21d850e54027_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy02LTEtMS0w_f199ce52-5ac3-44a8-974c-f9a0bb93c456"
      unitRef="usd">654000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i53d153096cf74722befa5ea904fa6b4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMC0xLTEtMA_f9c16a73-bec2-4cd4-9f61-295c27518fc7"
      unitRef="usd">280000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i53d153096cf74722befa5ea904fa6b4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMi0xLTEtMA_d948488b-07c5-4ceb-971a-556c1ebcb51b"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMi0xLTEtMA_8e74d3fb-6a23-4430-aa81-982b1650df63"
      unitRef="usd">14726000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNC0xLTEtMA_45a603dd-2b5d-49dd-8f8d-280f75196dbd"
      unitRef="usd">86000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNi0xLTEtMA_35d7698a-ca6b-4088-af1b-b9ef133a3cd1"
      unitRef="usd">78000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtOC0xLTEtMA_bb0052e3-9ef7-47c7-9893-83a429516f00"
      unitRef="usd">15063000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTAtMS0xLTA_0efdf456-38a8-4ff8-ae56-e0fc881d0434"
      unitRef="usd">94000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTItMS0xLTA_c67f3af8-1e1b-4b8a-91ee-179cc84bfdd1"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNC0xLTEtMA_588bf4de-9f3b-4fd6-bac3-b554a2f9a1cb"
      unitRef="usd">521000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNi0xLTEtMA_afdae661-fa74-47b4-918e-6720f8f866c9"
      unitRef="usd">732000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTAtMS0xLTA_56603fdf-c2cb-4086-b264-66f70613f317"
      unitRef="usd">373000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTItMS0xLTA_3aa28942-fc2f-4020-8f84-4d3807740f23"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie3d739b69c924476ab9fc489134e052f_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595"
      unitRef="usd">5100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1"
      unitRef="usd">5000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0NA_259b0f86-551d-4f94-aca0-5a7d19cf623f">&lt;div style="margin-bottom:5pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Hedged item&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;OID = Other (income)/deductions&#x2014;net, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net loss of $45 million in the first quarter of 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;a net gain of $70 million in the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785"
      unitRef="usd">202000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5"
      unitRef="usd">-529000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d"
      unitRef="usd">-268000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b"
      unitRef="usd">-26000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc"
      unitRef="usd">386000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3"
      unitRef="usd">26000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056"
      unitRef="usd">-386000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e"
      unitRef="usd">154000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a"
      unitRef="usd">384000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a"
      unitRef="usd">147000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee"
      unitRef="usd">38000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2"
      unitRef="usd">8000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff"
      unitRef="usd">56000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52"
      unitRef="usd">45000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d"
      unitRef="usd">42000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a"
      unitRef="usd">-59000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="idcaa753284e740be9e09512ba86381ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5"
      unitRef="usd">42000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee"
      unitRef="usd">-59000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab"
      unitRef="usd">460000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31"
      unitRef="usd">83000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc"
      unitRef="usd">-230000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="idcaa753284e740be9e09512ba86381ee_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153"
      unitRef="usd">23000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5f3171903a684fc3919479487e325172_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYwMw_b0a8ecb0-2cfa-4532-b323-63e4b6ecec6b"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYzOQ_52488f92-a4e6-4772-aa85-547239d4eaf6"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjgzMQ_6400a353-5a9e-45a7-9a99-8ef9cfb5aded"
      unitRef="usd">-20000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MzA0OQ_7920a480-e60e-4a8f-9bd0-ccaaa2fc75c9">P22Y</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DebtCurrent
      contextRef="iea937bd52464448b93d716a8cf093ae8_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MTY3NQ_a4a55cd9-af84-436c-9b3a-a90fc1d23ba5"
      unitRef="usd">1200000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="iea937bd52464448b93d716a8cf093ae8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMzE1MA_35ea1271-218c-40e1-a508-2807fc83ed0b"
      unitRef="usd">872000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0661f5622ccf41418edc8cfa0839da72_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MjIwMg_2591fdf1-2144-4862-9168-41b1bbc579a5"
      unitRef="usd">2100000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3MQ_d0dd2570-be24-49ff-b8e0-ff2a06aeabb9">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1.35pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ief79afe80dd041288f169705b94e7059_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289"
      unitRef="usd">494000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ief79afe80dd041288f169705b94e7059_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy00LTEtMS0w_770f16d8-49ea-49e3-bf14-98b4833707ad"
      unitRef="usd">21000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ief79afe80dd041288f169705b94e7059_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy02LTEtMS0w_e0fe65e8-9aca-48cd-90dc-9c488dfe8ebe"
      unitRef="usd">1202000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b"
      unitRef="usd">2016000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMC0xLTEtMA_4178d95c-8f13-4b8f-847e-07bcf294c65c"
      unitRef="usd">117000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMi0xLTEtMA_bf551ad1-557c-43d9-92d6-7c9b8dda588a"
      unitRef="usd">1149000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjQ4OA_b1ec973b-7377-41c3-b716-5a93e7aa0bbd"
      unitRef="usd">613000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjUzMg_06037b28-5528-4ce2-b957-14eb2f05c586"
      unitRef="usd">675000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <pfe:DerivativeNetReceivablePositionAggregateFairValue
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjczMg_d1ae70fc-a071-4554-b119-0f7d9f415b12"
      unitRef="usd">53000000</pfe:DerivativeNetReceivablePositionAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3Mjc3OA_87068f9e-1540-4a59-b911-ae15fb63db72"
      unitRef="usd">124000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzUw_3e7953e3-b4ea-4ff9-a04a-7a47f34d5ab3">Other Financial Information&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A.&lt;/span&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"&gt; Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Other Current Liabilities&lt;/span&gt;&lt;/div&gt;Other current liabilities related to the gross margin split with BioNTech for BNT162b2 totaled $1.4&#160;billion as of April 4, 2021 and $25&#160;million as of December 31, 2020.</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM1_a36b9ba9-a689-4188-a72d-47a010f6647e">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzU5_3332a7de-1085-4771-8a8c-d29eacb33bed">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi0yLTEtMS0w_661eb3d8-831f-467d-b168-e26c414f81fc"
      unitRef="usd">3289000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi00LTEtMS0w_d1a6fc00-5937-4ead-8286-a5475ddfd251"
      unitRef="usd">2878000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy0yLTEtMS0w_402e2127-d6fb-40d6-9756-054e3866e171"
      unitRef="usd">4364000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy00LTEtMS0w_0d8c0f2b-2520-4da7-981b-115bc6924801"
      unitRef="usd">4430000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC0yLTEtMS0w_959c1455-3c94-463b-a3a1-5d097abaf83a"
      unitRef="usd">840000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC00LTEtMS0w_4bac4008-392a-45ab-8d95-fb42212dabd9"
      unitRef="usd">738000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959"
      unitRef="usd">8493000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f"
      unitRef="usd">8046000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc"
      unitRef="usd">981000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3"
      unitRef="usd">890000000</us-gaap:InventoryNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if40f67d115f744f597392dd0dafbaa4e_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTcyNQ_1e3e8133-5bad-4af6-973d-c230e6ac3938"
      unitRef="usd">1400000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie113bce7166d40bdacd5506226e15172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTc0NA_7f23cac2-a3d1-48de-a85f-bf20d048b160"
      unitRef="usd">25000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwMw_cfab5511-c498-4695-81c3-e9902fa1a5ca">Identifiable Intangible Assets&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nearly all of our identifiable intangible assets are managed by our commercial organization, with only 9% of total IPR&amp;amp;D assets managed by our R&amp;amp;D organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of finite-lived intangible assets was $883 million for the first quarter of 2021 and $861 million for the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1OQ_240060ae-aa21-4342-a5ca-6d2fd61a610b">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc3Ng_411ebbe7-a724-4981-b743-ae3dd88c4500">&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f"
      unitRef="usd">74056000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e"
      unitRef="usd">51840000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icb29d5d4227b48adb270b164dfc6d257_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7"
      unitRef="usd">22217000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e"
      unitRef="usd">73545000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4"
      unitRef="usd">50902000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4317cb0568ef4d6aa675535e255cdab3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5"
      unitRef="usd">22643000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0yLTEtMS0w_57ffaeb8-ef50-4f03-96bf-85e8e1debe68"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS00LTEtMS0w_1c436919-9f5b-46fa-ae00-2db25b374627"
      unitRef="usd">782000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS02LTEtMS0w_e66d8482-0a5a-4d6e-93bd-52628b3bf06a"
      unitRef="usd">140000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0635462155884026ba26888ed78b96f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS04LTEtMS0w_5c3156eb-a804-46ec-aaea-76b7c63c4b3b"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0635462155884026ba26888ed78b96f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMC0xLTEtMA_eea1ccc3-f558-4bcd-98e4-5a203e57c583"
      unitRef="usd">774000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0635462155884026ba26888ed78b96f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMi0xLTEtMA_2eb936e2-e300-4733-829e-b7d774fbb0e3"
      unitRef="usd">148000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if36997883bf644fda424001760b39437_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0yLTEtMS0w_d2a4d4eb-792d-469d-8cd2-8d03787db944"
      unitRef="usd">2305000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if36997883bf644fda424001760b39437_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi00LTEtMS0w_903337d3-be4c-4ebc-ba30-c7eb59f70b95"
      unitRef="usd">1223000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if36997883bf644fda424001760b39437_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi02LTEtMS0w_afd53bde-ae40-485b-a3cc-315b5f5756c7"
      unitRef="usd">1082000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi04LTEtMS0w_b2c909d4-864f-4ae2-9aa5-e945ece94dd0"
      unitRef="usd">2292000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMC0xLTEtMA_948d361f-08f3-4ff2-957d-70dee7dd975c"
      unitRef="usd">1186000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMi0xLTEtMA_ea5d323f-80e2-4126-8cf9-b30b00a2067d"
      unitRef="usd">1106000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0yLTEtMS0w_17f0d32f-fc4a-4638-b53d-cab80a618b42"
      unitRef="usd">77284000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC00LTEtMS0w_aa39b511-1159-4618-a7d3-8efb650bc89e"
      unitRef="usd">53845000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC02LTEtMS0w_49a0e508-ab6f-4056-8305-2aa8c460fe00"
      unitRef="usd">23439000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC04LTEtMS0w_d4dbb544-4a8b-479f-a6a0-661df11bfb7d"
      unitRef="usd">76759000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMC0xLTEtMA_808eabda-ba6c-42ef-844d-acc2cf61c368"
      unitRef="usd">52862000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMi0xLTEtMA_7cce6d33-2af3-4fef-8ed3-8bf619184a9f"
      unitRef="usd">23896000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9f5d302584f242a887a90c5ba675f0f7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMi0xLTEtMA_21e0af34-2a12-46e2-b8d9-e49cab2d4696"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9f5d302584f242a887a90c5ba675f0f7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtNi0xLTEtMA_92421b8b-a67c-4818-8eff-e48b38da0df6"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3d9cb52c2c4d4db882a1c475c695052f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtOC0xLTEtMA_efacb928-2066-41fd-a3f7-6a6d22774775"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3d9cb52c2c4d4db882a1c475c695052f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMTItMS0xLTA_03e9776c-6053-47ef-b7b5-1424442aae28"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMi0xLTEtMA_a275d43a-7336-432f-a95c-7cee9c1861ab"
      unitRef="usd">3135000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtNi0xLTEtMA_77d8c623-6b87-4997-b311-01049540d5c9"
      unitRef="usd">3135000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia4631e305af2483e8890f326b9fef89d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtOC0xLTEtMA_e4becf38-ee61-4cbb-8e99-2daf35227ff7"
      unitRef="usd">3175000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia4631e305af2483e8890f326b9fef89d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMTItMS0xLTA_28d8c399-5add-4f29-81ec-7d543142f052"
      unitRef="usd">3175000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib3aa408a10c644979d8878d88bca2e75_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMi0xLTEtMA_4c8ca8de-e276-48c0-b518-986b8566fb19"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib3aa408a10c644979d8878d88bca2e75_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItNi0xLTEtMA_7f2667b7-d939-4d7e-ba0c-f07c315852ac"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItOC0xLTEtMA_84186afa-80e2-40dc-ab67-16603619fc4a"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMTItMS0xLTA_785b6755-5573-4c6d-ad4a-59fcdfd38ca2"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMi0xLTEtMA_1a1aa527-03b0-4f20-92e2-afb58c8f7eb1"
      unitRef="usd">4535000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtNi0xLTEtMA_9b8f0a38-2570-4e77-8aa5-b0bfcc8cd912"
      unitRef="usd">4535000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtOC0xLTEtMA_cba7b496-64b2-4e5b-bbe5-6df7c075fa48"
      unitRef="usd">4575000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMTItMS0xLTA_7d6cbbd7-70a8-4b97-b1c1-d8c421231cdb"
      unitRef="usd">4575000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858"
      unitRef="usd">81819000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a"
      unitRef="usd">53845000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934"
      unitRef="usd">27974000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610"
      unitRef="usd">81334000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7"
      unitRef="usd">52862000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6"
      unitRef="usd">28471000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYzMg_ec8a44d4-8876-45ea-9f2e-7366615c50b2"
      unitRef="usd">300000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="i96110322c78c4e7d8e3fd05494f58fbb_I20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYyNw_52442337-e16e-4ee9-be53-e91ca7a24e8e"
      unitRef="number">0.09</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ0Ng_2c508c5e-b98b-47bb-b20a-61ecd80c5f89"
      unitRef="usd">883000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ3OA_b9eb3dbb-e3b0-48c1-9e6b-51069273e904"
      unitRef="usd">861000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzM5OQ_264568b5-6a8d-4797-ab10-591a5e009433">Pension and Postretirement Benefit Plans&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost/(credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended April 4, 2021, we contributed $83 million, $40 million, and $19 million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzQxNQ_6a2add9a-9548-4003-b208-30111899700b">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMi0xLTEtMA_8687b3ce-db3e-4cb2-bfbf-ec42a396982b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtNC0xLTEtMA_8a939fa7-2d34-493f-ae2f-9102f6506285"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTAtMS0xLTA_a8dfa0cd-d993-4d8a-afd4-456f681bc72c"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTItMS0xLTA_ce2d5b3a-1a61-4b0c-99be-39e93b20b725"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTQtMS0xLTA_b6b825d7-439f-4d37-b2c5-995c131591ad"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTYtMS0xLTA_1c911f5c-11cb-4034-86e2-a7b4a69d2795"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMi0xLTEtMA_ba9272fe-72a6-486c-813d-cbdcacfb796c"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtNC0xLTEtMA_c75929a4-d3d3-4db7-b2a1-e8f2b84223cb"
      unitRef="usd">141000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTAtMS0xLTA_20ca625b-08c8-4088-bbc9-a2b47ef13616"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTItMS0xLTA_70f018c0-3d15-4208-bc06-f0cae88d2201"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTQtMS0xLTA_0eee66b5-36eb-4ea2-8d19-e94784e66fe6"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTYtMS0xLTA_0ee67451-f51d-46d4-9af9-3dd979d4604f"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMi0xLTEtMA_f23540e6-9c8b-44fe-ae0c-98cc746c5f18"
      unitRef="usd">261000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctNC0xLTEtMA_81e605c1-cec9-4885-988e-523c910d6f05"
      unitRef="usd">252000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTAtMS0xLTA_779c6d88-5c3e-4ebf-8d68-05ddc941f75b"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTItMS0xLTA_a5768e51-76da-4789-ab9c-ee900aa74cbd"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTQtMS0xLTA_120b8bfe-2971-4685-b205-11934317ad9f"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTYtMS0xLTA_b747664b-d8fa-4585-9ce9-122d619f0076"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTItMS0xLTA_bd80891a-acc2-4214-bc84-1a6ab5c39836"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTQtMS0xLTA_e2322c30-936d-4e52-9fb2-036af65cd0bc"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEwLTEtMS0w_5ce3488e-10a0-4810-a358-0feadd783023"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEyLTEtMS0w_964fb994-e5fd-42d7-91b6-b4d0cd226fac"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE0LTEtMS0w_1ce86a28-0f04-4fd2-a084-f040ae3ce5e6"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE2LTEtMS0w_656bd82b-911b-48ba-a196-b19f37c69159"
      unitRef="usd">-43000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTItMS0xLTA_ff97d46c-fced-476a-b2a5-54106c04e446"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTQtMS0xLTA_5f84e636-9bbf-4595-8639-ea37be2b0c54"
      unitRef="usd">-163000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEwLTEtMS0w_044b0c2c-994d-416e-83b6-e67d5f636a87"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEyLTEtMS0w_d51533d3-6263-4abf-91a0-3da58876c737"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE0LTEtMS0w_0bf5e105-1467-4fb9-8409-5f0d8cd83943"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE2LTEtMS0w_b1fbfc66-3292-4a4f-b592-602046d88abb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTItMS0xLTA_5ae04baf-f60c-4f40-acb6-c2306ef6700f"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTQtMS0xLTA_d015451d-2db4-467d-ac30-e4346ce7e5e8"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEwLTEtMS0w_603a616e-3578-438d-b9ad-ad0ec331fff8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEyLTEtMS0w_8842c90b-452f-4485-bdab-713c259e6abe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE0LTEtMS0w_dd0e93ac-3718-441e-8a41-4b8d0bc1f4d5"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE2LTEtMS0w_60213122-1ebf-497d-ba70-0f5a512abd03"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTItMS0xLTA_9fefa320-0775-408d-a824-2607b2160ab4"
      unitRef="usd">-187000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTQtMS0xLTA_68520c5b-b502-4386-a00f-427048342f84"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEwLTEtMS0w_244d5c8d-eaff-472f-a1bb-92d486288ae1"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEyLTEtMS0w_2a57a0ab-238e-479f-bcbd-4f94673d4750"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE0LTEtMS0w_6f6beb1f-cefc-4e0c-89b8-90a419443c5e"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE2LTEtMS0w_cedf8bff-dc8d-4f66-8a38-261a00606227"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTE_61d9fc06-f971-4e1a-bd1b-60702afc5d59"
      unitRef="usd">83000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTY_bceb8feb-be42-41c5-95f8-393229dd26c0"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NjU_d1d72d09-6397-47cf-a422-479864a03710"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI1NA_f96deb72-44b6-40d9-9803-8891bc8b5b7b">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI0MQ_366e801e-c252-4bec-9279-8d6ce96bfe50">&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtNi0xLTEtMA_1125ce2f-542b-4f09-aa91-14cc328e1643"
      unitRef="usd">4868000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtOC0xLTEtMA_4c7ca253-9bac-4b7f-939d-2a2c06753108"
      unitRef="usd">2474000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctNi0xLTEtMA_6f8d4680-ddfb-4616-81de-e822e9e17389"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctOC0xLTEtMA_14a58154-6cc7-4314-a23c-e958f0e54318"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtNi0xLTEtMA_a73aafb6-82db-4f69-96c9-860c812b3103"
      unitRef="usd">4868000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtOC0xLTEtMA_511b2ca2-dbed-45a0-ba60-7fe83af468ab"
      unitRef="usd">2474000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktNi0xLTEtMA_5944ba14-19d5-4c71-a51c-16b551a6353e"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktOC0xLTEtMA_4132dcb7-62f2-4428-a3ac-59e2f71702c0"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTYtMS0xLTA_67bad856-d181-47b8-a462-bb33c85c5142"
      unitRef="usd">4877000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTgtMS0xLTA_a6e25586-5a1b-4152-bc03-0750e704b661"
      unitRef="usd">3354000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTYtMS0xLTA_3930246c-ef83-4ef5-9f57-118b0fc5b2f9"
      unitRef="usd">4868000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTgtMS0xLTA_f7a6ccef-0247-4155-84d1-600db8211e57"
      unitRef="usd">2474000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTYtMS0xLTA_ece5396d-10ea-4d1d-96f8-96e7cda58994"
      unitRef="usd">9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTgtMS0xLTA_786e5dfd-6dca-415e-98a5-8c1527a41f8f"
      unitRef="usd">881000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTYtMS0xLTA_3bf9d328-0a72-40a8-b86c-8a084ea4d727"
      unitRef="usd">4877000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTgtMS0xLTA_20ae953a-8de0-4b65-9256-3f5d7a042ecc"
      unitRef="usd">3355000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTYtMS0xLTA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9"
      unitRef="shares">5584000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTgtMS0xLTA_1ce1f538-b793-443a-8e14-be3400178559"
      unitRef="shares">5545000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTYtMS0xLTA_fade8507-b85c-420b-837d-7b877518ba4b"
      unitRef="shares">78000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTgtMS0xLTA_3ba6178b-fcaf-4f1e-8a63-086f591f54a7"
      unitRef="shares">68000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTYtMS0xLTA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da"
      unitRef="shares">5662000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTgtMS0xLTA_56fa12c0-55ed-4708-b561-3527a11165d8"
      unitRef="shares">5613000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzM4MjU0_045665f4-6571-4532-95a6-ced1712f9abe">Contingencies and Certain Commitments&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of these contingencies could result in increased expenses and/or losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. In August 2020, the SEC amended its disclosure rules regarding the threshold for disclosure of proceedings under environmental laws to which a governmental authority is a party. In accordance with the amended rule, we have adopted a disclosure threshold for such proceedings of $1 million in potential or actual governmental monetary sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A1. Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings, which remain pending, with respect to two of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those two patents, and one other patent, are now being challenged in federal court in Delaware. Challenges to other pneumococcal vaccine patents remain pending outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor&#x2019;s vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#x2019;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#x2019;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025 (the 2025 Patent), the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023 (the 2023 Patent), which Zydus challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2020, we settled the case against Zydus on terms not material to us. In February 2021, we brought a separate patent-infringement action against Zydus asserting the infringement and validity of our composition of matter and crystalline form patents challenged by Zydus in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2021, we settled our remaining action against Zydus on terms not material to us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the 2025 Patent and the 2023 Patent, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inlyta (axitinib)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ibrance (palbociclib)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2019, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance. The companies assert the invalidity and non-infringement of two composition of matter patents, one of which expires in 2023 and one of which expires in 2027, as a result of a U.S. Patent Term Extension certificate issued in January 2021, and a method of use patent covering palbociclib, which expires in 2023. In 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Matter Involving Our Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#x2019; allegedly unlawful conduct. In 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#x2019;s and/or its affiliates&#x2019; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, a new lawsuit was filed in the U.S. District Court for the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Array Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, two purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In 2018, the actions were consolidated into a single proceeding. In March 2021, the parties reached an agreement in principle to resolve the litigation on terms not material to us, which is subject to Court approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zantac &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. From June to December 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of two Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#x2019; sale of Zantac in Canada; (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in New Mexico; and (iv) Pfizer received service of a suit filed by the Mayor and City Council of Baltimore naming Pfizer and other defendants alleging various claims under Maryland law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A3. Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#x2019;s discontinued industrial chemical facility in North Haven, Connecticut. In 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative Order on Consent with the EPA. In 2019, the EPA acknowledged that construction of the site remedy has been completed. In March 2021, the State of Connecticut, Department of Energy &amp;amp; Environmental Protection issued a Stewardship Permit to Pharmacia &amp;amp; Upjohn Company LLC, our wholly-owned subsidiary, that will govern the ongoing operation, maintenance, and management of the North Haven site, and which will not have a material impact on Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#x2019;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy to address the discharge of impacted groundwater from the facility to the Raritan River. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#x2019;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the two adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and, in 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#x2019; motions to dismiss and dismissed all of plaintiffs&#x2019; claims. The plaintiffs are appealing the District Court&#x2019;s decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allergan Complaint for Indemnity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In 2018, the District Court dismissed the lawsuit. In 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian. That suit was voluntarily discontinued without prejudice in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Breach of Contract&#x2013;&#x2013;Xalkori/Lorbrena&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#x2019;s sales of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#x2019; summary judgment motions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Greenstone Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;U.S. Department of Justice Antitrust Division Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;State Attorneys General Generics Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subpoena relating to Manufacturing of Quillivant XR&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Inquiries relating to Meridian Medical Technologies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we received a civil investigative demand from the U.S. Attorney&#x2019;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#x2019;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to Russian Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, we received an informal request from the U.S. Department of Justice&#x2019;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#x2019;s FCPA Unit. We have produced records pursuant to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for information regarding a government investigation related to Docetaxel marketing practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice Inquiries relating to India Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#x2019;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to China Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#x2019;s FCPA Unit. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zantac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;State of New Mexico Civil Action&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12A2. Contingencies and Certain Commitments: Legal Proceedings&#x2013;&#x2013;Product Litigation&#x2013;&#x2013;Zantac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in New Mexico.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April&#160;4, 2021, the estimated fair value of these indemnification obligations was not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages. In addition, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Contingent Consideration for Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold
      contextRef="i05f859e329d9409390fed7a56b8d7dbd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5Mjk4MDg_b242f245-28fd-48cc-b7e2-19d4308d5b7f"
      unitRef="usd">1000000</pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold>
    <pfe:GainContingencyPatentsWithoutCourtProceedingsNumber
      contextRef="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NTYxNDI_b2627468-3145-4b6a-a6ab-2ce69ebcc070"
      unitRef="patent">2</pfe:GainContingencyPatentsWithoutCourtProceedingsNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5NDc_77c6a750-e364-489f-93c0-284ee70769b7"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5Nzg_5a441330-748b-431a-94d2-f5706f4cd8c7"
      unitRef="patent">1</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NzEyMjI_288e97f8-41cd-4d69-9b4a-02865f9bcade"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5ODI3Mzg_d1cdeca3-fb26-463a-890c-5b8db8696bad"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDE5NjI_0814ad79-3138-4bea-bfec-5e4ec5e97291"
      unitRef="defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIxODE_b9c86de9-60b5-4db7-8dd9-5e122e5032ae"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
      contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIyMzI_099b6f05-21ef-4f1e-b175-8053924514ed"
      unitRef="patent">1</pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDI5MTY_d113a473-d837-4ddd-b8d6-76bdc1f97633"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:LossContingencyNumberOfLawsuits
      contextRef="i02973e07500446c182f01c27b105cb67_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDMxMzM_4c051b5e-7e11-41d1-99e8-3a143c43e2ea"
      unitRef="lawsuit">1</pfe:LossContingencyNumberOfLawsuits>
    <pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant
      contextRef="i104649887c064a40a045fee23a147e9b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY1NTQ_edc14692-2ca4-4fa7-8989-81c9a2231a3f"
      unitRef="manufacturer">8</pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant>
    <pfe:LossContingencyClassActionsFiledNumber
      contextRef="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY4Njc_56f66725-4c77-40f0-a3f3-4bf5f497a549"
      unitRef="classaction">2</pfe:LossContingencyClassActionsFiledNumber>
    <pfe:LossContingencyClassActionsFiledNumber
      contextRef="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDg2MTY_dc06a69e-9cf7-46bc-8552-b1b8bb708859"
      unitRef="classaction">2</pfe:LossContingencyClassActionsFiledNumber>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzAyNDQ_0ba37e9b-bfa7-4454-bedd-6bb05d58a2f5"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzA3MjY_9a70d49c-7f8b-49b7-b2ea-175879c0f1e6"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NzE_ad2b7d5c-3a7d-499e-b0e6-3ca6da407328">Product, Geographic and Other Revenue Information&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 under such agreements. We currently sell the BNT162b2 vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February 2021 with the European Commission (EC) on behalf of the different EU member states and certain other countries. Each EU member state submits its own BNT162b2 vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Other Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For information on our significant wholesale customers, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form 10-K. Additionally, revenues from sales of BNT162b2 to the U.S. Government represented 14% of total revenues for the three months ended April&#160;4, 2021. Accounts receivable from sales of BNT162b2 to the U.S. Government represented 12% of total trade accounts receivable as of April&#160;4, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,083&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BNT162b2 alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Active immunization to prevent COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Nimenrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inlyta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sutent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xalkori&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bosulif&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Retacrit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ruxience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zirabev&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Braftovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;-mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Mektovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Braftovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chantix/Champix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Premarin family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Pristiq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Depression&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Toviaz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Hospital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sulperazon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vfend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Fragmin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zyvox&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Precedex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;IVIg Products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xeljanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;824&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Genotropin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Somavert&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total Alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Deferred Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of BNT162b2. The deferred revenues associated with the advance payments related to BNT162b2 total $1.9 billion as of April&#160;4, 2021 and $957 million as of December 31, 2020 and are recorded in current liabilities. The increase in the BNT162b2 deferred revenues during the first quarter of 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries. During the first quarter of 2021, we recognized revenue of $192 million that was included in the balance of BNT162b2 deferred revenues as of December 31, 2020. The BNT162b2 deferred revenues as of April&#160;4, 2021 will be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, which we expect to occur within the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the end of our fiscal first quarter of 2021 and through April 30, 2021, we received or were due additional advance payments associated with agreements to supply BNT162b2 totaling approximately $3.8 billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzOTA_bf3f5d34-59cf-4e71-aeeb-171700febc4b">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3825cb911e8746189fdd8101073ce536_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtMi0xLTEtMA_de616e87-1519-47cd-9d73-0bcf081dad42"
      unitRef="usd">7597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNC0xLTEtMA_b5af4009-5eda-4358-a596-188d87a9f7df"
      unitRef="usd">5289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i3825cb911e8746189fdd8101073ce536_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNi0xLTEtMA_e5ff1e2c-68e3-4b01-ae44-60d27e63a162"
      unitRef="number">0.44</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtMi0xLTEtMA_01253d63-32a6-4ac7-99b6-3af454234e37"
      unitRef="usd">3038000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNC0xLTEtMA_1eb771c2-4ae9-446f-bb60-dd7ac1730661"
      unitRef="usd">1708000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNi0xLTEtMA_a356971f-6228-4e86-b047-2c6d428572a0"
      unitRef="number">0.78</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtMi0xLTEtMA_caa8c2c5-70f2-4f42-a281-455ba55a28bb"
      unitRef="usd">1123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNC0xLTEtMA_77192e04-c3ab-4179-8c09-24e7cb03264f"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNi0xLTEtMA_d82da09a-6f12-483a-83ce-4051f6ccdc81"
      unitRef="number">0.22</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtMi0xLTEtMA_f4d97e43-ba99-43e5-bfbb-054297d02cf4"
      unitRef="usd">2824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNC0xLTEtMA_4cc4c45d-28e1-4d20-b64d-41e921c59925"
      unitRef="usd">2166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNi0xLTEtMA_5e8e94de-c1f4-4740-9605-a313777e45c9"
      unitRef="number">0.30</pfe:PercentageChangeInRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctMi0xLTEtMA_b07bfd7f-a947-4f55-8fbf-7c1b292bb668"
      unitRef="usd">14582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNC0xLTEtMA_37369dd6-3ee5-4f7a-a187-378163a1cc80"
      unitRef="usd">10083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:PercentageChangeInRevenue
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNi0xLTEtMA_e2672cd5-c588-4984-a57b-33a273632093"
      unitRef="number">0.45</pfe:PercentageChangeInRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4NzM_201eed17-5824-4b80-b7e8-ba039c52ba9e"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66c5094c3226447689dc0560d6f61760_D20210101-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4Nzk_f2fd3772-681a-4779-a755-28b9caf83164"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzODY_c0e2d0ec-3d0b-4518-aee1-3f82aff1a47f">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,083&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BNT162b2 alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Active immunization to prevent COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Nimenrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Meningococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inlyta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sutent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xalkori&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Bosulif&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Retacrit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ruxience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zirabev&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Braftovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;-mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Mektovi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;In combination with Braftovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chantix/Champix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Premarin family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Pristiq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Depression&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Toviaz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Hospital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Sulperazon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vfend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Fragmin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Zyvox&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Precedex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;IVIg Products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Xeljanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;824&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Genotropin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Somavert&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;All other Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total Alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747"
      unitRef="usd">14582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711"
      unitRef="usd">10083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtNDEx_b6cd2341-d5eb-423a-b6f7-bd4311b1fcd3"
      unitRef="usd">4894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtNDEx_1239f2e4-df26-4abe-912d-6aa92d6c05da"
      unitRef="usd">1611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtNDEx_047f2551-2d31-4a04-945d-b1aee1a1574a"
      unitRef="usd">3462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtNDEx_75508515-00df-4d48-b53e-e1f8f79259ca"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtNDEx_8afd91f6-c82c-4872-aa5c-593b5b1a1dc2"
      unitRef="usd">1284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtNDEx_76e08ad5-aa23-4561-9c06-72739acbfba5"
      unitRef="usd">1450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMTU0Njk_cdd602b5-de4f-421a-8c2c-916e3ada821f"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMTU0Njk_b9f4d774-f901-4bb3-96f6-a35e5d73852f"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtNDEx_8726d48d-8349-4710-bd7c-e0f10a7c0b99"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtNDEx_acc2ac48-92c9-470a-9769-004bccb56a5b"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNC0xLTEtNDEx_6ce406ec-37a0-4b1e-9221-b03994d0e0c8"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNi0xLTEtNDEx_5f483b36-9728-4c58-b9fd-29878c1e5ace"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00018897a8a546288611fca2330ad40d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtNDIx_928ced8e-9364-4991-91fd-c1d23fb2a965"
      unitRef="usd">2862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtNDIx_e7f64f4b-8131-40ee-8a62-3d37973a10d3"
      unitRef="usd">2435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTQtMS0xLTQyMQ_8a6df27e-b519-48c7-adc2-6729f72aeaf0"
      unitRef="usd">1254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTYtMS0xLTQyMQ_bb8a2b8e-6188-45bd-82b6-17110ded7572"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTQtMS0xLTQyMQ_7b83ff17-208f-493a-9933-90d9502a39eb"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTYtMS0xLTQyMQ_2f4a5b71-9ec8-4cee-94a3-88c3b568e0c2"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTE1NDc5_bceabdd8-7534-4cea-a052-c38e0d3e6633"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTE1NDc5_db811494-315b-4d83-a24e-549adae28480"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTQyMQ_0db56c24-c460-464d-a8e2-a7b6e742ff1b"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTQyMQ_c48e51fd-c9dc-4449-b947-dd36146c9671"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTQtMS0xLTQyMQ_ca32fa01-cc30-405f-ac07-b427eda4bdbd"
      unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTYtMS0xLTQyMQ_31f833f6-7c86-4a66-b12b-6542c47c563a"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTQtMS0xLTQyMQ_417f3cc0-13fe-4f1b-9985-eec2b6361b66"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTYtMS0xLTQyMQ_d346a5cf-775f-4676-8c95-1f09b9273b9a"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTQyMQ_3ade3a2d-1545-405b-b634-f67e081a3366"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTQyMQ_403841b9-443a-439b-8c4c-ff0163ecaa7e"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTE1OTE5_739edb05-224b-4255-bbc3-e9bf50ab2d7d"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaee0a8c94344749aad179a107f5379d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTE1OTIx_5cf5a222-3fff-4ab3-bc51-355906a66881"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTQtMS0xLTE1OTE5_bb3a233d-7d4d-458e-9f0f-88f0c696b71c"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTYtMS0xLTE1OTIx_988e52bd-6b03-4dfc-9ab2-d9853c4496f5"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTQtMS0xLTQyNw_045f8b7a-7116-4421-a75d-65e7355959ac"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTYtMS0xLTQyNw_13d5fa33-ad3d-4226-b1d5-f7bc20b713a9"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTQyNw_e37145f4-b52f-4d1b-8f0c-2445176083da"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTQyNw_a68467e4-52d7-4bb7-b8fe-7ef2b559ef1c"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTQtMS0xLTQzMw_f450758b-8d5a-410b-9288-185b6a433d67"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTYtMS0xLTQzMw_07090c70-f7cd-4d57-884a-d76c1575f1e1"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d86911b85754856a091d39a9a619036_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtMA_339104d8-f2a4-4d92-84f7-27a037baaa1d"
      unitRef="usd">2594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtMA_5014e54f-62a2-4e20-98eb-ddb9f083ea7d"
      unitRef="usd">2332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtMA_edb58811-4e34-4158-b753-89b65192d859"
      unitRef="usd">1643000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtMA_733a49ad-6056-4006-a78f-f628caf2663d"
      unitRef="usd">1300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15547904869341898a05e8608012fdf7_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtMA_98ecd8b0-ce73-4f0e-ad3b-b4e6d421f10c"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia665187179da484eb6e599146133e64c_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtMA_e86b12cc-2864-4a84-8391-1f89eddd02a2"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMA_5c35c781-e928-457a-a06d-00e984fa2688"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMA_94c3315b-2bc4-4522-a5f5-9ea8155295f5"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTQtMS0xLTE1OTI1_f3c4b946-e74d-4718-834d-f3aaefd26598"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6217a5b597e247debffac06a2be42229_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTYtMS0xLTE1OTI3_0e370ed6-70bb-4668-84b9-3c50308f771d"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTQtMS0xLTE1NTA2_39aa5fb6-f7ab-4c36-9267-8ce00c67fe65"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39d647526b664456a53481f1fcd29c09_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTYtMS0xLTE1NTA2_705ed196-8bdd-4fd9-8ede-323e57b5669b"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtMA_33dc4f68-76c4-4c27-8126-a984b828a987"
      unitRef="usd">474000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtMA_a1dfa7ac-d7e6-429d-bf04-d09ab44960ce"
      unitRef="usd">509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9"
      unitRef="usd">2343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5"
      unitRef="usd">2088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTQtMS0xLTA_49b33136-137f-4266-b009-9abe46fa6a7b"
      unitRef="usd">192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTYtMS0xLTA_de5f1774-8826-4e53-9fd3-e3c6d33f793d"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTQtMS0xLTA_2b5ce3e7-021e-4d46-b192-8d36813d04d2"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTYtMS0xLTA_851f1a5b-b3a2-4039-bc1e-d270c02c061b"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTE1NTEy_c42c1f8f-dc46-4a67-a03a-c301c52f9ac1"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTE1NTEy_65d30d6c-b9fb-441e-8d25-f0ab9195d9a8"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTQtMS0xLTA_6374d573-a87c-4a36-bd53-98926d72ed72"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTYtMS0xLTA_f696e168-af9b-41fc-8d90-2dc8ad63a4e2"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTQtMS0xLTA_7040c689-76f9-435e-9e12-73c7b0f245dd"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTYtMS0xLTA_71555e69-a4a7-44e1-880f-f09dcfe9899d"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTQtMS0xLTA_58e27134-cc8c-411c-8d27-cfb478f8478e"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTYtMS0xLTA_c121e5fe-55af-468a-87a8-47ed849c8cc7"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTQtMS0xLTE1NTE4_abd76629-91b8-4df2-9764-2f1b7d507e15"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia251f6f252be4fca87be237b62587e21_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTYtMS0xLTE1NTE4_38330553-8b6c-4ea4-90b7-4aa3f8986b35"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTA_93246ed8-93c0-4762-8596-8ccda3564dec"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTA_c84d0308-24dd-46a9-8f30-1d958b299b8a"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTQtMS0xLTA_a888aabe-459b-4a99-ba25-7fc696a5a372"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTYtMS0xLTA_2467aa26-882b-48e1-9dd4-df09ca9d7188"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9846250722404133a31c34c978297518_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9903f105558492aac6500bc30eaadca_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTQtMS0xLTA_ca95dd51-916a-4255-bd9d-a716c45cc979"
      unitRef="usd">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTYtMS0xLTA_a4546b05-e2e6-4e18-a4e6-db2aa4824564"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTQtMS0xLTA_61c4df76-99cb-4cb9-b405-9868e8bf29b6"
      unitRef="usd">648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTYtMS0xLTA_196978d1-8811-4173-805a-cb4e89c79f3e"
      unitRef="usd">610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTQtMS0xLTA_7ecad3a3-8c46-4190-8dd2-fa2e19fb293e"
      unitRef="usd">1065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTYtMS0xLTA_95e4717a-1518-49fc-970b-c5b38526cae5"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTQtMS0xLTA_ddadfa0c-9ceb-4970-9c72-4859224c3b9d"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTYtMS0xLTA_935639d7-1a10-4379-8129-801d55562c24"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTQtMS0xLTA_9a855437-f4ba-439f-88b9-eebfb24bceae"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTYtMS0xLTA_a513e818-5ce6-49b2-8931-4fdcd584d3cb"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTQtMS0xLTA_8293a04a-3b4a-46a1-b694-c678651ea32d"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTYtMS0xLTA_4a57a4d2-851b-4e9e-9c13-45638fb3d25e"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTQtMS0xLTA_d56874f4-3998-4385-af11-fc158e9be52a"
      unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTYtMS0xLTA_5b8ba429-9a55-4fa7-93e6-42409ade7405"
      unitRef="usd">639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTQtMS0xLTA_aad9c342-75af-47a6-9620-bc10c9e7c4e0"
      unitRef="usd">453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTYtMS0xLTA_2d16c412-a3f1-41de-b782-cebb95709037"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTQtMS0xLTA_e2c0992f-ed1e-4545-9c37-d622e529bb27"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i217f041566f14b16a835176fc12cebe4_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTYtMS0xLTA_2bcb6ee4-01d5-497a-9d1c-7669f2b87f28"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTE1NTM4_b7c97c54-0a5a-4451-9752-829a7a659ddf"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTE1NTM4_1d8d54d4-8fc6-4aff-93c7-7cdd6a7f7c02"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTA_bde9b100-345e-488a-b63d-754151871331"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTA_e213e133-cc55-4c55-a28e-3a455669d91a"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTQtMS0xLTA_ed4ac610-7ee3-4bf9-bbac-228146dd059a"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4045f62b3268485d984a63420d9173d9_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTYtMS0xLTA_ed64a288-fd5e-4f2b-9812-25b5cddf0101"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTQtMS0xLTA_875bf804-d477-4808-b4b3-10d13202e587"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTYtMS0xLTA_e8fb6c9c-3db1-40f8-9b5c-8e868eae59d5"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTQtMS0xLTA_1f83642f-54d9-4c7e-bdf4-a904b5ac0eb4"
      unitRef="usd">1770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTYtMS0xLTA_c58ca481-4b90-46ab-a793-9fc2f7b5a2c8"
      unitRef="usd">1382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c"
      unitRef="usd">1482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d"
      unitRef="usd">1401000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzI5ODA_82b6ca28-7195-461b-94d1-537364e140ea"
      unitRef="usd">1900000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iadcb9082716e49ad8217f6c35c00c9da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDY2NjU_51ec06dc-3a69-4560-a820-b394619b1382"
      unitRef="usd">957000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDc3ODU_1d94c7b1-9909-4901-92b7-865fbbbda8d2"
      unitRef="usd">192000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NDAyOTY_a59c8cee-4655-44be-bb86-1c3bc049ce01"
      unitRef="usd">3800000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#x2014;net, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI were reclassified into OID.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI into COS were:<xhtml:div style="padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $45 million in the first quarter of 2021; and</xhtml:span></xhtml:div><xhtml:div style="padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $70 million in the first quarter of 2020. </xhtml:span></xhtml:div><xhtml:div style="padding-left:9pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x2013;&#x2013;</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($561 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($156 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represent investments in the life sciences sector</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </xhtml:span><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</xhtml:span><xhtml:span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external costs for banking, legal, accounting and other similar services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($628 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($169 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Exclusive of amortization of intangible assets, except as disclosed in </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 9 </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in this Form 10-Q and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1L </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#x2014;net of tax</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#x2019;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#x2014;net of tax</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099256246920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">235 East 42nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,597,693,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, $.05 par value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member', window );">0.250% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">1.000% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099262478712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 14,582<span></span>
</td>
<td class="nump">$ 10,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,783<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">872<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,004)<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">805<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,886<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.87<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.86<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,584<span></span>
</td>
<td class="nump">5,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,662<span></span>
</td>
<td class="nump">5,613<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1L </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099265761256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,886<span></span>
</td>
<td class="nump">$ 3,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">465<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">214<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">259<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">473<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(242)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income/(loss), before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="num">(1,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">647<span></span>
</td>
<td class="num">(1,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,533<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income/(loss) attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income/(loss) attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,523<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255931496">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 1,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,899<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$512; 2020&#8212;$508</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,864<span></span>
</td>
<td class="nump">7,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,493<span></span>
</td>
<td class="nump">8,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,419<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,091<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,533<span></span>
</td>
<td class="nump">35,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,532<span></span>
</td>
<td class="nump">16,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, less accumulated depreciation: 2021&#8212;$15,105; 2020&#8212;$14,812</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,011<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">27,974<span></span>
</td>
<td class="nump">28,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,791<span></span>
</td>
<td class="nump">49,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158,818<span></span>
</td>
<td class="nump">154,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$3,676; 2020&#8212;$2,002</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,064<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,798<span></span>
</td>
<td class="nump">11,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,652<span></span>
</td>
<td class="nump">25,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,347<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">635<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,759<span></span>
</td>
<td class="nump">11,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,953<span></span>
</td>
<td class="nump">90,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">472<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,002<span></span>
</td>
<td class="nump">88,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(111,349)<span></span>
</td>
<td class="num">(110,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,158<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,664)<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,620<span></span>
</td>
<td class="nump">63,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,865<span></span>
</td>
<td class="nump">63,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 158,818<span></span>
</td>
<td class="nump">$ 154,229<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099263784200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property, plant and equipment, accumulated depreciation</a></td>
<td class="nump">15,105<span></span>
</td>
<td class="nump">14,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099256396376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Add'l Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>Accum. Other Comp. Loss [Member]</div></th>
<th class="th"><div>Shareholders' Equity [Member]</div></th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 63,447<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 87,428<span></span>
</td>
<td class="num">$ (110,801)<span></span>
</td>
<td class="nump">$ 91,397<span></span>
</td>
<td class="num">$ (5,367)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,143<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="num">(1,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,441)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 29, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">9,393,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,841,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 29, 2020</a></td>
<td class="nump">65,341<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">87,680<span></span>
</td>
<td class="num">$ (111,010)<span></span>
</td>
<td class="nump">94,680<span></span>
</td>
<td class="num">(6,808)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,028<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,407,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">63,473<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">88,674<span></span>
</td>
<td class="num">$ (110,988)<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">63,238<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">646<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCashAbstract', window );"><strong>Cash dividends declared, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="num">$ (361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Apr. 04, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,445,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,851,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 04, 2021</a></td>
<td class="nump">$ 68,865<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
<td class="nump">$ 89,002<span></span>
</td>
<td class="num">$ (111,349)<span></span>
</td>
<td class="nump">$ 95,158<span></span>
</td>
<td class="num">$ (4,664)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 68,620<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099252426840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099256077816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">$ 4,886<span></span>
</td>
<td class="nump">$ 3,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations before allocation to noncontrolling interests</a></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="num">(291)<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Other changes in assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="num">(1,327)<span></span>
</td>
<td class="num">(1,515)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="nump">4,530<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities from discontinued operations</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">3,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(6,054)<span></span>
</td>
<td class="num">(2,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">3,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess', window );">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="num">(996)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="nump">163<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by/(used in) investing activities from continuing operations</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) investing activities from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="num">(2,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(610)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="num">(2,807)<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InterestPaidReceivedInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestPaidReceivedInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Paid (Received), Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestPaidReceivedInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255053288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;28, 2021 and February&#160;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&#160;4, 2021 and March&#160;29, 2020.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer&#8217;s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&#160;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. New Accounting Standard Adopted in 2021</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards adopted in 2020, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Change in Accounting Principle</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (&#8220;MTM Accounting&#8221;).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a &#8220;corridor&#8221; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $6.3 billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March&#160;29, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,763&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt 0 10pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(377)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,523)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,664)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,688)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Revenues and Trade Accounts Receivable</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,848&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;4, 2021 and March&#160;29, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253680408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock', window );">Discontinued Operations and Equity-Method Investment</a></td>
<td class="text">Discontinued Operations and Equity-Method Investment<div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Upjohn Separation and Combination with Mylan</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the first three months of 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $871 million as of April&#160;4, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was recorded as a payable to Viatris in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8211;&#8211;net of tax.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:71.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.753%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#8217;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Formation of Consumer Healthcare JV</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in the Consumer Healthcare JV is $16.3 billion as of April&#160;4, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&#160;4, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $126 million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as well as dividends totaling approximately $274 million, partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in the first quarter of 2021, was $71 million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2019, which we recorded in our operating results in the first quarter of 2020 was $11 million. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-top:5pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:53.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,811)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255781896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base aligns appropriately with our revenue base. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. In addition, we are taking steps to restructure our corporate enabling functions to appropriately support and drive the purpose of our business and R&amp;D and PGS platform functions. The program costs discussed below are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect costs for this program, primarily related to corporate enabling functions, to total $1.6 billion on a pre-tax basis, with substantially all costs to be cash expenditures. Actions will include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of this program, we expect to incur costs related to manufacturing network optimization, including certain legacy cost-reduction initiatives, of $500 million, with approximately 20% of the costs to be non-cash. The costs for this effort will include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through April&#160;4, 2021, we incurred costs of $1.0&#160;billion.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:40.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.096%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&#160;4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($169 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($561 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($156 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255228008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text">Other (Income)/Deductions&#8212;Net<div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(34)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(401)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(115)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255673064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text">Tax Matters<div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was 14.2% for the first quarter of 2021, compared to 12.6% for the first quarter of 2020. The higher effective tax rate was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of April&#160;4, 2021. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#8217;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2010.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(380)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255248696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.818%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,008)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,664)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099350117864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,165&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,119&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,278&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.402%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying values and estimated fair values using a market approach:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding the current portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,504&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,533&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April&#160;4, 2021 and December 31, 2020. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Short-Term, Long-Term and Equity-Method Investments</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,899&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,228&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represent investments in the life sciences sector.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,531&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,032&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,774&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,002&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona, Canadian dollar and Chinese renminbi. Additionally, we hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar for up to two years.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(529)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(268)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(386)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(230)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI into COS were:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $45 million in the first quarter of 2021; and</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $70 million in the first quarter of 2020. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:27.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from drug wholesalers. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., U.K., Germany, France, Japan and Canada.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&#160;4, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $613 million, for which we have posted collateral of $675 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of April&#160;4, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $53&#160;million, for which we have received collateral of $124 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253958840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div>Other current liabilities related to the gross margin split with BioNTech for BNT162b2 totaled $1.4&#160;billion as of April 4, 2021 and $25&#160;million as of December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255273560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets</a></td>
<td class="text">Identifiable Intangible Assets<div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,284&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,439&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,759&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,896&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,819&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,334&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,471&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly all of our identifiable intangible assets are managed by our commercial organization, with only 9% of total IPR&amp;D assets managed by our R&amp;D organization.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of finite-lived intangible assets was $883 million for the first quarter of 2021 and $861 million for the first quarter of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255161880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text">Pension and Postretirement Benefit Plans<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April 4, 2021, we contributed $83 million, $40 million, and $19 million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255135816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</a></td>
<td class="text">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253916120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Certain Commitments</a></td>
<td class="text">Contingencies and Certain Commitments<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. In August 2020, the SEC amended its disclosure rules regarding the threshold for disclosure of proceedings under environmental laws to which a governmental authority is a party. In accordance with the amended rule, we have adopted a disclosure threshold for such proceedings of $1 million in potential or actual governmental monetary sanctions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings, which remain pending, with respect to two of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those two patents, and one other patent, are now being challenged in federal court in Delaware. Challenges to other pneumococcal vaccine patents remain pending outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor&#8217;s vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025 (the 2025 Patent), the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023 (the 2023 Patent), which Zydus challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2020, we settled the case against Zydus on terms not material to us. In February 2021, we brought a separate patent-infringement action against Zydus asserting the infringement and validity of our composition of matter and crystalline form patents challenged by Zydus in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2021, we settled our remaining action against Zydus on terms not material to us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the 2025 Patent and the 2023 Patent, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance. The companies assert the invalidity and non-infringement of two composition of matter patents, one of which expires in 2023 and one of which expires in 2027, as a result of a U.S. Patent Term Extension certificate issued in January 2021, and a method of use patent covering palbociclib, which expires in 2023. In 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, a new lawsuit was filed in the U.S. District Court for the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Array Securities Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, two purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In 2018, the actions were consolidated into a single proceeding. In March 2021, the parties reached an agreement in principle to resolve the litigation on terms not material to us, which is subject to Court approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. From June to December 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of two Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico; and (iv) Pfizer received service of a suit filed by the Mayor and City Council of Baltimore naming Pfizer and other defendants alleging various claims under Maryland law.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative Order on Consent with the EPA. In 2019, the EPA acknowledged that construction of the site remedy has been completed. In March 2021, the State of Connecticut, Department of Energy &amp; Environmental Protection issued a Stewardship Permit to Pharmacia &amp; Upjohn Company LLC, our wholly-owned subsidiary, that will govern the ongoing operation, maintenance, and management of the North Haven site, and which will not have a material impact on Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy to address the discharge of impacted groundwater from the facility to the Raritan River. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the two adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and, in 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. The plaintiffs are appealing the District Court&#8217;s decision. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In 2018, the District Court dismissed the lawsuit. In 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian. That suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breach of Contract&#8211;&#8211;Xalkori/Lorbrena</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General Generics Antitrust Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State of New Mexico Civil Action</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A2. Contingencies and Certain Commitments: Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in New Mexico.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April&#160;4, 2021, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages. In addition, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255257208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product, Geographic and Other Revenue Information</a></td>
<td class="text">Product, Geographic and Other Revenue Information<div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Geographic Information</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 under such agreements. We currently sell the BNT162b2 vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February 2021 with the European Commission (EC) on behalf of the different EU member states and certain other countries. Each EU member state submits its own BNT162b2 vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Revenue Information</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K. Additionally, revenues from sales of BNT162b2 to the U.S. Government represented 14% of total revenues for the three months ended April&#160;4, 2021. Accounts receivable from sales of BNT162b2 to the U.S. Government represented 12% of total trade accounts receivable as of April&#160;4, 2021.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:31.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Vaccines</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BNT162b2 alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME/IMMUN-TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Vaccines</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Internal Medicine</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">EpiPen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Epinephrine injection used in treatment of life-threatening allergic reactions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zyvox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Precedex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">IVIg Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Hospital</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:31.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other I&amp;I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Rare Disease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">824</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">639</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of BNT162b2. The deferred revenues associated with the advance payments related to BNT162b2 total $1.9 billion as of April&#160;4, 2021 and $957 million as of December 31, 2020 and are recorded in current liabilities. The increase in the BNT162b2 deferred revenues during the first quarter of 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries. During the first quarter of 2021, we recognized revenue of $192 million that was included in the balance of BNT162b2 deferred revenues as of December 31, 2020. The BNT162b2 deferred revenues as of April&#160;4, 2021 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, which we expect to occur within the next 12 months. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the end of our fiscal first quarter of 2021 and through April 30, 2021, we received or were due additional advance payments associated with agreements to supply BNT162b2 totaling approximately $3.8 billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099256281368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;28, 2021 and February&#160;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&#160;4, 2021 and March&#160;29, 2020.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer&#8217;s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&#160;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standard Adopted</a></td>
<td class="text">New Accounting Standard Adopted in 2021On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Change in Accounting Principle</a></td>
<td class="text">Change in Accounting Principle<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (&#8220;MTM Accounting&#8221;).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a &#8220;corridor&#8221; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $6.3 billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span>We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Trade Accounts Receivable</a></td>
<td class="text">Revenues and Trade Accounts Receivable<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,848&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253999640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Change in Accounting Principle</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March&#160;29, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,763&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt 0 10pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(377)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,523)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,664)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,688)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock', window );">Schedule of Balance Sheet Classification of Accruals</a></td>
<td class="text">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,848&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255210680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract', window );"><strong>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summarized Financial Information of Discontinued Operations</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:71.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.753%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#8217;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:53.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,811)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255173960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Components and Changes in Restructuring Accruals</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:40.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.096%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&#160;4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($169 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($561 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($156 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099347963912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other (Income)/Deductions - Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(34)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(401)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(115)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(103)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255239864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(380)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099254009832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.818%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,008)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,664)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261921368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,165&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,119&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,278&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.402%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying values and estimated fair values using a market approach:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding the current portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,504&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,533&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Investments by Classification Type</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,899&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,228&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represent investments in the life sciences sector.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of Held-to-maturity Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,531&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,531&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.150%"/><td style="width:0.1%"/></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,531&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock', window );">Schedule of Gains and Losses on Investment Securities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Borrowings</a></td>
<td class="text"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,705&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,032&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,774&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,002&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(529)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(268)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(386)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(59)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(230)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI into COS were:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $45 million in the first quarter of 2021; and</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $70 million in the first quarter of 2020. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:27.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255141320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Components of Inventories, Noncurrent</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,493&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253998120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,284&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,439&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,759&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,896&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,819&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,334&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,471&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,840)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,284&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,439&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,759&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,896&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,819&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,845)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,334&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,862)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,471&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099254989608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253929080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255457864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:31.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Vaccines</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BNT162b2 alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME/IMMUN-TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Vaccines</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Internal Medicine</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">EpiPen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Epinephrine injection used in treatment of life-threatening allergic reactions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zyvox</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Precedex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">IVIg Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Hospital</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">610&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:31.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other I&amp;I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Rare Disease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">824</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">639</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099260696024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Decrease to retained earnings</a></td>
<td class="num">$ (95,158)<span></span>
</td>
<td class="num">$ (90,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Increase to AOCI</a></td>
<td class="num">$ (4,664)<span></span>
</td>
<td class="num">$ (5,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember', window );">Change in Accounting Principle, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Decrease to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Increase to AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099262033544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="num">$ (1,004)<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision for taxes on income</a></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.87<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.86<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="num">$ (1,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Condensed Consolidated Statements of Cash Flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Condensed Consolidated Balance Sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">95,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember', window );">Previous Accounting Principle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="num">(857)<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision for taxes on income</a></td>
<td class="nump">5,536<span></span>
</td>
<td class="nump">2,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">$ 4,763<span></span>
</td>
<td class="nump">$ 3,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.85<span></span>
</td>
<td class="nump">0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="num">$ (1,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="nump">72<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Condensed Consolidated Statements of Cash Flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Condensed Consolidated Balance Sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="nump">2,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="nump">4,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">95,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,688)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember', window );">Impact of Change [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision for taxes on income</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="num">$ (81)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="nump">81<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Condensed Consolidated Statements of Cash Flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Condensed Consolidated Balance Sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099266769768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 4,848<span></span>
</td>
<td class="nump">$ 4,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable, less allowance for doubtful accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">3,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Accrued Liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099350120328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details) - Viatris [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Nontrade receivables</a></td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities', window );">Payment pursuant to terms of the separation agreement</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Pursuant to Terms of Separation Agreement, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ViatrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ViatrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099262681320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Income Statement Disclosures</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Pre-tax income from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer&#8217;s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Costs and Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261169224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="nump">$ 16,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="nump">16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation', window );">Decrease due to foreign currency translation</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Dividend received</a></td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment earnings</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_GSKMember', window );">GSK [Member] | Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Increase (Decrease), Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ConsumerHealthcareJVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255925800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ConsumerHealthcareJVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253998952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - Focused Company Plan [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember', window );">Manufacturing optimization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring cost</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of expected costs to be non-cash</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099260979544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember', window );">Acquisition-related costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember', window );">Cost reduction/productivity initiatives [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income)/deductions&#8211;&#8211;net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, informational and administrative expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">64<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges/(credits):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation&#8211;&#8211;asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents external costs for banking, legal, accounting and other similar services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&#160;29, 2020 includes the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099260329912">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($169 million).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($561 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($156 million).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099262312008">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">336<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">336<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty-related income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net (gains)/losses on asset disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(401)<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights', window );">Income from collaborations, out-licensing arrangements and sales of compound/product rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit costs/(credits) other than service costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization', window );">Consumer Healthcare JV equity method (income)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,004)<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The first quarter of 2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099265753944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 372<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneAndBioNTechMember', window );">Allogene and BioNTech [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneAndBioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneAndBioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099347014792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Detail) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099262373544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 21<span></span>
</td>
<td class="num">$ (247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives qualifying as hedges, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">93<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 84<span></span>
</td>
<td class="num">$ (380)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261013816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">647<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(5,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,664)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (6,808)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(5,450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">442<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,008)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(428)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">380<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(142)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(33)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 419<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099258849512">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158,818<span></span>
</td>
<td class="nump">154,229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,165<span></span>
</td>
<td class="nump">14,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent', window );">Long-term equity securities held in trust</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,292<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,719<span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">394<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">389<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,198<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">726<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">853<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">494<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">494<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,119<span></span>
</td>
<td class="nump">11,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,292<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,719<span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">394<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">389<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">77<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">726<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">853<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">494<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">494<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,178<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">7,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">7,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">903<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">902<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">902<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Long-term equity securities of $168 million as of April&#160;4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Investments Excluding Held-To-Maturity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 30<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73718008&amp;loc=d3e42732-111610<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099253761544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">$ 35,347<span></span>
</td>
<td class="nump">$ 37,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">$ 40,504<span></span>
</td>
<td class="nump">$ 45,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261077464">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments by Classification Type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,292<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,899<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNINoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrivateEquityInvestments', window );">Private equity securities at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">467<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Total Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,532<span></span>
</td>
<td class="nump">16,856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term investments and equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,228<span></span>
</td>
<td class="nump">20,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldToMaturityCashEquivalents', window );">Held-to-maturity cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of April&#160;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represent investments in the life sciences sector</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldToMaturityCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-To-Maturity Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldToMaturityCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099260711432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Investment Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 10,667<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss', window );">Debt securities, gross unrealized losses</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity', window );">Debt securities, fair value</a></td>
<td class="nump">10,637<span></span>
</td>
<td class="nump">10,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue', window );">Debt securities maturities, within 1 year, fair value</a></td>
<td class="nump">10,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue', window );">Debt securities maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue', window );">Debt securities maturities, over 5 years, fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency - non U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">7,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,178<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">6,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">6,178<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities, fair value</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Next Twelve Months, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Year Two Through Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255134728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (401)<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (372)<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The gains in the first quarter of 2021 include, among other things, unrealized gains of $409&#160;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255006520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative impairment losses and downward price adjustments on equity securities</a></td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustments on equity securities</a></td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261167272">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting', window );">Current portion of long-term debt, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">260<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Total short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">2,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,352<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099251732200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="nump">35,347<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">2,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt, principal amount</a></td>
<td class="nump">34,032<span></span>
</td>
<td class="nump">35,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term debt</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="nump">35,347<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255296056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261109576">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">435<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">654<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,799<span></span>
</td>
<td class="nump">24,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">408<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">654<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">450<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,726<span></span>
</td>
<td class="nump">15,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HedgedItemAxis=us-gaap_SalesMember', window );">Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion as of April&#160;4, 2021 and $5.0 billion as of December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HedgedItemAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HedgedItemAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099258099160">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 214<span></span>
</td>
<td class="num">$ (501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax', window );">All other, net - Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">460<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">OID [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember', window );">Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(230)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">202<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">154<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged item</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">26<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI were reclassified into OID.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI into COS were:<div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $45 million in the first quarter of 2021; and</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $70 million in the first quarter of 2020. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $20 million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 22 years and relates to foreign currency debt. </span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&#160;4, 2021 was $1.2 billion. The long-term debt carrying values as of April&#160;4, 2021 and December 31, 2020 were $872 million and $2.1 billion, respectively.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261514072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (259)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Pre-tax loss expected to be reclassified within the next 12 months</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember', window );">Foreign currency debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Remaining period of hedging exposure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (45)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099259497768">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - Long-term debt [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 2,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 1,149<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099255319384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net liability position</a></td>
<td class="nump">$ 613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DerivativeNetReceivablePositionAggregateFairValue', window );">Derivatives in a net receivable position</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Collateral received</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DerivativeNetReceivablePositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Net Receivable Position, Aggregate Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DerivativeNetReceivablePositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099263722264">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,289<span></span>
</td>
<td class="nump">$ 2,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,364<span></span>
</td>
<td class="nump">4,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">840<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,493<span></span>
</td>
<td class="nump">8,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 981<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099254990168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 12,798<span></span>
</td>
<td class="nump">$ 11,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | BNT162b2 alliance revenues and direct sales [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BNT162b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099252451080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 77,284<span></span>
</td>
<td class="nump">$ 76,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(53,845)<span></span>
</td>
<td class="num">(52,862)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,439<span></span>
</td>
<td class="nump">23,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,535<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">81,819<span></span>
</td>
<td class="nump">81,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(53,845)<span></span>
</td>
<td class="num">(52,862)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,974<span></span>
</td>
<td class="nump">28,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">827<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">573<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">74,056<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(51,840)<span></span>
</td>
<td class="num">(50,902)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">22,217<span></span>
</td>
<td class="nump">22,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(51,840)<span></span>
</td>
<td class="num">(50,902)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology rights [Member] | BioNTech [Member] | BNT162b2 alliance revenues and direct sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Finite-lived intangible assets, period increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">922<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(782)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(782)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">License Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,223)<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,223)<span></span>
</td>
<td class="num">$ (1,186)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The increase in the gross carrying amount primarily reflects $300 million of capitalized BNT162b2 sales milestones due to BioNTech.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BNT162b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099251285672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of total identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for finite-lived intangible assets</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099256069208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Actuarial (gains)/losses</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Actuarial (gains)/losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Actuarial (gains)/losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099251249912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099348472952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,868<span></span>
</td>
<td class="nump">$ 2,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: Preferred stock dividends&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,584<span></span>
</td>
<td class="nump">5,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,662<span></span>
</td>
<td class="nump">5,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261136152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Patent Litigation) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($) </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>patent </div>
<div>defendant</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold', window );">Threshold for disclosure of proceedings under environmental laws | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember', window );">Pneumococcal Vaccine Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber', window );">Number of patents without court proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember', window );">Other Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember', window );">Pfizer Versus Generic Companies [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_XeljanzMember', window );">Xeljanz [Member] | Pfizer Versus Zydus [Member] | Patent Infringement [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EliquisMember', window );">Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019', window );">Number of patents allegedly infringed upon, expired December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Without Court Proceedings, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsWithoutCourtProceedingsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Site Contingency, Regulatory Proceedings, Disclosure Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099260705592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)<br></strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>classAction</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>manufacturer </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>classAction</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember', window );">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant', window );">Number of defendants other than main defendant | manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_ArraySecuritiesLitigationMember', window );">Array Securities Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyClassActionsFiledNumber', window );">Number of class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_ZantacRanitidineNDMALitigationMember', window );">Zantac/Ranitidine NDMA Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyClassActionsFiledNumber', window );">Number of class actions filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember', window );">Environmental Remediation Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeasibilityStudyNumberOfLagoons', window );">Feasibility study, number of lagoons | lagoon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | EpiPen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeasibilityStudyNumberOfLagoons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feasibility Study, Number Of Lagoons</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeasibilityStudyNumberOfLagoons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyClassActionsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Actions Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyClassActionsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Defendants Other Than Main Defendant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DocetaxelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_ArraySecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_ArraySecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_ZantacRanitidineNDMALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_ZantacRanitidineNDMALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099362744072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 14,582<span></span>
</td>
<td class="nump">$ 10,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,597<span></span>
</td>
<td class="nump">5,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,038<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,824<span></span>
</td>
<td class="nump">$ 2,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PercentageChangeInRevenue', window );">Percentage Change In Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PercentageChangeInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage change in revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PercentageChangeInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099261169480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product, Geographic and Other Revenue Information - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member', window );">BNT162b2 alliance revenues and direct sales [Member] | Revenue Benchmark | Product concentration risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member', window );">BNT162b2 alliance revenues and direct sales [Member] | Trade accounts receivable [Member] | Product concentration risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">Government and Government Sponsored [Member] | BNT162b2 alliance revenues and direct sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">Government and Government Sponsored [Member] | BNT162b2 alliance revenues and direct sales [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BNT162b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140099342973416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Product, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 14,582<span></span>
</td>
<td class="nump">$ 10,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember', window );">Total Alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember', window );">Total Biosimilars [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">530<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember', window );">Total Sterile Injectable Pharmaceuticals [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,894<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | BNT162b2 alliance revenues and direct sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Prevnar 13/Prevenar 13 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | FSME/IMMUN-TicoVac [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Nimenrix [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | All other Vaccines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,862<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ibrance [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xtandi alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">267<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Inlyta [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Sutent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xalkori [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">134<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Bosulif [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Retacrit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">109<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ruxience [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">98<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Zirabev [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Lorbrena [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Aromasin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Besponsa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Braftovi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Mektovi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | All other Oncology [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Eliquis [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,643<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Chantix / Champix [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Premarin family [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Pristiq [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Toviaz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | All other Internal Medicine [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">474<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Sulperazon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">192<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Medrol [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zavicefta [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zithromax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Vfend [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Fragmin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | EpiPen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zyvox [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Precedex [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | IVIg Products [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">105<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Pfizer CentreOne [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">391<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | All other Anti-infectives [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">397<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | All other Hospital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">648<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Xeljanz [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">538<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Enbrel (Outside the U.S. and Canada) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">319<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | Inflectra/Remsima [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">177<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology (I&amp;I) [Member] | All other I &amp; I [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">824<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Vyndaqel/Vyndamax [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | BeneFIX [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | ReFacto AF/Xyntha [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Genotropin [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Somavert [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | All other Rare Disease [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BNT162b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BNT162b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NimenrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NimenrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RetacritMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RetacritMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RuxienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RuxienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZirabevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZirabevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LorbrenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LorbrenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AromasinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AromasinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PristiqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PristiqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_HospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZaviceftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZaviceftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZyvoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZyvoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrecedexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrecedexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IVIgProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IVIgProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VyndaqelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VyndaqelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWJS1J9ML,%<#6*,:,$ZD7MH$>P\*9@4C,EF+M#I\N& MFK-\ULCRYRM8'Z)
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M$;N72&W#D,K7:\;%\V4#-]X>/ 2KM38/G.%@0U=LQO33YE["G9.ML@A"%JE
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M/FU)_;2UL_/K(UKYC(Z' :!.*O8D<<VI ^QK&Y\0J3__@-9&_C*SP$SC$4P
M,ZT-+U'G:,88F@K-4'=R7G=LD ]54C]4[93M^HC6+^&Q&NSLG>F$3*[BLS$%
MK0Q&:/+MG#W-SM^NXU.GPO,1OAACR_,K@B]&Q/8&@@9O;&L!?'@3'U4YN5')
M$>$ME2L@SXBS)1C8.N]"X<CDU"VYT6(3GT/-A=8BC"_7C,)7DA& ]TL!\4MO
MS ;9V>?P7U!+ P04    "  )7*U2G +)?JT(   F(P  &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;*V:6V_;.!;'OPKA+1:[0!*+%]TZ28#<=J= IPV:
MSN[#8!]HB;:)2J*'HI-F/OT>2HYE2R3= >;%UN60^A^*/+]#4I<O2G]KUT(8
M]+VNFO9JMC9F\WX^;XNUJ'E[H3:B@3M+I6MNX%2OYNU&"UYVA>IJ3J(HF==<
M-K/KR^[:H[Z^5%M3R48\:M1NZYKKUUM1J9>K&9Z]7?@B5VMC+\RO+S=\)9Z$
M^77SJ.%LOJ^EE+5H6JD:I,7R:G:#W]^SQ!;H+/XCQ4M[<(RL*PNEOMF3#^75
M++**1"4*8ZO@\/<L[D15V9I Q^^[2F?[9]J"A\=OM?^K<QZ<6?!6W*GJO[(T
MZZM9-D.E6/)M9;ZHEY_%SJ'8UE>HJNU^T<O.-IJA8ML:5>\*@X):-OT__[YK
MB!\I0'8%R*@ 9IX"=%> _F@!MBO NI;I7>G:X9X;?GVIU0O2UAIJLP==8W:E
MP7W9V/?^9#3<E5#.7-]]_G3_\.GIX1[!T=/GCQ_N;[["R>W-QYM/=P_HZ>>'
MAZ]/Z!S]^G2/_O'NG^@=D@WZ1585O+3V<FY @JUH7NP>=]<_CG@>=[/1%RAB
M9XA$!#N*WX>+WXOB E'<%8^.B\_!\;WW9.\]Z>JC/CEM*TP;J(CN*Z)=1<S7
MC+Q=(]Z4J+ 'XO>M?.:5:,9U]TW45Y5T5=EQ^7R-TR2[G#\?-H3+*&-[HR.5
M;*^2!54^K94VYT;H&M[BLVA-[9/8UQ,?/AUG>3[2Z+"*&$W=(N.]R#@H\JOF
MI8!X4*@MB(/84@AHS$4ESE EVA;Q"F(5;PJ!(.JA4FT79KFM]@7>=UWK[W_+
M""8_O8OAI^LL^PM1YO(WGGB29PD;N3LU2G,:N;U-]MXF06\_P'MHC-)2N-[#
M;;CP;_A_+F>2B<Z,Y73DC,,H8HG;F73O3!H>!5NMP1MD^'?$'4.KEY=.GDP9
M'G<MAQ%)/-T_V\O+@O(^F[70$%1[D7Z!V>39+,KQ2.#4B"91[!:8[P7FX:ZO
M#*]^0& ^?78>T_$;=EC%4>(9G3@:@!$%13Y <#.OY[4P:U6>BB.[NHY"1!)3
M,I+J-,MB3W?$!W##0:T?5;/ZH7BWJ^?X=>;)6*;#BD4^E0.$, FJ?-20QFGS
M>H8V%;<O'CAB$;*Q<M^B7E%LZVW%C2@AK8$4KY#<)D['X0['9SB*CR,>9F<9
M)DZGR;35683'/=UE1O/($_CP@$P<9N:'$MR32VEC.[P?PYN5M(?>?G][HL+?
MB#,<[DH=ZB=IGHZCN\LL8RGVN#DP%X>A^V^ERA=(F)S2I@1E>3J)-4ZS./4-
MY8&T.(S:3ZIY"S:0*@LX*@]B=]</51<SF\$P'-OQE)$D/L@(=OXXK&A&/>X,
M*,5A''X>:PWHG.*/I6S2)1Q6<9)[= Z4Q&%,]F$^(&X*/QQG&1ZGB$X[1HA/
MX,!)G 73XH\P)F4E#20E72?H0WX@3<8#X7 8<0<IZ$)I*"Z;57L&P[^HMB4<
M[^FW 3L[,51+5.VC>"D6YCCBT;,D38X#'CF+(G>\FQ*1T7C"HJD522-/YR0#
M-DD8FZ.T=L-?;=QSR213& )DQGW3944CSZLG S%)F)CW\EE"7"[#"J<<C,;R
MIB8$)\0C[V"^%D;EAZ90M;!!2(05NM$V%NFPBIBO#0>PD3"';HI";R&4@M2-
M:%K>+W# .-*B![@THG:.?#)E$,ZS>"Q[:D6C.//('D!%PJ"Z?T. %C GV3HG
M)'=DBB(23<:0PPIC[!M# Z](F%?'"7PU1"FGTBED,'!_'$1=9C@F'K:2 48D
M#*/C7/Z4UBEH2)),F]5A%N?$DXF1 4@D#*2/1P'6*= Q'XLI&X/=999BZGOQ
M Y!(>.;VN%MH7(A&+*5!:E')53>NW,WIF,'%9)S-NZS2Q)/-DX%P)$RX1]4:
M+8S4PJ;O/RQY2IV$3@:^PXAYYIQT(!,-D\F7!9[HL]0%H'@LV645)9X.00=,
MT3"F^DAP$@-T2B&,TWB\V. TBQ//N*(#K6B85I.$]%233GF4).EXD#FM?%DI
M/5C!#%.K#UBG%$[1D^5Y/%YZ<)CE4>J;S],!432,J#M5U[*?Q7= O5,P@VQ6
MHBE\>H/UV4V5]^V&%^)J!E/J5NAG,;M&KG7IOZ"B8Y\'Z-$P]*S/$/I:HXIO
M3A>G &/IF!Q.(U__'AA'PXR[*4MI(QKTFPV7Y;EL4,$W$OJ14ZACR3'O4O5C
MJ0ZS+$D]:W]T@!P],>O2@K=;_1IHR2F]SFW:PB;QPFD8Y9DG!Z,#Z&@8=%^$
MX7"I1(+KQDZ-G#JGX,IC'$]V$!QF$<T].3@= $?#@+LY6(KJEP=LHJO%VD+Z
M6<!TK77+GM+KG"63B8W++*;8TUG9@#EV8@+6Q;?'I?P#%,,\X@*U:PZJ554*
MW7:3Q_2G;MUM/-7=;8E,299D"1E/?%QFE%!/SV #\5B8>/T<''%CM%QL3;=H
M9E0'%PB"6E65G3W+!M(XT7HV=1QS,C8&MLN(>G(,-I"0A4G8-WZ@<1U,@U$_
M$><P@RS4DTZP@7WL3[)OOP;KD>O8G7.MT#CM_"LTS(+P^,J "1;&A'LOZ/9$
MJ:]K@8HU!X2BI58UNA>%J!<P0-XV6>W>OMVC;^T2C8V@T#9VWZT0VD8JM-&J
MW,+MPR4<N=O3>D6+K:S*SKX1+V^VJ.+;IECO&KGF^INPF6<-9V?=)=[L'X;*
M;=?-H0HA5PT2WWNU%P&TLH%?[,3^F7/!^/9$*=MFI=CIDY!_:@E.R.KU32RO
M[=K5'UVR?P9DA!->P6VU7+;@ZN(5&=OL/2EW=G:=RUZ]_?05)V1!4"TK&,>J
M$3:_[3.>4K0%#'X(NWRAGMUM,#_X%* 6>M5]4M&B;M6IWRC>7]U_MG';?=TP
MOL[8^SO&''>@3\&=V'DG@3O=-R#SX>']%R2_<+V238LJL00AT44*'5/W'V7T
M)T9MNL\4%LH857>':\$A-EL#N+]4RKR=V ?L/XVY_C]02P,$%     @ "5RM
M4L.%ZB^B @  !08  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R-5-M.
MXS 0_14KX@$D:"YM"D)MI) 6@02E(F7W8;4/;N*T%HX=;*>%O]^Q4Z( ;;4O
MB2]S9LXYMF>T%?)5K0G1Z+UD7(V=M=;5M>NJ;$U*K'JB(AQV"B%+K&$J5ZZJ
M),&Y!97,#3QOZ):8<B<:V;6YC$:BUHQR,I=(U66)Y<<-86([=GSG<^&9KM;:
M++C1J,(KDA+]4LTES-PV2TY+PA45'$E2C)W8OTY"$V\#?E&R59TQ,DJ60KR:
MR7T^=CQ#B#"2:9,!PV]#$L*8200TWG8YG;:D 7;'G]EOK7;0LL2*)(+]IKE>
MCYTK!^6DP#73SV)[1W9Z+,%,,&6_:-O$7D)P5BLMRAT8&)24-W_\OO.A _ '
M!P#!#A#\+Z"_ _2MT(:9E37!&D<C*;9(FFC(9@;6&XL&-92;4TRUA%T*.!TE
M3[/)=)9.)PA&Z=/#_21>P.0F?HAGR12E=]/I(D6G\_AY.EO<31?W2?QPAB[0
M2SI!IR=GZ 11CAXI8W F:N1JH&02N]FN_$U3/CA0/JYD#WF#<Q1X@;\'GAR'
M3TC60WW?PKVO<!>,:-T(6C<"FZ]_(%^JL29P1S42!;JE'/.,8H;F0E%[Z?[$
M2Z4E7+V_1XKUVV)]6VQP2#N#)P05"(+'B')1+W51,[C8F:BYWFMFDW!H$YKW
MN8E"/QBYFZYC>V*\JS;F"]-!RW1PE.E<0M>0^N,<50R#.9CGB+S5M#)6G1O&
M=5DSL"Z'%P3-!$PS=NU3T!0*.^S\T/?";QKV1 VN.DJ_J A;%>%1%4DMI3G:
M2DA[F'#$3/#5A2:R!-Y+O8]O^,/-_O!R^(WNSR!HHM_9NIU':AKD(Y8KRA5B
MI "8U[N$++)I.LU$B\J^VZ70T 7L< U]FD@3 /N%$/IS8EI!V_FC?U!+ P04
M    "  )7*U2O?JZ.[((   *)P  &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;+U:;5/C.!+^*ZK<UBY431);\NL<4 4A$,C"<!/8JZNI^R!B)?&-7[*V
M L._OY9CXD22E;!S=?-A<.RG6]VMEOIIV2>O>?&]7##&T8\TR<K3SH+SY>=^
MOYPN6$K+7KYD&3R9Y45*.?PLYOUR63 :54)ITL>6Y?53&F>=LY/JWD-Q=I*O
M>!)G[*% Y2I-:?%VP9+\];1C=]YO?(WG"RYN],].EG3.)HP_+1\*^-7?:(GB
ME&5EG&>H8+/3SKG]>4Q\(5 A_HC9:[EUC80KSWG^7?RXB4X[EK"()6S*A0H*
M?U[8@"6)T 1V_%DK[6S&%(+;U^_:KRKGP9EG6K)!GOPSCOCBM!-T4,1F=)7P
MK_GKB-4.N4+?-$_*ZG_T6F.M#IJN2IZGM3!8D,;9^B_]40?B$ %<"V!) +LM
M J06(+( ;A%P:@%'$B!VBX!;"[CR"$Z+@%<+>+* WR+@UP*^;!)I$0AJ@4 2
ML-L$PEH@E$=HG3CK?>8L6:3-;7LSV>ND6V=)E6*7E-.SDR)_187 @SYQ4>5I
M)0^9%6=B24UX 4]CD.-G@R_WE\/[R? 2P=7DR^\WE^>/\&/R"'_NAO>/$_3E
M"@W_\73S^"]T]'1__G1Y \^/41<]32[1T2_'Z!<49^@N3A)8(>5)GX-10G5_
M6AMPL38 MQCPF'.::,0&9K$'6'FL*%B$)CR??D??[ECZS(I_:S1=FC4-\C2%
MM;U7S="LYCR*?DO0 XVC+L1C0)<Q^&72=[4G+K!!EJOB;;]AUV9%7QF'G14"
M-:1%%F?STJ1KM,?)Z725]M 7OF %@L M>^CWO#1JO#5KG"QHP19Y$K&B_ T-
M_US%_,VD;FQ6=Y]GTSSC10[IF,W13<99P4K>9F$?5LMFR>#-DL'5&$[+&!=L
M'F<BDK"7)S2;,G0$,UX*1\IC1#FZ9-,>(O8GA"T[U*7V6K];Z1<U[^7,(?9)
M_V4[:55,2+S0JO[M0J]4* F(*T%W7"4;5\D'73W O8NU3F_+'H\XCK]K]4!%
MV1+D4H4X7K"+&:J8P'>PA+I245W;M@)+BOJUB@MM$DIVC33:7.))J%M=&&R'
M[*+&*HI81#]KSF;6G$J(M,S:3385FP?D)4Q5=74L]NAJ(U&6VE=8*@C8R2LM
M(M/J<#>#N\:4N0<:&,,B3)DN-5PU58GG2).@ [FN%-U#0&,5%.I#ZVV\\XS>
M53O?KW^S/>OOX"*0V(5@ER^L=KE_E,!V>/P)91"%?(8X_:&+@J>8U;4=1\K%
MT4&HVWVH'3?]C9N^,8,&M%R@*'Z)(Y9%)5#4:0*[6_0)+6'?KW8Z0Z8$FT$"
M8RSKPEN*M-1%*5 ]\^7U>@#FUHS9,3W<F!X:36_81ZOUH3)JRUYL6PU5L\Q+
M:[>XQ>_%34NZK(/'WZ**MG'\JE9W10,3H25]@\:*(U[0K*15>U1NUT$M#[,5
MFS#15C0-TC/5,[NIW;:Y>._S01M+3;V6]JS+&K-3SJ1*I5&#72Q[KNKI8BN4
M4MILT6YHFEIOFXO]PZJ8+B PI=BYIGL69ZWKD/QJRI;M?&15@0W9"]2J*K5H
M%D$''[%T>4BJ#>J1I&VQQ<"FM-GFVO8! [4Q4\M15TJ208WQ#)CA 7INS9A=
M_YOB9Q]0_;2>J56H+1N:$F3[QL&&663@V'>TZ"$<"A**+6T&^.H240BF!A22
ML&5/4K$D<&SCMM240MM<"R5G#W#PPE;KFN<2F1\,:IB19VLPCF_)6:>.%_A>
MH(1)U054V[9L"7BMT1<ZBKZ1!M8%5"#GNRX:EMP'C#4P8N.6V6O8@&VF Q_I
M"%NRU407ZDE2(:%C^?I<5;&0JY8I5W%#0["9ANQK"O7IBE5" EVA+[5#@QKF
M&0*A@:C9JADN"#Q?*MM7&EVB,0P#*7&N-?I"BX12^1YI8- :RKE_LR?"WVSM
M28HVA)C(.:Z!8>*VS'I#_K#]_V\J\=:9BYFWF=M*K.%#,-WR'.I0OMRV'X0:
M:U MK25N"!@V$[#_37.)56;FR8<O(RW(D[/4;.XWK,_2 U2/-: 6=H(;^HC-
MQQX_U;3BA@1B,PG<U[9B#?,*Y"..0T"W>T"[]C<D#IM)W &]*SZ8SN&&SF$S
MG?M(\XI5JM4V?L.PL)EA_6SSBC7,(= ?QZI(VT@3<4,TL)EH_)7N%:M<H$N4
MFAHJ=1#+%57#*7 H^Z[JZ1)/;D[VF+1[5-WP$F*NFA_J7\G!YR.D*9'$?#[R
MD^TA40\]VDQJRB8QE\W6CHVH]:N+I2IQ?0CH=@]HU_"M%P_FXF+N_LZ7T!Q9
M3L4V;1V?)J;CB?KE@@H)'4=^;5*_/E"Q)'"-BYHT=8N8CSW4WF^?>Q>UQIUW
M"\!WI./O@0:F1$&%.+Z\]#6@(+0L^>Q* Q.M'W%".:]48.C:KD1D1SI]CB>_
M+KC5!L/#DJ=C#0P[+;28"#:P>Z>IK\1<7_7D_6*/U'F:KS)>"JJ7K"*&8-VB
M.%W"OBYV,XI@9\OF@@DB.IT*J$B990'P>)FP'IHPANYSSI ]Z!EH#FGJ-3'7
M:SV[N]@C]>Y&E*,LYQMO9GG!XGF&IBO8'K/IV[IH)73]54WTGU7)12V#;9+S
M(GY><?J<0 R$$CUKZ(GNXC"5$*24%G'RMK%F3F/8D6=%GE9A+CDHF,-5U=,*
M8@TWGWKC'EJ",\ ?V:K(JPW\')06-(EI!@XFP"X1K73Q6F32J^]_JN""IZ_'
M*A@8!G4!/-J=V'Q55+ 8*L7:8+1@T7P]N?F\H"G05UKPF";@0#Z;E0!^?JMD
M1#? :C\.#O"6)6)L5C5LW93Q11YM6P&))BP=0*U:I<"?1XPF?#&%'1C=_H&.
MRO=TPQ?H6)MP_:UO4D#!O/ILJD15[JY?96[NKC_-&MF?;ZIO6J3[Y\3]/":N
MY@FL*7CB:9_X[]]Y]9O!UU^)W=%B+N8D83,PQ.KYL*L7ZP^OUC]XOJR^EWG.
M.<_3ZG+!*#2X @#/9SDX7O\0 VP^?SO[+U!+ P04    "  )7*U2G',!_W,"
M  !3!0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;'U4;6_:,!#^*Z=H
MTEII:]+ NJV"2 %2%:E0UL"F:=H'DQABU;%3VT#[[W=V0LJJPI?$=[[GN3??
M]792/>J"4@//)1>Z[Q7&5->^K[."ED1?R(H*O%E)51*#HEK[NE*4Y Y4<C\,
M@BN_)$QX4<_I9BKJR8WA3-"9 KTI2Z)>!I3+7=^[]/:*![8NC%7X4:\B:YI2
MLZAF"B6_9<E9285F4H"BJ[X77UX/N];>&?QD=*</SF S64KY:(5QWO<"&Q#E
M-#.6@>!O2X>4<TN$83PUG%[KT@(/SWOV&Y<[YK(DF@XE_\5R4_2];Q[D=$4V
MW#S(W2UM\OEB^3+)M?O"KK$-/,@VVLBR 6,$)1/UGSPW=3@ (,_[@+ !A&\!
MW2. 3@/HN$3KR%Q:(V)(U%-R!\I:(YL]N-HX-&;#A.UB:A3>,L29:'@_'273
M-!D!GM+[N_$HGJ.0SO$W2:;S%.YO(/FQ&,]_P]EB&B]&8[P_A[-9_(#7M\E\
M/(SOSN$S?  ?=$$4U3W?8&26W\^:* 9U%.&1*#HPD<(4&A*1T_Q_O(\9M6F%
M^[0&X4G"N%(7$'0_01B$E^_$,SP-GQ"$A]\=/#@13J>M<L?Q=8[PI888BF_?
M@%Q!:F3V6$B>4Z4_0O*T8>8%_L1+;10^ZK\GW'5;=UWGKGNLJ407D+,MRZG(
M-;[JC&-?<JBHJEL$9TQ +CFJ]:OV_+W&U9ZNG">[$K81%F1[6,I3%G7X_L'[
M+*E:N['5D,F-,'5/6VV[&6(W$&_T ]P8]8"_TM3K!CNV9D(#IRND#"Z^XKRI
M>H1KP<C*3<%2&IPI=RQPZU%E#?!^):79"]9!NT>C?U!+ P04    "  )7*U2
MB3X5HS4(  !F)   &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;+6::W/;
MMA*&_PI&[9RQ9Z*(!*A;CNT96W8:=^K+5$G[&2(A"RUO!2$[[J\_"Y F9 *@
MY"3GBTU)"W#?!;#/ N3)4R'^KC:,2?0U2_/J=+"1LOPP&E7QAF6T>E^4+(=?
MUH7(J(2/XF%4E8+11#?*TA$.@LDHHSP?G)WH[^[%V4FQE2G/V;U U3;+J'B^
M8&GQ=#H(!R]?_,X?-E)],3H[*>D#6S+YI;P7\&G4]I+PC.45+W(DV/IT<!Y^
M6$03U4!;_,'94[5SC92455'\K3Y<)Z>#0'G$4A9+U06%?X]LP=)4]01^_--T
M.FCOJ1KN7K_T_E&+!S$K6K%%D?[)$[DY'<P&*&%KNDWE[\73)]8(&JO^XB*M
M]%_TU-@& Q1O*UED36/P(.-Y_9]^;0*QTP#Z<3? 30/<;1!Y&I"F =%":\^T
MK$LJZ=F)*)Z04-;0F[K0L=&M00W/U3 NI8!?.;239XN[V\NKV^75)8*KY=UO
MUY?GG^'#\C/\N[FZ_;Q$=Q_1XGSY"7W\[>[/)3KZ<GO^Y?(:;([1$'U97J*C
MGX_1SXCGZ(:G*8Q,=3*2X)CJ?A0W3ES43F"/$P3=%+G<5.@J3UCRNOT(!+6J
M\(NJ"]S;X7DIWJ,@>H=P@$.'/XO^YC<4FN.Y;A[TN$/:(!/='_'T=U<R027/
M']"YFK5<<E;U=!NUW4:ZV\C3[2VL<I['1<;0BL&*9HBF:1%3O3YD@?("?LRE
M*&!<X-X\ETRP2CH'J+[31-])+?W'LV@VFYR,'G>C9AL1,HE:HU<BQJV(<:^(
MZUK 6A092GBE'.;YEB6HJ(,&$^H_/\UP&/ZW^9>#ZF*-)/WJTE'?;+SCXKPC
MPK:8S4*WADFK87+H0&@=C0@5=*/B^\=H8GD>S:;3CCS;"$<SXM8W;?5->^?O
M>?(79")(WK)2/@L&+L<\92C_QAFH?X.V,:TVJ!3%(X=UCU;/+^$"6]JNE \]
M2V76*ICUCM E \C%O':,Y@FB62$D_U=_X8KUS ICB'%W/3B,PLG$'>MYZ^F\
MU]/SJH+ / DNV;!8KROM+<]*RH4> )>S<WMB=%UUF'@6;A@8= 2]KOX"50*"
M>,+XERG3H86%N8"YOLV80)\83>4FIC K?OT#24'SBFIVOT/-&M;##Q/DD3UW
MTWZ#C<!R.^@(<Y@,/4,0[D QW#-=UDP(F)*095C5LZB=3H?VM)AWLY##:(8]
M;F/C-NYU>[F!8 ]559/H08%JJY[Q[*NZ9DYOL>WM%'>]M8W&4X^W!HHAZ?7V
M@N5LS24J4YKKZ J^VM:IDBN78U95:I8TSH_J1./40.PY0*:D*\)AA:>^N6(@
M'/93^$YN8+)3DR+U]':Z&3D<F(==-VVK$ <>+PUEPW[,UE[&&YH_,!U?JO),
MG5U23E<\U;FV79HT_F?+*UX/AS)*H-JN))=;T:U=&G$V5X<AP5T\.<W&X=BC
MSQ XW(_@@VCRUL7L@.Z86$G(0=UP[!-EL!M.?Z0H3_GDE#7=6R>Y3*8SCR3#
MX; ?Q =+<GIM Q<&8]9UW+8B(?&40*'A<CCO+8*N<[T #BWBL<$H[L?H_5;
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M(.IAX=O]B.+:^RD^P%#P/N3 6_@S%\_X2BY!)$Z+_>A-W74.[,M$"2KN8^!
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MZ\9@/HX:X'>Z5=@\T #MC>XW_PM02P,$%     @ "5RM4BA*4H!T"@  Q1P
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MF'!H$WP(38/* XU2"-,/DZN)R @U;#>0I695 V:9AT84I0Q(G7B]%!T'-O4
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M:1/PU?19A9>E&XG);"BFDVGRC+ZC-H%'K._HNQ)(N;A3.6?J,B9 (Y__NEQ
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MTY!D,/@*K"H-F""'%7PTX./P4^G7[".@0<5$&B_KJFV@F=*35YE"\(6%&Y;
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ME:<%>%\ZB%!W0P[V_RJX_#=02P,$%     @ "5RM4D@8N#0=!   2@D  !D
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M#BS#"B'R/6P]T[HU82VWKHX<N-'['1HXPY'ZY+>B8%<%XZ,:T-/V=4#7MWY
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M^FPBQZ4[E!NK:9=3GEU\LA5J^, EDP5G M:R.VCJV"RT5,"%A44/MNK XF?
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MAX,(3-UJU1.GR]#>K+6C9BG\YM2=HO$"M+_1VNTGWD#;[\[^!E!+ P04
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M!!X#K ![SKGJ PP:T(^#4;3"&E<7H]H95Q!](:?+#@C)6BY-,I*."@#'OF1
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M?SM%(]9AA10!;9#4A[77=%_ICV#^3;H4=(BUW2-\KD+"XI0W#AL2#T?AR!P
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MB9J_T+FN%F I:(5@#_ "_<1 ^7 V.2SZ -K.LQ57A6/MBT>'H<YFOG"Z,PS
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MBW#2[5GYY$9NT$SR#-<1?I*]9GY /G"^XUEV-7IVHTKQV1,Y/:A7XAEXO'#
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MK<RTT8K-G6YJX2)B$!1>])G/7DZ^<F<=L&*+#V![[(>+Y-CM.KJFY-YQ[HN
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M<VAE971S+W-H965T,C$N>&ULM5IK;]M(LOTK#6]VD0"T'M1[G 20%&=B3/R
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MGYYXPVYW;VZ$B)9)H/9>I5QQ.%-Z9\J-G-!Q7"3ZA],:7DIY!T+Z\O;LTS'
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M">M^L>*^Y";E7XFL3 [O\L>MDG <+<#SM4'O6'XA!O7/AC[^'U!+ P04
M"  )7*U2A0K.>;(,  #B(   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6RM6MMRVS@2_164=VHKKI)E2W;LW*MLSV4S.TZ\<3+SL+4/$ F)&),$ X!2
MG*_?T]T@12FRD^SLPS@2!33Z<OIT-S@O5L[?AL*8J#Y591U>[A4Q-L\.#T-6
MF$J'L6M,C5_FSE<ZXJM?'(;&&YWSIJH\G!X=G1Y6VM9[KU[PLVO_ZH5K8VEK
M<^U5:*M*^[L+4[K5R[W)7O?@G5T4D1X<OGK1Z(6Y,?%#<^WQ[;"7DMO*U,&Z
M6GDS?[EW/GEV<4;K><'OUJS"X+,B2V;.W=*7U_G+O2-2R)0FBR1!XY^EN31E
M28*@QL<D<Z\_DC8./W?2?V;;8<M,!W/IRC]L'HN7>T_V5&[FNBWC.[?ZATGV
M/"9YF2L#_U6KM/9H3V5MB*Y*FZ%!96OY5W]*?OB6#=.T8<IZRT&LY8\ZZE<O
MO%LI3ZLAC3ZPJ;P;RMF:@G(3/7ZUV!=?7>A@@W)S=>U-,'74XJLZ5S=V4=NY
MS70=U7F6N;:.MEZH:U?:S)J@'G6?]E\<1FA"\@ZS=.J%G#J]Y]1C=>7J6 3U
M4YV;?'/_(2SHS9AV9EQ,'Q1XWOBQ.CH9J>G1=/* O./>+<<L[_@>>6_]0M?V
M,WMCI"Y='6!LOG;.AK?@O9]MK>O,ZE+=X*$!:F-0_SZ?A>B!N_\\H-%)K]$)
M:W3R/8':Y?G_08SZPRBD=*.]R54L\(/*'")3!WS/>N/Q9=[;&=9VVIH6$4'8
M> ?\QD)]&-^,U2_GY]<CWF]#Q$I:J,L2\(W&DPRHT" [@^R)A</!NFE*BY.P
MUK6>XGFD*/_4Y.C@GR-E/F6FB4H'E=N0E2[(TC<N&C6Y5&-U'E1C2!-2MX41
MGBQ2-S]=XKB/K?5)::B+C:1(A1\:YPG=T-;X""K#SR[6$ I?>>4@P0]LM[6P
M(;FNT$NC9L;4 Y?1%M%@K-ZS.^_Q6U:VN6&?U"2P9&QYD[7>4Z[I_$\P@"R.
MA8;9WH@_81;.J4UF0@"7LC5DYEQ;OSZ"X@P?@Z!"OZ*S&4ZR+@\4=\)!4G7#
MM*0?.S@6@$T7AW^I4+BVS&&WHDJ0$/!G6PO5IG":;\ .&:S!+E6CZSNR69P^
M//I+&"#,[\S2U*T)A(B&O(Y/.@231)96SVQI(Q$5&$PMR4EYRUXU.BO4QU9[
M.((\1(K>&>W9 :@)SIL1/^Q<1P*C-W4>Q!,4T,Z-.XVJ]!W9(>YI^D0#4/@X
M@GD?L!;!E].OY_:S\7__VY/IY.PY @9\0VQ2] #'\Z;0SA!^JSV9AMKL-=,R
MZBVA@F5R\B%<FA-=IXWT2RR\,:H2[C7$O>IG,_,M>6?Z1-B3-ZR?'O/3HU$O
MAZ5O:/&M1X&D;:E.!L=<:8]83)_*&6-UT0;P54!R([RE:QC$7+@EE!8PR3:Q
MU 5)(K,+UC?00_CA_#Y6(5UXR72LWA*;+$TU SHFIYWU*P)SU90F"D6JT-CZ
MP,W%:,%Z-8-6746@8SXT?[JB7EO%>7%U5P*0T9&G*O6[U=';,"9MD.^YI?V;
M%#-2H;-@>K'; M;Z1[ !:SV=]%H7%OZ=@V#805L(8PR+QCAQ;GV(P[R@*(W2
M'K8RZ;KEB$ALN[:;'K&)![]JY#06EZ6>.2\+FM:'ECH*V(\?]0(@X2 +1:P=
MGV#'Y\+W**-UF!M/K.=-R8MM#0J(CB%(RU(R@'*$+%=(9H6:%K^N%K3I X$"
MHA.JA ;66&M<L'T+T &/8KT^.1VU'?D.)/>K0-3>@[:K;XYZKM9LV$8)1A5C
M!]*O\<0?R ];12I(C<+:R,Z#Q: ZZHT93E1QN& ,^AXPFF^SV'HS?J!_>=SW
M+X\?;#S>H$$?M)%HD^I<>Y!"[IJXW0-*)_.7!!+>"<%(C%]US5PF:3'A9-9I
ME48177$%2G)")T<:!& =Z-.?!%*FM(QUJBJI49"&1%#G.,:+%@6OSDP/U/0<
MG8UW5'M2Z^%UBA2)1T1=EM*=%E<&=2)WI5M(<4<IR-I2N'ZM%5=*2J3-JM[#
M#:V$0Q??Y2:F%4DA.G%8(NF$KH+,N$/,[1QK#<P(TAB0FWK+=!F<"F#C$A,"
MI5_JXQ+Z!^XDR7,D;X;^H5.9M#.U$'E6Z'HA9K!2>L4=EV<?T\*L1)'A0W9(
M9EK0V2#I)2O9*PBE:0[:IBL-)'_6M;\+Y_*5+4LQCM'0$QA6]);F-N=2SFV>
M7K>N4HF4$S;^CF[YH5PZ[7/I]$'H7[+3R*[A8(;F)K,@YEVI]%?DJ==UXL&=
M!6(CF;)>TB!232^)6!\]@5 =\*5G>-C0''F7>O5^<*"UMJH,FHQHRKL.RI\)
M Q$ZD%<72,#4[SGT?O@(!F=L>%>E!*B,#JWOVV&*5I/N%&@C*!VM74QC@6I
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MX;",L@OP_TI*LR/L ?V7K(O_ %!+ P04    "  )7*U237JS@UH%  #+#
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M_GIA?:/HA73-H15-PG-T>/C=;+6#Y?-9X^!D-"*<<MY[2[?M3JL* C!R7KN
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M(4K:A)-C>'"Z]*>UN78X^_G;%0[;PI  OB\T^*E^( /M\?W\'U!+ P04
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MH%6UD?K#JL*?^ MEZ?[@AQE=V%"[!32_5,1T^^$<-%? R4]02P,$%     @
M"5RM4I#HUQ2& P   @@  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
MK57;;MLX$/V5@5H4$I!&-[MQLK:!.&VQ 9(V2-+=AV(?:&EDL:5(EZ3LI%^_
M0TI6'+3)%MB^2+S,G#-W3K=*?S4UHH6[1D@S"VIKUR=Q;(H:&V8.U1HEW51*
M-\S25J]BL];(2J_4B#A+DC=QP[@,YE-_=J7G4]5:P25>:3!MTS!]OT"AMK,@
M#78'UWQ56W<0SZ=KML(;M)_65YIV\8!2\@:EX4J"QFH6G*8GBY&3]P)_<=R:
MO34X3Y9*?76;\W(6),X@%%A8A\#HM\$S%,(!D1G?>LQ@H'2*^^L=^GOO._FR
M9 ;/E/B;E[:>!9, 2JQ8*^RUVOZ)O3]CAU<H8?P7MIWL41Y T1JKFEZ9+&BX
M[/[LKH_#GL(D>4(AZQ4R;W='Y*U\RRR;3[7:@G;2A.86WE6O3<9QZ9)R8S7=
M<M*S\UMV!Y?,6M0&PENV%&BB:6P)V=W'18^RZ%"R)U!RN%32U@;>R1++Q_HQ
M6328E>W,6F3/ IZN]2$DHP/(DBQ]!B\?W,P]7OX$WKDL5(/@O'W+32&4:37"
MY].EL9H*XY]G*$8#Q<A3C)Z@N*%^*5N!H"K/<Z75AKO:C<,%2JRXC8#*\*.M
M4<.9:JB':E?<&X3>NO!"F9]'_WEF!Z8D2FMVW.L'[N4>M_+<Q2-N[KGC4#AN
MMQ-MB2=P6VO$1UF%\/+\XN+\XX>;""@]7 "EYY+IHH;L^ "H1Z@#)-6LUBB+
M>Z# 2B-8UWOE%RKEQIEX ))&3<@B> E92I\P&QU%\$G22!'\._'42I1<KF!%
M(\5TAE%1.OM+U'S#7!M#Q263!6>"3*8<MGO8XV,(TSR/X!H+P8SA%2]^, -H
MGD'H*:*XH]@Y7]+" W6A@7P$Z1B.<T)-)[]H*=LP+EPWO2:>UX9161BDT'#+
ML3<S32!\\]N,#/,D@HR"2;]P_!^P&BDO!&$5L$9IR[]W,E0]E%CB-*@WO$ J
M%4/B3)9=Z?2Y2QU'FD9]+;]Z,<G2[(_A_W#_OTKQ)4Q&KCSRB8-C'HW\9]2W
M4MD.U\7!Q:CZQ>+K/'<I(]>YW.#NG(+))0U!Z56HJDR[-+SD3%.^P-;,PA:]
MB/1A<YFG+8U_+KE%<7_XLPD2[\WE!O7*OSZ&O&ZE[4;T<#H\<*?=7'\0[UY'
M:K05E0$(K$@U.3P:!Z"[%Z?;6+7V4WZI++T9?EG3(XW:"=!]I93=;1S!\.S/
M_P502P,$%     @ "5RM4@+:@]0M!   _0@  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&ULC5;?<^(V$/Y7=CQ]@!F"C7%HFB', )?K<<VO.9+K0Z</
MPE[;ZLD2)\F0]*_O2C8^TDER><&6O/OMM[O?2DSW2G\S):*%QTI(<Q&4UF[/
MP]"D)5;,#-46)7W)E:Z8I:4N0K/5R#+O5(DPCJ))6#$N@]G4[]WIV5355G")
M=QI,755,/RU0J/U%, H.&U]X45JW$<ZF6U;@&NW#]D[3*NQ0,EZA-%Q)T)A?
M!//1^2)Q]M[@*\>].7H'E\E&J6]NL<HN@L@10H&I=0B,'CM<HA .B&A\;S&#
M+J1S/'X_H'_TN5,N&V9PJ<2?/+/E17 60(8YJX7]HO:?L,WGU.&E2AC_"_O6
M-@H@K8U55>M,#"HNFR=[;.OP'H>X=8@][R:09_F!63:;:K4'[:P)S;WX5+TW
MD>/2-65M-7WEY&=G\S2MJUHPBQG<VA(U+%5%[2U=W7<(5\J8 5P^IJ+.N"S@
M1LE42:N5$&ZYDA8U&FN@=\\V DU_&EJBY<##M*6P:"C$KU 8PS4AE@8N98;9
M<_^0TNERB@\Y+>(W >=;/80H&4 <Q:,W\,9=C<8>;_P*WN7WFMLG^&N^,5:3
MC/Y^ S/I,!./F;R"N:;IRFJ!H')8EDP6:(!+>$\[7JKPV\'N2X2<.J;VKF?-
M_/%_*2)%@+2)/@!)1P"QL>QQ\'\JRE-)GU$11 7.X8:\'B2=!X(0,_B=S@$3
M]AQ/$@,L4&+.+=P))DDCUZNKJ]7MS;H/-%(T,!*6M=8HTR>XUV1!T=RHSK-_
M2/DT^J2K#ZCYCKG1A8]<,IER)DAVU(FZ,9CO&!=.>R>$>;)F5-,UIK7FEE.&
M=YHK31MZQU.$WE*15OOA4F/&R9?)0YE_5O@5R;[")C%*BU$^*0Z(78K5AJS'
M(R^W"'JL#[] [W20G$;^+8G/W',TFM!O<AHW7\<C^GK[0EEY&TCX0+U-'Y(D
MAO$9(8^2F';&XSY,DLD/#B1W+J"5>X,>16=-[.813]PC&?WF]P:32=+W/.>5
MJET)*2:--WHY\&I+$G="8*TTG!A8FCI3)Q^*1DW8"AQ269$.!(LP6@X]U0-@
MID JV^'F;;/30[/M4;/94;.9M9IO:NO:"=:!/#MM^.&T&7;Z^2DDT75J%T\=
MF\))%'*M*I\P*0EE06_2A7 #0)L/PS^&L*5DL@%@K957RKQV\R\XDY2@$$P#
M\UBV=5D/V_V!-W?SU,32V B+,GI>8E5K;\;E#AO"0,="T919%9I5 ]@R;4GS
ME(#*<T/&FR?O(_R(-7F\N\!'3%QL]"?;286V5-DQ"VJY8[I4DDX+TN@GFF];
MIDPC?/X*/7-H?+R _O"EXS \NI((H/ 7KP&OHN9VZG:[NWW>7&D_S)L_!M=,
M%ZZ* G-RC8:_G@:@F\NV65BU]1?<1EFZ+OUK2?]/4#L#^IXKHMHN7(#N'\_L
M/U!+ P04    "  )7*U23P1_E3H1  "B2@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6SM'&MSV[CQKV!<3\>:H6T2?$F^)#..D[MS)[ED[%P[G4X_
M0!0DL4<1.C[LJ+^^NPL^0)&BE<?UOOB+!%+ 8A?[Q"Z@%X\J^RU?2UFPSYLD
MS5^>K(MB>W5YF4=KN1'YA=K*%'Y9JFPC"GC,5I?Y-I-B08,VR26W[>!R(^+T
MY-4+>O<Q>_5"E442I_)CQO)RLQ'9[K5,U./+$^>D?G$7K]8%OKA\]6(K5O)>
M%K]N/V;P=-E 6<0;F>:Q2EDFER]/KIVKUTZ( ZC'WV/YF!MMAJ3,E?H-'VX7
M+T]LQ$@F,BH0A("O!WDCDP0A 1Z_5T!/FCEQH-FNH?](Q ,Q<Y'+&Y7\(UX4
MZY<GTQ.VD$M1)L6=>OQ95@3Y""]224Z?[+'J:Y^PJ,P+M:D& P:;.-7?XG.U
M$,<,X-4 3GCKB0C+-Z(0KUYDZI%EV!N@88-(I=& 7)PB5^Z+#'Z-85SQZL<X
M%6D4BX3=IGF1E;#@1<[./HEY(O/)B\L"YL">EU$%[[6&QP_ <]E[E1;KG+U-
M%W+1'7\)N#4(\AK!UWP4X/4VNV"V9S%N<V<$GML0[!(\]Q#!(L[8WT522O8F
MSJ-$Y64F<_:OZSF0#S+R[Y$YO&8.C^;P#LQQ#[JS*!/)U)*U"WR=YQ+65J0+
M]BX6\SB)BQAF?B\%HK!@UP4SD/L $LON9%1F69RNV&N1Q_D0.\8Q.7YVT9E=
M#<Q.8XT^/\<R$UFTWEFLS+&78.]%]AM8DNOM-E,B6E]!*XL35G&/O9&1W,QE
MQER'WMCL[/WMNW>W'WZYG[!/J@ TW\D'F3"G^N8'WK9D"2+KBMVO55:<%S+;
ML#A]D'FA!?DF@0[Q,D8"<R9_+^-BQW*D2Y/_&!=KAM8L3G:@S#@>0(/LLR42
M^H"$ G20:;D#M2/JEF6ZR-DI<RR/A_#]U[],N<-_,-[X0?<]/G<Q$0\B3G">
M<S"LY[F "1=R7ABH7;&?U(/,4J2#5AYL9!KM*J"I2L]_O;B_8('E!+-F*OT4
M6J'3OM-/8\ (D&-QX% ]2#_-IKQY@^T;E6U5)@I),%2Q!E;.;*,/M!W+MJ<&
M''R:6GS6]M)/,RNT6R3UDV9V/LS*68<J_>38%@^#=C;]^($00]DE<K7@OY%9
M_"#0!30R<YO") "?$4D1V"TT #GS&X ^<PQ:I@P< 9CYE,G/T5JD*W.0.VV1
MPS9WO>89VYHV-82:.VN[8IO[+2.P_4ZEJS](M-F9F##7<K@+G[87L#!DW)H"
M+[@5PE*Z_(\27(.5K.5@\+2@!D;O@#FFT$)[2$3KWX_]#GVSZ7!#!*"M&9D,
M\@16<C:M5M+Q.2SBS VJI70"NY),6(.O%TZ#7F@Z3M@B!^T1 75L4U&"CI1K
MFA;[6 "]!GAH.YP;SQQCAC(#2VS.<S:?L)"W<V$[F+DMTZ!M*D-_-:9^VQO;
M4Z?5#VSKT55GL+H>6#T?&GK=X85C.6 <Z!<>3J&A.4"_^+9CN(^D=857>W;#
M^,GD3V?$R'+#I.ZLXP7T,\[?\0WP/&0;S.EQ9&M+9C2F81ZT>V+UC;A[AD'"
MMC]KY\?V ?:9LQX'PAQQRD*P-N;2Z&=@IFWON5E\@Y:KM8Q]^P>QUZD33"%H
M3A**_^E5-R!!&W'JS.R]3OTXY1%TD:UEL@!U9ZB661P58!$A8LYAP< 6,KG9
M)FHG)9O+5"[C@FT3D>87I ^W:924"T JB9<20-1:LU5)'"&RXZ#)[J'E_+T4
MB3;%AV;[M)8,XA.9)3L,R;1Q(M--V@)3 -=RD]D"*-.1#3F'=@4M]KB.HS5U
MB 0$@CI*;+V'I7V,%A^"W?X&E$1JE<;_E427EM"S.(W41DXN86M0TJXLK]T"
MQ%5G.9#SBP)KY[')Q4@8[C=AN/\58;@9_<)LWQI_CZ* >^JK?"LB^?($-LVY
MS![DR:L;6$SB3N6#40J!2S'L,0$-TSO7<745>8JOB:N;V31=;YN)#&*!K75H
M_87=A]>UU4L,#BRT,2#_"!7DH#%QX*AI9PZ6V[=<#V-FSP8#[>&;T')<%]_X
ME@^-$7$(&G$(1L7AUG#4\UT3UT2"D/BTV\HA_H[#1'5;JB11CTB<3FV S(,5
M*;-.9  31MT)"YCPRF344SP]L,5Y^PV17W?+<OUD;->)W7\&FW5>J',0#_QY
MU^O,+6=J0]Q3.[@#!)!;GL[(8=N6YX8' MZO)?2T"G!/J\CV"#*KL.])"ET'
M!)5]) <K!WP0*$JD((9#'^#!"GMNLZ,=)!%1#68!?7L0HVF2SS>R6*M%IZ<3
M@%IP_)KZP6A,2M;E(!Q8%-@T\6G5"'B?Z$CD:X( ZUF-"= APR8'9>CZ@%_M
M"; %$U=N<-/?3\-XU!U@9..SP&^0Y_N4D8G>$=A5NS] ;FC_>B?)NL([DS;M
M[+3/S<'-@L?-D3N%RL;<2]C8D_!H]]);M/M&"(:,RBC@8:=Q7737V"(30P+9
MTDPF%>Q1K-#!@\?"903T]N4VSO,2O7F4J3QG"X@-,X@)VJ4%WQ]U-E++QLQ#
M\%+$14G.VXP06B3.5YE82!V*U&%&B?%B9GBY:J$HS,#A(J_L:/ZT<_N)L/XU
M!;%(*,!XWP##$(/]4XHLG_2[F;9V@[X'7]Z@?OXD@"S020B2<M/1_0,,# "$
M"!M6IO[RCQU]A*$9W.WJ4-?YH?IBS9X9%,_B]HSV$O!QYGL3>N?0)D<G?TY9
M=]<16OX,.SLNFI4S&A%:(?='=MK-U'5F:-IN@<^<";T)JQR1L1W'N-S;Z^C8
M[H&TD<W:7=X,>IF))#-]!/OGO732DV;Y4[S!I=ZJ/*X,H)[4XVYO"GSGSH :
MV*';C$_[/?#=E_$)W)D7#A"#;_&30X3K&!OP_D:\2P\YQH"2BMPGQON3ZJ4;
MZH;OXK9RYI$WQ98UFSG$]BD-J/H[W!L+I::-Z9L>;?H&I'S<^(V"?C9^S\;O
MV?@]&[\_P?C-&N,W&S5^-X9:&\HW; IQP7HL>X,DCAO)412>C>2SD7PVDL]&
M\D\PDH[='BRQCXX1M?S3V0.M RIE;3KN"5/XQ#S=%%R5!\AUHE$D49GH=!M@
M@:_JG",\EH;>KQ#!R66BL2O6HF"9A)'XH/J)'3.C>3"W8NFL/H#"B3-)4\.
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MLAN0OY+2'!;60/]/,_L;4$L#!!0    (  E<K5)J>O3)60,  $8'   9
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M1*;\(:7\DNO,_7BQT#F&"O=Q+07& EZ YTL-IJN^L(+ZUZSW_P502P,$%
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M2QV['*[I$4;M#&A_J91]GKBV73_KHU]02P,$%     @ "5RM4D$,/*4/"P
MN$<  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULS9Q;<]NX%<>_"L;=
MZ<0SD47BSM3Q3&SO3O<ANYYXTSYT^D!3D,4N1:HD96?WTQ>\1)"( TB*:#<O
MMBX'Y#D@<'XX?T*\?"[*WZN%4C7ZLLSRZOW9HJY7[Z;3*EFH95Q=%"N5ZV_F
M1;F,:_VV?)Q6JU+%L[;1,IOB(.#399SF9U>7[6=WY=5EL:ZS-%=W):K6RV5<
M_G&MLN+Y_5EX]O6#3^GCHFX^F%Y=KN)'=:_JSZN[4K^;;HXR2Y<JK](B1Z6:
MOS_[$+Z[C433H+7X1ZJ>JZW7J GEH2A^;][\/'M_%C0>J4PE=7.(6/][4C<J
MRYHC:3_^VQ_T;'/.IN'VZZ]'_ZD-7@?S$%?JILC^F<[JQ?LS>89F:AZOL_I3
M\?QWU0?$FN,E15:U?]%S;QN<H61=U<6R;ZP]6*9Y]S_^TG?$5@-]'+@![AO@
M80/J:$#Z!N30!K1O0-N>Z4)I^^$VKN.KR[)X1F5CK8_6O&@[LVVMPT_SYKK?
MUZ7^-M7MZJOKN$HK5,S17:DJE==Q=S7R&;I/'_-TGB9Q7J,/25*L\SK-']%=
MD:5)JBHT0??=6&E:WRSB_%&A--\Q+=,\25>90F]N51VG676N6WV^OT5O?CA'
M/Z IJA:Q/FW3['.>UM5;_:%^_3'-,NU%=3FM=82-G].DC^:ZBP8[HB'H8Y'7
MBPK]F,_4;+?]5/?,IGOPU^ZYQMX#?EB5%RB@;Q$.< CX<^-O_C'6S7'4-@^
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M75UDJHE56W\76"J+-PL_W.#E#[0SP/V54O9QXJX7S75R\A=02P,$%     @
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MU&:]X"J %!>L%/9>K7_CMAXO,%'"^%]8;W.C )+26)5OP:0@Y[)ZLK=M'_8
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M)>GUPGH/!?X^V?JMYBRPOC&QOL!L5Z5*3)S6:33&[,ZTL0=X Y4/ZR"?4=*
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MZ1O\X/"-NS'R]JJ+^R8,]YKA&,=AA6;X5T-,B:JXPBD61F;N4F,IC9&I>TR
MQJ L ;Y?241=+JR"ZB)M^C]02P,$%     @ "5RM4@2S2NM_ P  Q L  !D
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MWO5$9U"4DVJY4#RWH]B6*SW8V<=$3_<@C(%^O^=</2U,@/K_PN)O4$L#!!0
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MX-L]&U>>C9V>]93&XN?,;?#1_VH+;MSRW)\V@FN+A!W!3:K@)DY?_A8DDZ3
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M(B<=U0PT,[Q]LW,3Y=[TVJ\G9CU:]SIM4E_<=!]&T>'!&*7%'2 J"JAY6-_
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M2_!+<U%DB9=+850"2:/ 3H8ZT#R$3GHJKSU^@O"0'Y<5QL<8VE%-W+E9RGW
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M0J4Q@/&E ':K&[- ?4 X_0]02P,$%     @ "5RM4FYH2N5#!   0@T  !D
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M]I!.G2X%>_EB5>XE[%Q9$L3^<4D[CMHMH/F4-.K+BW-0?39-_@-02P,$%
M  @ "5RM4HW0!YEU @  UP4  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&ULA53=3]LP$/]73A&30-J:-&UA0VFD?C"-!R8$8WN8]N FE\;"L3/;H?#?
M<W;2K*"V>TG\]?NXL^^2C=*/ID2T\%P)::9!:6U]&88F*[%B9J!JE+13*%TQ
M2U.]#DVMD>4>5(DPCJ+SL&)<!FGBUVYUFJC&"B[Q5H-IJHKIESD*M9D&PV"[
M<,?7I74+89K4;(WW:!_J6TVSL&?)>872<"5!8S$-9L/+Q<2=]P=^<MR8G3&X
M2%9*/;K)=3X-(F<(!6;6,3#Z/>$"A7!$9.-OQQGTD@ZX.]ZR?_6Q4RPK9G"A
MQ"^>VW(:? X@QX(UPMZIS3?LXO$&,R6,_\*F/3NY""!KC%55!R8'%9?MGSUW
M>=@!$,]^0-P!XO> \0' J .,?*"M,Q_6DEF6)EIM0+O3Q.8&/C<>3=%PZ6[Q
MWFK:Y82SZ0_V##?,6M0&/L%WIC5S>873)5K&Q1DM/MPOX?3D#$Z 2YAS(2C]
M)@DMJ3N.,.N4YJU2?$!I!#=*VM+ E<PQ?XL/R75O/=Y:G\='"6>U'D T_@AQ
M% _W^%D<A]\P@L=?/#PZ8F?49W+D^48'^*YEIBH$E] E-YE0IM$(OV<K8S4]
MUC]'),:]Q-A+C ](7!4%^F</EE3HIA"HCNE:O'*A5049Y9C+ALLU4*6[RSQP
M6<>5AN-!''W8E]3_X.+!^7O<FU G?:B3HT1W6#.KN??OHQ6<K;C@]F5?,"W7
MN>=R?>LI'4Z2\&E7/]RID0KUVK<.0_EJI&W?7+_:=Z>9+\IWZW/J6FV3^4?3
MMCQZ46LN#0@LB#(:7) MW;:1=F)5[2MQI2S5M1^6U'E1NP.T7RAEMQ,GT/?R
M]!502P,$%     @ "5RM4M3/=L>K!    0\  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#@N>&ULQ5?=C^(V$/]71N@>0#HV) $65BS2+K3J25UUM=MM'T[W
M8)(!W'-LSC:P>W]]QTXV?"2DI_:A+Y X,^/?;SQ?GNR5_FK6B!9>,R'-;6MM
M[>8F"$RRQHR9*[5!25^62F?,TJM>!6:CD:5>*1-!U.L-@XQQV9I._-JCGD[4
MU@HN\5&#V689TV_W*-3^MA6VWA>>^&IMW4(PG6S8"I_1OFP>-;T%I9649R@-
M5Q(T+F];=^'-/!PZ!2_Q!\>].7H&1V6AU%?W\BF];?4<(A286&>"T=\.9RB$
MLT0XOA5&6^6>3O'X^=WZSYX\D5DP@S,E_N2I7=^V1BU(<<FVPCZI_2]8$!HX
M>XD2QO_"OI#MM2#9&JNR0ID09%SF_^RU<,2/*$2%0G2F0!O7*\2%0GRNT+^@
MT"\4^MXS.17OASFS;#K1:@_:29,U]^"=Z;6)/I?NW)^MIJ^<].ST=_8*#\Q:
MU :Z\$QAE6X%@EJ"^_*HU8Z[(P[:]RAQR6T'Z+!^LVO4,%,9A=K:Q< .X9-,
M5(;0_E49TX'V'"WCHD,V7Y[GT/[0@0_ )3QP(<B<F026P#L(05( G>5 HPM
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MV-7Y?2M_L6KC;R +9>D^XQ_7=$=%[03H^U(I^_[B-BAOO=._ 5!+ P04
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M98#J%BL!1G1(]%)LG=FR\Z%RG.)#VM]R*Z1HZFLV/KZ )]\<S*P7UI]$[N#
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MPJ.<O0CE7%X$L41AKA"+8ZJ+]4-,?&W&L,&6/,;T1O@4NIGH0]P-8"%O&.L
M<B8O@DBF$E?5N4!+?(Z@*C1#U3X.,'$Q%'$]0.AFB@\Q/("%XF&D_14T#I+Q
M%3):$GF$1Q:RA[TL?_P=(.*& #?)(0"Q0X"%'F*L-]A;;<TR/841?EFX(@[T
MAHF7!D0; 6[R1D"$?Z_!'%V-=08[AX19IJ<PPC(+C<3^SG#4. #Q28";A!*
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M8#ZBK: 6VHK]O6#B50 15E W"2LH(JR@%L**L4ZPOFMD6@6,,CV%.]CJO86
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MB)&HBIZO&!BY<5W07!KLJ=SG&A\&H*P KB^E-,\#NT'5>4]^ %!+ P04
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MNT.Z>W39-)<#JU:^C;Q5EII2_YI1?J!V"^C[0E&MJ@9N@_JOR_1?4$L#!!0
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M*WZ@T/H#O+_@&=PX_M(,3U[^$U!+ P04    "  )7*U2LO\AFJX#  #)"@
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MC(>CO53?]88Q@YZ26.B+SL:8[;GGZ<6&)51WY98)6%E)E5 #KVKMZ:UB=.E
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M_BLJ-K65J4H RS:03)*J$'9N4[79F9K<WCVDYD$! ;ZU+582D%S=C[^6;"S
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M=0U#=!O!Y/W(%I4:XQ6@S+5V4(GWHF*1.0\KPN)M\:'G#HS*/.CT/AVSA'X
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M#4]37>SBK*^TZ\:!?E*Y.=ZXB3K<Q.!&Y&I9@-^T]=FN?E^'7,>-'N,>(^^
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M?X%G;O3FF#U1'N94I4RH2B+<?#7'<*FQ4(?HABW=\&!9%T9\2=>5?1X*U@^
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MVBV@^;6BJE8/+D']CXSY_U!+ P04    "  )7*U24\P(>JH#  "Q#0  &0
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M\4P%RAK@^[64YGY@/U"?TJ9_ 5!+ P04    "  )7*U2=FP-VG\/   '90
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M8Q7-,J>"#*M;',.?.QJF#3PP'F#ZO5KCNXUWR/-]@.WI<QV"98IW(I8I7FM
MW'4#CR1Q[S;& Q[8+F"] _QN'N@IMT\4P:YBVK G&$>2!$.@%]T]&L=(=6+X
MN/<'>TJB*$G<"&!N!5&$(? TX@BF #1@2!1UY^#!>11LSJE@^P^"V2]02P,$
M%     @ "5RM4I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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ME+W+6.@8YIV/B2R4$5L(3FJ'+1WN=NMS0T+8TI&%LCYW)(28R$(9L84PIC\
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M;%!+ 0(4 Q0    (  E<K5(5=>P9[@   "L"   1              "  :\
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M2P$"% ,4    "  )7*U2RNM%AIX%   '%0  &               @(%R%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ "5RM4IP"R7ZM
M"   )B,  !@              ("!1AL  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    (  E<K5+#A>HOH@(   4&   8              "
M@2DD  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  )7*U2
MO?JZ.[((   *)P  &               @($!)P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ "5RM4IQS ?]S @  4P4  !@
M     ("!Z2\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M  E<K5*)/A6C-0@  &8D   8              " @9(R  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  )7*U2AM]$G*00  #=+0  &
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M970Q,RYX;6Q02P$"% ,4    "  )7*U22!BX-!T$  !*"0  &0
M    @(&E:P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M  E<K5(VUJ(O A0  &5!   9              " @?EO  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ "5RM4J=9AOHJ P  V08  !D
M             ("!,H0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  )7*U2\(0=!D,$  "U"0  &0              @(&3AP  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  E<K5+P,41PD00
M ((*   9              " @0V,  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ "5RM4IV0=#/\ P  ^PH  !D              ("!
MU9   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  )7*U2
M!#NW--\F  !_A0  &0              @($(E0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    (  E<K5)$4B!.N \  $(D   9
M      " @1Z\  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ "5RM4H4*SGFR#   XB   !D              ("!#<P  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  )7*U2+"$#O3('  #5$@
M&0              @('VV   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    (  E<K5)->K.#6@4  ,L,   9              " @5_@  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ "5RM4F#&('H1
M!@  R@\  !D              ("!\.4  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  )7*U2KQ/\J(8$   ."@  &0
M@($X[   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  E<
MK5*0Z-<4A@,   ((   9              " @?7P  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ "5RM4@+:@]0M!   _0@  !D
M         ("!LO0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  )7*U23P1_E3H1  "B2@  &0              @($6^0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  E<K5)D*>9S2P,  (<)
M   9              " @8<* 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ "5RM4B=[12 '!   WPP  !D              ("!"0X!
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  )7*U2:GKT
MR5D#  !&!P  &0              @(%'$@$ >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    (  E<K5(QQ^JV$00  * *   9
M  " @=<5 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M"5RM4D1F.3UL#   V1H  !D              ("!'QH! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  )7*U2P3]9.;<"  #B!P  &0
M            @('")@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    (  E<K5)!##RE#PL  +A'   9              " @; I 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ "5RM4BM5>6TF P
M6@H  !D              ("!]C0! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  )7*U2DFP0)L "  !!!@  &0              @(%3
M. $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  E<K5(I
MH:_<B@4  %03   9              " @4H[ 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ "5RM4@2S2NM_ P  Q L  !D
M     ("!"T$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  E<K5+)T8VLX@4  "P4   9              "
M@:=8 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ "5RM
M4FYH2N5#!   0@T  !D              ("!P%X! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  )7*U2C= 'F74"  #7!0  &0
M        @($Z8P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   (  E<K5+4SW;'JP0   $/   9              " @>9E 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ "5RM4CLI?]3M!0  7AD
M !D              ("!R&H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    "  )7*U23IQM<@T0  !GDP  &0              @('L< $
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (  E<K5)+RQLF
ML (  "\'   9              " @3"! 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ "5RM4J"KO)%<!   A0\  !D
M ("!%X0! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  )
M7*U2%7\18:P&  !P+   &0              @(&JB $ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (  E<K5*U\X2I@@0  ,8,   9
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M970U."YX;6Q02P$"% ,4    "  )7*U2>A*&2Y($  #E$P  &0
M    @('9H $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M  E<K5+ )L49 PD  "TQ   9              " @:*E 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ "5RM4H?-%]@P!   Z@T  !D
M             ("!W*X! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    "  )7*U2%'1WKAP#  "3"   &0              @(%#LP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (  E<K5*?D#\+/@(
M ' %   9              " @9:V 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ "5RM4A.DXAZ: P  0@H  !D              ("!
M"[D! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  )7*U2
M8^&';HT"  "F!@  &0              @('<O $ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    (  E<K5*W\.NN208  -@A   9
M      " @:"_ 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ "5RM4I([Z[J\ @  1 <  !D              ("!(,8! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  )7*U2>)0?#Y\$  "4%
M&0              @($3R0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    (  E<K5(=T:$.FP(  *0'   9              " @>G- 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ "5RM4E?XKIGG
M!   ]1$  !D              ("!N] ! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    "  )7*U2W."Q<P\$  "1#P  &0
M@('9U0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (  E<
MK5(-U:(;Z@,  &,-   9              " @1_: 0!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ "5RM4C@AV?ZE!   U!   !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  )7*U2EXJ[',     3 @  "P
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52P4&     %, 4P"\%@  %@4"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>467</ContextCount>
  <ElementCount>457</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>161</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - Discontinued Operations and Equity-Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2145108 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2149109 - Disclosure - Identifiable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssets</Role>
      <ShortName>Identifiable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2153110 - Disclosure - Pension and Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2157111 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2160112 - Disclosure - Contingencies and Certain Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitments</Role>
      <ShortName>Contingencies and Certain Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2163113 - Disclosure - Product, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation</Role>
      <ShortName>Product, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Discontinued Operations and Equity-Method Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherFinancialInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Identifiable Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables</Role>
      <ShortName>Identifiable Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2354310 - Disclosure - Pension and Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionandPostretirementBenefitPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2358311 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Product, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables</Role>
      <ShortName>Product, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails</Role>
      <ShortName>Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Tax Matters - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetail</Role>
      <ShortName>Tax Matters - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Financial Instruments - Investments by Classification Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails</Role>
      <ShortName>Financial Instruments - Investments by Classification Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Investment Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Financial Instruments - Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Financial Instruments - Derivative Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails</Role>
      <ShortName>Financial Instruments - Derivative Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2441426 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2443428 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2444429 - Disclosure - Financial Instruments - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails</Role>
      <ShortName>Financial Instruments - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Other Financial Information - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails</Role>
      <ShortName>Other Financial Information - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2451432 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2452433 - Disclosure - Identifiable Intangible Assets - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail</Role>
      <ShortName>Identifiable Intangible Assets - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459436 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2461437 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesandCertainCommitments</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2462438 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesandCertainCommitments</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2465439 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2466440 - Disclosure - Product, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Product, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2467441 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Product, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="pfe-20210404.htm">pfe-20210404.htm</File>
    <File>pfe-20210404.xsd</File>
    <File>pfe-20210404_cal.xml</File>
    <File>pfe-20210404_def.xml</File>
    <File>pfe-20210404_lab.xml</File>
    <File>pfe-20210404_pre.xml</File>
    <File>pfe-exh18x0404202110q.htm</File>
    <File>pfe-exh22x0404202110q.htm</File>
    <File>pfe-exh311x0404202110q.htm</File>
    <File>pfe-exh312x0404202110q.htm</File>
    <File>pfe-exh321x0404202110q.htm</File>
    <File>pfe-exh322x0404202110q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-20210404.htm": {
   "axisCustom": 1,
   "axisStandard": 38,
   "contextCount": 467,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20210404_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20210404_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-20210404.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20210404_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20210404_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20210404.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 716,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 73,
   "keyStandard": 384,
   "memberCustom": 93,
   "memberStandard": 62,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20210404",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - Discontinued Operations and Equity-Method Investment",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment",
     "shortName": "Discontinued Operations and Equity-Method Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145108 - Disclosure - Other Financial Information",
     "role": "http://www.pfizer.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149109 - Disclosure - Identifiable Intangible Assets",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssets",
     "shortName": "Identifiable Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153110 - Disclosure - Pension and Postretirement Benefit Plans",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlans",
     "shortName": "Pension and Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157111 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160112 - Disclosure - Contingencies and Certain Commitments",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitments",
     "shortName": "Contingencies and Certain Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163113 - Disclosure - Product, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation",
     "shortName": "Product, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Discontinued Operations and Equity-Method Investment (Tables)",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables",
     "shortName": "Discontinued Operations and Equity-Method Investment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Identifiable Intangible Assets (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables",
     "shortName": "Identifiable Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354310 - Disclosure - Pension and Postretirement Benefit Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358311 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Product, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables",
     "shortName": "Product, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i08a420875e0f49f2a79116b4b03bde63_I20200101",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i1fb4d5f76cd341e2a3579da45c669e20_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NontradeReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details)",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails",
     "shortName": "Discontinued Operations and Equity-Method Investment - Discontinued Operations Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i1fb4d5f76cd341e2a3579da45c669e20_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NontradeReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details)",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i82a840208e554416a672c485a012d030_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details)",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
     "shortName": "Discontinued Operations and Equity-Method Investment - Equity Method Investment Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "if62466171dbf47ec977eb962afa99747_I20190731",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details)",
     "role": "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails",
     "shortName": "Discontinued Operations and Equity-Method Investment - Schedule of Equity-Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ice6f2159d3d7436abcb7d83886acbb6f_I20210404",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i7156c3363822440b89afce39f1a1c27e_D20191001-20210404",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "icab05669a9bf4c4b91e115cdf8dcca85_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "icab05669a9bf4c4b91e115cdf8dcca85_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail",
     "shortName": "Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Other (Income)/Deductions - Net - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail",
     "shortName": "Other (Income)/Deductions - Net - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Tax Matters - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetail",
     "shortName": "Tax Matters - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail",
     "shortName": "Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "icab05669a9bf4c4b91e115cdf8dcca85_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ic844430bda8d4a429c4c1873dec0c67b_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ib94b4929257f4fa59c82eaf1fff65f72_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ib94b4929257f4fa59c82eaf1fff65f72_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Financial Instruments - Investments by Classification Type (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails",
     "shortName": "Financial Instruments - Investments by Classification Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Financial Instruments - Schedule of Investment Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails",
     "shortName": "Financial Instruments - Schedule of Investment Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Financial Instruments - Short-term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ibd7df84abf8144f9838662606d730b41_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i436945b9fb544d1485596c97366973bf_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Financial Instruments - Derivative Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
     "shortName": "Financial Instruments - Derivative Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i436945b9fb544d1485596c97366973bf_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ice7f96cabae24782889c935aac35f1e1_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ice7f96cabae24782889c935aac35f1e1_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441426 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ief79afe80dd041288f169705b94e7059_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443428 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
     "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "ief79afe80dd041288f169705b94e7059_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444429 - Disclosure - Financial Instruments - Credit Risk (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails",
     "shortName": "Financial Instruments - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Other Financial Information - Inventories (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails",
     "shortName": "Other Financial Information - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Other Financial Information - Other Current Liabilities (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "if40f67d115f744f597392dd0dafbaa4e_I20210404",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451432 - Disclosure - Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i96110322c78c4e7d8e3fd05494f58fbb_I20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452433 - Disclosure - Identifiable Intangible Assets - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail",
     "shortName": "Identifiable Intangible Assets - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i96110322c78c4e7d8e3fd05494f58fbb_I20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i088397c030f64354a28cbf48f10fa861_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i088397c030f64354a28cbf48f10fa861_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i088397c030f64354a28cbf48f10fa861_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Pension and Postretirement Benefit Plans - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
     "shortName": "Pension and Postretirement Benefit Plans - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i088397c030f64354a28cbf48f10fa861_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459436 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461437 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
     "shortName": "Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i104649887c064a40a045fee23a147e9b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462438 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
     "shortName": "Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i104649887c064a40a045fee23a147e9b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465439 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Product, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "2",
      "lang": "en-US",
      "name": "pfe:PercentageChangeInRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i05f859e329d9409390fed7a56b8d7dbd_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466440 - Disclosure - Product, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
     "shortName": "Product, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467441 - Disclosure - Product, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Product, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20210404.htm",
      "contextRef": "i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 161,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pfe_AccruedRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AllOtherInflammationandImmunologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Inflammation and Immunology Products [Member]",
        "label": "All Other Inflammation and Immunology Products [Member]",
        "terseLabel": "All other I &amp; I [Member]"
       }
      }
     },
     "localname": "AllOtherInflammationandImmunologyProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Internal Medicine [Member]",
        "label": "All Other Internal Medicine [Member]",
        "terseLabel": "All other Internal Medicine [Member]"
       }
      }
     },
     "localname": "AllOtherInternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherRareDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Rare Disease Products [Member]",
        "label": "All Other Rare Disease Products [Member]",
        "terseLabel": "All other Rare Disease [Member]"
       }
      }
     },
     "localname": "AllOtherRareDiseaseProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllogeneAndBioNTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allogene and BioNTech",
        "label": "Allogene and BioNTech [Member]",
        "terseLabel": "Allogene and BioNTech [Member]"
       }
      }
     },
     "localname": "AllogeneAndBioNTechMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllogeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allogene [Member]",
        "label": "Allogene [Member]",
        "terseLabel": "Allogene [Member]"
       }
      }
     },
     "localname": "AllogeneMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AromasinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aromasin",
        "label": "Aromasin [Member]",
        "terseLabel": "Aromasin [Member]"
       }
      }
     },
     "localname": "AromasinMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArraySecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Array Securities Litigation",
        "label": "Array Securities Litigation [Member]",
        "terseLabel": "Array Securities Litigation [Member]"
       }
      }
     },
     "localname": "ArraySecuritiesLitigationMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "verboseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BNT162b2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BNT162b2",
        "label": "BNT162b2 [Member]",
        "terseLabel": "BNT162b2 alliance revenues and direct sales [Member]"
       }
      }
     },
     "localname": "BNT162b2Member",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BesponsaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besponsa [Member]",
        "label": "Besponsa [Member]",
        "terseLabel": "Besponsa [Member]"
       }
      }
     },
     "localname": "BesponsaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BionTech [Member]",
        "label": "BioNTech [Member]",
        "terseLabel": "BioNTech [Member]"
       }
      }
     },
     "localname": "BioNTechMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BraftoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Braftovi [Member]",
        "label": "Braftovi [Member]",
        "terseLabel": "Braftovi [Member]"
       }
      }
     },
     "localname": "BraftoviMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "terseLabel": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "terseLabel": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations and Equity-Method Investment"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_CK1AssetsSoldToBiogenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CK1 Assets Sold To Biogen, Inc [Member]",
        "label": "CK1 Assets Sold To Biogen, Inc [Member]",
        "terseLabel": "CK1 assets sold to Biogen, Inc [Member]"
       }
      }
     },
     "localname": "CK1AssetsSoldToBiogenIncMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix / Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Condensed Consolidated Balance Sheets:"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Condensed Consolidated Statements of Cash Flows:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Comprehensive Income",
        "label": "Consolidated Statements of Comprehensive Income [Abstract]",
        "terseLabel": "Condensed Consolidated Statements of Comprehensive Income:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Income",
        "label": "Consolidated Statements of Income [Abstract]",
        "terseLabel": "Condensed Consolidated Statements of Income:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfIncomeAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsumerHealthcareJVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare JV",
        "label": "Consumer Healthcare JV [Member]",
        "terseLabel": "Consumer Healthcare JV [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareJVMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CostReductionInitiativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Reduction Initiatives",
        "label": "Cost Reduction Initiatives [Member]",
        "terseLabel": "Cost reduction/productivity initiatives [Member]"
       }
      }
     },
     "localname": "CostReductionInitiativesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting",
        "verboseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Gain",
        "label": "Debt Securities, Accumulated Gross Unrealized Gain",
        "totalLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Loss",
        "label": "Debt Securities, Accumulated Gross Unrealized Loss",
        "negatedTotalLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Amortized Cost Basis",
        "label": "Debt Securities, Amortized Cost Basis",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, After Year Five, Fair Value",
        "label": "Debt Securities Maturities, After Year Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "label": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "totalLabel": "Debt securities maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "label": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "totalLabel": "Debt securities maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Schedule of Gains and Losses on Investment Securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfCashConveyed": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "negatedLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfCashConveyed",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DerivativeNetReceivablePositionAggregateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "label": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net receivable position"
       }
      }
     },
     "localname": "DerivativeNetReceivablePositionAggregateFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Costs and Expenses",
        "label": "Disposal Group, Including Discontinued Operation, Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs",
        "label": "Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DocetaxelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Docetaxel [Member]",
        "label": "Docetaxel [Member]",
        "terseLabel": "Docetaxel [Member]"
       }
      }
     },
     "localname": "DocetaxelMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "verboseLabel": "Enbrel (Outside the U.S. and Canada) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnvironmentalRemediationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Environmental Remediation Litigation [Member]",
        "label": "Environmental Remediation Litigation [Member]",
        "terseLabel": "Environmental Remediation Litigation [Member]"
       }
      }
     },
     "localname": "EnvironmentalRemediationLitigationMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "EpiPen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "label": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "negatedTerseLabel": "Decrease due to foreign currency translation"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Noncurrent",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "label": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "terseLabel": "Long-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedNoncurrent",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "label": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative impairment losses and downward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_FSMEIMMUNTicoVacMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FSME/IMMUN-TicoVac",
        "label": "FSME/IMMUN-TicoVac [Member]",
        "terseLabel": "FSME/IMMUN-TicoVac [Member]"
       }
      }
     },
     "localname": "FSMEIMMUNTicoVacMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FeasibilityStudyNumberOfLagoons": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Feasibility Study, Number Of Lagoons",
        "label": "Feasibility Study, Number Of Lagoons",
        "terseLabel": "Feasibility study, number of lagoons"
       }
      }
     },
     "localname": "FeasibilityStudyNumberOfLagoons",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "terseLabel": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "xbrltype": "stringItemType"
    },
    "pfe_FocusedCompanyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Focused Company Plan [Member]",
        "label": "Focused Company Plan [Member]",
        "terseLabel": "Focused Company Plan [Member]"
       }
      }
     },
     "localname": "FocusedCompanyPlanMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Debt [Member]",
        "terseLabel": "Foreign currency debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyDebtMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign currency short-term borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "label": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "terseLabel": "Number of patents allegedly infringed upon, expired December 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsWithoutCourtProceedingsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Patents Without Court Proceedings, Number",
        "label": "Gain Contingency, Patents Without Court Proceedings, Number",
        "terseLabel": "Number of patents without court proceedings"
       }
      }
     },
     "localname": "GainContingencyPatentsWithoutCourtProceedingsNumber",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GovernmentAndGovernmentSponsoredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Government Sponsored",
        "label": "Government and Government Sponsored [Member]",
        "terseLabel": "Government and Government Sponsored [Member]"
       }
      }
     },
     "localname": "GovernmentAndGovernmentSponsoredMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HedgedItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Item [Axis]",
        "label": "Hedged Item [Axis]",
        "terseLabel": "Hedged Item [Axis]"
       }
      }
     },
     "localname": "HedgedItemAxis",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_HedgedItemDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Hedged Item [Axis]",
        "label": "Hedged Item [Domain]",
        "terseLabel": "Hedged Item [Domain]"
       }
      }
     },
     "localname": "HedgedItemDomain",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HeldToMaturityCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-To-Maturity Cash Equivalents",
        "label": "Held-To-Maturity Cash Equivalents",
        "terseLabel": "Held-to-maturity cash equivalents"
       }
      }
     },
     "localname": "HeldToMaturityCashEquivalents",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital [Member]",
        "label": "Hospital [Member]",
        "terseLabel": "Hospital [Member]"
       }
      }
     },
     "localname": "HospitalMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IVIgProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IVIg Products",
        "label": "IVIg Products [Member]",
        "terseLabel": "IVIg Products [Member]"
       }
      }
     },
     "localname": "IVIgProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 4.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights"
       }
      }
     },
     "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "negatedTerseLabel": "Consumer Healthcare JV equity method (income)/loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InflammationandImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflammation and Immunology [Member]",
        "label": "Inflammation and Immunology [Member]",
        "terseLabel": "Inflammation and Immunology (I&amp;I) [Member]"
       }
      }
     },
     "localname": "InflammationandImmunologyMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraRemsimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflectra/Remsima [Member]",
        "label": "Inflectra/Remsima [Member]",
        "terseLabel": "Inflectra/Remsima [Member]"
       }
      }
     },
     "localname": "InflectraRemsimaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "label": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "terseLabel": "Percentage of total identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetPercentageofIntangibleAssetsNet",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_InterestPaidReceivedInterestRateHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Paid (Received), Interest Rate Hedges",
        "label": "Interest Paid (Received), Interest Rate Hedges",
        "terseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestPaidReceivedInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Medicine [Member]",
        "label": "Internal Medicine [Member]",
        "terseLabel": "Internal Medicine [Member]"
       }
      }
     },
     "localname": "InternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "License Agreements and Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "terseLabel": "Current portion of long-term debt, principal amount"
       }
      }
     },
     "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "totalLabel": "Total long-term investments"
       }
      }
     },
     "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LorbrenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lorbrena",
        "label": "Lorbrena [Member]",
        "terseLabel": "Lorbrena [Member]"
       }
      }
     },
     "localname": "LorbrenaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyClassActionsFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Class Actions Filed, Number",
        "label": "Loss Contingency, Class Actions Filed, Number",
        "terseLabel": "Number of class actions filed"
       }
      }
     },
     "localname": "LossContingencyClassActionsFiledNumber",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "label": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "terseLabel": "Number of defendants other than main defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendantsOtherThanMainDefendant",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits",
        "label": "Loss Contingency, Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuits",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_ManufacturingOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Optimization [Member]",
        "label": "Manufacturing Optimization [Member]",
        "terseLabel": "Manufacturing optimization [Member]"
       }
      }
     },
     "localname": "ManufacturingOptimizationMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MektoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mektovi [Member]",
        "label": "Mektovi [Member]",
        "terseLabel": "Mektovi [Member]"
       }
      }
     },
     "localname": "MektoviMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NimenrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nimenrix [Member]",
        "label": "Nimenrix [Member]",
        "terseLabel": "Nimenrix [Member]"
       }
      }
     },
     "localname": "NimenrixMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20220.250Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2022, 0.250% [Member]",
        "label": "Notes Due 2022, 0.250% [Member]",
        "terseLabel": "0.250% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "NotesDue20220.250Member",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "1.000% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accruals",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherAntiinfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Anti-infectives [Member]",
        "label": "Other Anti-infectives [Member]",
        "terseLabel": "All other Anti-infectives [Member]"
       }
      }
     },
     "localname": "OtherAntiinfectivesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "All other, net - Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.pfizer.com/20210404",
     "xbrltype": "stringItemType"
    },
    "pfe_OtherHospitalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hospital Products [Member]",
        "label": "Other Hospital Products [Member]",
        "terseLabel": "All other Hospital [Member]"
       }
      }
     },
     "localname": "OtherHospitalProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeDeductionsAndCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (Income) Deductions And Cost Of Sales [Member]",
        "label": "Other (Income) Deductions And Cost Of Sales [Member]",
        "terseLabel": "Other (Income) Deductions And Cost Of Sales [Member]"
       }
      }
     },
     "localname": "OtherIncomeDeductionsAndCostOfSalesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "All other Oncology [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherPatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patent Infringement",
        "label": "Other Patent Infringement [Member]",
        "terseLabel": "Other Patent Infringement [Member]"
       }
      }
     },
     "localname": "OtherPatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Vaccines Products [Member]",
        "label": "Other Vaccines Products [Member]",
        "terseLabel": "All other Vaccines [Member]"
       }
      }
     },
     "localname": "OtherVaccinesProductsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "label": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "terseLabel": "Payment pursuant to terms of the separation agreement"
       }
      }
     },
     "localname": "PaymentPursuantToTermsOfSeparationAgreementFinancingActivities",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "label": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedTerseLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense/income"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PercentageChangeInRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage change in revenue.",
        "label": "Percentage Change In Revenue",
        "terseLabel": "Percentage Change In Revenue"
       }
      }
     },
     "localname": "PercentageChangeInRevenue",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "label": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "terseLabel": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]"
       }
      }
     },
     "localname": "PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerCentreOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer CentreOne [Member]",
        "label": "Pfizer CentreOne [Member]",
        "terseLabel": "Pfizer CentreOne [Member]"
       }
      }
     },
     "localname": "PfizerCentreOneMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusGenericCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Versus Generic Companies [Member]",
        "label": "Pfizer Versus Generic Companies [Member]",
        "terseLabel": "Pfizer Versus Generic Companies [Member]"
       }
      }
     },
     "localname": "PfizerVersusGenericCompaniesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusZydusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Versus Zydus [Member]",
        "label": "Pfizer Versus Zydus [Member]",
        "terseLabel": "Pfizer Versus Zydus [Member]"
       }
      }
     },
     "localname": "PfizerVersusZydusMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PneumococcalVaccinePatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumococcal Vaccine Patent Infringement",
        "label": "Pneumococcal Vaccine Patent Infringement [Member]",
        "terseLabel": "Pneumococcal Vaccine Patent Infringement [Member]"
       }
      }
     },
     "localname": "PneumococcalVaccinePatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precedex [Member]",
        "label": "Precedex [Member]",
        "terseLabel": "Precedex [Member]"
       }
      }
     },
     "localname": "PrecedexMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevnar 13/Prevenar 13 [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PristiqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pristiq",
        "label": "Pristiq [Member]",
        "terseLabel": "Pristiq [Member]"
       }
      }
     },
     "localname": "PristiqMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Equity Investments",
        "label": "Private Equity Investments",
        "terseLabel": "Private equity securities at cost"
       }
      }
     },
     "localname": "PrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RareDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rare Disease [Member]",
        "label": "Rare Disease [Member]",
        "terseLabel": "Rare Disease [Member]"
       }
      }
     },
     "localname": "RareDiseaseMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF/Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RebatesAndDiscountsAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts",
        "label": "Rebates And Discounts Accrual",
        "terseLabel": "Total accrued rebates and other sales-related accruals"
       }
      }
     },
     "localname": "RebatesAndDiscountsAccrual",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "netLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of expected costs to be non-cash"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RetacritMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retacrit [Member]",
        "label": "Retacrit [Member]",
        "terseLabel": "Retacrit [Member]"
       }
      }
     },
     "localname": "RetacritMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RuxienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ruxience",
        "label": "Ruxience [Member]",
        "terseLabel": "Ruxience [Member]"
       }
      }
     },
     "localname": "RuxienceMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario, Change in Accounting Principle, Adjustment",
        "label": "Scenario, Change in Accounting Principle, Adjustment [Member]",
        "terseLabel": "Impact of Change [Member]"
       }
      }
     },
     "localname": "ScenarioChangeInAccountingPrincipleAdjustmentMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScenarioPreviousAccountingPrincipleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario, Previous Accounting Principle",
        "label": "Scenario, Previous Accounting Principle [Member]",
        "terseLabel": "Previous Accounting Principle [Member]"
       }
      }
     },
     "localname": "ScenarioPreviousAccountingPrincipleMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Table]",
        "terseLabel": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "label": "Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Accruals"
       }
      }
     },
     "localname": "ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "totalLabel": "Total short-term borrowings, principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Investments Excluding Held-To-Maturity Securities",
        "label": "Short-term Investments Excluding Held-To-Maturity Securities",
        "totalLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "label": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "terseLabel": "Threshold for disclosure of proceedings under environmental laws"
       }
      }
     },
     "localname": "SiteContingencyRegulatoryProceedingsDisclosureThreshold",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalAllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Alliance Biopharmaceuticals [Member]",
        "label": "Total Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Total Alliance revenues [Member]"
       }
      }
     },
     "localname": "TotalAllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalBiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Biosimilars [Member]",
        "label": "Total Biosimilars [Member]",
        "terseLabel": "Total Biosimilars [Member]"
       }
      }
     },
     "localname": "TotalBiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalSterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Sterile Injectable Pharmaceuticals [Member]",
        "label": "Total Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "Total Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalSterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "terseLabel": "Vaccines [Member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViatrisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viatris",
        "label": "Viatris [Member]",
        "terseLabel": "Viatris [Member]"
       }
      }
     },
     "localname": "ViatrisMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VyndaqelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vyndaqel [Member]",
        "label": "Vyndaqel [Member]",
        "terseLabel": "Vyndaqel/Vyndamax [Member]"
       }
      }
     },
     "localname": "VyndaqelMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi Alliance Revenues [Member]",
        "label": "Xtandi Alliance Revenues [Member]",
        "terseLabel": "Xtandi alliance revenues [Member]"
       }
      }
     },
     "localname": "XtandiAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZantacRanitidineNDMALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zantac/Ranitidine NDMA Litigation",
        "label": "Zantac/Ranitidine NDMA Litigation [Member]",
        "terseLabel": "Zantac/Ranitidine NDMA Litigation [Member]"
       }
      }
     },
     "localname": "ZantacRanitidineNDMALitigationMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZaviceftaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zavicefta",
        "label": "Zavicefta [Member]",
        "terseLabel": "Zavicefta [Member]"
       }
      }
     },
     "localname": "ZaviceftaMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZirabevMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zirabev",
        "label": "Zirabev [Member]",
        "terseLabel": "Zirabev [Member]"
       }
      }
     },
     "localname": "ZirabevMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZyvoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyvox [Member]",
        "label": "Zyvox [Member]",
        "terseLabel": "Zyvox [Member]"
       }
      }
     },
     "localname": "ZyvoxMember",
     "nsuri": "http://www.pfizer.com/20210404",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r82",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r227",
      "r366",
      "r372",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r463",
      "r468",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r703",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r227",
      "r366",
      "r372",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r222",
      "r366",
      "r370",
      "r640",
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r222",
      "r366",
      "r370",
      "r640",
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r401",
      "r463",
      "r468",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r703",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r401",
      "r463",
      "r468",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r639",
      "r703",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r192",
      "r270",
      "r271",
      "r479",
      "r493",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r192",
      "r270",
      "r271",
      "r479",
      "r493",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Change in Accounting Principle, Adjustment [Member]",
        "terseLabel": "Change in Accounting Principle, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r366",
      "r371",
      "r705",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r366",
      "r371",
      "r705",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable [Member]",
        "verboseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r27",
      "r43",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2021\u2014$512; 2020\u2014$508"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r91",
      "r96",
      "r99",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r96",
      "r106",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r96",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r93",
      "r95",
      "r96",
      "r682",
      "r715",
      "r719"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Increase to AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r92",
      "r96",
      "r99",
      "r159",
      "r160",
      "r162",
      "r523",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Accum. Other Comp. Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r84",
      "r96",
      "r99",
      "r523",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).",
        "label": "Acquisition-related Costs [Member]",
        "terseLabel": "Acquisition-related costs [Member]"
       }
      }
     },
     "localname": "AcquisitionRelatedCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r44",
      "r479"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Add'l Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r50",
      "r230",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r144",
      "r289",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common stock equivalents (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r153",
      "r210",
      "r214",
      "r220",
      "r263",
      "r517",
      "r525",
      "r590",
      "r648",
      "r680"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r79",
      "r153",
      "r263",
      "r517",
      "r525",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r235",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r239",
      "r241",
      "r675"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r239",
      "r240",
      "r674"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r232",
      "r236",
      "r278",
      "r655"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Available-for-sale debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r234",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r234",
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r539",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "verboseLabel": "Integration costs and other"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r25",
      "r59",
      "r146"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r139",
      "r146",
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r139",
      "r592"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) investing activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by operating activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Hedged item"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r181",
      "r182",
      "r183",
      "r186",
      "r188",
      "r198",
      "r199",
      "r200",
      "r263",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r36",
      "r649",
      "r681"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r72",
      "r324",
      "r656",
      "r687"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Certain Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITEDPARENTHETICAL"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock, $.05 par value [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r102",
      "r104",
      "r105",
      "r117",
      "r666",
      "r697"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income/(loss) attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r104",
      "r116",
      "r515",
      "r516",
      "r529",
      "r665",
      "r696"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r104",
      "r115",
      "r514",
      "r529",
      "r664",
      "r695"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income/(loss) before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r114",
      "r127",
      "r663",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r227",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r227",
      "r588",
      "r589",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r227",
      "r588",
      "r589",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r202",
      "r203",
      "r227",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r227",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r347",
      "r348",
      "r367"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r402",
      "r450",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate and other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r121",
      "r640"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r122",
      "r153",
      "r263",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings",
        "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2021\u2014$3,676; 2020\u2014$2,002"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r38",
      "r336",
      "r650",
      "r678"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total long-term debt, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r70",
      "r156",
      "r340",
      "r341",
      "r342",
      "r343",
      "r603",
      "r604",
      "r606",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r337",
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Net unamortized discounts, premiums and debt issuance costs",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale and Held-to-maturity",
        "totalLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "(Gain) on completion of Consumer Healthcare JV transaction"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r154",
      "r489",
      "r496",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r482",
      "r483"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39",
      "r377",
      "r378",
      "r400"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r379",
      "r417",
      "r444"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "negatedTerseLabel": "Actuarial (gains)/losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r379",
      "r418",
      "r445",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r91",
      "r93",
      "r421"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r394",
      "r402",
      "r404",
      "r448",
      "r450",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "verboseLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r379",
      "r416",
      "r443",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r379",
      "r383",
      "r415",
      "r442",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r413",
      "r440",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit costs recorded in Other (income)/deductions\u2013\u2013net",
        "totalLabel": "Net periodic benefit cost/(credit) reported in income"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r381",
      "r414",
      "r441",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r80",
      "r81",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Noncurrent derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r540",
      "r543",
      "r552",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r537",
      "r540",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r551",
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r80",
      "r81",
      "r585"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Liability",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Current derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Noncurrent derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net liability position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Remaining period of hedging exposure"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r531",
      "r533",
      "r534",
      "r537",
      "r538",
      "r545",
      "r552",
      "r567",
      "r568",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r16",
      "r112",
      "r692"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Pre-tax income from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r16",
      "r21",
      "r484",
      "r495",
      "r502"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r301",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r17",
      "r24"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Other (income)/deductions\u2013\u2013net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r17",
      "r24"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Income Statement Disclosures"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r458",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Cash [Abstract]",
        "terseLabel": "Cash dividends declared, per share"
       }
      }
     },
     "localname": "DividendsCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r68"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r344",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedTerseLabel": "Preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r457",
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r118",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r178",
      "r181",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r667",
      "r698"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator\u2013\u2013Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r118",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r181",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r667",
      "r698"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "verboseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r165",
      "r174",
      "r177",
      "r197",
      "r269",
      "r339",
      "r344",
      "r476",
      "r477",
      "r478",
      "r492",
      "r493",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r111",
      "r138",
      "r144",
      "r690"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Dividend received"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r24",
      "r153",
      "r263",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r24",
      "r153",
      "r263",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r60",
      "r211",
      "r259"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Net (gains)/losses recognized during the period on equity securities",
        "negatedTotalLabel": "Net (gains)/losses recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r258",
      "r699"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net (gains)/losses recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r258",
      "r699"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date",
        "verboseLabel": "Unrealized gain (loss) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r450",
      "r575",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r574",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r574",
      "r575",
      "r577",
      "r578",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r402",
      "r404",
      "r409",
      "r450",
      "r575",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r402",
      "r404",
      "r409",
      "r450",
      "r575",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r450",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r579",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r248",
      "r252",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r290",
      "r292",
      "r295",
      "r298",
      "r641",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r295",
      "r645"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets [Member]",
        "terseLabel": "Finite-Lived Intangible Assets [Member]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r295",
      "r641"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Finite-lived intangible assets, period increase"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "negatedTerseLabel": "Pre-tax loss expected to be reclassified within the next 12 months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r402",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r402",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Government and agency - non U.S. [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r457",
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net (gains)/losses on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Certain legal matters, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r284",
      "r285",
      "r647"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r119",
      "r153",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r263",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r537",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r232",
      "r242",
      "r655"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "totalLabel": "Held-to-maturity securities, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity securities, gross unrealized gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r245",
      "r251"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity securities, gross unrealized losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-maturity, Current",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r247",
      "r254",
      "r673",
      "r675"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r246",
      "r253",
      "r672",
      "r674"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r243",
      "r249",
      "r655"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-maturity, Noncurrent",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r248",
      "r252",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table Text Block]",
        "terseLabel": "Schedule of Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r120",
      "r145",
      "r169",
      "r170",
      "r171",
      "r172",
      "r184",
      "r188",
      "r513"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r110",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r646",
      "r660",
      "r670",
      "r700"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income from continuing operations before provision for taxes on income",
        "totalLabel": "Income from continuing operations before provision for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r164",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r263",
      "r514",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income from continuing operations before allocation to noncontrolling interests",
        "totalLabel": "Income from continuing operations",
        "verboseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r107",
      "r118",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r181",
      "r186",
      "r187",
      "r658",
      "r661",
      "r667",
      "r691"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r107",
      "r118",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r181",
      "r186",
      "r187",
      "r188",
      "r667",
      "r691",
      "r694",
      "r698"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r21",
      "r24",
      "r504",
      "r692"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from discontinued operations\u2013\u2013net of tax",
        "totalLabel": "Income from discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r16",
      "r21",
      "r514"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "verboseLabel": "Income from discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r112",
      "r118",
      "r182",
      "r186",
      "r187",
      "r667",
      "r692",
      "r694",
      "r698"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Income from discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r182",
      "r186",
      "r187",
      "r530"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Income from discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r111",
      "r144",
      "r208",
      "r259",
      "r659",
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity method investment earnings"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r458",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r19",
      "r22",
      "r23",
      "r24",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r494",
      "r499",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r176",
      "r177",
      "r209",
      "r484",
      "r495",
      "r501",
      "r701"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Increase in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r291",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r291",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r288",
      "r293"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r108",
      "r207",
      "r602",
      "r605",
      "r668"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r136",
      "r141",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r402",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r51",
      "r283"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r26",
      "r76"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r53",
      "r54",
      "r283"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r52",
      "r283"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r124",
      "r206"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r67",
      "r153",
      "r215",
      "r263",
      "r518",
      "r525",
      "r526",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r49",
      "r153",
      "r263",
      "r590",
      "r652",
      "r685"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r69",
      "r153",
      "r263",
      "r518",
      "r525",
      "r526",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.",
        "label": "Life Settlement Contracts, Fair Value",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r38",
      "r338",
      "r650",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, excluding the current portion"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Total long-term investments and equity-method investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Investments [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r70",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Investments by Classification Type"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r75",
      "r153",
      "r263",
      "r590",
      "r651",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by/(used in) investing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r139",
      "r142",
      "r145"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r139",
      "r142",
      "r145"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r100",
      "r103",
      "r113",
      "r145",
      "r153",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r184",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r263",
      "r590",
      "r662",
      "r693"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Income attributable to shareholders",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders",
        "verboseLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r100",
      "r103",
      "r176",
      "r177",
      "r520",
      "r528"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r178",
      "r179",
      "r185",
      "r188",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r180",
      "r185",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "verboseLabel": "Net periodic benefit costs/(credits) other than service costs"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r192",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r490",
      "r491",
      "r492",
      "r493",
      "r642",
      "r643",
      "r644",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standard Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r344",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivative Financial Instruments Not Designated as Hedges [Member]",
        "verboseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Nontrade receivables"
       }
      }
     },
     "localname": "NontradeReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets",
        "totalLabel": "Total other noncurrent assets",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r421"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "verboseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "totalLabel": "Available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r114",
      "r260",
      "r593",
      "r598",
      "r600",
      "r663",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income/(loss), before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r85",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "totalLabel": "Derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r85",
      "r93",
      "r542",
      "r547",
      "r570"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net",
        "verboseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r549"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "auth_ref": [
      "r86",
      "r93",
      "r97",
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r86",
      "r93",
      "r548",
      "r556",
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Amount excluded from effectiveness testing and amortized into earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r83",
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r83",
      "r94",
      "r591",
      "r599"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r101",
      "r104",
      "r106",
      "r114",
      "r339",
      "r593",
      "r598",
      "r600",
      "r663",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other\u00a0comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) before allocation to noncontrolling interests",
        "verboseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r94",
      "r514"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r90",
      "r93",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Benefit plans: actuarial gains/(losses), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r256"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r94",
      "r256"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r94",
      "r114",
      "r484",
      "r500",
      "r503",
      "r593",
      "r596",
      "r600",
      "r663",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive income/(loss)",
        "totalLabel": "Tax provision/(benefit) on other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r87",
      "r93",
      "r256"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersScheduleofTaxProvisionBenefitonOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r539",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]",
        "verboseLabel": "Other current liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r68"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r38",
      "r650",
      "r681"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r60",
      "r688"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Total Long-term investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesScheduleofBalanceSheetClassificationofAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income)/deductions\u2013\u2013net [Member]",
        "verboseLabel": "OID [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r428",
      "r431",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Plans [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39",
      "r377",
      "r378",
      "r400"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other short-term borrowings, principal amount"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r78",
      "r657",
      "r689"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "verboseLabel": "Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r128",
      "r130",
      "r157"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r401",
      "r403",
      "r409",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r450",
      "r452",
      "r455",
      "r456",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r150",
      "r434",
      "r453",
      "r454",
      "r456",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Change in Accounting Principle"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r375",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r428",
      "r431",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r456",
      "r457",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Less: Preferred stock dividends\u2013\u2013net of tax"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "verboseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r132",
      "r135",
      "r157"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r131",
      "r134",
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product concentration risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r24",
      "r100",
      "r103",
      "r137",
      "r153",
      "r164",
      "r176",
      "r177",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r263",
      "r514",
      "r519",
      "r521",
      "r528",
      "r529",
      "r590",
      "r670"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r35",
      "r303",
      "r686"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, less accumulated depreciation: 2021\u2014$15,105; 2020\u2014$14,812"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Principal payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r308",
      "r310",
      "r316",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r308",
      "r310",
      "r316",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r144",
      "r307",
      "r313",
      "r318"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Provision",
        "totalLabel": "Restructuring charges/(credits)"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges/(credits):"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r309",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Additional depreciation\u2013\u2013asset restructuring"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r45",
      "r344",
      "r479",
      "r683",
      "r714",
      "r719"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Decrease to retained earnings",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r165",
      "r174",
      "r177",
      "r269",
      "r476",
      "r477",
      "r478",
      "r492",
      "r493",
      "r710",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r431",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r457",
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r431",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r457",
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r428",
      "r431",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r428",
      "r431",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r204",
      "r205",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r227",
      "r365",
      "r366",
      "r640"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Trade Accounts Receivable"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r369",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r109",
      "r153",
      "r204",
      "r205",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r227",
      "r263",
      "r590",
      "r670"
     ],
     "calculation": {
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "negatedTerseLabel": "Royalty-related income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherIncomeDeductionsNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Inventory sales [Member]"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r202",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r96",
      "r598",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r70",
      "r156",
      "r340",
      "r341",
      "r342",
      "r343",
      "r603",
      "r604",
      "r606",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r434",
      "r435",
      "r438",
      "r439",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNarrativeDetail",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansNetPeriodicBenefitCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative assets at fair value.",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Assets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r540",
      "r552",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r531",
      "r533",
      "r534",
      "r537",
      "r538",
      "r545",
      "r552",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r19",
      "r22",
      "r23",
      "r24",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summarized Financial Information of Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r24",
      "r153",
      "r262",
      "r263",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentEquityMethodInvestmentNarrativeDetails",
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentScheduleofEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r290",
      "r294",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r33",
      "r55",
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r33",
      "r55",
      "r56",
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r168",
      "r171",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Summary of Change in Accounting Principle"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r311",
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r309",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Components and Changes in Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r109",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Borrowings"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/DiscontinuedOperationsandEquityMethodInvestmentSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, informational and administrative expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r144",
      "r307",
      "r313",
      "r318"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r37",
      "r653",
      "r654",
      "r679"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "totalLabel": "Total Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsbyClassificationTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r152",
      "r153",
      "r181",
      "r182",
      "r183",
      "r186",
      "r188",
      "r198",
      "r199",
      "r200",
      "r263",
      "r339",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r74",
      "r159",
      "r160",
      "r162",
      "r165",
      "r174",
      "r177",
      "r197",
      "r269",
      "r339",
      "r344",
      "r476",
      "r477",
      "r478",
      "r492",
      "r493",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r600",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r197",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r41",
      "r42",
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r41",
      "r42",
      "r344",
      "r470",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r42",
      "r47",
      "r48",
      "r153",
      "r231",
      "r263",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r159",
      "r160",
      "r162",
      "r165",
      "r174",
      "r263",
      "r269",
      "r344",
      "r476",
      "r477",
      "r478",
      "r492",
      "r493",
      "r511",
      "r512",
      "r527",
      "r590",
      "r593",
      "r594",
      "r600",
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetail",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r601",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r601",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r601",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ProductGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid (received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsFinitelivedandIndefinitelivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r248",
      "r252",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r73",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r73",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r339",
      "r344",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofAcquisitionsandCostReductionProductivityInitiativesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesScheduleofComponentsandChangesinRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r402",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsScheduleofInvestmentSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r178",
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3098-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "325",
   "URI": "http://asc.fasb.org/extlink&oid=73718008&loc=d3e42732-111610"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r736": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r737": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r738": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r739": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r741": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000078003-21-000065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-21-000065-xbrl.zip
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M4RE&GM*2_TF ?.5];-?GXX/_B^[,C^W7YQ=XYV["HP)DSKYXJ1V*-BI%*^7
MG8D*/*L'X,IQ1M;[]HYR?J)?]<N%3G?U[-%&[JR?Z.5@X3\_J_JZR[]E+#D_
MU>U_*I^</6J\U?_WW7LNY>#*GL)QPYZCZ= 0.Q ;@+DP> F*Q7NJ"W3_!-U;
M/YGHZN,O]2&??'9QIUZ^V1?W_VLBM$"0R!:^JZ4JH)K0C89(E;LH(OHC+NXZ
M38O>Y_QHH\[9.ZUJA@R,FJNT$A)G[8[\<:<Y$X1N?[E1ZD*,"2,C0<S$#@=4
MK@77:X:I+ *;"H:'U]H1:\06@T8:#39D=.N6F*N+JC%SGX#6GBS@!UE95+A
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M5"^WN/WC?+6[*'?YC5Z4@QMGS]*2E=4-8"WA5<@I5VB-(Z1&+?F6TIS@O9R
MVIU]HV*GV6OOK WC"PN>);8NQ!8)>FTFMC0AMES$=Z H!7E2+3&.&=O##&;T
MXE)REBV%9'*K5\F5<JS)B]86CWCCRA_VQI^=/C[9/%6];RIZ.[:%363EEF8-
MH148':0 <L0<J63MJ0=?W;/UDM.&:%C=S=U.S^Z</N;5=EQ^*GN.0G>N>Z;&
ME<"%A#WKJ*;@FJO-/:]X/VET7AOJ?>WLB6"44@E<6D0:!;5\PQ:Z%G"5$9V*
MGY,XN4)O=WAE8L;7O!:MO72HXL;6(M_#V%(>F7@*BUJ/S$<>'E-N;'B&/DH;
MP]@2X$6RC@HH79VO4QK /2K/>GADL68,%BPC6F8HWIRO#XDB:FXE8=&)+9LZ
M'JVYQ\IJ@7INY$NR^%@Y8 S-TH <+*,WM5EF -&5:\W]H9.YC^DM&8T*1X.+
M&L:JPV"1+I*)39P!.@?2FGO<(I50NX.6O,O06=BW[ N4487 DFN90/C:S[:+
MFR<GFX>Z5D/XT]7FW@-MC^88U!( U:ZQN!8AQFY1K2?B!,%GS3"%-J+[Q7N.
MHV2%$,A!"KUV"-+1N]9*[*V0BI0P$:/^UX5%WM%"W]G//WCZV*AT<[L=!3/'
M)_SM&I23$ZZ;RUFO5\Z:HX.(U66JJ=;8O.6E0-K8_A][\QP'@>-OUO*;J<U7
MBVI=3&$^;^@V2ER<;$99A]VG3U^KC[&S2YR<BT7Q-Y?!>&7L_;_\A3C;W=^<
MR(.-\=)\BKUZ7\1\Y[(=KYUX^< ^<?_TZ5@Y=6]S9?4\WDMC%L:*L8W^N4Y'
MXT'**A&JNJH5!8ZX1N^_WXGK@7F9W<DETE,KUMM]$LVH&'@4MDK,8ED :8<.
MHE'GB-<7O%I_N=GM[NG9+=X]^OQD\_-_JCS4*^G4M2_@)#1B'L!%,OF +,ZE
M0.@I%\L3)E!"\8\#9X!]N]XJGZQ^U5<4Y',\)X(<!^]CBF9@V &@H^5R&5(.
M'EP%G<"LVQ]'[K;VT5;R4U/Q?74V]N#L7KI*@_6BY=5]2]9734?R?FNKLIJ*
M*4**8]]LCY !BD@-"J/AN$;1)@DGH.&//O@=7FV;6VTQ5=>2H,$<B:ISX(.E
M;CW4-H7AE^F$S,/#36- M+ML/EH ,6!KT!.E405# N59PWWE@?;P>(-2-4/.
ML6B%I!X+BFO@1;A0:%/:/SG=\'QX&J@IL\"I1.X()L'(>6F5(U//HW/3\4^$
M'&T(?S_EL;VR!T^%HH)&RXDTE3'NP(FKY@G,_!Y_,'X_U2PP@SKJ9F )<FOH
M&Y5<0V,ML=<X1^ .F;_N<:YXE#CHY@^1*O1&&!23"&HM-61?YXC<L03(]P-H
MB:-B1''<+:%)G=3 )(#@>J2D1]R;\#E2GZ_6O&XK/KFS'O/Z_SPM=-?P?7J7
MMW_7L\_/U_(V4WOG-WY[&Y#[CS;;LP>Z/7UI[WM[]\]YM?V.3\[UTZ=W+ZM>
MC\M_OM5_G.NZ/7W]@[PX^9531XNL\^V$UD"$5@@L <N6AH-BYE*EF6+KTIN2
M3B!J+%1]\>M_VHT<^X^??CEV'_\+MMY9/SX_VUV<X1>[^;<K8S,K>!<"R.C3
M;G93 # 6"&.DDB>0UBQV\YZI>J6F'"9B-Z'YXF)@-V;98HUC.[EFR3Z6*$Z/
MN!_P8C>3</'[FX5RED4SJ/<A=7"4*^:&Z*.&CE3<!&;R%ZHNTNCJ[0:Q>TFN
MCI*JH\1J#1%ZY>R<2I)4%KLY?KM9I-'5VXUOJ1"'P-P3C%DSK,)B82=RD,H3
M2,47^OY11_+Y9JNKA^LO-D]TNQZ';VL]NS\^QI2Z#_M10L9+K)(0QIHYYA);
M'IL%-<<T@:UH1\/<ZR18%C/Z;:\"C>1#PU(SA)!(0G Y,XBJ2E\"P,+<^>JH
M_9E1\[ZYG(B)%6)O.,J-.JK4"4!)CC__6,QH2@%@C^6C(DE/78F\0(@-:XWF
M_U-)D7NO:6'NHJ,6,WK[ )0&3\7R:,0(++4&S<'T4V8*Y)@6,UJ8.UL=M<>=
MC,!$N6&BC%!):Q>1S"Y2=Y33$3=_?F?6?'O_)6%N/C1R&U7>#W&NBT4?2Q*@
MW<>8*PEY#W$(J]"5DW.9"X0IK(9=R'N]5=VQ6)(I*?*:QO+_ #5#C=):=:51
M\Y+Z! 9W%TLZ8F%W]()J?Y946XS1Q0 A-"A.J"5+[+.+7<45G</$^&))QQ4&
M]E@\VQ=A;*6/;?E4L8ZMVM%T561IPG4A[Q3)NPBJ Y0XKZ&8V_=I;/<*+556
M=IY9S)I0X@3F)Q9+6@3545A2SDXC0"TJP+Y0$?NE:^E%$J0)[+-;Z/M'7<NM
MS?;QJ$:IDUSBD8)O1J%>L!=C;*ZC"$+&&E*R!P +8Q?ILIC/OUXA5:OW37QJ
MEH3$D-$+9>) 4J1QH<5\%L;.3B_MSWR<XU1R820G4#$C0(/6!56S>)E +=G%
M?*;@\/=8";((I42^MQ!!*8[Z*-AR=UQ;"SR!7/EH&+OHI>MG/KDA<(S9ETZ0
MF"EE%WI.ZB^RY,5\%L;.3R_MT7PH]HORI)4<J&N<,+@$A6*JH#J!PES7Q7R.
M16$'H!P@-H\5C#$)(TI*)7&JGBJ%A3&+7CEB^G+ 4)2P! ;P1E_Q:@XU!@E2
M($Q@R>?1T/=H],+1Q^O]T;<(2TE).T4$C*WF*-TEHL@=P"WC&T=#WV-1>!$=
M-:I%@\5KQY$:=\?VFQ;%CG%AS!*OCYB^8-3%9.E([PJMC=:R6"@D3,Y;XC^!
M15E'0]\E7A]@OZNJ=PTMH6X*4J%V:#6&I"6AKZX?O]R\;5_VR45KS)?#,=^L
M=G]_':,[HY6G<?<;/M-;=@.VW,YF3.&WV_1%R^A;]JYC].JBA^1$%&9.Y)KE
M0]$W,H49N!;O?$PM!ZI)IE#V]9@B]F(^U\M\)# &3&8R78"A8"EC;@^\0QXU
M-H_??!;&7@UC9Z27]KB!*%))D*JB"I@I$=020NHFEK14G,#XQF(^4W#X^U/X
M8[$&IR(=TUAKA#5G; DEHVLI,AX_8Q>]M)C/X1+DX(B%47LI0,$Q.H+>?>]C
M*Q[YXS>?A;&+7CK<^@UPH682RFQ2R7O"V"T*<>\Q89/9I!O/BA]]]DM[Q.N'
MBP5-.D=6S($4H+=>(! 1%&]LS:U[J0 3J+=Q;*0]O&Y;+.A*"\"2QRZA.+ T
M61(Q)Y#H' 171R*R6-!"VCD*ISVN X,0*N4< WC(F%'&&C H(IQ[#+/).Q8+
M.KC;WV.]2D'U[$?Y[PK&*--,(@Y\3Z:H($R@O-*QD7813M?+@IH/EFIT-9?O
MP25'F@@T-:K*H7>W6-!"VCD*I_U9D&@WRQGU:&(%<68X$B..$D]9D@,Y_M3C
M>I#W6(2VK^A=U\#J$9IYW"(I4>).I7O5"8Q0+G+AVI*70RZ6#;;NO0)CYD"%
MV=50-9<VA6)&UX,O,XK4>UR*QDE:+26U-$K%C1*,3EA')_(6Q4^@U\[U(.^Q
M*#N-,4%/7$=78Z)<>VQ-B@\ &FO*D^++$JFO%WG)NQ*K[^IK@EP*DT,,$4 Z
M:@@3Z(AT/?@RHTB]QSV:*9;**5+K .0*$3LN9*D30:U] GLN_C53'G?]^,O-
M^N'9U/>W'8NL:U4JN*R%&D&+'G-,XEG$Y91X"G._QT"6ZZ0/CH6YQJ28<HK:
M8@%/J08IY#)J\^;[R@36_1P#<X]%'!Q_@-[CBC4.R1M175""[K F#]QZ%[74
M"-NDJ\S-AKG'HN8D,4;6P)4#8.Z4NF8(#*T4@ P+698 ?9S,]9U:2-+KV(31
M:B*49%XO"K>HGA;F'@-99A2@]U@F1DJ)R,W$8X06I!+[ZJA+2 E\FL LX\+<
M/U !]I!=W/>8R;M1M5CL+Q%XU5HZH"LQ.]<PT 0Z^!X#::^34%@LZ#?%:&-R
M#FKTVL 4MN>DM:.+I9#949E >:5CL*!K0MH9":?]65#T/M12!1H3)!>I:O"Y
MIC0"4<I]D?R+!1V=VD^4*/BH+O< HMW2T]P+NUXIU%J7/'413HL%O655+I&K
M2=2/=J(@-8-OK5#$0IQI E5KCL&"K@EI9R2<]F=!M07NWM(/C&/;J*NMYX(I
M!JG $2;02& 2/:YG8\S'(O@Y9T!S^SD%9YY?*P"TBI1Z"MIH AVE%]Y>6QEW
M+$:DJ4M4*C&.I?4Q8P2Z6'G*L?32%N<_-2,Z&B5W] IJ?T9$L9; 2F,M#4B7
M6J(D<+$H!"IM"OM3%B.:C//?8\T]UZ.B"^I#@MPZ=?:!H$867S5-H K'PMM%
M01W:B,Q6>K=+BC"4D)%=<1"A ")(FT!?G\6(%@5UZ'U#["P-Z9E;KF9$%8&+
MCX A.(==E^GO:3'W&#NU[W'@J10-X'/RS;)E%K8 X+/&FK5U#+B0==$JB^6\
MT<U+9\W1,70%#81LHJES**ACJ89;+&<AZYP$TAYW'#:F"L$E;06H"67(O=8>
MF(,CG73SV\5RCL+-[T_-ATR%BFLA)6]NOA#XF(+OE4JLE2<PKG0,9%T$TO6S
M'%(NF<PT*'A@\I2Z@P"*(?L".('*1<=@.3,GZXP$TAXKBH-WJ8%X<1EB)H9<
M:H_0B&K.\^D?M+3?>E/AIGN;=9M@5<Y8/?5$K<JH[Y4!O2DFE[I@&.4-)T#:
MH](KBP5=.POJL4B4DA6P T#ADC2'FIA[CBU-H(CW0MHK(^V,A-,>&U4SU@;%
M<W8,U84J/@"+0XU.8IY LKY8T$3<_A[S9 D%"U9S\0$$N$*./4,O4GR+48^?
MM(MP6BSHD!:$GB@ "HY*K9 [VW^^(:<@K<0^F[9Q"VD7X?2^=IXVGR$))]>A
MA,@MJ?>Q &/T.>E<4H^E ]<Q>/X]EIK),:>0*"<&(#"ZUN02"T#-O=($RBX?
M&V\/+^ 6([KJ]1CL92S_D]@ .C;+H3.$7EP3H9C"8D0+;V>JH/9G1 6[MQ0^
M^  %'%/U6AW75#%S]L\J#\P@!UF,Z!B<_QYKM.:21KDQIUU C+2EFON/XF+-
MN90)+,8[-MXN"NK:&1'F:-Z^!(JY0%+B7+%'!NTEN,(36.IT;$8T;][.2$'M
MSXB,U9!*ZHXM#2FIU!"DAAY++@*J$\CEKPU_CT5T8].<?>P*)K%[8PPA% 4)
M4K11G,!6RT4W7&?^EMXAUN2<APH!/9,/V0>OX&,.:0*UYJ\-9684LO?H?QF8
M+$"'TH?8#=1)&U:'29F3:\>O>Z\-?X]&Y<780LI=*"#TV+ U:>;R6)4E^ G,
MU2\A^SKSM\4&;+&Y$^)EC<[64\EB3R1?_ 26&%X;RLPH9.^1O\9:B*X*HP!#
MH ;-8XFBS;5<ZB(YCT]F^5( 2^HFLR)H; 2AUR:5@L\-TA2J U_/F'DL!(JF
MRUT*SL+46!K3:JC0T&=3[C5XFD K^R,,6L<?-?:X-<F1\[TQE]0 $M;FJ/>@
MHQ;":*N[J)[CB_0L.7B4D!Q7J"4A-HHN@).JI=0I%'-<HL8A"50TIEQC[PH=
MLA3,-1#97\56+ V:%(&6J'& GNN65$CH.02GD!-7I9RB  ;+GIN4XY<=[YB8
MWKK,2K]<<5V=[+7LQ36;ES\6O6->+8BOG)ID"+YB"9:!%5 404<+<Z?'W$5!
M7+T991.>';ESQ 0I1PQ03$SDF)U(#Q-8TK&8T:*C#FY&$:5K\CWE8MEWCM4G
MD]]CMU[A7G,X?B&^F-&4 L#^,@"%:!JJQ)Y0@<9(A$N^NIY=#X'[PMSI,7?1
M40<H"!A2[YE:;A&!DU+5%AV J]D1\Z3[P5]3,UITU &Z T/JS:7N2R(08JQ%
M<[;8U"BRGT)WX(.;T51\[QZGOE(*O4;'+79@(LSB8^[<P(T1HDGW>;AZTBSJ
MX0 ]?L3XZ[4XH P:"W5VT7.CDD&\7P8SCXDT,PK<^V.P*$D%HZ_/8(&;:@/V
M55U3[A'"!!9=7B,&'XO:\RZI2/39%0^> &,+% @2A-JS=PMIEL!]W QNC;S#
M4GMH"'VXP)R*!LP^8(4V@557Q\3@)7 ?8 F1U^I3]N1+A=ZPHDA(L4E.,44W
M@0V.?WAKPC)V-9N\R6@;4PU9$YGL!/10!.V'BYV!)[!58B'O(F2.P9*(L0D)
MNR("ZHFT!Z!"RM@U^PEL8%DL:1%4QV!)O80<,O<$S! E4(MC%<C8RQ.@A/G,
M!"Z6="QA8'_90,S>Y= S,WG(%YM0 _NQ2%RCI"X+>:=(WD50':!GC+< T%/K
M8)' 9> (*61+M+$&Z'4"6W,62UH$U3%8DL96<XX]^>+ UU OMMIC%^ECB=4$
MBI\?@R5-Q0/O<4K2F-)B9),N'4*I6)HT%S21KTEP NU.CXPWBXPX0/TVB:BA
MDB(1:"=,1F A "K%"2WC,D?&FQE%\#UZ8H\04U1A9_':,5MNV3-J8Z.S>]8M
M?='"1T/B8U%^.0:20!RT,]2>JP8'17R'FE(H\UD?LD3P^9*X:\XYU=9E+!$1
M0F.P-HF>V61H608"CHPW,XK@>]R705"! H54.G1.U# H=]][SZF7">3@;R;0
MI[Q;[5Z'Z19OMT^-)M_HX\WV3.7FZ>;<F/;\Y;=7NW:R&:^?B/BJI>8""E*X
M@ZN>FF2MW8&$G#U,8(W$.T/WV>YL=<IG^E5_\9(_CMN,[']_)&I1)'BS?8<,
MS?N:H[#$@HT))4Q@E_#$['^/)9X2N.)J\1(2A+'$ [/FR+UUW\!/M@+\8O]7
M&?];'\-/OE 1TP$7=6VA:O.A$':90GG2U=I$[(I/7DXDO7$2Z8O-$]VNQ^';
M6L_N#]'X+D+V6!QU])Y[3PJE5>B.F3.22"Z![:=.8!_.40.UQUDM+LF5!MF%
M!A53)6]J+'E7:P32">QT?BM0W]Y_B='-AY:F&3I3-2KD[%*FHE!S(&I1HQ;7
MDX,2YV!4!\9JCV.&Z'/R8-K4(A;9?^Q;S-G^)R\&W0SLZM9F:]+4=,XDC2D$
M]4@04-F!Q\J=64,:,M6 \Q/8,G64 .TQ,MG-!VJ)20,DJ5AZ";%)K*TT=1.8
M<GPK0)_R^N\/['6W+<?;K2;3C$Z'F NU1(,"I'5,N?8"/D53#Z%,8&GQ<2&S
MQ_Q(BG0$KAT]0">,F'/(+DN)KH(_?IOY<K-^>*;;T^&R'CQ]K+^1!^O=<&,J
MX_!$K"51<F8O<:R: '!48S%OUB,X\VOL)F MQX+)'GO9FPP#RW5Z30#B 5.B
MW*B80K-_:O_?VQ=V8G]N'+O!O,^EJ?\&7 ;)]NRV:8YG1C3^OKC.BV,O;J6\
M<NJK]O;\R+^!+;&KH59?FF6TR45, :51,D6>,,<)%+$YBM7&_ZGR<+5^>%MW
M]B9OF&M]?D#EYN[9N2\_[41<<RLPDH!<8PN0F5 MKS9MJ2Q4LN#QN^:%*E<4
M,4SD N>2,5:T?+Y0\):#H#@LP0--H#[!NU'ECGWGK>[.OC&XK@]/]KE0UGO)
MW6=2T]N!L,36%86=3PZG,*RP\.0J_$E*"&T4GG+LP1>Q?R5XP>0T@0L34"G'
MB](><[<H/D5GN4$O4$*HVCDIDX/.N<($<K?C16F?_>L$/&7UZAOT%IG%N5JT
M16K%13U^6YJ$C+NW6<L+MDS$@#,'A<3@V!1^T%1+Z8Z5R+D>7.+C-^"%&N]M
M/Z>42#53HP!0,E?J#9!\A-$"MR]>XW<_Q..N%[10N7.FIZ^_Y7T^V=^2Z^.-
M8'M<'%N]:QPL>#ES5YHK*U1-&%SWTKM?W-3"Q:ORBQE$8\#,6!%,1]6F5%!S
M4[;,MOAE;'S2G#G\ 'W7CI4$)*J#+(E";QA2<:K>1;XDF'M.,*-$H(5@$R68
M>W>"V:GQ1J!]S !UUXU4F2P1A J!I73*CKHOP6)K6CS8'R/8G77;G.K],X-C
MO/_K>^]&[+W8=W=YUFV5\S:.[FZNY=9F=_95GW,$/KPWY5H[QTZM:0='PAB5
M*S>F$G%T3EV\Z4+VN7AV5RU+\KWV0 X0(SM,''.!0?Z6=?'L?XQ@;_H0NR]X
MM?YRL]M]^O09I[[1DPOR[1ZM'O]VD]KNT><GFY^?G7@=>'\0)U^17,9,F<6!
MN(9%9(Q<V7N$"$2+DU]X/TM_;SHF!"T1O$ !P1)# 5""U)/GL/C[Z8J;Q0:G
M$7MB"M1["E$P0:&,DBR?9J!6?,]!EMBSV. ULL&#Q,%6?9'8-2'JV/]>S<H<
M2BL0B@0NLXN#[W-YV>\:X&]+26T,)3L\"#9>]=DOC^UR>ZO=<,Q$/TBPL3 #
MC(VJ@PYC%4]FTEXX9^>S#_.;&UB(?G"B'R:S@5*#=O6:!6I +L2U=<OK0^/6
M\^P\^I%G]/?T[,[ZB1GB>.$UDC,'\?+*68)4C;G*J#QBB46,/N90FX[NS;/S
M\@OYCY+\!_'\6HWJ!8"A=V@E8C/OWRAVITU19?'\US>?OJZ&>)AU2"Y$A]Y4
M6+'X$X +5OOKJ0661'6)0HLA7C=#/$A$Y.Z=<-,BG &@88VF"S5=F&)W\UEQ
M.HS@F1%>-K)O3^\_VFS/'NCV]-/-=KOYV;"^%JM'#E,9PD-M9 0#Z5 T5@^C
MFV2)&=FR[ODLE5IX=E!_)J/83ZLM8W,0N*%OU3>HE2L$8]6$_-FQQ_2%\T?B
M6R.2KT@!4_?@,IN"SB5T,MI+DS2E@?N%\]/C_$'\?/>2 OO<4DH@F8@=8PAY
M[);*N<QG).<-/'N'8F^S(-9!G"G$GFL/#GH3X Z8I7;EF+64ZKA-R)DNQ#HF
MCU5BP02M17#FC;I42"90+=6&6)W$.B&/->DH?5U(?A#OZ8*B5%32Q$ ^$I;>
M8NA)NJE3C1/RG@O))T#R@WCR5#A$'YS)S@R),H[^ IA[K=+!$T_(DQ__Y,5Q
MK95ZS\5V#N_ 641R*)63:P#B,-9BR96DUK%AG)(#7[A]O-P^D-]6B-1#(!&H
MGFN44:  >ZRI]#0EOWT%XF22[DL:<TDQ(&@!5TV'.DH^5,8<T:M.R'U- .+#
M6'&/OGARD3..BI/D"0H!%HTA^3*E&9[I1*AK5F#A,-(KH9?>NFNE@OC1&CXR
M>O3)98M24YK&68A]I,0^S*I;IEBJI !CB1%6BE)\9C2J4V3%J5?[_/?&7_X-
M*-]+_4N7L^\IA]!:!P\>59I!PY;ZD7"90%_OXT-GCY5R>R'NBD[$@0^(H[U!
M<:F2*5R7)M#+\E,^X773^X]4_X4/'CVN'CSK<341H['L,6!30I$(F>I8VT;!
M8&@B&ML$BL8>$2Q[[!0#KN<BWJ=> 'JB$BF8Y0CWR@Q'7(U^MSTS+7(^=J0^
MMIC\]!Z?ZDO_]>EJ<^^!MD?[DBBCD]Q7_>9V.W37^(2_%44G)UQ'^U+SJ:^<
M]6???GS)K[>;D:M^M;VOVR>K]NJ7O/? YU##1%R >A]K4U,R6<!5X2;)E'H(
M6?U%'GJT+F#AVM5P;7]^K=5 D@1"L-0066HHKOH,EBYF"6D"'6L^7ZU79_JE
M82QWUG8;'J[JB=[<[?1L]^G3N_S39GOKA'>[WV9*3_1D\UAE\'&].=D\?/K-
MZN&CR33KA>A+JRYEU Z2F7-)*28-*37A&H_714P0MCUV*$W$6&)NS2/4T&K2
MTLAT'C;IP!/H-_=OP?9@RZ(C%DS%O%R."7+P*2&""[ERR(B6OQ:LE'N>J7E=
M$4Y[5.4Q$Q7$6'LV52X, 9SS);L:":;0%?8/X33TQ9>F-NP:ZX<W'V[U0L^,
MF9F+&9N)&%?RH:B:+2E?M,NFECD%"9;X5LMP96;&=4C0]F=IU)-$%Q)"#Q 8
ML3"YENH0'MWU"5C:G;5H/V*ON#\#BT*F+,+HE"T@%3&P;U!2RY1>], Z:@,[
M=JSV:%?9>Q=#: 4;:!'4V,4E(.@)>ZTSMJL[:\NBF^YVW^A.>=L>F4M\)O#?
MSWS5>S$VAAR]1I?8'"-&1237HTE&&AUQ: +1;)( [L\":V0&A^Q=,PU)A<2"
M&]H_HRN!EC1#"YR'CG0JS;/$$E&A841,@BU[KLCJM<[0\N:A)6OL/5#J:91\
M+\&2ZY9KY9*KCQS836"=U=4.=%_I6-D[??=#C'\??AU5@2PAA%0L%8(6E5KW
ME#0!DV24*2T0_+<H]3LOFB/<BB.2-*^M$T@?5<5B=FIPF+-*S^IS3V/9W,3@
M/DSQ7L1(I;GH>H9H1AVPU0[8O>N,>4H%J[[1L]7V0AM\?<+K,4_Z.K)?7[Y@
M'-S='A)$Y5-=VR][6R+Y^B>X_WBSWFVVKZ\&:2-^;I]^_.W]>;D-B:G[48+J
MHNQ9[36!5'7$,9FSZ%/:Z+3PZ)#;^C-%JLURFU1!"!EZM80G9 K4-;?)^J,W
MHOB;I=OCO/?#H3VR>)+N*4EIU-D1F7L*OG&!6AIP$H;2W90Z_RRT.AYO!=J-
M18K<_!A%*UA3=BDY1>W.N#59;_7/P%Z,M7R]V9UM7YSX#-AKXD)B]2(=:\B)
MH>%H&B:A46H^B*MM2I6,IH3U5=GUN:5]%T _MM>LSUY =ZJ\.]_JQ3#/Y:'G
M%WA^Y/GC<84W#_V)RZ&4Z!T'*.I)1BF7G#0YB>VRP(4OSYCCRS$/WHZZTV-C
MV6K]4-=MI99(W^,SNPLOQ\*^7NOYZ:9M6N.3[[@UH\K7%_?MSKIO5^^V'/5/
MDL:7=R:-G?K:".^?J:&752(Y*:,/3BJ,*28/WG,#ZAUA0L%@&C ?J(%Q$T70
M8 A'Z,B5";+]A9X9*\\,YLM0<#V ':W9"A94B! *DK-\LPE C41%^P3<]._/
M4OR/GOS$ZU_WE0J\BY/XH\1YYS?_<G6V>GB1\HP=R>>_&<2]KV=G)RHO3]K'
M],_+J]WBW:M?LJ]^U>UWNMV=[WY\*N?O>9SX,,$MNM&QTT-)HWVUE]J=@J3,
MBJYINNASY>FY<="Q&L>[8/B%Z=KMJMW:G#[F]6I_&]E_G[*6.(L9R?XH^S[-
M],]2F-Z=PO1G*/Q"U(MV>R7_"UW_XN@?EO;Y@OT0,S-"-H%/Q;.VVH./16.:
M?,SX[&3UC_/55&W@[2;/:_GT[OU+P[^O3^R)DV?V?Y?7YYW;L)3MWK[_,1KC
M5<63%\9XPC_OSE=O-L5GQ_ZP(;I ):HKR3F W#R.;CLME.I=:C4?\5+MP=%O
MQC;-2PJ,AW=7Z]7I^>G[7;/RV>.5V=OQ+GM[09?35PSQC9QY]80_3!SC1 9"
M+,UE8'#L('75$-G$CEZV3O/XW(/C,7KPHW6N-]?RGYO=X]66[;?OV- ^WUVN
MV7O5MUXZW[NKW6[\??QX=?/L;+-=Z],+1\PG[]<,;F^:GO$O^K:W^;->%M_=
MR^)>O&P;:UOXHHS=&ZWFXOC-B^-_7/8T54VU2RX=0NXXRK!7(:XU0B&:B.SY
M5^P=^^:?WM=VOK43=/?.)C.52/R;G6F=4+T!ZD?#^H$A9J4FW#$(N&?S&OG9
MO,;4L/S1(@XW"[!VW/R?WKM]]^95 3IF)/([3U[L1UH]W/P+>[\\],<G+WKU
MVH@+C?6 *.RP:LJI@(>6W&5\C,]-/1XC/5Y6X-GMWBB^O^HOGW[ZBD):/UEM
M-^OQ+GSRC7U@65V0YLK\07QW?Q#WY@\ 2N@U&<I8+NKY>@[FWGWOK8A+."5!
M-#7 KTHD_*;?6; 4B;P?@&>/U,5 -X!+;)IBGL"$Q@@ +RI3?J&;AUM^_&C5
M^&3>BRXMY6VE*6 7#U20"W2?9<PMBUEKF,"2A,,C=Y@^P;5RC-U9HIE!&:K)
MJ]@KH"\ $:>P<.@MR%WD5L]WXWQVOK4?<YPT-(<92LK84FS0>ZIFARU)<T''
MGRFL"CHZ( ]BD5F9V64I@038=^XJB@3F3VN4/(4.B'\$R&]T%&K^?F.7G*-9
M4C??:CZU%H-P]!(JA9-7[UK [-(4^F,?)YJ'Z4X: 174M$[PHWA.3=20<D0H
M$AS/0*%>9!^GNAW5R^_R]N]SW5PHH4H>-3]R!=:.J)G,*!M%84HSB997"^1A
MMNEP#C*FW!P*Y#[FO4=;J]S5?A/H$[#(EQ53UTU'JX21WX\ZYY\^_537[=&I
MH?>;546CK<$WYG/7YWI/][:4Z0T?X W[*BXG,/[IW/<[.3+G?>TYM^0(6@R6
M@D')2*;:4W9&XCR*Z4V;PA-CT'NPUIOM8O# #+;IZ@G7DUGFGY1=5"=4@Q>@
MEJJFU'((/;="B:?4!OD;?;S9CD'9;]>KLY<,>K:X?)9ZR%4?N(BX7BI414P-
M!'TG]BX0U GHH>- [S"[_[!%1,+(%*#F@D7)LA$SQ"R:^I0BR)]#;U$9_SKC
M228M:FRCG0&D")Q"B;''8)EKZ&U*Y52N T<.XD>H.T^*7;L;R91E4$YS;8E]
M=IDQ3L"/_#YX7V_UR9JWXX?:S\_Y='7R=%^*\!K*AI&AF.;K+?<.P;-%'6-0
MA>+,K0!-973S6A+F,),;XFO&%K Q@'>U]EZ]S_:$ZRR3*#YX%%'H\_MW/[MS
M]^ZW]QZLVL;><H[.I80H%'T%$8(@6E,2EUT(7,=Z^BDXE^O(E<,TCXZ%M!LO
MHE;@4L@A*B-!9RREIL6OO!M7[HT3MZM?YNA/8H>DV:1M=?9;*5PUFY+/A7)-
M(;C%GQP51PXSG32:%^>LY#)"+96D$R5D[MJ:Y<H3\"._#][%KI?G/'EVVMXV
M%5[##$AR9-]204\)! #+2(82U2%='.4).)5K2YC#U+DU,B!28>31Y PQ>]\;
MAQ@="[@I+.]Z"WI?K=M%O?-9FGM/*J''$!*!JF>'62OJJ+='7' "YGX<Z!W$
M]EKAE#4$;-B@6Z)@CEH5-3JL =T4HOM^T/N3,>%.W8X>XW,T\%B3=/"YA*90
M7:JN]!QR\!=E@(&NC8%/@B*'&FM(E,5"0>G +M3A*%Q6R?9[YBELF3@*BOS/
M&:]E=?/D9#68\FPYVRR3A!"U%R1UDB*("^REQ$0-4C+VQ!F,/,R8,0?Q,1J]
M>@\2:Q'P)9)CB)J1B\G-5F:PFNJ*PM#ZY.D9S]&G-,8HFNI%"7G?I=;L%#RY
MY-22R1FLYY@10PXSEEEX;,?MM00C1AG[ <&[V$KJ ;J;4K^L@S+D_OFH@S9'
M'Q+&0K T1KE+!23+<#!%;*%Q<A#]%+9M7Q^&'&BT$K4Z]36X"-V//36QM)IK
M(*Q99[!>XXJ4*Y_\?;-=S=&)5&@./7>M&B%P-F]B/. P9&LC2(L3.2:*',2+
M5$V H?<XM*H2,30H)E7#V&G@^I0VZ1V4(I]N=N<GJSY'+Y*;<" *V1L[/!E1
M&K$F9]K5"./[XD6.B2('\2+(4KB5*L6RFIJ!DT\L/@OXT0MI&1-Y1XI\HV?<
MMJM99C2YEQQ;EL2C7T:O6-,HO5Q"+4HF7Q<W<E0<.8@?\>#3: D+8VUQ[PF3
M>E]*SA)=S1/K['E(CIS_LM*93@.G7JN75+*K8$F-U@3*E=&W49;)S6#M^:PX
M<IBL!@%&:R8O!< W)8?9PDR.6%N*95E-\HX<^7&UY:I/YNA&P)54V;C@O(":
M9*7>>C8EDE(+4GEQ(\=$D</LW8_5U\C:G H43%Q;&6F-I<+).5W4R#M2Y,O-
MMFYU/<NY7L(Q(Y/8.^Q FJJ6U#UZ=4E*2#.HSC$KCAQFMC=R[-A&'U^"' $Y
MH2F4I&(YL7I=_,B[<>3F=G/*N]7[;LAPF-7KK.H8&T$$*$!L<::,$C^ECPV4
MLOB1H^+(84994X[<6W4M9K $QR0K<N.NVD:A!US\R#L.Q.ON\6:]FZ4>";[G
M#+VFTCSTJ-6)3STC01,NN*P].RZ.'&;E2'-CD5DHY *8)L&&04,/Q8=>.$RA
MEM!Q<&3+_6SS9)9+1YSV!M'[@*F#Z56FFK-T]0V29)Y"%>;KQ)&#^!$15.P1
MW*A)QK761KFTQA9HFLM]"KMM?A^\N_KW=\#NBH@X23?"7CFJ\:%UA>8SNR!>
M4\U1FK/X,P$W<HTH<A O$DI!JII)54#(L:\U6Y;#EO@ZE2EXD:.(-!?5()Z_
MU3M6@YBD3_%*+?#%GM\.XFJ]:))E*K:SSR9B)^!3KBUA#E39$#-Y7S&5!)@L
M")&72$R</;E)-"]\"V'NV+?=KD<;;%F-\BQS-'O)*95.2)$(.E:BBF"/DD1A
MK#,8V;AB% ^S,@-\<^![BRD8BDRN4AQ5C;&T$&0*.]]^WZM^=K+ZQ_GJ?9=A
MN@X&'UJ5"#UG1H92<E4)BK$4,0$ DQC*O(94.<RZT93 LDFP.!_!(R&[I)@=
M.A^Z]"FL]_I]JMQZQ';E7^S'Z>.WEG><&&,.,S"1<_)8?"%A0-":-1%YR#Y&
MS3"%\<WKRYC#9!'4RNA>9SE$@1:Y6NK@QR/MB5*?P:S)'T3Q3Q+TZZV>\G:U
M?J?"_9/T,='8DL3W&FN"R(DY:"R9T+M69 X#%3-FS(%:9O;>*C$W%BC!40 ,
M7B@%'7W#IU K_6T0KG9GJW_,*QP=9CM=\(6-$E0T@*5$M7=N+G.H"B&$*6RG
MNX94.8A781.W2JDZ::,*MJ<PNKSTI(%CS3B%,9>CBD,/-D]6_.L<G4HDR5!2
MR#5G@)0Y14#??6\2J+DI.)7KQY3#9$-<Q5A1J[?LV0M38"2OHVM4MP T_1&7
MFR<G%Q-D^R;,<<6CPTS@IMS5E$JCYB&,C@PE^-$ IF9)C:>P9V;ASJ&T#'4R
MV4M=JIA/41(?M0 Y)]'QLRH2Q^UWWH+B?VYVCU=G \7Y67YPD!7%L$L>'%9V
M.)KW>!]32Z7/8$3DBM [3 ]::*C0FJ6<!-TG\JS:307TGGOP4UA'\;9BD2=V
M._C7S=NV#TV$)8?I9HW1.%$ 50C -4J>FF9,J;<4FT[ QJ\72PY313UQZ#F5
MZGL 5>44N(U2R. DQS*%ZJ5O6Q@LV\W;H)L(0P[38S:"!+&<(!%:0NG1N]JX
M5=  (>KT9VCGQ)"#^)!.E40K-LH1M'D,R8W1<-".+:<IS);L![T_2<0?>3SN
M\VS&4#"3<8-\Z U<39Q:J*%Y']01QAELK)\720ZS(U8K(;8:2^L0?&52Q,Q=
M-+E4_!1&%=Y6I>GLT:B,\,N/]O\\0LYAML5ZHX@TJ#Y9G$G,):F'(.2:AI2G
M+TIF2)3#S(\$S[DP@Y1D;#%O(L*C>A@(6UH\@UH=5Q-VONL&PAP]B7!NL:J4
M,$B2"D-CIH2^A3% .H,RIO,AR&&RFYA4Q_;&7A6\.H84NZ\4M%NV,XE]L;^/
MW.=;?GCZUDI-$PDR!UI@VD*.%FG$FQ@!J,%2XBS-)ZQD[F4"/N0:4>0P<S:8
M.WM1)@LSOK4*HIAJ[AA3E+KHD'?=J_5X];7.LO(@A^3'_%T:*T=[8RQ50RPU
MAX1%P_69DYT"0P[35;MK4$U*!1,4'RR7R=68$*3DF.H,NKM<T1#:TR>;M^74
MDW0AOG$01',A/4% 2V*\"!"U[#CB)!9T71N"'&9?2W47M9^Z.@',GF/T:HFN
M!VW%Z+!XD'?> =54=)9.!+)Y"NAC\Y- [TQQ%,M6I"%,O)M!L\I9<>1 V0SD
M,<D;@GD('R-'WR(T$R:!2O)3R&;>TO+\NSL/W[$4TT2RWL-T90@Q)!:'G#K0
MJ$N) 7+RD*IYE#[]LH/SX\EA=$G*HSV4CHW9T')!SK5Z3$T34O%+9O.N,:>O
M?M7M+?O$6_UJGIM6*I&+W71(2@@43*6,)D"U1:?,TF;0+VJ.5#E,WRAM,7#B
M;"0!UTV>E)PY);;'$6@&E4*NABH7>ZANVG=8K;NVL]43G64]4RA];&(BC\Y#
M;;YJ[S%H"J/<84]3J'-V3>ERF!RH80MY#-D[A:21>+"D)W]14O'9@L;%N[P;
M79Z_U9SK)0/ZT02FU=X%%!2=!:>QNS^C.1Y=E,L1$^8P:]=\(5!+G5/K@)UK
M#K6:HH$T*D&X_Y^]+V]J*TGV_2H*S[OW=4=T,;4O[GL=@2U@Y.=SU&!A1OJ'
MJ!5)2,@CB0;TZ5^6 ".\0;MMBP.G9XR-=-:L7'Z9E<LCT#"MDS2RX[&=P\'V
M)+3&X].31SN#P4C!?72*F12Y=,89BYG&BCN3K!=5"(8\T.5<3P=EK+!VP43J
M.9>8&<T4MH%R; $9B"K$++ZN9_\=1T-[<E?7E*KRS'IR/!CE"5"  J'GV!#G
MO+)2&!$T#^"B5D %/&6>64_6!X[:,:D5J!GNK#+6!QLPBQ'G42VD\GIFZ\1-
MXX^NOWQ2:B80K[6W6!O)0:\HJV72AB<L+0LQR,JKF4?-,NNIO,/1*D$80%/-
M;<*::FV)-I'%8%6J0F;('3MUL)K1SZ=V+XYG@_%=Y9-599XUM1,B*CH;"6!B
M3BGH&L4H_-\YY:3R54A=K9EG;?@&F,1JX!,)J#CDRBN9A.66:5A;3:O0/>"^
M7>B^L*H_*8'@2:DD!UXX$8%S0$+<,V:D3C)@3X(DU.OJJZ2GSE7KV?,)Q$27
M\@_#.>@MA4EBP5LCI37\$>PH[]EI; YFT<X>9?:(,89)2XCE(<'Z*1L%Y]:
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M?2MG1%-M#:=(.VP!9!N-M+$""<N9#9: X5C?X-"JD/,FWXY[0G+2+GA_"EQ
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MW8O>&-!I$^Y%M_,D0UH.NZ1<['_2&+8[[-+>SC:L5$[YWKTHFZ_'W?'V<7$
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MSUYD+NE.IL<?\]H/6*2_['M<K>+2SK:G?\"1@Q-?3:?C;RQEIW6H+?,D<86
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MEY[C= E):G;^H>Q<0Y(?RO$WD"2/+6&)*>0C38ASJ9#Q1B(M*(N@ZAFLV=^
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MU>QE]58^9B_.3D>7 *S]/E[>O5:OCT"]+EF"\5J_UD!K&03'5S:!U2DMC]"
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M2G$FL2)Q%HDWFM.-BUD&VCB;:WRMP<@<^S"E,%U7Q *,<>ZQC41Y4OKAN&I
M-<E&%NL:![B//WSVI0@[/KY+0,]1GA<Q.V(X?NV3JOM.G-A YWYX>K;F/CS
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MK;<VMM??9-NMUSN[S?7V]DYK%@UO1OKF*S-1VQ0P5^QW.4ON7#,.TCLLZ$M
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MAZ0+4'/&<'F2^Y?3%+23;Y_3SWI%/JW^,'SHVR)FI,>PHKVPK!W_>M2K9IG
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M2U1<*D_!<AVV P<+62D):$X=D 8%)4Y#*Y"$U&%]&_]:BB%*@/,4]-<$.(L
MG"G=5$MFL8 .$.<4H([FP$BA@>$"&R]4+ 89 8?/V<\IA0W5;&0*&WJ<84.N
MZ(R&WJ7 H10XE *'4N!0"AQ*@4//-@A@*8%#FV,!G+S@\UL:EXKTQ.+Q,K<<
M,*THH(PY8!Q&@ MJL-"003YV;2S!"YY"AYXP:BPE="BAQAU08\H_@2%CT"$(
MI/((T%Q;()%S #$JD/0:2V*JX*$Y*P:EL[,4/)2"AYY>\%#"W5OC[J720MY
M([$TP*,\UDEW&FAE'8!0.X&=D)3P%#Y4=Q9=<OA08L8[,..4$N08(5QQ#41
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M^=,8F<Z-:[$-R6NY5%WS%O)L_<Q_/A%;4UZ-E,EY1_%UJ1T/S7.!C8+ 2(<
M=9X *2 !-N=>&@$YH7D07_SZZ?'2O!G)5_FH?)6)G>^;G:>U4>$E1L%&1"B7
M@"IJ@&9.@? WYG-JJ%5L98W,GI>];-]DO56$IS'R61S;_]037/E6O8OU3:\V
MO#DIBWZ9A8=^*:P/RS,(PV/GEGZ$NW22_RR%Z))TXBG*O.[?>1N'5XF'U3W>
M!D(M_; H_5BV]GQ>#-]VP@(%$=SRP[>1K/?&5+T1QFZ4WA5)!M].!A]?"@&
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ML=];'P[+PHR&L6A(N]^ZQ$;;$RY*BL-<BH.]Y'.FTBB))?#"$D =#CI#L')
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M22@R#XI,GXD:9Q&"6@)B<4"1/':!$0@!& 1YSEDLK4U6UF2#JMI7P7QN//8
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MNQ65?,SH\Q#GXPEX;ILX$$'GHI@L-#I( >> 5;&8K%<:&$\QD-!*R:TE1L@
M/6K^_E(UZYN;./2!3],3A]Z!0UM3Y4T#4^*<Y( R"0&E*@>2$0V@U$P$7B4\
MUX%#60/RNG6V?CJ6?\Q:&YZ"KA\>]5W*_JFK6C#>IF:U2RD3X;;PLSVM(#"K
ML+,$ 97G 8,(#9^PJ@K1(D:<5!K&ZLH\* C78Y>3&^"IB_G$<8OAN"F![S$W
M5%H*6,XBG[' <9!:0(7DTB*GL&$5QTF6#N+OP$AO^KW#E,U;:WE>.1GC/J74
MPKO 2W-:H!.O"?$HC]Y% BC,"5 :,<"4Q!KS"#&D<C:J):!+XK@ZN/43Q]V=
MXZ8$NLR=,S:/<:L& ^K#)XV\!PSQ'!&FE*6J"H.!3T>>+RN;]VW9/PE3.FUD
M)QT=/?L]5U4_.XE4?);1:^VH.^KHH7>!34[*P GC0G8/G\H[3W+*V9PWIZ8<
M/G=\U1V]Y]:[L5'Z]^KO9\OP-BY"^&[K; D2'\_%Q^^&S3,^WE#PX/^.H.U^
MZ.F/:K33?1VNLW3_^!ULM=_C_>^[GYO?+6UM;L/FG_NP]3',Z?CO3K-MO__?
M=_OM4RXULQ8Z8&V. #42 L4,!<&*QE;D@GH5RVBP!OK!*=\2DH 3:3X/TCS\
M^DE#PH3#!@1YI&.]"06DIQZ(G& (L>80FD":M"%_D)^>TH?K9S?=R&,I0>(6
M;#;5>I-KB#C70!D;;*> GR!L) 2(8J1SI3CEM&(4B%),5,W8[@$D86*[!;+=
ME &EA#7.F!R$'8P=;QT!DB )F,$,&B>=X3BP'6DHF)*([Y)$')L&%7E1=0@I
M>D/=.RSBQQ3I7#\1OWV^/>-(BP Q6]]L9Q07]<]^WWTM.IV$.7-ASOMI48^Q
MMQ@;##3-8]7#<<$F!Z@@!B(I).=P90V+AA*I6$C-V.]!4HX3^RV<_:9$/J,4
M"Z008"X>5>B< B,I!4P:;@CCS,=#4"P;5"Q!TWXZ(O^,5I-PKY-P3PAR*P39
MGQ;@FBO#E4? (RP!I08"G<M@-""HL*<80^Y6UJAJB)2_5#<6>P !GECLEBPV
M):1S1:!4D ?U6 0=&7,$)'(V%IZ$R!LL,:85BS'Q=.H4+X%S6OW>6::2\[D/
MG]Q4^9#JC+-?I2;W+@:F\B+U$NVQZL'F9//."Q\$JV&]YRX70[C8[ 1-<T&3
MO12V+#W1&GG H%6 HO!#0J. B =:2G"7TR#]<8,MHX)Z8L(EEAY)3'B_3#CM
MM_>4*8XU$%XC0!E2(.PJ QHKDA-O)3$V,B&12ZC:]W34@YVKLC_)_?K(_1_4
M2TC@<DMP.9R6\(HY0:2G 5QB6R(74Y0D@<!1+Z&C1#D;[?N&H,D_7S-V>]CR
M)(G=;LUN4[*<T!QYZWB5^!<4:NZ!M,'JSRD)V!D;#UH>V8WQ)=3R^X4L=\7@
MI*-/XYS\SSFT?B.?<OF5.^LI"RGD4+>UN:GY[.QO^53DQ(,5DDF"82[!\'E:
M#^,<8VH]!MXB&J2#AT :;0',A;!*<0MI'N/:94.B.1M6UZR$3$*;)XTV#U84
M)Z'-G&@SI89"K9&U1@,-*0%48 $4(13P''.+N(/C5M>,-C">4Q%]J'(X9\^;
MT"FI,.:6!N.MADZ]:'AXU=*RXZ^]Z=*?^50<=..9!43HE^,TPU$O+$4<M;+V
MIM"FZ!3#PH^/\<;E-!;AN9MIH6H'US]FT&?]_D\L0;?J%#TNNQ$PH>Q_#9,?
M-+*B-PF>/*_)>1)3!H/$[N=9Y[Q2A_-F6.<TW;/,^<TPSU3[[A;2_GC[YK3&
MX_7OK>X6;GU\QP[:[T[WP_6Q ^K^\1]%"S=IZWB;['P,WQ]_./J_[Y9\PE!I
M2G,(3)X+0%T,3\FM!Q(%C4$;QP2KJN)S<3WOOLX)MXG(ZD)DA_@39(@R:05
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M]]9F$^ZT/W\[^+.5-X\MW-FT9*>]CG?:[_#.NT_!_D 2$0\$APS0''*@-73
MYK%ZFL#66'=S,<_D&TQ#T] T] =#ER'%ER:RQ^U-!Y<Z829(3$-K.O1QFZ5S
M9>W?/8#ULGY[KM1.*;H;E1Z<;-%Y=-KIF%6BO-1*DFB&"D 94T!1&7>$$24=
MA9S&:HK7*RG>E&F?8E4?+<,N_'@D,>QB&';Z2$1IQ"7""N12Q X03 )#, '&
M&.0\(5+CQ+#/A6$7[?E-#+L@AIWR]@HL+<50 "9B31M%<R"M)\!AK)G"E!AL
M'YQAGY.%^+;TN2__?_;>M:FM)-D"_2L*[HD;/1&4N]Z/[A-$8*!GF-N ;?#T
M<7\AZFGD%A(C";OM7W^S]I9 0F!+(- 6U(DS-$:E_:BJM7)E5E96/X;B)):F
MZ]%TO4W8*&+=U(7A,F1ER)[!D*UN&\==ZX_7BXYCBUL$Y'T$Y-'TE@Y.& L!
M"T0%=8@K'9'A1B"F=<).&!)"NN>9?VLH)0EY19N5-#!=$N:6X[>+T"Q-2],7
M;JX;KK!*YY;.71NA>=#N]OI5J;;:U.Y&WX]V$'_K]\YWVX.Z7AL\ZN"N>FW_
MJ@N^%56ZB"J=3F*E7@IMA43:YM*W6@ND,0O(:YYD]%AZ85Z.*FU:(FN5\XD<
M8"*T+NS7<WBBUK /5ZS[_X5JTV?*P[<>E4>P4\K'8#3#/!CA#.?.2J9E"LPX
MO/#:4.7+U^?B[5[VH?/>P'OT0GU>7O7S=9YN>=] A'F6'['PZR)E,4^VAQ.)
M&<D+AZFV"$8/^-4:@C2,&TI<6:^$8)[CC:U%RXH7$?3X(NBID/<?V[F,!7A+
M =[$_FX6C:**<V2498@;PY".+,%8.8VC"H%JOK&UX*%)!7>/C[O(39!$<&JL
MYPX;(WQ27 );>I*4%@5WS<-=];_CC+WM4ZL9490Q1$BN$N9(0B9AA:QTT0CM
M!5$.+!XM=<)6G8ETJ^ 402=.O: *8\Z3<Y[8) 5-Q,C A2J"LY'XV[_"'Z@3
MD"W6( ) 1#Q2@)[W' F.!9@]:7S>CD9F=X W,+/PN2)OUNHM 797A^05\_?D
M\'M[!3_*9&+>>&1R=B 'Z8*,20DQ&#42P#A2(<#\R;7 WSHU?3E<L80$_\(5
M*^.*3]=2&1/P:BR+N1 21CQ0C+01\$^MJ*0VQ.C 5+/YS\=\=E3Q@D#]\#6W
M NK5@?I: '"N99 D(ASR86W4$Z3S&1)1.ZT4_)1&/CFH7_@ZVIO+OC^#63[(
M!7E]V6K^XINNMUTI>3(OMW/7J6F9"&LW$=9[R)J7XW:2,]HN^U\K$5Y)[FW_
MW\MV/PONP? @#L]ZH<CMA>3VWI3<9L1X@S5'446#N!<8&1H9$C)P!7I;4$+6
M)H&MNH6X%L\3$GQ63#<+>C>VYV:PP?,-<I9:RW9#"SZ)YQ?366LOEJ<:;EI*
MYZZ=W2YJ8.TF0NG<TKGKV;GKU+1,A+6;".L]9,WQ02]2G%S\V>Z&=R#"X_DM
MZT [5VI]U*J6ZKU4?;\XJ LYJ/M3#JI(5A)"*:+>Y\-OG$6&*8EB"HI:SHW"
M=&T<U+E7AE8"O>K$BV5XEZ5I8?:U,\:E<TOGELYM=I;/THMI5_KLK-X'O_??
MR_;P:V4$BV);2+$=# ]./EPIMNB3Y4HDY!RAB.NHD:-!(1.%#,P;E;#?V**S
MYSJ5M+QG!]BE%],N@%T28"?R:*,BPJE\[A(3 ?'(0SZ!R2/GP;'64?KJS,/U
M .QZ0ZL(C:;PUK)KBA?>6A9O78>&HN$Q*JJ1D#X";]F(M(L*N1@\<WG_7K)/
MSELO)F/AM>W8KH^;K>V+?KO3XINMC(0YPD>NUP<4H/KI?V'0":%WZ3JQ-7[H
M!7CHA]<:-1CV+G[)W3WH==IAYD;KQ&*+;4>.FC''?#31*^Z S;AE%AM'DU$A
M<GNZ?QM]X?F2L^H]R'5T?*.<J+D(D0&)39PY+7%(0DLDG'2($^N1EDPBD,T6
M6V&MBOB>(>[EX6.Y4N/>'/ TN&]>;/Y_'GV %QC89A'?+350[L5Z\^:DSDJY
M_:[O7.:.?-/KYV?;'M;%%RT,Q%W%%XOR6Y P)VN!BR"8E0(I0A,(/R60T28B
ME8 \@2VC#O==$WQVA%E$T\*B*6GO=5*&>I^XXM1JP0RVB3B-P1^4\]%']_(\
M](:CS^>23H4)YF2":^D4=3)&<<"_##&7BZ!(,R^1T]I9P9-DN5R$V>1<O' >
M*,*I"*<?"J?[,U^12 T@QHGZC=*I1(CBB'MM<X$,CJQG%A$,/[UCQF=BY&K!
M"HZ%%@LMOCQ:E,EH3GEBQDH>8G 84VN%MA;+((Q9AB LC+F2*-Q$Y4WE),<>
M:V0IN)8\&(8,9P3EA 4FG)1>X8TM;39A]%\X:Q:G<O'*H-YC$A1.G!O"#=?&
M>&Z)B\+X$#4GQ:M<-15<%P&E-FFCC432!)%3F ARE$LD*.%.!2ID5!M;;%.+
M^>L0/CL2*-+II4JG13(I[D][5_78BHAJ.G->YV28Y&ER7(-T\@J8DWNDE4DH
M,89YPEQZ:W+Y9++)^&P)\\*=A3N?.7<NXG:&R C)<6P:N=5!:TH=3DDQG[0.
MH;B=Z\N8U^GRQEE-C25(,(<1IP(CIXA#A$<M@]""2[VQ9<0F$0L><U18L[#F
M,V'-A38)I>24)$XF23F1VDJ:%(V$4JJ=$]_)_BB*<VWX\^/U@3F>6*J91E9Y
MCL#%2$C;"+\%'87'X&4$O+'%-Z7D16\6YGQIS+D <5*3CW@3)EA'.+<)WI(1
M)2)WH#\5ID5OKBU?3NSVDEPG0R1%FI*$8&P9TLP*)$5(W.+$9 2]*?6FI+-%
MUHO>+*Q96'.*-;&S2M-(E?.2<R6U5."V88$C(2&0DC/3=&J\7O;Q>7V'&HYB
M( IQK"BRP6B$#<_Y4)X0#M1(2RYAX<7"BS_D19&T,)%1$PS'AAF<8E!62*>#
M"JY$+]>8,M].J$G!7> &!2PT^-S>(ILB05$K'B*H2>5$I2:U7#O6'&WE'3_0
M" BZHL))1E7B)J7F9YJ73W^P8?C.M_QQ<LY2+B+4 E>YA<5]S#![&A93\Y5:
M_VW_S[UWK?W#G5>MXW]MO]O[U]'ONWOOCN??NKRRP5CM1>;<VKZ,"CGFQ\_8
MH'FW>)'_XZG3L^XQ0G.-]//LQ9WZ +*GZ<*F7>=Y#NGXF)<7.JC/_SK-;/K"
MCW7\Z6#_]]_WCPZ/-UM[_[>S]^:D]>;=WF][[][M[=;"Z/AZ?6R)!SS>E[@:
MZ [7"==-XZLUZ;NA'8(2JNJG+[?H]'/JI#+![J^V;?\Q9M=Z=<)V"%4=#/5K
MYW]=_V?HE'9 ^]W6CKUH#VVG *\ [Q$<M,'P)6/N71Q:^&-H[=E^%QY[*2?V
MK6MG;'M_>?ZJ556[;('K?O&JXJ'?>X,7W2T5OZ"J*T8+&".:;M4+&2^Y;PY[
M732Q3M-JCQ9J7O2$.>F!N;YM<MQW_> 6N_(<JI'^VW8O;?]KO;1$JJ*D>+DG
MICZ[C<P+[F..*AGIK;.1<J6IUL8;)JSU3"02JPU]Q!#*R(V2HJ5XZ))68/^:
M+![JI=46"X&B< )QESQRS$KD":$N),FX"1M;G,UN5)YG]?6I4U+FRSAY*0DE
M+RI?Y'Z\4O+H&D))$^4YG<)$6DN0%5'FZ@D.614L2A('^$@Y3MG&%IFMR[Y.
MC%2$P4UA8, 2$8H39BQQJJ3A)'"M%<#:YHW_=P.X%#AY$H1>BP;&A'0T:"0U
MB2 :A$+&<) /-L6D<1)*N5PVD\G9/?I-!.F]@G!%4SQ[37%_2BJ:H@&,-5'/
M4DA)HP,Y <HB &.9A#1/ 06-P?%QBF%+P,V1]]LBWQ1142CIV5-24EBZF(RS
M)A?UP%HY*9G.FYB-Y@0O0R45MEI)4&:BEJ0.BLK$* H$M!7G42.=M$1>",^<
M#\$GOK&EU2:GZ\U8+\$-6K#0H]"8.N64D$IQ@;6+VGH0U9&+0 ,N?M#*<7J]
MXX\Q!D-D"&*$6\0E4<AIPY!U$6N!I<2:584>V>SNE1\4CR@^4!$<C:B'<W\^
M*O5PUH;2KG?D@8,K)),&12RSIX09 HVI$+/Y1 >I+?$V5V#$FQHO7+VV*;*C
M\-9Z\M8BA[A%A[EVE&$2.3-):RJXTM@&CH/4NCA*Z\M6U]4/N0.)Y;A .%J'
M\F%]R*E\6$G4Q'-!*%? 5H9L,K/>ZT6%L=:3L1:J=1VE5A)T%6.24R&- ^%%
MK?$R!<R9*TKK&7#7=>5!'!S1%%/05XH@SJ5%,.(&P5!3X2R7QH#S*#:9G/\(
M\L):A;6>>(U,@<KBX")&0S@QS D9"<,XZJ2#Y"4@O;Y<-5GU+U#*)5<HIGPH
M7" 664[ *^0PREBED'2NT\(V"6=%9Q7&:C)C)64C9M((J0*GSEDB0I!6<<;!
M$LNRJM]T6KJ.OSNE02J+A"@!X<0]D4A;+1",J'<LA) "N'\,%TXJG-1H3I+*
M8@O:*3*;BX!2[5,45#%BK$W"J**BUI>NKF/K.27="RN09XXA+GQ"6AB-=/"!
M,"]\<+I243 '&L98CU3K9#4;!..PU8;)??Y(6_M+T])T&4WIK?!:E[2718Y<
M44D(PC05@G.KF29!D^2C=A(TN8NGNWD;)B:8H.H71LV]S>";?B^UAWG_>#%E
MBYBR' R86'C!5$0:K$:>&Y4/B#?(Y;, $E4>.RFI\#QGOC"Q8-W6%>:@%10_
M",6 8(]#PM$S 7ZUU"9)DWC0RIE@,2\H;@:*)\)Z2:ID PR(31($J<Y:U >,
MA'%*5>>VU/EKZX3B%X,WC+7D5OJ4?("A [QIPI*BU#"L YO':A90+0U4UT&I
MX*611&JD(K:(FR20]<HA8$.IHY<RX7PB8P%4TP!E76(:X)08\YP"IJ0+&BL=
M%=><1E8,6$.P=AU149&%1(-!UL1\?H",R''&D0P!!_B7B)I4!NR6T_L>'6\O
MO#YL5;.K[F3?.[_HQ[/8';0_QU'LY>>?.C#[_['9ZL9AJY=:0_OW8Y2++4U+
MT^8W76\;NTB2FTP>? WCJ7:&1Y</)F<J<<F95<%P/8>173S;K:*BG4D2VJ\X
M*-O?PS@\2B?V[V*'%[+#>].Y;,H$*;A"#'..N!4)Y=/'453:*J>ICC9L;)%-
MSN??,U D[U/L[GEXT*; L1EPG(CK$$=R_AU&7&N)N.<Z'ZNED<0^>L^X4=X7
M.#X1'*O*K/37XMZOFNN6X-\7KFL(UUV' %A4)&E@.!JM!<*S$FF/,5+2>L:H
MC 3357#="_?^=^S@K 4/VX9G"8,,HX[MQ[#9NHC]5E7XX)?6_WP/O&]BOZI3
ML%P0TVGH?HO]7H GO8G:^I"P*F5J=_P.XP?:';U**3N[$&KWAP>C>DR')WOB
M:,?@/__O#/OS_W3M'^;RZ--_.H?G^U\__)'?]P#_>0+/>])I?_CTGS/X71S^
M<?C7X>X!/]S]3_O_ONVSP]V/#-[ER^&GO\C![MM3[50 MR-+G) 3U%- .K&
M"!'<\N2%Y.3*%,_P0 D\E::E:6EZ2]-5F/&5V>SZ:,Q!-GNMPHFE:=.;OAS?
M=0DIDM,*]TK63DC=G4H)%U]T 55[,)45&2PU(2J0G312Q(WQR-&\/<EYY:V
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M(Y$JASKH)M>L28!?3 W5L.4W\U0K8329I8K,1<.0O!T^70Z&Y_!P@ZQ^^A$
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M&MJA<K"K0)F]CH+6ODP^6J@R+/,'7E_=8ECF -XC9 3/";S?JMEZ;67A_^^
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M?]DKRBM>C"H'031_!6?9M>D+:=V?M-[.K/#XI")5P2--',@=X"MD4K#(2&'
M\KA /%L;N?-20?KP]9("TB:!=&I?V<G'4^-B/G2*(H<)1]PHAK2-&%EE8-1!
M7*A\X'8!::-!^O#5B0+21H'TQNI%(H$S$A2*C$4 :=1@4Z-!CAGCL3)*J%!
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MY21Z9D,^+;C M-$P;639L0+3^YK2'4RO3.G)^V]@2K'35#L42<I;I(-%UOB
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M:$^$65G7>LYDD^=4>-=TK[FQC\SD@2AKGC?F9#9K#IG%M_ 0:_0.7<!N:AY
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MYK P04IW'>E\^CIY/SW9N;H+]*R;0'NES;E]X%90G4RS9#G?M?Y];/W[:9H
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M['UB^YA88@@)*! M$'<V(2/@'XRCE3J316=7UNG5_8(+02G3.!&4*A6N,8\
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MY\ZP5/*KY/> R$^Y3+WWD0H9@!KKN3<L<5?*+?I 3=5W=T=SDUB?@< 5XYH
MHY* 28(X"IFPTB$1O-72A1N?HZD,5QGN 3$<E=F@3R2XC1:H%9;F%+5#<6>B
M1C^J,MS=,=PD;II5E%H[3I@J[;$#-\1D6KJR@!#)",V80 ^6K5TCV ?:8/4A
MEU=G[0_O$RYCRK0G296VE$H",8D!X8*C$\FCBOS&O4R77T-_U))B>]3KI&EV
ML%*M2YI=KU8X[O<11JV#KO/= US.DU)K=SZ CY[.URL4+5,2,0@3G 2=HP\F
M4:5RL-P)3:\Y<'JS#I'WQ'[]1&>FC]_:7]ZCV0^424,HY9Q 3$"<8(*$LDF+
MPP\VLT=/%;^8SWO:)'+4/W8%T8 WN\Z "#2[8(-58"PHK;P&)V).#G)064,%
MQ*T#0K1?OK=!,)V$(C%H=#R#\,39[(@*@5M$1.2YY+>KB_O99X!XH VD:IO4
MU5G+^\_YSLOW20?.&*JQH+TBP$H#8&H4L0 L4ZM+$_>;2K+MT[9O[BR'9M22
M$?_!B3D:BY%PTAI.\FT>:"^H4)V$IJW-R_=!9T=-Z4&=T%, %!BE=[TAP67C
M'$21K*M.PET["0N^S6MO:BY-E%10S'@75=#@LS/)<TMMD*GX")3/ME%9-='L
MJ,7W;+X7Y5B?,D!22"48']&.".8(T\J!!Q&3EX^>2L7NBY.P-H#PN/C1EGM0
M4(ZB2!^"0'\Y@-""R;'77 %QFV;LR\[F>^6",3RCW9*2$G"!$L>,))0G$S(.
M9#"Y[$ZI&SH)%]OR7?Q+D4O-V%.7LD4$JA0<"&6L"SP%EIAC7+L$[V5I!G1!
M8TTU\C%7"BH)5H>;K/59^W45(00;K06W'6RPCG:Y=Y@VCV+SV_/22GR0MKJ#
M<- ;'/?3JC0<W'EVNJ0W)2[)+YVM%UU<OB=O]U]^>_NMC<NZL]_9>GG2WFW3
MG:U-V=[Z[][W2[J]=?"QO;5)V__^A<OWKVYGJX-+'Y<U1QAL;7\M\&AO??S2
M^??%B.,_O(\BFLQ2("6GD> Z"L0XZPBZ"LDG%U)0%QH.6L.2,!P92"9(%+Q5
M*2ME*$O:! /?-QP<4>XOHXGX]<G6:2_+P3A=I9.&%SM43KL(EW:T^N%=W%U3
MR^8!.[VCWJ<T:F<_>M3Q6MLM6R(/>)GQ]LOWJ-PLBC=/C%#H $!2Q'M<=>@$
M" =9 747ELW,#<GDPAJ2_41#/,TVK+6+:$4E9FX==DG*P>GS(R[2RKQSYD%E
M;$.Q)0_J7#?+9^N<=NFY%2:O2!2YHJO@#0ZMG%Y_ZB,EJM/-)TMJ#O9LTO^K
MEQ<CQR=W,KOG0">>PR_=L1F+Y\T8^WW\?T=IN.@;O_8VNZ,XQ&^7G*.Y:=N;
M13='V^QWW<%/M42[/#?B1L\X0W>DVZ/&>;J&7C+XH^;!JY6AM+O73ZG5QO?M
M#5K/CQ F\[1>6HF:L MHP[>4U;78=]YHQ:Y@2EUS<K(%CYM6==,')Q=-(_=E
M -NN'_9:W)Z-()T'\3./0I.5)IM[^IX5SNT3P<9E1TR7.D+;A:;38-@:B8<'
MP!=S3>[]R#[^T4.N.(KOMJ+#+"?(MH\^I]$6\RB><HJBE0E#WS"8,DH^WN]T
M\=HE!/VML_N1O]MZ^>7MX1MH[[^%]K?P96?K[;>WNQ_HN_WG_/ODXS;?QN>(
MASM;;;:S^^YC9^N/[KO=#R>=<JUOFX#?NK>S]>JPO?ON?(U4*V+D5E-BJ,H$
M J/$IR"(#*"T3[*<OKCM3D@KV*BDDL^JD<\\]62<S\*$G+,0 7@$HWPT5)ND
MP0!/(_:AI^Q#J>#V^@,.E6=NAV<FAQR41CM 32;>FD @>4YL3(8P:CEU6@53
M-LK$[%7/%\LN\_FD]T&'IM'6Q ,0HO>DX-8R*VF?KIKQ?E:EQ3EH\5PENT!C
MYLQXHE3F!"PWQ%/&B/24>H<3[;A&6A07\P=J%;MEU\JX?=%10?43H)IH#<8L
M#UPFDGBVZ--$U!H. DD)5 B165VRU(2E]ZDT_:49TTQ,1,DY$;(L?'52B7A=
M(3E^NB+\^@F/GSN.O]X$>@NJY(I^5:=,^BI]3D?'IUDWN/8JI\[#J=-E.+1S
MU@KOB)%!HO\6;(D8">*9XM+QY*B+-Q J*];/MB+TMB5.1>AB$3K5$C9GR. $
MH=Y$ M(ZXAB*(&>BU4KA/ :#"+TD%7F=6L*N<:CE5>_$'0Q/2'-DK#D5]$!V
M_NZ);[B4"N=GAR]&BV<4CIY.+*Z$.0]A=J<D#;7<1Z\TH4XS M9EXE#'D)"=
MX#H(H3D\>LKT1<*L_7?NTV9/A=8M06NB16+(PC()1.J(T,I!$ O,$FDUUUGH
M%&TY%L56JA? 2B0:SA-(^>6#ZQX-?GURT!L,\-*E.2#^,&P5,]P;X&JOVN(^
M$N"M:XL_<1G]C6MHYVBK63E-98.=O%D6TX!5%IR'!<_U'S91T"Q+AR*._W*4
M$B]E)EYQFIT,A@5>XM!57SR(F$>%V6W";"(V)("PWB9BLE6(-1F(C]H2!<H:
MCO.G+$6Q<>\W>V %]WJ^DRC]%'H?CO BL16;,@*MX5YJH=[N]F+1+^G_CKO#
MD]8@!7QU847:U ;3/]6Q2/ 92X$^Q"VM=;0/2Y5?SYM%__ILS;_XW.F>VHIJ
M%>:P"COG>D0B]3L+G!A/'8%@#3'622(="!<=LUKB0@9ZT2Y4]74?U5=%V>VA
M;**](#!&12GC%G5&%R<I8A7-Q,8"-DC2<T09EW.V9ZCJZQ82>TLXLY7[O<-6
M4^O"]_I-K93!XU;O>$@.NB$=#8H$<_V^._J01H4;2W6N 6*A.6T?RMG[XZ/X
MY%._5XZVMYIA7T]1YJLH6S.SL;2.PB/H%,/P M'S[!QX_CZ%S>:'?AIA9O,H
MOBZ(V<G/QGCY9P275PU:JG&9Y\S([N:PTZ5?&P.S^5YE4$HS3Q) +LT=*;'&
M>J*<XYZC6(C.H'D15<2M%!IO;8NNHG'I:$2Y=XI&R:UQ"H"P*"4!;C(Q4GE4
M?"*(H*. Q,JNWD6QMX:[>O.D5(_^MLPXVRB$U@TMGXY2[@YQ) ;#P9-?0C_%
M[G#P:ZO7E"H:[I7[2_W/B)O16]92R\W1$KQJN;6S'HO+"T>D_#,&RA:BY"C%
M/T9P&8P34$LZ:A_=GYT\_L/SKZ5T%H[VZQ%HGB%FSBJ255LRERUY/JWL M>0
M06NBE>9H2X(A7AI&O! XZ=J""1Z5G:K)5RN%S<7%YRHVEXO-:9V70"K(G!@E
M&6*3*^)8#L0&*7.(,G&-7A>C8H5UW@A[\.-$\;&>6RE$/L.;<=VCUD'ZX Y:
MAVXXQ)7_N'54JB+7C*[U8-65$#RG&QRO1D<.=GM_H][^T/C.K]-P>-"XS)4J
MYZ+*[6D9D[,/F8(G697NU,%0XI+,Q$7.K2WY7\H^>BJ7D'SR(*7,2BB9"KI%
M@&Y*GW"O=$I4$PL)?0=D3>(9TX2C:)$Y.D<C/'IZ,:URV5N.JVUN[\<[ZQ0L
M_9T/?./]6>]H4/J+M/Z3W,%P+[A^:OWUW]/4QL,TW.O%2<WXDABYEC'86&.P
M:R:.5F0_?92(U6YP,*FS..BDX?.O(0T&?[A!=[!YV,.1^]:(IBJ5YI)*;Z?]
M$QZ\-BQJHHT3!&<I$^],(C(%"S%%'YTJ7;UKE/5>NR85A7>/PBF'!9BF3#M'
MO(V!@!>*>.X0E)R"5N!SYJX4SUDYCV6MCL0VW7AJE'2M6'%IFN3Z!GVU$-&\
M?!>F58=6(4J:/6&I=$7521$CI"":*:>L9II)^N@I9W5S=Z4 =JMI>Q5@MPVP
M*4$1F#"40Y'US! 04A(OM"4I<6-2-#Z;<N25WRW 9FOK,^G8V8J]X]*A\XIJ
M8DM7&\TE%]$-</9V4C\>K'45,+,\Y^\/J5_'SPW!/3)#M]Q+Z-J>]M=;J6JB
MYC)1'\Y%GJ@(WE)'G*21@'.,6.X#,='SLEFNE2G)XH\IG;OGQT\AY7;5XXUI
MNM+?0Z*_E<A+J%QWJUPW)<<U<..MIT0Y7Q(F12(>HB-6N.PXB!"90*Z;M^'
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M@[7:1?$_OXORT$H @A3"&)4%*  =H^<)$+P^"63:*,VMUA3HI.%.7JFCM6O
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MZ8-AZV;\%N'S/!!,!\8"5=(ZZQ*(' SW45"+2L@")!MGVP^JF%X"IL]M(IL
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MH\@,3A%OLB&)@Y)!2Y4"@H'1QURK^T$-%<:+"NA7!-\=@B>1?8>>EDD*-;E
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M!ZS 6Q#PIC8@)0B9<,)("J)T"BAG ZGRA('+.*\A!^IK_8T5A1\7DE+P@J4
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M5G]I7/3R?"IP3C1 ))%I04!90;R"<BHU4$D=]ZITE*]&?R7AY]!+XL"49$%
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M\J2%(XM+O=^4PAX,TNUL(JQ9:]EU_,K:>KBV'I[?X&ZEQI9U/Z<QVFMOX37
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M89*RT@QX51&GB3&4ZZ!S]@*7R<)_B-=6T. 52Z1(LB5@:W3PR7V(RH:(HM:
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MPY:QU9#'IY)M45Y-'NR6U.GTVYU^7$M<SK&/]][GJ"P/4>7( 2%S($%$UNN
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M1" 66\^Y0J!_:,0IL<@D@I%Q2L<(RHK,)DPACT(>RR:/<6WD6^QV@NV=C!<
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M'Q>%90Z^-Q3'V9I$C/%14"2L9XASJY%1W*.4M[(ZPSP7\AY;(Q<5BF6:?3R
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M_7^UBDMKO[4J OW]38CAJ$)E?[1YI!,'JS7XM"KRFDL./LH!HO.WJ&[XMC4
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M,,9[PD/2R7K-..'),N,(<Y%;KJ.D:9BU@._$L)YWQHL0N&)"^!0HYSH81G#
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M>#"?+$EXV.N&(_AX4C7D++8[J;FC5CM4UW? .D;7UMKVJ./WXG 3PH'M_8P
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M8%L^DDT(O_Y=JP=-MA,[)-@)JGON)HEEJ=6]AF?-OD>PP9:KNXYI>-1PF..
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M.\D/8!VXPCD9G55'*;\H1=X/%A_.<_B6D'.=4-M,J!GUL(!+F.%$)-$3SZ"
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M/OY\]%X['ASL:?N#0^WTPZO3X\/C_?>?M(.3_KO]P?'1Z8XL=7!R=G2JG9W
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M"\9YFQ7%:^"=@Y)U3DK.V9T@_"T]?[+?GO-Y_.&J?_$7W.>3^\GZR_ATMN_
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M2BP]CEBL.RXQ](AXANXG++!) @85B6[EG=KVN)AEC^!LT@9SB\!LIWBV#M<
MEY1Y\C7 =J/KZK>"9(];+M\!ZKK.^7]8H[!*! _8["0Y(]\[0;N1H/U:AU%N
MZ#@1 3O8#&-7=ZAOZL0UJ6YZD>N:Q+-=&PA[L>JW<TP]>"#4,=PO8[AZW,VT
MK9A&ONY9"1:?68%.;$)U-V16XIN^86'SA2!8')6\;??3;FO:QW%E=P1;O_)W
M=L*"@-=$*[+.VWI]DN/-]>D//X5IS7=\-)CJ5R9& J=5B*OS)=TQXCJZ>GOV
M"2<2 ^K:_^+Y$8D#U]-C,S!U!PY9)XYGZ5$$X#EPJ6LZ%G<5^_X=.9.VX"?N
MY-*CE4N_,NFRDTOW+9?.2[E$/&:Y;N#I+C$CW3%=$$G4L'7#=PWF&T[D>>:3
MEW;/=N_*R;T%#_<.2YA;%JK)MB6_DQM[:=V8#?039W.T#W:K6G--";QVW?SM
MRNH>X?;\SJ;QG><G\;Z7I"A R.!N3F!WL"OF;V=)/QY<^CC1YP-)J(J%5NX
MZ6: U*@;RG9H&Y;C49TE@:T[+''U,'%]W32#R$BH&UE)V-43=L+E89FVG7#9
MHG"IK-W$)QZE+-%!Q/AH[;IZX,2F[AE&'*%AQ5S_@10<_HY96[T[Q[>/%]G^
M=MDH6TW_JO?2/<O>LVD&>S@Y/X(OS*XZD;V9R#;K>)!1YMJA%^NFP8@.PCK6
M0R\)X#_,IS%Q@S!TNN2PW6/'K2:'=>QXM^Q8(2@_\)@;)['NQ90@@F)Z&!"
M4=1T+9\X9A(DNYDZ]J@]@[=/FNE<@'=1T/1@3/CU7_/1:*+=3*DY[,SYVR@C
MJ^$KC)(PMJU -P@.T3!(H$>!1_6 &('#B!/[EG^W236[F5?3B:@'+J)V,[NF
M$U&W%5$57K8,PD+7)GH0,T-W(L_50\OU=#MQ8Y\8<+B4BOP:=\=$U&^38G/(
M)MDXG6"2S>_D%_Q=$D:Z?)HNGV;%=GSDO[!8)_ :Y)QIH#@CL)6SI&$I%UHV
MGQ4S,)3A-:YK&/_83>5'[L04A[U%ZU'1X[X@QP&GQI.$#ZPK3BH:[-*>;P'+
MG$94(39HXMC ^32V=8=&H1[8B:<G)LX3-D(W)N&3EV[/#;80".XB"S<QY:^T
MESJFO%^FK&PEDS(S<>U C_P0F-)!JXF9CAXQ&XC&] /7%4SI;&@K==D9:_.A
M\ +HG.LT]I]Y^@W(>3(KGFNB*70VY8&VGOPU+8HY#S1PFTH-O&<(GZ9L4H@Y
M@0 E\!LBN#!+\?)IJ]<T#T)0RD88R<._\N?G;#K/Z9 43"/G.>,-2+O<C<<I
MTN\\?6.IW)8NK07AO1]?S(L9TE<GP3>3X&X=5B4D9G"(O@Y'277',B* 57ZL
MP]'ZOFL&$7&B)R_]G<_<_1T9\,X3-CH&_%4,>%Z+B!$/@%*D)Y0DN@/FC!X0
MS]:-P$O<$-"50_PG+[>1.M_YF7[&S]2N]_P-/4V_3<?9775#K1+=G<#>2& ?
M7]81DVD[+K69IX?,='7'=@T]"B-;9Z"+/6+&MA$3M'D]S]JQ^.!/(ZK?FZ%W
MP(75,?2=,72%P%PO(:9%#=UUL6NT;P1ZY'JF;F-ZK&F:GAL'G*%->\<8>KW)
MT.([&T9"'SZ$VY_,4IV7X*7?6(G:N.^JYB531W>G*_36&OS]8IH5*4]OR-F(
MX"I?(*GH]E(7(RF82(!X2IZM#2K7IH#'ASI7O_/ZV0&/4HW=N=L.&4WQV2FC
M\QR(FA5'W^EH'K-85,Z.I_,9=RV?)$<DG\ &%^]8SO78_CB;=SZ$3378]SHD
MI49@1&X"D-2T/-VQ(@L@*8WU(&"$^K:=4 ^+9&^EO>Z"C^X6L/Z\4.N$Q=9<
MC)VPV(ZPJ. N(Z'K62S0#:S1=%A =8(CD%ADQIYOFX[GV4]>W@[J;E-8<##\
M!R^B4LAH;9P:WCU*=?>LF_C16HT!K;U@30QXIXL.UEIR?2OM/<OAFP?4DF39
M;)+-V,/DR<__# TZ_GM"/H;SD_'1C_[%^??!QV.[?_CA:G &O&3]#?SUUX_^
M#WCN!?#E6=_^9'U.@;]^G.Q_"9@9)U'@Z,QDKN[$--"#B-@ZLVA$/9R3X3OH
M !!;]#[#\QK.9M/G?_QQ>7FY]SW*1WM9?OX'"M$_<OCX#W7MDY=G0U:L-F&T
M2Y:SNB,:W0S:;,BT*1QO%A<8NR_@2A;WM&@^$]?#G;'^D(M=^(%?3RO1BYYN
MV;]$PY1K<<NLJ&X:,4KF\#M\,<W%K; ,4;O,YJ-8&Q(PNH8DUH Z2<,28TG"
MZ&R/RQ?UBB];%HT0/;R38DK%[[)VF"].<#:G,H.P)&1@KV,6F.T%(:$6HR8S
MP:3W"7.^F*;[9(D\&)/\/)UP>12L9'[7"7UZ)[K87\)(3UX.D%E,:T_[O\8+
MWP%>;RI=3!%)>:BNV)_$HH_-.9M0T+Q8E3W*BGG.SN")KT9 6UO7J1\4_W[M
M__@ .@STHO4W\-NY\6G<-T\.WZ>#\5_XO.\#ZT_0C\??!PO\"VLZV[<&A^\O
M/G_\ZSM^Y]./#\[@S;'U^7 T_/3CR/XT_NNR?W%D_?.C[Z!L^&(XKN>YB:/#
MCINZX]J6'KK$TRF+3=^TDI!$[(E6UK#OHQ\O\9(P(($7Q['MA)Y'0C,B;D*-
MB,6 E((G&@.H,H6SF.5SALDZM;WG.30'(.,)\%_MC!;IO\X<+5X0AW7S.IKK
MIJY)0ML/0H,X#H&?S< V" UB@[' -\TGFS/+/0)72X3D^'Y1N5\@G[)YKA7S
MJ ! 27*^GR#7X \7(%^PCGJ"^Y?-"_GNY:[G:8%24@H] ";IA.17<-4\!WD&
M-XY DDU84?2DA,2K9^0[?_Z(G9-1\XY[&@AHD)"C47;)NSO.9[C\@B]PZ?6O
M09H2WDMG7A12VN+%^)#&I3VM8$R[%UU?;3N_X_-T!BB#KG$07&JYK_;N>577
MKD%K\L06!/M&FW9=0=/^GO:6T\B[/*.,(;$5Z[S=5CRK?/-/EI.U@A,"9!")
M,48IB#4 $;.LQ]FM9)/GZ[PDV HO?CET7W,;,-!O>2^VQP;-G7&%K_T=F<&^
MP+;/TG-.:SWM<IC2H3:[FJ(M,;J"<_J6C;[!*N@0?F=P?@6*2X$ 9;X#B+H_
M0$@!Q 3I.KM" 37E=P:I-H$_ P:<([#,XCF=@9B:(O$6!0J]'*R[ N^!T2X0
M=BBX<R8 Z0A$]RQ-$B5\Q^0BR^7]9QSE"FL3OK8/P#'&WA8<V_)&&? E^3'^
M*%[K<MG=*<>@@'KG(T2Y&B"<HGH%7.R,"?='(B1Q/C_OP;\%F%EI MN$.RB_
MD[-O#/1F(?J?S89DQB_']TS'4Y+FJ+/E^G&_YER%D*+(:,HS8^%'-BOV.G*_
M%W(7% CT3J)TA)2$2CJ#L\@5=>K<M(:#6.0).&@EM="N*;()"+5T<C'/KWCV
M,_98R7MPGHD^ O0WPEN.,W&'HO1>];B% P"OF/&G1SDC<'.>*S29H?]$HT":
M8[P0++ASL;P"[POD6+'C$%YU=,6ML!'[SC.UX:_",8 ()-/&H!XHREVPO.2+
MB'5=2C\9?SY\(R43RI!3A<VF/H95@Z1&'@$K@WU+@::H@%5)RDU'7"*=S<F(
M<_0WGB@N]J.VKV,RF\'Z.XJ^%XI&0X#E(#M&M2U'&9(C#8/4F4_*W^1)+"-G
M0O\S3X5O20<J22F;(.K5$=/.&(A]?LQXRD#XLRL=Z7T$Q"01BHY/HIE>$GS)
M1;@HQ5E3,$^0- 5Y\X_8Y%N:9Q,4BDBHU0?3"M[TY$HYW2MZYZPDY.ME.AJA
MCKD2,E>\):=__E-'>/=">&]0]_.#PZ-AA1*6)7D)<27*/ 0M2-0 NXK4]0T_
M.)^/2@?2=$CR,:%L/A-2"PZ:3/"4HRMMPJ]"05/,X%["MLKPLO-J':2"EOQ!
M'_9.]_B5: !RQ@#1E!8@% 5HN(DPI'\:X^L[@:0/*F-V)GU\=4#=AC' VZ!:
M"MAX]AV+=80+ 7$:@A76L%=C,H;=@S\EW!25U]'T6PI,SV#CA>:2@H,_*.+6
M,WH19RD>C/I.GF*SA1'"Q1QNN:GAMY_#W7["X;R&M5>=Z_:<$Z"&4X"*0H*A
M,5^3?3%+Q''!(4J9O8!@B;@J1NPI'1G54:!%5<$7@ ;P=2!_X!$ #//)-$=@
M(!K(<2'\'<$X,B2P$GY2 ";7,@J(A>-Q^ 5ML\:2R:2&PM4BN23FOER"?V,Y
M5TL2E@M/+J(,?%V@,P =^+F*:>QI_\HNX?Z H"Z9I#$@T#ER;7S.75T]#?W2
MZ#X&40(P>382)6.H?0!XIQS\YYS<Z4Q.S  90W+ADQDR;=%SO.@IEL0@3\Q!
M]E^,NURF\6RH@J2U;TG:,JJOD*C(T#.^\BNUP!7E[[<EJK3LUN[4_CO,J]#8
M.=,1LW[5"4CX_#D979*KXLD?34X#-I,W]WR>H;3IV[_\ORC_X^4"*]_WUBQW
MO;][??SYZ+UV/#@ 2W-PJ)U^>'5Z?'B\__Z3=G#2?[<_.#XZW9&E#D[.CDZU
MLQ-8V.#P:'!Z=(@_G9Z\/3[</X-?7A\/]@<'Q_MOM=,S^$/_:'"V*TM_^F&P
M_^'P&%;Y;,F*A+QJ1I Y")T6[+GZX87*_$HG_/[\2R\6]7DK5LJ)4'Q<$>J>
M(8A5IDS*)\N/]_A'K;BV^,RV]BS;7OFQL6>N_&Q;MW76NJU,(&T)2)NKT7K"
M3'AS"OCRK)LE0?EKHA@W1B5:40S;=YD;QYX31J'C4KC&HC&-(LHLTXIL8VD4
M8^M807FS0-FV[;<J='JCNA6HD'NHZM.D!&3C\(,40RT999<E>A:1VPIXX-\(
M3Z@1H1-":3X7-N:4I/'>@X!=8K?DRI,2"DM, V\%BQRB\1F5Z @Q-)@>$4 G
MM'+&^,&>=EKA+?@ _J.",NWH42/&5/<8SB<R.#63P3WN\<X9K(KU -W!>8(6
M5<!EE'X%^#7,X$307RC\C?+\N&L45CG/F?(N(CSCEZ#I')56\YYV .?._C/G
M4+"GP.1\HIH)BS><"0]I3N ]A%.SW * -06O\.=W!^(0X)$_4Q&'V-X]#3W_
MZ'PH"HG>!"%)"X4;ZZ3T7^&9,GZ?$NYI) +JUY+Y;([-"KZ)O\&1-+:N)\Z-
M&SI [>H-:HV/14L#<<:< "(&EFF,_09JQ\O0S@0: WR#3Q<HFG]G3*ZX?XOO
M4,1$(V98](QQM^Z$(%*&1_;DXI L:#KE-F]MU33-Z7R,5 ,[QF_*(;9\!M*I
M)G(DYMS!#O83;K]PR:U\JP? =ON2+G(,:,6*[WA$:(D+J&G2PFKOF%S$4?#[
M CD/&0$3]^I:PMG3CB?:_OP<';:8MB@B4Z='!T#Q8(%A0@Q:3&5JA);/1ZQM
M>,R&\![8=Y._?>UB='Q4OB[59Z.Q)R-RR2E"L ^IN3QP"^= (3PH F8> 5&<
MSZ[XBH$J8;NY9_<RG2GY+1:,*^3<+^1AG$VYKZZ^KN:"BSD=-M8)R_ZO#1J@
M&FX2N"&SK3 .'2.T0R-AL4]<+PIB/X[B+\<_-=?M-)VQ*EGBZKWP*V7Y52U*
M6LM=4:^V0YFAOSR+Y>KD[-SL__C+[5]\=?J'YU\BR[$2RW%U*TABW0DHU2.?
M6;H9QHYM!+$;^<F3EXM]_T%TC48<E$U .V#$#&$(!LJ$S[A!K>-LPF;HJ@6!
MLLH+MQTIA4D9TQQ$.PAN[O/BK*L\&R7WE>X7SFC\9YF8P= E!@"*,U]=?5\.
MF?#*M^XJ&;9\IOBK]'Y,BA0% 8<C_YGSB!%W/'#A!'\8J=\3V.9,K%#HVA(*
M@DSH"<8E"[&D"LSQU#WA_>/WQD\F9"9%DW";8HB()0#?Y[!?/2V%'Z? A$G*
MXA<<]'Q+X1!D4!.SD 32Y"'BRJTE_U+,<C8YGPT58%+>KA?E1O'%"9$RG><X
MVZ,0FK?']2V^#-X7 9"XBH,G6!5ZJ5#4\Y7U%E96PU "[\F[<+<5@B3U540"
M(KX]SV<O^(]USW$3$U=2$0]4'G'U,F4@1(:B*P R WQ5R"Y)&*T +9<"+<WR
ME-;==R\XF$.?%F@\E.8BZ('8HX??P[?\.LDN1RP^QQWB3ZV<YV5J)2RZ2(%Q
M2%X7Y-5"FSJI=@:7RMV;CO$L$+LBL2%RBD63@Z9#CWOH)>*K/,Q+'B,QC\ Y
MZGZ\(8+_HBCUNE3KJY[! _;\1@A!!0['Q:<3H3E2'M:$'4-N4]VP52A"/%*<
M<"6[,%!/RR!][7Q+8TKEO;XH688'-?AWIO-HE%(>-P,U,ZMR%W@PBFMF,'UE
M7!D5,UPUE?:!S#A8Y?1MI"TT!$6#O^$Z$3?C&335GI7&!V6UE^,!<9GC4)&^
M6,G3XIG&MZZ8H\TC[=#J=8JV\"L#BC*2S%=?@6KE0Y9@?-&P6=^\P/,$>P>6
M?<LX3M"LO<'V-&ER]1!2P,PE.6#-=B(RK>=M*41V1,G*Y!X9RQ4R:9[.FFD+
MR&(R>Z@N0- <6TP10RI;4,#]C/.=#!@+#01T#=B0)TSSA!QXESGJ3A!$N21'
ME;+$TYI$:F:9%E)H3\N<]M+2KT7 _RACYAP9P(.*9]?D.:EMP(0I9<;+, M_
M>H,Y)<NM7/Z>MC\J,@S)SU'HE-DCF.L/ A'^51E8&,Q&#<7%*I7AVDHC)>D(
M-=4(C#-AM\C8E,@@X.HK2[@21NX'\XCK98:2EH+JD=*+5]\4"[)-I>*6&XJR
M"V#-?(8.B(2D0FNQ6:IT.D\I2[,148^N9<Z@3=00IF5.VD*6&@\#J[,M'3TM
MHFFOOK9@>=SENC>E ^&?8#SS02V.D[XZE66Q:9[TR[X3M'8!Q4G)N_ X7,R2
M)P)E+-N)>GZ>*,1HOC2L"9"]SC>LM1S)N6"691+Z5NI*P4?!RK47:]P#L5PQ
ME^A!*(;5#(G'<<7_K<P'OO,R5PM64+K7&/M:"V$+1P$\G.?J(2FS&-.DR)QO
M40R"AK^_>C;<. >#>5^2$;KS!'*LMI5[#!J[OG*C;Y RV:*,*<D*UUMJ>\Z3
M8@5">-23:^1QK978LE5O*Z<6P@%E+76MEH_1R/*1IHI 3GR+N1<%$7P/@<%,
M/\^1?-2?<J8C@Z23DA.RJ8JZ-N\<<:=J)0RD>L1S/<L! <)^?=5.$L!&3("F
MHSDF.L&>R2O59R4!XOT -2B1BXM=5&)+4Z<TZ;!=_J%D1&5Y%4JT@W$#EG,I
MBB01I4@U\TE<^B6%/@$B;/MK>B599C4Q^XW5I;%"^< 0^#=^3E)PX :QF73%
MU:HA6)ZI@H2"C(0_3D3@P8ZI4W=;GF&<GY18O7P?@:^G$S8?9S2CF-_S#? >
MT):&ID>2C=),%*0U)>D2DA%99&VJ:?BPZFE"H$DLP_3%\<M3/\M56MW^%*AA
MI+W*2!YK3]^=[;]Z!M^&'>2F76.?E8][S'6=L 87@?Y*UYG8BI;W+(H-S_)]
MVS2(Y?C,#./0M$//9:X1VS0D6-1E^K*H"ZN/;+/N1CL>O&[XT8"C*?K2+K,\
M+MBD[DA[ ZNN.=+$1A0?8?5@@QV@.5S#G*+/4.E$,WYC)]K@[-/WP>'QE\B"
M@W*\0+=-Q\5Q0$0G'HETBS(O9!&EAF\\>3F[S!;=:(JWEQ*_.(=:B@PG4Z!#
M/&:4O5P&*))L4#D1ZO\R4S+WF@>\D,AF,_),/!;;H1'[S(L=UR>!:[NF8YJ$
M.F&2!,X-/4+6)$]5GKB<1/>5IC^>)*A76?QARFOB?F\*/?Y^<O85?NZ;_;-]
M=W!(O_@^]8CO&CJS/4=W@C#10YL:NA4XC/F&[X61OX)"2Z,,1>*&$HS&#!Y@
M 7783A*0B(2.!_]S$H]@U^".1':%1'Z<?W&)XYBV;>B^$T2Z8YM$#YW8TA/7
M-[S$H7% @40 CRP18A*>SW@$551U72XU?A(6<PC ?:SXAT- 3Y?PC3WMH&&X
MW"RU6MJ6%[>G<0WOG0U+<%1F&]=<A=?!CPIV"(!4>@E%U!]>CI1X*JN<EVJ%
M+00U'8&]P,$&1T\8HFRG4Y:KP<T3Z*[T$J!34U!N[_K'"L]JQ!7!,(VXOX3;
M13S#3L4D):KC-4W5S:HOY]@V0'JGP1Q#HXIH>79%1K.K!V!\*'.UEG\Q;9>[
M+3%*.<Z&71 60PJ 3UF;:&G68R5_\.C_Q1PC63R;G4=)T'.@IB.PNA5:GIY*
MTD!K69TV8'9AW)?E'*6M@;SUC=<[M% T?N%?63%-<[)8V5PWMJ:5O2-^+,LS
M,%UNCJ!9.9W2IF\GXL2B;(=6ACZO7DJS6E1!F!*\] ))"RB]8;>(O[*XNK1N
MP:CMD?3>=$WPI)?J.%1DJ_87GE$!5(M"!&/<7:KO-:F^3I?JVZ7Z=JF^7:KO
MPTCUO3%UMY7J&R5>Y/B^G1#3=F*'!;$7$X>0V(PB*R*K&Y9L#['44T/+:BQT
M"3.EV*:\MKR$<@G@9H0'I>--Q+"$9L4$55"/"JS(.[#)$(._F-VFC:6W%?.\
MF)Y@HE>:B+2"NLINX(JZMN8>:LR<2.:B2X!$IFMI[YU!C\NET[Z,6 !._\@Q
M(<#)?<!4:$>\4_'WW7Z%HVGZCNU*V%<X5XV>]F_A#"US&J@T,%)^@2EL'+0R
M+H<@Y:_T[!(]6R4- NJ+<IZ$Q!.P.))M@&J5#W0.9U3,M%.X7_:CX><]5 DV
MW)E9]CXK_PR4BB_])^;0(U6C8)G([@_<B2ON65I<)(K0L\S!] 2^R*,^9#H=
M 2?S+ST%$+'_3(96RT3,UX?[9> *KL;B^5&%F[$-&IO"-DZ'N; BT8 A8K":
MXF_Y;E5?#A$!G-53K=EW, Z8V%[+[551)Y[EA9J00WNQ4C*?9>))&0]P:)B+
MS%=<7XO*I2E08HAL51XQX?0&QX-'B-Z8'6?Q?]CH@DQ^:$]G64(HP/=)&BV#
M(MM@EU<8?I_(,(N(2@"S*,I?3?=%2?@JOJ(,MR7)#H(@"P;R&.U4I-)B;?H4
MAJ*Z.Q:<J A];3LU3K'2KR*,:I[."%>YVEB$54T#?Y*9$2HS4'H8X6O\^G2,
MC2Q4U3=/M.(YS&R$U<VJ;\Q9!MIN5LMJ%O6A5>(=?S>U,<T-P>P!AED9F']1
M5M+ Z\YEMR[A8.*;(>^F\,:FPD5YN5#UQJR@>1J5>2N[PC'7"?$F+:XEA3]?
MQ?-">]?P'13:TP^G(!:/)U24Z!^0.!T1[5^,C&9#BAOT=A;O:4\1[3/N7\&X
M/+_5,Y6/(N58\]G*7R;3'#9T4Q//,_S #YAC.Q:6EC&/TMAQ(CL,?9;<3:"M
M<U/_7*SMQ]%5_^+XBQ4$+/230'=,&NM.[(5Z&#E$-ZS <Y,PHB1F3UYR?+LR
MEO&\YG)M:D<BG'KP*U;+X\=<F4JI?,@HXR.^4*^"$H$O\)_$&3[K+;TM:G5>
M')2-1=YL75C6[PZWLGIE:NG";;1I-KH:9_D4=#PGMQON99<+M*L%"H @>+,5
M3 >1C>K@6H#2%O[M)7 )+Q4 =W@/8/EJQPPN1)2 YEE;8@9L76!<*Y3AAJ]9
ME,^QE  #1BVI5*JUM<73!B)%^FG+5).R,E,D"N57Q0RV$[$2/YLRXZ?:Y.A*
M/O6N=MNR<+L75&-]__>G>3JJ]DIMOLAG;FJW30[B(>BLX'KJT*ZCCC/VC2SH
M+E!=/:&ZGN+G&RFD*G^GXNBEF&9>RWMLH"J>_D_:!,47>E?T!*;8=?2T\X?^
M)\"[.Q -^_,\BU*PLR0%:&]E[O'3\I.-SKZE)DH)7Y/,2C!7C[XOX5S![UT[
MUN46V_%D=#4CVE/R?6>L-=,M94S8T][ *?%,PK:X**E&7?$,1:FH-)I+<RR=
M\2(=F8$]$6>\MKM@V8&+_=JKEB4(M9!D6M(E-]BSB=Z.3G*UO%R9<<M&G@=?
MO? S% )OV(9*IPLY[TE+<Y[.2L8JUW1+ZZG7XKK&R]SN17:=^M&S0IGV=$I&
M4493.MI!#FB[':HJM 5ZAT.YJE'\9NZ'98X'N4'"7J\>+.AD79K?S%JT#>8&
M@>GXKAD[OAE'B<&<V/4("PS*W)!;BZ&R%L/.6MR&M7AR>&SW?YQ_B<%(9)38
M>A+AU"O/)CJ8]U1WHR". B_T(A*OR'M;#O9+5ZN,EM0]KD5I>?'"U]47^+Q,
MAZ@F!SQ.4D]1/P/@K1V)AHGP=%FA2A&_\*(\C@F::(=W+]#&;#84)77HQ6T#
MSIH0Z2U?>%.$-WV/RP!SY7M4W6SK)4O(Y'FC-*21_E5L+,^7&U7U1Y8B8$]K
M^%-/V736,D1S,.933)6A68XYVME$=+KE8;8;9-H5WK8AU$2Y+,\5NHWH6GS.
M9B*,6Z<KM-V2D[:=UOZ<T%G6V)U;GGVQ[%7NC@!6O.):6OQ73*58KL7[0G0<
M\]PL?%=LD7/0J!][6Y8=O9-%1KL-3(Y&*;8.WCX4:3JI5VKRLFUF>] EU]F.
M[1$2.)YID- W":-18IFVSVSWWFHLA*[.DD.UL*+3V_"L_N&1.[@X_F( P"*Q
M'^JV:0>Z$S&B1PD#O<T<1ET6^E9HHMX&YK_2$Q#CB_I[40[A?"OM5?\4>8R<
MYV0ZU(__KFE7I!@PB641/AXK,B1^835X7<"KM2+#NK27#--KQ&UOE'GUK%0I
M C<#J[^&OCNP^I-$?PS7'GV)0AIX,0MUSXAP/%SDZT$<AT#TIF4QU[ M<F-H
M0QN!X5Q-:SL1W=Q>9=E7;O5*,MS;23):78IV'0D=SME9=L31S?%$16@0PW:T
M)6CKJO\#!&H81EYBN+IELD1W$I/ID>F[>F"X=F@YKNDP,(1.EE9W-,&W ))Q
M*QYFAJ5?LPHLE'A]GLLVU*)TF^?=-[)4//YM *;FGJ)1$+6%:%!PD:7\RS&
M\E$VE?,%TD)5F)39\P 9N$6 (ALO>9? 7_*]UN]2?J^348'E(HO6S.TB_W)W
MN@3U:Q+4W2Y!O4M0[Q+4NP3UAY&@?F/">2M!W?!)Q"+;I[$#*C<T""6)&88L
M8DZ8A&;T9(LV]+H*[2-V-_L[17).2=.!0Y:[ 4L#3*;/\KX765$O"+N4<Q]D
M*5C]+E5+LNH!#95<\P;*9F4MC5WS%F:3T96,O=IF6;#*^^S4?8J9#$CPJP0P
M 812UK=*YV[S_:[J=T#<L(L(NS/4?A9,N_VS3U]BT[2)X]MZ'-@^&&IQK$?
M^[KO13$UD]#W;/LF0VUY?^&-827V])6-+6MD6U)K+=F@)'@.PI=4%Y=- !5[
ME@6@93N7:LGXS;93?8GOG_ 6*C+=J_E>93(]4G%1Z^7%]T"\.KRI:,)2E+OP
M6GJ0#["O=CK;T][E:9:K[]8V%+=&%!X(\(U&@,I_XB%'VABL5/,379/Z)+B_
M=D>LL1%W%3<5Q;M+?>"\+R-O4[U)^^['T;S0NKEYH6Q[MZO="TL/LFB85HZ-
M)JV96HL-"Y?W*^S5!Z3Q]+#%,NO&B$I@O[(*2=%3(7(H%XO4FRU\:]-8SW,L
MY6KT26M/M10)]Z"=LC&0,+;DW/$LB?TB E"2[4HTXA6;7:+;P@P]7^1;A8'5
MTSZ2'(2"_I:@Q 31QHN<]OGT=ECCR50<^T&&K8]5$5'KTS*!MU;(((0XK\O!
M*&::\P[HY?C:;TBYWU):-K@76Z45)&$SP"RCC+>-Y:*]7?2$ @OK#+D8;B\T
MG2Q_+W(.6D]6]L=L/ $!);3*/ > 5(@N:J7L52-9TR83J8_5<AN#)66O8][O
M<J_]>$R1+ O,0*%)EP_W,AE&N]1,:Y>:X:LJKU'KSFDAL\-Q),CDG)Q77E;9
MS)JWR>3Z 5M+E[4BPM<URKC6%5PX9F0B!P<7(B;84^PL7FM7&&[%='<E_; ?
M)V__6.9.MLBDIPZ )TE7"I<WP< 2.KC+XC&H;A:JM<N2 #(G>CX44H22%QM"
M7B/@1%.4[U,Y\R"K#)%:ZTC8!94?K9BF-FNUO&Y(?I \YH<JD8*LDJN(;]-W
MWW1XXKVJ]34F*VZ7&,]P? [O^?(__\_TC!>B47\Q1AMLPFT7W/224N^*INKD
M4Q((=C@B5 HT>;*BK!+XHCSKBC*PE0P^9]GA;WNW5P3^DX1]S_*=4;7-FDFS
M5S4XKK2)'"> J3ZU^0%8+HN4(Z(!*W-42M'V\8J!3A1#!R9MXZ&\)4G@?BD?
M*(/.$O6=ZGHN/FI@LMX^5&ZN]L][I>A3D;BK<O+U):4"/+HLOBARB:8-E%CW
MI31>7V!&>&K.0!KQV+@:C<#[RXM6GK)GEI"@2V;L8F8QRW-L(84D#VH5@&X.
M* *G1DF5SW=L\:]B?F<ZCN9Y(>(Q*8\6*4M/75A[0=@9_)8RKVI_%8."JGY:
MM1WF'_TYGS#-='H( P)M#OLSXM?-@!Q;7U!NJDK&SR<@/I(YU^G<2*%\PNZR
M[:XU&"N#2?P^L@>QW, 1F4_$N2QYEQLVF=-?V2$;[U$)L'JC[!MIE?^BOE+-
MLB^QH^C'W6I8S>^,8^OE3;G %'W'1?!/I30*VD]R,H_G(Q']RZ)2I>)KC44#
M7/A@)*FM[!8N X<\9+VP,;6@=D_V(5_CRV+JE&R$QCNTD7I+L&JPK("P_"<.
M@\GJYLX+'5ZKY^UI1W4O9D4DR':P5SG#8(+2+$\3H0K8*%%OB2SS+8VQ4;"B
M)-ZD \S'(8'+U)WG<B2,8%TUQF^YR'O6A$7P3HSW )-3F]M;MIS5;I(!18II
ME V&PX;&BB\*MF0J"M)>QAOU5:AZ\\X-#Z,PS>DM\8:A>V"<<O< ET9<6M:,
MIHJ E'A2$P[4"#PN5JZG9S'=KMX[5CZ5?UFJII5/+DTN\1KNTM?@',9D]SP@
MW81/!:]-:Q,SBX :EC*<FF)0*6_A/!%A!H&=VBLL)&O'.N\>7]LJI45KW%<Y
M)-=Q-I[QYC6EJ['1+GJ#;V(;:I87Z[E!"SE_$J@M5G6RXJCEDIO?WW&\^#:=
MHEQ89Y'VUOAR"8Q<(4 ;<$V^VT8PLCV22Q@"O5)Y*9.QA)&]4HV/<;Y)6X>_
M)Y.(?+]J8,SR;^5-EB$5(8K5:E>#0M%H_S*-64],J]*%C83S ?$'_$1L$FLC
M1X4:L7TEXHS[1(CJ,)[B@*QK0(]2:/+Z9S<BQSZ!A_!.1C78B/-=2OBU,7SD
MA?D'G*[>\7F[SQ8.:#W0*%]B$T3XASJWVT&_7FT< -^>I^DS&6 "7%T)\L4.
MJS5GB")0%8YI(K>Z%DO+G'EUOK4\+M[BGU6W(VIV!A^ZRX?@+"N15'>J\:HH
MT\"$,B4(A,O\2EC_B@WA9=-G-R%J[,*N9O+*_9:S<E16[S*@*A?51(UUIBQ6
M#/MJXLB;X.'-\._6?!3/RRX:==)NS3Y;@FH7)A%)@UN)QF4BKAQETQ"4K6&'
MV&%95-'4YA%R 2?C(J4<J?BNG!34Y>E=DZ?G=7EZ79Y>EZ?7Y>D]C#R]&_/N
M6GEZQ'3-,*9VZ 7$<4(2V:9I))$9A69 +#=9V4AV>R8,AA!P2*N84:":LZOI
M>%+]*2.ZRM2O3?B]P754ZUM'(@ -'+$N,2!6^'10U8)%H<]X+DUK'A/1^MRP
M*"W;MW4$N.@,NB$^EB3WN-':/0?GKGWX(W&"U1/'3%MF6-[H%^.^5J"ABWF<
M4E8G;&6#M1U#''NJTF9\2JT=V<\]CKOY.1!?3;D5JA3NSQK*Y$RR3FX<EXJ%
M6I7$UZG*?EA8X^U\6A4Z7^IZ%&)@J0\-O8:X0A .DZMJ=7)@(3KZP.81UU6#
MG2="&HP8;D+]&CD+E#](O4O[-5I.N(6W_!T\;<OY2HX,Y+MCB]TY%8Z:5M)V
MU6Z(E(/-FQ?4@N M:ZQNOE]C<!5MBZNHI:(U#=05:Q0G@P-])K.JS[E86&FC
M_7JEMRLD\ #:?R_I9[QJE]=RH$97I8^P[OO'X+#H0MWV&ZA9/>A\K:+R_U;A
MQSZ\5IR227FA>F[IJBR_)95!_VHD+Q<_RKP.[6"(!'7TG=$Y=[6(N:&P@G\Q
MPG7$*Z!D.ESMA%WM?.6BO/+ UORLXVF>BO&_*YRL4Y(*08N^3=SVFK<2@R5S
M'MQ1'E3I#,)ARV57;YG':!E&>%>N3RF^,5N<E PK<W-X[EY)!9M$ /\-9$J*
M!0(0?>?5.9<"0)Q=N5<-B41J-+IT[_&B:X)S8N=+_[7<296!67JXN>>TY6Q6
MW5H-[:W8CV< &Q:$[R)%]ZXE*='I7<XM0X\R%Y[B?E4[^V7W58=9B].A2W_!
M19NS<Y+S4%WYMF!6P\O+WC<,1RTW,AW$9:M=UI7?N>6HEO._]V<('N#7E24V
MDJ):-3:&%?HV,WS7,!S'HV9@)89)+3\R#9=&GO_E^">F$&+Q^MNL*!9Z?)PD
M\CR[#A_\68?][_T?_2\.-5PS<IGN,]/4'3,V=;#( ]TFIF-3QV86(RO&#2IY
M(09-<[(NZG2MZ%DPNB RB>\4D;TG%&>2\:X\R6C.Q'P4[$B>Y?E\.M-.\G,R
M27_(9JS[&+1Y?WQP\JR1A,\7("368BYA&5Q1:&IYB&4^P3(.X!)@C6$M!EX+
M&'(H5(4=512)S$  1G/I[<I&F)@\ P@H7GNY]FLS:^-UA/II!A3J 8.%3!'!
MR"+? \.F-7!.EN1[]#3VG8+I5\KPNK23V7@+3@.:9;A@.7+YCAP(-^N26C&/
M>,TJ!;W5(^"Z[6X%OWJ+Z$-.RYRI<8,[@S!7=]F=CZY*%8[#3WY:?1_@XDF<
M-57Q$K!7H]8*(Q5<:<LHUTJ=?<<H2<6A<I9@KC^/4_,QGYR#!<44%6<8]96O
MD%@528"I7[Z=E%O%D(T2?90F:AP&+_3 M<;2?!+/7(P$-Z0>2# NCN8S5E_1
MTI2T.N?/L3 $<1]H\OJ+\O?F.Z"VJ ;(.60?<W]+Z:)IAB-WAMA7!$C8]W0^
MUBSG7R)[\!U([FR2?M\1 VN_EMY>#ZO"2D6>1I6Y56:_WQ1K;94I-"LRA(B3
M16G-:K7F9)5U<NLY:95UXZTH;-7IY6L:3]A5*7QY 0<NIH3IB&R;O31%\B20
ML&*!,M[.SP^^.I["!7Q";I;+W!A11M=R=LAIJN7!JRUH$P97G.7XUTR6T$T1
MCO("K*HNC_.GJ#<7A8--IN/9%2"=YF+IF(U7G&>YZ$[3<GV5.ULWHKDW#F5&
M#H25L#Q?6XOR?-@[TZ)U=_1^P96;:E-YH(!0;>K+GW^+%9-:]=F;TW^+%X4/
MA]RZ4X5E(#G@!G)41KW.3/7WP=2%6F49Z%AA*F=SO@H^0[9FP4B'$4^RG]7+
M,FOGO..BZA .<D:^L]&:RU11-7W$DMGS4-45XU9.9L_U\#Y?9,/R([1#+>_%
M+M5$-7?/W>/G_DX5F1V+(C,Y3G"W,Q_WEY5(K5(2:NIT+05K<TG?\I5PJ05"
ML/*RE:1<TP* WN!5D3N'),U%33(7V_7YF6-RD>6UF0M2I*.-AB;Z0NE-,\N8
M-1/[Y3WX9+NJ4TE/.R/?,\QP7C2<;I3_.R-"KDM.]YK*1>RA/*1?KU*.2 &;
M/6FHEK?9'*0YF:S=NW^;LNY12+8^AA[A?]-IJNW/@+X!D6EOA&-1>X->@0FW
M!H3$VVV!5\X&0O):>!D@K_K+2O%7BTH"S=8O6!8H6U.4<!&QTH%9OT'+BVD:
MCN>$0>!3PW.(8Q##<1/&+'2<^2R,>*>@0'4*"GZB%^<*=V;5LO@$)>K9D$SZ
M\.J'58OESLUY.3C\9 [._OK"8FHZ7FCI%B6.[B3$UX,P"/7 I"&QX&R(G3QY
MR2ET2>=-KK':MI726377@=3,O5+7]A8JTY9>K24D'<DBYB[A]9J$5[]+>.T2
M7KN$UR[A]6$DO-Z8P-I*>(U])W)I$A$64"<.?.+YL1E&H1.&$>JH'4QXO21@
M%Y (73I$R]/BJ_3RM^W$I0[Q.H8K_5'OJL#</F8JG)7E+M)!3M-O*;9" "-_
M)AVBW"$Y$7V61&+1SEAY*WIEY3FYTDX9G>?"-W9-O[6=.N^;9WSPD(+X8[NY
M)IBDS(V2V/,3Q_*2@-J.$<7 %Y'M^&%X=^WK6Y"9%T))1]!K-":Z9IIUA.P,
M+N@7UTL\S[=<W:&^KSM&8NB B6W=B1(W<4*?N$ZX8D37>OEDMPI%-IU6G&M4
M-3EV?U0=QD1J6ZCZBJ%_>T5GL=ZR-E R@2P3"6-%E:N@_"]%Q:B\@#-=[-*F
M;HG]!4>\)1'6,V*U+@9KQNELAN6UT95XB5H& +[[X/W^J3Z>S[C_# #\!!@5
M+=3SG(Q5O$$:RXW-;?5KX)X>=+&/6,T#Q&^@RF=Q2!F/\H@X-ZR#T*%,0RVK
M1GF0!BR<=#IB(A&NX &85F^#:QMTEHUS8.\OI/$C#ES-:-F=#/GE,OHSG :A
M:RWR@7B.[\);7'F#U3UF5U,1;Z8X2"WG! ^&,H;(T4S.>9.>$AO([_-.,?+Z
M38*(XE!N]#H7-_N=Q9OQK1J"Z,FP81Y*C'931UZIC9WDU*/E+F(P# F_]EF9
M:6!XJC\U)D3C!=B+[^R@,1-8%"F+=,R-O=@_'<7<E5EM*V%&?<2\<4VL=1L.
M\5/ N\.V1_PU; V(XCWM==GI"IY4&\YB&<]YG?Y"HN@UBUG*P#RW@/=*:-,T
M::J$,MNMKIAK?M3*3[6LJ+W$ZV7>2#US12C2)>ET\O.R0,<UJNY4D[B]Q!G6
MP>BHCJY *5UE-ZYUT8Q86)5J&%@VK1BK<</P!-$ !U5S57B>\_J"*;]IC44%
M5[\0_0;DWI?S*H&RO\DTI%M@8==,PH"9 (A-VR$!8N# 8R&-21)8L6,@%D8Y
MPK$P:/\."_\2+'QN\<;RU/"(%S(]I E@82^B>N"ZE@Z6>Q!%OA$$[BHL?$ F
MA&>/+:?B @^FY35>#(C6:?AF3<#I^J;>T;U:-8#*PUB2_EYFF\M^PU*O@9CB
M+T8X+\A6(V7)$,K\/ON>TJP*U7 ;7;[]NM*K5^/Q1N:YX&VU 3AH"D<$DDN5
MH[L$CE];$;'D]:IW>"%;C'R[EN6)F*DNWE=V[.]S\<73EQ&)@,H ",VC6:_0
M5<''!]Y\_(N;(-^2-W)'((^9KC&^_XU*_+'UK[=O[%]_4$XAXYM[(HI#^>37
M'9_EV@>!#.>?Z>]EYM..K7HE4#/#T.]I:OE ]F(.R]/7PJI6'SSC"I"GRM=Z
M#8'Q.6ZE+O(4,1!H$GKP0M6JFR\';Q-VB>4[^  ^.%KU:N\!,AL!WB5@\@)2
M?RI_>R9%*HA.-/)E*B_)!4:1%TD[VP"LV5HYF.3YN<J+>2<R+N$1_T/&TQ?:
MA^E%-IR4;PU7\XG(Y65[M6_ <R<-O"IZ=@/F _PWYY'OZKUK+TIE8D[=C8$*
M/EZRZUR0J2TOS?!9]?(\3Q]T%_8/.Y=^@D):0Y@[SG45FRFOBF'5W^#:ON[V
M)GW==YZLVQJ%)^*"W:H+"EJU6SVM?@(R23*6T'=)4_YJ;WF^))YA/6>RE@99
M7ED6C$F_58."HCGH=H:)68UUH+4J=$QEU:;J3UPCE>M8HDU;FHBKG\I&:>9U
M]D0ZNEJV]%HM6Z+8E'*^9+DGS>5<(M.H+;FJ73X6XW'0/*]JX\J/E6.K<K3Q
M?-.E;_# B3%5,E@)OTV);@7!M<1@27:ES%8'B9T-]]N-AU/>53NK%7!)!',P
M)%,<Q&Z:RH#CIO8K,OF*-5\4D1/Z3>7;E(]5RU<SHK-H),^OV0]R@V6+\08Y
M&%5YROL?E\-BBG2F:D/4KB)IE;WDA:!FBWW5=D1N5"]UNP.M967VE@S3$0^4
M&=S54QO[)5]A;^$@>0N0VLM6'^ WIM*TK[TZY^SKWEYX_!JYYM,IK\,K!PV4
M]6)X4UB[& '5;"BZ\2[AX<G*LDI\%E(W<U=FB>L;&XJ$@=*2;ZA$+N4"RU%^
M;/(MS3.>U(<YH L]>9?-0)AFHRLZ1$^4\(!%Z13DYQ5V["C/155/U,FM'*UT
MO[I@(PH4VD&YLCOUL*K=1(-,'HK5@.T,^% X0(<B.M;HF]-\J7I. /=B:4^/
MWNT_X[[$/)<#EL:,B+!;,9O'O$ NRV<J 0]/>3F(PH"=RL) (IL7PF-<DJ0T
M/GC_UP'<<JC]"X@2./9 <@:=ET5!8#Q@\/'F59%"QL$J]P&\43G7C@_3YM70
MZ"R=Y7-:=WBB<L*&.2SFBT+VXH6_4L'">7Z8"N]JETUX339AT&43=MF$739A
METWX,+();\P.;&43VJ9AQ20)W=!.',^R0]OU?<NB1ARXQ/-69Q-NL7E:#((4
MHZ"B.OV$-[7+)CPYL!P$(W6E4KEA3_T%(/37278Y8O$YD\-X;]*>)1XL[;&E
MV3)EJ*.F\GO:(<.PI6K)<S1A^?F5] JNA"\IF#@\0G(Z8Y> 28IA.L46W0"!
M&O!DN7?Q[=N#7BV[25_,;A(&)K8"..<50:(YX.0\:WA5>]H8HU%L@AD8/161
M(>=E?R&>E%1A';YG$IR(Y"M\ IJ$HH5BE?T#L)M@.'SR,/Q\V*U/6N!M-(II
M*-]2-"'PY77>QR(!,)=*2T/@N1:\%-.6_I6-1*9!;8QHB3>?JC%TO6I,X\$5
MP<!0K [ZV6:H]!4.D]5>Y7P24[WF^UC-T5B]+K >L6&:2 %K\=]I93CMEW8X
M#ZNT&1-CD._9&-.Z9/V9:J0%J'2-NSYKL'9[5_'/M7<LWUTX7RB@[1@)N;K'
MNH_M2:PM73%M:<$3F)"PQTI>H*D<QSF3LWKPE'@G'N[PXJ0/MQ'#?2^1):H8
M:WE>\GW>@Z4\@P>\A[7EZJ2L2I:5@D*,[N'/3\N.II,R=V'9OI2T-N;]%D9$
M3!LGM:R\JB%9NKB%V80I(2">"PS'X&CG:BX4BJ UN$.]EGTM 3X%F=W^' 3=
MLW*(D4AL_ GJ;-"6F'L$CYSS& LWF6;D*_H_9H2'<]D$!!,3$\IBAEEFC=VX
M*O>^M;VJ$P)(61X#0N<4G1<\C[0M-_ 6U_1-.\\6,D:B)#(9#8D?)B&H_Y@8
M0<1<S_4=TZ&N(0H.;94];?]$QLCK:K6GN-BJ@1HNJ^N?QI_U8_]J</C7%R,B
M-I9[ZA'6%#J.Z^@1BV/=BR+#C=V 6(F[(E6$Q!>$\BY^8E];$[W0#=);;-3*
MO02+%;$J&0OO!X<.[%!1O4J;VZAAB&SOBIQ2+.%.T0%-"$Z9;,$9134#P4^$
MV_9&MI&=7YJ+?RHD53&?\C["K-A(KC_C#A8E/Z1_I?7Z(F?<;:57;R)Z-^-?
MQ_&M)'*!:0/?L4@<F,2BMF,F"?5CPPWNKF"XX]^U^-?N7WSZ O+4B)V0ZGX2
M1+H31KX>68SHIN\&?DB-Q&3>FOQ[I]IUI>:H!I$)VV<):^Z\WBP%WFX;!Q^9
M-&\HS><RNYAW*"IFZ5CFUQ:S8M&N3%G5Y[UN1>$F+\%KN]]O$'9"S/,6>;HB
M-:6L.Y"MR&H9UE$NVGH+?_2,=X@?3W,V9),"2;!I'K]GQ10IKL>OXLF.(B(&
M&_6VC.SL"PUEAH'!Q]SR?O4J0BJ6P+,%>]HH0P-)#/QF2(6J9D?PI\CXQ?#H
M5;L+N= R5$[XFV)S6QDMD^'"FB[8F2-;[ES$E%\45;*'YG%._I-J?2$'>!Z.
MZ/NU(TWTJH:E-;KB@2"5<RD[&/9$:FE*)C) ..,#"_BBD.T4Y;6ZA6Q8? 9+
MP$"IS%NMKZG5<(][3H B\&?57IIR&SYMQ-#K"9_7-/?K+>G'5\L,;?30Y:^S
M/YFE^AG+\RQ/BW%5,-M*FU>A^=;],/Z48D)0,A>!7[X=\F[85K+>?'<VY%LK
M-QPS:/$&J RI: 18#AJ\<8]$)F!%G+BL501:94.#.0NJ<U:Q+8=NM3ZH2T">
MFDVXF HLAF,4]>F[^*!J\(ALG;MJXN_BJ,A<S1)157TWS+W8'?6WHD89* <I
M@$ME04Q('\<B#C^[VBG1$:@9KASY+TO D(F/M7(3VGBO5+T7,B$6PW#2%,WK
MRS3O<D]>I]QWRO'64_779W?0!)GCA79IT<DPS03!E4VWU3P-F;'0>(-Z-LN_
MB9BN(/VV90X3[RNK%4.,1D_YB$A\OW^7@R(,V%'0DEE>=:WY7YG[*0*]O$MS
M-5?":!E2U\[5EF]1<^&7&ZM,6S658$&,G\ZGJ(6KF3,+M0B?LOQKKY9'L]X6
MX?[B;!/50_D;J & )SR'JN&-5<D[U< ?6-F?9***U<RU.Z*MG81_WZS^BJ?#
MR  'E\S-K/I_R.@KZ(0_WF9YE+,)6?F"6WBC&Q!KB_^C\DV5#E)5*@HY !<H
M(M(^3%)>#C;#Q.I/'YYM1H/:T\9US_8TN$=3(:<<=/)6V'(:>IY=R;X690RE
MU!Q"Z6;)KYE]MIQ4MCIX3=)AS:X0!>B\( ?,",;C=L)N$".(*PM7S5'A9P!7
MG,[/,8F'%PK4?UY(<:\GP^W/SW%,@!F&H0 FU^R&95JN%=[C;MQG6OXV3K?>
MZH4KJCP]1P\<EGJH+A+HVFXY2IO,V%0TJ@*M<IG(MLTECPJNQ;EE(YY'=0CF
M12$&JM1&F"G,MCBJK%58O+ @ 5(K[6 L730#>P%.+L,Y<J(S0UF)-Q]S2[4<
MW":!ZRXKF95 30T!%/N G%BJ>XREX_ZO%M#M,L*&I72#(%624U,:;)D(X4X<
M;!4 "]/K(F&)9,$'E[+E]G5X#Z'HSKFQZ*[6?/1X\@W=8S(O?T=,! D&:IU(
M>)/Q0K2+.I_+<G(0G.?5FQ!,-$U940?MO;):4S7!4"/KRW;_V#*%8<$84HCZ
MM/0]73)5.;"G'>0 <2<\IL^'N?3J@_0P]E U^V^UO.K5$L<Y>:/'6/G):J-I
M5#(UAS[3*5 "SRG#WOT% %<Y#4;5SS$>[#X7731$12HO4@,)5_"9:EFM1TS!
M?7"7(#3QWYR)B1*\!!FU4D,W=LFG2Y)/PR[YM$L^[9)/N^33AY%\>F,R:7MV
M>V(3,PA]DQ''L3T[\ (S2'P6)+$7AW;P9(MPH&I*-9U'H!1%DA?.O96J?LQK
M:+ 5UBA6%8T\D:L&#](&T&EX]JJ 5$/3-E! G-4J==LEA$0#4TZ;D7'I[FL$
MKVJK ,@VXD"!5\?!HK^Q">O)F.L(FX; RV#D6 Z'*N:L;%TA'8XYH#ZX'S<"
M!<ZHM9BJM=E<R$2IE@%RFK</$MVZ&ONR E,A'*MV6A3AS+G5%@&PNKFQQ78]
MXV\ !($E@H'\&_#N\EYQW2B$GQR%(!SHC?3K/]&VI8Q'Q,24TM*2;YS1;K?S
M.^4-Y&1,2_DJ5K_M_Q;+WK=645^^."_)S%7'@!H!RW&P14T<?<2*RU'*>,='
ML*K31GDLF93YY%&>$5%PIM;0X/Y24,B)LZVXH,QJON(/Y(D6HAT>K\K$E)EF
M6;=82OW^ZP70.G[[>7Z33C(YIZ.HIHXHXJFH\ $U,MZ?YJ#M1,BJQA%ENZ><
M_6?.BIF*'(GD.]Z43R5UUYBOP9XBXZ4L%9&CR-4G[7DGLN3D2H7"%K89OL>;
M1\V&L$^.:J>G34?SXIKL!1P/-0?HG6GO&ZVYJM2 F_,;EN8RU/:JFD$EPI,2
M.=7*:FJM_GA =8WPZ+)Q0^_89%)<C;[!8HAH-I$M7T=/IO"T\Q]01O%>:C/1
M/4WY2*Z;?[UL[G6C5>IB\T,Q&IOG)4Q8W=^[@H/4J> $UV4G,^+5!=7YK'\@
M6./#.\BI2"K?"2*=/MC2 =9/89]Y*P&^@(+QO8[S^3G/;TB+VIK0(U_O722=
MW=>>9IF<L>. [G0>33/T"M<53K_9D2K1_IH#BDZ_82SQG_<[XMIL.-51D%W6
M!!@B??EBI<@2:4.2#LO(HA10U_8WK84U#P>?GM6Z;"XJ:U$@(KN'8HF;X/V)
M=)\"@36',_$(E<A(BN?55.YQ^P@X:=[4FJ1Q3M>@BWK.$O?]R\W:<6)M>-LQ
MYE>V[5&$JR88]V76U1FCPPFL[AROW!W"K77X-<,VY0I3M(;WL.,E#[QM2LM
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M-&0V-JCX)C6]"1O0^&ICZI&1GQC\\=L D^N=WTOFN!QPL24Z.6V?SW;49AJ
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M.!X<'A_LGX$DTD[>:P=O]T]/=V$_=V1PT+HBX$['6-U"&#_NW;W5>*O?%];
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MS9EG3,D4^N3:)N=9J<6(QX;(>WT\QB-3U%(!*(PHQ!Q7R.KH$=$*!"L.W#A
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M,R3</_)S+^G <A\9AOUU@=F2VQ*@%1$$.VZ99WJ$R0^-GW_O\[.URA"P>I#
M2B'&K4>*6(&PQ("1@Y=<-@5WMTT4';'JYZ8K#!Z1_G-AIKZZW+CHB^8M9-KP
MG:LH<[F)T#"(E47MZ?/7KYYO%]/VW]/G1Z^>CQD.M\LXY5IX'[F,S)3$)LQ8
MBI"+2X0Q8X;#\+3,QPNH45I%8\02=DA%Q#0U2&M*D2Z]YB4Q5 >[]8P(.91
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MB?-+^Y7%^7]=PZ$W?\[!Z*NK'_ V3=6]$AICJT"N,<6%*37V5!MM!-8E%3>
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M1Y1JLLQ9]@>E#YITN<),)@5<IYKY?.<Y7";XG95VZLF;QR!HUU'] 7 _I9F
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M/.4%.I.\)@*5.C6N#LZP^-D:^Z8I"<E4;4S.>>:71?Y>@MH@&VP-_->B[>,
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MFHO%I-_.LU?)V<L,Z-\T@GV&4J;E;%7B,UG1LKE3KG,X,:#/3)&"=775](>
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MUOH7Z(;!O,\-B$^JVJ/DW#]O;[8!$?HJ,MVA:+L.P)] K93QE3X*])MTS1N
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ML6F[/[9G,G5QVD HH,.2 KII@<Q AW(/U7;(@#O5):X.5*O"LL)O>L+B5G7
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M39_EA'9<QS&@#OI3B#]F+""60WU?5B?$!%8%&/%#:\1G.37 V+%"[=TOUU[
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M<P?*<]W&9J3=:O#<"@_T*_BO=(OT A1AQ=:H5 ]YDW#EF\&&9 MEWJYH88W
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MOER>-LV:6MW7*O<.*K=,ROO*OJMO0+F -P9<*^-:&2_A\OZAE7&MC!?0 J7
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M&I)BX'\L)KU%.ZTQOX4.?,\)@_6W/*L"VS>Y,Y:;MXRE)+34S[&8ZT C=CH
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M)H:"H"^76_4:E$[2K.<]JA<=SQ$]$P?'W+LY@//ZB4SH#!TE MNW1:05;"I
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M,!S15V1AEI"],IC@Q]$$R1R2$E+,*!\3:D"X.WP2O_.>CUP^Y!;()8*M)F+
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M2B"46?/\+#*62-Y)WAAZ(R0Z9&K#P/Y6I$F&ISS%R>!XM 9RFC)%%^4=>>3
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M^\"L]^0^>!@SPH9#9N$<,#V>". L1,AXSB91^.^)^L1HUYO_0&8+X/XA%WY
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M<@^& Y@>(H"Z+NQ;B]G+RSE%OJ[H%KU(6C'#=,^]"7 1&**>];W<QP2H2@I
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M2#'GA@A<B"K%P B+L11\=^,<C8#@GSQ;+MN1/M^T2 1K&_I:.3:)/[0?Y7(
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M4%LT'E+@@JEJ<-LFQXEV60$4"#[Y760G )# ,6:_HC$/Z9$)AS5QCS:.]]V
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MCI! S:3I\$]PEA15!HA$82T9QZ%Q"^7>"!QUQM"N]%_![E;!6WDLS8< E@!
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M,@XAPT(^/9PG$H$4H3=-6;"0E$>ME34B%N7:>.':>'85("8/YP6S"JZC22A
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M9_:W\[/J^>'\GP^K-?W;1[PWW5^^)PS=_[UKO,M]"G]];1);3H =,%0$F$^
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M\+W6R"7CRN6[_\NW7I^_?.OU<OGNP?+M4C])P-&UHRA!AN6A]26QD>Y;Z 8
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MO2IQ*V-C<V6FBWG62E^YEZE)<4&ML!T%0G#I>V\*),K,%_.\4THXAYC_DCG
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MAT4BKA%9L 5F#BS(:%A,;0OD>><WKI$8M[G564;2.^+7K S?H/,O@'..Y]>
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MHBU!S9ZDC%(RS9)KHOK&PH!1&?TQ;M&Q"6PGQ ZS7[^ZZ:PX34C_!S=+'U)
M1;.:IN4U+Z[)IP3#>,H=!&X5>O1)@=,\HN*1D<3 -#G"AMME!:U8^=N\2VY6
M,/[S8E;BI%+@4*@[G6_0<U>37[-6.Z>U#AXB*_ F^)O5R0-ACDJ>B:"T2>UI
MLQ6-R7TXS@[85@L-"YY!U KJ_)E;+J=Y&AY0K!?</LW72[Q>#T^,4(:AH264
M@K"1@(LQ0V:.*6]]]+))1G"[)8W*5(][.PR,GT'VPPNW_/QZMOC]YQ0_I<OM
M?9)7J;N]TNM%$&FIU)I B(6CBN(B%$M@O*".<QF%&_QF;X]U#,[6]9/O(&C>
M]][17.H8E0:+;A@(+R68S"5(QRC5)GD7FZ345UW%<S&MK5&_BT9I"Y7C*9&'
M.>F$$%8&!L&)HIN#!:.3A,PY<8XES^7@]^*[+>'9&,W1 [T.2@9!^35ITB>O
MK*! 7<GJ,9(5#G'DD$^9DRQT;E(SL$=BQ_&]!1H(#]X8B(1:E*/3X*V+H'6T
M5I%,31K';M_%6QBO:=L/I0?OXXH@&.'Q$J."LNPL!.TPC+4NE91W#8DDKFVI
MP>!-JLH:'2\=-\?RN.AM)_AG<S%K?$#KJ1.PF&BIUT^ET(] $I91S;,URCW[
MB]DC=TAL#_(QH600E8T;%D4W?W'>=6D>OGWLW'SIPF5<5/XUNW4DLW'NPB71
MR0A0T92Q5C*#C]: ,S0R*Y6Q9G %?L!Z=FRN^,R1/@90#%V^]N/)+R=O7[SZ
M\/.K5Q\_U*I1N_FEC0K1'J&\4K79NAOA6N2E09?/*CE12E\Y")T$6!H%,".L
MQY#5*-;D?NH&%0<G!Z)/C8 M_WGU7^?3K^B8H"8_6;UP7?=M.O_T[VYVGB:1
M$U3#2D%VY9+6X@_O"FH9NM:X=[6W3:IXMJ)N3 '2_@BYD]E773#5;.5)")?V
M/B%AZ-*B5;]<,W6")C318 (M^3=ERH/#WZB--JD@,J%-HN['B!I3$%(/(=7$
M4+%"_RL^>]%]0T(F(3ATX#(#EE+)3O$2#,'U>:F5R5IFE1NUZKDF8D?/_)D(
M?F\VU_66;RZ(,":)#!R\$0X$9PQ,S ;0]XJ>"D91(35S=!\QB<?U4>L)_4"6
MUQ7]A\^+;O4Q=6<%BFOO=CG1B@<=H@2,W7BY'0I@D^% A7=:B*P9:1?JW$?1
MCEVWGQ,0#A9 E3;8/2FEU.#&XGRD*2L:P!.%T8T3%HPB&ACS@DL6$N&W4E4>
MSO6^_>4[-K4>N4CK\+#:UOYEZOQTUA])7M*ALLR<6PM)%O_2)P=6, G$\1A\
M9#JR)NF-=TDY_&S37SE'R42M32; HT3NQH@J5);X6PKNN<LNWAX)4.L<TN_B
MD@X5M!PH][OG@_MQNGI\\LY]*U[Q)2V2)A&,8: B-;@F@>92HJ)$*XHQ$Z$8
M,#5Q2.\G9TPQ264 5.!_O2N-Z==I3/-XFQANB=74$-341<&68816HO:65@@1
M#5.4-PE3'Z!G3(%*;75000+5X- W7+]%"'$:3:UW$%RY;W!<@+/4@9;*":9L
MSJG).=X]M(PI=*D,@T,Y7Z\?Y]F7V>);2A?#/>Y9)C>2,L5*20KU(!+Z<R8D
MC<O,B@0MG;1-KBF?I&Q, 4UE>-252MUH]QYB'$;8GN6,>DLG$*:X--0(X"K'
M1)TVP;0K^]D/&$.%196!44,"%5LIW!UH>DG;MTO*K"%1,8S_=)((5(MHM9P(
M\,P&'PB/C9+TMB%N3(-Y*@.ENFQ:Q-5E+.EJ$?[Q>3%#7B_+S<[JVT0E7AI>
MYP)CAC]( !>% N^3=X8K&VP39_0IPBHN?!*3\<(2%*CTZ.X)IL%I&='=RT'(
M3%-P38SJ!@TCC;D/Q\3MK; OWVNVG#F;KD\ERQUFW]CW4YJ'0I#**9ND(L1
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M)JF1NTA\V J>@R2^%U^K5.I<QNE7A28(MLL.WM>O;9SK$,_*1$G@I96^,#&
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MB*=)%?.;Y?(<UYK6!:S7= 66+$.2E'"^T(513\P138_WF2:"K&A>4W\_:<]
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M><LB4.ICLBRA-_04\_=\=-MP[YJ$O@/8Z3QMT%"H6F[P0&7M;)1@,BG-ZZ(
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M5D&'[B+*H0\CRA J9HB!8#CZW9E+,)9:="9TEC2I$%D3'W>?PXAQ14W5D=5
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M-L%C:]\4QH537WYXMTS_]B__#U!+ P04    "  )7*U2O:M DZR7  "!BP8
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MY!B&VE@%!#*O%6<A)&'I?<U6;;93;?"P?7;AWS'21C-Y-LRS6E82[60AJAZ
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M[FF"^!@59ALZ.C8TGH^&DXMS'/^*,)B>)1CC__K'XK!5FK950L!\3G6Q3C$
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M*K4_/7=UQNT=LICAZ66),DNC&8\.YS<W'F5@1AB7M0O)IC;Y!K/'/V6MV(&
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MVH+I#Y&1L,(?\?K?UTN\,\3X9G4@:'&0(T-MZ*OCEB0>=6*V"!=+#L6+)L4
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M7*U^QQ72DS^^FN>;RI\[7>Y92OH$R-HHBJ!I7J]<32ZQ!+Y8+#J0G])FO^F
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MI](2JTE8[;W7'-M<L_@ RJGMF1$8VXT##Q/WB"9QJE>_++]>_/W]!:+,LJY
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M'KC@3C@H2H@"173@[=!KAQG0?]N\Y,Z[?_E6IU&L3T&GR,C M^3V"\VBA,3
MJRRS+BADD]*6PY"&7-3Y?K;&VZ=^_1T_7%W6/_YU,XP:Z_R6.R'7/VA!J[I5
M72B9LP_@F;"@R<1UCI%15%A2@8MH.9G \@EM'O#ZZ9V(D13B[D6=4XA^Q+!
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M;AUIKW*>>;!TYM7DNQ).R$ZWWSY'ZON.YAB?^3["'?GX_^'M'\+**+=Y6UI
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M9_N??M[<C2"QD2<-_L=B]7FVANTEDLXJ8[E%6IB#B@18*$FP)%W*MBCG2^K
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M82;D$)+)P$WLP..]AYX[<\=+:$]^>E#,X_5'F*]G?]*_/GW^EH)U):@H0+(
MGFQ980T#2VN3PDLG0H*DNWQZ^YY][LP-EM<> @=%0=XM\1,L9_-[=2L1M,9"
M6)!S2^=OG8D,61-%45F9<DRJ8]7/@V>?.X&#Y;6'P$%QD7?+V6H]^Y\;)-D:
M,I[(<G(Y1Z:+*G0N)\4\;0:Z!)]+*)V8N_/0\Z?L6 GMX6I07.0/,IO@?V^
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MCPY<U'SSV_6'2&?'_____3]02P,$%     @ "5RM4ID(*'W*7@$ $&(. !0
M  !P9F4M,C R,3 T,#1?;&%B+GAM;.R]>Y/;.)8G^O]^"MR>B+EV1*+,!_A
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M!?OI+G]ZHVZIIY_Z87_F'30WRK0[I<1ZSIW\WGZ)=)L_D"=1+->KH( B(I&
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MU&.GCM61K_NMDS]EI)KOVKY:\"H_RWT^5_>7[_^^4C2PR<LA6( X8PD,2)I
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M_M,]AU:;O%,:](Y]Y$F(.=I6]22T/;(;/BFY>@=2[UO#G_-E*\=RPB(DF!=
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M&:9&CHT*EO.\#_AF=# PI .S1B/]ML2.EK_*1 76&ER!C0Y@K43G_ILUQ5P
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M:[O?$N6O(KN[U^F<GE1G=^+S2N\X?)'5N[S\LEJ62_7XZ<1/ZY!PCWNIX(1
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M<(]2M"<[-)HC+U!9MI87%HV'1Y]*L:=!-J.7RS ;R2>FEK&I[%D9)!LQ';K
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MF,Z\ZZF1G)(<,%W-^[&1'=!GL'D! ;(1W([R+,;"C.V&07A@HM/@5J72O[;
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M[VS0#H2Y&=^[1')@NK\,1&NF-T7&)=&?[7-4GC=%8)_FC>^[]+2I8Q&_=[+
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MG<BQBG1>BZ_=AU]I#4"V> V.P3Y(.'1_$!TG8[258NQ\BSU1.I)2L6]+EX:
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MUM8QYC#-0A8&%(912&HC0T4"QD0PCD@<I&':(RFJ>]6I"90MM55!ZYU<\!<
MC3L"_/'+CU\N2Y$ZLP-V0L8[KF.$96KZM)C9TEWZ+O0EPZ5.V6$T0 K5F85?
M(Y7*#HL3*566-[OWG6_>BS!BM_EZ+F<Q8X$(,8,1EMJ2X&$,"2D]'U$2JR!
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MD^H%/UAYN)?=!/G?W&D:B[>_SC69TB2W\^7=(O^7%$!H1O1WL+Z7X%&N\J4
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M-?:UK[UZ9E-<'0,>,'X5MX IR=U0#DK206O2KB%^((3[^@/\(?TZWH!+$+_
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MKE;+OS1;!?@K7]_K?<SO<E.I_;"C.ZX-R^"AY%E? ^;2=FBVMTVWDX%C;N7
M4O+;SIZ]V7*C-^1MVSHV+%V!ABF@96O)%OA]LUV?N[;+6:#ZPMBGR+V8IE&%
MLB\$]\6VM^=>X/([XD\T)\GU@R:A'DN]G6-J"#4^Y6_F<OV+1>63_+8LUBNY
MSJL4AG=R(56^-C6_Q:?E2DNW;ZM\N?HA5\\YEZ9QV_N5%/GZEOZ<L2C,*-&O
MB BYUDY3XULTH\,59T))IK!43ADWK\_2U Z7[Y+7!@FO9XQO6"_ JNZ,N%X"
MVD+''"&/AD%05!SN]ZF\ @OIV._V]7?&Q>/Z;_,*C>+:W0W.O:GP>%O&3*_T
M<:;RA7Z':@;+=@M7H&0.U-R5G3?!FXK!MU?@X)W<8EF=G@;-*S-(SK/[>!+;
MZMU/_;I<C>\0G\0N'O6\3X,R]ZK!'_E:MN9,?9=W)N*X7+W4&HHQ.+;);$8/
MT3;)7,S2*(V3 $402Q% A.,48J0-O30B6"24"2&0;6E@3QJF=MYN""OGG(H-
MP=69NN$$/"WTU@"Y>,Y7RT59T30'<_J7I9EVR:9U'X,C;<7 YY;AH#T/SYPY
M#1.@Q<55:^P&V# R_![8E]N-L!<CU=0-M"=.)7,7HME1%]?WR:,5OUW(>KO"
M[=)']6Q\0HO[;V:*M#"AE3\**6X6]224Q=TU7^?/I?_KZ*"48B;#E,<F*UHF
M D,4A0HRGG H(I[&C) TLCNJO% SM4/+>"#+*6Z/-4<FKKELN %TPTZEGHOV
M3*/MJ&_'CB87;:>=+3?:)@U\G!D^P+?6WKPQO(!\\19LV %;?JY.3)WRZ%3T
M@JS7[B07$31N.Q(?V!WT'_'R4"^%*>_HW!3)_KB7<JVMFFLARG@4G;?F4[U[
MV1EP56P&IATGL(R8SR(9LB#F' 9F!"UB40BI(@+&4C#%%:&"6S7Z&YGNJ4G[
MW6%UQ?EI=4VKW\OJ:@9[+6SSD":WV0.?&@/L\Z5E04.C/F"9T6"DOV;9TM#[
M<:8,:O#E^TX]9.N;A>E?:XC\8U''1J0HEWQ:K+^MY$/^]*!)+B\MBB?#1CF3
M2*O2LRA)@A2'2!L7L9EWEB"(TQ3#(,A23%-!D4C=<JXNI&B:25E/6S8JDT+S
MH:748\5*%6X2)KLUK]FIPE"N<Q8OV\L,2XJS)(4A1P@BQ%)(S3QBJE@D9$(Y
MBU6SE[<N\R['WM#;D>S(?XM=M5,9QMBDL69Q,M/4MV'E"K28 0TWX$W-S]MR
MDZI[FDTJF;H"7SKBOCUF=WK!U^^(S\M(&GD2J!?\#@>&^GFL>QSJ;U+<:<-5
M*P?EC"A.TRB640HE-SVH HXAD5S"0#&%"*(HCJT*1PX?/363K**N;"GK-&GK
M"&CGPSO]H1A82GE$P3[ TA^-D>(F#J@XQ4*.,]X1XMB[8;3(Q7%"VP&)$U=<
M6NM662MF^*C>3ZW6ITQ(I<51J%  418ED%"N!9,,(A2'82PQZJ$*GEIOHCI>
M0Q[(2VK[UIOM86OKP[D JK'KQ.HN!M4L8D/E$,5?QW$8IK!K;ZU7*MHZSO'I
M@JP3U[LK)]?S>9F@4SYJ87ISBISGBTWSN$@0IM),6_F*010Q!*D(%10JB'%*
MN,J0L%56NI>:FO*BJ:W20D%#+V@([M'<^ S,Y]4;?^ -+"H,;E_'PLU>(?*'
MWT@*TD4X.JE,=M!TJ%!G'C":2F7'2%O%LKS#7:P>&?=^(DII[,T=5W#7S(6/
M_WS*UR]51]%6=>ZFN1O%@21(8BBD/O80900R2B(8,RP#G/&0(^NI!J_#PM2.
M@08%T(;A9"I"V4_]($)U<CA+=7V%"*@@:;<9<>[]]XIOWOD3;/KOT\ GX_]]
ME>Q>)?M#??JOU$C*PM1?+2=]Y'5WM4//>27"1M.?7A?XME[VRI3T<[%]RA?Y
M6G[6R^J'K_6Z.9O+JEO!-[G*S9+<3).6'V3UWUF"%15*"BBR $.$M9W-,I;"
M#*M,TC!(&4Y=4K^<*9B:ME4Q .>& Y!O6*CZFIAX:\F%<=*5Y+NYZ=SWQ\Y_
M-RCJ ^LD-> E\6!+?=W_Y I4#("& _"FX>&M/[]?;_Q\.@3=B1C54]@;HWT7
M8O\']? M-LW>U')E6KUM^[EM6P"8GZZ5EBW_2]+5)TW6IL_\#',>24$#&&8)
M@2@E":1(A9 *JH*(BR1,F+7O\2)2IB8FCW31*S8,756)*-O>*5=@^2Q7( $O
MFB_]DS(S&IX[1\_XWDH+_^9H&S2T__-P;WZT]J;,/_F]M3<E0\!P! Q+5I.!
M?&^/@QMUM&T:R\TZPG:Y>6.](-SEK;UL@?&\N5Z V/'V^GEBWPGG!U7T7^3Z
MJS(]/.*$!30TLTZ$TG9 * BD)M,6D3 +(Q62+..S]7)-YW9V0,=:3D?99L7A
MOK_=+AQ5]/W7-_.R+1_=[_%>S:_4#/WB.F?\-/9V.KXG1 <^>SKF#91)CJ9<
M7U-\=:)[OL^IWV?A\CO$^_1R(\_D/LOWX8CM\[?TDSC?I<EVY%6C+?V#7#W+
M[\OY_--R]1==B9D($QZKR,R\I@HB(0)(4**@Z5^82AR*6$@7[\.9]::F1.^0
M"VIZP9^&8E"3[%@:=@YP.U'C$<:!Q<U%"#K+%$M<?,J5<TN.*ELL^=^7+[:W
M]8AQZQ=CN2AHG8NA0LF"),Z@)(F$*"848BJYMMYC)&2*4D$BZ]CSSJ.G)CD:
MZGKDL^QA9A$U[8W$T-%,;R XQ/MZ@S%6',X:%+>(V%&^NR)5NS>,%T$Z2NA.
M9.?X%6[21\A\]EG>T?G'Q3I?OY2Y\9@G* @$A5D:48A0BB%A 88\R+!D(J(!
MM_(6'GGVU.1/21ZHZ',J*3B&6[<(NA"-@660"Q#6'UP'RUO=HFB4BT+R7^Z6
MS[_JNRJ]0O]E7YTX]L11/LD.5IIOLNL2MX^R6*VULO&H]_:>%O+Z;B7K@=A/
M)KGND:[6+U_T7GY8/M!\,<-4J" ,%*12$FU\!!12'D>0)%$8(TX"$5MUO7!:
M=6H?<IM*8,@$?U:$6G[/;I!W?^F# 3FXS\,90VM1T N3#@-$/Z]E?.B?]B6%
MVX*CR)!>&#32I=_-/2<ZU)W&;Y?7_)]/^4I^6YDN7NL7TV9T76=_/)I+9DE$
M0Q0F&8R#E$$4L%"+(<RATO8*C6F*"<W<6AG8+V[UZ8S:M>!;O3U%W<VSI/L*
M/!K*RYIIV=#N.&W!?D/L/".>01YI@D(S,&&]!#79X-L&Y)+RJQ+ECV=1=A^2
MX R8UW$(]JN/._C &96#$0?N3W W<-X;=6PEZ?NED#,<9$AB'$'%8VI\M0KB
M+!$08Q(IGC'$E95S9?_!D].(C"9OB .&.GNK9@>L\R9-7PB&UF7LN'<R98ZQ
M>H$=L_.XT8R88TRT+9BCOW?W:'Y:\J=""A.2H8OR8VX&S>.8$HX45&F<0I0F
M(<2Q2*$(%,[,4 \DJ*UO\]0B4_L4:SI!36AY5/5P]IW$]+SOTP=2 W^Q0X-D
M[QOU =9(7M)^H#EY3,^AT>$[/7GK:%[4<\2W_:EGKW57/#[4;T&5#_IQ(<QT
MSUG,E 8*9U#+N@0BB1)(<,9AEB)!,A2'-+:*%I]<86KRKR&RR8'^:(IF-)WV
M2LEQ(,]K)Q?#,[#0<T;&26'IY/X"S>7X<T=383K9:NLRW1>Z*S4F_:?5U_[+
MDQ$/7]5G^E?QE*^+F1!,,,PDS)"95A;Q&%(5<RBT?8$RA3D*K=.LSZPUM4^\
MHL^X/>8UA?9']CE8SZLW'L$:.LZR+$L+6T,N:N2^*O#9.W+V.H]'!$=2?2Y"
MTDD#LL2F0Q$Z]X31]"%+5MIJD>TM_5S-7^1Z6SYHVG3I96J%/:2,$9Q&D H>
M063&2#$6"Q@2Q;GDJ101=TFJ.[W4Y(2I7+?*@D%-JZ,Q9(&PG:_8#VX#R]6^
MD#D[@L^CX=/QV[':J([>\USO.W8M[KADF(212F9 WHDZY%DHE4!$81C&/(0H
MC15D49I"I86&0CQ0Q*[BS6G5J<F1NM' 0]5H(-]^'I*N%F8(4Y]Y#>>0MQ,J
MWO$<6+[L5 !44XY.MG'P/1W!$B7_LPW.+?P*DPDLL3@^5\#VYKY3 <I!MZV)
MG-</97/S[Y(O[Q:F0?+-XM08T).#.]^9$BMIRFM"SC*<QA+&7*00T2B&1!']
M1XH#KH) <IQLVHO:5S@-3':/(/WM",52S51B5D\E?BRG$M.*<[#:L*ZE9MV[
MD!\IKP)5>54Y[OK(1.PK_7@# UAW3"I^E7?)3DA/X=7X=YYC3<L*UXYIUIL7
MQ.LHZY&VS6];_6%)'KGM_BCX'[;E'V?9GCEEJZ6FRGQ*,YEQ%<=IIE^&4)IN
M%"'$E F8$!Y3AG!&:>A2H[M]M),"/L(I8ZS2^J2H/W0Z+[]?(P;62[#0+]1R
ML=;TS(VUFM=-B!WU\A:T$4E%&BD",VY:D"<Q@21B$H8DC7#,2!*D5DV&+X1V
M)!_)J-"B*$%QC&.H2*0MRBC $ N<P"@E0F99B$@L9\]RQ9;#@MM>8@QX>P-F
MIV/T V$4;]).S?=V-MXW,^W$'.-[E=]?=M\X_UW=#Z'RFF.X??JX.80'7!WD
M"!Y>X:V-L/W@N%,=[Q;"E()J6N[+>3?/<KXL\Q5;#?-:LZ[ES_4[S?T_9L@,
MFV8QUZ(Y0A Q(B&-> 0S%B"2IC&EB%S87_BU>)O:47&J=R?=].*$!TZ<BUN[
MOMJ+=3Y:.C&*)R3W3S=_=1R4>M71Y-6T@&UPJOK';I%J-XL%6ZS GP8M4,)U
M>=?A5WLU+VY'_._PBKYZG^)_AU?51Q?CUWX9W-L;OQK%K]WW^+6WRJ(A\JN3
MV,^M4D=6/\@BOZN8*4O1LXAC$E,&(RDSB!!/(4&8FVAHA@(:H$Q:U01W+S,U
M1:^)^K?(="KJ/P.JG4%[.50#*SD]4'(V5;M!\&FVGEAI5!.VF]M]<_;,U>ZF
M[7LME);S7)C867MB^G8.A$I"HDR1FR0AU\:FX)"F5,),9*GI%8 EP[;&YMG5
MIB85-,%"+JHJB2WIH*8=5,3_I[U6?1[N\R:85Q 'EA<=J/6:A7(>/WL[P2N.
M(VGN'7CZT9>M0>G08,\_8S2=TIJ=MI9G?U,_O>L'OY?B:2Z_*J,"+O1FO+Q_
M6IG6G[?&'[RU>6/"(\9I (5D6A.3*=6B-TR@Q(0FE$1!'(4NFICMPE.3P@W=
MID3 Q!^7B]+"U#\U?)1-H6M>W/0UZ\VPT^"&@'A@&=U&=T/T!DUMDY=!"J^6
M>5^T?"I_UFN/J@ZZ(K*O(#K?WT^$?5XN[O27_V Z=M_J1]2]C:C0JF&L(J@8
MCK2NB"*(,4<0J81$)!,X2ZP"$]W+3$T\&2JA(;/L4W\%#*6.+:3.X&HG>RY'
M:V!)TP\H9ZG2C8-/&7)BI5$E1C>W^_+AS-4]%9I[NI+O:%T K>VE2OGF*%,)
MXQA2J?] "$M(@B2$*,M2$B6AQ,(IH>3X,E.3!B65D!DRR[S/ADX@?YJ_.^9$
MG(#64AFY&+"A58\65G4WGW9HX*K,BZ#%/?AX!CMWS:,3&J]ZQO&5QM4J.KD]
MT"&ZK^XG(RK/]W;6QZ?G+_F,19RS"&50(1)K R=6D*2<PS!2!&<HRH1P<C4?
M6V1J\J&.F&TG18&_\O4]6$DJ\OD+$-*(YWQ1*MW;&5&.N6='T;83&I=B.+#(
MJ.%K3P?Z]'?XY<:?:.@"P*=@.+K.J&*AB]-]H=!YK;O?^3>M=;0J@[_1=1D'
MF\_EG13SEYN%,HWRI?A#&_M5V?"')WF[U.= OI(WBP^2E_6 41"2&0YD*%@:
MP10K"1&. TAH3*%D+,%,\C AUAYJCW1-3?!LVRP\5ER9K->*+9 W?($GS=B5
MT54T/R9F7_$##$/V;EJ?NWO>(?Y*>S:PH#-<[?8HJ!D#&\[ AC7P1[EM]19K
M]L#M$E0,ZHNFL(WV?OE7VLZ1//CC;ZN3_W\ \#LB!3Y7&RVF, !$[>C#$(_O
MI[*?JO<QV=0')?K2T&U^LU^RUBI")9ED68:A8DQ Q!2%1%$&]3^I!.ECFH=.
M_@#/]$WMO*XJL,QY;4@O?BVK"63QME44J"5$64[^]?V-J5)9@J\W'\K4Y/=?
M?[@9#+[WVL[6>,4='/CT/E84>F02X%[;$7E5[O7FDGU.AZGY'&@7?-I*ODD<
MU<P:"-]]"VVH9=Q;5WXLAYC4L8LX26+,,8(1%=HZHXI!PE4$LSB,D<!ARA(K
MJ;__X*F)ZX_U_!NGN,\!6MUR\Q(,AO;+6++OU(3R&*\7])[<>=QH+2>/,='N
M-'GT][T+I;F4HFQ4TG3'_[1<E9+A4[Z@"ZY5QVN^SI]+'\XLBA'%6O&"%(E
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MR3_ORDQ@2D?<<[:(@-BJ:FYH_M&\!8VZ8/L..&Q.CS;C]K[1!&9^))]I$F^
MDU,U\-ST.%M#C3R:$S8P=%WG;.BA+CTF/N$NU@4C1%X4>40QQ"HQA\*H@"PJ
M$JA,V&RD#8.46D7(N@T[Y:7^Y#Z*7X4.RWEP/?L-A>Z(JZX_L!><Z=K@-,P)
M;N_(KW1>:X/&Z=-9J[O=79[W\KN<+9ZD,'6<;]0_%LN9:$I5JD(Q0:B$$>>F
MS0F3D&AF@FF6%;GBG&"";+V6T\-,C8TVD@(C*KA1H!+6HQ1H#[3G?8(P@ U,
M,*-@96]-A\%L)(/8&SLG(_8\)#UV:,_-HYF2YQ7H6H,65[]*GM1^T/3;33YI
M6L0X3U0,)>(11#E)(.%Y#FG*.2Y2C9:T)MDA!9T:3?=E2#4:Z$^KVE*^>?<1
ME//U MQ\?%]O*-]\&S59YO3LGU\'IC*G Z\D@Z3%["M^!=X&3C>_^ 48-54J
MR(OP[YPGY?5"C)TD=7:6ALV0.CW\OU-ZU%D0 ^=&G1_/;R.I]OJV3>;^46K_
M[WG]55)1SE[>2W/V5<Z-#[@)T_W;T^]T*;XL2RZO-X43WCT_/L\J'>J%\RZ-
M.9<XSB&F#$.4Q!@20LROA+ BBG#$G,)LAQ)T:G;'5C[P7,D/GHP".S4J%O,V
MB&[;%]-MWVJP:;?;Z9K"9 YL<#3[85L=JRZ 6DG0: FZ:G;2(:Y K2JH= 5;
M9:] Y]VX[L_ <]Y3&WI&0N["#2;KJ/MV0R.^O],W^'B^>1HKJ6]ZN)Z+QKDV
M@S1')\T.#94"8\X0C%B>:1]6:A\VCC,8B3RBLH@41M2MB[W%J"Y<,DY#^U;H
MRL<46[&!K.7V;5EO,P5VO!X8UH$I>@?/CKR;,^#P3=<=  J;^W%^V)'30*QQ
M.,P(L;_5CY(LRBU=GRVW9%UI:>NK(QQ+F:$81E1QB"(B(4-"0"'R/%*,LY@X
MM7U_)3VF9E&_[99O^]-^_;:?W]3UV[3W/I>.)0U>ZT6Q(^-_@^E__4V_]TV-
MOVZ]R:M A26=5X=7GK&0*\YKJ3+J*O;*\[6_,KZV..%7VP]ZA/)^_NYYN91S
M_G*[U +2*C);*U+]-JMVP[;>R98D<\D1%D*9Y!13\1]Q6!0\@CPOF%Y,$Z82
MI^24@>2<VFK9J )XHPM8;\7O;D(%7BXOF>G+E\.1YN_UE[MV=EM-04?5NII;
M9[:[6T]C+W<!9F2LY>P242>S7 7 VV4Y"C'<@($6J\JYW/QF5902%RE-$**P
M4*R 2$8))"1ED,>Y0%%$"A%9%6 :6M"I+3BO6HK69Z(#QE0,/'VOO][L'J&O
MP'6UT[;Y_=4+T/K,_P A%0._!U,-J3CW/KR=5-G9"R8I1$2%S_#3BZBX $2O
MB(I+QO/S9S^;)FLK;=R8,CMMB#$A19'$#!:Y8J;O+8(%YQB*(I-2X)CGN>,!
MUI%1IG=@U?W2YXLUV$H,Z H\2'%O=M3THK]>/C>Y(EX'6,<@ST@L<I5H2YYG
M%*(DQY#EB$"52@.W1)%=<D$@P$=N-_RAU"\S-YO<'SOH?M9S\'YG#JH8HY"P
MV_GB%X(YL%US'";SJF[!'.!LL >4D*[LL6%&=4-[]-QW(?LN=6-G(<N[7^;K
M<OUB%HKETV)9,7[5NNZ=<4"6+^\60MXA$0F6L 06B:$-_:I JB2%J2!YDI,4
M86+5)]1RO*E12"TRV)'YJFZSJ&$&C>3 B&['%;:X]_/& &@.'?X5 $AK!G&$
M9\LFJY9.5I+_\7[Q_6?]I)I)] _[!&([RBADXJAR2RRNMWGL,>GGSA;W+\UZ
MF&0HEC&-H%2*0,20@$QF'.(D18SP5$J96N\*[3QZ:M312N>1G+>'F<4&BS<2
M0V^)! /!89?!&XRQ]@6L07%SW(_JW>=J[]XPGG-\5- ==_;X%7X.Z#7GALE,
MRH#4_@";F;2">J=]?9>G'*DXS;03FG"(,LFU6Q0A;>DHQ"3A<8RM*D79##8U
MAKI=4B$!;20&RXW(5V!FJF?2V6SQNW:;ZM:08O',UNIYMKGA3\"\47_X#Y+$
MR9__$^O_F#]$FS]$Q,U]ZITG.S\J%/H#LV(K)OC:@9PJ/>?@>@?S=TLIRC4P
M.S17S1EEP!AW&[1">EJ]XXWJ<MEHON][6=WC6W)4*JD?)+ZM%_R?[\OOI9!S
ML:JW\#;=Q#\^/IFV]C''*8]1 2F*S=Y9+&O&XI&*<YGB7" K"\IG\*DQV"=-
M4W\"&PW RJ@ 1*M#147QGYO_F\OJ5&UM>W#B-3MV/#44Y@/SUA;H2FZP$?RJ
M/=?8R YJX4/6"76'+&QE4(?Q1ZX%ZH[,8?5/CV?XD=WFX;MCOJ.KASLB%>41
MSB 3&!GO,(<TCF.8B1C'4<)91&*'5@(60UI]7>.W"MBC-#?"ZD/8CI\N!6RD
M:CA;^MEC)FTL:5'#D8\%'B&YIF^X4:G%0N]])K&YQ8\XFA@I$Y7;GFFI@B L
M"YA5.=5$"D@*D9L\.,%PP6-)G1)$#D:8FKWS<:Y'F==GLS//4ZI#&.TXX2)P
M!F:"-HRSZDT4_B3JI.HA/_K#04;]U$_JN/^!G[[0.^%UO7SFZRJ4WB2S+;_+
MNX0)6<A<P42F$4081["(!(99D<H(B23/$W+W5,7=:^MDN;;[OH\-Y?(6[P\X
MW O]EL[,)H ) ;LOYW,MKG,*ZR&H,39U)O)"OWRQ@DA;4[ H8@S3'*51DK*\
M2'@#ZB]S,2:D[7 C *J7IC!HVK'FI?@,3)P[XH%&OJ#IO2>U#YS/>SC.V F\
M)S4]DK%[^EKW$[:VK=BVJ]C_^7NSLD<LDTS[3C#+A?[B99)"PK($(A0IE2>X
M(-BZV-WI8:9F)9WHL^9^!-6#[/DSN3!X#?S]CP&5_<E=&,A&.L4[#EV8H[SS
M0/0<Z_7</-H1WWD%NL=]%E=?WLO+=+&AS 0X+):KNYQD*<XY@CA+-#,FBD"&
M<K.+CN(D*U@>B\PM O7D6"[O[CAQJ+L=H'A76/^&6[OXVNZ#!\!L\$WO+ECO
MK,"ZJ O642"&:G*U.]BK]; ZJG-?BZKC-W@&"'RGY:PJ]+18FM97[R5;;^M"
M77->5WB2XB_+Q6KUM_E2TY1)PS+'LMNL6YYP)25+(.:QMK (+R!CB$">J(1S
M[;&B7+9[UW:,$D0NCPWN@=EGHQ;4(D+3_P\(K5FG=M\5N#<:@>>-2J N2N(8
M4!!D7NV8;+RY&JO2O)Z1;YT9.9PU_;>M6J#2"VP5:X(6ALB3#HIUT "'((*-
M&PD1$LN#D(F@#_<-<+\60G\9*U/B@\[^W_*IBJ]F&<TEX9JH,XKT?YB 3&5$
M_R1R&65%1M+8+:[]V#!3\XR;*.Q&U"M0"PNTM%XA[$>1[>?+<'@-3("^4'D$
MJ?<A<7%L^M&'CQR2WJ?@821Z[]6>10[^3CDOYW*E34CQS->K=FN"TC0F+(,I
M010B2@6D19'#C"C"$%5$YI%3C8+CXTR-!JYG,["HDI-;>7WBLWMP/;\[%@BM
M@4G@9A>D5L[ :#DFT%^.VJCY[Q[HN>>K]V-R+MW\Q-WC9HOWJW"0['WF<M_8
MK-730MOVVAY[?OHXY[-G<UBF_ZJ56)?S9RENGF2=(O1>/BTE+VE3H^:ZKI!6
MO\(T(5DDM .<BEQH6D5*&U=Q!G,ITQA3D2GI5.L^C%B38^&.;"8PM=0?Y/R^
M--7/J79V>YJL#SEW=N[N^#,RM+_;* 0JC:IXUEHGT%4*;+0RE3*W>E45.+J:
MA0P]"XETV"BU()*-'- 6$LW#V+>@3P\03_-.&]'Z\<TA\_6/<G6'XR1%& F8
MID1!1$@*::ZMWSCF$<Z%C J1N9#SF?&FQKJ[$0^W^OG@-R.G>XWX7I3M:#0@
M=@/SHSMLEP6+G 9CL+B1(T.^7@C):?U[HTEZ;O-CD[_*F;A=_$K-X[O=,LQ6
M7O-7LY7'M PF_85PFHD(1Q KE4,4TPS2A"M(!4(921(B8Z<&VV[#3XUK#C;1
MC3IPO8"/C4)7H%5-?TV-$HY$Y#A!=KPT'.QC'UM<AK@SA_D!%Y+2'"48E>'\
MT-DG/,^G!/"(ZU^T%:?>OICSC,^+]5'CKMW821E#A> 1+)C$F@U%!$EFV% I
MP5E!<RR<2FY?(LSDN+$1WWB^[ 48#3P3&BZ:(@]W=T#@1W9RC\S!55T4[:C/
M&W+G+B2R@SFUKO*\GBOKB5RO ^O[3#^B_<MB(7XO9[,[E+)8"JD-QS@W=3BH
MR5+(,LAP+ NA5(8X=XO,:Q\]O4"\5C(WPMM 94=>/NH/3$1G]7;FD7TE0W+"
MYMFC?M_[&NU_JP?_[GXT^E5^T!;2XEK]U\M\_4";)9&K-%<D%Q"G&@Z4L0(2
MFF90)6F42)8KEEN5Q#DYPM1,D49(</WAYUI,C_.]XU">/P>]&*#!]WU "PX(
M#([]L>?%((UTX.D#EM-99R\0/:><Q^\;[7RS5^SNR6;_A6&B>T\YC*;_:SF_
MF<O_EG2Y:?EZET<YRDFLS1&.)#2UPB MN("Y5$E."TH$==HNOTR<J5'GD5C>
M;AAO%=?[N-'IJNKY7,Y!#%ZT5E= F2[/WXUBET7V.LZIG=TTWDR-O2FV.VNU
MV]=MN/WK9K/,E"/C==7GN0#?ROF]GN'-#MI[_2]7P*@-M/K#!?CZ(3]D9*^C
M1*\:TNN'WKE87L^GN@?QOF_6[JH+4FD6\*_R:;%<WRDD!::Y?HFE3"&2,H=%
M2F(H<B05C44DN57P7M\@4^/;5DZP%134DMK'[IX$M)\60\$T--FY(^04LGL.
M@@L"=D\^>K1PW7/*=8-USU[KX8\^_RBE%K)M<Y]BFE*1PCQ.$40T(I I5$ 1
MH21-&=7?/K-V1'<>/;7/NI7.Q[?:Q<S"X_1&8FA7,Q@(#IZE-QACN92-@('\
MQZ/J]CF.NS>,YS$>%73'53Q^A:>/N-0D=E_5.#0-DCXOYG3[ETXSQDW$=DID
MGC()!4<91"A+89%'B:E6Q%.<Z-\CJZX8GN-/C;ZVR;BFUTY'F3HNLO-['1*N
M7?LYV+WIM_>+1UK.'8_^7.?-TO$;;C8&IM Q)L+=F_.#,ZC[YBC"N/Z:'SX'
M#IKG8\)W*3_M*A[K5ITD5"8(2UB0-(9(>VV09H6"<1(7D2)"H(3>K1=K.K/C
MTF"2.;'L1K[A/N[ZD^4[[23+IIWDK&X02?NWXYID[#7]<04JB</U*W>;<SL>
M?I69')BA;]Y]-*D#%AMR.YT_F^8 K]B W OPL5J.NPDWF2;C7IBZM!7W&\!O
M1= B/)K.4=WZX5_D\ML#7<KWIK'H4HH['G$D,.,P$QF&*"TP9$ADD--$9(7^
M7QI;N?0N@T[.6J:KAVV/ B :,<&3_L)71G#P1G_YPEAER]7VKS^YD;75=-CQ
M<&B0!S>"C;AM(?!ND7 -926T8>!:['#<Z0)22%JT&G=4QG-!8I_,G.[UXZE?
M_O=Y)VSXP_?/Y=>F\$C;#ODN8P@7!"'($X(@(A1!EFO:2EB6Y+DH6)JG'HT(
M;,:V^I+&[TA0MUKY+-?@S;V6=/73SW5))M,V:G$_KTK^B#H[2"](H*[K"_1W
M*"N=.W8H6"UF1ZYUHS>K6;2CMV"3,E)ADAK/KOGXX>_PLS8K6Z&[IF,X@G.!
M*23!68T[*L&Y(+%/<$[W>O9): ]=/\Z?GM>K3_*[G"7-!IA2J58X2V&&> H1
MS1)(:<$ABY,LDFD>H5PY=4PX/=;4S*Y*-I#X=DWH =6.9@)!-3"[=,- :D&O
M@#5R[HT5SF,2M,5"SW#C-ELXK_=!VP6+6P8O^F$*]6JCK/[E+LH8QQG"D.;8
M5$Y# M)8")BEI.!$9 G&B5NDOJ\H+A_0.)'].^*!M=E^K;OA#%;48W=N[#AI
M#+P')BSWPAT[FKQ*H8ZC6+Y2:8Y=6:9:C.,H8A>4WSC^O N.0JZKBCUMM]HB
M$G&L5 8+R34SIBF%+*4YY 6/!4Y93H4C,QX.,CW.:PXH:O&\:A@=@=+AJ, ;
MGJ'W_"M<:ND&:.-[6O?@V^^[HXR_CWY4RZ,;XL>O](\^_7^>Z5)[*;.7)E82
M1U$1)Q&!*B\BB 2)(2T$@4E6",QH%N'$JM!%SQA3<Z VD94;.;U#3_?1[/_(
M V$TM"'B#(]7W.D)  *$G>X_>?2HTQ.J'0LZ/77I)5O"FQHI,J:*%#F'41XI
MO7JC%%)$%"28)B1!(HJQTR'5[N.G]EDW^XF^]6?VL'/9<IU@_1A[,#SW3X<L
M_;(WPBOLB9XKW7+B*O=(\?=R67ZO M8^R_57R:7^C<WDET4=B7Y]?[^LCD:V
M.5\HR25&,H5IFIA>L01!DB0%3%G,19YQ2F5J&TSN//K4OOFM BM0S@$%<[DV
M!SF-(N"IT<0^ MM]0OJ98G"8A[8&-K)?58=F6_%!*_\5V&C0R;X;$G+[N/A!
MH1\I=#[\%#C%VGM#V!..[_[,T2+VO=7M!O7[/\1]"?FBRG_)Y=\UVSZO_B+G
M>F1NHJCHO)1MN#BAA,B<Q7JM-6L&4Q2R+$*P$'F4B"(1.+%J$F(WW-06B5IB
M4(L,&IG!1FB/-!T+R,^O"F&!''@9>!4,[6D^+)8C\?K%F#K1N#U$/;QM\9#1
MB-I>H2XS.]SEYX-O@U9->[_CA<;THG"C;NF/+W+YEJY*7H6%W:$XY4F4%3"G
M&GN$8^VI(Y5I0Y]C@9$2>>Y49=%;DJD1>*U(W;=2= _#%AL]_O ?)(GC/S?_
M9[R A3+Y 4%"4/VGU&X7892)&GB!:.:H#M:JI^I4\463PK4Y[=33=.*ZVMC5
M_WYKTCQ,S&NE>!WY&FX[XV+P0^Y\^ LSZB;)Q9CM[Z=<_D#?6/]YM8-CBGV\
M>UZMM1#+3R5EY:Q<OVP.084JJ.(,JA1IZUDE!#*122AC4L0F1D1%5O4Y7 :=
M&@6_EW74!UC*[U+/B^-YJ!7.=F09&KV!>;$5MZH8!5J!K\!&Y $.4ET@"AO"
M;S'NR"'\]D@<AO [W.N9KB]$M1] 9Q_*.9WSDLX^SM5B^5BW5M$T.%NLGI?R
M5OY8O]5Z_?,N8TJ(*,L@YKS07&0\>44%Y"H2$6<L$8@X)>R[2C U8JIC$C;"
M@X[TCBGXSG-AQU>#(CPP>6UE/XXPV(H/?C,*@$J#D#GWON@%S;IW%F+<O'M?
MC XR[[T?Y-G26/O<MV9?]"[.9)RF<0&S)(\@8K& VI&+H!(J)RF-,(^M&NT=
M/'EJ=-4*IS\7(Y[E?MDA8/W<<Q$,0Y],VR+@WH!X7]M+>PYOGC=NF^%]-0XZ
M"Q]<X-M@[8F^5&4V;M2WA\5R?2N7CR:E_TX1E<2T8) GB31AGQ@2$6.8YD(K
MQ*EB.6FS!NWLC)-C6;V9NUF"0Q\7+$M-?4]ZI6M%-ME_*R,TU!3Q"-ABN5S\
M7L[O'9V@TWC;61*783A6F>TM: I\VX)FY S98NT,%&&;JYT:;.2V:F=T/FRH
M=NX&SSR;S>%FZR*9-GIUN:6[G,=)AJ3V2%B>0H0%@T1F#&8TI40@0:1"3JV"
M>@:;VN*^E15LW'Z_>F"]$-NQ12C@!B8,+\S<<UHLP B:M](WWKBY*1::'^2?
MV-SCQQW_D.7]@U[#K[_+);V7GY_-B=N->E_.GO5?JRW=U<WS>K6F<Y/S<I?(
M..)8%C"*E(*H4 @6"2*0$DI21"0BW*EJO>/X4V.85GQ(:_GKXZR]TR]1*^/&
M.*X3DV6,1C1-8*S-06TBYIKG>29-;'&!LR+%J2(NU<Z&G)@1:IH=3,R\4L 8
M0;PNXU+/%%AL==B=M493\*:^T/&(TG7Z[-:0 2=EX&6EE1PTHH//F_FHQ08=
MN4UQG?Y/QGG!\40NY!KD*L*HRY(G/OLKE>]CW*/LJGWF8]MBEAD#5L^8T ?4
MLZ_NG&)AAY]]M%=0'$<*]O(YIW"*[[(&I2>\Z_PS1HONLE:G&]QE?Y,; :R6
MZ[M/Y;J\KW.NZ4IVW#%$4IJGN82,L0@BDE!($J4=8,XD5A&C,K(ZDNL;9&IV
MZ%9.8 1U]')[X>RGT5 @#<R>SOA8?^HV /18$?KVC@6A?]NW'GJ?/\K7;Z-A
M^]%;7>N92TF7<[/'VU;MJV*.[F2D1"P%A7&2Y1 E60(9CC*8,"ZB",<T23(7
MM^?H*%-S;DP<7E.@F:[7RY(]KZOLD_4"-#','^?\CSN.SL-BIJ%>!0F_/#X3
M=A[,Q?@.?1K6R->MZ5G)&#!?LP^"H&F;1P<:-WNS3]>#),[>B]U=!&UOS"37
M=L97^;@J']OVH(PJ2I-"0$*HI@R!""1Y5,""Q)',6,QD9)VP>7R(J5D'&RE_
M;L3T2 \Y >9Y)^MRB ;^Y =$Q]Z%NARED?PF#[2<W*9^('I\I1,WCN8@]0O>
M]8K.7.EG'GWC#U(\S^2-^CC_KE^#Q?+ELQ:Z#HNLHA.V@7)"ZQ9'A$&:"0Y1
M7BC(,D4AY;%BVIJ*B]@J_=!C[*E18RNZV8@T>4>+>7M6WJI2%<+=JN-F*KG,
MBIT!-1#6 W-L%^:-W%U8F^@C,$C0H@=F(>TPE^%'M<X\<-FWV7P><4$UO#HO
MY7HN?OGQ).<KN=KL5O*,H"))!>11RB#"4M-9CE*8H"PC*N6Q4%81BW;#38W&
MZMW,)N?+Y'.U GN7WSD#MQU9A0-QE-UU3_S\"NN=A25XD;W3(XY?<.^L]D>+
M[YV_ZW+C24A5SLNU_%1^E^*CMJ?G]Z6FL;KN7QWLRU/&,2::81(F(")(0I)I
MFU3_51(AA$RX\+6?S@\_->[97=M;^6&E -AJT-2I= NT]IP@=U,J+.RC6E,7
M(WZ1/64/W% FE84$KV95V:/39U@Y/&7,IHNFX1ZG!2]4CB"1QI4LA((DD1CF
M$4Y4)C*A8C5\D\4)-E6\[N^8.&ZKQ*%;(_[_M!7B!'H@3JKGX;])C\/@/0W]
M>QAN4H1>/I2S)ASJ#A.9(JSTI A35R8R]0L0(; H!$<RR2D2U"FYKO/PJ1F'
MM7S "-B$_#EFV'6!ZZ>P2^$8^F31'@GW3+LC*E^:;-=]Y+CY=D>4.4BY.W9-
M>-OGLUR;;:UZ/?BK%/>R;:55-S?]:CH'KE:E*GD=UC079JDML$J5*>HG!='^
MH<#:4V180HE%1%D:*\6="D>%%W%J-'']N'B>5\6%C/2KGZLU6:Y^,K4UVR:
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M*!^2&(X-,RHG].BY3P=]E[KW1WYG*FK*Y1-=KE\^ZWFNUK D3](\2C#,8II
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M \,^,!W78C;]0J] _6OS_\U$-$4;P/5R:4KTF9^OFD)\VA]5LEP_+P.4\0F
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M7@(0@[E@""+)&"2B4# 3#%.>QPK9I>:<&6=J?'X]FS6-;EIY/6*2^W#M)]N
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MC#7C)A&"5&J %<J*C))"%=31?CTQTO0LV?H%;S.S9UN)/2J('4'6SLP*@-;
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MY!V.;6R1&9)Q+HXY*>O8(G#(/-;W>=9Z(TM1-<V0/HDVLC]CJ8@S&0$2QCF
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MRXP\PD1,U01I3_";?=]9+;^R[A3:GV5]SO1N;+1=6C&.A?I$9#\"^HY= WT
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MRI^&3$'OQ6'85/330TV<DMZK[W%J>O_EP]DSMU4E-M7MSMU\T'$&Q3#/I82
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M[:[M0 <,=KO"]MMK.OC=! :O8 >A&:3^98.B^8U9?;= NKBV_IJON$-?U[^
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M5SS)?6=MSOCK8_WW;84:O8?7._;/\BM9BJHMO(XSBA&.U$H6J5TWTJWN<D0
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M_Y33Z.0U&!;Q'F_#0 --YJ48%IBN=V/@)_M9V]]*4__QQ3RKCF1+0XJBA(0
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M75]Y[BH\#1MMU$C7M0* _??P;N$F/:X%9'&]FG])TY3'BU$0O$S"XN"D+0F
MI,!PW#$X#TQH'IQTHAZ.'] S;,Q1#X.'";X!'_#[2PD_L0K>WY<X"Q6V6,S&
M_G)16I6?=X^L(AY5T+B5@"M>B]"4@TT(F"Q"0J$+RQ(;QHSNP\ZP4<TP%K2Z
MVILQGE=2>#F>AY4@4KR1P[NT.,WE-)%Q%IP0#C0N8?3!A03#,JYSPY52DAJO
MJ^09=R%RV-"H/E![5%$#MO?]K,,=H_ V$B9%30T%)B3ZX%9JL*5;6!:"2$(E
M\W)#[?7AX+HA8=BXIP9T]A1O W8) 7V#^ZT,KPTR4R$E)%NFG@J"X:%6%HA
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M33CFKM420@X.EH[B/M[PEE6Y?*1P>W51@B &Y>Y80+#F4BME'2%5;M9L1=W
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MZGK88L2#5RHI#YHF H)0 Y81OIQ-I%RR(:0JJ>.GB!KV#E./$.I-\@V@J"R
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M-VP^I]FXB[A 9HN6KE\$+IE@5@&5FH-P* 5K@@0GE9"$"2M"E?+.8UZ_^"$
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MJ2;!5]9(6QH4",6<Q,"[2I^V6S0\FZ/!0R"SK\P;N*!^-T7_8I4!&D\_WJ2
MKC-$[TL/(=3;8G5P5#;X\V[E<RZ0*GS"QS=E ##*=A12H-PI#5PX@\XF,6!*
M';A"X4K)A.2J2F/N.NP\FR/#0T#< !+V7@]?TLQW/>V[JW5<Y#"B#AU8HQ)8
MRRD(4T8^4DL@&>*2E$&'H&J@^(:$9W-,> CR]I1X$VAYEQ8W"V>$/H$Q)BEP
MT3ET,25*@:'Q]SI8'WC4D5<Y<KY#Q3!-E8Z,F?WEWN81\J9V9FX:E[V?5@VH
MYO.N-/1+\<_QXM.M-F?E8^43'U#LH;R!RVGYZ@M*_\T4/[.\CK_/<?(1B.KA
M:/G8HCOPF/DF+KU%]O) ;=FN[F;T[_4!FHZ:&XF!*\\"T1UH ",<A<PR)T9J
M9_TV%WSV2!-L2>'A"9'O/.BF\\DY2O\7_-L_1MDGSDDPX&GP(#RQN.8)@R2L
M)4DZ9V*5,]]]B!TVT5(':0_S+)65^(]JN)>IU#;-]YJT9V'$-XGQZ*;<,BZ\
M]P%26/:P2[2X+!H8HY3ZD,M_G[4IOW'_'GGD4IFW# #AU&3N0"LN0+A@P4:9
M("JN6+#*J?L5['T?M&Q%YW,QX+O@Z_$#E_Y5UT ^_1'V2AW3[$OZY=LY?L]I
M+CS>L(CB\E:;TN^LL)AL!N-U!DLUU22+&$CEID5;TSIL;GY0A/:FPG]4#Z.'
MIG8#$/DLO(ZJ[?!V7WV&AI3*3&!/R_UBXDNM/5$0<948SVG.HLJ)4&O^Q[(Z
M008C<RIG>\9R%$:.X+@N5_VMP5#$YQ"J'%+L0.-S\3MVP=6>?L?.*FO Y[AK
M7Y"-=>$T[E;+XC[#(K<86X-G*>!F& CX+ /0J#/C5!(9JI3U?H>N5NI">L;#
M4PF+ Y73 -96SL\=IM:5?T''S".NRQBR0T<=(8$ND0 5-/-&6&E\%90]2E%#
M5NU0O7<UE#!P7>UO;GJ9W9K\T\^+\<5Z=-"Z[%,S*XH;#RR6R1.E:9))SJ*H
MA%:1N,SU-K?.O_.884'2DR*[.E)MP-S<$<W[B9LNUXY*@B=& Q"C,-HB3H'A
MD8.*SM(L3):N2N/WC=2T4JYVQ&UL+T6TB*;U8HN,R> ,+K;(<"ED3U$PG +S
MF1/*'7.TRCRC1^AI:./:3]/?P\X>8A]XLWK=A<MY64P7G]WT6^%A;4^5%5DC
M%^!(*#4!:%D]#P$,Q=5F A4T;=.X[K'O;PP*^RBNZUF*K=F1N[[=V^NZ$R&X
MBUE9W+*1$R%,!*N]ANRB8PQW<":JE'5M0UPK];*#A5[[J:DUZ-V56!G>%M:O
MZ2AE:R4-#*CP<CU_TVH./#NEE?>$AV.> 3X@L"'+U@LTMJM3.$Q/ V^"=WAR
M=W@J9;EN_FF=W+[5>B\Y@MY!H*!8Z=ZN"<8Q,J-Y3TH[33T76UV1W./1#1U5
M]0FP8RBB;3OW9AI*[[/EZY&)U#LB!<1$(PCF''BA ZXFF72*+.<ZM;!;TC?L
M1CNDE=M;2_^HQZ,WS8CV^./5N5^3)ZI]\/4L#F%[5^#1SVVID3(S9<#I3,J]
MB(#+E'-P/A(;76EK6J7!;)OGMBXJ245 HDN5JO4&C!$*4N+9)REYX)6[/?TP
MY[:[X.J@<]L=5-: CW-O\.;;\@=%=R7?QK0*1)$$R$^YX"DHV"@LA@59,Z*S
M(+)*^/8$3<_HO'87'&R\H'BX4MK%USJ)1S*53J0,E@5;_#X)EJ-WY@DUEA!K
MMALNU!?"6DA]]Z;[[3"UAR(:0-728\(PLUO=V"V7< MW):LQG:=U0C>[Y++)
M#!2)!J7%,*@@,> &P)3FC"5KJU2 ;4-<DQC;!PM=9<4T +95FXPS-TGS-0/1
MI1Q#3! 9R2 H+7T>#0>1$E6)2VMR%;/U@))A\TOU8'28R!O S%E:]@;X-4UQ
M'4S003B)%^-IZ42^#+76Z^&*.>-]UHX7W]0*$)IQL%EI<"I:9X*CQ-89*;0+
ME<.FD>IAK9ZJ&L#AAXV]:^^:8R>((%QE"+$<;RG"P#HBP$ACLZ<J)E*EX=(6
MM W;CJ0>YOI62Q,-(KY;;2@)<:;4CT7!0$B"BXA9#YEX2=G_S]Z;-K=Y).N"
MORAC:E\^2K+=QS-JR2&K[XWYQ*@E2\)I"O %0-DZOWZR "X@")!8WL);=,^)
M#AU1EH!<GLK*S,K%D?.:NRT![J-VZHR0<DCE=&#7]A<M!HR9)VD@*D<QD@X<
M7) (5@G'%3(CL8DU>ZTEP,?H_> 2X&.4T &:-G+EFZ?NUA#'$%FRG /%):$^
M'!$SD5N0@B&:.N?,-T'4LU3U6C-\E.9GK=0P^KCFC<>6C0>66TX\$S)&KX&9
M&LL(<B1=3 6D#T:K)$/DARV:?>Y;QKW6A@7(P#+MP.(<]"J>' LJ8'VLM@Q4
MW5KEA!-0]_X%8XL5%YB&\_JK]]IX3:>IJ3OHK1^A'U[)BL^%N0!<.0IJM!;$
MBW=@3-&%(HY47*,YS?N)ZM:!.A$"SV+L#'UT@*W?*9B=AVG"U?GC5YS[6)A/
M)!<DN:@<P'ECP*AH.+F8@H4V4R4>T]$3@LY1\)/,U>G2[JF,\\UB@<M?O_T1
M)O.:!KD5T96(GH><.'@78TWY2@B^.D)&VE"D<VX[7_!RV>;NK^JI3', ?+00
M\!D3OY?-KJVKPJ5QWG(2AU!D=[,"GR.'4G1@!'IM4A/[LHN8GLHL!S0R9\M]
MQ-'?>Q;#[8DS5UN,PRJ^6/U\%26&6.M$$Q<.%$8+(3 /Q;)LC%$V%G6  3J=
M@I[LTH">SP75TH%/M(/3.C+\RWK4^":G5UK(FNQ/H%G0H%Q831 G^RSJ./TH
M@Q)- K[#2>S)R#7PQ1OI:M3GF2?>P-WM,,U[3MP5HHTA<PJ95:TSLLE3R)P3
M2*F#2 RY9R_5=!__K>.^]34U=@W%W\%BC9^PD(3R6YS2;Y:UH_8#+G_#^626
M)^GV3U<=&)63'%P$6U8+0WA-_14/2+]*9C@6W60*U:$$CKN"H+EQ:Z*G#B[8
M1X*[>]M*":]K"1KFGY (JTT5I,>K$*--0A5PB3P&E4ATL>@,!6-Q*J=(OG#S
M@.%Y&L==:G#9=-> VAHYH?%K[7/Z=J>IM1VG*-H9SM@ZWZRRJQUGQ$A,47&1
M,2=QR#O/CH\^""/VU6%D"$'VE-BZN^IWW_-AFG<QZS5WOB0!@J\$IQEX5/1+
M01E29D&HDYVO8P@Y"&/N56+LLDH:S$5[M<VD==C*;%I7XM1_^C5,Z;LFT\<I
MRI3F-^'Z=321'L_/*VL>/5-A%V\:E<ER%;(CCQ4Y*&TD1!T1+!U#4W3@I;1_
MMNRE:52$R%2N38ZV)F=MG8R$FNY-I7E0/&!*OLFCV]^O:?087)W3-'J,RGJ+
MN'84%=+-F%T*'K24@0)((\![8HPSKW@BIQU%^]G;KWG8[U%X.++2]QCE=("U
M9RK)9*VQ#QILDN0")L$I3C2UDLR1_&0HW#<9N_)**WV/TOOAE;Y'**$#-/U,
MGN3L!^)]Z<1M^6"249 P/ 1E2#A19'!UE6NP)2=EM->Z26_"'GJZK>X]1MNS
MX44_^D/*5B7%7?6II@.$UD;(VI.?D%9%K<H"<R5QKI-B[I YT;L_O=M*WA/
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MRCTAM^UYM\-:MH9T*Z4C*R@ANE 'DG(.#AG=XLPG2Z<K*WU(OWXC\OJU2,?
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M S#NZ_.^8P>5\\GQ"$8D0[ZK3E![#X&I0/S)4.<(M@#?"W2-&\(V ]N0VN@
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MTL50B ^S:;[GZR[SS:(5+GC0NLY$E'15QV(]8.!)6[+KRC?I=]U!R]A+W1O
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M]E+4>3H(3CH#-@KIT<6,[C^W O,,!VH <7<)FKLYP"%XI:* M&KN]8E#-*(
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M/O9C/]_G^1BW<>_%\,-@\L_X',SE(@'C3^\N1@-@F+9][0UL>S@9@O>3ORZ
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M1W1IM H(*8W&;A]O6[:%@!" " M9/[E*Q[P8@6^LSBN%$G&/M^+!%FS[J?%
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M;B#<7"G!4O,^U-42?_M9%%2S*.Z/M'O"R<7AJ]_JP?+R^,7IV6USUH!\I-;
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M_N5O@OI9_6/A_CLY^ =02P$"% ,4    "  )7*U2[$!)*(B: P#3Q"X $
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M '!F92TR,#(Q,#0P-%]L86(N>&UL4$L! A0#%     @ "5RM4F+.<O*LSP
MSGX) !0              ( !*?,% '!F92TR,#(Q,#0P-%]P<F4N>&UL4$L!
M A0#%     @ "5RM4I8-!H>/!0  I!(  !D              ( !!\,& '!F
M92UE>&@Q.'@P-# T,C R,3$P<2YH=&U02P$"% ,4    "  )7*U2'>]?>!\$
M   7)   &0              @ '-R 8 <&9E+65X:#(R># T,#0R,#(Q,3!Q
M+FAT;5!+ 0(4 Q0    (  E<K5+5Z%VVS <  %(C   :              "
M 2/-!@!P9F4M97AH,S$Q># T,#0R,#(Q,3!Q+FAT;5!+ 0(4 Q0    (  E<
MK5+HHQ]3W0<  &4C   :              "  2?5!@!P9F4M97AH,S$R># T
M,#0R,#(Q,3!Q+FAT;5!+ 0(4 Q0    (  E<K5)CS"2=X00  )(1   :
M          "  3S=!@!P9F4M97AH,S(Q># T,#0R,#(Q,3!Q+FAT;5!+ 0(4
M Q0    (  E<K5+LQ<+7_ 0  )81   :              "  57B!@!P9F4M
L97AH,S(R># T,#0R,#(Q,3!Q+FAT;5!+!08     #  , #(#  ")YP8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
